PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DAVLETOV, B; SONTAG, JM; HATA, Y; PETRENKO, AG; FYKSE, EM; JAHN, R; SUDHOF, TC				DAVLETOV, B; SONTAG, JM; HATA, Y; PETRENKO, AG; FYKSE, EM; JAHN, R; SUDHOF, TC			PHOSPHORYLATION OF SYNAPTOTAGMIN-I BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; SYNAPTIC VESICLE PROTEIN; TRANSMITTER RELEASE; ESCHERICHIA-COLI; PURIFICATION; EXOCYTOSIS; P65; ACTIVATION; CLEAVAGE; BINDING	Synaptotagmin I is an abundant synaptic vesicle protein that binds Ca2+ in a phospholipid-dependent manner and is thought to function in synaptic vesicle exocytosis. We have now studied the phosphorylation of synaptotagmin I. Synaptotagmin I is one of the major substrates in brain for casein kinase II, which phosphorylates synaptotagmin at a single threonine. The phosphorylation site was mapped using recombinant proteins to threonine 128 of synaptotagmin I, which is located in the sequence between the transmembrane region and the C2 domain repeats of synaptotagmin I. The phosphorylation site of synaptotagmin I is also present in synaptotagmin II and is evolutionarily conserved between different species. Preceding the phosphorylation site, synaptotagmins I and II contain a lysine-rich sequence. Casein kinase II phosphorylation of many substrates is strongly stimulated by the addition of polylysine, but phosphorylation of synaptotagmin I by casein kinase II is not. In recombinant proteins, removal of the lysine-rich sequence of synaptotagmin I makes its phosphorylation dependent on exogenous polylysine, suggesting that the lysine-rich sequence in synaptotagmin serves as an endogenous polylysine stimulation signal for casein kinase II. Our data demonstrate that synaptotagmin I is an efficient substrate for casein kinase II at a conserved site with a possible modulatory role in nerve terminal function.	UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275; Jahn, Reinhard/0000-0003-1542-3498; Petrenko, Alexander/0000-0002-6689-6546				ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; INOUE A, 1992, J BIOL CHEM, V267, P10613; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	33	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6816	6822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454654				2022-12-25	WOS:A1993KT36800105
J	EAKIN, AE; MCGRATH, ME; MCKERROW, JH; FLETTERICK, RJ; CRAIK, CS				EAKIN, AE; MCGRATH, ME; MCKERROW, JH; FLETTERICK, RJ; CRAIK, CS			PRODUCTION OF CRYSTALLIZABLE CRUZAIN, THE MAJOR CYSTEINE PROTEASE FROM TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION; CLONING	The major cysteine protease of Trypanosoma cruzi, cruzain, has been previously expressed in Escherichia coli as a fusion polypeptide. The proteolytic processing events required to obtain active, mature cruzain from the recombinant expression system have been characterized using mutational analysis of the cloned gene. An inactive variant of cruzain (cruzain-C25A) revealed that the proteolytic cleavage of the COOH-terminal domain from the recombinant cruzain is independent of cruzain activity. This cleavage event, presumably performed by another protease, was reduced, although not completely eliminated, in a variant in which the cleavage recognition site was altered (cruzain-E219P). To obtain a homogeneous COOH terminus of the recombinant enzyme, a truncated form of cruzain (cruzain-DELTAc) was engineered by insertion of a stop codon in the gene at a site corresponding to autoproteolysis observed with the native enzyme, purified from epimastigotes. Diffraction quality crystals of recombinant cruzain (cruzain) and the truncated variant (cruzain-DELTAc) have been produced and characterized. Cruzain and cruzain-DELTAc were cocrystallized with the peptide fluoromethyl ketone (FMK) inhibitors, Z-Phe-Arg-FMK and Z-Phe-Ala-FMK, respectively, (where Z is benzyloxycarbonyl). The crystals are monoclinic, space group P2(1), with a = 45.5 angstrom, b = 51.0 angstrom, c = 45.7 angstrom, and beta = 116.1-degrees. One cruzain molecule is present in the asymmetric unit. The crystallographic data reveal that the high resolution structure determination is feasible. This system will facilitate the three-dimensional structure determinations and biochemical analyses of cruzain and cruzain variants.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK39304] Funding Source: Medline; NIEHS NIH HHS [ES04705] Funding Source: Medline; NIGMS NIH HHS [GM07175] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004705] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BABBITT PC, 1990, BIO-TECHNOL, V8, P945, DOI 10.1038/nbt1090-945; BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I; EAEKIN AE, 1992, J BIOL CHEM, V267, P7411; HARTH G, IN PRESS MOL BIOCH P; HELLMAN U, 1991, MOL BIOCHEM PARASIT, V44, P15, DOI 10.1016/0166-6851(91)90216-S; MCKERROW JH, 1989, EXP PARASITOL, V68, P111, DOI 10.1016/0014-4894(89)90016-7; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PAMER EG, 1990, NUCLEIC ACIDS RES, V18, P6141, DOI 10.1093/nar/18.20.6141; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SMITH SM, 1989, J BIOL CHEM, V264, P20487; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WATANABE H, 1991, J BIOL CHEM, V266, P16897; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	17	90	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6115	6118						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454586				2022-12-25	WOS:A1993KT36800009
J	TANG, YQ; SELSTED, ME				TANG, YQ; SELSTED, ME			CHARACTERIZATION OF THE DISULFIDE MOTIF IN BNBD-12, AN ANTIMICROBIAL BETA-DEFENSIN PEPTIDE FROM BOVINE NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								BNBD-12, a prototype beta-defensin peptide from bovine neutrophils, was chosen for determination of the disulfide motif in this family of tridisulfide antimicrobial peptides. Disulfide-containing fragments of BNBD-12 were generated by incubation with trypsin, and the amino acid composition of one tryptic fragment allowed for the assignment of one of the three disulfides. The remaining two disulfides, contained in a 16-residue tryptic oligopeptide, were characterized by amino acid analysis of fragments generated by a single round of Edman degradation which cleaved the Cys-Cys peptide bond present near the carboxyl terminus of BNBD-12. Cleavage of this bond produced two disulfide-containing oligopeptides, the compositions of which provided unambiguous assignments of the disulfides involved. The cystine motif in BNBD-12 differs from that of classical defensins, and indicates that the beta-defensins and defensins must have differently folded chains, though they share several functional properties.	UNIV CALIF IRVINE,COLL MED,DEPT PATHOL,IRVINE,CA 92717; UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine					NIAID NIH HHS [AI22931, UO1-AI31696] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031696, R37AI022931, R01AI022931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Klemm P, 1984, Methods Mol Biol, V1, P243, DOI 10.1385/0-89603-062-8:243; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	10	100	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6649	6653						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454636				2022-12-25	WOS:A1993KT36800082
J	ADOLPH, EA; SUBRAMANIAM, A; CSERJESI, P; OLSON, EN; ROBBINS, J				ADOLPH, EA; SUBRAMANIAM, A; CSERJESI, P; OLSON, EN; ROBBINS, J			ROLE OF MYOCYTE-SPECIFIC ENHANCER-BINDING FACTOR (MEF-2) IN TRANSCRIPTIONAL REGULATION OF THE ALPHA-CARDIAC MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE-SPECIFIC ENHANCER; GERM-LINE TRANSMISSION; EMBRYONIC STEM-CELLS; CREATINE-KINASE GENE; THYROID-HORMONE; DEVELOPMENTAL REGULATION; SKELETAL-MUSCLE; EXPRESSION; PROMOTER; ACTIN	The intergenic region between the mouse alpha-cardiac myosin heavy chain and beta-myosin heavy chain genes has previously been shown to direct expression of the bacterial chloramphenicol acetyltransferase reporter gene in transgenic mice in a tissue-specific manner. Sequence analyses located a putative myocyte-specific enhancer-binding factor (MEF-2) site situated in the regulatory region of this gene proximal to the start site of transcription. The role of this element in directing the cardiac compartment-specific expression of the transgene was assessed. The polymerase chain reaction was used to perform substitution mutagenesis of the MEF-2 binding site, and lack of MEF-2 binding was confirmed by gel retardation assays. The resultant construct was used to generate transgenic mice. Surprisingly, transgene expression was not down-regulated, but was significantly increased in the hearts of the MEF-2 mutant mice. In addition, cardiac-specific expression of the transgene was perturbed with significant levels of ectopic expression occurring in the aorta.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MED, DIV CARDIOL, CINCINNATI, OH 45267 USA; MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Cincinnati; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center					NHLBI NIH HHS [HL07382, HL46826, HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, P01HL046826, P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DECHESNE CA, 1985, CIRC RES, V57, P767, DOI 10.1161/01.RES.57.5.767; DIEDERICH KW, 1989, HUM GENET, V81, P214; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FRIEDMAN DJ, 1984, P NATL ACAD SCI-BIOL, V81, P3044, DOI 10.1073/pnas.81.10.3044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GULICK J, 1991, J BIOL CHEM, V266, P9180; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOGAN B, 1986, MANIPULATING MOUSE E, P152; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KORETSKY AP, 1992, AM J PHYSIOL, V262, pC261, DOI 10.1152/ajpcell.1992.262.2.C261; LIEW CC, 1986, P NATL ACAD SCI USA, V83, P3175, DOI 10.1073/pnas.83.10.3175; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1989, CELLULAR MOL BIOL MU, P369; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Nadal-Ginard B, 1982, MUSCLE DEV MOL CELLU, P143; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; QUINNLAQUER BK, 1992, GENOMICS, V13, P176, DOI 10.1016/0888-7543(92)90218-H; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SUBRAMANIAM A, 1990, J BIOL CHEM, V265, P13986; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; Walter C A, 1989, Biotechniques, V7, P1065; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	39	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5349	5352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449897				2022-12-25	WOS:A1993KR82200003
J	ESSER, V; KUWAJIMA, M; BRITTON, CH; KRISHNAN, K; FOSTER, DW; MCGARRY, JD				ESSER, V; KUWAJIMA, M; BRITTON, CH; KRISHNAN, K; FOSTER, DW; MCGARRY, JD			INHIBITORS OF MITOCHONDRIAL CARNITINE PALMITOYLTRANSFERASE-I LIMIT THE ACTION OF PROTEASES ON THE ENZYME - ISOLATION AND PARTIAL AMINO-ACID-ANALYSIS OF A TRUNCATED FORM OF THE RAT-LIVER ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; OUTER MEMBRANES; SYSTEM; SENSITIVITY; SEQUENCE; CLONING; INNER	Our objective was to isolate from rat liver mitochondria the malonyl-CoA-regulated and detergent-labile enzyme, carnitine palmitoyltransferase I (CPT I), whose properties and relationship to CPT II have been the subject of debate. After exposure of mitochondria to the dinitrophenol derivative of etomoxir-CoA (DNP-Et-CoA, a covalent inhibitor of CPT I), followed by detergent solubilization and blue Sepharose chromatography, the DNP-Et-labeled CPT I could be readily visualized on immunoblots using an anti-DNP monoclonal antibody. This material was used to raise a rabbit polyclonal antibody that recognized CPT I regardless of whether it was carrying a covalent ligand. Exposure of membranes from untreated mitochondria to a mixture of trypsin and chymotrypsin caused rapid loss of CPT I activity with a concomitant disappearance of immunodetectable protein. However, inclusion of malonyl-CoA in such incubations afforded major protection of CPT I activity. Under these conditions CPT I simply underwent truncation from approximately 90 to approximately 82 kDa. This was also true if CPT I had first been labeled with Et-CoA or DNP-Et-CoA prior to protease treatment. Thus, the presence of an inhibitor, whether reversible or irreversible, at the active site of CPT I limited the action of trypsin/chymotrypsin to removal of a small portion of the protein which was probably not necessary for catalytic function. These and other experiments with antibodies and proteases provided additional insight into the membrane topology of CPT I. They also strengthened our conviction that CPT I and CPT II are distinct proteins and that the former exists as tissue-specific isoforms. Finally, the 82-kDa truncated form of rat liver CPT I was isolated and subjected to partial amino acid analysis. Four unambiguous peptide sequences were obtained.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; ESSER V, 1993, J BIOL CHEM, V268, P5817; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; GHADIMINEJAD I, 1991, BIOCHEM J, V277, P611, DOI 10.1042/bj2770611; GHADIMINEJAD I, 1990, BIOCHEM J, V70, P787; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KASHFI K, 1991, BIOCHEM BIOPH RES CO, V178, P600, DOI 10.1016/0006-291X(91)90150-6; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; MCGARRY JD, 1992, NEW DEV FATTY ACID O, P47; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WOLDEGIORGIS G, 1992, ARCH BIOCHEM BIOPHYS, V295, P348, DOI 10.1016/0003-9861(92)90527-4; ZAMMIT VA, 1989, BIOCHEM J, V263, P89, DOI 10.1042/bj2630089	21	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5810	5816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449947				2022-12-25	WOS:A1993KR82200068
J	YI, Z; LINDBERG, I				YI, Z; LINDBERG, I			PURIFICATION AND CHARACTERIZATION OF THE PROHORMONE CONVERTASE PC1(PC3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; GENE ENCODES; KEX2; EXPRESSION; PROTEASE; FURIN; CELLS; PC2; IDENTIFICATION; ENDOPROTEASE	The prohormone convertases PC1 (also known as PC3) and PC2 have been implicated in the biosynthesis of several polypeptide hormones and neuropeptides. In order to understand the regulation and the cell biology of prohormone cleavage, we have purified recombinant mouse PC1 from the conditioned medium of overexpressing Chinese hamster ovary cells. Recombinant PC1 was found to be an 87-kDa calcium-dependent proteinase with an inhibitor profile similar to that of Kex2 and furin. However, unlike furin, the optimum pH for PC1 activity is between pH 5.5 and 6.5. Like furin, the enzyme is activated at millimolar rather than at micromolar concentrations of calcium. Chinese hamster ovary/PC1 cells secrete the mature form of PC1, converted by a proteolytic cleavage on the carboxyl side of the RSKR motif located at residues 80-83. This conversion occurs very early in biosynthesis, suggesting that, like Kex2 and furin, PC1 may be activated autocatalytically. Specificity studies with fluorogenic substrates showed that the enzyme prefers substrates with an arginine 4 amino acids amino-terminal to the cleavage site; synthetic tripeptide substrates containing only pairs of basic amino acids are not well cleaved. However, the neuropeptide precursor proenkephalin is cleaved by PC1 to yield a peptide B-sized peptide; since peptide B represents the naturally occurring carboxyl-terminal fragment of proenkephalin, these data suggest a role for PC1 in the processing of this precursor.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,1901 PERDIDO ST,NEW ORLEANS,LA 70112	Louisiana State University System			Lindberg, Iris/Q-3825-2019		NIDA NIH HHS [R56 DA005084, R01 DA005084] Funding Source: Medline; PHS HHS [05084] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15227; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATHIS JP, 1992, IN PRESS ENDOCRINOLO; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOCCHETTI I, 1984, EUR J PHARMACOL, V106, P427, DOI 10.1016/0014-2999(84)90734-9; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297	44	166	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5615	5623						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449925				2022-12-25	WOS:A1993KR82200042
J	SHENG, ZQ; CHARBONNEAU, H				SHENG, ZQ; CHARBONNEAU, H			THE BACULOVIRUS AUTOGRAPHA-CALIFORNICA ENCODES A PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; NUCLEOTIDE-SEQUENCE; FAMILY; PURIFICATION; CD45; CLEAVAGE; MEMBER; REGION	The genome of the baculovirus Autographa californica encodes a 19-kDa protein (BVP) containing an active site sequence motif ((I/V)HCXAGXXR(S/T)G) that characterizes a large family of protein tyrosine phosphatases (PTPs). The baculoviral protein was expressed in Escherichia coli and purified so that its enzymatic properties could be examined. We have demonstrated that recombinant BVP has intrinsic protein tyrosine phosphatase activity. Like VH1, a PTP encoded by vaccinia virus, BVP also dephosphorylates seryl or threonyl residues. However, the similarity of BVP to VH1 or the catalytic domains from PTPs of eukaryotic origin is restricted to a small region surrounding the active site motif. In contrast, the similarity of BVP to two putative PTPs encoded by the CDC14 gene of Saccharomyces cerevisiae and a gene of unknown function from Caenorhabditis elegans extends throughout its sequence. We postulate that BVP and its two homologs constitute a unique subfamily that may differ from other PTPs in having a specialized function, mode of regulation, or substrate preference.	PURDUE UNIV, DEPT BIOCHEM 1153, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27713] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beavo J A, 1974, Methods Enzymol, V38, P299; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKHOLZ RG, 1991, YEAST, V7, P913, DOI 10.1002/yea.320070903; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POSSEE RD, 1991, VIROLOGY, V185, P229, DOI 10.1016/0042-6822(91)90770-C; POT DA, 1992, J BIOL CHEM, V267, P140; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TILAKARATNE N, 1991, J GEN VIROL, V72, P285, DOI 10.1099/0022-1317-72-2-285; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; WAN J, 1992, J BIOL CHEM, V267, P11274; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	42	65	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4728	4733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444848				2022-12-25	WOS:A1993KP88400029
J	HACKENG, TM; HESSING, M; VANTVEER, C; MEIJERHUIZINGA, F; MEIJERS, JCM; DEGROOT, PG; VANMOURIK, JA; BOUMA, BN				HACKENG, TM; HESSING, M; VANTVEER, C; MEIJERHUIZINGA, F; MEIJERS, JCM; DEGROOT, PG; VANMOURIK, JA; BOUMA, BN			PROTEIN-S BINDING TO HUMAN ENDOTHELIAL-CELLS IS REQUIRED FOR EXPRESSION OF COFACTOR ACTIVITY FOR ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN C4B-BINDING PROTEIN; FACTOR-VA INACTIVATION; HUMAN FACTOR-VIII; BLOOD-COAGULATION; FACTOR-XA; BETA-HYDROXYASPARAGINE; MONOCLONAL-ANTIBODIES; PROTEOLYTIC FORMATION; THROMBOTIC DISEASE	An important feedback mechanism in blood coagulation is supplied by the protein C/protein S anticoagulant pathway. In this study we demonstrate that the binding of human protein S to cultured human umbilical vein endothelial cells (HUVECs) is required for the expression of cofactor activity of protein S toward factor Va inactivation by activated protein C (APC). The initial rate of endothelial cell-mediated factor Va inactivation was 21.7 pM factor Va/50 pM APC min-1, which could be enhanced twice at a protein S concentration of 5 nM. This increase appeared to be specific for protein S because it could be inhibited by C4b-binding protein and polyclonal antibodies against protein S. Furthermore, thrombin-cleaved protein S did not accelerate factor Va inactivation by APC on endothelial cells. The binding of I-125-protein S to endothelial cells was time-dependent, specific, saturable, and required the presence of calcium ions. Scatchard analysis revealed (8.0 +/- 0.3) x 10(5) binding sites per cell with an apparent K(d) of 24.4 +/- 2.2 nM. To study the physiological importance of the binding of protein S to human endothelial cells, seven monoclonal antibodies were examined for their ability to influence the protein S cofactor activity and binding capacity. Monoclonal antibodies directed against the gamma-carboxyglutamic acid domain and the thrombin-sensitive region of protein S completely inhibited the protein S cofactor function in factor Va inactivation by APC on HUVECs. These monoclonal antibodies also inhibited I-125-protein S binding to HUVECs. Another monoclonal antibody, directed against an epitope on the third and/or fourth epidermal growth factor-like region, did not influence either protein S cofactor activity or binding of protein S to HUVECs. We conclude that binding of protein S to HUVECs is essential for the expression of its cofactor activity for APC. At least two regions in protein S, the gamma-carboxyglutamic acid domain and the thrombin-sensitive region, are involved in the expression of cofactor activity.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1066 CX AMSTERDAM,NETHERLANDS		HACKENG, TM (corresponding author), UNIV HOSP UTRECHT,DEPT HAEMATOL G03647,POB 85500,3508 GA UTRECHT,NETHERLANDS.		Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780; Hackeng, Tilman/0000-0003-0142-0843				BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAKKER HM, 1991, THROMB HAEMOSTASIS, V65, P781; CHANG GTG, 1992, THROMB HAEMOSTASIS, V67, P526; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1986, J BIOL CHEM, V261, P5111; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAIR DS, 1986, BLOOD, V67, P1168; FULCHER CA, 1984, BLOOD, V63, P486; GARDINER JE, 1984, CIRCULATION, V70, P205; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HACKENG TM, 1991, THROMB HAEMOSTASIS, V65, P781; HARRIS KW, 1985, J BIOL CHEM, V260, P2007; HESSING M, 1990, J IMMUNOL, V144, P204; HESSING M, 1991, EUR J IMMUNOL, V21, P2077, DOI 10.1002/eji.1830210916; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; HUISVELD IA, 1987, THROMB RES, V45, P109, DOI 10.1016/0049-3848(87)90262-3; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KANE WH, 1981, J BIOL CHEM, V256, P1002; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LEATHERBARROW RJ, 1987, ENZFITTER, P13; MALM J, 1987, EUR J BIOCHEM, V165, P39, DOI 10.1111/j.1432-1033.1987.tb11191.x; MEIJERS JCM, 1987, BIOCHEMISTRY-US, V26, P5932, DOI 10.1021/bi00392a053; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MITCHELL CA, 1987, J CLIN INVEST, V79, P374, DOI 10.1172/JCI112822; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSON RM, 1991, J BIOL CHEM, V266, P20586; NELSON RM, 1992, J BIOL CHEM, V267, P8140; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NISHIOKA J, 1990, J BIOL CHEM, V265, P9072; OATES AM, 1991, BLOOD COAGUL FIBRIN, V2, P601, DOI 10.1097/00001721-199110000-00003; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1985, THROMB HAEMOSTASIS, V54, P75; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STERN D, 1986, J CELL BIOL, V102, P1971, DOI 10.1083/jcb.102.5.1971; STERN DM, 1986, J BIOL CHEM, V261, P713; SUGO T, 1986, J BIOL CHEM, V261, P5116; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; TANS G, 1989, THROMB HAEMOSTASIS, V61, P386; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1984, SEMIN THROMB HEMOST, V10, P131, DOI 10.1055/s-2007-1004415; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1988, SEMIN THROMB HEMOST, V14, P216, DOI 10.1055/s-2007-1002780; WALKER FJ, 1981, THROMB RES, V22, P321, DOI 10.1016/0049-3848(81)90125-0; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926; WILLEMS C, 1982, EXP CELL RES, V139, P191, DOI 10.1016/0014-4827(82)90332-9	68	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3993	4000						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440691				2022-12-25	WOS:A1993KN53300031
J	HALPERT, JR; HE, YA				HALPERT, JR; HE, YA			ENGINEERING OF CYTOCHROME-P450 2B1 SPECIFICITY - CONVERSION OF AN ANDROGEN 16-BETA-HYDROXYLASE TO A 15-ALPHA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-INDUCIBLE CYTOCHROME-P-450; SEX-DEPENDENT EXPRESSION; CATALYTIC ACTIVITY; RAT-LIVER; TESTOSTERONE 16-ALPHA-HYDROXYLASE; LAURATE (OMEGA-1)-HYDROXYLASE; SUBSTRATE-SPECIFICITY; SEQUENCE REQUIREMENTS; ESCHERICHIA-COLI; GENE SUBFAMILY	Six site-directed mutants of cytochrome P450 2B1 were constructed, and function was evaluated in COS cell microsomes by monitoring testosterone and androstenedione hydroxylation and inactivation by chloramphenicol. Mutants Ile-114 --> Val and Ile-114 --> Ala exhibited marked decreases in androgen 16beta-OH:16alpha-OH ratios and increases in 15alpha-OH:16-OH ratios. Since substitution of Gly-478 with Ala or Ser reduces 16beta-hydroxylation in favor of 15alpha-hydroxylation, four double mutants containing Val or Ala at position 114 and Ala or Ser at position 478 were examined. For any given residue at position 114 (Ile, Val, or Ala), the 15alpha-OH:16-OH ratio increased as residue 478 was changed from Gly to Ala to Ser, and for any residue at position 478, this ratio increased as residue 114 was changed from Ile to Val to Ala. As a consequence, the Ile-114 --> Ala, Gly-478 --> Ser mutant displayed an approximately 1000-fold higher androgen 15alpha-OH:16-OH ratio compared with the parental enzyme and functionally resembles mouse P450 2A4 much more closely than P450 2B1. All three mutants with Val at position 114 retained susceptibility to inactivation by chloramphenicol, whereas inactivation was suppressed by Ala at this position. The results suggest the feasibility of an empirical approach to P450 engineering involving the appropriate combination of residues at a few critical sites to confer new regio- and stereoselectivity with retention of overall monooxygenase activity.			HALPERT, JR (corresponding author), UNIV ARIZONA, COLL PHARM, DEPT PHARMACOL & TOXICOL, TUCSON, AZ 85721 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003619] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03619] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AOYAMA T, 1989, J BIOL CHEM, V264, P21327; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; CIACCIO PJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P284, DOI 10.1016/0003-9861(89)90279-8; COON MJ, 1992, FASEB J, V6, P669, DOI 10.1096/fasebj.6.2.1537454; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; ESTABROOK RW, 1990, BIOCHEM SOC T, V18, P34, DOI 10.1042/bst0180034; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRAVES PE, 1987, BIOCHEMISTRY-US, V26, P3887, DOI 10.1021/bi00387a022; HARADA N, 1984, J BIOL CHEM, V259, P1265; HE YA, 1992, BIOCHEMISTRY-US, V31, P9220, DOI 10.1021/bi00153a015; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KEDZIE KM, 1991, ARCH BIOCHEM BIOPHYS, V291, P176, DOI 10.1016/0003-9861(91)90121-X; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEWIS DFV, 1992, J COMPUT AID MOL DES, V6, P235, DOI 10.1007/BF00123379; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; MATSUNAGA T, 1988, J BIOL CHEM, V263, P17995; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SUWA Y, 1985, J BIOL CHEM, V260, P7980; UNO T, 1990, BIOCHEM BIOPH RES CO, V167, P498, DOI 10.1016/0006-291X(90)92051-Z; WAXMAN DJ, 1983, J BIOL CHEM, V258, P1937; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462; WOOD AW, 1983, J BIOL CHEM, V258, P8839; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	34	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4453	4457						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440727				2022-12-25	WOS:A1993KN53300092
J	LEE, JS; OHARE, T; PILCH, PF; SHOELSON, SE				LEE, JS; OHARE, T; PILCH, PF; SHOELSON, SE			INSULIN-RECEPTOR AUTOPHOSPHORYLATION OCCURS ASYMMETRICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; STRUCTURAL BASIS; LIGAND-BINDING; CYTOPLASMIC DOMAIN; HEPATOMA-CELLS; HUMAN-PLACENTA; HIGH-AFFINITY; BETA-SUBUNIT; PHOSPHORYLATION; REGION	The unoccupied insulin receptor is a structurally symmetric, disulfide-linked dimer, comprising two alphabeta halves, each with a potential insulin binding alpha subunit and a kinase active beta subunit. In the accompanying paper (Shoelson, S. E., Lee, J., Lynch, C. S., Backer, J. M., and Pilch, P. F. (1993) J. Biol. Chem. 268, 4085-4091), we described the utility of a novel insulin analogue, L-benzoylphenylalanine(B25),B29epsilon-biotin insulin (BBpa insulin)1 as a probe for receptor behavior, and we determined that binding and cross-linking of one BBpa insulin molecule could fully stimulate insulin receptor autophosphorylation. Here we use this analogue to determine the symmetry of the autophosphorylation reaction. The alphabeta half-receptor that does not covalently couple to BBpa insulin incorporates 50% more orthophosphate than the alphabeta half that becomes coupled to the insulin analogue. Phosphopeptide mapping of each receptor half shows minimal differences in the phosphorylation sites or their relative contribution to the phosphate content of each half. The kinetics of P-32 incorporation into each receptor half are essentially identical over a 10-20-min time course. Phosphopeptide mapping analysis reveals that the phosphate incorporation patterns do not change between the two alphabeta half-receptor forms (BBpa insulin-linked and unlinked, respectively) at different time points or concentrations of ATP ranging from 12 to 200 muM. Based on these and other data, we propose a model of insulin receptor activation whereby binding of one insulin molecule can trigger autophosphorylation in an asymmetric fashion.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115	Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.			Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059; Pilch, Paul/0000-0003-1997-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043123, P30DK036836, R01DK036424] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43123, DK36836, DK36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; COBB MH, 1989, J BIOL CHEM, V264, P18701; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HONNEGER AM, 1990, MOL CELL BIOL, V10, P4035; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOHANSKI RA, 1991, BIOCHEMISTRY-US, V30, P2406, DOI 10.1021/bi00223a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; MASSAGUE J, 1980, P NATL ACAD SCI USA, V76, P4918; OHARE T, 1988, BIOCHEMISTRY-US, V27, P5693, DOI 10.1021/bi00415a045; PANG DT, 1983, J BIOL CHEM, V258, P2514; PANG DT, 1984, J BIOL CHEM, V259, P8589; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; SCHENKER E, 1988, BIOCHEM BIOPH RES CO, V157, P140, DOI 10.1016/S0006-291X(88)80024-X; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	44	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4092	4098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440700				2022-12-25	WOS:A1993KN53300046
J	TURNER, JS; MORBY, AP; WHITTON, BA; GUPTA, A; ROBINSON, NJ				TURNER, JS; MORBY, AP; WHITTON, BA; GUPTA, A; ROBINSON, NJ			CONSTRUCTION OF ZN2+/CD2+ HYPERSENSITIVE CYANOBACTERIAL MUTANTS LACKING A FUNCTIONAL METALLOTHIONEIN LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROKARYOTIC METALLOTHIONEIN; PLASMID; CLONING; GENE	Eukaryotic metallothioneins (MTs) have been extensively studied, but the precise functions of most of these molecules are not yet fully understood. Prokaryotes are often more tractable for the analysis of gene function and we report here the generation of mutants of Synechococcus PCC 7942 (strain R2-PIM8) deficient in the MT locus, smt. Viability of these mutants, designated R2-PIM8(smt), reveals that prokaryotic MT performs no ''vital'' role (such as donation of metals to metallo-proteins) in Synechococcus. R2-PIM8(smt) has reduced (approximately 5-fold) tolerance to elevated Zn2+, with detectable hypersensitivity to Cd2+. Restoration of Zn2+ tolerance was used as a selectable marker to isolate recombinants derived from R2-PIM8(smt) after reintroduction of a linear DNA fragment containing an uninterrupted smt locus. These smt-complemented cells also exhibited restored Cd2+ tolerance. Hypersensitivity to Cu2+ was not detected in R2-PIM8(smt) indicating independence of Cu2+ resistance from smt mediated metal (Zn2+/Cd2+) tolerance.	UNIV DURHAM, DEPT BIOL SCI, DURHAM DH1 3LE, ENGLAND	Durham University			Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; CIFERRI O, 1989, ALGAL CYANOBACTERIAL, P239; DZELZKALNS VA, 1988, PLANT MOL BIOL PRACT, P277; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUPTA A, 1992, P ROY SOC B-BIOL SCI, V248, P273, DOI 10.1098/rspb.1992.0072; GUPTA A, 1993, IN PRESS MOL MICROBI; HUCKLE JW, 1993, IN PRESS MOL MICROBI; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; LAU RH, 1979, J BACTERIOL, V137, P648, DOI 10.1128/JB.137.1.648-652.1979; LAUDENBACH DE, 1983, MOL GEN GENET, V192, P402, DOI 10.1007/BF00392182; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; OLAFSON RW, 1980, BIOCHEM BIOPH RES CO, V95, P1495, DOI 10.1016/S0006-291X(80)80066-0; OLAFSON RW, 1988, BIOCHEM J, V251, P691, DOI 10.1042/bj2510691; OLAFSON RW, 1986, ENVIRON HEALTH PERSP, V65, P71, DOI 10.2307/3430165; ROBINSON NJ, 1990, P ROY SOC B-BIOL SCI, V242, P241, DOI 10.1098/rspb.1990.0130; ROBINSON NJ, 1988, PLANT SCI, V56, P197, DOI 10.1016/0168-9452(88)90098-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI JG, 1992, FEBS LETT, V303, P159, DOI 10.1016/0014-5793(92)80509-F; SILVER S, 1988, ANNU REV MICROBIOL, V42, P717, DOI 10.1146/annurev.mi.42.100188.003441; THIELE DJ, 1987, METALLOTHIONEIN, V2, P423; VALLEE BL, 1991, METHOD ENZYMOL, V205, P3; VANDENHONDEL CAMJJ, 1980, P NATL ACAD SCI-BIOL, V77, P1570; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VERMA SK, 1991, FEMS MICROBIOL LETT, V84, P291, DOI 10.1016/0378-1097(91)90371-G; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	28	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4494	4498						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440732				2022-12-25	WOS:A1993KN53300098
J	BARNARD, JP; REYNAFARJE, B; PEDERSEN, PL				BARNARD, JP; REYNAFARJE, B; PEDERSEN, PL			GLUCOSE CATABOLISM IN AFRICAN TRYPANOSOMES - EVIDENCE THAT THE TERMINAL STEP IS CATALYZED BY A PYRUVATE TRANSPORTER CAPABLE OF FACILITATING UPTAKE OF TOXIC ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-PHOSPHATE DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; KINETIC CHARACTERIZATION; MONOCARBOXYLATE CARRIER; GLYCOLYTIC-ENZYMES; HEPATOMA-CELLS; BRUCEI; PURIFICATION; INHIBITION; METABOLISM	The protozoan parasite Trypanosoma brucei derives its metabolic energy exclusively from a unique type of glycolysis in which pyruvate derived from glucose catabolism is released into the host bloodstream. In this study, this terminal metabolic step has been examined in detail. Pyruvate release from trypanosomal cells supplied with glucose is very rapid, proceeding with an apparent V(max) of 214 nmol x min-1 x mg-1. Counterflow experiments with [C-14]pyruvate demonstrate that this metabolic end product can be taken up by actively metabolizing cells consistent with the presence of a plasma membrane transporter. The findings that [C-14] acetate exhibits a much lower capacity for cell entry and that the structural analog alpha-cyano-3-hydroxycinnamic acid inhibits pyruvate release provide additional support for the presence of a pyruvate transporter. The substrate analog and alkylating agent 3-bromopyruvate inhibits completely both cell motility and pyruvate release. Surprisingly, however, it is a poor inhibitor of pyruvate transport per se. Rather, its preferential site of action and that of iodoacetic acid were identified by radiolabeling studies and microsequence analysis as glyceraldehyde-3-phosphate dehydrogenase. In extending these studies, 3-bromopyruvate was found to be over 20 times less effective in inhibiting glyceraldehyde-3-phosphate dehydrogenase in intact erythrocytes than in trypanosomal cells. However, in sonicated preparations from both cell types, the enzyme exhibits nearly identical sensitivities to inhibition by 3-bromopyruvate. Experiments reported here provide the first direct evidence that pyruvate release in African trypanosomes is catalyzed by a specific transport system and implicate this transporter as a vehicle for delivering toxic alkylating agents into trypanosomal cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205	Johns Hopkins University								BARNARD JP, 1988, MOL BIOCHEM PARASIT, V31, P141, DOI 10.1016/0166-6851(88)90165-X; BERGMEYER HU, 1983, METHOD ENZYMAT AN, P496; BODE J, 1975, BIOCHEMISTRY-US, V14, P1146, DOI 10.1021/bi00677a008; BODE J, 1975, BIOCHEMISTRY-US, V14, P1153, DOI 10.1021/bi00677a009; BUSH H, 1958, J PHARMACOL EXP THER, V123, P48; BUSH H, 1956, SCIENCE, V124, P981; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CAPUANO F, 1990, FEBS LETT, V261, P39, DOI 10.1016/0014-5793(90)80631-R; DECKER LA, 1977, WORTHINGTON ENZYME M, P42; DUSZENKO M, 1986, MOL BIOCHEM PARASIT, V19, P223, DOI 10.1016/0166-6851(86)90004-6; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOVING H, 1984, BIOCHEMISTRY-US, V23, P4335, DOI 10.1021/bi00314a013; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10036; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; MISSET O, 1987, EUR J BIOCHEM, V162, P501, DOI 10.1111/j.1432-1033.1987.tb10668.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NALECZ MJ, 1991, BIOCHIM BIOPHYS ACTA, V1079, P87, DOI 10.1016/0167-4838(91)90028-X; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; WIERENGA RK, 1987, EMBO J, V6, P215, DOI 10.1002/j.1460-2075.1987.tb04741.x	24	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3654	3661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429041				2022-12-25	WOS:A1993KM16100095
J	BENNETT, JS; KOLODZIEJ, MA; VILAIRE, G; PONCZ, M				BENNETT, JS; KOLODZIEJ, MA; VILAIRE, G; PONCZ, M			DETERMINANTS OF THE INTRACELLULAR FATE OF TRUNCATED FORMS OF THE PLATELET GLYCOPROTEIN-IIB AND GLYCOPROTEIN-IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; MEMBRANE-RECEPTORS; SECRETORY PROTEINS; GPIIB-IIIA; RETENTION; EXPRESSION; COMPLEX	The platelet glycoproteins GPIIb and GPIIIa are integral membrane proteins and form calcium-dependent heterodimers in the endoplasmic reticulum (ER). In the absence of heterodimer formation, GPIIb and GPIIIa are retained in the ER and degraded. To produce soluble forms of these proteins, we truncated each at a site just proximal to its transmembrane anchor and expressed the mutants in COS-I cells. We found that both truncated GPIIIa (GPIIIa(tr)) and heterodimers composed of truncated GPIIb (GPIIb(tr)) and GPIIIa(tr) were secreted by the transfected cells. However, GPIIb(tr) was retained by the cells and was immunoprecipitated as a doublet with a 115,000 molecular weight protein. Incubation of transfected cells with the calcium ionophore A23187 or the calcium chelator 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl) ester (BAPTA-AM) failed to induce appreciable GPIIb(tr) secretion, suggesting that formation of intracellular calcium complexes was not a factor in GPIIb(tr) retention. Further, immunoblotting of immunoprecipitated GPIIb(tr) and GPIIIa(tr) revealed that the chaperone binding protein (BiP) was associated with each, arguing that BiP alone was not responsible for GPIIb(tr) retention. These studies indicate that the intracellular retention of GPIIIa involves sequences located in the transmembrane or cytoplasmic domains of the molecule. GPIIb contains an additional retention signal located in the extracellular portion of the molecule whose effect is abrogated by formation of a GPIIb-IIIa heterodimer. This signal may be involved in the fate of nascent GPIIb monomers and the generation of correctly configured GPIIb-IIIa heterodimers.	CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	BENNETT, JS (corresponding author), HOSP UNIV PENN,DIV HEMATOL ONCOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008038, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08038, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KOLODZIEJ MA, 1991, J BIOL CHEM, V266, P23499; KOLODZIEJ MA, 1991, BLOOD, V78, P2344; LAM SCT, 1989, BLOOD, V73, P1513; LENNY N, 1991, J BIOL CHEM, V266, P20532; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MELNICK J R, 1991, Journal of Cell Biology, V115, p1A; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	36	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3580	3585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429034				2022-12-25	WOS:A1993KM16100085
J	LIU, K; PIERCE, GN				LIU, K; PIERCE, GN			THE EFFECTS OF LOW-DENSITY-LIPOPROTEIN ON CALCIUM TRANSIENTS IN ISOLATED RABBIT CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SARCOPLASMIC-RETICULUM; CHANNEL ANTAGONISTS; VENTRICULAR MYOCYTES; PLASMA-MEMBRANES; CHOLESTEROL; FIBROBLASTS; FLUORESCENCE; TRANSPORT; EXCHANGE	The purpose of this study was to examine the effects of low density lipoprotein (LDL) on Ca2+ transients of isolated rabbit cardiomyocytes. Incubation of cardiomyocytes with greater-than-or-equal-to 1 mg of LDL cholesterol/ml of perfusion medium induced a slow (greater-than-or-equal-to 30 min) but significant increase (2-fold) in the cellular Ca2+ transient. The time course for the effect was similar to that observed for the accumulation of cholesterol in the cells. Using Dil- labeled LDL as a fluorescent marker for LDL interaction with the cardiomyocytes, it was concluded that LDL interacted via a receptor-mediated event, but probably this was not the primary mechanism whereby the lipid entered the cell. LDL-treated cells were resistant to the depressant actions for ryanodine, nicardipine, and dichlorobenzamil on the cellular Ca2+ transient. Lowering the extracellular Ca2+ concentration removed the stimulatory effect of LDL on the Ca2+ transient. It is concluded that LDL can induce an increase in the magnitude of the Ca2+ transient in isolated cardiomyocytes. This is a relatively slow process. The mechanism appears to involve a stimulation of a trans-sarcolemmal Ca2+ transport pathway. These findings have important implications for cardiac contractile function in hypercholesterolemic and drug-treated hypercholesterolemic subjects.	UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R2H 2A6,MB,CANADA	University of Manitoba	LIU, K (corresponding author), UNIV MANITOBA,ST BONIFACE GEN HOSP RES CTR,DIV CARDIOVASC SCI,ION TRANSPORT LAB,WINNIPEG R2H 2A6,MB,CANADA.			Pierce, Grant/0000-0001-7674-0142				ALIVISATOS SGA, 1981, BIOCHIM BIOPHYS ACTA, V643, P650, DOI 10.1016/0005-2736(81)90361-8; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BERG KA, 1986, BIOCHIM BIOPHYS ACTA, V887, P304, DOI 10.1016/0167-4889(86)90158-8; BIALECKI RA, 1989, AM J PHYSIOL, V257, pC306, DOI 10.1152/ajpcell.1989.257.2.C306; BIELEFELD DR, 1986, CIRC RES, V59, P381, DOI 10.1161/01.RES.59.4.381; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BURTON KP, 1990, J MOL CELL CARDIOL, V22, P1035, DOI 10.1016/0022-2828(90)91043-7; CHEUNG JY, 1989, AM J PHYSIOL, V256, pC1120, DOI 10.1152/ajpcell.1989.256.6.C1120; DIETSCHY JM, 1985, BIOCHEM SOC T, V11, P639; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GRUNDY SM, 1990, CHOLESTEROL ATHERSCL; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERBETTE LG, 1989, J MOL CELL CARDIOL, V21, P187, DOI 10.1016/0022-2828(89)90861-4; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; JULIEN P, 1981, CIRC RES, V49, P248, DOI 10.1161/01.RES.49.1.248; KUTRYK MJB, 1991, CORONARY ARTERY DIS, V2, P1093; KUTRYK MJB, 1988, J BIOL CHEM, V263, P13167; LANGER GA, 1987, AM J PHYSIOL, V252, pH214; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LINGREN FT, 1975, ANAL LIPIDS LIPOPROT, P204; LIU K, 1991, MOL CELL BIOCHEM, V108, P39; LIU KZ, 1992, AM HEART J, V123, P285, DOI 10.1016/0002-8703(92)90636-A; LOCKER R, 1984, BIOCHEM BIOPH RES CO, V124, P822; MADDEN TD, 1979, NATURE, V279, P538, DOI 10.1038/279538a0; MASON RP, 1992, MOL PHARMACOL, V41, P315; MOORE S, 1973, LAB INVEST, V29, P478; NEMECZ G, 1988, BIOCHEMISTRY-US, V27, P7740, DOI 10.1021/bi00420a024; PETERSON DW, 1980, AM J PHYSIOL, V239, pH674, DOI 10.1152/ajpheart.1980.239.5.H674; PETERSON DW, 1979, CIRC RES, V45, P338, DOI 10.1161/01.RES.45.3.338; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; RAZSZETTI R, 1984, PHARMACOL RES COMMUN, V16, P795; REYNOLDS GD, 1985, AM J PATHOL, V121, P200; RUTLEDGE JC, 1990, CIRC RES, V66, P486, DOI 10.1161/01.RES.66.2.486; SALE FO, 1984, ANAL BIOCHEM, V142, P347, DOI 10.1016/0003-2697(84)90475-5; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SENGES J, 1981, J MOL CELL CARDIOL, V13, P253, DOI 10.1016/0022-2828(81)90314-X; TILTON RG, 1987, CIRC RES, V60, P351; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; WHITE E, 1990, BRIT J PHARMACOL, V101, P399, DOI 10.1111/j.1476-5381.1990.tb12721.x; WIMSATT DK, 1990, J BIOL CHEM, V265, P14849; WOOD WG, 1990, BIOCHIM BIOPHYS ACTA, V1025, P243, DOI 10.1016/0005-2736(90)90103-U; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614; YOKOYAMA M, 1979, CIRC RES, V45, P496	46	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3767	3775						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429051				2022-12-25	WOS:A1993KM16100112
J	PODSCHUN, B; JAHNKE, K; SCHNACKERZ, KD; COOK, PF				PODSCHUN, B; JAHNKE, K; SCHNACKERZ, KD; COOK, PF			ACID-BASE CATALYTIC MECHANISM OF THE DIHYDROPYRIMIDINE DEHYDROGENASE FROM PH STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME MECHANISMS; PIG-LIVER; PURIFICATION	Primary deuterium (NADPH(D)), solvent deuterium, and multiple isotope effects and the pH dependence of kinetic parameters have been used to probe the mechanism of the dihydropyrimidine dehydrogenase from pig liver. Isotope effect and pH-rate data suggest a rate-determining reductive half-reaction in which reduction of the flavin by NADPH has only a minor rate limitation ((D)V is similar to D(V/K(NADPH)) approximately 1.1), while protonation of the flavin at N-1 occurring in a step following reduction is slow ((D2O)V = 3, while D2O(V/K(NADPH)) = 2). An enzymatic general acid with a pK of 8.2 is required to protonate N-1 of the flavin. In the second half-reaction, uracil is reduced at C-6 by flavin and protonated on the opposite face at C-5 by an enzymatic general acid with a pK of 9. The hydride transfer from N-5 of the flavin to C-5 of uracil is facilitated by an enzymatic general base with a pK of 5.6 that accepts a proton from N-1 of the flavin. There is also evidence from the pH dependence of V and the V/K for reduced dinucleotide substrates that a second enzyme residue with a pK of 6.4 must be unprotonated for optimum activity, but is not essential for activity. None of the functional groups reflected in the V/K(NADPH) pH-rate profile have a role in binding, while both of those observed in the V/K(uracil) profile have a role in binding as shown by the pH dependence of the dissociation constants for the competitive inhibitors ATP-ribose and 2,6-dihydroxypyridine.	TEXAS COLL OSTEOPATH MED,DEPT MICROBIOL & IMMUNOL,3500 CAMP BOWIE BLVD,FT WORTH,TX 76107; UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST BIOWISSENSCH,W-8700 WURZBURG,GERMANY	University of North Texas System; University of North Texas Health Science Center; University of Wurzburg					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036799] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36799] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W. W., 1991, ENZYME MECH ISOTOPE, P247; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1991, ENZYME MECHANISM ISO, P231; GANI D, 1985, J CHEM SOC P1, V1, P1355; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HINES V, 1989, BIOCHEMISTRY-US, V28, P1227, DOI 10.1021/bi00429a041; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; PETERS GJ, 1989, INT C S SERIES, V158, P21; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PODSCHUN B, 1992, BIOCHEM BIOPH RES CO, V182, P609, DOI 10.1016/0006-291X(92)91776-M; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; RUSTUM YM, 1989, INT C S SER, V158, P11; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WOODCOCK TM, 1980, CANCER-AM CANCER SOC, V45, P1135, DOI 10.1002/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q	18	24	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3407	3413						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429016				2022-12-25	WOS:A1993KM16100061
J	NORTHROP, JP; ULLMAN, KS; CRABTREE, GR				NORTHROP, JP; ULLMAN, KS; CRABTREE, GR			CHARACTERIZATION OF THE NUCLEAR AND CYTOPLASMIC COMPONENTS OF THE LYMPHOID-SPECIFIC NUCLEAR FACTOR OF ACTIVATED T-CELLS (NF-AT) COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; TRANSCRIPTION FACTOR-AP-1; PROTEIN COMPLEXES; ANTIGEN RECEPTOR; CYCLOSPORINE-A; LEUCINE ZIPPER; GROWTH-FACTORS; FOS; GENE; AP-1	The lymphoid-specific transcription complex, NF-AT, is involved in early gene activation in T cells and is assembled from a pre-existing, T cell restricted cytoplasmic factor and an inducible ubiquitous nuclear component within 30 min after activation through the antigen receptor. Recent studies have implicated the family of AP1 factors as components of the murine NF-AT complex. Evidence is provided here that the nuclear component of human NF-AT contains the phorbol ester-inducible transcription factor AP1 (Jun/Fos). We further characterize which AP1 family members can assume this role. Antisera to Fos inhibits NF-AT DNA binding as does an oligonucleotide containing a binding site for AP1. Constitutive expression in vivo of Fos, and to a lesser extent Fra-1, eliminates the requirement for phorbol 12-myristate 13-acetate (PMA) stimulation, leaving NF-AT-directed transcription responsive to calcium ionophore alone. Overexpression of cJun or JunD, but not JunB, also eliminates the requirement for PMA, indicating that many but not all Jun- and Fos-related proteins functionally activate NF-AT-dependent transcription in the presence of the cytoplasmic component. NF-AT DNA binding can be reconstituted in vitro using semi-purified AP1 proteins mixed with cytosol from T lymphocytes. Fos proteins are not needed for this reconstitution, and although JunB is not functional, it can participate in the NF-AT DNA binding complex. Finally, we have partially purified the cytoplasmic component of NF-AT and show by elution and renaturation from SDS-polyacrylamide gel electrophoresis gels that it has a molecular mass between 94 and 116 kDa and may have multiple differentially modified forms.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University				Ullman, Katharine/0000-0003-3693-2830	NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER; NCI NIH HHS [CA39612] Funding Source: Medline; NHLBI NIH HHS [HL33942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	38	352	364	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2917	2923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428966				2022-12-25	WOS:A1993KK81500097
J	POGULIS, RJ; FREYTAG, SO				POGULIS, RJ; FREYTAG, SO			CONTRIBUTION OF SPECIFIC CIS-ACTING ELEMENTS TO ACTIVITY OF THE MOUSE PRO-ALPHA-2(I) COLLAGEN ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; GENE-EXPRESSION; 1ST INTRON; SYNERGISTIC ACTIVATION; REGULATORY ELEMENTS; FACTORS INTERACT; TRANSGENIC MICE; DNA-SEQUENCES; II GENE; PROMOTER	Intronic transcriptional regulatory regions are found in several collagen genes. We demonstrate here the importance of two distinct cis-acting elements for the activity of a transcriptional enhancer located in the first intron of the mouse pro-alpha2(I) collagen gene. Enhancer subfragments were tested for their ability to stimulate a linked promoter following transient transfection into NIH/3T3 fibroblasts. A 92-base pair subfragment retained significant enhancer activity. DNase I footprinting identified a binding site for a nuclear factor (designated CIBF-I) within this subfragment. Electrophoretic mobility-shift experiments demonstrated that an oligonucleotide containing 18 base pairs from the protected region was sufficient for specific binding of CIBF-I and suggested that CIBF-I may be related to a protein(s) that binds to the rat c-mos enhancer. A second cis-acting element, identified by electrophoretic mobility-shift and methylation interference experiments, bound affinity-purified Sp1 and an Sp1-like protein present in crude nuclear extracts. Small deletion mutations in either the CIBF-I or Sp1 site abolished factor binding in vitro and reduced enhancer activity in vivo. Our results represent the first identification of specific cis-acting elements required for full activity of the pro-alpha2(I) collagen enhancer.	HENRY FORD HOSP,MOLEC BIOL RES PROGRAM,EDUC & RES BLDG,RM 7041,2799 W GRAND BLVD,DETROIT,MI 48202; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan								ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BOAST S, 1990, J BIOL CHEM, V265, P13351; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DECROMBRUGGHE B, 1991, ANN RHEUM DIS, V50, P872, DOI 10.1136/ard.50.Suppl_4.872; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN RH, 1991, AM J PHYSIOL, V261, pL29, DOI 10.1152/ajplung.1991.261.2.L29; HERRMANN K, 1991, J INVEST DERMATOL, V97, P219, DOI 10.1111/1523-1747.ep12480157; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KINDY MS, 1988, J BIOL CHEM, V263, P11426; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NAKSHATRI H, 1990, VIROLOGY, V178, P92, DOI 10.1016/0042-6822(90)90382-2; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PHAN SH, 1989, LUNG CELL BIOL, P907; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHERWOOD AL, 1990, BIOCHEM J, V265, P895, DOI 10.1042/bj2650895; VAAGE J, 1990, J LEUKOCYTE BIOL, V48, P274, DOI 10.1002/jlb.48.3.274; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUUST J, 1985, EUR J BIOCHEM, V151, P449, DOI 10.1111/j.1432-1033.1985.tb09122.x; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZIYADEH FN, 1990, AM J PHYSIOL, V259, pF704, DOI 10.1152/ajprenal.1990.259.4.F704	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2493	2499						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428926				2022-12-25	WOS:A1993KK81500039
J	STEINRAUF, LK; HAMILTON, JA; BRADEN, BC; MURRELL, JR; BENSON, MD				STEINRAUF, LK; HAMILTON, JA; BRADEN, BC; MURRELL, JR; BENSON, MD			X-RAY CRYSTAL-STRUCTURE OF THE ALA-109-]THR VARIANT OF HUMAN TRANSTHYRETIN WHICH PRODUCES EUTHYROID HYPERTHYROXINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; HUMAN-SERUM PREALBUMIN; THYROXINE-BINDING; HUMAN-PLASMA; PRE-ALBUMIN; MACROMOLECULAR STRUCTURES; LIGAND-BINDING; DYNAMICS; RESOLUTION; REFINEMENT	The structure of the Ala-109 --> Thr mutation of human transthyretin, a nonamyloidogenic variant with enhanced thyroxine binding, has been determined by x-ray diffraction to a resolution of 1.7 angstrom. The model, including 175 solvent water molecules, has been refined by constrained least squares to an R-value of 0.157. The standard deviations for protein geometry are 0.016 angstrom for bond distances, 0.5-degrees for bond angles, 0.031 angstrom for 1-4 distances, and 0.005 angstrom for deviations of planar groups from their least squares plane. The estimated error in protein atomic coordinates is 0.12 angstrom. Residue 109 extends inward between the two beta sheets which form the major component of the monomer, as does the side chain of residue 30 in the amyloidogenic Met-30 variant. Comparison of the Thr-109 structure with that of the normal shows that the extra atoms of the threonine fit into empty space between sheets and make no extensive changes to the molecular conformation. The substitution at 109 causes small local changes in the secondary structure of the A, G, and H strands resulting in a shift of residues 15-17, 108-110, and 117 in each monomer. The thyroxine-binding sites of the Thr-109 and Met-30 variants and of the normal protein are compared, and the results suggest that the variation in affinity for thyroxine between the three proteins may arise from differences in the size of the binding pocket.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	STEINRAUF, LK (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034881, R01DK042111] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00750] Funding Source: Medline; NIDDK NIH HHS [NIDDK-42111, NIDDK-34881] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1991, ARQ MED, V3, P41; BLANEY JM, 1982, J MED CHEM, V25, P785, DOI 10.1021/jm00349a004; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHENG SY, 1977, BIOCHEMISTRY-US, V16, P3707, DOI 10.1021/bi00635a031; CODY V, 1974, J AM CHEM SOC, V96, P6720, DOI 10.1021/ja00828a030; Cody V, 1978, Recent Prog Horm Res, V34, P437; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRUICKSHANK DWJ, 1949, ACTA CRYSTALLOGR, V2, P65, DOI 10.1107/S0365110X49000175; DAMAS AM, 1989, 1ST INT S FAM AM POL, P33; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; FEX G, 1984, EUR J CLIN INVEST, V14, P146, DOI 10.1111/j.1365-2362.1984.tb02104.x; FRAUENFELDER H, 1973, 5TH MOSSB EFF P INT, P401; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HELLER J, 1973, J BIOL CHEM, V248, P6308; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MOSES AC, 1990, J CLIN INVEST, V86, P2025, DOI 10.1172/JCI114938; MURRAYRUST P, 1979, J AM CHEM SOC, V101, P4373; MURRELL JR, 1992, J BIOL CHEM, V267, P16595; PETERSON PA, 1971, J BIOL CHEM, V246, P44; RAZ A, 1970, J BIOL CHEM, V245, P1903; REFETOFF S, 1986, J CLIN ENDOCR METAB, V63, P1432, DOI 10.1210/jcem-63-6-1432; ROBBINS J, 1960, PHYSIOL REV, V40, P415, DOI 10.1152/physrev.1960.40.3.415; Robbins J, 1978, Recent Prog Horm Res, V34, P477; SCHONER BE, 1984, P NATL ACAD SCI-BIOL, V81, P5403, DOI 10.1073/pnas.81.17.5403; STEINRAUF LK, 1991, BIOCHEM BIOPH RES CO, V179, P804, DOI 10.1016/0006-291X(91)91888-J; TRAGARDH L, 1980, J BIOL CHEM, V255, P9243	38	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2425	2430						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428916				2022-12-25	WOS:A1993KK81500029
J	HIROSE, K; LONGO, DL; OPPENHEIM, JJ; MATSUSHIMA, K				HIROSE, K; LONGO, DL; OPPENHEIM, JJ; MATSUSHIMA, K			OVEREXPRESSION OF MITOCHONDRIAL MANGANESE SUPEROXIDE-DISMUTASE PROMOTES THE SURVIVAL OF TUMOR-CELLS EXPOSED TO INTERLEUKIN-1, TUMOR-NECROSIS-FACTOR, SELECTED ANTICANCER DRUGS, AND IONIZING-RADIATION	FASEB JOURNAL			English	Note						MNSOD; IL-1; TNF; ANTICANCER DRUGS; IONIZING RADIATION	S-TRANSFERASE-PI; RADICAL FORMATION; GLUTATHIONE-PEROXIDASE; NADH DEHYDROGENASE; EXPRESSION VECTOR; OXIDATIVE DAMAGE; CYTO-TOXICITY; RESISTANCE; PARAQUAT; DNA	Interleukin-1 (IL-1) and tumor necrosis factor (TNF) selectively induce mitochondrial manganese superoxide dismutase (MnSOD) production in various cell types. We have evaluated the capacity of tumor cells that overexpress MnSOD to recover from the cytostatic and cytotoxic effects of cytokines (IL-1 and TNF), chemotherapeutic agents, and ionizing irradiation. Clones of human melanoma cell line, A375, which overexpressed MnSOD after sense MnSOD cDNA transfection, showed increased recovery from treatment with cytostatic and cytotoxic doses of IL-1alpha and TNFalpha, whereas clones of A375 cells that were transfected with anti-sense MnSOD cDNA recovered less well than normal cells from IL-1alpha and TNFalpha. In addition, Chinese hamster ovary (CHO) cells transfected with sense MnSOD cDNA showed increased survival after treatment with doxorubicin, mitomycin C, and gamma (gamma) radiation in vitro. It is hypothesized that mitochondrial MnSOD, by scavenging oxygen radicals induced by cytokines, some cytotoxic drugs, and ionizing radiation, is protective and promotes the survival of cells from the lethal effects of these treatments.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Longo, Dan L./F-6022-2011					ADOLPHUS PGM, 1986, P NATL ACAD SCI USA, V83, P3820; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHABNER BA, 1982, CANCER PRINCIPLES PR, V1, P287; Crapo J D, 1978, Methods Enzymol, V53, P382; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DAVIES KJA, 1983, FEBS LETT, V153, P227, DOI 10.1016/0014-5793(83)80153-7; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Doroshow J., 1982, PATHOLOGY OXYGEN, P245; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ENDO Y, 1988, J IMMUNOL, V141, P2342; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; KAKO KJ, 1987, J MOL CELL CARDIOL, V19, P209, DOI 10.1016/S0022-2828(87)80563-1; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KRALL J, 1988, J BIOL CHEM, V263, P1910; MANIATIS T, 1982, MOL CLONING LABORATO, P309; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; McCord J. M, 1979, REV BIOCHEM TOXICOL, V1, P109; McCord JM, 1977, SUPEROXIDE SUPEROXID, P129; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; NETA R, 1986, J IMMUNOL, V136, P2483; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SCHNEIDER WC, 1948, J BIOL CHEM, V176, P259; SCHURIG JE, 1986, CANCER CHEMOTH PHARM, V16, P243, DOI 10.1007/BF00293985; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SINHA BK, 1989, CANCER RES, V49, P3844; WESLEY MB, 1979, P NATL ACAD SCI USA, V76, P1967; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	46	329	341	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					361	368		10.1096/fasebj.7.2.8440412	http://dx.doi.org/10.1096/fasebj.7.2.8440412			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440412				2022-12-25	WOS:A1993KN88500011
J	VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP				VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP			ITERNATIVE MESSENGER-RNA FORMS AND OPEN READING FRAMES OF THE MAX GENE	ONCOGENE			English	Note							DNA-BINDING; MYC	The max gene encodes a heterodimeric partner of Myc. We have recently identified an alternative max mRNA (DELTAmax) that contains an additional internal exon introducing an in-frame translational termination. Here we have studied the expression of human max mRNAs by Northern blotting analysis. In addition to the major 2.3-kb mRNA form, four bands were identified. Our results indicate that these bands represent differentially spliced mRNA forms, which contain altogether three open reading frames. In addition to the previously identified Max and DELTAMax proteins, sequence analysis of a 3.5-kb mRNA form predicted a protein that resembles DELTAMax in structure. Like DELTAMax, this protein enhanced the number of transformed foci in the ras-myc co-transformation assay. Although the 3.5-kb mRNA represents a minor form in actively proliferating cells, a shift from the major 2.3-kb mRNA to the 3.5-kb form was observed in response to high cell densitiy or acidification of the growth medium. Our results indicate the presence of several differentially spliced mRNA forms of the max gene, and suggest a possible mechanism for the production of functionally distinct Max proteins.	UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, CENT HOSP, TRANSPLANTAT LAB, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	VASTRIK, I (corresponding author), UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.		Vastrik, Imre/C-2690-2009; makela, tomi/B-3734-2009; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; 				BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SPENCER CA, 1991, ADV CANCER RES, V56, P1; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111	13	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					503	507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426752				2022-12-25	WOS:A1993KN00600031
J	BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ				BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ			SUPPRESSION OF ONCOGENE-INDUCED TRANSFORMATION BY A DELETION MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; RAT EMBRYO CELLS; LEUCINE ZIPPER; HETERODIMER FORMATION; ENHANCER ELEMENTS; PROTO-ONCOGENE; V-JUN; FOS; ACTIVATION	Jun and Fos proteins are DNA-binding proteins that are involved in the control of gene expression through transcriptional regulation. We have made a deletion mutant of the c-jun gene that lacks amino acids 3-122 of c-jun, and thus is missing the major transactivation domain of c-jun, but retains the DNA-binding and leucine zipper domains. Unlike c-Jun, the mutant protein is unable to stimulate the transcription of an AP-1 responsive gene, and unlike c-jun this mutant gene is unable to transform rat embryo celts in cooperation with an activated ras gene. However, this mutant protein blocks in vitro DNA binding of Jun-Jun homodimers and Jun-Fos heterodimers, transcriptional activation induced by c-jun or c-fos and transformation of rat embryo cells induced by an activated ras gene and a deregulated c-jun or c-fos gene. In addition, transformation of rat embryo cells induced by an activated ras gene in the presence of the tumor promoter 12-0-tetradecanoyl phorbol 13-acetate (TPA) or by ras plus SV40 large T antigen is also inhibited by this dominant-negative mutant, suggesting that a member of the jun or fos family is involved in the pathways leading to transformation in these systems as well. The possible molecular mechanisms by which this dominant-negative mutant of c-jun blocks the functions of wild-type jun and fos family members are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, 5516 NICHOLSON LANE,ROOM 100, KENSINGTON, MD 20895 USA; UNIV HLTH SCI, UNIFORMED SERV, BETHESDA, MD 20814 USA; HOWARD HUGHES MED INST, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute				Alani, Rhoda/0000-0003-2741-2665; Szabo, Eva/0000-0003-3891-0942; Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOSAKA AH, 1991, ONCOGENE, V6, P371; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIRAI SI, 1990, ONCOGENE, V5, P39; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MULLER R, 1987, ONCOGENE RES, V2, P19; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMBROOK J, 1987, MOL CLONING LABORATO, P1666; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	250	254	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					877	886						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455942				2022-12-25	WOS:A1993KT22000008
J	ARVINTE, T; CUDD, A; DRAKE, AF				ARVINTE, T; CUDD, A; DRAKE, AF			THE STRUCTURE AND MECHANISM OF FORMATION OF HUMAN CALCITONIN FIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; MEDULLARY CARCINOMA; SECONDARY STRUCTURE; AMYLOID FIBRILS; AMIDE-I; PROTEINS; DISEASE; FLUORESCEIN; NUCLEATION; GELATION	Turbidity measurements of the kinetics of human calcitonin (hCT) fibrillation showed a linear dependence of the logarithm of fibrillation time (the time the sample is not fibrillated) and the logarithm of hCT concentration. This In/In plot linearity and electron microscope observations of fibrils indicate that the fibrillation process can be explained by the double nucleation mechanism that was proposed for the gelation of sickle cell hemoglobin (Ferrone, F. A., Hofrichter, J., Sunshine, H. R., and Eaton, W. A. (1980) Biophys. J. 32, 361-380). Circular dichroism, fluorescence, and infrared spectroscopy studies of fibrils showed that hCT molecules have alpha-helical and beta-sheet secondary structure components. A model for the structure of hCT molecules in fibrils is proposed.	UNIV LONDON, BIRBECK COLL, LONDON WC1H 0AJ, ENGLAND	University of London; Birkbeck University London	ARVINTE, T (corresponding author), CIBA GEIGY PHARMACEUT CORP, WIMBLEHURST RD, HORSHAM RH12 4AB, ENGLAND.							ARVINTE T, 1993, J BIOL CHEM, V268, P6408; ARVINTE T, 1992, Patent No. 51913; ARVINTE T, 1992, Patent No. 490549; AUSTIN LA, 1981, NEW ENGL J MED, V304, P269, DOI 10.1056/NEJM198101293040505; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; BENSUSAN HB, 1958, J AM CHEM SOC, V80, P719, DOI 10.1021/ja01536a050; BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290; BUCHT E, 1991, CLIN CHIM ACTA, V195, P115, DOI 10.1016/0009-8981(91)90131-U; BUTLER M, 1986, ARCH PATHOL LAB MED, V110, P647; BYARD R W, 1990, Pediatric Pathology, V10, P581; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P455; CLARK A, 1987, LANCET, V2, P231; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; DAMMRICH J, 1984, HISTOCHEMISTRY, V81, P369, DOI 10.1007/BF00514331; DELELLIS RA, 1978, LAB INVEST, V38, P263; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; DYKES G, 1978, NATURE, V272, P506, DOI 10.1038/272506a0; EHRLICH P, 1952, J AM CHEM SOC, V74, P2258, DOI 10.1021/ja01129a028; EIDELBERG D, 1987, BRAIN, V110, P993, DOI 10.1093/brain/110.4.993; EPAND RM, 1983, BIOCHEMISTRY-US, V22, P5074, DOI 10.1021/bi00291a005; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; FERRONE FA, 1980, BIOPHYS J, V32, P361, DOI 10.1016/S0006-3495(80)84962-9; FREY TG, 1975, P NATL ACAD SCI USA, V72, P3402, DOI 10.1073/pnas.72.9.3402; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GHATAK NR, 1980, ACTA NEUROPATHOL, V52, P73, DOI 10.1007/BF00687231; GOFFIN YA, 1989, ACTA CLIN BELG, V44, P37; GOLDMAN M, 1968, FLUORESCENT ANTIBODY, P97; GUSTAVSSON A, 1991, BIOCHEM BIOPH RES CO, V175, P1159, DOI 10.1016/0006-291X(91)91687-8; HIRANO A, 1968, J NEUROPATH EXP NEUR, V27, P167, DOI 10.1097/00005072-196804000-00001; HITT AL, 1990, J BIOL CHEM, V265, P1639; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; ISHII T, 1981, ACTA NEUROPATHOL, V55, P59, DOI 10.1007/BF00691532; JAGGI MP, 1950, FED PROC, V9, P66; KUMAR MA, 1963, LANCET, V2, P480; MAIER R, 1977, ACTA ENDOCRINOL-COP, V85, P102; MOTTA A, 1989, BIOCHEMISTRY-US, V28, P7996, DOI 10.1021/bi00446a005; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P2364, DOI 10.1021/bi00223a010; MOTTE P, 1986, J IMMUNOL METHODS, V87, P223, DOI 10.1016/0022-1759(86)90535-1; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RANDALL JT, 1955, FIBROUS PROTEINS THE, P127; SAMUEL RE, 1990, NATURE, V345, P833, DOI 10.1038/345833a0; Sieber P, 1970, Helv Chim Acta, V53, P2135, DOI 10.1002/hlca.19700530826; SILVER MM, 1988, J HISTOCHEM CYTOCHEM, V36, P1031, DOI 10.1177/36.8.3392392; SIMPSON I, 1978, ANAL BIOCHEM, V89, P304, DOI 10.1016/0003-2697(78)90755-8; SLETTEN K, 1976, J EXP MED, V143, P993, DOI 10.1084/jem.143.4.993; STAUB A., 1955, JOUR BIOL CHEM, V214, P619; Waugh DF, 1944, J AM CHEM SOC, V66, P663, DOI 10.1021/ja01232a516; WAUGH DF, 1953, J AM CHEM SOC, V75, P2592, DOI 10.1021/ja01107a013; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WIMALAWANSA SJ, 1990, MOL CELL ENDOCRINOL, V71, P13, DOI 10.1016/0303-7207(90)90069-K; WOLOSZCZUK W, 1986, J CLIN CHEM CLIN BIO, V24, P451	55	163	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6415	6422						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454614				2022-12-25	WOS:A1993KT36800051
J	ZELDIN, DC; KOBAYASHI, J; FALCK, JR; WINDER, BS; HAMMOCK, BD; SNAPPER, JR; CAPDEVILA, JH				ZELDIN, DC; KOBAYASHI, J; FALCK, JR; WINDER, BS; HAMMOCK, BD; SNAPPER, JR; CAPDEVILA, JH			REGIOFACIAL AND ENANTIOFACIAL SELECTIVITY OF EPOXYEICOSATRIENOIC ACID HYDRATION BY CYTOSOLIC EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MOUSE-LIVER; AFFINITY PURIFICATION; CATALYZED-HYDROLYSIS; RENAL CORTEX; CYTOCHROME-P-450; METABOLISM; EPOXYGENASE; HYDRASE; RABBIT	The hydration of cis-epoxyeicosatrienoic acids to the corresponding vic-dihydroxyeicosatrienoic acids by cytosolic epoxide hydrolase demonstrates moderate regioselectivity with rates of hydration highest for the 14,15-epoxide and lower for the 11,12- and 8,9-epoxide (4.5, 1.6, and 1.5 mumol of product/mg of protein/min, respectively). Incubations of the 8,9- and 14,15-epoxides with cytosolic epoxide hydrolase show stereoselective formation of diols (7:3 and 4:1 ratio of antipodes, respectively) and concomitant chiral enrichment of the remaining unmetabolized substrate. In contrast, hydration of the 11,12-epoxide is nonenantioselective. The K(m) value of the enzyme for the 14(R),15(S)-epoxide is 3 muM. Incubations of the enantiomerically pure 8,9- and 14,15-epoxides with lung or liver cytosol, followed by chiral analysis of the resulting diols demonstrate selective cleavage of the oxirane ring at C-9, and C-15, respectively. On the other hand, cleavage of the 11,12- oxirane ring was less selective. The stereochemical preference of the cytosolic epoxide hydrolase, together with the known chiral composition of the endogenous arachidonate epoxide pools, suggests a functional role for this enzyme in the metabolism of these important compounds.	UNIV CALIF DAVIS, DEPT ENVIRONM TOXICOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT ENTOMOL, DAVIS, CA 95616 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University			Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Falck, John/0000-0002-9219-7845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002710, R01ES002710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27274] Funding Source: Medline; NIEHS NIH HHS [ES02710] Funding Source: Medline; NIGMS NIH HHS [GM37922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; ARMSTRONG RN, 1980, J BIOL CHEM, V255, P4698; BELLUCCI G, 1981, BIOCHEM BIOPH RES CO, V102, P838, DOI 10.1016/0006-291X(81)91614-4; BELLUCCI G, 1989, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39890001170; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, ANAL BIOCHEM, V207, P236, DOI 10.1016/0003-2697(92)90006-S; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; CHACOS N, 1982, BIOCHEM BIOPH RES CO, V104, P916, DOI 10.1016/0006-291X(82)91336-5; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; DANSETTE PM, 1978, ARCH BIOCHEM BIOPHYS, V187, P290, DOI 10.1016/0003-9861(78)90037-1; DIETZE EC, 1991, BIOCHEM PHARMACOL, V42, P1163, DOI 10.1016/0006-2952(91)90250-9; DUBOIS GC, 1978, J BIOL CHEM, V253, P2932; FALCK JR, 1987, J LIPID RES, V28, P840; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; GILL SS, 1974, J AGR FOOD CHEM, V22, P386, DOI 10.1021/jf60193a058; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; HAEGGSTROM J, 1988, BIOCHIM BIOPHYS ACTA, V958, P469, DOI 10.1016/0005-2760(88)90233-0; HALARNKAR PP, 1989, ARCH BIOCHEM BIOPHYS, V272, P226, DOI 10.1016/0003-9861(89)90214-2; HAMMOCK BD, 1980, LIFE SCI, V27, P1635, DOI 10.1016/0024-3205(80)90636-0; HAMMOCK BD, 1980, MOL BASIS ENV TOXICI, P239; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HANZLIK RP, 1976, J AM CHEM SOC, V98, P1952, DOI 10.1021/ja00423a050; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1991, J BIOL CHEM, V266, P7561; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KOBAYASHI J, 1991, American Review of Respiratory Disease, V143, pA639; LU AYH, 1980, ANNU REV PHARMACOL, V20, P513, DOI 10.1146/annurev.pa.20.040180.002501; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MIKI I, 1989, J BIOL CHEM, V264, P5799; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; MUMBY SM, 1979, PESTIC BIOCHEM PHYS, V11, P275, DOI 10.1016/0048-3575(79)90067-1; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1982, J BIOL CHEM, V257, P3771; PLATT KL, 1990, ENVIRON HEALTH PERSP, V88, P37; SAYER JM, 1985, J BIOL CHEM, V260, P1630; SCHLADT L, 1988, EUR J BIOCHEM, V176, P715, DOI 10.1111/j.1432-1033.1988.tb14335.x; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; SILVA MH, 1987, COMP BIOCHEM PHYS B, V87, P95, DOI 10.1016/0305-0491(87)90475-5; WANG P, 1982, BIOCHEMISTRY-US, V21, P5769, DOI 10.1021/bi00266a007; WATABE T, 1971, BIOCHEM BIOPH RES CO, V44, P199, DOI 10.1016/S0006-291X(71)80178-X; WESTKAEMPER RB, 1981, ARCH BIOCHEM BIOPHYS, V208, P195, DOI 10.1016/0003-9861(81)90140-5; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4	58	194	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6402	6407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454612				2022-12-25	WOS:A1993KT36800049
J	SON, M; GUNDERSEN, RE; NELSON, DL				SON, M; GUNDERSEN, RE; NELSON, DL			A 2ND MEMBER OF THE NOVEL CA2+-DEPENDENT PROTEIN-KINASE FAMILY FROM PARAMECIUM-TETRAURELIA - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; REGULATORY DOMAIN; SENSITIVE METHOD; CALCIUM; CALMODULIN; ACTIVATION; BINDING; BRAIN; AUTOPHOSPHORYLATION	The ciliated protozoan Paramecium tetraurelia contains two protein kinase activities (CaPK-1 and CaPK-2) that are dependent on Ca2+ (Gundersen, R. E., and Nelson, D. L. (1987) J. Biol. Chem. 262, 4602-4609). We purified Ca2+-dependent protein kinase-1 (CaPK-1) 1,000-fold from the EGTA-extracted soluble fractions of Paramecium. The purified enzyme was a single polypeptide of 52 kDa on SDS-polyacrylamide gel electrophoresis with a native molecular mass of 60,000, suggesting that the active enzyme is a monomer. The purified kinase used casein as the best substrate in vitro, and its activity was absolutely dependent on Ca2+. The physical, catalytic and regulatory properties were clearly distinct from those of casein kinase, protein kinase C, and Ca2+/calmodulin-dependent protein kinases. CaPK-1 was half maximally activated by submicromolar (0.2 muM) free Ca2+, and the purified kinase bound Ca2+ in a blot overlay assay. CaPK-1 and the previously characterized CaPK-2 were biochemically and immunologically different enzymes sharing a similar activation mechanism. CaPK-1 and CaPK-2 appear to be members of a new family of Ca2+-dependent protein kinases. A protein immunologically related to the CaPKs was also detected in rat brain.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032514, R01GM034906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32514, GM 34906] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLERSBERG M, 1987, J NEUROCHEM, V49, P1105, DOI 10.1111/j.1471-4159.1987.tb10000.x; Adoutte A., 1988, P325; BATTEY NH, 1988, ANAL BIOCHEM, V170, P116, DOI 10.1016/0003-2697(88)90097-8; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BONINI NM, 1991, ADV SEC MESS PHOSPH, V23, P227; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT P, 1988, P NATL ACAD SCI USA, V85, P2914, DOI 10.1073/pnas.85.9.2914; BURGESSCASSLER A, 1987, BIOCHIM BIOPHYS ACTA, V913, P321, DOI 10.1016/0167-4838(87)90142-7; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; Engvall E, 1980, Methods Enzymol, V70, P419; FEIT C, 1984, HYBRIDOMA, V3, P377, DOI 10.1089/hyb.1984.3.377; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GUNDERSEN RE, 1987, J BIOL CHEM, V262, P4602; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALL FL, 1990, J BIOL CHEM, V265, P6944; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HIDAKA H, 1990, ADV SEC MESS PHOSPH, V24, P485; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KING MM, 1988, J BIOL CHEM, V263, P4754; KUO JF, 1980, P NATL ACAD SCI-BIOL, V77, P7039, DOI 10.1073/pnas.77.12.7039; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; Martell AE, 1975, CRITICAL STABILITY C, V2; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSS SE, 1990, TRENDS BIOCHEM SCI, V15, P11, DOI 10.1016/0968-0004(90)90118-U; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; NAKAOKA Y, 1985, J CELL SCI, V77, P185; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; Oi V.T., 1980, SELECTED METHODS CEL, P351; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; POLYA GM, 1987, BIOCHIM BIOPHYS ACTA, V931, P68, DOI 10.1016/0167-4889(87)90051-6; PUTNAMEVANS C, 1989, CELL MOTIL CYTOSKEL, V12, P12, DOI 10.1002/cm.970120103; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RAHMATULLAH M, 1991, BIOCHEM BIOPH RES CO, V175, P500, DOI 10.1016/0006-291X(91)91592-Z; ROBERTS DM, 1989, PLANT PHYSIOL, V91, P1613, DOI 10.1104/pp.91.4.1613; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHALLER GE, 1992, BIOCHEMISTRY-US, V31, P1721, DOI 10.1021/bi00121a020; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANWAGTENDONK WJ, 1974, PARAMECIUM CURRENT S, P339; YAMAUCHI T, 1982, BIOCHEM BIOPH RES CO, V109, P975, DOI 10.1016/0006-291X(82)92035-6	72	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5940	5948						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449957				2022-12-25	WOS:A1993KR82200087
J	WATKINS, JD; HERMANOWSKI, AL; BALCH, WE				WATKINS, JD; HERMANOWSKI, AL; BALCH, WE			OLIGOMERIZATION OF IMMUNOGLOBULIN-G HEAVY AND LIGHT-CHAINS INVITRO - A CELL-FREE ASSAY TO STUDY THE ASSEMBLY OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL VESICLES; BINDING-PROTEIN; RAT-LIVER; NUCLEAR-ENVELOPE; SUCCESSIVE COMPARTMENTS; MEMBRANE-VESICLES; DEPENDENT FUSION; PEPTIDE-BINDING; CA-2+ EFFLUX; FREE SYSTEM	A biochemical assay to study the assembly of the endoplasmic reticulum (ER) in a cell-free system is introduced. Incubation in vitro of ER vesicles containing only immunoglobulin gamma1 heavy (H) chains with ER vesicles containing only K light (L) chains results in fusion and oligomerization of the H and L chains to form the H-2L2 complex (immunoglobulin G). ER fusion/H-2L2 oligomerization is time and temperature dependent and requires energy in the form of ATP. It is stimulated by the addition of cytosol and requires protease-sensitive components present on the membranes. The addition of guanosine 5'-O-(thiotriphosphate) inhibits membrane fusion and subsequent H-2L2 oligomerization without affecting the assembly of H-2L2 from detergent-solubilized pools, suggesting an important role for GTPases in vesicle recognition or fusion. The development of a rapid and quantitative assay to study the assembly of the ER in a cell-free system will allow us to identify components involved in the recognition, fusion, and post-fusion events critical for ER function in vivo.	YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Yale University; Scripps Research Institute	WATKINS, JD (corresponding author), SCRIPPS RES INST, DEPT CELLULAR BIOL, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM 42336, GM 33301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301, R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COMERFORD JG, 1988, BIOCHEM J, V249, P89, DOI 10.1042/bj2490089; COMERFORD JG, 1989, BIOCHEM J, V258, P823, DOI 10.1042/bj2580823; COMERFORD JG, 1991, BIOCHEM J, V280, P335, DOI 10.1042/bj2800335; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LEE C, 1989, J CELL BIOL, V109, P2045, DOI 10.1083/jcb.109.5.2045; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; PAIEMENT J, 1983, J CELL BIOL, V96, P1791, DOI 10.1083/jcb.96.6.1791; PAIEMENT J, 1980, J CELL BIOL, V86, P29, DOI 10.1083/jcb.86.1.29; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHOER TA, 1991, ANNU REV PHYSIOL, V53, P629; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Yelton D E, 1978, Curr Top Microbiol Immunol, V81, P1	65	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5182	5192						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444894				2022-12-25	WOS:A1993KP88400090
J	MOSIALOS, G; GILMORE, TD				MOSIALOS, G; GILMORE, TD			V-REL AND C-REL ARE DIFFERENTIALLY AFFECTED BY MUTATIONS AT A CONSENSUS PROTEIN-KINASE RECOGNITION SEQUENCE	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE; TRANSCRIPTION; TRANSFORMATION; DORSAL; EXPRESSION; CLONING; SUBUNIT	The avian retroviral oncoprotein v-Rel and its cellular homolog c-Rel are members of a family of related site-specific DNA-binding proteins. Towards the carboxy-terminal end of the highly conserved Rel homology (RH) domain in the majority of Rel proteins, there is a consensus recognition sequence for protein kinase A (PK-A). We have investigated the importance of this sequence (Arg-Arg-Pro-Ser) for several functional properties of v-Rel and c-Rel. Disruption of the PK-A sequence by a two amino acid insertion between the arginine and the proline residues completely abolished the ability of v-Rel and c-Rel to bind a kappaB site in vitro. When the phosphorylatable serine in this sequence (Ser-275 in v-Rel, Ser-266 in c-Rel) was replaced by an alanine, DNA binding by v-Rel was not affected, whereas the ability of c-Rel to bind DNA was reduced approximately fourfold by this mutation. Similarlv, a serine to tryptophan change greatly reduced the DNA-binding ability of c-Rel, whereas v-Rel was not appreciably affected by this change. When this serine was replaced by an acidic amino acid, DNA binding by v-Rel was reduced approximately twofold and the DNA-binding activity of c-Rel was nearly abolished. Glutaraldehyde cross-linking experiments indicated that mutations at the PK-A recognition site that reduced DNA binding also negatively affected protein oligomerization, which is likely to be responsible for the reduced ability of mutant v-Rel and c-Rel proteins to bind DNA. Domain-swapping experiments showed that structural differences between v-Rel and c-Rel in the central region of the proteins are primarily responsible for the higher sensitivity of c-Rel to a serine to alanine mutation in the PK-A site. One difference between v-Rel and c-Rel, a glutamine to alanine change in v-Rel located three amino acids carboxy-terminal to the PK-A phosphorylatable serine (Ala-278 in v-Rel; Glu-269 in c-Rel), is mainly responsible for the lack of an effect on DNA binding by v-Rel when Ser-275 is replaced by alanine. That is, a v-Rel double mutant (v-275A/278E) showed reduced DNA-binding and transforming abilities as compared with v-Rel and v-275A. Similarly, the mutations in c-Rel that affected DNA binding showed a corresponding effect on the ability of c-Rel proteins to activate transcription in yeast from a reporter gene containing upstream Rel binding sites. In summary, our results indicate that the structure of the PK-A recognition sequence is important for dimerization by Rel proteins, and that there is a good correlation between transformation by v-Rel and its ability to bind to kappaB target sites in vitro. In addition, our results show that c-Rel is more sensitive to mutations in the consensus PK-A recognition sequence than v-Rel, which has acquired mutations that may allow v-Rel to bind kappaB sites in a deregulated fashion.	BOSTON UNIV, DEPT CHEM, 5 CUMMINGTON ST, BOSTON, MA 02215 USA; BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University; Boston University					NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BHAT GV, 1990, ONCOGENE, V5, P625; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	42	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					721	730						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437855				2022-12-25	WOS:A1993KN00800024
J	CHANG, JY				CHANG, JY			IDENTIFICATION OF PRODUCTIVE FOLDING INTERMEDIATES WHICH ACCOUNT FOR THE FLOW OF PROTEIN FOLDING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-A; REDUCED PROTEIN; REGENERATION	Reduced hirudin N-terminal fragment (Hir1-27, 4 cysteines) refolds to form two-disulfide structures. The isomer containing the native disulfide prevailed as the predominant product. The disulfide folding pathway was elucidated by trapping the intermediates with acid (4% trifluoroacetic acid). All six possible one-disulfide intermediates were detected to exist in equilibrium with molar ratio of approximately 1:1:1:0.4:0.4:0.18. These intermediates were purified and structurally characterized. They were also allowed to resume the folding by reconstituting into alkaline buffer in order to evaluate the productivity of individual intermediate along the pathway. These results demonstrate that the most productive intermediate that specifies the pathway flow is neither a well populated species nor the one that contains the native disulfides.			CHANG, JY (corresponding author), CIBA GEIGY AG,PHARMACEUT RES LAB,CH-4002 BASEL,SWITZERLAND.							ALTMANN KH, 1990, J AM CHEM SOC, V112, P4926, DOI 10.1021/ja00168a044; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1986, METHOD ENZYMOL, V131, P86; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DODT J, 1985, BIOL CHEM H-S, V366, P379, DOI 10.1515/bchm3.1985.366.1.379; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUYGHUESDESPOINTES BMP, 1992, BIOCHEMISTRY-US, V31, P1476, DOI 10.1021/bi00120a026; KARAS M, 1990, TRAC-TREND ANAL CHEM, V9, P321, DOI 10.1016/0165-9936(90)85065-F; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4741, DOI 10.1021/bi00262a034; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4734, DOI 10.1021/bi00262a033; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MEYHACK B, 1986, Patent No. 225633; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RAO SP, 1974, BIOCHEMISTRY-US, V13, P943, DOI 10.1021/bi00702a019; RICHARDS FM, 1991, SCI AM, P34; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697	31	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4043	4049						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440697				2022-12-25	WOS:A1993KN53300039
J	HAATAJA, S; TIKKANEN, K; LIUKKONEN, J; FRANCOISGERARD, C; FINNE, J				HAATAJA, S; TIKKANEN, K; LIUKKONEN, J; FRANCOISGERARD, C; FINNE, J			CHARACTERIZATION OF A NOVEL BACTERIAL ADHESION SPECIFICITY OF STREPTOCOCCUS-SUIS RECOGNIZING BLOOD GROUP-P RECEPTOR OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; BINDING; GLYCOSPHINGOLIPIDS; ERYTHROCYTES; ATTACHMENT; CELLS; PIGS; IDENTIFICATION; GLYCOLIPIDS; ADHERENCE	Streptococcus suis causes sepsis, meningitis, and other serious infections in piglets, and meningitis in humans. Hemagglutination inhibition experiments with mono- and oligosaccharides and glycoproteins indicated that galactose-binding strains of S. suis recognized the Galalpha1-4Gal sequence present in the P1 and P(k) blood group antigen structures. In thin-layer chromatography overlay assays the bacteria bound to trihexosylceramide (GbO3) but not to globoside (GbO4) or Forssman glycolipid (GbO5), in contrast to P-fimbriated Escherichia coli, which bound only to the latter two. The S. suis adhesin also differed from that of E. coli in that some of the hydrogen bonds formed with the receptor, as determined with chemically modified receptor analogues, were different. In agreement with the binding specificity, the S. suis bacteria agglutinated best among P blood group erythrocytes those of the P1k and P2k type, and from different animal erythrocytes those from rabbit, which express GbO3 as the predominant glycolipid. Binding to frozen sections of pig pharyngeal tissue was decreased by the free GbO3 oligosaccharide and its protein conjugate, which indicated that the corresponding glycolipid may function as receptor for galactose-binding strains of S. suis in pig pharyngeal epithelium.	UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND; STATE UNIV LIEGE,GROUPES SANGUINS & TRANSFUS LAB,B-4000 LIEGE,BELGIUM; UNIV TURKU,INST BIOMED,DEPT CHEM,SF-20520 TURKU 52,FINLAND	University of Eastern Finland; University of Liege; University of Turku	HAATAJA, S (corresponding author), UNIV TURKU,INST BIOMED,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND.		Haataja, Sauli/AAR-5103-2020; Finne, Jukka/B-6881-2008	Finne, Jukka/0000-0002-8076-3344				ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; ARENDS JP, 1988, REV INFECT DIS, V10, P131; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BHATTACHARYYA L, 1988, EUR J BIOCHEM, V176, P207, DOI 10.1111/j.1432-1033.1988.tb14270.x; BOCK K, 1985, J BIOL CHEM, V260, P8545; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; BROESEKER TA, 1988, MICROB PATHOGENESIS, V5, P19, DOI 10.1016/0882-4010(88)90077-0; CALDERWOOD SB, 1990, INFECT IMMUN, V58, P2977, DOI 10.1128/IAI.58.9.2977-2982.1990; DORKEN B, 1989, LEUKOCYTE TYPING, V4; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P95, DOI 10.1016/S0338-4535(80)80050-X; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; Gray G R, 1978, Methods Enzymol, V50, P155; HASTY DL, 1992, INFECT IMMUN, V60, P2147, DOI 10.1128/IAI.60.6.2147-2152.1992; HOLGERSSON J, 1990, J BIOCHEM-TOKYO, V108, P766, DOI 10.1093/oxfordjournals.jbchem.a123279; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LAMPIO A, 1988, GLYCOCONJUGATE J, V5, P513, DOI 10.1007/BF01049922; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LIUKKONEN J, 1992, J BIOL CHEM, V267, P21105; LUNDBLAD A, 1980, EUR J BIOCHEM, V104, P323, DOI 10.1111/j.1432-1033.1980.tb04432.x; MARCUS DM, 1971, CARBOHYD RES, V17, P269, DOI 10.1016/S0008-6215(00)82534-3; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MURRAY PA, 1982, BIOCHEM BIOPH RES CO, V106, P390, DOI 10.1016/0006-291X(82)91122-6; NOWICKI B, 1985, FEMS MICROBIOL LETT, V26, P35; PALLESEN G, 1987, J CANCER RES CLIN, V113, P78, DOI 10.1007/BF00389971; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; Pauling L., 1980, NATURE CHEM BOND, V3rd; PAULSEN H, 1988, CARBOHYD RES, V175, P163, DOI 10.1016/0008-6215(88)80168-X; PERCH B, 1983, J CLIN MICROBIOL, V17, P993, DOI 10.1128/JCM.17.6.993-996.1983; Race RR., 1975, BLOOD GROUPS MAN; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; SIHVONEN L, 1988, ACTA VET SCAND, V29, P9; STAHL E, 1962, DUNNESCHICHT CHROMAT; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; SVENSSON G, 1986, CARBOHYD RES, V146, P29, DOI 10.1016/0008-6215(86)85021-2; SWITALSKI LM, 1984, J BIOL CHEM, V259, P3734; VALENTINWEIGAND P, 1988, INFECT IMMUN, V56, P2851, DOI 10.1128/IAI.56.11.2851-2855.1988; VANDIE I, 1985, FEMS MICROBIOL LETT, V28, P329, DOI 10.1016/0378-1097(85)90105-3	45	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4311	4317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440715				2022-12-25	WOS:A1993KN53300073
J	ISHIDA, Y; HONDA, H				ISHIDA, Y; HONDA, H			INHIBITORY-ACTION OF 4-AMINOPYRIDINE ON CA2+-ATPASE OF THE MAMMALIAN SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; K+ CHANNELS; MUSCLE; CELLS; TETRAETHYLAMMONIUM; CHARYBDOTOXIN	In the isolated guinea pig diaphragm muscle, 4-aminopyridine (4-AP) elicited-a marked potentiation of twitch contraction evoked by direct electrical stimuli. Although tetraethylammonium (TEA) and charybdotoxin only slightly potentiated twitch contraction, 4-AP, but not TEA, also augmented a contractile response to caffeine. These effects of 4-AP on muscle contraction could not be interpreted by a simple inhibition of potassium channels on the plasma membrane. In the fragmented sarcoplasmic reticulum (SR) prepared from the guinea pig psoas muscle, 4-AP inhibited the ATP-driven Ca2+ uptake from the extravesicular medium. Furthermore, 4-AP at concentrations less than 10 mM elicited a selective inhibition of Ca2+-activated SR ATPase in a competitive manner against the Ca2+ concentration of the medium and 10 mM 4-AP showed the unsurmountable inhibition. 4-AP at 30 mM apparently inhibited activities of other ATPases such as Na+,K+- and myosin ATPases. In contrast, other potassium channel blockers such as TEA, apamin, charybdotoxin, and glibenclamide did not inhibit the SR function. These results suggest that, although the specific concentration range is rather small, 4-AP elicits an inhibition of SR Ca2+-pumping activity, leading to the marked potentiation of muscle contractile responses to electrical stimuli and caffeine.			ISHIDA, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN.							AUDIBERTBENOIT ML, 1975, J PHYSIOL-PARIS, V72, pA1; BOWMAN WC, 1977, J PHARM PHARMACOL, V29, P616, DOI 10.1111/j.2042-7158.1977.tb11417.x; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GLOVER WE, 1981, EUR J PHARMACOL, V71, P21, DOI 10.1016/0014-2999(81)90383-6; GLOVER WE, 1982, GEN PHARMACOL-VASC S, V13, P259, DOI 10.1016/0306-3623(82)90046-5; HARVEY AL, 1977, EUR J PHARMACOL, V44, P303, DOI 10.1016/0014-2999(77)90303-X; KAHN AR, 1979, ACTA PHYSL SCAND, V105, P443; KIM DH, 1983, J BIOL CHEM, V258, P9662; KOBAYASHI M, 1988, J PHARMACOL EXP THER, V246, P667; LAMBERT P, 1990, BIOCHEM BIOPH RES CO, V170, P684, DOI 10.1016/0006-291X(90)92145-P; LUNDH H, 1977, J NEUROL SCI, V32, P29, DOI 10.1016/0022-510X(77)90037-5; LUNDH H, 1979, J NEUROL NEUROSUR PS, V42, P171, DOI 10.1136/jnnp.42.2.171; MAETANI T, 1979, HIROSHIMA J MED SCI, V28, P43; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NAKAMURA Y, 1986, J BIOL CHEM, V261, P4139; Paskov D, 1986, HDB EXPT PHARM, V79, P679, DOI 10.1007/978-3-642-70682-0_33; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; SATO K, 1991, J BIOL CHEM, V266, P16989; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; WEBER A, 1966, BIOCHEM Z, V345, P329; WESTON AH, 1987, TRENDS PHARMACOL SCI, V8, P283, DOI 10.1016/0165-6147(87)90114-3; YAMAMOTO T, 1968, J BIOCHEM-TOKYO, V64, P137, DOI 10.1093/oxfordjournals.jbchem.a128873; YAMAMOTO T, 1982, J BIOCHEM, V91, P477, DOI 10.1093/oxfordjournals.jbchem.a133720; YANAGISAWA T, 1979, N-S ARCH PHARMACOL, V307, P207, DOI 10.1007/BF00505935	29	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4021	4024						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440694				2022-12-25	WOS:A1993KN53300035
J	SOLLITTI, P; MERKLER, DJ; ESTUPINAN, B; SCHRAMM, VL				SOLLITTI, P; MERKLER, DJ; ESTUPINAN, B; SCHRAMM, VL			YEAST AMP DEAMINASE - CATALYTIC ACTIVITY IN SCHIZOSACCHAROMYCES-POMBE AND CHROMOSOMAL LOCATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; NUCLEOSIDASE; ENZYME; DEGRADATION; SEPARATION; CLONING	The AMP deaminase gene was mapped to chromosome XIII of Saccharomyces cerevisiae strain JM1901. The AMP deaminase gene is located near SUP5, GAL80, SUF7, and SUF22. The presence of AMP deaminase in the fission yeast Schizosaccharomyces pombe was examined by comparing DNA hybridization, protein immunoreactivity, and catalytic activity from S. cerevisiae, known to contain the protein, to S. pombe. DNA hybridization experiments using the cloned S. cerevisiae AMP deaminase gene failed to hybridize to the genomic DNA from S. pombe strain 972h-s. Protein extracts from S. pombe and S. cerevisiae were analyzed in parallel and exhibited comparable AMP deaminase activities. Analysis of reaction intermediates in cell extracts of S. pombe established that IMP is formed directly from AMP without intervening steps. The AMP deaminase of S. pombe was purified 1,100-fold to a specific catalytic activity of 67 mumol/min/mg of protein. Purified protein interacted weakly with polyclonal antibodies prepared against S. cerevisiae AMP deaminase. AMP deaminases from both S. cerevisiae and S. pombe were activated by ATP with micromolar activation constants, are inhibited by coformycin, and are specific for AMP when compared to other purine nucleosides and nucleotides. The results establish that S. pombe contains an AMP deaminase with catalytic properties similar to that from S. cerevisiae, even though the DNA sequences of the genes and the immunoreactivity of the protein from S. pombe differs considerably from the AMP deaminase of S. cerevisiae. Genetic analysis of the pathways of purine metabolism in S. pombe (Pourquie, J., and Heslot, H. (1971) Genet. Res. 18, 33-44) had indicated the absence of AMP deaminase. The presence of a regulated AMP deaminase in S. pombe supports the hypothesis that eukaryotes regulate adenine nucleotide pools by the activity of AMP deaminase.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; UNIGENE LAB INC,ANALYT PROT & ORGAN CHEM GRP,FAIRFIELD,NJ 07004	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM010599, R01GM028572, R01GM021083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28572, GM 10599, GM 21083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROACH JR, 1981, MOL BIOL YEAST SACCH, P653; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHAPMAN AG, 1973, J BIOL CHEM, V248, P8309; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; FLURI R, 1985, J GEN MICROBIOL, V113, P527; FOURY F, 1975, J BIOL CHEM, V250, P2354; JONES EW, 1982, MOL BIOL YEAST SACCH, V2, P181; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEUNG HB, 1984, J BIOL CHEM, V259, P6972; LEUNG HB, 1989, BIOCHEMISTRY-US, V28, P8726, DOI 10.1021/bi00448a008; LEUNG HB, 1980, J BIOL CHEM, V255, P867; Maniatis T., 1982, MOL CLONING; MERKLER DJ, 1990, BIOCHEMISTRY-US, V29, P8358, DOI 10.1021/bi00488a023; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1987, ANAL BIOCHEM, V167, P148, DOI 10.1016/0003-2697(87)90145-X; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; POURQUIE J, 1971, GENET RES, V18, P33, DOI 10.1017/S0016672300012398; REINER P, 1991, COMPUT APPL BIOSCI, V7, P337; SABINA RL, 1989, METABOLIC BASIS INHE, V1, P1077; SCHRAMM VL, 1973, J BIOL CHEM, V248, P8313; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	26	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4549	4555						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440738				2022-12-25	WOS:A1993KN53300107
J	BALDARI, CT; HEGUY, A; TELFORD, JL				BALDARI, CT; HEGUY, A; TELFORD, JL			RAS PROTEIN-ACTIVITY IS ESSENTIAL FOR T-CELL ANTIGEN RECEPTOR SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; INTERLEUKIN-2 GENE; CYCLOSPORINE-A; CHLORAMPHENICOL ACETYLTRANSFERASE; LYMPHOCYTES-T; ONCOGENIC RAS; PHORBOL ESTER; ACTIVATION; EXPRESSION; PHOSPHORYLATION	In a Jurkat cell model of T-cell activation an interleukin-2 promoter/reporter gene construct was activated by antigen receptor agonism in combination with the lymphokine interleukin-1. Antigen receptor signals could be mimicked by suboptimal activation of protein kinase C (PKC) with phorbol esters in combination with calcium mobilization by an ionophore. In cotransfection experiments, oncogenic ras obviated the need for PKC stimulation but did not replace either the calcium signal or interleukin-1. Activated ras expression also replaced the requirement for PKC stimulation in activation of the T-cell transcription factor NF-AT. A dominant inhibitory ras mutant specifically blocked antigen receptor agonism, indicating that ras activity is required for antigen receptor signaling. In addition, an inhibitor of PKC blocked both activated ras and phorbol ester stimulation, suggesting a role for ras upstream of PKC.	IMMUNOBIOL RES INST, VIA FIORENTINA 1, I-53100 SIENA, ITALY; UNIV SIENA, DEPT EVOLUT BIOL, I-53100 SIENA, ITALY	University of Siena			Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASAGLI MC, 1989, PREP BIOCHEM, V19, P23, DOI 10.1080/10826068908544894; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	48	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2693	2698						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428943				2022-12-25	WOS:A1993KK81500065
J	LI, J; BROYLES, SS				LI, J; BROYLES, SS			RECRUITMENT OF VACCINIA VIRUS-RNA POLYMERASE TO AN EARLY GENE PROMOTER BY THE VIRAL EARLY TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; INITIATION; MECHANISM; INVITRO; EXPRESSION; COMPLEX; ATP; PURIFICATION; REPLICATION; REQUIREMENT	Transcription of vaccinia virus early genes in vitro requires the virally encoded RNA polymerase and early transcription factor, VETF. VETF is a promoter-binding protein with DNA-dependent ATPase activity. We have investigated the functional role of VETF in transcription activation by analyzing the interaction between the RNA polymerase and promoter DNA. Using a gel shift assay, a novel protein-DNA complex was detected that required both RNA polymerase and VETF. The complex was suggested to be a transcription initiation complex by its ability to incorporate P-32-labeled nucleotides in combinations compatible with synthesis of a short RNA chain. Competition binding studies indicated that the RNA polymerase associated specifically with a viral early promoter. These experiments demonstrate that VETF activates transcription by directly recruiting the RNA polymerase to the promoter. Sedimentation analysis showed that VETF and RNA polymerase did not form a stable complex unless promoter DNA was present, indicating that protein-protein contacts are not the sole basis for initiation complex assembly. DNase I cleavage and methylation interference analyses revealed a hyperreactive site in the center of the promoter. Radiolabeling of RNA in the RNA polymerase-promoter complex did not occur when AMP-PNP (adenyl-5'-yl imidodiphosphate) was substituted for ATP, suggesting that ATP hydrolysis is required for the initiation of transcription. A model is proposed to account for these findings.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; FIRE A, 1984, J BIOL CHEM, V259, P2509; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GERSHOWITZ A, 1978, VIROLOGY, V88, P149; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QUICK SD, 1990, VIROLOGY, V178, P603, DOI 10.1016/0042-6822(90)90362-U; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; VANDEUSEN J, 1989, OCCUP THER J RES, V9, P243, DOI 10.1177/153944928900900405; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	44	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2773	2780						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428951				2022-12-25	WOS:A1993KK81500077
J	TRUANT, R; XIAO, H; INGLES, CJ; GREENBLATT, J				TRUANT, R; XIAO, H; INGLES, CJ; GREENBLATT, J			DIRECT INTERACTION BETWEEN THE TRANSCRIPTIONAL ACTIVATION DOMAIN OF HUMAN P53 AND THE TATA BOX-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; CRITICAL STRUCTURAL ELEMENTS; SELECTIVE BINDING; CELLULAR P53; GENE; EXPRESSION; INVITRO; CELLS; VP16; ASSOCIATION	The human p53 tumor suppressor gene product can activate transcription by RNA polymerase II in the yeast, Saccharomyces cerevisiae, as well as in human cells. Several viral transcriptional activator proteins have been shown to directly contact TBP, the TATA box-binding subunit of the general initiation factor, TFIID. In this report, we use protein affinity chromatography to show that the cellular transcription factor, p53, interacts directly and specifically with yeast TBP. The TBP binding domain of p53 was localized to its N-terminal 73 amino acids. This highly acidic portion of p53 functions as a transcriptional activation domain and is deleted in some tumors induced by the Friend leukemia virus. A human tumor-derived oncogenic point mutation of p53, which lies outside the activation domain of p53, but reduces its ability to activate transcription, greatly reduced the ability of p53 to bind yeast TBP in vitro. This mutation probably affects the overall conformation of the protein and indirectly interferes with the ability of p53 to contact TBP and activate transcription. In contrast, a mutated oncogenic form of p53 that is unaffected in its ability to activate transcription bound yeast TBP as well as wild type p53. The human TBP activity in a HeLa extract also bound to the activation domain of p53. Our data support a general model in which DNA-bound activator proteins activate transcription by interacting with TBP.	UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CRESS A, 1991, GENE, V103, P235, DOI 10.1016/0378-1119(91)90278-J; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FIELDS S, 1990, SCIENCE, V249, P1049; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P688; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SAMBROOK J, 1989, MOL CLONING LABORATO, P60; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STEINMEYER K, 1988, ONCOGENE, V3, P501; STILLMAN B, 1986, CANCER SURV, V5, P389; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	44	227	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2284	2287						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428901				2022-12-25	WOS:A1993KK81500005
J	MACKRELL, AJ; KUSCHEGULLBERG, M; GARRISON, K; FESSLER, JH				MACKRELL, AJ; KUSCHEGULLBERG, M; GARRISON, K; FESSLER, JH			NOVEL DROSOPHILA LAMININ-A CHAIN REVEALS STRUCTURAL RELATIONSHIPS BETWEEN LAMININ SUBUNITS	FASEB JOURNAL			English	Note						DROSOPHILA; LAMININ-A CHAIN; EVOLUTION	NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; SEQUENCE; DOMAINS; SECRETION; BIOSYNTHESIS; EXPRESSION; COLLAGEN; VARIANTS; HOMOLOGY	Laminins are trimeric glycoproteins composed of A, B1, and B2 chains that play important roles in cell adhesion and dffferentiation and in the assembly of basement membranes. There is evidence that multiple independent gene products can be used to supply the A, B1, and B2-like chains, thereby generating diverse laminin molecules. The set of A chain-like polypeptides are the most divergent. The amino-terminal portion of each chain, called the short arm, is composed of alternating cysteine-rich and globular domains. The amino-terminal two-thirds of the newly characterized Drosophila laminin A chain appears to encode a novel structure, but the analysis presented here shows that substantial portions of its amino acid sequence are related to sequences found in other A, B1, and B2 chains. A portion of the Drosophila A chain is composed of sequences like those found in B2 chains. These sequences parallel a portion of the vertebrate A chains, suggesting a structure for a shared ancestral A chain. However, unlike vertebrate A chains, the Drosophila A chain also contains sequences typical of B1 chains, suggesting that its gene must have arisen by recombination of segments from different primordial laminin genes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695	NATIONAL INSTITUTE ON AGING [R01AG002128] Funding Source: NIH RePORTER; NIA NIH HHS [AG02128] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BECK K, 1991, PATTERNS PROTEIN SEQ, P231; CHI HC, 1989, J BIOL CHEM, V264, P1543; Dayhoff M. O., 1976, ATLAS PROTEIN SEQ S2, V5, P1; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; FRENETTE GP, 1988, CANCER RES, V48, P5193; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER I, 1992, J BIOL CHEM, V267, P6006; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PETERS BP, 1985, J BIOL CHEM, V260, P4732; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY J C, 1989, Journal of Cell Biology, V109, p44A; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119	37	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					375	381		10.1096/fasebj.7.2.8440414	http://dx.doi.org/10.1096/fasebj.7.2.8440414			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440414				2022-12-25	WOS:A1993KN88500013
J	ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A				ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A			CODING SEQUENCE OF THE OVEREXPRESSED TRANSCRIPT OF THE PUTATIVE ONCOGENE PRAD1/CYCLIN D1 IN 2 PRIMARY HUMAN TUMORS	ONCOGENE			English	Note							CANDIDATE ONCOGENE; CHROMOSOME 11Q13; SQUAMOUS-CELL; AMPLIFICATION; BCL-1; GENE; CARCINOMAS; EXPRESSION; CYCLINS; LOCUS	PRAD1 (cyclin Dl) is a recently identified member of the family of cyclin genes, believed to play roles in regulating transitions through the cell cycle. The PRAD1 gene, located at 11q13, has been implicated in the pathogenesis of a variety of tumors, including parathyroid adenomas, t(11;14) bearing B-lymphoid tumors (particularly centrocytic lymphomas) where it is highly likely to be the BCL1 oncogene, and possibly in breast carcinomas and squamous cell cancers of the head and neck as well. PRAD1's tumorigenic influence appears to be effected through overexpression of its normal-sized transcript, but it has not been established whether the transcript's coding sequence is normal or contains oncogenic mutations. We have sequenced the coding region of the overexpressed PRAD1 transcript from two primary tumors with clonal PRAD1 region rearrangements: a benign parathyroid adenoma and a malignant centrocytic lymphoma. Each sequence is identical to the normal PRAD1 cDNA sequence, and presumably encodes normal PRAD1 protein. Thus, PRAD1 likely functions as a direct-acting oncogene whose rearrangement in tumors leads to overexpression or deregulated expression of its normal protein product.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, WELLMAN 503, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019		NCI NIH HHS [CA55909] Funding Source: Medline; NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BERENSON JR, 1990, ONCOGENE, V5, P1343; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LISCIA DS, 1989, ONCOGENE, V4, P1219; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PROCTOR AJ, 1991, ONCOGENE, V6, P789; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sambrook J, 1989, MOL CLONING LABORATO; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; THEILLET C, 1989, ONCOGENE, V4, P915; WILLIAMS ME, 1992, IN PRESS LEUKEMIA; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	63	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					519	521						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426754				2022-12-25	WOS:A1993KN00600034
J	GARLATTI, M; TCHESNOKOV, V; DAHESHIA, M; FEILLEUXDUCHE, S; HANOUNE, J; AGGERBECK, M; BAROUKI, R				GARLATTI, M; TCHESNOKOV, V; DAHESHIA, M; FEILLEUXDUCHE, S; HANOUNE, J; AGGERBECK, M; BAROUKI, R			CCAAT ENHANCER-BINDING PROTEIN-RELATED PROTEINS BIND TO THE UNUSUAL PROMOTER OF THE ASPARTATE-AMINOTRANSFERASE HOUSEKEEPING GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; LIVER NUCLEAR-PROTEIN; NUCLEOTIDE-SEQUENCE; MAMMALIAN-CELLS; MESSENGER-RNAS; RAT HEPATOMA; ALBUMIN GENE; C/EBP FAMILY; CYCLIC-AMP; EXPRESSION	The cytosolic aspartate aminotransferase (cAspAT) gene is ubiquitously expressed but it is regulated by hormones in a tissue-specific manner. In vitro DNase I footprinting studies of a 260-base pair fragment carrying the basal promoter activity revealed that three CCAAT sequences bind liver nuclear proteins (protected regions P2, P3, P4). Competition studies, the heat resistance of these proteins, and identical footprints obtained using a recombinant CCAAT/enhancer-binding protein (C/EBP) alpha fragment indicate that they belong to the C/EBP family of transcription factors. A fourth protected region P1, overlapping the P2 region, was observed in the liver in the presence of competing oligonucleotides containing the C/EBP site. In cotransfection experiments, the C/EBPbeta protein trans-activated 10-15-fold the cAspAT gene promoter in HepG2 cells. Deletion studies revealed that regions P2 and P4 are critical for promoter activity. In gel retardation experiments, the P4 region bound different C/EBP-related proteins in different tissues: the brain protein is heat sensitive in contrast to the liver protein. The synthetic oligonucleotide OL 1-2, which covers the P1 and P2 regions, binds C/EBP-like proteins as well as NF1 and CP1 (or NFY) transcription factors, but the preferential binding of one of these protein is tissue-specific. In summary, using the cAspAT gene promoter, we have shown that ubiquitously active promoters may be recognized by different proteins in different tissues.			GARLATTI, M (corresponding author), HOP HENRI MONDOR, INSERM, U99, F-94010 CRETEIL, FRANCE.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAROUKI R, 1989, EUR J BIOCHEM, V186, P79, DOI 10.1111/j.1432-1033.1989.tb15180.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRODERICK TP, 1987, P NATL ACAD SCI USA, V84, P3349, DOI 10.1073/pnas.84.10.3349; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHRISTEN P, 1985, TRANSAMINASES, P173; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COOPER AJL, 1985, TRANSAMINASES, P534; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HORIO Y, 1988, J BIOCHEM-TOKYO, V103, P805, DOI 10.1093/oxfordjournals.jbchem.a122350; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JS, 1991, J BIOL CHEM, V266, P19095; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SETOYAMA C, 1990, J BIOL CHEM, V265, P1293; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOMMA MP, 1991, NUCLEIC ACIDS RES, V19, P4451, DOI 10.1093/nar/19.16.4451; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6567	6574						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454627				2022-12-25	WOS:A1993KT36800071
J	UCHIDA, K; STADTMAN, ER				UCHIDA, K; STADTMAN, ER			COVALENT ATTACHMENT OF 4-HYDROXYNONENAL TO GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE - A POSSIBLE INVOLVEMENT OF INTRAMOLECULAR AND INTERMOLECULAR CROSS-LINKING REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; ASCITES TUMOR-CELLS; LIPID-PEROXIDATION; PROTEINS; PRODUCT; CONSEQUENCES; HISTIDINE; RESIDUES	Cytotoxic action of membrane lipid peroxidation product 4-hydroxynonenal (HNE) is due mainly to its facile reactivity with proteins (Esterbauer, H., Schaur, R. J., and Zollner, H. (1991) Free Radical Biol. Med. 11, 77-80). In the present study, the detailed mechanism of HNE modification of a key enzyme in intermediary metabolism, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is studied mainly focusing on the formation of HNE-amino acid adducts in the enzyme. When GAPDH (1 mg/ml) was treated with 0-2 mm HNE in sodium phosphate buffer (pH 7.2) for 2 h at 37-degrees-C, the enzyme was inactivated by HNE in a concentration-dependent manner. The loss of enzyme activity was associated with the loss of free sulfhydryl groups. Following its reduction with NaBH4, amino acid analysis of the HNE-modified enzyme demonstrated that histidine and lysine residues were also modified. At concentrations lower than 0.5 mM, HNE reacts preferentially with cysteine and lysine residues. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the HNE-modified enzyme suggested the formation of intra- and intermolecular cross-links of the enzyme subunit. The HNE-dependent loss of amino acid residues was accompanied by the generation of protein-linked carbonyl derivatives as assessed by reduction with NaB[H-3]H-4 and reaction with 2,4-dinitrophenylhydrazine. Thus, the conjugation of all the amino acids appears to involve Michael addition type reactions in which the carbonyl function of HNE would be preserved. The modified histidine residues were quantitatively recovered as the HNE-histidine adduct. However, only 28% of the missing lysine could be accounted for as the HNE-lysine derivative, and only 15.6% of the modified cysteine could be accounted for as the HNE-cysteine thioether derivative. It is proposed that the carbonyl groups of the HNE-derived Michael addition products may undergo secondary reactions with the amino acid groups of lysine residues to yield inter- and intrasubunit cross-links.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Uchida, Koji/0000-0003-3894-5299				AMICI A, 1989, J BIOL CHEM, V264, P3341; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BOND JS, 1970, J BIOL CHEM, V245, P1041; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CHURCH FC, 1985, ANAL BIOCHEM, V146, P343, DOI 10.1016/0003-2697(85)90549-4; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FORCINA BG, 1971, EUR J BIOCHEM, V20, P535, DOI 10.1111/j.1432-1033.1971.tb01424.x; FRANCIS SH, 1973, BIOCHEMISTRY-US, V12, P346, DOI 10.1021/bi00726a026; FRANCIS SH, 1973, BIOCHEMISTRY-US, V12, P355, DOI 10.1021/bi00726a027; GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084; HARRIS JI, 1976, ENZYMES, V13, P1; JONES LA, 1956, ANAL CHEM, V28, P191, DOI 10.1021/ac60110a013; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; KANAZAWA K, 1991, ARCH BIOCHEM BIOPHYS, V288, P71, DOI 10.1016/0003-9861(91)90166-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHEW E, 1967, J BIOL CHEM, V242, P5024; SCHAUENSTEIN E, 1971, MONATSH CHEM, V102, P517, DOI 10.1007/BF00909348; SCHAUENSTEIN E, 1979, SUBMOLECULAR BIOL CA, P225; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P5611, DOI 10.1073/pnas.89.12.5611; UCHIDA K, 1992, FASEB J, V6, P2133; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P232, DOI 10.1016/0005-2760(84)90122-X; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8	33	497	507	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6388	6393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454610				2022-12-25	WOS:A1993KT36800047
J	GUYCAFFEY, JK; WEBSTER, RE				GUYCAFFEY, JK; WEBSTER, RE			THE MEMBRANE DOMAIN OF A BACTERIOPHAGE ASSEMBLY PROTEIN - MEMBRANE INSERTION AND GROWTH-INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; GENES; SEQUENCE; LOCALIZATION; EXPRESSION; PRODUCTS; DNA	The gene I protein (pI) of the f1 filamentous bacteriophage is a non-capsid protein that is required for the assembly of the bacteriophage. It spans the Escherichia coli inner membrane once with its amino terminus in the cytoplasm and its carboxyl-terminal portion in the periplasm. The presence of moderate amounts of this protein in the membrane results in rapid inhibition of cell growth, probably from a loss of membrane potential. Previous observations defined a 55-amino-acid sequence within pl required for its membrane insertion which includes a 20-residue hydrophobic stretch preceded by a 13-residue positively charged amphiphilic helix. To define the minimal sequence required for membrane translocation and for growth inhibition, a deletion analysis was performed on a tripartite fusion construct containing the 55-residue pl sequence flanked upstream by the amino-terminal portion of EcoRI endonuclease and downstream by the enzymatic portion of alkaline phosphatase. Only the 20-residue hydrophobic stretch immediately preceded by 1 arginine residue is required for membrane insertion of the fusion proteins. This region also sufficed to inhibit cell growth provided it contained protein domains exposed in both the cytoplasm and periplasm. It was not possible to separate the domains required for membrane insertion and cell growth inhibition. No requirement for the positively charged amphiphilic helix was detected either for membrane insertion or growth inhibition, suggesting that it plays a role in phage assembly and not membrane insertion.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM18305] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018305] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYER ME, 1968, J GEN MICROBIOL, V53, P395, DOI 10.1099/00221287-53-3-395; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; GUYCAFFEY JK, 1993, J BIOL CHEM, V268, P5488; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORABIN JI, 1988, J BIOL CHEM, V263, P11575; HORABIN JI, 1986, J MOL BIOL, V178, P137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; LOPEZ J, 1983, VIROLOGY, V127, P177, DOI 10.1016/0042-6822(83)90382-3; LOPEZ J, 1985, J BACTERIOL, V163, P1270, DOI 10.1128/JB.163.3.1270-1274.1985; LYONS LB, 1972, VIROLOGY, V49, P45, DOI 10.1016/S0042-6822(72)80006-0; MANTIATIS T, 1982, MOL CLONING LABORATO; Model P., 1988, BACTERIOPHAGES, P375; NEWMAN AK, 1981, J BIOL CHEM, V256, P2131; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YAMADA Y, 1991, J BIOL CHEM, V266, P17863; YEN TSB, 1981, J BIOL CHEM, V256, P1259	27	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5496	5503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449912				2022-12-25	WOS:A1993KR82200025
J	TSCHAN, T; BOHME, K; CONSCIENCEEGLI, M; ZENKE, G; WINTERHALTER, KH; BRUCKNER, P				TSCHAN, T; BOHME, K; CONSCIENCEEGLI, M; ZENKE, G; WINTERHALTER, KH; BRUCKNER, P			AUTOCRINE OR PARACRINE TRANSFORMING GROWTH-FACTOR-BETA MODULATES THE PHENOTYPE OF CHICK-EMBRYO STERNAL CHONDROCYTES IN SERUM-FREE AGAROSE CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE ORGAN-CULTURES; X COLLAGEN-SYNTHESIS; POLYACRYLAMIDE GELS; FILM DETECTION; EXPRESSION; INVITRO; DIFFERENTIATION; CELLS; BONE; CHONDROGENESIS	Sternal chondrocytes of 17-day-old chick embryos in serum-free agarose culture secrete transforming growth factor-beta. Media conditioned by such cells prevent serum-induced chondrocyte hypertrophy and cause a phenotypic modulation in serum-free culture which is similar to that observed for chondrocytes in monolayer culture. The modulated cells lose the round shape of differentiated chondrocytes and increasingly with time resemble tendon fibroblasts embedded into agarose. In addition, they produce less matrix macromolecules which include collagen I rather than cartilage collagens II, IX, X, and XI. All of these effects are abolished upon addition to the conditioned media of a monoclonal antibody against recombinant human transforming growth factor-beta2. The same factor caused effects closely similar to those elicited by conditioned media. Therefore, the phenotypic modulation in adhesion-dependent cultures of chondrocytes in vitro does not directly result from cell-matrix interactions but can be produced also in suspension culture under the direction of appropriate diffusible stimuli that include transforming growth factor-beta. In addition, the results support the concept of transforming growth factor-beta as a multifunctional cytokine acting differently on cells of the same developmental origin depending on their stage of differentiation.	SWISS FED INST TECHNOL, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND; SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis; Sandoz			Kalies, Kathrin/A-8114-2014; Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611; Kalies, Kathrin/0000-0002-8929-4249				ADAM M, 1983, CLIN CHIM ACTA, V133, P25, DOI 10.1016/0009-8981(83)90017-7; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BOHME K, 1992, J CELL BIOL, V116, P1035, DOI 10.1083/jcb.116.4.1035; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; CARRINGTON JL, 1990, EXP CELL RES, V186, P368, DOI 10.1016/0014-4827(90)90318-5; CARRINGTON JL, 1988, J CELL BIOL, V107, P1969, DOI 10.1083/jcb.107.5.1969; CASTAGNOLA P, 1986, J CELL BIOL, V102, P2310, DOI 10.1083/jcb.102.6.2310; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CASTAGNOLA P, 1987, DEV BIOL, V123, P332, DOI 10.1016/0012-1606(87)90391-5; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DANIELS K, 1991, J CELL SCI, V100, P249; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; Fell HB, 1925, J MORPHOL PHYSIOL, V40, P417, DOI 10.1002/jmor.1050400302; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; HOFFMANN HP, 1976, P NATL ACAD SCI USA, V73, P4304, DOI 10.1073/pnas.73.12.4304; HOLTZER H, 1960, P NATL ACAD SCI USA, V46, P1533, DOI 10.1073/pnas.46.12.1533; HOYLAND JA, 1991, BONE MINER, V15, P151, DOI 10.1016/0169-6009(91)90005-K; JAKOWLEW SB, 1991, DEV BIOL, V143, P135, DOI 10.1016/0012-1606(91)90061-7; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; KULYK WM, 1989, DEVELOPMENT, V106, P449; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LONSDALEECCLES JD, 1981, BIOCHEM J, V197, P591, DOI 10.1042/bj1970591; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MAYNE R, 1976, P NATL ACAD SCI USA, V73, P1674, DOI 10.1073/pnas.73.5.1674; MORALES TI, 1991, ARCH BIOCHEM BIOPHYS, V288, P397, DOI 10.1016/0003-9861(91)90212-2; MORALES TI, 1991, ARCH BIOCHEM BIOPHYS, V286, P99, DOI 10.1016/0003-9861(91)90013-9; PFEILSCHIFTER J, 1991, PEPTIDE GROWTH FACTO, V2, P371; ROSIER RN, 1989, CONNECT TISSUE RES, V20, P295, DOI 10.3109/03008208909023900; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHREIER MH, 1982, LYMPHOKINES, V5, P443; SEYEDIN SM, 1983, J CELL BIOL, V97, P1950, DOI 10.1083/jcb.97.6.1950; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SPORN MB, 1991, PEPTIDE GROWTH FACTO, V1, P1; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; TEES R, 1980, NATURE, V283, P780, DOI 10.1038/283780a0; TSCHAN T, 1990, J CELL BIOL, V111, P257, DOI 10.1083/jcb.111.1.257; VONDERMARK K, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P221; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; ZENKE G, 1991, J IMMUNOASSAY, V12, P185, DOI 10.1080/01971529108055066	44	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5156	5161						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444891				2022-12-25	WOS:A1993KP88400086
J	KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB				KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB			MOLECULAR-CLONING AND ANALYSIS OF CDNA-ENCODING THE MURINE C-YES-TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							SEQUENCE-ANALYSIS PROGRAMS; HEMATOPOIETIC-CELLS; COMPREHENSIVE SET; SRC FAMILY; GENE; CD4; EXPRESSION; P56LCK; VAX	The cellular yes (c-yes) gene is a member of the class of proto-oncogenes that encode non-receptor tyrosine protein kinases. In this report we describe the isolation of cDNAs that encode the murine c-yes gene product and analysis of the nucleotide sequence of the murine c-yes cDNA clones. The reading frame encodes a protein of 541 amino acids with a calculated molecular mass of 60.63 kDa that is reactive with anti-Yes antisera and possesses protein kinase activity.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Bristol-Myers Squibb; Howard Hughes Medical Institute; Johns Hopkins University			Adam, Dieter/E-9763-2010; Adam-Klages, Sabine/E-9761-2010	Adam, Dieter/0000-0002-5668-5032; 				BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KING FJ, 1990, ONCOGENE, V5, P337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEELE RE, 1989, ONCOGENE RES, V1, P223; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	32	8	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437854				2022-12-25	WOS:A1993KN00800023
J	ASSARAF, YG; SLOTKY, JI				ASSARAF, YG; SLOTKY, JI			CHARACTERIZATION OF A LIPOPHILIC ANTIFOLATE RESISTANCE PROVOKED BY TREATMENT OF MAMMALIAN-CELLS WITH THE ANTIPARASITIC AGENT PYRIMETHAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DIHYDROFOLATE-REDUCTASE GENE; ORNITHINE DECARBOXYLASE; FLUORESCEINATED METHOTREXATE; FLOW-CYTOMETRY; TRIMETREXATE; AMPLIFICATION; TRANSPORT; CARCINOMA; LINES	We describe the characterization of an antitumor drug resistance following multiple step selection of hamster cells to the 2,4-diaminopyrimidines (DAP metoprine, pyrimethamine (Pyr), and trimethoprim (Tmp). Pyr and Tmp are DAP lipophilic antifolates currently used as antiparasitic and antibacterial antibiotics, respectively. Dihydrofolate reductase (DHFR) from hamster cells bore a low or poor affinity to these DAP as compared to the hydrophilic folate antagonist methotrexate (MTX). Metoprine-resistant cells overexpressed DHFR enzyme and consequently displayed a high level of resistance to both hydrophilic and lipophilic antifolates including DAP but maintained wild type sensitivity to pleiotropic drugs involved in multidrug resistance (MDR). In contrast, although Pyr- and Tmp-resistant cells expressed parental levels of wild type DHFR, they displayed a high degree of resistance to DAP and, surprisingly, to the lipophilic MTX analogs piritrexim (PTX) and trimetrexate (TMTX), while maintaining sensitivity to MTX. These drug-resistant cells maintained wild type mRNA levels of the MDR gene product P-glycoprotein and showed collateral hypersensitivity to pleiotropic drugs. To study the underlying mechanism of this apparently new resistance phenotype, we have employed fluorescein-methotrexate (F-MTX) labeling of cells and its displacement by different antifolates. Parental AA8 and Pyr-resistant cells showed a similar level of F-MTX labeling, however, while DAP, TMTX, and PTX showed an efficient competitive displacement of F-MTX from AA8 cells, Pyr-resistant cells displayed a persistent retention of F-MTX labeling in the presence of high concentrations of these lipophilic antifolates. Pyr-resistant cells showed a wild type displacement of F-MTX with MTX. This DAP resistance phenotype was unstable as it was rapidly lost upon growth under nonselective conditions. Furthermore, when the antifolate resistance levels of Pyr-resistant cells were plotted versus the ratios of the 50% F-MTX displacement values obtained with resistant and parental AA8 cells, a good correlation (r2 > 0.98) was obtained. We conclude that Pyr-resistant cells possess a novel phenotype that derives its resistance to lipophilic antifolates solely from a predominant decrease in the accumulation of DAP and lipid-soluble analogs of MTX.			ASSARAF, YG (corresponding author), TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL.							ALLEGRA CJ, 1987, J EXP MED, V165, P926, DOI 10.1084/jem.165.3.926; ALLEGRA CJ, 1987, J EXP MED, V155, P1027; ALT FW, 1978, J BIOL CHEM, V253, P1357; ASSARAF YG, 1989, CYTOMETRY, V10, P50, DOI 10.1002/cyto.990100109; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; ASSARAF YG, 1989, J NATL CANCER I, V81, P290, DOI 10.1093/jnci/81.4.290; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1989, ANAL BIOCHEM, V178, P287, DOI 10.1016/0003-2697(89)90640-4; ASSARAF YG, 1992, J BIOL CHEM, V267, P5776; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P1997, DOI 10.1093/nar/11.7.1997; CHABNER BA, 1990, CANCER CHEMOTHERAPY; COWAN KH, 1984, J BIOL CHEM, V259, P793; DJURHUUS R, 1981, ANAL BIOCHEM, V113, P352, DOI 10.1016/0003-2697(81)90088-9; DUCH DS, 1982, CANCER RES, V42, P3987; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1980, BIOCHEMISTRY-US, V19, P4321, DOI 10.1021/bi00559a027; FREI E, 1985, CANCER RES, V45, P6523; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1988, CANCER RES, V48, P6986; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HABER DA, 1981, J BIOL CHEM, V256, P9501; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KAMEN BA, 1984, BIOCHEM PHARMACOL, V33, P1697, DOI 10.1016/0006-2952(84)90298-3; LAMPIDIS TJ, 1989, J CELL PHARM, V1, P16; LIN JT, 1987, J CLIN ONCOL, V5, P2032, DOI 10.1200/JCO.1987.5.12.2032; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MELERA PW, 1984, MOL CELL BIOL, V4, P38, DOI 10.1128/MCB.4.1.38; NAKAMURA H, 1972, J BIOL CHEM, V247, P179; PIZZORNO G, 1988, CANCER RES, V48, P2149; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; ROSOWSKY A, 1985, CANCER RES, V45, P6205; ROTHENBE.SP, 1966, ANAL BIOCHEM, V16, P176, DOI 10.1016/0003-2697(66)90095-9; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHERWOOD SW, 1990, CANCER RES, V50, P4946; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; WEBSTER LT, 1990, PHARMACOL BASIS THER, P985; WRIGHT JE, 1987, BIOCHEM PHARMACOL, V36, P2209, DOI 10.1016/0006-2952(87)90152-3	43	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4556	4566						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440739				2022-12-25	WOS:A1993KN53300108
J	SHEEHAN, JP; WU, QY; TOLLEFSEN, DM; SADLER, JE				SHEEHAN, JP; WU, QY; TOLLEFSEN, DM; SADLER, JE			MUTAGENESIS OF THROMBIN SELECTIVELY MODULATES INHIBITION BY SERPINS HEPARIN COFACTOR-II AND ANTITHROMBIN-III - INTERACTION WITH THE ANION-BINDING EXOSITE DETERMINES HEPARIN COFACTOR-II SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; DERMATAN SULFATE; HUMAN-PLASMA; ACTIVE-SITE; PURIFICATION; ACTIVATION; HIRUDIN; BOVINE; DNA; ALPHA-1-ANTITRYPSIN	Thrombin is a multifunctional serine protease that plays a critical role in hemostasis. Thrombin is inhibited by the serpins antithrombin III and heparin cofactor II in a reaction that is dramatically accelerated by glycosaminoglycans. The structural basis of the interaction with these inhibitors was investigated by introducing single amino acid substitutions into the anion-binding exosite (R68E, R70E) and unique insertion loops (K52E, K154A) of thrombin. The rate of inhibition of these recombinant thrombins by antithrombin III and heparin cofactor II was determined in the absence and presence of glycosaminoglycan. The second order rate constant (k2) for inhibition by antithrombin III without heparin was 3.7 x 10(5) M-1 min-1 for wild-type thrombin; rates for the mutant thrombins varied less than 2-fold. For inhibition by antithrombin III with heparin, the rate constant was 4.5 x 10(8) M-1 min-1 for wild-type thrombin with no significant differences between any of the recombinant thrombins. In contrast, the rate constant for inhibition by heparin cofactor II without glycosaminoglycan was 4.3 x 10(4) M-1 min-1 for wild-type thrombin; rates were 10-fold slower for thrombin K52E and 2- to 3-fold slower for thrombins R68E and R70E. The rate constants for inhibition of wild-type thrombin by HCII in the presence of heparin or dermatan sulfate were 9.2 x 10(8) M-1 min-1 and 9.0 x 10(8) M-1 min-1, respectively. Compared to wild-type thrombin, the rate of inhibition by HCII with glycosaminoglycan was 5- to 15-fold slower for thrombins K52E and R70E and 50- to over 100-fold slower for thrombin R68E. Thrombin K154A was inhibited by heparin cofactor II with rates similar to wild-type thrombin in all assays. These results suggest that heparin cofactor II interacts with residue Lys-52 in the proposed S1' subsite and with residues Arg-68 and Arg-70 in the anion-binding exosite of thrombin, and that these interactions contribute to the molecular basis of heparin cofactor II specificity for thrombin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED & BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SHEEHAN, JP (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X; Wu, Qingyu/0000-0003-0561-9315; Sheehan, John/0000-0002-4328-2613	NHLBI NIH HHS [T32-HL07088, HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Blow D. M., 1971, ENZYMES, VIII, P185, DOI DOI 10.1016/S1874-6047(08)60397-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1989, PROTEINASE INHIBITOR, P405; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; DANIELSSON A, 1982, BIOCHEM J, V207, P21, DOI 10.1042/bj2070021; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; ELMORE D T, 1973, Biochemical Society Transactions, V1, P1191; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; HARPEL PC, 1987, HEMOSTASIS THROMBOSI, P219; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAFFE EA, 1985, BIOCHEM BIOPH RES CO, V132, P368, DOI 10.1016/0006-291X(85)91031-9; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACGILLIVRAY RTA, 1980, P NATL ACAD SCI-BIOL, V77, P5153, DOI 10.1073/pnas.77.9.5153; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; OLSON ST, 1985, J BIOL CHEM, V260, P153; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PEI G, 1991, J BIOL CHEM, V266, P9598; RAGG H, 1990, J BIOL CHEM, V265, P5211; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P1699, DOI 10.1093/oxfordjournals.jbchem.a135645; SHUMAN MA, 1976, J CLIN INVEST, V58, P1249, DOI 10.1172/JCI108579; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPEIJER H, 1986, J BIOL CHEM, V261, P3258; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1991, J BIOL CHEM, V266, P23016; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	52	61	64	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3639	3645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429040				2022-12-25	WOS:A1993KM16100093
J	LIN, CS; CHEN, ZP; PARK, T; GHOSH, K; LEAVITT, J				LIN, CS; CHEN, ZP; PARK, T; GHOSH, K; LEAVITT, J			CHARACTERIZATION OF THE HUMAN L-PLASTIN GENE PROMOTER IN NORMAL AND NEOPLASTIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ACTIN GENES; HUMAN-FIBROBLASTS; ESTROGEN-RECEPTOR; EXPRESSION VECTOR; TRANSFORMATION; PROTEIN; IDENTIFICATION; POLYPEPTIDE; TRANSCRIPTS; ACTIVATION	Plastins are a family of human actin-binding proteins (isoforms) which are abundantly expressed in all normal replicating mammalian cells. One isoform, L-plastin, is constitutively expressed at high levels in hemopoietic cell types while T-plastin is constitutively expressed in all non-hemopoietic cells of solid tissues that have replicative potential (fibroblasts, endothelial cells, epithelial cells, melanocytes, etc.). L-plastin is, however, constitutively synthesized in many types of malignant human cells of solid tissues suggesting that its expression is induced during tumorigenesis. The frequency of L-plastin induction in some cancers of the steroid-regulated female reproductive tract (breast, ovary, uterus, and placenta) appears to be especially high (79% in a limited survey). To learn the mechanism of L-plastin gene activation accompanying tumorigenesis, we have begun to characterize the promoter and regulatory elements of the L-plastin gene. Transcription initiation from this promoter was found to occur at multiple sites and as near as 10 base pairs from the 3'-side of the TATAAA box. The promoter and its flanking DNA were cloned and sequenced to identify potential regulatory elements that participate in the induction of the L-plastin gene in neoplastic cells. Examination of upstream sequences revealed the existence of two potential progesterone, one potential estrogen, and four potential Ets-1 responsive elements flanking the promoter. A 315-base pair fragment spanning the TATAAA box and a potential Sp1-binding site exhibited maximum promoter activity using CAT as a reporter while longer promoter fragments extending into upstream flanking sequences spanning the hormone receptor-response elements exhibited reduced promoter activity. An expression vector, pHLPPr-1-neo, was constructed using a 5.1-kilobase pair EcoRI-HindIII fragment of the L-plastin gene that contained the potential upstream regulatory elements, the TATAAA box, and part of the first exon. This promoter could direct the constitutive expression of the reporter beta-galactosidase at high frequency in transfected colonies of transformed cells that express L-plastin constitutively; by contrast, this promoter was virtually inactive in transfected colonies of normal fibroblasts and it exhibited a low frequency of constitutive activation in transfected colonies of in vitro SV40-transformed fibroblasts which did not exhibit L-plastin expression. The utility of this recombinant promoter in determining the mechanism(s) that leads to activation of the L-plastin gene in tumor cells is discussed. The potential significance of regulation of the L-plastin gene by reproductive hormones in cancers arising in hormone-responsive tissues is also discussed.	PALO ALTO MED RES FDN,RES INST,CANC CELL BIOL LAB,PALO ALTO,CA 94301; ADEZA BIOMED,SUNNYVALE,CA 94089	Palo Alto Medical Foundation Research Institute					NCI NIH HHS [CA34763, CA49423] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049423, R01CA034763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BERNSTEIN L, 1992, AM J EPIDEMIOL, V135, P142, DOI 10.1093/oxfordjournals.aje.a116267; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; CELIS JE, 1990, ELECTROPHORESIS, V11, P1072, DOI 10.1002/elps.1150111203; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOLDSTEIN D, 1985, CANCER RES, V45, P5643; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEAVITT J, 1982, CARCINOGENESIS, V3, P61, DOI 10.1093/carcin/3.1.61; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEAVITT J, 1987, MOL CELL BIOL, V7, P2467, DOI 10.1128/MCB.7.7.2467; LEAVITT J, 1987, MOL CELL BIOL, V7, P2457, DOI 10.1128/MCB.7.7.2457; LEAVITT J, 1980, J BIOL CHEM, V255, P1650; LEWIN B, 1980, GENE EXPRESSION; LIN CS, 1990, MOL CELL BIOL, V10, P1818, DOI 10.1128/MCB.10.4.1818; LIN CS, 1988, MOL CELL BIOL, V8, P4659, DOI 10.1128/MCB.8.11.4659; LIN CS, 1993, J BIOL CHEM, V168, P2781; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SZERKERESBARTHO J, 1992, IMMUNOSUPPRESSION PR; SZERKERESBARTHO J, 1989, J REPROD IMMUNOL, V16, P239; VARMA M, 1987, EXP CELL RES, V173, P163, DOI 10.1016/0014-4827(87)90342-9	31	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2793	2801						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428953				2022-12-25	WOS:A1993KK81500079
J	MELEFORS, O; GOOSSEN, B; JOHANSSON, HE; STRIPECKE, R; GRAY, NK; HENTZE, MW				MELEFORS, O; GOOSSEN, B; JOHANSSON, HE; STRIPECKE, R; GRAY, NK; HENTZE, MW			TRANSLATIONAL CONTROL OF 5-AMINOLEVULINATE SYNTHASE MESSENGER-RNA BY IRON-RESPONSIVE ELEMENTS IN ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; FERRITIN SYNTHESIS; BINDING-PROTEIN; UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; HEME FORMATION; HEAVY-SUBUNIT; LIVER; PURIFICATION; BIOSYNTHESIS	Hemoglobin synthesis in red cells is the major iron utilization pathway in the human body and accounts for >80% of systemic iron turnover. The first step in erythroid heme biosynthesis is catalyzed by a tissue-specific isoform of 5-aminolevulinate synthase (ALAS). The previous identification of iron-responsive elements in the 5'-untranslated region of human and murine erythroid ALAS mRNA raised the intriguing possibility that eALAS expression might be under iron-dependent translational control. As a consequence, a single post-transcriptional regulatory system could coordinate cellular iron acquisition via the transferrin receptor, storage via ferritin, and utilization via eALAS. We directly demonstrate iron-dependent translational regulation of eALAS mRNA in murine erythroleukemia (MEL) cells. The iron-responsive element motif contained in eALAS mRNA is shown to be sufficient to confer translational control to a reporter mRNA both in transfected MEL cells and in vitro.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,POSTFACH 102209,W-6900 HEIDELBERG 1,GERMANY	European Molecular Biology Laboratory (EMBL)			Melefors, Öjar/N-6164-2015; Johansson, Hans E./C-5113-2017; Hentze, Matthias/V-3980-2017	Melefors, Öjar/0000-0003-4115-1190; Johansson, Hans E./0000-0001-9495-6107; Hentze, Matthias/0000-0002-4023-7876; gray, nicola/0000-0002-0413-1767				ANDREW TL, 1990, BIOSYNTHESIS HEME CH, P163; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BOTHWELL TH, 1983, IDIOPATHIC HEMOCHROM, P1269; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COTTER PD, 1992, P NATL ACAD SCI USA, V89, P4028, DOI 10.1073/pnas.89.9.4028; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; GARDNER LC, 1988, J BIOL CHEM, V263, P6676; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GREISERWILKE I, 1981, P NATL ACAD SCI-BIOL, V78, P2995, DOI 10.1073/pnas.78.5.2995; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JOHANSSON HE, 1991, J BIOL CHEM, V266, P1921; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; MAY BK, 1990, MOL BIOL MED, V7, P405; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PONKA P, 1985, J BIOL CHEM, V260, P4717; Ponka P, 1990, BIOSYNTHESIS HEME CH, P393; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SRIVASTAVA G, 1983, BIOCHEM BIOPH RES CO, V117, P344, DOI 10.1016/0006-291X(83)91582-6; SRIVASTAVA G, 1983, BIOCHEM BIOPH RES CO, V110, P23, DOI 10.1016/0006-291X(83)91254-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YACHOU AK, 1989, NUCLEIC ACIDS RES, V17, P8005, DOI 10.1093/nar/17.19.8005; YAMAUCHI K, 1980, J BIOL CHEM, V255, P1746; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	48	177	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5974	5978						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449958				2022-12-25	WOS:A1993KR82200091
J	ROHLFF, C; CLAIR, T; YOON, SCC				ROHLFF, C; CLAIR, T; YOON, SCC			8-CL-CAMP INDUCES TRUNCATION AND DOWN-REGULATION OF THE RI-ALPHA-SUBUNIT AND UP-REGULATION OF THE RII-BETA-SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE LEADING TO TYPE-II HOLOENZYME-DEPENDENT GROWTH-INHIBITION AND DIFFERENTIATION OF HL-60 LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; AMINO-ACID SEQUENCE; CYCLIC-AMP; RECEPTOR PROTEINS; MESSENGER-RNA; HUMAN TESTIS; ANTISENSE OLIGODEOXYNUCLEOTIDE; HORMONAL ACTIVATION; CATALYTIC SUBUNIT; MOLECULAR-CLONING	8-Cl-cAMP, a site-selective cAMP analog, induces growth inhibition in a variety of cell types of human cancer cell lines. This inhibitory effect of 8-Cl-cAMP was related to its ability to differentially regulate type I versus type II cAMP-dependent protein kinase. In the present study we demonstrated a unique mechanism of action of 8-Cl-cAMP in the regulation of these kinase isozymes in HL-60 human promyelocytic leukemia cells. High-performance liquid chromatography (HPLC) resolved various isoforms of protein kinase present in HL-60 cells. In control cells, type I protein kinase (PKI) comprised more than 90% and type II protein kinase (PKII) less than 10% of the total cAMP-stimulated kinase activity. Treatment with 8-Cl-cAMP (5 muM, 72 h) decreased PKI to a level below 30% of that in untreated control cells and markedly increased PKII composed of three peaks. Photoaffinity labeling/SDS-polyacrylamide gel electrophoresis of column fractions identified the molecular species of regulatory (R) subunits present in protein kinases. Control cells contained high levels of the 48-kDa protein (RI) that composed PKI and low levels of the 50-kDa RII associated with PKII. 8-Cl-cAMP treatment brought about a decrease in the 48-kDa RI along with an increased formation of the truncated 34-kDa RI associated with PKI and an increase in the 50-54-kDa species of RII associated with PKII. A similar protein kinase profile as that shown by 8-Cl-cAMP treatment was observed in cells infected with the human RII(beta) retroviral vector: the 48-kDa RI of PKI decreased and the 52- and 54-kDa RII associated with PKII increased as compared with uninfected control cells. However, unlike 8-Cl-cAMP treatment, RII(beta) retroviral vector infection brought about no increase in the 34-kDa-truncated RI but exhibited an increase in the free 48-kDa RI subunit. As the 48-kDa RI and the 50-kDa RII were present in control cells, the enhanced expression of the 52- and 54-kDa RII proteins was due to overexpression of the RII(beta) gene. We identified the 48-kDa RI as RI(alpha), the 50-kDa RII as RII(alpha), the 52-kDa RII as RII(beta), and the 54-kDa RII as the phosphorylated form of either the RII(alpha) or RII(beta) subunit. In vivo labeling experiments using [H-3]8-Cl-cAMP demonstrated that 8-Cl-cAMP enters cells and binds to both PKI and PKII. The [H-3]8-Cl-cAMP binding profile of HPLC showed that 8-Cl-cAMP selectively down-regulates PKI and up-regulates PKII, and such an effect of 8-Cl-cAMP is mimicked by exposing cells to RI(alpha) antisense oligodeoxynucleotide, which suppresses RI(alpha) and enhances RII(beta) expression. Dot-blot hybridization analysis demonstrated that both 8-Cl-cAMP treatment (5 muM, 6 h) and RII(beta) retroviral vector infection elicited a marked induction of RII(beta) and C(alpha) mRNA with little or no change in RI(alpha) and RII(alpha) mRNA. These results suggest that the RI(alpha) and RII(beta) regulatory subunits determine the distinct roles of type I and type II cAMP-dependent protein kinase isozymes in the regulation of cell proliferation in HL-60 cells and that the formation of the 34-kDa-truncated RI is an efficient mechanism for type I protein kinase down-regulation.	NCI,CELLULAR BIOCHEM SECT,TUMOR IMMUNOL & BIOL LAB,BLDG 10,RM 5B38,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLY S, 1988, P NATL ACAD SCI USA, V85, P6319, DOI 10.1073/pnas.85.17.6319; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CAMPAGNE MMV, 1991, CANCER RES, V51, P1600; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1991, LIFE SCI, V48, P1123, DOI 10.1016/0024-3205(91)90449-L; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; COBB CE, 1987, J BIOL CHEM, V262, P16566; CONNELLY PA, 1986, J BIOL CHEM, V261, P2325; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; FRIEDMAN DL, 1981, BIOCHIM BIOPHYS ACTA, V675, P334, DOI 10.1016/0304-4165(81)90023-4; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KAPOOR CL, 1984, CANCER RES, V44, P3554; KAPOOR CL, 1983, CANCER RES, V43, P295; KAPOOR CL, 1983, CELL BIOL INT REP, V7, P49, DOI 10.1016/0309-1651(83)90104-2; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LANGECARTER CA, 1990, J BIOL CHEM, V265, P7814; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LITVIN Y, 1984, J BIOL CHEM, V259, P296; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; OYEN O, 1988, FEBS LETT, V229, P391, DOI 10.1016/0014-5793(88)81163-3; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; RICHARDS JS, 1980, J BIOL CHEM, V255, P5481; RUSHDI A, 1983, SCIENCE, V222, P390; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SCHUSTER MJ, 1985, NATURE, V313, P392; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TORTORA G, 1988, BLOOD, V71, P230; TORTORA G, 1989, P NATL ACAD SCI USA, V86, P2849, DOI 10.1073/pnas.86.8.2849; WEBER W, 1981, EUR J BIOCHEM, V120, P585, DOI 10.1111/j.1432-1033.1981.tb05740.x; WEBER W, 1982, BIOCHEM BIOPH RES CO, V104, P1134, DOI 10.1016/0006-291X(82)91368-7	58	128	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5774	5782						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449943				2022-12-25	WOS:A1993KR82200063
J	ROUSSEAU, DL; SONG, S; FRIEDMAN, JM; BOFFI, A; CHIANCONE, E				ROUSSEAU, DL; SONG, S; FRIEDMAN, JM; BOFFI, A; CHIANCONE, E			HEME-HEME INTERACTIONS IN A HOMODIMERIC COOPERATIVE HEMOGLOBIN - EVIDENCE FROM TRANSIENT RAMAN-SCATTERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYRIN FORCE-FIELD; DIRECTLY COMMUNICATING HEMES; RESONANCE RAMAN; SCAPHARCA-INAEQUIVALVIS; DIMERIC HEMOGLOBIN; LIGAND-BINDING; NICKEL OCTAETHYLPORPHYRIN; QUATERNARY STRUCTURE; INFRARED-SPECTRA; ISOTOPE SHIFTS	The comparison of the resonance Raman spectrum of the deoxy dimeric hemoglobin (HbI) from the Arcid clam, Scapharca inaequivalvis, to its CO photoproduct at 10 ns reveals several significant differences in the low frequency vibrational modes including those involving motions of the peripheral substituents on the heme such as the propionates. This finding reflects the involvement of the propionates in a hydrogen bonding network which connects the two heme groups across the subunit interface and is sensitive to ligand binding. A frequency difference in the iron-histidine stretching mode of 6 cm-1 in this invertebrate hemoglobin is substantially smaller than that detected in tetrameric vertebrate hemoglobins under similar conditions. Time evolution studies of the vibrational modes from the photoproduct demonstrate that the transient form relaxes to the deoxy structure concertedly with a half-life of 1 mus, the time scale in which tertiary relaxations of tetrameric hemoglobins occur. These data establish that the tertiary and quaternary structural changes take place on the same time scale and confirm a mechanism of cooperativity involving direct interaction between the two heme groups through the peripheral substituents. This direct structural communication provides a very tight linkage between the heme groups prohibiting modulation of the oxygen affinity by factors in the physiological milieu.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461; UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI,CTR MOLEC BIOL,CNR,I-00185 ROME,ITALY	Yeshiva University; Albert Einstein College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	ROUSSEAU, DL (corresponding author), AT&T BELL LABS,MURRAY HILL,NJ 07974, USA.				NIGMS NIH HHS [GM-39359] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039359] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J PHYS CHEM-US, V69, P4409; ANTONINI E, 1984, J BIOL CHEM, V259, P6730; ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; BENESCH R, 1974, SCIENCE, V185, P905, DOI 10.1126/science.185.4155.905; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CHIANCONE E, 1989, J BIOL CHEM, V264, P21062; CHIANCONE E, 1990, BIOPHYS CHEM, V37, P287, DOI 10.1016/0301-4622(90)88028-Q; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; COLETTA M, 1990, J BIOL CHEM, V265, P4828; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; INUBUSHI T, 1988, FEBS LETT, V235, P87, DOI 10.1016/0014-5793(88)81239-0; KINCAID J, 1979, P NATL ACAD SCI USA, V76, P549, DOI 10.1073/pnas.76.2.549; KINCAID J, 1979, P NATL ACAD SCI USA, V76, P4156; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; Kitagawa T, 1987, STRUCT BONDING BERLI, V64, P71, DOI DOI 10.1007/BFB0036788; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LI XY, 1989, J AM CHEM SOC, V111, P7012, DOI 10.1021/ja00200a018; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; OHNOKI S, 1973, J BIOCHEM-TOKYO, V73, P715; ONDRIAS MR, 1982, BIOCHEMISTRY-US, V21, P3428, DOI 10.1021/bi00257a028; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; ROUSSEAU DL, 1983, J BIOL CHEM, V258, P1740; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SASSAROLI M, 1987, BIOCHEMISTRY-US, V26, P3092, DOI 10.1021/bi00385a022; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SHELNUTT JA, 1979, P NATL ACAD SCI USA, V76, P4409, DOI 10.1073/pnas.76.9.4409	35	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5719	5723						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449934				2022-12-25	WOS:A1993KR82200054
J	SHAH, N; KLAUSNER, RD				SHAH, N; KLAUSNER, RD			BREFELDIN-A REVERSIBLY INHIBITS SECRETION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PERIPHERAL MEMBRANE-PROTEIN; ADP-RIBOSYLATION FACTOR; GOLGI-APPARATUS; COATED VESICLES; BETA-COP; YEAST; TRANSPORT; COMPLEX; BINDING; CELLS	Brefeldin A has proven to be a useful pharmacologic tool, which, when added to mammalian cells, results in a block in secretion as well as the structural disruption of specific intracellular organelles. In spite of our understanding of some of the biochemistry underlying the action of brefeldin A, the most proximal molecular target(s) of the drug remain elusive. In attempting to address this problem, a genetic approach will undoubtedly prove useful and complementary to the biochemical identification of such a site(s). As a result of the relatively resistant nature of wild-type Saccharomyces cerevisiae to brefeldin A, an approach utilizing yeast genetics has not been possible. We report the selective sensitivity of three drug-sensitive strains of S. cerevisiae (ise-1, ISE-2, and erg6) with enhanced membrane permeability allowing uptake of brefeldin A. Upon addition of the drug, growth is dramatically inhibited and invertase secretion is rapidly, specifically, and reversibly blocked at the level of the endoplasmic reticulum. In addition, only structural analogues of brefeldin A effective in mammalian cells are active in these yeast strains.	NICHHD,CELL BIOL & METAB BRANCH,BLDG 18T,RM 101,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BARD M, 1978, J BACTERIOL, V135, P1146, DOI 10.1128/JB.135.3.1146-1148.1978; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDSTEIN A, 1975, METHOD ENZYMOL, V42, P502; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P7410; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KISTAKIS NT, 1991, J CELL BIOL, V113, P1009; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LOCK JDB, 1969, J CHEM SOC CHEM COMM, P237; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCCAMMON MT, 1984, J BACTERIOL, V157, P475, DOI 10.1128/JB.157.2.475-483.1984; NITTIS J, 1988, P NATL ACAD SCI USA, V85, P7501; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; SINGLETON VL, 1958, NATURE, V181, P1072, DOI 10.1038/1811072a0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WINSOR B, 1987, ENVIRON MOL MUTAGEN, V9, P114	33	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5345	5348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449896				2022-12-25	WOS:A1993KR82200002
J	D'SOUZA-SCHOREY, C; ELBEIN, AD				D'SOUZA-SCHOREY, C; ELBEIN, AD			PARTIAL-PURIFICATION AND PROPERTIES OF A GLUCOSYLTRANSFERASE THAT SYNTHESIZES GLC1MAN9(GLCNAC)2-PYROPHOSPHORYLDOLICHOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE TRANSFER; PROTEIN GLYCOSYLATION; P-MANNOSE; GLUCOSYLATION; YEAST; GLUCOSE	The glucosyltransferase that transfers the first glucose residue from dolichyl-P-glucose to Man9-(GlcNAc)2-PP-dolichol has been solubilized from porcine aorta and purified 720-fold. The purification strategy involved ammonium sulfate precipitation followed by ion-exchange, gel filtration, and hydroxylapatite column chromatographies. Analysis of the products produced by enzyme fractions at different stages of purification indicate that three different glucosyltransferases are involved in the conversion of Man9(GlcNAc)2-PP-dolichol to Glc3Man9(GlcNAc)2PP-dolichol. The first glucosyltransferase appears to be specific for dolichyl-P-glucose as the donor substrate. Man9(GlcNAc)2-PP-dolichol, Man7(GlcNAc)2-PP-dolichol, and Man5(GlcNAc)2-PP-dolichol (with two different oligosaccharide structures) were tested for their ability to accept glucose from dolichyl-P-glucose. Studies on the comparative rates of transfer of glucose to these different acceptor substrates demonstrated that Man9(GlcNAc)2-PP-dolichol accepts glucose at a higher initial rate and to a greater extent than does Man7(GlcNAc)2-PP-dolichol and the biosynthetic Man5(GlcNAc)2-PP-dolichol. The other Man5(GlcNAc)2-PP-dolichol (i.e. Manalpha1,6[Manalpha1,3]-Manalpha1,6[Manalpha1,3]Manbeta1,4GlcNAcbeta1,GlcNAc) was not an acceptor, indicating that the Manalpha1,2-Manalpha1,2Manalpha1,3Man arm is necessary. Man9(Glc-NAc)2 and Man9(GlcNAc)2-protein were not acceptors, indicating that both the lipid and the oligosaccharide portion of Man9(GlcNAc)2-PP-dolichol are required for enzyme activity. The partially purified enzyme has a pH optimum of 6.5 and exhibits a requirement for divalent metal ions.			D'SOUZA-SCHOREY, C (corresponding author), UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEIANNINO NI, 1988, ARCH BIOCHEM BIOPHYS, V260, P139, DOI 10.1016/0003-9861(88)90434-1; DSOUZA C, 1992, ANAL BIOCHEM, V203, P211, DOI 10.1016/0003-2697(92)90305-Q; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; HERSCOVICS A, 1977, J BIOL CHEM, V252, P2271; HOFLACK B, 1981, EUR J BIOCHEM, V117, P285, DOI 10.1111/j.1432-1033.1981.tb06335.x; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUI T, 1978, J BIOL CHEM, V254, P4554; MURPHY LA, 1981, J BIOL CHEM, V256, P7487; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TROMBETTA S E, 1991, Glycobiology, V1, P155, DOI 10.1093/glycob/1.2.155; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411	24	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4720	4727						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444847				2022-12-25	WOS:A1993KP88400028
J	LANKFORD, SP; COSSON, P; BONIFACINO, JS; KLAUSNER, RD				LANKFORD, SP; COSSON, P; BONIFACINO, JS; KLAUSNER, RD			TRANSMEMBRANE DOMAIN LENGTH AFFECTS CHARGE-MEDIATED RETENTION AND DEGRADATION OF PROTEINS WITHIN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; MEMBRANE-SPANNING DOMAIN; PRE-GOLGI DEGRADATION; AMINO-ACID; COMPLEX; CHAINS; GLYCOPROTEIN; EXPRESSION; TRANSPORT; ER	Previous studies have shown that the presence of potentially charged amino acid residues within the transmembrane domains of type I integral membrane proteins can result in protein retention and, in some eases, degradation within the endoplasmic reticulum (ER). An apparent exception to this observation is the CD3-epsilon chain of the T-cell antigen receptor complex, which is relatively stable in spite of having a transmembrane aspartic acid residue. A chimeric protein (TepsilonT) made by replacing the transmembrane domain of the Tac antigen with that of CD3-epsilon was normally transported to the cell surface, indicating that the transmembrane domain of CD3-epsilon was essentially unable to confer the phenotype of ER retention and degradation to another protein. Progressive shortening of the TepsilonT transmembrane domain, however, resulted in increasing retention and degradation of the mutant proteins in the ER. Conversely, a mutant Tac protein containing a single aspartic acid residue in its transmembrane domain was found to be retained and degraded in the ER, but when the transmembrane domain was lengthened, ER retention and degradation of the protein were abrogated. The aspartic acid residue in the transmembrane domain of all of these mutant proteins could mediate assembly with another protein having an arginine residue in its transmembrane domain, independent of the length of the transmembrane sequence. These findings demonstrate that the length of the hydrophobic transmembrane sequence has a critical influence on the ability of potentially charged transmembrane residues to cause protein retention and degradation in the ER.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Bonifacino, Juan S./0000-0002-5673-6370				ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DAVIS GL, 1987, J CELL BIOL, V105, P1191, DOI 10.1083/jcb.105.3.1191; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	26	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4814	4820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444858				2022-12-25	WOS:A1993KP88400041
J	FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS				FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS			C-ETS-1-PROTEIN IS HYPERPHOSPHORYLATED DURING MITOSIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; NUCLEAR-ENVELOPE BREAKDOWN; LEUKEMIA-VIRUS HTLV-1; PROTEIN KINASE-II; V-ETS ONCOGENE; DIFFERENTIAL PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATORS; C-ETS-1 PROTOONCOGENE; MAMMALIAN-CELLS; DNA-BINDING	The ets-1 and ets-2 proto-oncogene products can serve as transcription factors and become phosphorylated in response to Ca2+-mediated signals. We have examined expression of Ets proteins during the cell cycle in cells svnchronized by centrifugal elutriation or nocodazole-induced mitotic block. Both methods revealed the presence of a hyperphosphorylated isoform of Ets-1 during the mitotic phase. This isoform showed a characteristic mobility shift and was observed during mitosis in each of four cell lines (three human T-cell lines and a human astrocytoma) that express ets-1. In elutriated cells, only a small portion of the Ets-1 in cells from the G2/M fractions was hyperphosphorylated, while in nocodazole-arrested cells more of the Ets-1 was shifted. When cells were released from nocodazole arrest, this isoform disappeared within 1-2h as cells completed mitosis and entered G1. This suggests that hyperphosphorylated Ets-1 is present transiently during early mitosis, before or around the time of the metaphase-anaphase transition. Exposure of unsynchronized cells to okadaic acid resulted in a dramatic hyperphosphorylation of virtually all Ets-1, suggesting that changes in cellular phosphatase activity are important for cell cycle regulation of Ets-1. Hyperphosphorylated Ets-1 appears to arise from multiple phosphorylations on serine in the exon 7-encoded domain of the protein and did not appear to alter sequence-specific DNA-binding activity. Although enhanced phosphorylation of Ets-2 was detected in nocodazole-arrested cells, no Ets-2 hyperphosphorylation was seen.	NCI,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	FLEISCHMAN, LF (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3163; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	49	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					771	780						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437861				2022-12-25	WOS:A1993KN00800030
J	HAMILTON, KK; ZHAO, J; SIMS, PJ				HAMILTON, KK; ZHAO, J; SIMS, PJ			INTERACTION BETWEEN APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-A-II AND THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT - AFFINITY OF THE APOPROTEINS FOR POLYMERIC-C9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; SYNTHETIC PEPTIDE ANALOGS; HUMAN ENDOTHELIAL-CELLS; 9TH COMPONENT; AMPHIPATHIC HELIX; CIRCULAR POLYMERIZATION; MOLECULAR-WEIGHT; HUMAN PLASMA; PROTEINS; C5B-9	We have previously observed enhanced binding of HDL and apolipoproteins A-I and A-II to human endothelial cells exposed to activated complement. Induction of these binding sites required complement activation through C9, suggesting a specific role for the C9 component of the C5b-9 complex. We now report that specific and saturable binding sites for apoA-I and -A-II are expressed by C9 polymers (polyC9), whereas little binding was observed to native monomeric C9. These data suggested an interaction of the apoproteins with a site(s) which is exposed only upon C9 polymerization, and also suggested that binding of the apoproteins to this new site might interfere with assembly of C9 into the polyC9 tubule and insertion into the cell membrane. ApoA-I was found to inhibit zinc-catalyzed polymerization of C9 in a concentration-dependent fashion. Formation of SDS-resistant C9 polymers was completely inhibited at apoA-I or -A-II concentrations greater-than-or-equal-to 5 muM. ApoA-I also produced a concentration-dependent inhibition of C9 incorporation into C5b-9 complexes on endothelial cells, which was accompanied by a corresponding decrease in SDS-resistant C9 polymers associated with the cell membrane. In summary, the ability of the HDL apoproteins A-I and A-II to interact with an activation-dependent conformer(s) of the C9 component of the C5b-9 complex appears to explain the expression of HDL binding sites on endothelial cells exposed to complement. These apoproteins are also inhibitors of C9 polymerization, which may underlie the protective effect of HDL for blood cells exposed to activated complement.	OKLAHOMA MED RES FDN,WILLIAM K WARREN MED RES INST,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	HAMILTON, KK (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73190, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061, R01HL036061, K11HL001749, R01HL036946] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946, HL01749, HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHUNG BH, 1985, J BIOL CHEM, V260, P256; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DISCIPIO RG, 1991, J IMMUNOL, V147, P4239; ESSER AF, 1979, P NATL ACAD SCI USA, V76, P1410, DOI 10.1073/pnas.76.3.1410; ESSER AF, 1990, YEAR IMMUNOLOGY, V6, P229; HAMILTON KK, 1991, J CLIN INVEST, V88, P1833, DOI 10.1172/JCI115504; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HAMILTON KK, 1990, BLOOD, V76, P2572; HATTORI R, 1989, J BIOL CHEM, V264, P9053; ISHIDA B, 1982, J BIOL CHEM, V257, P551; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KUNITAKE ST, 1985, J LIPID RES, V26, P549; LAINE RO, 1989, NATURE, V341, P63, DOI 10.1038/341063a0; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LI WH, 1988, J LIPID RES, V29, P245; LOVETT DH, 1987, J IMMUNOL, V138, P2473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCCLOSKEY MA, 1989, BIOCHEMISTRY-US, V28, P534, DOI 10.1021/bi00428a019; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; PACKMAN CH, 1985, BIOCHIM BIOPHYS ACTA, V812, P107, DOI 10.1016/0005-2736(85)90527-9; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; PERESCHINI PM, 1992, BIOCHEMISTRY-US, V31, P5017; PETROSSIAN GA, 1989, CIRCULATION, V80, P122; PODACK ER, 1979, P NATL ACAD SCI USA, V76, P897, DOI 10.1073/pnas.76.2.897; PODACK ER, 1982, J BIOL CHEM, V257, P5204; PODACK ER, 1982, P NATL ACAD SCI-BIOL, V79, P574, DOI 10.1073/pnas.79.2.574; ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833; SEGREST JP, 1983, J BIOL CHEM, V258, P2290; SEIFERT PS, 1989, LAB INVEST, V60, P747; STANLEY KK, 1987, EMBO J, V6, P1951, DOI 10.1002/j.1460-2075.1987.tb02457.x; STECKEL EW, 1983, J BIOL CHEM, V258, P4318; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SUTTORP N, 1987, AM J PHYSIOL, V253, pC13, DOI 10.1152/ajpcell.1987.253.1.C13; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TSCHOPP J, 1984, J BIOL CHEM, V259, P569; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; TSCHOPP J, 1982, NATURE, V298, P534, DOI 10.1038/298534a0; WIEDMER T, 1985, J BIOL CHEM, V260, P8014	45	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3632	3638						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429039				2022-12-25	WOS:A1993KM16100092
J	MORICE, WG; BRUNN, GJ; WIEDERRECHT, G; SIEKIERKA, JJ; ABRAHAM, RT				MORICE, WG; BRUNN, GJ; WIEDERRECHT, G; SIEKIERKA, JJ; ABRAHAM, RT			RAPAMYCIN-INDUCED INHIBITION OF P34CDC2 KINASE ACTIVATION IS ASSOCIATED WITH G1/S-PHASE GROWTH ARREST IN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; GENE-EXPRESSION; PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES	The macrolide rapamycin (RAP) is a potent inhibitor of interleukin-2 (IL-2)-induced T-cell proliferation. Current models suggest that RAP, when complexed to its intracellular receptor, FK506-binding protein, interferes with an IL-2 receptor-coupled signaling pathway required for cell-cycle progression from G1- to S-phase. Here we show that RAP treatment inhibits the growth of an IL-2-dependent cytotoxic T-cell line, CTLL-2, in late G1-phase, just prior to entry of the cells into S-phase. In contrast, RAP-treated CTLL-2 cells retained the ability to respond to IL-2 with enhanced cytolytic activity, indicating that RAP was not a general suppressant of cellular responsiveness to IL-2. Subsequent studies revealed that IL-2 stimulation triggered a delayed activation of the p34cdc2 kinase, the timing of which correlated with the G1- to S-phase transition. The IL-2-dependent increase in p34cdc2 kinase activity was blocked by RAP. The RAP sensitivity of the p34cdc2 activation mechanism implicates this signaling pathway in the control of S-phase commitment in IL-2-stimulated T-cells.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,RAHWAY,NJ 07065	Mayo Clinic; Merck & Company	MORICE, WG (corresponding author), MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905, USA.							ABRAHAM RT, 1986, J TISSUE CULTURE MET, V10, P93; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FARRAR WL, 1986, IMMUNOL REV, V92, P49, DOI 10.1111/j.1600-065X.1986.tb01493.x; FARRAR WL, 1987, J IMMUNOL, V139, P2075; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FORESBURG SL, 1991, ANN REV CELL BIOL, V7, P227; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GILLIS S, 1978, J IMMUNOL, V120, P2027; HEFENEIDER SH, 1983, J IMMUNOL, V130, P222; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANIER LL, 1985, J IMMUNOL, V134, P794; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAYA CV, 1989, J IMMUNOL, V142, P666; PINES J, 1990, New Biologist, V2, P389; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RUEGEMER JJ, 1990, J IMMUNOL, V144, P1767; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511	41	172	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3734	3738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429048				2022-12-25	WOS:A1993KM16100107
J	WANG, XY; MOLLER, C; NORSTEDT, G; CARTERSU, C				WANG, XY; MOLLER, C; NORSTEDT, G; CARTERSU, C			GROWTH HORMONE-PROMOTED TYROSYL PHOSPHORYLATION OF A 121-KDA GROWTH-HORMONE RECEPTOR-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INTERLEUKIN-2 RECEPTOR; EXPRESSION CLONING; BETA-CHAIN; ERYTHROPOIETIN RECEPTOR; MOLECULAR-CLONING; IL-2 RECEPTOR; GENE FAMILY; GM-CSF; SUPERFAMILY	Previous work in multiple cell types has shown that endogenous GH receptors, as well as the cloned liver GH receptor, associate with a tyrosine kinase. However, in SDS-PAGE gels of highly purified, kinase-active GH receptor preparations from S-35-labeled 3T3-F442A cells, only one broad band was detected corresponding to the molecular weight of the GH receptor rather than two bands which might be expected to result from a kinase-receptor heterocomplex. In the present study, a transfected Chinese hamster ovary (CHO) cell line (CHO4) that expresses an 84-kDa GH receptor rather than a 121-kDa GH receptor was used to examine whether the GH receptor might form a complex with a protein (e.g. tyrosine kinase) that comigrates on SDS-polyacrylamide gel electrophoresis gels with the endogenous GH receptor (M(r) 121,000) in 3T3-F442A cells. GH.GH receptor complexes were immunoprecipitated with anti-GH antibody from GH-treated CHO4 cells and incubated with [gamma-P-32]ATP. P-32 was incorporated into a 121-kDa protein as well as the 84-kDa GH receptor. Phosphorylation of both the 84-kDa GH receptor and the 121-kDa protein was on tyrosyl residues as determined by Western blotting with anti-phosphotyrosine antibody. The 121-kDa protein does not appear to bind GH. It was also not detected in the immunoprecipitate when cells had not been incubated with GH or when untransfected CHO cells were used. These findings suggest that in CHO4 cells, the 121-kDa protein is precipitated by the GH antibody because of its ability to form a complex with the GH receptor (p84). Western blot analysis of whole cell lysates using anti-phosphotyrosine antibody revealed that GH promotes the tyrosyl phosphorylation of a 121-kDa protein and several other proteins (p97, p42, p39) in a dose- and time-dependent fashion. Taken together, these findings are consistent with either p121 being the tyrosine kinase that complexes with the GH receptor and is activated in response to GH binding or with p121 forming a ternary complex with both the GH receptor and a tyrosine kinase and serving as a substrate of the GH receptor-associated tyrosine kinase.	KAROLINSKA INST,CTR BIOTECHNOL,S-14152 HUDDINGE,SWEDEN	Karolinska Institutet	WANG, XY (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109, USA.				NIDDK NIH HHS [DK-34171, R01 DK034171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, R01DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, IN PRESS J BIOL CHEM; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODMAN HM, 1974, HDB PHYSIOLOGY     7, V4, P211; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOSTYO JL, 1974, HDB PHYSIOLOGY     2, V4, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MASSAGUE J, 1981, J BIOL CHEM, V256, P3182; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; WANG XY, 1992, J BIOL CHEM, V267, P17390; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	42	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3573	3579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429033				2022-12-25	WOS:A1993KM16100084
J	WEISMANSHOMER, P; FRY, M				WEISMANSHOMER, P; FRY, M			QUAD, A PROTEIN FROM HEPATOCYTE CHROMATIN THAT BINDS SELECTIVELY TO GUANINE-RICH QUADRUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERIC DNA; OLIGONUCLEOTIDES; COMPLEXES; PROMOTER; RAP1	The single-stranded oligomer Q, whose nucleotide sequence 5'-d(TACAGGGGAGCTGGGGTAGA)-3' corresponds to the IgG switch region, forms in concentrated solutions and in the presence of alkali metal cation parallel four-stranded complexes termed G4 DNA (Sen, D., and Gilbert, W. (1988) Nature 334, 364-366). We show that G4 DNA was also formed during storage of dried oligomer Q. This quadruplex complex migrated more slowly than mono-strand oligomer Q during nondenaturing gel electrophoresis, the rate of its formation depended on the mass of stored oligomer Q, and N7 positions of guanine residues were involved in its stabilization. Here we report the purification of a protein designated QUAD that binds specifically to the G4 form of oligomer Q, from nonhistone protein extracts of rabbit hepatocytes. QUAD was 80-90% purified by sequential steps of column chromatography on Sepharose 6B, DEAE-cellulose, phosphocellulose, and phenyl-Sepharose. Purified QUAD migrated on SDS-polyacrylamide gel electrophoresis as a 58 +/- 2.6-kDa polypeptide and had a native molecular mass of 57 +/- 2.5 kDa as determined by Sepharose 6B gel filtration. The dissociation constant of G4 DNA binding to QUAD was in the range of 2.5 to 7.0 x 10(-9) m/liter. Excess unlabeled mono-stranded oligomer Q did not compete with 5'-P-32-labeled G4 DNA on its binding to QUAD. Further, that QUAD recognized the G4 DNA structure rather than a DNA sequence was also demonstrated by the inefficient competition on the binding of 5'-[P-32]G4 DNA to QUAD by excess unlabeled single- or double-stranded DNA molecules that contained guanine clusters of different length or various other nucleotide sequences.			WEISMANSHOMER, P (corresponding author), TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL.							BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; EVANS T, 1984, NUCLEIC ACIDS RES, V12, P8043, DOI 10.1093/nar/12.21.8043; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOOGSTEEN K, 1959, ACTA CRYSTALLOGR, V12, P822, DOI 10.1107/S0365110X59002389; KILPATRICK MW, 1986, J BIOL CHEM, V261, P1350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PANYUTIN IG, 1989, NUCLEIC ACIDS RES, V17, P8257, DOI 10.1093/nar/17.20.8257; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; Sambrook J, 1989, MOL CLONING LABORATO; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHARF R, 1988, BIOCHEMISTRY-US, V27, P2990, DOI 10.1021/bi00408a049; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHOEMAN RL, 1988, J BIOL CHEM, V263, P18744; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; WALSH K, 1992, J BIOL CHEM, V267, P13714; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	33	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3306	3312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429007				2022-12-25	WOS:A1993KM16100046
J	DIAMOND, DL; CARRUTHERS, A				DIAMOND, DL; CARRUTHERS, A			METABOLIC CONTROL OF SUGAR-TRANSPORT BY DEREPRESSION OF CELL-SURFACE GLUCOSE TRANSPORTERS - AN INSULIN-INDEPENDENT RECRUITMENT-INDEPENDENT MECHANISM OF REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; HUMAN-ERYTHROCYTE; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; HEXOSE TRANSFER; MESSENGER-RNA; PROTEIN; RAT; STIMULATION; ATP	Protein-mediated sugar transport is nominally absent in normoxic pigeon erythrocytes. Following exposure to metabolic inhibitors (cyanide or carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone), pigeon red cells transport sugars by a saturable stereoselective pathway that is inhibited by cytochalasin B or forskolin. The sugar transport capacity of fully poisoned cells is consistent with a transporter density of approximately 30 carriers/erythrocyte. Immunoblot analyses and competition enzyme-linked immunosorbent assay indicate that pigeon red cells contain approximately 200 copies of an integral plasma membrane protein immunologically related to the glucose transporter isoform GLUT1. GLUT1 is quantitatively restricted to the plasma membrane at all times. Pigeon red cells and brain lack proteins immunologically related to the sugar transporter isoforms GLUT3 and GLUT4. Specific immunodepletion of red cell GLUT1 content results in the subsequent loss of reconstitutable protein-mediated sugar transport. These findings demonstrate that avian erythrocyte sugar transport is mediated by a GLUT1-like sugar transport protein and that sugar transport stimulation by metabolic depletion results from derepression of cell surface sugar transport proteins.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01606; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01606	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036081, R56DK036081] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLOCH R, 1973, BIOCHEMISTRY-US, V12, P4799, DOI 10.1021/bi00747a036; BROWN JN, 1975, J MICROSC-OXFORD, V104, P293, DOI 10.1111/j.1365-2818.1975.tb04028.x; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CALDERHEADDM, 1990, J BIOL CHEM, V265, P13800; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P2712, DOI 10.1021/bi00307a027; CARRUTHERS A, 1983, BIOCHIM BIOPHYS ACTA, V728, P254, DOI 10.1016/0005-2736(83)90478-9; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CARRUTHERS A, 1978, J PHYSIOL-LONDON, V284, pP49; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHEUNG JY, 1977, BIOCHIM BIOPHYS ACTA, V470, P212, DOI 10.1016/0005-2736(77)90101-8; CLAUSEN T, 1975, CURRENT TOPICS MEMBR, V6, P169; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; HARRIS JR, 1971, J ULTRA MOL STRUCT R, V36, P8, DOI 10.1016/S0022-5320(71)80085-0; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HEBERT DN, 1986, J BIOL CHEM, V261, P93; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HELGERSON AL, 1989, BIOCHEMISTRY-US, V28, P6410, DOI 10.1021/bi00441a038; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; HELGERSON AL, 1989, BIOCHEMISTRY-US, V28, P4580, DOI 10.1021/bi00437a012; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; KABAT D, 1967, BIOCHIM BIOPHYS ACTA, V138, P382, DOI 10.1016/0005-2787(67)90498-4; KONO T, 1981, J BIOL CHEM, V256, P6400; LEFEVRE PG, 1959, J BIOL CHEM, V234, P3022; PESSINO A, 1991, J BIOL CHEM, V266, P20213; SHANAHAN MF, 1987, J BIOL CHEM, V262, P5978; SIMONS TJB, 1983, J PHYSIOL-LONDON, V338, P501, DOI 10.1113/jphysiol.1983.sp014686; SIMONS TJB, 1983, J PHYSIOL-LONDON, V338, P477, DOI 10.1113/jphysiol.1983.sp014685; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; WARDINSKI BE, 1987, J BIOL CHEM, V262, P17683; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WHITFIELD CF, 1973, BIOCHIM BIOPHYS ACTA, V307, P181, DOI 10.1016/0005-2736(73)90036-9; WIERSMA PA, 1985, ARCH BIOCHEM BIOPHYS, V242, P90, DOI 10.1016/0003-9861(85)90483-7; WOOD RE, 1969, J BIOL CHEM, V244, P1451; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; YU KT, 1978, AM J PHYSIOL, V234, P407; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZENTGRAF H, 1975, EXP CELL RES, V96, P81, DOI 10.1016/S0014-4827(75)80040-1; ZENTGRAF H, 1971, J BIOL CHEM, V246, P2986	53	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6437	6444						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454616				2022-12-25	WOS:A1993KT36800054
J	HUANG, LQ; FRANKLIN, AE; HOFFMAN, NE				HUANG, LQ; FRANKLIN, AE; HOFFMAN, NE			PRIMARY STRUCTURE AND CHARACTERIZATION OF AN ARABIDOPSIS-THALIANA CALNEXIN-LIKE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; ESCHERICHIA-COLI; RETENTION; MEMBRANE; IDENTIFICATION; CALRETICULIN; EXPRESSION; MUTATIONS; RECEPTOR	A cDNA clone (pTE-83) encoding a protein (CNX1p) related to the microsomal Ca2+-binding protein, calnexin, was isolated from an Arabidopsis thaliana expression library. Southern and Northern hybridization indicated that CNX1 is a single-copy gene encoding a message of 1900 nucleotides. The open reading frame encodes a polypeptide with 530 amino acids, a molecular mass of 60.5 kDa, and overall 48% identity to dog calnexin. Both animal calnexin and CNX1p contain a large luminal domain followed by a single potential membrane-spanning domain near the C terminus and a small C-terminal domain exposed to the cytoplasm. The in vitro translation product from the cloned cDNA yielded a polypeptide of 67 kDa that was co-translationally imported into dog microsomes and processed to a 64-kDa product. Antibodies generated against the C-terminal half of the protein cross-react with an identically sized protein present in the microsomal fraction from Arabidopsis. Both the imported and native proteins are cleaved by trypsin to a 59-kDa product indicating that the gene product was indeed correctly processed and translocated into dog microsomes and that the membrane topology of CNX1p resembles that of dog calnexin. The presence of a calnexin-like protein within the plant kingdom indicates that this protein is widespread and involved in processes fundamental to all eukaryotes.	CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Carnegie Institution for Science; Stanford University					NIGMS NIH HHS [GM42609-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CLINE K, 1986, J BIOL CHEM, V261, P4804; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EVANS DE, 1991, J EXP BOT, V42, P285, DOI 10.1093/jxb/42.3.285; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GALLAGHER S, 1988, P NATL ACAD SCI USA, V85, P8003, DOI 10.1073/pnas.85.21.8003; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARLOW E, 1988, ANTIBODIES LABORATOR; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; HOVANESSIAN AG, 1988, IMMUNOL TODAY, V9, P161, DOI 10.1016/0167-5699(88)91288-1; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KEEGSTRA K, 1988, METHODS PLANT MOL BI, P173; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WADA I, 1991, J BIOL CHEM, V266, P19599; [No title captured]	33	85	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6560	6566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454626				2022-12-25	WOS:A1993KT36800070
J	MATSUNOYAGI, A; HATEFI, Y				MATSUNOYAGI, A; HATEFI, Y			STUDIES ON THE MECHANISM OF OXIDATIVE-PHOSPHORYLATION - ATP SYNTHESIS BY SUBMITOCHONDRIAL PARTICLES INHIBITED AT F(0) BY VENTURICIDIN AND ORGANOTIN COMPOUNDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-LINKED REACTIONS; ADENOSINE-TRIPHOSPHATASE; PROPIONIGENIUM-MODESTUM; MITOCHONDRIAL ATPASE; ESCHERICHIA-COLI; F1; COOPERATIVITY; SYNTHASE; BINDING; ACID	Oligomycin, N,N'-dicyclohexylcarbodiimide (DCCD), venturicidin, and tetracoordinate organotin compounds (R3SnX) are potent inhibitors of the mitochondrial ATP synthase complex, all acting on the membrane sector, F0. Oligomycin and DCCD inhibit proton translocation through F0 and energy transfer between F0 and the catalytic sector, F1, of the ATP synthase complex. Our results have shown that venturicidin and organotin compounds (tributyltin and triphenyltin chloride were used) greatly attenuate these processes, but do not cause complete inhibition. As a result, bovine submitochondrial particles (SMP) treated with venturicidin or tributyltin chloride were shown to be capable of ATP hydrolysis and synthesis, albeit at very slow rates. We had shown previously that in ATP synthesis V(max) and apparent K(m) for ADP and P(i) increase or decrease, respectively, as the steady-state membrane potential is elevated or lowered (Matsuno-Yagi, A., and Hatefi, Y. (1986) J. Biol. Chem. 261, 14031-14038). These changes occurred at constant V(max)/K(m) suggesting that the apparent K(m) changes were due mainly to k(cat), changes. Results presented here show that, in respiring SMP treated with venturicidin or organotin compounds, the membrane potential is near the static-head level, but the slow rate of ATP synthesis takes place with a low K(m)ADP value of 2-3 muM. In agreement with our previous conclusions, these results indicate that it is not the membrane potential per se that affects K(m)ADP during ATP synthesis, but rather it is the rate of energy transfer from F0 to F1 that influences both V(max) and K(m)ADP. Further conclusions from the above studies have been discussed in relation to the possible mechanism of energy transfer between F0 and F1 and the manner in which venturicidin and organotin compounds might attenuate this process.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENEFSKY HS, 1991, ADV ENZYMOL, V64, P173; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; CHANG T, 1973, J BIOL CHEM, V248, P2746; CHANG TM, 1974, J BIOL CHEM, V249, P1090; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GRIFFITHS DE, 1977, BIOCHEM SOC T, V5, P205, DOI 10.1042/bst0050205; Hatefi Y, 1974, Methods Enzymol, V31, P770; HATEFI Y, 1982, P NATL ACAD SCI-BIOL, V79, P1756, DOI 10.1073/pnas.79.6.1756; HATEFI Y, 1982, BIOCHEMISTRY-US, V24, P6614; Hatefi Y., 1992, ADENINE NUCLEOTIDES, P33; HEKMAN C, 1988, BIOCHEMISTRY-US, V27, P7559, DOI 10.1021/bi00419a057; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; KLUGE C, 1992, BIOCHEM SOC T, V20, P572, DOI 10.1042/bst0200572; LAUBINGER W, 1990, BIOCHEMISTRY-US, V29, P5458, DOI 10.1021/bi00475a008; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P20308; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MATSUNOYAGI A, 1988, BIOCHEMISTRY-US, V27, P335, DOI 10.1021/bi00401a050; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; MATSUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550, DOI 10.1073/pnas.82.22.7550; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; NAGLEY P, 1986, FEBS LETT, V195, P159, DOI 10.1016/0014-5793(86)80152-1; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3735; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SKULACHEV VP, 1989, FEBS LETT, V250, P106, DOI 10.1016/0014-5793(89)80693-3; SKULACHEV VP, 1991, BIOSCIENCE REP, V11, P387, DOI 10.1007/BF01130214; VERSCHOOR GJ, 1977, BIOCHIM BIOPHYS ACTA, V462, P438, DOI 10.1016/0005-2728(77)90141-4	32	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6168	6173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454592				2022-12-25	WOS:A1993KT36800017
J	MEEDEL, TH; HASTINGS, KEM				MEEDEL, TH; HASTINGS, KEM			STRIATED MUSCLE-TYPE TROPOMYOSIN IN A CHORDATE SMOOTH-MUSCLE, ASCIDIAN BODY-WALL MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; ALPHA-TROPOMYOSIN; RABBIT SKELETAL; MESSENGER-RNAS; HALOCYNTHIA-RORETZI; CIONA-INTESTINALIS; FUNCTIONAL DOMAINS; THIN-FILAMENTS; SINGLE GENE	Body-wall muscle tropomyosin (Tm) of a marine chordate, the ascidian Ciona intestinalis, was studied by protein and cDNA clone analyses. Our results indicate that body-wall muscle of Ciona contains one major Tm isoform encoded by a single gene. Unexpectedly, the sequence of this Tm resembles vertebrate-striated muscle Tm isoforms, rather than those of smooth muscle or nonmuscle tissues, despite the fact that body-wall muscle is a nonsarcomeric (i.e. smooth) muscle. We also found that an apparently identical Tm isoform, derived from the same gene, is expressed at high levels in Ciona heart, a striated muscle. This is the first example of an organism in which a single Tm isoform is prominently expressed in both sarcomeric and nonsarcomeric tissues. Our results demonstrate that the characteristic features of ''sarcomeric'' Tm isoforms are not primarily related to sarcomeric ultrastructure per se. Instead, because ascidian body-wall muscle, unlike vertebrate smooth muscle, contains troponin, we suggest that it is the interaction with troponin that generates the selective pressure to maintain the characteristic C-terminal structure of so-called sarcomeric Tm isoforms. Our results further document the remarkable molecular similarity between the nonsarcomeric ascidian body-wall muscle and vertebrate-striated muscle. We suggest that these muscle types represent sarcomeric and nonsarcomeric variants of a fundamental class of troponin/Tm-regulated muscles, contrary to the traditional smooth/striated classification of muscle types. The possible relationship of this class of muscle to vertebrate smooth muscle is discussed.	MARINE BIOL LAB,DEV GENET LAB,WOODS HOLE,MA 02543; MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL H3A 2B4,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B4,QUEBEC,CANADA; MCGILL UNIV,DEPT NEUROL NEUROSURG,MONTREAL H3A 2B4,QUEBEC,CANADA	Marine Biological Laboratory - Woods Hole; McGill University; McGill University; McGill University	MEEDEL, TH (corresponding author), RHODE ISL COLL,DEPT BIOL,PROVIDENCE,RI 02908, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021823] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-21823] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AGELLON LB, 1986, GENE ANAL TECH, V3, P86, DOI 10.1016/0735-0651(86)90008-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; Berrill N.J., 1955, ORIGIN VERTEBRATES; BOLTON TB, 1981, SMOOTH MUSCLE ASSESS, P199; BONE Q, 1973, J MAR BIOL ASSOC UK, V53, P873, DOI 10.1017/S0025315400022530; BONE Q, 1974, PROC R SOC SER B-BIO, V187, P315, DOI 10.1098/rspb.1974.0077; BRITTEN RJ, 1978, CELL, V15, P1175, DOI 10.1016/0092-8674(78)90044-2; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; COLOTE S, 1988, J MOL EVOL, V27, P228, DOI 10.1007/BF02100079; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; CROWTHER RJ, 1990, DEVELOPMENT, V109, P953; DABROWSKA R, 1980, COMP BIOCHEM PHYS B, V65, P75, DOI 10.1016/0305-0491(80)90114-5; ENDO T, 1981, J BIOCHEM, V89, P1599, DOI 10.1093/oxfordjournals.jbchem.a133355; FLOREY E, 1967, COMP BIOCHEM PHYSIOL, V22, P617, DOI 10.1016/0010-406X(67)90757-8; GOODBODY I, 1974, ADV MAR BIOL, V12, P1; HALLAUER PL, 1987, J BIOL CHEM, V262, P3590; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; HASTINGS KEM, 1982, P NATL ACAD SCI-BIOL, V79, P1553, DOI 10.1073/pnas.79.5.1553; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; Hoyle G., 1983, MUSCLES THEIR NEURAL; KALK M, 1970, Tissue and Cell, V2, P99, DOI 10.1016/S0040-8166(70)80010-6; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARLIK CC, 1986, MOL CELL BIOL, V6, P1985; KATZ MJ, 1983, BIOL BULL-US, V164, P1, DOI 10.2307/1541186; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KOBZAR GT, 1985, COMP BIOCHEM PHYS C, V80, P395, DOI 10.1016/0742-8413(85)90074-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LINDQUESTER GJ, 1989, NUCLEIC ACIDS RES, V17, P2099, DOI 10.1093/nar/17.5.2099; MAK A, 1978, P NATL ACAD SCI USA, V75, P3588, DOI 10.1073/pnas.75.8.3588; MAK AS, 1980, J BIOL CHEM, V255, P3647; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENDES EG, 1972, COMPARATIVE, V3, P261, DOI 10.1016/0010-4035(72)90002-X; MONTARRAS D, 1981, J BIOL CHEM, V256, P4081; NEVITT G, 1986, TISSUE CELL, V18, P341, DOI 10.1016/0040-8166(86)90055-8; OBINATA T, 1983, COMP BIOCHEM PHYS B, V76, P437, DOI 10.1016/0305-0491(83)90272-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHSHIMA S, 1988, COMP BIOCHEM PHYS B, V90, P779, DOI 10.1016/0305-0491(88)90334-3; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OLIPHANT LW, 1972, Z ZELLFORSCH MIK ANA, V129, P395, DOI 10.1007/BF00307296; PARISH JH, 1972, PRINCIPLES PRACTICE; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; PORSSER CL, 1974, ANN REV PHYSL, V36, P503; PROSSER CL, 1982, BASIC BIOL MUSCLES C, P381; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; RUIZOPAZO N, 1985, NATURE, V315, P67, DOI 10.1038/315067a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENDER PM, 1971, FEBS LETT, V17, P106, DOI 10.1016/0014-5793(71)80575-6; SHINOHARA Y, 1982, J EXP ZOOL, V221, P137, DOI 10.1002/jez.1402210203; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SOBIESZEK A, 1981, EUR J BIOCHEM, V118, P533, DOI 10.1111/j.1432-1033.1981.tb05552.x; SOMLYO AV, 1980, HDB PHYSL 2, V2; Squire JM, 1986, MUSCLE DESIGN DIVERS; SUCOV HM, 1987, DEV BIOL, V120, P507, DOI 10.1016/0012-1606(87)90254-5; TAKAGI T, 1983, J BIOCHEM-TOKYO, V94, P1753, DOI 10.1093/oxfordjournals.jbchem.a134526; TERAKADO K, 1987, CELL TISSUE RES, V247, P85, DOI 10.1007/BF00216550; TOSELLI PA, 1977, TISSUE CELL, V9, P137, DOI 10.1016/0040-8166(77)90055-6; TOYOTA N, 1979, COMP BIOCHEM PHYS B, V62, P433, DOI 10.1016/0305-0491(79)90114-7; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; WALSH MP, 1989, PHYSL PATHOPHYSIOLOG, P855; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	76	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6755	6764						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454648				2022-12-25	WOS:A1993KT36800097
J	WAGA, S; MIZUNO, S				WAGA, S; MIZUNO, S			DIFFERENT BEHAVIOR OF CHROMATIN DOMAINS ENCOMPASSING FIBROIN HEAVY-CHAIN GENE IN ACTIVE, TEMPORARILY INACTIVE, AND PERMANENTLY INACTIVE TRANSCRIPTIONAL STATES IN SILK GLAND NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCATED FAR UPSTREAM; BOMBYX-MORI; MESSENGER-RNA; LYSOZYME GENE; DNA; REGIONS; CELLS; SITES	Chromatin structures of an approximately 46-kilobase pair region encompassing fibroin heavy chain gene of the silkworm, Bombyx mori, were compared in active (in the posterior silk gland nuclei of the fifth instar larvae), temporarily inactive (in the posterior silk gland nuclei of the fourth molting stage larvae), and permanently inactive (in the middle silk gland nuclei of the fifth instar larvae) transcriptional states. Chromatin structure of the second exon, the major body of the protein-encoding region, was highly sensitive to both DNase I and methidiumpropyl EDTA-Fe(II) in the active state but highly resistant to those agents in both temporarily and permanently inactive states, except that the fibroin ''amorphous'' region-encoding subregions remained relatively sensitive to DNase I. Distributions of DNase I hypersensitive sites in the 5' upstream region were generally similar between active and temporarily inactive states, but those of the permanently inactive state were markedly different. In the promoter-enhancer region, phosphodiester bonds between nucleotide positions -41 and -42 and also -42 and -43 were remarkably hypersensitive to DNase I in the active chromatin, but the same positions in the other two states were not.	TOHOKU UNIV,DEPT APPL BIOL CHEM,MOLEC BIOL LAB,1-1 TSUTSUMIDORI AMAMIYAMACHI,AOBA KU,SENDAI 981,JAPAN	Tohoku University				Waga, Shou/0000-0003-4986-8735				BURCH JBE, 1990, NUCLEIC ACIDS RES, V18, P4157, DOI 10.1093/nar/18.14.4157; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CHAN L, 1973, P NATL ACAD SCI USA, V70, P1870, DOI 10.1073/pnas.70.6.1870; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITTON HP, 1987, BIOL CHEM H-S, V368, P111, DOI 10.1515/bchm3.1987.368.1.111; GAGE LP, 1974, J MOL BIOL, V86, P97; GAGE LP, 1980, J BIOL CHEM, V255, P9444; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KIKUCHI Y, 1992, GENE, V110, P151, DOI 10.1016/0378-1119(92)90642-3; KIMURA K, 1985, EXPERIENTIA, V41, P1167, DOI 10.1007/BF01951711; KONDO K, 1987, J BIOL CHEM, V262, P5271; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; Maxam A M, 1980, Methods Enzymol, V65, P499; McKnight S L, 1976, Prog Nucleic Acid Res Mol Biol, V19, P313; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MITA K, 1988, J MOL BIOL, V203, P917, DOI 10.1016/0022-2836(88)90117-9; MIZUNO S, 1987, Gunma Symposia on Endocrinology, V24, P27; PUGH BF, 1992, J BIOL CHEM, V267, P679; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; Suzuki Y., 1990, MOL INSECT SCI, P83; TAKEI F, 1987, J CELL BIOL, V105, P175, DOI 10.1083/jcb.105.1.175; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; TSUJIMOTO Y, 1979, CELL, V18, P591, DOI 10.1016/0092-8674(79)90075-8; YAMAGUCHI K, 1989, J MOL BIOL, V210, P127, DOI 10.1016/0022-2836(89)90295-7	28	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6429	6436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454615				2022-12-25	WOS:A1993KT36800053
J	WANANDI, I; WALDSCHMIDT, R; SEIFART, KH				WANANDI, I; WALDSCHMIDT, R; SEIFART, KH			MAMMALIAN TRANSCRIPTION FACTOR-PBP - CHARACTERIZATION OF ITS BINDING-PROPERTIES TO THE PROXIMAL SEQUENCE ELEMENT OF U6 GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; DNA-BINDING; SNRNA PROMOTER; PURIFICATION; INVITRO; COMPLEXES; UPSTREAM; DOMAINS; POLYPEPTIDE; SPECIFICITY	The DNA binding properties of human transcription factor PBP, which specifically binds to the proximal sequence element of mammalian U6 genes and which plays a pivotal role during their transcription, were analyzed both qualitatively and quantitatively. As a prerequisite, we analyzed the optimal conditions for DNA binding of the PBP by assaying the stability of the interaction against increasing concentrations of salt, dithiothreitol, and heparin. The protein, which does not induce DNA bending, has a characteristic sensitivity against elevated temperatures and precipitously loses activity between 41 and 43-degrees-C, a property which can be used for selective inactivation of the protein. Subjection of the PBP to limited proteinase K treatment showed that the protein consists of at least two functional domains, one of which is required for DNA binding. The PBP binds to the PSE with a much higher specific equilibrium constant (K(s) = 1.33 x 10(11) M-1) than to nonspecific DNA (K(n) = 1.18 x 10(5) M-1). The association and dissociation rates of PBP . PSE interactions were quantitatively determined by kinetic analyses. The pronounced lag phase during the initiation reaction of mammalian U6 transcription in vitro is probably correlated with the slow binding of the PBP to its target sequence. Once formed, however, the PBP . PSE complex is very stable and has a much lower dissociation (k(d) = 1.84 x 10(-5) s-1) than association rate constant (k(a) = 0.18 x 10(6) M-1 s-1). Collectively, the results demonstrate that the PSE binding protein stably associates with a high affinity to its cognate promoter sequence, and this process represents one of the primary events in the formation of the preinitiation complex on the U6 gene. Finally, we analyzed the effect of individual base pair mutations within mammalian U6 PSE sequences on the binding of the PBP.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,LAHNSTR 3,W-3550 MARBURG,GERMANY	Philipps University Marburg				Wanandi, Septelia Inawati/0000-0002-7963-8853				AGARWAL KL, 1972, ANGEW CHEM INT EDIT, V11, P451, DOI 10.1002/anie.197204511; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FRANKEL AD, 1988, CELL, V53, P675, DOI 10.1016/0092-8674(88)90083-9; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PAPOULAS O, 1988, CURRENT PROTOCOLS MO, P1; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SEIFART KH, 1989, J BIOL CHEM, V264, P1702; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WINGENDER E, 1984, NUCLEIC ACIDS RES, V12, P8971, DOI 10.1093/nar/12.23.8971; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	40	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6629	6640						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454634				2022-12-25	WOS:A1993KT36800080
J	WILLARDSON, BM; POU, B; YOSHIDA, T; BITENSKY, MW				WILLARDSON, BM; POU, B; YOSHIDA, T; BITENSKY, MW			COOPERATIVE BINDING OF THE RETINAL ROD G-PROTEIN, TRANSDUCIN, TO LIGHT-ACTIVATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ALPHA-SUBUNIT; OUTER SEGMENTS; PHOTOEXCITED RHODOPSIN; PHOTORECEPTOR-MEMBRANES; CGMP PHOSPHODIESTERASE; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; CARBOXYL TERMINUS; 48-KDA PROTEIN	Direct measurements of the binding between light-activated rhodopsin (Rho*) and transducin, the retinal rod G-protein, revealed a strongly cooperative interaction. Cooperativity was assessed by measuring the association of I-125-labeled transducin (G(t)) to Rho* in urea-stripped rod outer segment membranes at equilibrium. Analysis of I-125-G(t) binding curves gave a Hill coefficient of 1.8. These data were consistent with a two-site model in which binding of the first I-125-G(t) to Rho* increased the binding of the second I-125-G(t) almost-equal-to 40-fold (K(d) values were 80 +/- 30 and 1.9 +/- 0.7 nM, respectively). The effects of GDP on the binding were also investigated. GDP decreased the affinity between Rho* and G(t) almost-equal-to 100-fold but did not decrease the degree of cooperativity. Binding curves of I-125-G(t) in the presence of 1 mM GDP showed a Hill coefficient of 1.9. The data were also consistent with a two-binding site model in which binding of the first I-125-G(t) increased the binding of the second I-125-G(t) almost-equal-to 70-fold (K(d) values were 13.7 +/- 5.4 and 0.20 +/- 0.08 muM, respectively). The G(t)alpha subunit in the absence of G(t)betagamma also bound Rho* in a cooperative manner. These data implicate a role for the cooperative association of Rho* and G(t) in the light activation cascade of retinal rods.	LOS ALAMOS NATL LAB,DIV PHYS,BIOPHYS GRP,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory				Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY06816] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Blaurock A. E., 1977, VERTEBRATE PHOTORECE, P61; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V1071, P473, DOI 10.1016/0304-4157(91)90007-J; CHABRE M, 1975, BIOCHIM BIOPHYS ACTA, V382, P336, DOI 10.1016/0005-2736(75)90275-8; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; DRATZ EA, 1979, PHOTOCHEM PHOTOBIOL, V29, P661, DOI 10.1111/j.1751-1097.1979.tb07746.x; ENDRENYI L, 1971, CAN J BIOCHEM CELL B, V49, P581, DOI 10.1139/o71-085; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HINGORANI VN, 1987, FEBS LETT, V220, P15, DOI 10.1016/0014-5793(87)80867-0; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HINGORANI VN, 1987, BIOCHEMISTRY-US, V26, P1633, DOI 10.1021/bi00380a022; HOFMANN KP, 1985, BIOCHIM BIOPHYS ACTA, V810, P278, DOI 10.1016/0005-2728(85)90143-4; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KHAN SMA, 1991, EUR J BIOCHEM, V200, P53, DOI 10.1111/j.1432-1033.1991.tb21047.x; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; PANICO J, 1990, J BIOL CHEM, V265, P18922; RICARD J, 1987, EUR J BIOCHEM, V166, P255, DOI 10.1111/j.1432-1033.1987.tb13510.x; SHAW A, 1980, BIOCHIM BIOPHYS ACTA, V603, P313, DOI 10.1016/0005-2736(80)90377-6; SHINOZAWA T, 1979, J SUPRAMOL STR CELL, V10, P185, DOI 10.1002/jss.400100208; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	54	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6371	6382						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454608				2022-12-25	WOS:A1993KT36800045
J	BOURDINEAUD, JP; HEIERLI, D; GAMPER, M; VERHOOGT, HJC; DRIESSEN, AJM; KONINGS, WN; LAZDUNSKI, C; HAAS, D				BOURDINEAUD, JP; HEIERLI, D; GAMPER, M; VERHOOGT, HJC; DRIESSEN, AJM; KONINGS, WN; LAZDUNSKI, C; HAAS, D			CHARACTERIZATION OF THE ARCD ARGININE-ORNITHINE EXCHANGER OF PSEUDOMONAS-AERUGINOSA - LOCALIZATION IN THE CYTOPLASMIC MEMBRANE AND A TOPOLOGICAL MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; BROAD-HOST-RANGE; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; DEIMINASE PATHWAY; SALMONELLA-TYPHIMURIUM; STREPTOCOCCUS-LACTIS; NUCLEOTIDE-SEQUENCE; PROTEIN SECRETION; ANAEROBIC GROWTH	The arcDABC operon of Pseudomonas aeruginosa encodes the enzymes of the arginine deiminase pathway and is induced by oxygen limitation. The arcD gene specifies a 53-kDa protein with arginine: ornithine exchange activity. The ArcD protein of P. aeruginosa, like the LysI lysine transporter of Corynebacterium glutamicum, has 13 hydrophobic regions which could span the cytoplasmic membrane. Fusion of a Caa (colicin A) epitope to the N-terminal part of ArcD permitted the localization, by immunoblotting, of the hybrid protein in the inner membrane of P. aeruginosa. Fusion of PhoA (alkaline phosphatase) to the very C terminus of ArcD produced another hybrid protein, which exhibited PhoA activity. Both ArcD hybrid proteins retained arginine transport activity and served to support a topological model which proposes that the N terminus is oriented toward the cytoplasm and the C terminus faces the periplasm. Further ArcD-PhoA fusions were consistent with this model. When the Caa epitope was fused to a C-terminal ArcD fragment consisting of only 5 hydrophobic domains, the resulting hybrid protein could be recovered intact from the inner membrane, suggesting that the C-terminal part of ArcD contains sufficient information for insertion into the membrane. This study illustrates the utility of the Caa epitope to tag membrane proteins.	SWISS FED INST TECHNOL,DEPT MICROBIOL,CH-8092 ZURICH,SWITZERLAND; CNRS,CTR BIOCHIM & BIOL MOLEC,F-13402 MARSEILLE 9,FRANCE; UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); University of Groningen			Driessen, Arnold J.M./D-1876-2012; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BALLY M, 1991, J BACTERIOL, V173, P479, DOI 10.1128/jb.173.2.479-486.1991; BAUR H, 1987, EUR J BIOCHEM, V166, P111, DOI 10.1111/j.1432-1033.1987.tb13489.x; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BOURDINEAUD JP, 1989, J BACTERIOL, V171, P2458, DOI 10.1128/jb.171.5.2458-2465.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROER S, 1990, J BACTERIOL, V172, P7241, DOI 10.1128/jb.172.12.7241-7248.1990; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CAVARD D, 1986, J MOL BIOL, V187, P449, DOI 10.1016/0022-2836(86)90445-6; CELIS TFR, 1973, J BACTERIOL, V116, P619, DOI 10.1128/JB.116.2.619-626.1973; CHANG CN, 1986, GENE, V44, P121; DAVISON J, 1989, GENE, V83, P371, DOI 10.1016/0378-1119(89)90124-8; DRIESSEN AJM, 1989, J BIOL CHEM, V264, P10361; DRIESSEN AJM, 1987, P NATL ACAD SCI USA, V84, P6093, DOI 10.1073/pnas.84.17.6093; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GALIMAND M, 1991, J BACTERIOL, V173, P1598, DOI 10.1128/jb.173.5.1598-1606.1991; GAMPER M, 1991, J BACTERIOL, V173, P4742, DOI 10.1128/jb.173.15.4742-4750.1991; GARRIGA X, 1992, MOL GEN GENET, V236, P125, DOI 10.1007/BF00279651; GELI V, 1989, MOL MICROBIOL, V3, P679, DOI 10.1111/j.1365-2958.1989.tb00216.x; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; Gennis R. B., 1989, BIOMEMBRANES MOL STR, P91; GOLDBERG JB, 1990, J GEN MICROBIOL, V136, P789, DOI 10.1099/00221287-136-5-789; HANCOCK REW, 1978, J BACTERIOL, V136, P381, DOI 10.1128/JB.136.1.381-390.1978; HENDERSON PJF, 1990, RES MICROBIOL, V141, P316, DOI 10.1016/0923-2508(90)90005-B; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; ITOH Y, 1984, PLASMID, V11, P206, DOI 10.1016/0147-619X(84)90027-1; JANN A, 1986, P NATL ACAD SCI USA, V83, P4937, DOI 10.1073/pnas.83.13.4937; JEENES DJ, 1986, MOL GEN GENET, V203, P421, DOI 10.1007/BF00422066; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LUTHI E, 1986, J GEN MICROBIOL, V132, P2667; LUTHI E, 1990, GENE, V87, P37, DOI 10.1016/0378-1119(90)90493-B; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8120; MERCENIER A, 1980, J BACTERIOL, V144, P159, DOI 10.1128/JB.144.1.159-163.1980; MEYER R, 1982, J BACTERIOL, V152, P140; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MILLER RV, 1988, J BACTERIOL, V170, P2385, DOI 10.1128/jb.170.5.2385-2387.1988; MORLON J, 1988, MOL GEN GENET, V211, P231, DOI 10.1007/BF00330599; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; POOLMAN B, 1987, J BACTERIOL, V169, P5597, DOI 10.1128/jb.169.12.5597-5604.1987; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; RAMOS F, 1970, EUR J BIOCHEM, V12, P40, DOI 10.1111/j.1432-1033.1970.tb00818.x; Sambrook J, 1989, MOL CLONING LABORATO; SANO Y, 1984, J BACTERIOL, V158, P562, DOI 10.1128/JB.158.2.562-570.1984; SEEPFELDHAUS AH, 1991, MOL MICROBIOL, V5, P2995, DOI 10.1111/j.1365-2958.1991.tb01859.x; SHINOMIYA T, 1984, J VIROL, V49, P310, DOI 10.1128/JVI.49.2.310-314.1984; SIMON R, 1986, METHOD ENZYMOL, V118, P640; TOMMASSEN J, 1984, J BACTERIOL, V157, P327, DOI 10.1128/JB.157.1.327-329.1984; VANDERWAUVEN C, 1984, J BACTERIOL, V160, P928, DOI 10.1128/JB.160.3.928-934.1984; VERHOOGT HJC, 1992, J BACTERIOL, V174, P1568, DOI 10.1128/jb.174.5.1568-1573.1992; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; ZIMMERMANN A, 1991, MOL MICROBIOL, V5, P1483, DOI 10.1111/j.1365-2958.1991.tb00794.x	60	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5417	5424						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449902				2022-12-25	WOS:A1993KR82200014
J	HURLEY, MM; ABREU, C; HARRISON, JR; LICHTLER, AC; RAISZ, LG; KREAM, BE				HURLEY, MM; ABREU, C; HARRISON, JR; LICHTLER, AC; RAISZ, LG; KREAM, BE			BASIC FIBROBLAST GROWTH-FACTOR INHIBITS TYPE-I COLLAGEN GENE-EXPRESSION IN OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DNA-SEQUENCES; C-FOS; ALKALINE-PHOSPHATASE; ENDOTHELIAL-CELLS; BONE-FORMATION; MESSENGER-RNA; FACTOR-BETA; RAT; TRANSCRIPTION	We examined the effect of basic fibroblast growth factor (bFGF) on alpha1(I) procollagen mRNA levels, alpha1(I) collagen gene transcription, and alpha1(I) collagen promoter activity in osteoblastic MC3T3-E1 cells. Cells were stably transfected with ColCAT 3.6, containing 3521 base pairs of alpha1(I) collagen promoter DNA, fused to the CAT reporter gene, or an upstream deletion mutant of ColCAT 3.6 designated ColCAT 2.3. After 48 h, bFGF (0.1-10 nM) inhibited the incorporation of [H-3]proline into collagenase-digestible protein (CDP). Indomethacin did not alter the inhibitory effect of bFGF on CDP labeling. Aphidicolin, an inhibitor of DNA synthesis, did not block the inhibitory effect of bFGF on CDP. bFGF (1-10 nM) decreased alpha1(I) procollagen mRNA levels, with maximal inhibition, nearly 99% of control, caused by 10 nM bFGF. After 48 h, bFGF (1 nM) reduced alpha1(I) procollagen gene transcription by about 92%. ColCAT 3.6 activity was inhibited with 0.1-10 nM bFGF and was maximally repressed by about 83% with 10 nM bFGF. In contrast, bFGF (1 and 10 nM) caused a stimulation of ColCAT 2.3 activity. These data show that bFGF inhibits collagen synthesis by a transcriptional mechanism and the alpha1(I) collagen promoter contains DNA sequences which mediate bFGF inhibition of type I collagen gene expression in bone.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030	University of Connecticut	HURLEY, MM (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV ENDOCRINOL & METAB,FARMINGTON,CT 06030, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR029850, P01AR038933, R01AR029983] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-29850, AR-29983, AR-38933] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BOAST S, 1990, J BIOL CHEM, V265, P13351; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEMARQUAY D, 1990, HORM RES, V33, P111, DOI 10.1159/000181493; DIEGELMANN R, 1972, DEV BIOL, V28, P444; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; HURLEY MM, 1992, ENDOCRINOLOGY, V130, P2675, DOI 10.1210/en.130.5.2675; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KATAGIRI T, 1990, BONE MINER, V11, P285, DOI 10.1016/0169-6009(90)90025-B; KREAM BE, 1985, ENDOCRINOLOGY, V116, P296, DOI 10.1210/endo-116-1-296; KRONENBERG MS, 1991, J BONE MINER RES  S1, V6, pS203; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V182, P1389, DOI 10.1016/0006-291X(92)91887-V; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NEWFELD G, 1986, J BIOL CHEM, V261, P5631; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; Okazaki R, 1991, J BONE MINER RES  S1, V6, pS142; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654; RAISZ LG, 1991, J BONE MINER RES, V6, pS253; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RODAN SB, 1989, CONNECT TISSUE RES, V20, P283, DOI 10.3109/03008208909023898; RODAN SB, 1989, J BIOL CHEM, V264, P19934; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SHEN V, 1989, BONE MINER, V7, P205, DOI 10.1016/0169-6009(89)90078-0; SIMMONS HA, 1991, J BONE MINER RES, V6, P1301; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUDA H, 1983, J CELL BIOL, V96, P191; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	49	181	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5588	5593						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449921				2022-12-25	WOS:A1993KR82200038
J	KAMPFENKEL, K; BRAUN, V				KAMPFENKEL, K; BRAUN, V			TOPOLOGY OF THE EXBB PROTEIN IN THE CYTOPLASMIC MEMBRANE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; OUTER-MEMBRANE; TONB PROTEIN; NUCLEOTIDE-SEQUENCES; TRANSPORT; GENES; RECEPTOR; COMPLEMENTATION; SUPPRESSION; EXPRESSION	The ExbB protein together with the ExbD and TonB proteins is involved in energy-coupled transport across the outer membrane of Escherichia coli. To understand this unusual process it is required to determine the subcellular location of ExbB and its transmembrane arrangement. Using ExbB-beta-lactamase fusion proteins as reporters for a periplasmic versus a cytoplasmic location of the fusion sites, and accessibility of ExbB in spheroplasts and cell lysates to aminopeptidase K, trypsin, and proteinase K, we arrived at a model of ExbB topology in the cytoplasmic membrane. Starting with the N terminus in the periplasm ExbB contains three transmembrane segments (residues 16-39, 128-155, 162-194) a small periplasmic loop and two large portions in the cytoplasm. Two of the 18 fusion proteins studied, ExbB34-beta-lactamase and ExbB41-beta-lactamase, conferred a high ampicillin resistance. Protease experiments revealed a high respectively low percentage of the molecules in a reverse transmembrane orientation. Both proteins were lacking positive charges at the inner side of the cytoplasmic membrane which determine the orientation of transmembrane segments.	UNIV TUBINGEN,MORGENSTELLE 28,W-7400 TUBINGEN 1,GERMANY	Eberhard Karls University of Tubingen								ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; BRAUN V, 1989, J BACTERIOL, V171, P6387, DOI 10.1128/jb.171.11.6387-6390.1989; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; FISCHER E, 1989, J BACTERIOL, V171, P5127, DOI 10.1128/jb.171.9.5127-5134.1989; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; HUBACEK J, 1970, J MOL BIOL, V50, P111, DOI 10.1016/0022-2836(70)90108-7; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KAMFENKEL K, 1992, BIOCHIM BIOPHYS ACTA, V1156, P71; KAMPFENKEL K, 1992, J BACTERIOL, V174, P5485, DOI 10.1128/JB.174.16.5485-5487.1992; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MENDE J, 1990, MOL MICROBIOL, V4, P1523, DOI 10.1111/j.1365-2958.1990.tb02063.x; MILLAN J L, 1989, Journal of Bacteriology, V171, P5536; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; PEARCE SR, 1992, MOL MICROBIOL, V6, P47, DOI 10.1111/j.1365-2958.1992.tb00836.x; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Silhavy T.J., 1984, EXPT GENE FUSIONS; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6050	6057						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449962				2022-12-25	WOS:A1993KR82200101
J	LU, WP; SCHIAU, I; CUNNINGHAM, JR; RAGSDALE, SW				LU, WP; SCHIAU, I; CUNNINGHAM, JR; RAGSDALE, SW			SEQUENCE AND EXPRESSION OF THE GENE ENCODING THE CORRINOID IRON-SULFUR PROTEIN FROM CLOSTRIDIUM-THERMOACETICUM AND RECONSTITUTION OF THE RECOMBINANT PROTEIN TO FULL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE SYNTHASE; METHYLMALONYL-COA MUTASE; ESCHERICHIA-COLI K-12; ACETYL COENZYME-A; NUCLEOTIDE-SEQUENCE; CARBON-MONOXIDE; PROPIONIBACTERIUM-SHERMANII; POLYACRYLAMIDE GELS; METH GENE; DEHYDROGENASE	The corrinoid/iron-sulfur protein (C/Fe-SP) from Clostridium thermoaceticum acts as a methyl group carrier in the anaerobic acetyl-CoA pathway of CO and CO2 fixation. Consisting of a small (approximately 33 kDa) and a large (approximately 55 kDa) subunit, the C/Fe-SP contains 1 mol of cobalt in a corrinoid cofactor and 1 mol of [4Fe-4S]2+/1+ cluster/mol of alphabeta dimer. Cobalt is the site of methylation, and the [4Fe-4S] center appears to serve an electron transfer function. The genes encoding both subunits have been cloned previously and are located within a gene cluster that includes other genes required for CO2 fixation by anaerobic bacteria. When the genes encoding the C/Fe-SP were expressed in Escherichia coli, the protein was found to be inactive. We report the amino acid sequences of the large and small subunits of the C/Fe-SP based on the DNA sequences of the cloned genes. The [4Fe-4S] cluster was found to be located in the large subunit. Although the primary structural lattice for cobamide binding resides in the small subunit, both subunits are required for formation of a stable cobamide-binding protein. Based on sequence comparisons with other [4Fe-4S]-containing proteins, 3 of the 4 cysteine residues that serve as ligands to the iron sites in the cluster have been located. The two subunits were independently overexpressed in E. coli to a level of 30-50% of cell protein; however, the resulting protein was inactive, lacked stoichiometric amounts of Fe-S cluster, and lacked cobamide. By combining the recombinant subunits, unfolding them with urea, and refolding in the presence of cobamide, iron, and inorganic sulfide, the resulting C/Fe-SP was found to contain stoichiometric amounts of cobamide and [4Fe-4S] cluster and had spectroscopic and enzymatic properties similar to those of the native protein. We expect that the methods developed here may be used for heterologous overexpression and reconstitution of other complex metalloenzymes. The C/Fe-SP was found to utilize with equal efficiency either vitamin B12 or the natural cofactor 5-methoxybenzimidazolylcobamide as a methyl carrier.	UNIV NEBRASKA,DEPT BIOCHEM,E CAMPUS,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln								BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BERG BL, 1991, J BIOL CHEM, V266, P22380; Berger S. L., 1987, GUIDE MOL CLONING TE; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEKGRAEFE BK, 1988, P NATL ACAD SCI USA, V85, P46; DRAKE HL, 1981, J BIOL CHEM, V256, P1137; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEORGE DG, 1985, J MOL EVOL, V22, P20, DOI 10.1007/BF02105801; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; HU SI, 1984, J BIOL CHEM, V259, P8892; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAH.L, 1965, BIOCHEMISTRY-US, V4, P2771, DOI 10.1021/bi00888a030; Ljungdahl L G, 1978, Methods Enzymol, V53, P360; LOVELL CR, 1990, BIOCHEMISTRY-US, V29, P5687, DOI 10.1021/bi00476a007; LU WP, 1990, J BIOL CHEM, V265, P3124; LUCHINSKY CL, 1992, J MOL BIOL, V222, P557; LUNDRIGAN MD, 1989, J BACTERIOL, V171, P154, DOI 10.1128/jb.171.1.154-161.1989; MARSH EN, 1989, BIOCHEM J, V260, P345, DOI 10.1042/bj2600345; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORTON TA, 1991, J BIOL CHEM, V266, P23824; OLD IG, 1990, GENE, V87, P15, DOI 10.1016/0378-1119(90)90490-I; OTAKA E, 1987, J MOL EVOL, V26, P257, DOI 10.1007/BF02099857; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Pilbrow J. R., 1982, B12, V1, P431; PILBROW JR, 1973, MOL PHYS, V25, P1073, DOI 10.1080/00268977300100941; POSTON JM, 1964, ANN NY ACAD SCI, V112, P804, DOI 10.1111/j.1749-6632.1964.tb45057.x; Rabinowitz J, 1972, Methods Enzymol, V24, P431; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; REISNER AH, 1975, ANAL BIOCHEM, V64, P509, DOI 10.1016/0003-2697(75)90461-3; ROBERTS DL, 1989, P NATL ACAD SCI USA, V86, P32, DOI 10.1073/pnas.86.1.32; ROBERTS JR, 1992, J BACTERIOL, V174, P4667, DOI 10.1128/JB.174.14.4667-4676.1992; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	50	48	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5605	5614						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449924				2022-12-25	WOS:A1993KR82200041
J	SKARSTAD, K; THONY, B; HWANG, DS; KORNBERG, A				SKARSTAD, K; THONY, B; HWANG, DS; KORNBERG, A			A NOVEL BINDING-PROTEIN OF THE ORIGIN OF THE ESCHERICHIA-COLI CHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RNA-DNA HYBRID; NUCLEOTIDE-SEQUENCE; REPLICATION ORIGIN; TRANSPOSON TN10; INITIATION; OPERON; GENES; INVITRO; K-12	The replication origin of Escherichia coli (oriC) was probed for specific binding proteins, using the gel shift assay. A 33-kDa protein that binds specifically to the right border of oriC, next to the rightmost of the binding sites of the initiator protein, DnaA, was identified and purified. The stoichiometry of protein to DNA is about 6 to 1. Around 5000 monomers of the protein, named Rob (right oriC binding), are present per cell. The rob gene has been located near 99.8 min on the E. coli map, cloned, and overexpressed. The total protein sequence reveals strong homologies to several regulatory proteins with which it shares the helix-turn-helix motif.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT BIOPHYS,N-0310 OSLO 3,NORWAY	Stanford University; University of Oslo					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMEMURA M, 1986, J BACTERIOL, V168, P294, DOI 10.1128/jb.168.1.294-302.1986; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BRAUS G, 1984, J BACTERIOL, V160, P504, DOI 10.1128/JB.160.2.504-509.1984; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kornberg A., 1992, DNA REPLICATION; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; Miller J.H., 1972, EXPT MOL GENETICS; MOROHOSHI F, 1990, NUCLEIC ACIDS RES, V18, P5473, DOI 10.1093/nar/18.18.5473; NELSON K, 1991, P NATL ACAD SCI USA, V88, P6667, DOI 10.1073/pnas.88.15.6667; RUDD KE, 1990, NUCLEIC ACIDS RES, V18, P313, DOI 10.1093/nar/18.2.313; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLLMEIER K, 1984, J BACTERIOL, V160, P499, DOI 10.1128/JB.160.2.499-503.1984; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SINGLETON CK, 1980, NUCLEIC ACIDS RES, V8, P1551, DOI 10.1093/nar/8.7.1551; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SUGIMOTO K, 1979, P NATL ACAD SCI USA, V76, P575, DOI 10.1073/pnas.76.2.575; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; TOBIN JF, 1987, J MOL BIOL, V196, P789, DOI 10.1016/0022-2836(87)90405-0; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	30	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5365	5370						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449900				2022-12-25	WOS:A1993KR82200007
J	SERVENTI, IM; CAVANAUGH, E; MOSS, J; VAUGHAN, M				SERVENTI, IM; CAVANAUGH, E; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF THE GENE FOR ADP-RIBOSYLATION FACTOR (ARF)-2, A DEVELOPMENTALLY REGULATED, SELECTIVELY EXPRESSED MEMBER OF THE ARF FAMILY OF SIMILAR-TO-20-KDA GUANINE NUCLEOTIDE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS GENE; CHOLERA-TOXIN; MESSENGER-RNA; MAMMALIAN-CELLS; PROMOTER REGION; PLASMID DNA; FUNCTIONAL-CHARACTERIZATION; ADENYLATE-CYCLASE; ALPHA-SUBUNIT; GTP	ADP-ribosylation factors (ARFs) are a family of approximately 20-kDa guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activities of cholera toxin in vitro and function in protein trafficking in vivo. The six cloned mammalian ARFs can be grouped into three classes based on size and sequence identity. ARF 2 is a class I ARF, whose approximately 2.6-kilobase mRNA exhibits species and tissue selective expression and is developmentally regulated in rat brain. Here we report the sequence, structure, and functional promoter region of the bovine ARF 2 gene, which was facilitated by constructing a composite cDNA. The ARF 2 cDNA, constructed from a partial cDNA clone and polymerase chain reaction-amplified fragments from reverse-transcribed poly(A)+ RNA, was approximately 2270 base pairs (bp) (minus the poly(A) tail). In the 3'-untranslated region, there are two potential polyadenylation signals, ATTAAA and AATAAA, at positions 1064 and 2232, respectively, and two ATTTA motifs, believed to signal mRNA degradation, at positions 2115 and 2165. The ARF 2 gene, represented in three overlapping genomic clones, spans approximately 20 kilobase pairs with five exons and four introns. Consensus sequences for guanine nucleotide-binding and GTP hydrolysis are in separate exons, except for the NKXD sequence, which is divided by intron 4. There are multiple transcriptional initiation sites. Transient transfection of embryonic trachea cells with deletion constructs defined the functional promoter region to be within 400 bp upstream of the most 5' site of transcription initiation. This 400-bp region lacks a TATA-like sequence but contains six inverted CCAAT boxes, four potential Sp1-binding sites, and a potential AP-2-binding site. Although the pattern of expression of ARF 2 is unique among the ARFs, the structures of the class I ARF genes are conserved among its members and across species.			SERVENTI, IM (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N307,BLDG 10,BETHESDA,MD 20892, USA.							ALSIP GR, 1986, NUCLEIC ACIDS RES, V14, P2123, DOI 10.1093/nar/14.5.2123; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BAHNSON TD, 1989, J BIOL CHEM, V264, P14824; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, METHOD ENZYMOL, V152, P337; DEWIT JR, 1987, MOL CELL BIOL, V7, P725; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P337; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FROHMAN MA, 1989, TECHNIQUE, V1, P165; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1990, G PROTEINS, P201; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LEE CM, 1992, J BIOL CHEM, V267, P9028; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MATHIS DJ, 1981, P NATL ACAD SCI-BIOL, V78, P7383, DOI 10.1073/pnas.78.12.7383; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; PENG Z, 1989, Biofactors, V2, P45; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEFFENS DL, 1989, BIOTECHNIQUES, V7, P674; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	55	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4863	4872						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444865				2022-12-25	WOS:A1993KP88400048
J	BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y				BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y			ISOLATION OF PEBP2-ALPHA-B CDNA REPRESENTING THE MOUSE HOMOLOG OF HUMAN ACUTE MYELOID-LEUKEMIA GENE, AML1	ONCOGENE			English	Article							RECEPTOR ALPHA-GENE; HA-RAS ONCOGENE; POLYOMAVIRUS ENHANCER; TRANSCRIPTION FACTOR; PROTEIN; TRANSLOCATIONS; EXPRESSION; BINDING; DOMAIN; CELLS	Breakpoints of the t(8;21) chromosome translocation in acute myeloid leukemia are clustered within the human gene, AML1, located on chromosome 21 [Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y. & Ohki, M. (1991). Proc. Natl. Acad. Sci. USA, 88, 10431-104341. The product of AML1 has a region about 130 amino acids long that is highly homologous to the Drosophila segmentation gene runt (runt homology region). The cDNA isolated from mouse fibroblasts encoding the alpha-subunit of polyomavirus enhancer binding protein 2 (PEBP2/PEA2) revealed that it also has a runt homology region (E. Ogawa et al., submitted). In this study, a different cDNA clone presumed to represent the mouse homolog of human AML1 (PEBP2alpha(B) was isolated from a cDNA library derived from B cells. The deduced amino acid sequence of PEBP2alphaB is 99% identical to that of AML1 for the first 241 residues, including the runt homology region, though their sequences diverge thereafter. On the other hand, PEBP2alphaB and PEBP2alpha share only 92% and 82% homologies at the amino acid and nucleotide levels respectively, even for the runt homology region, indicating that these proteins are encoded by distinct genes. While PEBP2alpha is highly expressed in T-cell lines but not in most of the B-cell lines and functions as an activator of T-cell-specific genes, PEBP2alphaB is expressed in both types of cells. A possible functional relationship between PEBP2alpha and PEBP2alphaB is discussed in relation to leukemogenic potential of AML1.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SHOGOIN,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIM KJ, 1979, J IMMUNOL, V122, P549; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; OLD LJ, 1965, CANCER RES, V25, P813; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V14, P4767; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	26	268	274	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					809	814						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437866				2022-12-25	WOS:A1993KN00800036
J	DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A				DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A			DIFFERENCES IN THE INTERACTION OF P21(C-HA-RAS)-GMP-PNP WITH FULL-LENGTH NEUROFIBROMIN AND GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article							RAS P21; TYPE-1 GENE; GROWTH-FACTOR; H-RAS; GAP; PRODUCT; STIMULATION; BINDING; IDENTIFICATION; PURIFICATION	Neurofibromin, the product of the neurofibromatosis type 1 gene, was found to form a stable complex with immobilized p21c-Ha-ras-GMP-PNP (a non-hydrolyzable GTP analog). This complex, detectable as early as 30 min after addition of crude brain extract, is extremely stable, with less than 50% dissociating after 5 h at 4-degrees-C. We interpret this to suggest that the dissociation of full-length neurofibromin from p21c-Ha-ras-GMP-PNP is tightly linked to the hydrolysis of GTP to GDP. Failure to remove a significant proportion of the bound neurofibromin in the presence of EDTA and GDP implies that the binding of neurofibromin to p21c-Ha-ras-GMP-PNP results in the ras protein becoming resistant to guanine nucleotide exchange. Under conditions in which neurofibromin quantitatively binds to p21c-Ha-ras-GMP-PNP, we were unable to detect a complex between p21c-Ha-ras and GAP (GTPase-activating protein). The failure to detect GAP binding to immobilized p21c-Ha-ras-GMP-PNP cannot be explained by the known differences in affinities of the GAP-related domain of neurofibromin and GAP for p21c-Ha-ras-GTP. GAP is, however, able to interact biochemically with immobilized p21c-Ha-ras suggesting a difference in the interaction between GAP and neurofibromin with p21c-Ha-ras-GMP-PNP.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL & ATHEROSCLEROSIS,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NCI NIH HHS [CA53436, CA48662] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GOLUBIC M, 1992, ONCOGENE, V7, P2151; HALL A, 1986, J BIOL CHEM, V261, P963; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	29	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					637	643						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437847				2022-12-25	WOS:A1993KN00800014
J	MODAK, SP; PRINCIPAUD, E; SPOHR, G				MODAK, SP; PRINCIPAUD, E; SPOHR, G			REGULATION OF XENOPUS C-MYC PROMOTER ACTIVITY IN OOCYTES AND EMBRYOS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; BINDING PROTEIN; CELL-DIVISION; MESSENGER-RNA; EXPRESSION; GENE; ELEMENT; ONCOGENE; LAEVIS	We have studied the regulation of transcription of the Xenopus c-myc I gene in oocytes and embryos. Various 5' and internal deletions of a 1310-bp-long c-myc I promoter fragment have been ligated upstream of the chloramphenicol acetyl transferase (CAT) reporter gene and microinjected into oocytes and fertilized eggs. Activity was determined by CAT assay and primer extension. The c-myc promoter drives transcription very efficiently, and a truncated promoter - 158/+ 46 essentially retains full activity. This region contains an overlapping E2F/SP1 site and two tandem Sp1 sites homologous to those found in the c-myc gene of mouse. Internal deletions show that both elements are equally active in oocytes in driving the expression of CAT. A germinal vesicle extract contains a DNA-binding activity specific for an Sp1 consensus sequence but not the E2F site. The data suggest that the high transcription level of the endogenous c-myc gene in Xenopus oocytes is mediated by Spl or a related transcription factor. In embryos a different mechanism emerges and the functional role of the Spl binding sites appears to be less important.	UNIV GENEVA,DEPT BIOL CELLULAIRE,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V337, P664; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; Gurdon J. B., 1986, MICROINJECTION ORGAN, P269; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SAMBROOK I, 1989, MOL CLONING LABORATO; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SPENCER CA, 1990, ADV CANCER RES, V56, P1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					645	654						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437848				2022-12-25	WOS:A1993KN00800015
J	JACOBOWITZ, O; CHEN, JQ; PREMONT, RT; YENGAR, R				JACOBOWITZ, O; CHEN, JQ; PREMONT, RT; YENGAR, R			STIMULATION OF SPECIFIC TYPES OF GS-STIMULATED ADENYLYL CYCLASES BY PHORBOL ESTER TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; ACTIVATION; PATHWAYS; CLONING	Regulation of adenylyl cyclases by protein kinase C was studied. Types 1-6 were transiently expressed in 293 cells. The cells were treated with 4beta-phorbol 12-myristate 13-acetate (PMA), and adenylyl cyclase activity was measured. PMA treatment of untransfected or vector-transfected cells resulted in a 35% (mean) increase in basal and forskolin-stimulated activity. PMA treatment of type 2 enzyme-transfected cells showed a 3-fold increase in basal activity. This stimulation varied with Mg2+ concentration with up to 4.5-fold increases at low Mg2+. PMA treatment resulted in about a 60% increase in fluoride or GTPgammaS (guanosine 5'-O-(thiotriphosphate))-stimulated activity in type 2 enzyme-transfected cells. Expression of the type 1 and 3 enzymes resulted in pronounced Ca2+/calmodulin stimulation, which was significantly increased upon pretreatment with PMA. No effects of PMA treatment were observable on other activities of the type 1 enzyme, whereas all activities of the type 3 enzymes were stimulated. Expressed types 4, 5, and 6 enzymes showed modest (approximately 30%) or no increases in basal and forskolin-stimulated activities upon PMA treatment. These data indicate that specific types of adenylyl cyclases can be functional targets for protein kinase C. The pronounced effects on the basal activity of the type 2 enzyme suggest this adenylyl cyclase could in the appropriate environment be an intracellular signal generator for external signals not routed through the activation of G(s).	CUNY MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			; jacobowitz, ofer/U-2592-2017	Premont, Richard/0000-0002-8053-5026; jacobowitz, ofer/0000-0003-2290-0520	NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-07645, DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, T32DK007645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BELL JD, 1985, J BIOL CHEM, V260, P2625; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CRONIN MJ, 1986, J BIOL CHEM, V261, P13932; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; NAGHSHINEH S, 1986, J BIOL CHEM, V261, P4534; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1988, J BIOL CHEM, V263, P16087; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SIMMOTEIT RR, 1991, FEBS LETT, V249, P189; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	18	185	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3829	3832						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440678				2022-12-25	WOS:A1993KN53300009
J	LIU, K; MASSAELI, H; PIERCE, GN				LIU, K; MASSAELI, H; PIERCE, GN			THE ACTION OF OXIDIZED LOW-DENSITY-LIPOPROTEIN ON CALCIUM TRANSIENTS IN ISOLATED RABBIT CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FREE-RADICALS; LIPID-PEROXIDATION; ATHEROSCLEROTIC LESIONS; MONOCYTE-MACROPHAGES; VENTRICULAR MYOCYTES; CHANNEL ANTAGONISTS; HYDROGEN-PEROXIDE; CARDIAC MYOCYTES; TISSUE-INJURY	The effect of oxidized low density lipoprotein (oxLDL) on the Ca2+ transients of isolated rabbit cardiomyocytes was assessed. LDL was oxidized by a free radical generating system in vitro. The systolic Ca2+ concentration in transients was significantly increased after treatment with 100 mug of oxLDL cholesterol/ml for 16 min without having any effect on the diastolic [Ca2+]. However, a toxic effect was observed when the concentration of oxLDL was increased to 1,000 mug/ml. Cells treated with 100 mug of oxLDL/ml were more sensitive to the blocking action of nicardipine on the Ca2+ transient than were control cardiomyocytes. Furthermore, oxLDL failed to produce a stimulatory effect on the transient when the extracellular [Ca2+] was lowered. The malondialdehyde content in the oxLDL correlated well with the change in systolic [Ca2+] of treated cells. Lazaroid, a novel antioxidant, completely inhibited malondialdehyde formation in the oxLDL and prevented the increment of systolic [Ca2+] in the treated cells. The data indicate that oxLDL can induce relatively rapid alterations in cellular Ca2+ transients via a modification of Ca2+ entry through the L-type Ca2+ channel. LDL oxidation induced by free radicals may play an important role in influencing cardiac contractile function during pathological conditions such as ischemia/reperfusion challenge.	ST BONIFACE GEN HOSP,RES CTR,DIV CARDIOVASC SCI,TRANSPORT LAB,351 TACHE AVE,WINNIPEG R2H 2A6,MANITOBA,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba				Pierce, Grant/0000-0001-7674-0142				AKEMURA G, 1992, CIRC RES, V71, P96; AVIRAM M, 1992, J BIOL CHEM, V267, P218; BIRD RP, 1984, METHOD ENZYMOL, V105, P299; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; BROWN MS, 1981, SCIENCE, V212, P628, DOI 10.1126/science.6261329; BROWN MS, 1983, ARTERIOSCLEROSIS, V3, P149; BURTON KP, 1988, FREE RADICAL BIO MED, V4, P15, DOI 10.1016/0891-5849(88)90006-8; BURTON KP, 1990, J MOL CELL CARDIOL, V22, P1035, DOI 10.1016/0022-2828(90)91043-7; CARREA FP, 1992, J CARDIOVASC PHARM, V20, P230, DOI 10.1097/00005344-199208000-00008; CHEUNG JY, 1989, AM J PHYSIOL, V256, pC1120, DOI 10.1152/ajpcell.1989.256.6.C1120; FISHER M, 1991, ATHEROSCLEROSIS, V90, P197, DOI 10.1016/0021-9150(91)90115-J; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GALINANES M, 1992, CIRCULATION, V86, P672, DOI 10.1161/01.CIR.86.2.672; GALLE J, 1990, CIRC RES, V66, P1287, DOI 10.1161/01.RES.66.5.1287; GEERAERTS MD, 1991, AM J PHYSIOL, V261, pC889, DOI 10.1152/ajpcell.1991.261.5.C889; Grundy S. M., 1990, CHOLESTEROL ATHEROSC; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1977, BIOCHEM J, V163, P441, DOI 10.1042/bj1630441; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1987, FREE RADICAL BIO MED, V3, P65, DOI 10.1016/0891-5849(87)90040-2; HERRIKSEN T, 1981, P NATL ACAD SCI USA, V78, P6499; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; JULIEN P, 1981, CIRC RES, V49, P248, DOI 10.1161/01.RES.49.1.248; Kobayashi A, 1991, Bratisl Lek Listy, V92, P59; KRAMER JH, 1984, CIRC RES, V55, P120, DOI 10.1161/01.RES.55.1.120; KUTRYK MJB, 1991, CORONARY ARTERY DIS, V2, P1093; KUTRYK MJB, 1991, CIRC RES, V68, P18, DOI 10.1161/01.RES.68.1.18; LANGER GA, 1987, AM J PHYSIOL, V252, pH214; LINGREN FT, 1975, ANAL LIPIDS LIPOPROT, P204; LIU K, 1993, J BIOL CHEM, V268, P3767; LIU K, 1991, MOL CELL BIOCHEM, V108, P39; LIU KZ, 1992, AM HEART J, V123, P285, DOI 10.1016/0002-8703(92)90636-A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Napoli C, 1991, Cardiologia, V36, P527; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PITAS RE, 1990, J BIOL CHEM, V265, P12722; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAZSZETTI R, 1984, PHARMACOL RES COMMUN, V16, P795; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SALE FO, 1984, ANAL BIOCHEM, V142, P347, DOI 10.1016/0003-2697(84)90475-5; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; SEVANIAN A, 1987, LIPIDS, V22, P627, DOI 10.1007/BF02533940; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D., 1988, ATHEROSCLER REV, V18, P1; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; YAMADA M, 1990, CIRC RES, V67, P1211, DOI 10.1161/01.RES.67.5.1211; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	56	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4145	4151						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440703				2022-12-25	WOS:A1993KN53300053
J	POULOS, TL; EDWARDS, SL; WARIISHI, H; GOLD, MH				POULOS, TL; EDWARDS, SL; WARIISHI, H; GOLD, MH			CRYSTALLOGRAPHIC REFINEMENT OF LIGNIN PEROXIDASE AT 2-ANGSTROM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; HORSERADISH-PEROXIDASE; SODIUM-AZIDE; COMPOUND-I; EXTRACELLULAR PEROXIDASES; SPECTRAL CHARACTERIZATION; DIARYLPROPANE OXYGENASE; CRYSTAL-STRUCTURE; HEME ENZYME	The crystal structure of the major lignin peroxidase isozyme from Phanerocheate chrysosporium has been refined to an R = 0.15 for data between 8 angstrom and 2.03 angstrom. The refined model consists of 2 lignin peroxidase molecules in the asymmetric unit, 2 calcium ions per monomer, 1 glucosamine per monomer N-linked to Asn-257, and 476 water molecules per asymmetric unit. The model exhibits excellent geometry with a root mean square deviation from ideality in bond distances and angles of 0.014 angstrom and 2.9-degrees, respectively. Molecule 1 consists of all 343 residues, while molecule 2 consists of residues 1-341. The overall root mean square deviation in backbone atoms between the 2 molecules in the asymmetric unit is 0.36 angstrom. The refinement at 2.0 angstrom confirms our conclusions based on the partially refined 2.6-angstrom structure (Edwards, S. L., Raag, R., Wariishi, H., Gold, M. H., and Poulos, T. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 750-754). The overall fold of lignin peroxidase closely resembles that of cytochrome c peroxidase. A superimposition of alpha-carbons gives a root mean square deviation of 2.65 angstrom between the two peroxidases and 1.66 angstrom for the helices. The active sites also are similar since both contain a proximal histidine heme ligand hydrogen-bonded to a buried aspartate residue and both contain histidine and arginine residues in the distal peroxide binding pocket. The most obvious difference in the active site is that whereas cytochrome c peroxidase has tryptophan residues located in the proximal and distal heme pockets, lignin peroxidase has phenylalanines. There are four other especially noteworthy differences in the two structures. First, although the heme in cytochrome c peroxidase is recessed about 10 angstrom from the molecular surface, the heme pocket is open to solvent. The analogous opening in lignin peroxidase is smaller which can explain in part the differences in reactivity of the two hemes. This same opening may provide the site for binding small aromatic substrates. Second, lignin peroxidase has a carboxylate-carboxylate hydrogen bond important for heme binding that is not present in cytochrome c peroxidase. Third, lignin peroxidase contains 2 structural calcium ions while cytochrome c peroxidase contains no calcium. The calciums in lignin peroxidase coordinate to residues near the C-terminal ends of the distal and proximal helices and hence are probably important for maintaining the integrity of the active site. Fourth, the extra 49 residues in lignin peroxidase not present in cytochrome c peroxidase constitutes the C-terminal end of the molecule with the C terminus situated at the ''front'' end of the molecule between the two heme propionates.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,BEAVERTON,OR 97006; CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine								ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1987, BIOCHEMISTRY-US, V26, P2258, DOI 10.1021/bi00382a028; ANDRAWIS A, 1988, J BIOL CHEM, V263, P1195; ATOR MA, 1989, J BIOL CHEM, V264, P9250; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DEPILLIS GD, 1991, J BIOL CHEM, V266, P19334; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EDWARDS SL, 1987, BIOCHEMISTRY-US, V26, P1503, DOI 10.1021/bi00380a002; EDWARDS SL, 1993, BIOCHEMISTRY-US, V90, P750; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GOLD MH, 1989, ACS SYM SER, V389, P127; HAMMEL KE, 1989, ENZYME MICROB TECH, V11, P776, DOI 10.1016/0141-0229(89)90129-4; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HAYASHI Y, 1979, J BIOL CHEM, V254, P9101; HENRISSAT B, 1990, PROTEINS, V8, P251, DOI 10.1002/prot.340080307; HIGUCHI T, 1990, WOOD SCI TECHNOL, V24, P23, DOI 10.1007/BF00225306; HONZATKO RB, 1986, ACTA CRYSTALLOGR A, V42, P172, DOI 10.1107/S0108767386099580; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KUILA D, 1985, BIOCHEMISTRY-US, V24, P3394, DOI 10.1021/bi00335a002; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; LAMAR GN, 1982, BIOCHIM BIOPHYS ACTA, V708, P317, DOI 10.1016/0167-4838(82)90443-5; LEISOLA MSA, 1987, J BIOL CHEM, V262, P419; MARQUEZ L, 1988, J BIOL CHEM, V263, P10549; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MIKI K, 1988, BIOCHEMISTRY-US, V27, P4787, DOI 10.1021/bi00413a031; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1987, ADV INORG BIOCHEM, V7, P1; POULOS TL, 1984, PEPT PROTEIN REV, V4, P185; PURCELL WL, 1976, J AM CHEM SOC, V98, P7033, DOI 10.1021/ja00438a049; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; RENGANATHAN V, 1985, ARCH BIOCHEM BIOPHYS, V241, P304, DOI 10.1016/0003-9861(85)90387-X; RITCH TG, 1991, GENE, V107, P119, DOI 10.1016/0378-1119(91)90304-T; SARKANEN KV, 1971, LIGNINS; SHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; TIEN M, 1986, J BIOL CHEM, V261, P1687; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; VALLI K, 1991, J BACTERIOL, V173, P345, DOI 10.1128/jb.173.1.345-352.1991; VALLI K, 1992, J BACTERIOL, V174, P2131, DOI 10.1128/JB.174.7.2131-2137.1992; WARISHI H, 1991, J BIOL CHEM, V26, P20694; WEINDER KG, 1992, CURR OPIN STRUCT BIO, V8, P388; Yonetani T., 1976, ENZYMES, P345	50	388	392	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4429	4440						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440725				2022-12-25	WOS:A1993KN53300089
J	STAFFORINI, DM; ROLLINS, EN; PRESCOTT, SM; MCINTYRE, TM				STAFFORINI, DM; ROLLINS, EN; PRESCOTT, SM; MCINTYRE, TM			THE PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE FROM HUMAN ERYTHROCYTES - PURIFICATION AND PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; BOVINE BRAIN; ENDOTHELIAL-CELLS; LIPID EXTRACT; FACTOR PAF; RELEASE; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; AGGREGATION	Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid. Tissues, blood cells, and plasma contain PAF acetylhydrolases (calcium independent phospholipase A2 activities) that catalyze the hydrolysis of phospholipids containing short chain sn-2 acyl groups. They inactivate PAF and thereby determine PAF accumulation. We purified the PAF acetylhydrolase from human erythrocytes 15,600-fold. The enzyme has a molecular weight of 25,000, it behaves as a dimer during gel filtration, and it is a previously uncharacterized cytosolic esterase, as it has a unique amino-terminal sequence. The erythrocyte PAF acetylhydrolase requires the addition of sulfhydryl agents for maximal activity, is inhibited by 5,5'-dithiobis(2-nitrobenzoic acid), NaF, diisopropyl fluorophosphate, diethylpyrocarbonate, p-bromophenacylbromide, and a number of proteases. Antibodies against the purified protein precipitate all PAF hydrolase activity from erythrocyte lysates. The erythrocyte PAF acetylhydrolase is specific for short or oxidized sn-2 acyl residues. It exhibits surface dilution kinetics, suggesting that hydrolysis occurs at lipid interfaces. This suggests that this enzyme acts in vivo as a scavenger of oxidatively fragmented phospholipids that are toxic to the cell.	UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	STAFFORINI, DM (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, SALT LAKE CITY, UT 84112 USA.				NCI NIH HHS [5P30CA42014] Funding Source: Medline; NHLBI NIH HHS [HL 35828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANK ML, 1981, J BIOL CHEM, V256, P175; Dennis EA, 1983, ENZYMES, P307; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; INOUE K, 1989, OXYGEN RADICALS BIOL; JOHNSTON JM, 1989, PLATELET ACTIVATING, P129; KOBAYASHI T, 1985, BIOCHIM BIOPHYS ACTA, V814, P170, DOI 10.1016/0005-2736(85)90433-X; KORNECKI E, 1984, SCIENCE, V226, P1454, DOI 10.1126/science.6150550; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MIYAURA S, 1991, LIPIDS, V26, P1015, DOI 10.1007/BF02536494; PALMANTIER R, 1989, BIOCHEM BIOPH RES CO, V162, P475, DOI 10.1016/0006-291X(89)92022-6; PAYSANT M, 1970, B SOC CHIM BIOL, V52, P1257; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SASAKI R, 1975, EUR J BIOCHEM, V50, P581, DOI 10.1111/j.1432-1033.1975.tb09899.x; SATOH K, 1988, PROSTAGLANDINS, V35, P685, DOI 10.1016/0090-6980(88)90142-6; SISSON JH, 1987, J IMMUNOL, V138, P3918; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; SUZUKI Y, 1988, EUR J BIOCHEM, V172, P117, DOI 10.1111/j.1432-1033.1988.tb13862.x; TOKUMURA A, 1989, J LIPID RES, V30, P219; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352; YOSHIDA H, 1992, AM J HEMATOL, V40, P61, DOI 10.1002/ajh.2830400113; YOSHIDA H, 1992, ACTA NEUROL SCAND, V86, P199, DOI 10.1111/j.1600-0404.1992.tb05066.x; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x	39	76	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3857	3865						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440681				2022-12-25	WOS:A1993KN53300014
J	TSAIMORRIS, CH; XIE, XZ; WANG, W; BUCZKO, E; DUFAU, ML				TSAIMORRIS, CH; XIE, XZ; WANG, W; BUCZKO, E; DUFAU, ML			PROMOTER AND REGULATORY REGIONS OF THE RAT LUTEINIZING-HORMONE RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ULTRABITHORAX PROMOTER; RNA-POLYMERASE; SEQUENCE; INDUCTION; INVITRO; CELL	The region of transcriptional activity in the rat luteinizing hormone receptor gene was localized to the 5'-flanking 173-base pair (bp) sequence in transfected mouse Leydig tumor cells and non-expressing Chinese hamster ovarian (CHO) and HeLa cells. Repression of activity in all cell types was induced by at least two domains located between -174 and -990 bp. An additional inhibitory region between -1237 and -2056 bp observed only in CHO and HeLa cells may contribute to the absence of receptor expression in these cells. Analysis of the 173-bp region revealed a promoter domain between -1 and -137 bp containing no TATA or CAAT boxes, but with three SP1 sites and three initiator elements located at transcriptional start sites -14, -19, and -33. Gel retardation studies showed a protein-binding DNA domain about 30 bp upstream of the transcriptional start sites and an adjacent domain containing an SP1 element that are required for maximal activity in all cell types and may play a role in basal transcription. A second promoter domain (-120 to -173 bp) with a protein-binding SP1 element had minor activity in Leydig cells but was prominent in CHO and HeLa cells. Leydig cell-specific DNA-binding protein(s) for each of the promoter domains were detected and may be of importance in transcriptional regulation. The control of gene transcription by differential activation of these promoter domains could be involved in hormone-induced regulation of luteinizing hormone receptor expression in the gonads.			TSAIMORRIS, CH (corresponding author), NICHHD, ENDOCRINOL & REPROD RES BRANCH, MOLEC ENDOCRINOL SECT, BETHESDA, MD 20892 USA.			Tsai Morris, Chon Hwa/0000-0002-8113-0979				AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V14; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANCAR GB, 1982, CELL, V28, P523, DOI 10.1016/0092-8674(82)90207-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355	23	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4447	4452						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440726				2022-12-25	WOS:A1993KN53300091
J	YOKOYAMA, K; GELB, MH				YOKOYAMA, K; GELB, MH			PURIFICATION OF A MAMMALIAN PROTEIN GERANYLGERANYLTRANSFERASE - FORMATION AND CATALYTIC PROPERTIES OF AN ENZYME-GERANYLGERANYL PYROPHOSPHATE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; PEPTIDE-BINDING; ALPHA-SUBUNIT; RAS PROTEINS; FARNESYLTRANSFERASE; BRAIN; YEAST; GENE; EXPRESSION	A protein geranylgeranyltransferase (PGGT) that transfers the geranylgeranyl group from geranylgeranyl pyrophosphate (GGPP) to the cysteine residue in the C-terminal sequence Cys-Ali-Ali-Leu (Ali is an aliphatic amino acid) of proteins and peptides has been purified to apparent homogeneity from bovine brain. This was accomplished by affinity chromatography of partially purified enzyme on a gel containing a covalently attached hexapeptide SSCILL. This peptide was identified as a tight-binding ligand of the PGGT by employing a semi-random peptide synthetic strategy. The purified enzyme consists of two subunits of apparent molecular mass 40 and 48 kDa. Affinity-purified PGGT effectively catalyzes the prenylation of peptides that contain a C-terminal Leu or Phe residue. The PGGT forms a stable binary complex with intact GGPP that can be isolated by gel filtration. Addition of a peptide substrate to this complex results in the quantitative transfer of the prenyl group to the peptide. This transfer occurs without the equilibration of enzyme-bound GGPP with free GGPP. When the PGGT was incubated with farnesyl pyrophosphate, the amount of binary complex formed was about 25% of that formed with GGPP.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KOHL NE, 1991, J BIOL CHEM, V266, P18884; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; OHYA Y, 1991, J BIOL CHEM, V266, P12356; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	29	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4055	4060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440698				2022-12-25	WOS:A1993KN53300041
J	HAASS, C; HUNG, AY; SCHLOSSMACHER, MG; TEPLOW, DB; SELKOE, DJ				HAASS, C; HUNG, AY; SCHLOSSMACHER, MG; TEPLOW, DB; SELKOE, DJ			BETA-AMYLOID PEPTIDE AND A 3-KDA FRAGMENT ARE DERIVED BY DISTINCT CELLULAR MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; LOCALIZATION; SECRETION; RECEPTOR; CLEAVAGE	We have analyzed the cellular processing pathways which produce the 4-kDa amyloid beta-peptide (Abeta) and a 3-kDa derivative (p3) of the beta-amyloid precursor protein (betaAPP) found in conditioned media of tissue culture cells and in cerebrospinal fluid. Pulse-chase experiments reveal that both peptides are secreted in parallel with soluble betaAPP (APP(s)); no precursor-product relation between Abeta and p3 was found. The protease inhibitor leupeptin did not influence the production of either peptide. In contrast, the weak base ammonium chloride (NH4Cl) showed a dose-dependent inhibition of Abeta production with less decrease in p3. A similar effect was observed using the monovalent ionophore monensin. Brefeldin A completely inhibited the generation of both peptides, indicating that proteases located in the endoplasmic reticulum or early Golgi are not sufficient for the production of the small peptides. Deletion of the betaAPP cytoplasmic domain, which removes a consensus sequence that probably mediates reinternalization, caused an increase in secretion of both APP(s) and p3 and did not abolish Abeta production. These observations suggest that completely mature betaAPP within the late Golgi and/or at the cell surface is a prerequisite for Abeta production but processing within the lysosome might not be directly required. p3 appears to derive from the 10-kDa C-terminal stub of betaAPP following secretion of APP(s).	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.			Schlossmacher, Michael/0000-0002-0394-0300	NATIONAL INSTITUTE ON AGING [R37AG006173, R01AG006173, R35AG007911] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06173, AG 07911] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, IN PRESS NATURE; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	26	422	443	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3021	3024						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428976				2022-12-25	WOS:A1993KM16100002
J	ZOETEWEIJ, JP; VANDEWATER, B; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF				ZOETEWEIJ, JP; VANDEWATER, B; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF			CALCIUM-INDUCED CYTOTOXICITY IN HEPATOCYTES AFTER EXPOSURE TO EXTRACELLULAR ATP IS DEPENDENT ON INORGANIC-PHOSPHATE - EFFECTS ON MITOCHONDRIAL CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; INDUCED CA-2+ RELEASE; OXIDATIVE STRESS; PARENCHYMAL-CELLS; PLASMA-MEMBRANE; INJURY; TOXICITY; INHIBITION; METABOLISM; GENERATION	In isolated mitochondria extensive uptake of Ca2+ in the presence of an ''inducing agent,'' e.g. inorganic phosphate (P(i)), causes permeabilization of the mitochondrial inner membrane and a collapse of the mitochondrial membrane potential. In this study we tested whether the effect of phosphate occurs in intact hepatocytes. Rat hepatocytes were incubated with ATP to induce a sustained increase in intracellular Ca2+ ([Ca2+]i), dissipation of the mitochondrial membrane potential, and cell death (Zoeteweij, J. P., van de Water, B., de Bont, H. J. G. M., Mulder, G. J., and Nagelkerke, J. F. (1992) Biochem. J. 288, 207-213). Omission of P(i) from the incubation medium delayed the loss of viability. The nonhydrolyzable ATP analog adenosine 5'-O-(thiotriphosphate) (ATPgammaS) had similar effects on [Ca2+]i and viability, but now omission of extracellular P(i) completely protected against cytotoxicity. Exposure to ATP or ATPgammaS induced a large cellular uptake of P(i). With the use of video-microscopy a significant increase in mitochondrial free calcium was observed before the onset of cell death. Accumulation of mitochondrial calcium was reduced when extracellular P(i) was omitted. These results suggest that, after induction of high [Ca2+]i by ATP in hepatocytes, 1) mitochondria accumulate calcium which is associated with cell toxicity and 2) intracellular P(i) increases which stimulates mitochondrial calcium uptake. These observations support a calcium-dependent mitochondrial dysfunction, induced by phosphate, as a valid model for ATP-induced cytotoxicity in hepatocytes.			ZOETEWEIJ, JP (corresponding author), LEIDEN UNIV,CTR BIOPHARMACEUT SCI,DIV TOXICOL,POB 9503,2300 RA LEIDEN,NETHERLANDS.							BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BOOGAARD PJ, 1989, TOXICOL APPL PHARM, V101, P135, DOI 10.1016/0041-008X(89)90219-6; BRECHT M, 1992, BIOCHEM J, V283, P399, DOI 10.1042/bj2830399; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871; CHAVEZ E, 1991, BIOCHIM BIOPHYS ACTA, V1070, P461, DOI 10.1016/0005-2736(91)90087-O; CROMPTON M, 1988, BIOCHEM J, V255, P357; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FARISS MW, 1985, TOXICOL APPL PHARM, V79, P283, DOI 10.1016/0041-008X(85)90350-3; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HARPER AE, 1962, METHODEN ENZYMATISCH, P788; HUGHES BP, 1986, BIOCHEM J, V238, P793, DOI 10.1042/bj2380793; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KRAUSFRIEDMANN N, 1990, CELL CALCIUM, V11, P625, DOI 10.1016/0143-4160(90)90017-O; MASAKI N, 1989, BIOCHEM BIOPH RES CO, V163, P412, DOI 10.1016/0006-291X(89)92151-7; Moldeus P, 1978, Methods Enzymol, V52, P60; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAGELKERKE JF, 1989, BIOCHEM J, V263, P347, DOI 10.1042/bj2630347; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NOVGORODOV SA, 1991, BIOCHEM BIOPH RES CO, V180, P33, DOI 10.1016/S0006-291X(05)81250-1; NOVGORODOV SA, 1991, FEBS LETT, V295, P77, DOI 10.1016/0014-5793(91)81389-P; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; OLAFSDOTTIR K, 1988, ARCH BIOCHEM BIOPHYS, V263, P226, DOI 10.1016/0003-9861(88)90631-5; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; POUNDS JG, 1988, TOXICOL APPL PHARM, V94, P334; RICHELMI P, 1989, TOXICOLOGY, V57, P29, DOI 10.1016/0300-483X(89)90032-2; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; RINK TJ, 1985, CELL CALCIUM, V6, P133, DOI 10.1016/0143-4160(85)90040-5; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SMITH MW, 1991, P NATL ACAD SCI USA, V88, P4926, DOI 10.1073/pnas.88.11.4926; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; SZABO I, 1992, J BIOL CHEM, V267, P2940; TOMURA H, 1992, EUR J PHARM-MOLEC PH, V226, P363, DOI 10.1016/0922-4106(92)90054-Y; WEIS M, 1992, J BIOL CHEM, V267, P804; WEIS M, 1990, CHEM-BIOL INTERACT, V76, P227, DOI 10.1016/0009-2797(90)90090-A; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	46	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3384	3388						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429014				2022-12-25	WOS:A1993KM16100057
J	ELTIS, LD; HOFMANN, B; HECHT, HJ; LUNSDORF, H; TIMMIS, KN				ELTIS, LD; HOFMANN, B; HECHT, HJ; LUNSDORF, H; TIMMIS, KN			PURIFICATION AND CRYSTALLIZATION OF 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PSEUDOALCALIGENES; DIOXYGENASE; DEGRADATION; BIPHENYL; DIBENZOFURAN; CATABOLISM; CLEAVAGE; PROTEINS; GENE	2,3-Dihydroxybiphenyl 1,2-dioxygenase, an enzyme of the biphenyl biodegradation pathway that cleaves the first of the aromatic rings, was purified to apparent homogeneity from Pseudomonas sp. strain LB400 that had been engineered to hyperexpress the bphC gene. The enzyme had a subunit molecular mass of 33.2 kDa as determined by SDS-polyacrylamide electrophoresis. Kinetic studies indicate a K(M) of 7 +/- 1 muM for 2,3-dihydroxybiphenyl. The enzyme is strongly inhibited by substrate (K(SS) = 300 +/- 10 muM). Catechol, 3-methylcatechol, and 4-methylcatechol were cleaved less efficiently and showed weaker substrate inhibition. 3,4-Dihydroxybiphenyl was not a substrate for the enzyme. Ammonium sulfate and polyethylene glycol 6000 were used as precipitants to obtain two different crystal forms. Crystals grown from ammonium sulfate and polyethylene glycol 6000 had space groups of P4(2)2(1)2 and I222, respectively. Electron microscopy indicates that the enzyme is an octamer (265 kDa) consisting of subunits arranged in two planar tetramers in a staggered conformation.			ELTIS, LD (corresponding author), NATL RES CTR BIOTECHNOL,GBF,MASCHERODER WEG 1,W-3300 BRAUNSCHWEIG,GERMANY.		Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158				ADAMS RH, 1992, APPL ENVIRON MICROB, V58, P647, DOI 10.1128/AEM.58.2.647-654.1992; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BRAUN M, 1990, EUR J BIOCHEM, V196, P439; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; DELORENZO V, 1993, IN PRESS GENE; FORTNAGEL P, 1990, APPL ENVIRON MICROB, V56, P1148, DOI 10.1128/AEM.56.4.1148-1156.1990; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; FURUKAWA K, 1983, J BACTERIOL, V154, P1356, DOI 10.1128/JB.154.3.1356-1362.1983; FURUKAWA K, 1987, J BACTERIOL, V169, P924, DOI 10.1128/jb.169.2.924-927.1987; Harayama Shigeaki, 1992, V28, P99; KLECKA GM, 1981, APPL ENVIRON MICROB, V41, P1159, DOI 10.1128/AEM.41.5.1159-1165.1981; Kuhm A E, 1991, Biodegradation, V2, P115, DOI 10.1007/BF00114601; KUHM AE, 1991, J BACTERIOL, V173, P3795, DOI 10.1128/JB.173.12.3795-3802.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNSDORF H, 1986, J MICROSC-OXFORD, V144, P211, DOI 10.1111/j.1365-2818.1986.tb02801.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; NADIM L, 1987, 13TH P ANN RES S LAN, P395; NOZAKI M, 1963, BIOCHEM Z, V338, P582; RAMOS JL, 1987, SCIENCE, V235, P593, DOI 10.1126/science.3468623; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SELIFONOV S A, 1988, Biokhimiya, V53, P1040; STRUBEL V, 1991, J BACTERIOL, V173, P1932, DOI 10.1128/jb.173.6.1932-1937.1991; Unterman R., 1988, ENV BIOTECHNOLOGY RE, P253; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WALLIS MG, 1990, BIOCHEM J, V266, P605	28	90	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2727	2732						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428946				2022-12-25	WOS:A1993KK81500070
J	LARMINAT, F; ZHEN, WP; BOHR, VA				LARMINAT, F; ZHEN, WP; BOHR, VA			GENE-SPECIFIC DNA-REPAIR OF INTERSTRAND CROSS-LINKS INDUCED BY CHEMOTHERAPEUTIC-AGENTS CAN BE PREFERENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DIHYDROFOLATE-REDUCTASE GENE; DHFR GENE; CIS-DIAMMINEDICHLOROPLATINUM(II); REMOVAL; ADDUCTS; RECOMBINATION; MONOADDUCTS; CISPLATIN; MECHANISM	The gene-specific formation and repair of interstrand cross-links (ICL) were measured in the dihydrofolate reductase (DHFR) gene in hamster cells. Cells were treated with two different chemotherapeutic agents, nitrogen mustard and cisplatin, and the frequency of cross-links was quantified in the active gene and in a downstream, inactive region. About 5% of total lesions induced by these agents were ICL. Whereas the frequencies of cross-links formed were similar in the gene and in the noncoding region after cisplatin treatment, there were more nitrogen mustard-induced cross-links in the inactive region than in the active gene. At low levels of cross-linking, we found preferential DNA repair in the active gene as compared to the inactive region. At higher levels of cross-linking, there was no difference in repair rates between the gene and the noncoding region due to an increase in the repair efficiency in the inactive DNA. Implications of fine structural organization of cross-link repair are discussed.	NCI, DIV CANC TREATMENT, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bohr, Vilhelm/AAP-5931-2020					BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BRONSTEIN SM, 1992, CANCER RES, V52, P2008; BROOKES P, 1961, BIOCHEM J, V80, P496, DOI 10.1042/bj0800496; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; COLVIN M, 1982, PHARM PRINCIPLES CAN, P276; EASTMAN A, 1982, BIOCHEM BIOPH RES CO, V105, P869, DOI 10.1016/0006-291X(82)91050-6; FABRE F, 1977, P NATL ACAD SCI USA, V74, P1667, DOI 10.1073/pnas.74.4.1667; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FUTSCHER WB, 1992, CELL GROWTH DIFFER, V3, P217; GALLAGHER PE, 1984, BIOCHIM BIOPHYS ACTA, V782, P394, DOI 10.1016/0167-4781(84)90045-9; GELEZIUNAS R, 1991, J NATL CANCER I, V83, P557, DOI 10.1093/jnci/83.8.557; HARTLEY JA, 1986, CANCER RES, V46, P1943; HEMMINKI K, 1984, J NATL CANCER I, V73, P1021; HICKSON ID, 1988, TRENDS GENET, V4, P101, DOI 10.1016/0168-9525(88)90097-2; ISLAS AL, 1991, CANCER RES, V51, P2867; JONES JC, 1991, J BIOL CHEM, V266, P7101; KOHN KW, 1966, J MOL BIOL, V19, P266, DOI 10.1016/S0022-2836(66)80004-9; LEFEBVRE P, 1989, NATO ADV SCI I A-LIF, V182, P141; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; PIENTA KJ, 1984, J CELL SCI S, V1, P223; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; ROBERTS JJ, 1981, BIOCHIM BIOPHYS ACTA, V655, P146, DOI 10.1016/0005-2787(81)90004-6; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VOS JMH, 1987, CELL, V50, P789, DOI 10.1016/0092-8674(87)90337-0; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	35	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2649	2654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428941				2022-12-25	WOS:A1993KK81500059
J	VONECKARDSTEIN, A; CASTRO, G; WYBRANSKA, I; THERET, N; DUCHATEAU, P; DUVERGER, N; FRUCHART, JC; AILHAUD, G; ASSMANN, G				VONECKARDSTEIN, A; CASTRO, G; WYBRANSKA, I; THERET, N; DUCHATEAU, P; DUVERGER, N; FRUCHART, JC; AILHAUD, G; ASSMANN, G			INTERACTION OF RECONSTITUTED HIGH-DENSITY-LIPOPROTEIN DISKS CONTAINING HUMAN APOLIPOPROTEIN-A-I (APOA-I) VARIANTS WITH MURINE ADIPOCYTES AND MACROPHAGES - EVIDENCE FOR REDUCED CHOLESTEROL EFFLUX PROMOTION BY APOA-I(PRO165-]ARG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ADIPOSE-CELLS; PROTEIN-KINASE-C; STRUCTURAL-ANALYSIS; BINDING-PROTEIN; CULTURED-CELLS; HEPATOMA-CELLS; ACYLTRANSFERASE; RECEPTORS; SURFACE; FIBROBLASTS	Interaction of cells with both native and reconstituted high density lipoproteins (rHDL) containing apolipoprotein (apo) A-I mediates efflux of cellular cholesterol. To characterize structural requirements for this activity in apoA-I, six different genetic apoA-I variants and the corresponding normal allele products were isolated from heterozygous carriers, reconstituted with dimyristoylphosphatidylcholine (DMPC) into discoidal HDL and compared with regard to their ability to release intracellular cholesterol from murine adipocytes and peritoneal macrophages. In previous studies we determined the amino acid changes of these variants: Pro3 --> Arg, Pro4 --> Arg, Lys107 --> 0, Lys107 --> Met, Pro165 --> Arg, and Glu198 --> Lys (von Eckardstein, A., Funke, H., Walter, M., Altland, K., Benninghoven, A., and Assmann, G. (1990) J. Biol. Chem. 265, 8610-8617) and demonstrated that all apoA-I variants except apoA-I(Lys107 --> 0) form discoidal HDL particles with phosphatidyleholine analogues indistinguishable from normal apoA-I (Jonas, A., von Eckardstein, A., Kezdy, K. E., Steinmetz, A., and Assmann, G. (1991) J. Lipid Res. 32, 95-106). In the present study, all apoA-I-DMPC complexes except those containing apoA-I(Pro165 --> Arg) promoted cholesterol efflux as effectively as those containing normal apoA-I. Cholesterol efflux from adipocytes obtained after 180 min of incubation with apoA-I(Pro165 --> Arg)-DMPC complexes was decreased by 30% although this variant was bound to adipocytes with normal affinity. By contrast, apoA-I(Lys107 --> Met).DMPC complexes were decreased in their binding affinity compared to normal apoA-I.DMPC complexes but normally promoted cholesterol efflux. Incubation of mouse peritoneal macrophages with apoA-I(Pro165 --> Arg)-DMPC complexes did also result in a 30% decreased efflux of radiolabeled cholesterol if compared to rHDL with the normal allele product from the same donor. Together the observations suggest that the substitution of proline at residue 165 interferes with the formation of a structural domain in apoA-I that is crucial for cellular cholesterol efflux stimulation. Furthermore, our results suggest that binding of HDL to adipocytes and cholesterol efflux promotion by HDL requires different structural domains.	INST PASTEUR,SERV ETUD & RECH LIPOPROT & ATHEROSCLEROSE,F-59019 LILLE,FRANCE; FAC SCI NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE; UNIV MUNSTER,INST ARTERIOSKLEROSEFORSCH,W-4400 MUNSTER,GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Munster	VONECKARDSTEIN, A (corresponding author), UNIV MUNSTER,INST KLIN CHEM & LAB MED,ZENT LAB,ALBERT SCHWEITZER STR 33,W-4400 MUNSTER,GERMANY.		Theret, Nathalie/I-2871-2015; theret, nathalie/ABG-6780-2020	Theret, Nathalie/0000-0002-5857-7828; theret, nathalie/0000-0002-5857-7828; Ailhaud, Gerard/0000-0003-0596-2906; Wybranska, Iwona/0000-0002-7421-7005				ALLAN CM, 1992, J BIOL CHEM, V267, P13257; ALTLAND K, 1980, HUM GENET, V54, P221, DOI 10.1007/BF00278977; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; AVIRAM M, 1989, J LIPID RES, V30, P65; BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARBARAS R, 1990, BIOCHEM J, V269, P767, DOI 10.1042/bj2690767; BERNARD DW, 1990, ARTERIOSCLEROSIS, V10, P135, DOI 10.1161/01.ATV.10.1.135; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CASTRO GR, 1992, CIRCULATION S1, V86, P9; CHEN CH, 1982, J LIPID RES, V23, P680; CHEUNG MC, 1987, J LIPID RES, V28, P913; CRAIG IF, 1982, J BIOL CHEM, V257, P330; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; DELAMATRE JG, 1990, J LIPID RES, V31, P191; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; JABS H, 1986, J LIPID RES, V27, P613; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, J LIPID RES, V32, P95; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LI WH, 1988, J LIPID RES, V29, P245; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEL CM, 1988, J LIPID RES, V29, P1171; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENDEZ AJ, 1990, ARTERIOSCLEROSIS, V10, P768; MONACO L, 1987, EMBO J, V6, P3253, DOI 10.1002/j.1460-2075.1987.tb02643.x; MORRISON J, 1991, J BIOL CHEM, V266, P18780; NAZIH H, 1990, THROMB RES, V59, P913, DOI 10.1016/0049-3848(90)90115-S; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NOWICKA G, 1990, J LIPID RES, V31, P1947; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; RALL SC, 1984, J BIOL CHEM, V259, P63; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SEGREST JP, 1992, J LIPID RES, V33, P141; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TABAS I, 1984, J BIOL CHEM, V259, P3897; TAKATA K, 1988, J LIPID RES, V29, P1117; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; [No title captured]	55	48	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2616	2622						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428938				2022-12-25	WOS:A1993KK81500055
J	WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ				WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ			DEVELOPMENTAL AND CELL LINEAGE SPECIFICITY OF RAF FAMILY GENE-EXPRESSION IN MOUSE TESTIS	ONCOGENE			English	Article							COMPLETE CODING SEQUENCE; MALE GERM-CELLS; COMPLETE NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA GENE; KINASE-ACTIVITY; PROTEIN-KINASE; INSITU HYBRIDIZATION; BIOLOGICAL-ACTIVITY; MESSENGER-RNAS; A-RAF	The proto-oncogene c-raf-1 and the related genes A-raf and B-raf encode serine/threonine protein kinases thought to be involved in regulating gene expression by transducing extracellular signals into the cell. All three raf family genes have been shown previously to be expressed in mouse testis. Northern and in situ hybridization analyses with probes specific for each gene demonstrated that c-raf-1 mRNA is ubiquitously expressed in both somatic and germ cells as a 3.1-kb transcript. Additionally, the levels of c-raf-1 expression are developmentally regulated in the germ cells, exhibiting highest expression in early pachytene spermatocytes and decreasing progressively through later stages. A-raf is expressed predominantly in the somatic compartment as two transcripts of 2.6 and 4.3 kb. A-raf expression in Leydig cells appears to be elevated in testes undergoing spermatogenesis. In contrast, B-raf is expressed as two major transcripts of 4.0 and 2.6 kb, with the 4.0-kb transcript first expressed at low levels in pachytene spermatocytes and the more abundant 2.6-kb transcript restricted to post-meiotic spermatids. These studies indicate that each raf gene exhibits a characteristic, limited pattern of expression and suggests that the different forms may play a unique regulatory role in androgen production and/or spermatogenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR REPROD SCI,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NCRR NIH HHS [2-S07-RR05395] Funding Source: Medline; NICHD NIH HHS [P50 HD05077, F32 HD07414-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077, F32HD007414] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005395] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adashi EY, 1992, SPERMATOGENESIS FERT, P143; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAPMAN DL, 1992, IN PRESS MOL REPROD; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; GIZANGGINSBERG E, 1987, P NATL ACAD SCI USA, V84, P1600, DOI 10.1073/pnas.84.6.1600; GIZANGGINSBERG E, 1985, DEV BIOL, V111, P293, DOI 10.1016/0012-1606(85)90484-1; HANDEL MA, 1979, BIOL REPROD, V20, P1031, DOI 10.1095/biolreprod20.5.1031; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUMMEL KP, 1966, MOUSE NEWS LETT, V34, P31; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MATHER JP, 1992, SPERMATOGENESIS FERT, P169; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PARVINEN M, 1991, GROWTH FACTORS FERTI, P157; PONZETTO C, 1989, ONCOGENE, V4, P685; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STEPHENS RM, 1992, UNPUB MOL CELL BIOL; STORM SM, 1990, ONCOGENE, V5, P345; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	48	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455932				2022-12-25	WOS:A1993KT22000030
J	KLEMENT, JF; CVEKL, A; PIATIGORSKY, J				KLEMENT, JF; CVEKL, A; PIATIGORSKY, J			FUNCTIONAL ELEMENTS DE2A, DE2B, AND DE1A AND THE TATA BOX ARE REQUIRED FOR ACTIVITY OF THE CHICKEN ALPHA-A-CRYSTALLIN GENE IN TRANSFECTED LENS EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; B-CRYSTALLIN; DNA-BINDING; PROMOTER; ENHANCER; PROTEIN; MOUSE; INTERACTS; FEATURES; EXTRACT	AlphaA-crystallin is an abundant soluble protein of the vertebrate eye lens. In addition to the TATA box, four positive cis-regulatory elements of the chicken alphaA-crystallin gene have been identified by linker scanning mutagenesis, DNase I footprinting, and gel mobility shift experiments. The regulatory elements described here have been named DE2A (at positions -144 to -134), DE2B (at positions -128 to -118), and DE1A (at positions -114 to -103). DE2A and DE2B form a dyad of symmetry between positions -141 and -118 (5'-AGACTGTCAT....AGGTCAGTCT-3'), consistent with the close similarity in the mobility of complexes formed with lens nuclear proteins by these two elements. Mutations in DE2A, DE2B, and DE1A leading to loss of promoter activity using the bacterial chloramphenicol acetyltransferase reporter gene transfected into primary embryonic chicken lens epithelial cells resulted in a corresponding loss in the ability to compete for complex formation with lens nuclear proteins in gel mobility shift assays. Mutation of the alphaA-CRYBP1-like site (-67/-57), necessary for function of the mouse alphaA-crystallin promoter, did not affect the activity of the chicken promoter. The DNase I footprinting and gel mobility shift experiments confirmed the previously noted binding of nuclear proteins to a dyad of symmetry at positions -153 to -140. In contrast to DE2A, DE2B, and DE1A, mutagenesis and gel mobility shift experiments failed to correlate function and protein binding for the -153/-140 dyad. DE2A, DE2B, and DE1A agree well with the regulatory elements alphaCE1 (-162/-134), alphaCE3 (-135/-121), and alphaCE2 (-119/-99) (Matsuo, I., and Yasuda, K. (1992) Nucleic Acids Res. 20, 3701-3712) for this gene. The present results suggest, however, that the lens enhancer activity of alphaCE1 is due to the sequence -141/-134, which forms the upper half of the DE2A/DE2B dyad of symmetry, rather than the -153/-140 dyad as previously suspected.	NIH,LMDB,BLDG 6,RM 201,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA			Cvekl, Ales/B-2427-2013					ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; CVEKL A, 1991, GENE, V103, P253, DOI 10.1016/0378-1119(91)90282-G; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOVAN DM, 1992, J MOL EVOL, V35, P337, DOI 10.1007/BF00161171; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAWORSKI CJ, 1991, J MOL EVOL, V33, P495, DOI 10.1007/BF02102802; KANTOROW M, 1993, IN PRESS J MOL BIOL, V230; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOK S, 1989, NUCLIC ACIDS RES, V17, P3565; Maniatis T., 1984, MOL CLONING; MATSUO I, 1992, BIOCHEM BIOPH RES CO, V184, P24, DOI 10.1016/0006-291X(92)91152-G; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER H, 1987, METHOD ENZYMOL, V152, P154; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PUGH BF, 1992, J BIOL CHEM, V267, P679; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAX CM, 1990, MOL CELL BIOL, V10, P6813, DOI 10.1128/MCB.10.12.6813; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOMMER B, 1988, J BIOL CHEM, V263, P15666; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YASUDA K, 1988, UCLA S MOL BIOL EYE, V8, P205; ZABEL U, 1991, J BIOL CHEM, V266, P252	43	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6777	6784						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454650				2022-12-25	WOS:A1993KT36800100
J	SONG, WC; BAERTSCHI, SW; BOEGLIN, WE; HARRIS, TM; BRASH, AR				SONG, WC; BAERTSCHI, SW; BOEGLIN, WE; HARRIS, TM; BRASH, AR			FORMATION OF EPOXYALCOHOLS BY A PURIFIED ALLENE OXIDE SYNTHASE - IMPLICATIONS FOR THE MECHANISM OF ALLENE OXIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID HYDROPEROXIDE; TRIHYDROXY FATTY-ACIDS; ARACHIDONIC-ACID; CATALYZED TRANSFORMATION; SOYBEAN LIPOXYGENASE-1; SUBSTRATE-SPECIFICITY; PLEXAURA-HOMOMALLA; MARINE PROSTANOIDS; EPOXY ALCOHOLS; ENZYME	The allene oxide synthase (hydroperoxide dehydrase) of flaxseed is a cytochrome P450 that exhibits an exceptionally high catalytic turnover (greater-than-or-equal-to 1000/s) for hydroperoxy substrates. In a previous study, using a crude extract of flaxseed, we detected a secondary activity that could offer an insight into the mechanism of the enzymatic transformation of hydroperoxides. We observed that the substrate 8R-hydroxy-15S-hydroperoxyeicosa-5,9,11,13,17-pentaenoic acid is converted not only to allene oxide, but also to epoxyalcohol derivatives (Brash, A. R., Baertschi, S. W., and Harris, T. M. (1990) J. Biol. Chem. 265, 6705-6712). The transformation of hydroperoxides to epoxyalcohols has been investigated extensively in other systems, and heterolytic or homolytic cleavage of the hydroperoxide is associated with characteristic rearrangements and stereochemistry of the epoxyalcohol products. Using the purified enzyme, we established that the epoxyalcohols are products of the allene oxide synthase. Their structures were determined by UV, gas chromatography-mass spectrometry, and NMR. The major epoxyalcohol is SR,13R-dihydroxy-14R,15S-epoxyeicosa-5Z, 9E,11Z,17Z-tetraenoic acid, a trans-epoxide with an a-hydroxyl in the relative threo configuration. Two minor products are the corresponding 11E isomer and a cis-epoxide identified as 8R, 13-dihydroxy-14S, 15S-epoxyeicosa-5Z,9E,11E,17Z-tetraenoic acid. Gas chromatography-mass spectrometry analysis of a reaction with [(O-18(2)]hydroperoxide substrate indicated complete retention of the hydroperoxy oxygens in the epoxyalcohol products. Mechanistic precedents support a homolytic hydroperoxide cleavage as the initial step in the synthesis of these epoxyalcohols. We suggest that the same process initiates allene oxide synthesis, a conclusion that is also most compatible with the known chemistry of cytochromes P450.	VANDERBILT UNIV, DEPT CHEM, NASHVILLE, TN 37232 USA	Vanderbilt University	SONG, WC (corresponding author), VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA.			Baertschi, Steven/0000-0001-5497-4984	NIDDK NIH HHS [DK-35275] Funding Source: Medline; NIEHS NIH HHS [ES-00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAERTSCHI SW, 1988, BIOCHEMISTRY-US, V27, P18, DOI 10.1021/bi00401a004; BLAIR IA, 1990, METHOD ENZYMOL, V187, P13; BLEE E, 1993, J BIOL CHEM, V268, P1708; BRASH AR, 1990, J BIOL CHEM, V265, P6705; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1991, J BIOL CHEM, V266, P22926; BRYANT RW, 1985, J BIOL CHEM, V260, P3548; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; COREY EJ, 1983, TETRAHEDRON LETT, V24, P4921, DOI 10.1016/S0040-4039(01)99811-9; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P558, DOI 10.1039/c39880000558; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P556, DOI 10.1039/c39880000556; Crombie L, 1991, J CHEM SOC P1, V1, P581; DEGROOT JJM, 1975, FEBS LETT, V56, P50, DOI 10.1016/0014-5793(75)80109-8; DIX TA, 1985, J BIOL CHEM, V260, P5351; FENG P, 1979, LIPIDS, V14, P710, DOI 10.1007/BF02533895; GALLIARD T, 1975, BIOCHIM BIOPHYS ACTA, V409, P157, DOI 10.1016/0005-2760(75)90151-4; GARDNER HW, 1970, J LIPID RES, V11, P311; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GARDNER HW, 1974, LIPIDS, V9, P696, DOI 10.1007/BF02532178; GARDNER HW, 1984, CHEM PHYS LIPIDS, V35, P87, DOI 10.1016/0009-3084(84)90015-X; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1975, LIPIDS, V10, P87, DOI 10.1007/BF02532161; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V879, P410, DOI 10.1016/0005-2760(86)90233-X; HAMBERG M, 1987, CHEM PHYS LIPIDS, V43, P55, DOI 10.1016/0009-3084(87)90017-X; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1445, DOI 10.1007/BF02661968; LABEQUE R, 1989, J AM CHEM SOC, V111, P6621, DOI 10.1021/ja00199a022; LELLOUCHE JP, 1988, TETRAHEDRON LETT, V29, P2449, DOI 10.1016/S0040-4039(00)87904-6; LIEBLER DC, 1983, BIOCHEMISTRY-US, V22, P5482, DOI 10.1021/bi00293a005; MERCIER J, 1974, CHEM PHYS LIPIDS, V12, P239, DOI 10.1016/0009-3084(74)90078-4; MOGHADDAM MF, 1990, J BIOL CHEM, V265, P6126; NARUMIYA S, 1981, J BIOL CHEM, V256, P9583; PACEASCIAK CR, 1984, J BIOL CHEM, V259, P8332; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PIERRE JL, 1968, CHIM ANAL-PARIS, V50, P494; ROUSH WR, 1991, J ORG CHEM, V56, P1636, DOI 10.1021/jo00004a053; SONG WC, 1991, ARCH BIOCHEM BIOPHYS, V290, P427, DOI 10.1016/0003-9861(91)90562-W; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; VICK BA, 1979, PLANT PHYSIOL, V64, P203, DOI 10.1104/pp.64.2.203; VICK BA, 1979, PLANT PHYSIOL, V63, P490, DOI 10.1104/pp.63.3.490; WEISS RH, 1987, ARCH BIOCHEM BIOPHYS, V252, P334, DOI 10.1016/0003-9861(87)90039-7	45	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6293	6298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454602				2022-12-25	WOS:A1993KT36800035
J	WOJTCZAK, A; LUFT, JR; CODY, V				WOJTCZAK, A; LUFT, JR; CODY, V			STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING - CRYSTAL-STRUCTURE DETERMINATION TO 1.9 ANGSTROM OF THE HUMAN SERUM TRANSTHYRETIN-MILRINONE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA-2+-ATPASE ACTIVITY; THYROID-HORMONE; PHOSPHODIESTERASE INHIBITORS; TRIPHOSPHATASE-ACTIVITY; AGENT; PREALBUMIN; REFINEMENT; AMRINONE; CHANNEL; CULTURE	The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4'-bipyridin-6(1H-one), a positive inotropic cardiac agent, has been refined to R = 17.4% for 8-1.9-angstrom resolution data. This report provides the first detailed description of protein interactions for an inotropic bipyridine agent which is an effective thyroid hormone binding competitor to transthyretin. Milrinone is bound along the 2-fold axis in the binding site with its substituted pyridone ring located deep within the channel of the two identical binding domains of the TTR tetramer. In this orientation the 5-cyano group occupies the same site as the 3'-iodine in the TTR complex with 3,3'-diiodothyronine (Wojtczak, A., Luft, J., and Cody, V. (1992) J. Biol. Chem. 267, 353-357), which is 3.5 angstrom deeper in the channel than thyroxine (Blake, C. C. F., and Oately, S. J., (1977) Nature 268, 115-120). These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. To understand the weaker binding affinity of the parent inotropic drug, amrinone (5-amino-3,4'-bipyridin-6(1H)-one), modeling studies of its TTR binding were carried out which indicate that the 5-amino group cannot participate in strong interactions with TTR and the lack of the 2-methyl further weakens amrinone binding.	MED FDN BUFFALO INC,73 HIGH ST,BUFFALO,NY 14203				Wojtczak, Andrzej/H-8130-2014	Wojtczak, Andrzej/0000-0001-8801-7728	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041009] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41009] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIM DS, 1983, NEW ENGL J MED, V309, P748, DOI 10.1056/NEJM198309293091302; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRAVERMAN LE, 1991, THYROID; BUSH BL, 1988, PS300 FRODO MOL GRAP; CAVALIERI RR, 1981, PHARMACOL REV, V33, P55; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; CODY V, 1987, ACTA CRYSTALLOGR C, V43, P1325, DOI 10.1107/S0108270187091996; Cody V, 1980, Endocr Rev, V1, P140; CODY V, 1991, PROGRESS IN THYROID RESEARCH, P793; DAVIS PJ, 1987, BIOCHEM PHARMACOL, V36, P3635, DOI 10.1016/0006-2952(87)90013-X; DIBIANCO R, 1991, AM HEART J, V121, P1871, DOI 10.1016/0002-8703(91)90078-V; DILLMAN WH, 1991, THYROID, P759; DILLMANN WH, 1983, ENDOCRINOLOGY, V112, P2081, DOI 10.1210/endo-112-6-2081; DORIGO P, 1990, CARDIOVASC DRUG THER, V4, P509, DOI 10.1007/BF01857762; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOLMBERG SRM, 1991, CARDIOVASC RES, V25, P537, DOI 10.1093/cvr/25.7.537; HONERJAGER P, 1991, AM HEART J, V121, P1939, DOI 10.1016/0002-8703(91)90828-6; JORGENSEN EC, 1978, HORMONAL PROTEINS PE, V6, P108; KOEHRLE J, 1989, ENDOCRINOLOGY, V125, P532; KRIEGER NS, 1987, J CLIN INVEST, V79, P444, DOI 10.1172/JCI112831; KRIEGER NS, 1982, AM J PHYSIOL, V243, pE499, DOI 10.1152/ajpendo.1982.243.6.E499; MYLOTTE KM, 1985, P NATL ACAD SCI USA, V82, P7974, DOI 10.1073/pnas.82.23.7974; RUDINGER A, 1984, ARCH BIOCHEM BIOPHYS, V229, P379, DOI 10.1016/0003-9861(84)90165-6; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TRITSCH GL, 1972, J MED, V3, P129; UNDERWOOD AH, 1986, NATURE, V324, P425, DOI 10.1038/324425a0; WARNICK PR, 1988, BIOCHEM PHARMACOL, V37, P2619, DOI 10.1016/0006-2952(88)90255-9; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353	29	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6202	6206						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454595				2022-12-25	WOS:A1993KT36800022
J	INOUE, S; SHARMA, RC; SCHIMKE, RT; SIMONI, RD				INOUE, S; SHARMA, RC; SCHIMKE, RT; SIMONI, RD			CELLULAR DETOXIFICATION OF TRIPEPTIDYL ALDEHYDES BY AN ALDO-KETO REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; SUPERFAMILY; INHIBITORS; RESISTANCE; PROTEIN; DEHYDROGENASE; CRYSTALLIN	Calpain inhibitor I, N-acetyl-leucyl-leucyl-norleucinal (ALLN), a cell-permeable synthetic tripeptide with an aldehyde at its C terminus specifically inhibits the activity of cysteine proteases. Since the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in Chinese hamster ovary (CHO) cells is blocked by ALLN and ALLN has a cytotoxic effect on cells, we attempted to isolate ALLN-resistant cells that overproduce an ALLN-sensitive protease(s). However, we obtained an ALLN-resistant cell line that overproduced P-glycoprotein (Sharma, R. C., Inoue, S., Roitelman, J., Schimke, R. T., and Simoni, R. D. (1992) J. Biol. Chem. 267, 5731-5734). To circumvent the multidrug resistance (MDR) phenotype during selection, we have stepwise selected an ALLN-resistant cell line of CHO cells in the presence of verapamil, a competitive inhibitor of P-glycoprotein. These non-MDR ALLN-resistant cells overexpress a 35-kDa protein and have increased aldo-keto reductase activity. Partial amino acid sequences of the 35-kDa protein are highly homologous to members of the aldo-keto reductase superfamily. The aldo-keto reductases are NADPH-dependent oxidoreductases and catalyze reduction of a wide range of carbonyl compounds such as aldehydes, sugars, and ketones. Our findings support the concept that a physiological function for aldo-keto reductases may be detoxification.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA 16318] Funding Source: Medline; NHLBI NIH HHS [HL26502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016318] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1992, J BIOL CHEM, V267, P5776; BACHUR NR, 1976, SCIENCE, V193, P595, DOI 10.1126/science.959821; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHUN KT, 1990, J BIOL CHEM, V265, P22004; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MOLOWA DT, 1986, J BIOL CHEM, V261, P2624; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHARMA RC, 1991, CANCER RES, V51, P2949; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STOLZ A, 1991, J BIOL CHEM, V266, P15253; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WEST IC, 1990, TRENDS BIOCHEM SCI, V15, P42, DOI 10.1016/0968-0004(90)90171-7; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	29	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5894	5898						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449954				2022-12-25	WOS:A1993KR82200081
J	LEVY, O; WEISS, J; ZAREMBER, K; OOI, CE; ELSBACH, P				LEVY, O; WEISS, J; ZAREMBER, K; OOI, CE; ELSBACH, P			ANTIBACTERIAL 15-KDA PROTEIN ISOFORMS (P15S) ARE MEMBERS OF A NOVEL FAMILY OF LEUKOCYTE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHANYL PEPTIDE-BONDS; N-CHLOROSUCCINIMIDE-UREA; BINDING-PROTEIN; PIG LEUKOCYTES; SEQUENCE; CYSTEINE; INHIBITOR; ENDOTOXIN; CLEAVAGE	We have previously described the isolation and initial characterization of functionally distinct 15-kDa protein isoforms (p15s) from rabbit polymorphonuclear leukocytes (PMN) that bind with high affinity to Escherichia coli and modulate the antibacterial actions of other leukocyte proteins on this Gram-negative bacterium. We now report the cloning and sequencing of two distinct cDNAs from a rabbit bone marrow library that encode p15s differing at only 2 residues (His-3, Arg-88 versus Arg-3, Trp-88). Tryptophan-directed chemical cleavage of two isoforms purified from a single rabbit confirms the existence of multiple isoforms with distinct function and primary structure in a single rabbit. The p15 cDNAs encode putative signal sequences and studies of cellular and subcellular localization indicate that the p15s are granule-associated proteins of PMN. Both purified isoforms bind avidly to lipopolysaccharide (LPS), the major component of the Gram-negative bacterial outer membrane. Analysis of the deduced primary structures of the p15s reveals homology to three other leukocyte proteins: CAP-18, an 18-kDa LPS-binding protein from rabbit PMN, pro-indolicidin, a 16-kDa precursor of an antibacterial peptide of bovine PMN, and cathelin, an 11-kDa cysteine protease inhibitor from porcine leukocytes, suggesting the existence of a novel family of leukocyte proteins with LPS-binding, antimicrobial, and protease-inhibitory activities.	NYU,SCH MED,DEPT MED,NEW YORK,NY 10016	New York University	LEVY, O (corresponding author), NYU,SCH MED,DEPT MICROBIOL,550 1ST AVE,NEW YORK,NY 10016, USA.			Zarember, Kol/0000-0002-9624-7096; Weiss, Jerrold/0000-0003-1476-4485; Levy, Ofer/0000-0002-5859-1945	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK05472] Funding Source: Medline; NIGMS NIH HHS [5T32GMO7308] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CAMPANELLI D, 1990, J CLIN INVEST, V85, P909; COLMAN RW, 1989, NEW ENGL J MED, V320, P1207, DOI 10.1056/NEJM198905043201809; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELSBACH P, 1959, J GEN PHYSIOL, V42, P883, DOI 10.1085/jgp.42.5.883; Elsbach P, 1992, INFLAMMATION BASIC P, P603; GANZ T, 1991, EUR J HAEMATOL, V44, P1; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; KOPITAR M, 1989, BIOL CHEM H-S, V370, P1145, DOI 10.1515/bchm3.1989.370.2.1145; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; Levin J., 1988, Progress in Clinical and Biological Research, V272, P3; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; OOI CE, 1990, J BIOL CHEM, V265, P15956; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SHECHTER Y, 1976, BIOCHEMISTRY-US, V15, P5071, DOI 10.1021/bi00668a019; SMOLELIS AN, 1949, J BACTERIOL, V58, P731, DOI 10.1128/JB.58.6.731-736.1949; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; TALALAY P, 1946, J BIOL CHEM, V166, P757; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; WEISS J, 1987, BLOOD, V69, P652; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980; ZANETTI M, 1993, J BIOL CHEM, V268, P522	31	79	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6058	6063						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449963				2022-12-25	WOS:A1993KR82200102
J	MAXAUDIT, I; ELEOUET, JF; ROMEO, PH				MAXAUDIT, I; ELEOUET, JF; ROMEO, PH			TRANSCRIPTIONAL REGULATION OF THE PYRUVATE-KINASE ERYTHROID-SPECIFIC PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; TISSUE-SPECIFIC EXPRESSION; ERYTHROLEUKEMIA CELL-LINE; NUCLEAR-PROTEIN FACTORS; BETA-GLOBIN PROMOTER; MAMMALIAN-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; FUNCTIONAL-ANALYSIS; TRANSGENIC MICE; BINDING PROTEIN	Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.			MAXAUDIT, I (corresponding author), HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE.		Romeo, Paul-Henri/L-5989-2017; Eléouët, Jean-François/AAD-1994-2019	Romeo, Paul-Henri/0000-0002-8294-0367; 				BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHAO MV, 1983, CELL, V32, P483, DOI 10.1016/0092-8674(83)90468-3; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COGNET M, 1991, J BIOL CHEM, V266, P7368; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FUKUDA M, 1981, CANCER RES, V41, P4621; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEE ME, 1991, J BIOL CHEM, V266, P16188; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAXAUDIT I, 1988, BLOOD, V72, P1039; MAXAUDIT I, 1984, BLOOD, V64, P930; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINAKAMI S, 1966, J BIOCHEM, V59, P139, DOI 10.1093/oxfordjournals.jbchem.a128274; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NIJHOF W, 1984, BLOOD, V64, P607; NOGUCHI T, 1983, J BIOL CHEM, V258, P5220; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSTERMAN J, 1974, BIOCHEMISTRY-US, V13, P1731, DOI 10.1021/bi00705a027; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; TABILIO A, 1983, CANCER RES, V43, P4569; TAKEGAWA S, 1983, BRIT J HAEMATOL, V54, P467, DOI 10.1111/j.1365-2141.1983.tb02121.x; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TREMP GL, 1989, J BIOL CHEM, V264, P19904; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; YAMADA K, 1990, BIOCHEM BIOPH RES CO, V171, P243, DOI 10.1016/0006-291X(90)91383-4; YAMADA K, 1990, J BIOL CHEM, V265, P19885; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YU CY, 1991, J BIOL CHEM, V266, P8907; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	58	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5431	5437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449904				2022-12-25	WOS:A1993KR82200016
J	CLARK, EN; CORRON, ME; FLORMAN, HM				CLARK, EN; CORRON, ME; FLORMAN, HM			CALTRIN, THE CALCIUM-TRANSPORT REGULATORY PEPTIDE OF SPERMATOZOA, MODULATES ACROSOMAL EXOCYTOSIS IN RESPONSE TO THE EGGS ZONA-PELLUCIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL PLASMA; SEA-URCHIN SPERM; ANTI-MICROBIAL PROTEIN; MOUSE SPERM; STRONGYLOCENTROTUS-PURPURATUS; HEART-MITOCHONDRIA; FOLLICULAR-FLUID; BINDING-SITES; CA2+ CHANNELS; ION CHANNELS	Acrosomal exocytosis is initiated in mammalian sperm by stimulatory agonists in the zona pellucida. Recently, it was shown that exocytosis is modulated in bovine sperm by extrinsic factors present in seminal fluids (Florman, H. M., and First, N. L. (1988) Dev. Biol. 128, 464-474). Fractionation of bovine seminal fluids yields a M(r) almost-equal-to 6,500, basic (pI almost-equal-to 8.5) peptide that accounts for the positive modulation of zona pellucida-induced acrosome reaction (ED50 and maximal response at 0.2 and 1 mug/ml, respectively). In addition, application of purified peptide to fura 2-loaded, cauda epididymal sperm supported zona pellucida-promoted elevations of Ca2+i equivalent to those observed with sperm treated with unfractionated seminal fluids in vitro or in vivo. Finally, peptide treatment regulated gamete interaction in a manner consistent with the distinct behaviors of cauda epididymal and ejaculated bovine sperm. This purified seminal peptide was identified by sequence analysis as caltrin, a previously characterized regulator of Ca2+ transport in bovine sperm. We therefore propose that caltrin is a regulator of sperm signal transduction pathways activated by zona pellucida binding.	WORCESTER FDN EXPTL BIOL INC, 222 MAPLE AVE, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research								AGUSTIN JTS, 1990, J BIOL CHEM, V265, P6860; AGUSTIN JTS, 1987, FASEB J, V1, P60; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; BABCOCK DF, 1979, DEV BIOL, V69, P85, DOI 10.1016/0012-1606(79)90276-8; BALL GD, 1983, BIOL REPROD, V28, P717, DOI 10.1095/biolreprod28.3.717; BEDFORD JM, 1983, BIOL REPROD, V28, P108, DOI 10.1095/biolreprod28.1.108; BERG DK, 1989, TRENDS NEUROSCI, V12, P16, DOI 10.1016/0166-2236(89)90151-3; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BRADLEY MP, 1980, FEBS LETT, V121, P15, DOI 10.1016/0014-5793(80)81255-5; BREITBART H, 1990, BIOCHIM BIOPHYS ACTA, V1022, P27, DOI 10.1016/0005-2736(90)90396-6; BREITBART H, 1990, EUR J BIOCHEM, V192, P529, DOI 10.1111/j.1432-1033.1990.tb19257.x; BROWN AM, 1990, AM J PHYSIOL, V259, pH1621, DOI 10.1152/ajpheart.1990.259.6.H1621; BROWN AM, 1991, FASEB J, V5, P2175, DOI 10.1096/fasebj.5.8.1708737; BRYAN JHD, 1977, STAIN TECHNOL, V52, P47, DOI 10.3109/10520297709116742; CHANG MC, 1957, NATURE, V179, P258, DOI 10.1038/179258a0; COMTE M, 1986, BIOCHEM J, V240, P567, DOI 10.1042/bj2400567; COX T, 1989, BIOCHEM BIOPH RES CO, V161, P162, DOI 10.1016/0006-291X(89)91575-1; COX T, 1991, MOL REPROD DEV, V30, P135, DOI 10.1002/mrd.1080300210; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; First N L, 1987, J Reprod Fertil Suppl, V34, P151; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; FLORMAN HM, 1988, DEV BIOL, V128, P464, DOI 10.1016/0012-1606(88)90308-9; FLORMAN HM, 1988, DEV BIOL, V128, P453, DOI 10.1016/0012-1606(88)90307-7; FLORMAN HM, 1990, ELEMENTS MAMMALIAN F, P105; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERRERO A, 1989, BIOCHIM BIOPHYS ACTA, V980, P109, DOI 10.1016/0005-2736(89)90206-X; Hille B., 1991, IONIC CHANNELS EXCIT; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; KAZAZOGLOU T, 1985, P NATL ACAD SCI USA, V82, P1460, DOI 10.1073/pnas.82.5.1460; KAZAZOGLOU T, 1983, FEBS LETT, V164, P75, DOI 10.1016/0014-5793(83)80022-2; Kopf GS, 1990, ELEMENTS MAMMALIAN F, P153; Lardy H., 1989, Cell biology of fertilization., P29; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEWIS RV, 1985, P NATL ACAD SCI USA, V82, P6490, DOI 10.1073/pnas.82.19.6490; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V77, pR1, DOI 10.1016/0303-7207(91)90080-C; MILLER DJ, 1990, BIOL REPROD, V42, P899, DOI 10.1095/biolreprod42.6.899; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MILOS M, 1988, J BIOL CHEM, V263, P9218; MORTILLO S, 1991, DEVELOPMENT, V113, P141; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/biolreprod38.5.1171; REDDY ESP, 1979, NATURE, V279, P725, DOI 10.1038/279725a0; RENAUD JF, 1980, DEV BIOL, V78, P184, DOI 10.1016/0012-1606(80)90328-0; RENAUD JF, 1984, EUR J BIOCHEM, V139, P673, DOI 10.1111/j.1432-1033.1984.tb08056.x; RENAUD JF, 1981, P NATL ACAD SCI-BIOL, V78, P5348, DOI 10.1073/pnas.78.9.5348; RENAUD JF, 1989, ANN NY ACAD SCI, V560, P418, DOI 10.1111/j.1749-6632.1989.tb24126.x; RUFO GA, 1984, J BIOL CHEM, V259, P2547; RUFO GA, 1982, J BIOL CHEM, V257, P4627; SCHACKMANN RW, 1978, DEV BIOL, V65, P483, DOI 10.1016/0012-1606(78)90043-X; SCHACKMANN RW, 1981, DEV BIOL, V81, P145, DOI 10.1016/0012-1606(81)90357-2; SINGH JP, 1978, BIOCHEM J, V172, P549, DOI 10.1042/bj1720549; SITARAM N, 1986, FEBS LETT, V201, P233, DOI 10.1016/0014-5793(86)80615-9; STOREY BT, 1992, MOL REPROD DEV, V32, P41, DOI 10.1002/mrd.1080320108; THEIL R, 1983, EMBO J, V2, P1159, DOI 10.1002/j.1460-2075.1983.tb01561.x; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; THOMAS P, 1988, GAMETE RES, V20, P397, DOI 10.1002/mrd.1120200402; TRIMMER JS, 1987, J CELL BIOL, V105, P1121, DOI 10.1083/jcb.105.3.1121; TRIMMER JS, 1986, P NATL ACAD SCI USA, V83, P9055, DOI 10.1073/pnas.83.23.9055; VAZQUEZ MH, 1989, J CELL SCI, V92, P713; WAGNER S, 1990, DNA CELL BIOL, V9, P437, DOI 10.1089/dna.1990.9.437; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WILDE MW, 1992, MOL REPROD DEV, V31, P297, DOI 10.1002/mrd.1080310411; Yanagimachi R., 1988, P135; ZHANG JF, 1992, NEURON, V9, P97, DOI 10.1016/0896-6273(92)90224-2	76	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5309	5316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444904				2022-12-25	WOS:A1993KP88400106
J	GILCHRIST, JSC; PIERCE, GN				GILCHRIST, JSC; PIERCE, GN			IDENTIFICATION AND PURIFICATION OF A CALCIUM-BINDING PROTEIN IN HEPATIC NUCLEAR-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; CA-2+-BINDING PROTEINS; INTRACELLULAR CALCIUM; ION CHANNELS; PORE COMPLEX; CALMODULIN; ENVELOPE; CELLS	Recent evidence suggests that nuclei possess Ca2+ transport mechanisms to regulate nucleoplasmic/cytosolic Ca2+ gradients. We, therefore, investigated the possibility that Ca2+-binding proteins may also exist within the nucleus. Electrophoretic analysis revealed the presence of an acidic 93-kDa protein (p93) in the membranes of isolated nuclei. p93 stained blue with ''Stains-All'' in SDS-polyacrylamide gels and was the major Ca-45(2+) and ruthenium red-binding nuclear envelope protein in electroblot overlays. p93 was resistant to extraction by 6 M urea but was solubilized in 2% Triton X-100. Citric acid was highly effective in removing the outer nuclear membrane (ER) with concomitant reduction (<10-fold) of mannose-6-phosphatase activity, but not p93. Ca-45(2+)-binding assays of purified p93 revealed the presence of high capacity Ca2+-binding sites comparable to calreticulin. This evidence strongly suggests that p93 is a major Ca2+-binding protein of the inner nuclear envelope membrane. Partial amino acid sequence analysis revealed that p93 was close to 100% homologous with a recently identified ER Ca2+-binding protein known as calnexin. It is likely, therefore, that p93 is calnexin. However, mild CHAPS detergent treatment of nuclear envelopes and ER revealed distinctly different solubility properties of each membrane for the extraction of p93. This, together with the citrate data, strongly suggests that p93/calnexin, in isolated nuclear envelopes, is mostly bound to the inner membrane. It is possible that p93 may be involved with the regulation of Ca2+ transients between the nucleoplasm and perinuclear space.	ST BONIFACE GEN HOSP, RES CTR,DIV CARDIOVASC SCI,ION TRANSPORT LAB, 351 TACHE AVE, WINNIPEG R2H 2A6, MANITOBA, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba				Pierce, Grant/0000-0001-7674-0142				ARION WJ, 1983, J BIOL CHEM, V258, P2661; BACHS O, 1990, J BIOL CHEM, V265, P18595; BACHS O, 1987, J BIOL CHEM, V262, P10786; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CUTTING JA, 1984, METHOD ENZYMOL, V104, P451; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GURR MI, 1963, BIOCHIM BIOPHYS ACTA, V70, P400; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANINI L, 1992, J BIOL CHEM, V267, P11548; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARTONOSI A, 1982, ANNU REV PHYSIOL, V44, P337, DOI 10.1146/annurev.ph.44.030182.002005; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1991, J MEMBRANE BIOL, V121, P189, DOI 10.1007/BF01870532; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; RAESS BU, 1980, J PHARMACOL METHOD, V4, P273, DOI 10.1016/0160-5402(80)90019-4; RIEDEL N, 1987, BIOCHEM J, V241, P203, DOI 10.1042/bj2410203; RODLAND KD, 1990, J BIOL CHEM, V265, P11000; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SHELTON KR, 1980, J BIOL CHEM, V255, P978; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SOMLYO AP, 1985, J PHYSIOL-LONDON, V358, P579; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; WADA I, 1991, J BIOL CHEM, V266, P19599; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	54	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4291	4299						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440713				2022-12-25	WOS:A1993KN53300070
J	MATTINGLY, JR; YOUSSEF, J; IRIARTE, A; MARTINEZCARRION, M				MATTINGLY, JR; YOUSSEF, J; IRIARTE, A; MARTINEZCARRION, M			PROTEIN FOLDING IN A CELL-FREE TRANSLATION SYSTEM - THE FATE OF THE PRECURSOR TO MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; RAT-LIVER MITOCHONDRIA; HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONE; CONFORMATIONAL CHANGE; YEAST MITOCHONDRIA; STRESS PROTEINS; RNA-POLYMERASE; IMPORT; BINDING	The precursor to rat mitochondrial aspartate aminotransferase (pmAspAT) can be expressed in and purified from Escherichia coli as a fully active enzyme with remarkable trypsin resistance. Only two sites within the presequence are readily hydrolyzed (Martinez-Carrion, M., Altieri, F., Iriarte, A., Mattingly, J. R., Youssef, J., and Wu, T. (1990) Ann. N. Y. Acad. Sci. 585, 346-356). In contrast, pmAspAT freshly synthesized in rabbit reticulocyte lysate is significantly less resistant to proteolysis and is completely digested by trypsin. Extended incubation of the pmAspAT translation product slowly converts it to a species with qualitatively the same trypsin resistance as the purified pmAspAT. In addition, this species binds pyridoxal 5'-phosphate, exhibits catalytic activity, and loses its ability to be imported into mitochondria. This process appears to reflect protein folding. The rate of folding is unaffected by the addition of cofactor or the depletion of endogenous cofactor and is not significantly affected by the concentration of translation product in the reaction. Agents that decrease the availability of ATP partially inhibit the folding, whereas the sulfhydryl alkylating reagent N-ethylmaleimide and the detergent Triton X-100 completely prevent the conversion. Although the folding of pmAspAT in reticulocyte lysate is slow, folding is rapid once the translation product is sequestered within the mitochondria as the mature form of the enzyme. These results are presented as a model for the in vivo folding of pyridoxal-dependent, oligomeric mitochondrial precursors in the presence of cytoplasmic components and for the fate of true mitochondrial precursor proteins when not imported.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, 109 BIOL SCI BLDG, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NHLBI NIH HHS [HL-22265] Funding Source: Medline; NIGMS NIH HHS [GM-38184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038184] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, 1992, J BIOL CHEM, V267, P5637; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; Christen P, 1985, TRANSAMINASES; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENDO T, 1989, J BIOL CHEM, V264, P2951; FELIPO V, 1983, EUR J BIOCHEM, V133, P641, DOI 10.1111/j.1432-1033.1983.tb07511.x; FLUCKIGER J, 1988, J BIOL CHEM, V263, P4131; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIANNATTASIO S, 1991, ARCH BIOCHEM BIOPHYS, V290, P528, DOI 10.1016/0003-9861(91)90577-6; GLICK B, 1991, ANNU REV GENET, V25, P21; GUPTA RS, 1990, BIOCHEM INT, V20, P833; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JAUSSI R, 1982, J BIOL CHEM, V257, P13334; JENKINS WT, 1966, BIOCHEM BIOPH RES CO, V22, P376, DOI 10.1016/0006-291X(66)90656-5; KALOUSEK F, 1984, J BIOL CHEM, V259, P5392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARRA E, 1977, BIOCHEM J, V164, P685, DOI 10.1042/bj1640685; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MICHUDA CM, 1969, BIOCHEMISTRY-US, V8, P1095, DOI 10.1021/bi00831a041; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P207, DOI 10.1093/oxfordjournals.jbchem.a123182; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V277, P368, DOI 10.1016/0003-9861(90)90592-M; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PEREZRAMIREZ B, 1989, BIOCHEMISTRY-US, V28, P5034, DOI 10.1021/bi00438a020; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1992, NATURE, V356, P392; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEST SM, 1989, BIOCHEM J, V261, P189, DOI 10.1042/bj2610189; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811	63	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3925	3937						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440686				2022-12-25	WOS:A1993KN53300023
J	PIETZKO, D; ZOHLNHOFER, D; GRAEVE, L; FLEISCHER, D; STOYAN, T; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC				PIETZKO, D; ZOHLNHOFER, D; GRAEVE, L; FLEISCHER, D; STOYAN, T; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC			THE HEPATIC INTERLEUKIN-6 RECEPTOR - STUDIES ON ITS STRUCTURE AND REGULATION BY PHORBOL 12-MYRISTATE 13-ACETATE-DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR; MOLECULAR-CLONING; STIMULATING FACTOR; SIGNAL TRANSDUCER; HUMAN-MONOCYTES; DOWN-REGULATION; CROSS-LINKING; CELL-LINE; EXPRESSION	Recombinant human I-125-interleukin-6 (IL-6) was cross-linked with the homobifunctional reagent disuccinimidyl suberate to human hepatoma cells (HepG2). Three recombinant human I-125-IL-6-containing complexes of apparent molecular masses of 100, 120, and 200 kDa were immunoprecipitated with specific antibodies to human IL-6 or to the 80-kDa IL-6 receptor subunit. We show by immunoprecipitation, peptide mapping, and by the use of a cleavable heterobifunctional cross-linker (Denny-Jaffe reagent) that different polypeptides are involved in the formation of the 100- and 120-kDa IL-6-containing complexes. The molecular compositions of the 100- and 120-kDa cross-linked complexes were identified. The 100-kDa complex consisted of one ligand and one IL-6 receptor subunit, glycoprotein 80 (gp80), whereas the 120-kDa complex was found to be composed of one ligand and a polypeptide which was immunoprecipitable with the monoclonal antibody AM64 directed against gp130. Exposure of HepG2 cells to phorbol 12-myristate 13-acetate (PMA) or PMA-dexamethasone led to an increase in the 80-kDa IL-6 receptor mRNA and functional receptor protein. Whereas treatment of HepG2 cells with PMA led to an increase in the formation of gp80.gp130.IL-6 complexes determined by cross-linking, no corresponding increase in high affinity binding sites was found. The existence of a third IL-6 receptor subunit present in limiting amounts on HepG2 cells is proposed to explain this discrepancy. Evidence is presented that the 80-kDa IL-6 receptor up-regulation by PMA-dexamethasone is caused by the depletion of protein kinase C since the protein kinase C inhibitor staurosporine mimics the effect of PMA-dexamethasone.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,PAUWELSSTR 30,W-5100 AACHEN,GERMANY	RWTH Aachen University			Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; BAUER J, 1989, FEBS LETT, V249, P27, DOI 10.1016/0014-5793(89)80008-0; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; DENNY JB, 1984, P NATL ACAD SCI-BIOL, V81, P5286, DOI 10.1073/pnas.81.17.5286; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GROSS V, 1983, J BIOL CHEM, V258, P2203; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HENSCHLER R, 1991, FEBS LETT, V283, P47, DOI 10.1016/0014-5793(91)80550-M; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; JAFFE CL, 1980, BIOCHEMISTRY-US, V19, P4423, DOI 10.1021/bi00560a007; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LENSTRA JA, 1989, MOL IMMUNOL, V1, P7; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SANCEAU J, 1991, J IMMUNOL, V147, P2630; SCHERRER K, 1962, BIOCHEM BIOPH RES CO, V7, P486, DOI 10.1016/0006-291X(62)90341-8; SCHOOLTINK H, 1992, FEBS LETT, V297, P263, DOI 10.1016/0014-5793(92)80552-R; SCHOOLTINK H, 1991, BIOCHEM J, V277, P659, DOI 10.1042/bj2770659; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SIDELL N, 1991, J IMMUNOL, V146, P3809; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WOLF M, 1988, BIOCHEM BIOPH RES CO, V154, P1273, DOI 10.1016/0006-291X(88)90277-X; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	43	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4250	4258						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440709				2022-12-25	WOS:A1993KN53300065
J	ZHAO, Y; KAPPES, B; FRANKLIN, RM				ZHAO, Y; KAPPES, B; FRANKLIN, RM			GENE STRUCTURE AND EXPRESSION OF AN UNUSUAL PROTEIN-KINASE FROM PLASMODIUM-FALCIPARUM HOMOLOGOUS AT ITS CARBOXYL TERMINUS WITH THE EF HAND CALCIUM-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MUSCLE TROPONIN-C; MOLECULAR-CLONING; CATALYTIC SUBUNIT; MALARIA PARASITES; CALMODULIN GENE; MESSENGER-RNAS; PHOSPHORYLATION; CHICKEN; TRANSLATION	An unusual protein kinase gene, termed PfCPK, was isolated from Plasmodium falciparum. The gene, which contains five exons and four introns, encodes a product with a predicted length of 524 amino acids. The amino-terminal segment of the predicted protein contains all of the conserved sequences characteristic of a protein kinase catalytic domain and has a high homology to several protein serine-threonine kinase subfamilies (30-41% amino acid identities). These subfamilies include calcium/calmodulin-dependent protein kinases, calcium-dependent protein kinase, ribosomal S6 protein kinase, cyclic nucleotide-dependent protein kinases, protein kinase C, and the yeast SNF1 subfamily. All of these protein kinases are relatively close in the phylogeny tree and within the kinase catalytic domains have about 35% amino acid identities to each other, suggesting that PfCPK is also in this region of the phylogeny tree. An unusual feature of PfCPK is that its carboxyl-terminal segment displays homology to the EF hand calcium-binding proteins, for example 34% amino acid identity to chicken fast skeletal muscle troponin C and 35% amino acid identity to human calmodulin. Like troponin Cs and calmodulins, PfCPK also contains four EF hand calcium-binding motifs. Furthermore, the four introns in the PfCPK gene are all located in the carboxyl-terminal putative EF hand calcium-binding region (EF hand calcium-binding proteins from higher eukaryotes generally contain multiple introns). This combination of a protein kinase and an EF hand calcium-binding protein in a single polypeptide implies that PfCPK may be directly activated by calcium. Constructs containing the full-length PfCPK cDNA have been expressed in Escherichia coli at a high level to generate a 60-kDa recombinant protein. Compared with similar fractions from control cells, the fraction containing PfCPK recombinant protein exhibited an elevated protein kinase activity which was Ca2+-dependent.	UNIV BASEL, BIOCTR, DEPT STRUCT BIOL, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND	University of Basel								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BOOKCHIN RM, 1981, J PHYSL, V312, P1; BURGER D, 1984, BIOCHEMISTRY-US, V23, P1966, DOI 10.1021/bi00304a013; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CREEDON KA, 1992, MOL BIOCHEM PARASIT, V54, P113, DOI 10.1016/0166-6851(92)90102-P; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EPSTEIN P, 1987, METHOD ENZYMOL, V139, P217; FISCHER R, 1988, J BIOL CHEM, V263, P17055; GOMAN M, 1982, MOL BIOCHEM PARASIT, V5, P391, DOI 10.1016/0166-6851(82)90012-3; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HYDE JE, 1984, MOL BIOCHEM PARASIT, V10, P269, DOI 10.1016/0166-6851(84)90026-4; HYDE JE, 1989, MOL BIOCHEM PARASIT, V32, P247, DOI 10.1016/0166-6851(89)90074-1; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAWTON MA, 1989, P NATL ACAD SCI USA, V86, P3140, DOI 10.1073/pnas.86.9.3140; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; MCCALLUMDEIGHTON N, 1992, MOL BIOCHEM PARASIT, V50, P317, DOI 10.1016/0166-6851(92)90229-D; MEANS AR, 1982, PHYSIOL REV, V62, P1, DOI 10.1152/physrev.1982.62.1.1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOJIMA H, 1987, J MOL BIOL, V193, P439, DOI 10.1016/0022-2836(87)90258-0; PAWSON T, 1991, TRENDS GENET, V7, P343, DOI 10.1016/0168-9525(91)90252-L; RANGACHARI K, 1986, NATURE, V324, P364, DOI 10.1038/324364a0; READ LK, 1991, J PARASITOL, V77, P346, DOI 10.2307/3283117; READ LK, 1990, EXP PARASITOL, V71, P39, DOI 10.1016/0014-4894(90)90006-X; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; REINACH FC, 1988, J BIOL CHEM, V263, P2371; ROBSON KJH, 1991, MOL BIOCHEM PARASIT, V46, P19, DOI 10.1016/0166-6851(91)90195-C; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORIUS C, 1991, NUCLEIC ACIDS RES, V19, P1613, DOI 10.1093/nar/19.7.1613; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SCHREIER T, 1990, J BIOL CHEM, V265, P21247; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUEBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TANABE K, 1982, J CELL BIOL, V93, P680, DOI 10.1083/jcb.93.3.680; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WASSERMAN M, 1982, AM J TROP MED HYG, V31, P711, DOI 10.4269/ajtmh.1982.31.711; WEBER JL, 1988, EXP PARASITOL, V66, P143, DOI 10.1016/0014-4894(88)90087-2; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; YUTHAVONG Y, 1987, BIOCHIM BIOPHYS ACTA, V929, P278, DOI 10.1016/0167-4889(87)90254-0; ZHAO Y, 1992, EUR J BIOCHEM, V207, P305, DOI 10.1111/j.1432-1033.1992.tb17051.x	67	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4347	4354						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440720				2022-12-25	WOS:A1993KN53300078
J	ASHFORD, DA; ALAFI, CD; GAMBLE, VM; MACKAY, DJG; RADEMACHER, TW; WILLIAMS, PJ; DWEK, RA; BARCLAY, AN; DAVIS, SJ; SOMOZA, C; WARD, HA; WILLIAMS, AF				ASHFORD, DA; ALAFI, CD; GAMBLE, VM; MACKAY, DJG; RADEMACHER, TW; WILLIAMS, PJ; DWEK, RA; BARCLAY, AN; DAVIS, SJ; SOMOZA, C; WARD, HA; WILLIAMS, AF			SITE-SPECIFIC GLYCOSYLATION OF RECOMBINANT RAT AND HUMAN SOLUBLE CD4 VARIANTS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ALPHA-GALACTOSYL EPITOPES; CARBOHYDRATE STRUCTURES; N-GLYCOSYLATION; SUGAR CHAINS; GLYCOPROTEINS; GENE; RECEPTOR; SEQUENCE; ANTIGEN	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human). The glycosylation of soluble recombinant forms of human and rat CD4 (sCD4) expressed in Chinese hamster ovary cells has been characterized. The most obvious differences between the rat and human sCD4 oligosaccharides were the greater abundance of oligomannose and hybrid oligosaccharides on rat sCD4 and the presence of oligosaccharides carrying a terminal alpha-galactose residue on human sCD4. This is the first report of the occurrence of alpha-galactose residues on a glycoprotein expressed in Chinese hamster ovary cells. Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site. The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4. However, there was more oligosaccharide processing at this site in a truncated form of rat sCD4 consisting of the two NH2-terminal domains. These results indicate that not only the local three-dimensional structure but also domain interactions can influence the processing at individual glycosylation sites.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	ASHFORD, DA (corresponding author), UNIV OXFORD, DEPT BIOCHEM, INST GLYCOBIOL, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Mackay, Deborah JG/B-2879-2015	Mackay, Deborah JG/0000-0003-3088-4401				ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; CARR SA, 1989, J BIOL CHEM, V264, P21286; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P625, DOI 10.1021/bi00217a006; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; FAYE L, 1986, PLANT PHYSIOL, V81, P206, DOI 10.1104/pp.81.1.206; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1989, LANCET, V2, P358; HARRIS RJ, 1990, EUR J BIOCHEM, V188, P291, DOI 10.1111/j.1432-1033.1990.tb15402.x; HSIEH P, 1983, J BIOL CHEM, V258, P2548; HSIEH P, 1983, J BIOL CHEM, V258, P2555; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAGAWA Y, 1988, J BIOL CHEM, V263, P17508; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; Lowe J B, 1991, Semin Cell Biol, V2, P289; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; POTVIN B, 1990, J BIOL CHEM, V265, P1615; REDDY VA, 1988, J BIOL CHEM, V263, P6978; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SCHOCKMEL GA, 1992, J EXP MED, V175, P301, DOI 10.1084/jem.175.1.301; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH PL, 1990, J BIOL CHEM, V265, P874; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; SPELLMAN MW, 1991, BIOCHEMISTRY-US, V30, P2395, DOI 10.1021/bi00223a015; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; VANDENEIJNDEN DH, 1985, 8TH P INT S GLYC, P285; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILHELM J, 1990, BIO-TECHNOL, V8, P321, DOI 10.1038/nbt0490-321; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; YUEN CT, 1990, EUR J BIOCHEM, V192, P523, DOI 10.1111/j.1432-1033.1990.tb19256.x; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	49	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3260	3267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429003				2022-12-25	WOS:A1993KM16100039
J	PANTANOWITZ, S; BENDAHAN, A; KANNER, BI				PANTANOWITZ, S; BENDAHAN, A; KANNER, BI			ONLY ONE OF THE CHARGED AMINO-ACIDS LOCATED IN THE TRANSMEMBRANE ALPHA-HELICES OF THE GAMMA-AMINOBUTYRIC-ACID TRANSPORTER (SUBTYPE-A) IS ESSENTIAL FOR ITS ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; RECONSTITUTED PREPARATIONS; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; EXPRESSION CLONING; GABA TRANSPORTER; RNA-POLYMERASE; SODIUM; PURIFICATION; SYSTEM	The gamma-aminobutyric acid (GABA) transporter (subtype A) is located in nerve terminals and catalyses coupled electrogenic uptake of the neurotransmitter with two or three sodium and one chloride ions. It contains 599 amino acids and 12 putative membrane spanning alpha-helices and is the first described member of a neurotransmitter transporter superfamily. The membrane domain contains 5 charged amino acids which are basically conserved. Using site-directed mutagenesis, we show that only one of them, arginine 69, is absolutely essential for activity. It is located in a highly conserved region encompassing parts of helices 1 and 2. The three other positively charged amino acids and the only negative charged one, glutamate 467, are not critical. These results suggest that the translocation pathway of the sodium ions through the membrane does not involve charged amino acid residues and underline the importance of the highly conserved stretch between amino acids 66 and 86.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,POB 1172,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT JP, 1974, LIFE SCI, V15, P1046; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1973, BRIT MED BULL, V29, P130, DOI 10.1093/oxfordjournals.bmb.a070982; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KANNER BI, 1990, P NATL ACAD SCI USA, V87, P2550, DOI 10.1073/pnas.87.7.2550; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	27	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3222	3225						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428999				2022-12-25	WOS:A1993KM16100033
J	KATSUSHIKA, S; KAWABE, J; HOMCY, CJ; ISHIKAWA, Y				KATSUSHIKA, S; KAWABE, J; HOMCY, CJ; ISHIKAWA, Y			INVIVO GENERATION OF AN ADENYLYLCYCLASE ISOFORM WITH A HALF-MOLECULE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SOLUBLE GUANYLATE-CYCLASE; RAT LUNG; CLONING; SEQUENCE; DNA; IDENTIFICATION; EXPRESSION; POLYMERASE; SUBUNIT; PROTEIN	A truncated form of adenylylcyclase (type V-alpha) has been cloned from a cardiac cDNA library. It constitutes a half-molecule of type V adenylylcyclase diverging at the end of the first cytoplasmic loop. Northern blotting study has revealed the presence of such a mRNA species (approximately 3.5 kilobases in size) in the heart. Genomic sequence analysis has revealed that type V-alpha is generated via usage of a polyadenylation signal located within an intronic sequence of type V adenylylcyclase gene. When type V-alpha is co-expressed with an artificially generated half-molecule constituting the latter half of type V adenylylcyclase, the catalytic activity in transfected cell membranes is significantly higher than that of controls. However, when either alone is overexpressed, no significant increase in catalytic activity results. These results indicate that a half-molecule of adenylylcyclase, i.e. a protein containing six-transmembrane spans followed by a single cytoplasmic domain, can be generated in vivo, but catalytic activity is lacking unless heterodimerization can occur. This finding identifies another potential mechanism for generating diversity within this enzyme family.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,DIV MED RES,PEARL RIVER,NY 10965	Columbia University; Columbia University					NHLBI NIH HHS [HL-38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNEY DF, 1991, J BIOL CHEM, V266, P18786; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KHAMBATY FM, 1990, BIOTECHNIQUES, V9, P714; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; TABOR S, 1987, P NATL ACAD SCI USA, V85, P9436; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2273	2276						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428899				2022-12-25	WOS:A1993KK81500002
J	LEE, IW; LIVRELLI, V; PARK, SJ; TOTIS, PA; SUMMERS, AO				LEE, IW; LIVRELLI, V; PARK, SJ; TOTIS, PA; SUMMERS, AO			INVIVO DNA-PROTEIN INTERACTIONS AT THE DIVERGENT MERCURY RESISTANCE (MER) PROMOTERS .2. REPRESSOR ACTIVATOR (MERR)-RNA POLYMERASE INTERACTION WITH MEROP MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; REGULATORY PROTEIN; TRANSCRIPTIONAL ACTIVATION; PLASMID NR1; -35 REGIONS; BINDING; RECOGNITION; INITIATION; SPACER; OPERON	Transcription of the Tn21 mercury resistance (mer) operon is regulated by MerR which represses and activates the mer structural genes (merTPCAD) in the absence and presence of Hg(II), respectively. The promoter for the structural genes (P(TPCAD)) is divergently overlapped with the promoter for the regulatory gene (P(R)), and a dyadic operator lies between the -10 and -35 hexamers of P(TPCAD). Using in vivo dimethyl sulfate and KMnO4 footprinting of mutant mer operator-promoter (merOP) DNA to observe MerR and RNA polymerase-mediated interactions with the merOP region, we have identified three distinct domains within the palindromic mer operator. Dyad domain I consists of the outermost bases on the left arm of the operator palindrome whose alteration causes a shift, but apparently not a major loss, in occupancy by MerR, and no decrease in RNA polymerase occupancy. Mutants in dyad domain I are semiconstitutive but support additional Hg(II)-induced open complex formation at P(TPCAD). Dyad domain II consists of the four highly conserved inner bases (...GTAC....GTAC...) of the seven-base interrupted dyad, alteration of which severely modifies both MerR and RNA polymerase contacts in the promoter region. Mutants in domain II generally allow constitutive open complex formation at P(R). One unusual mutant of this group retains most of the wild-type dyad's ability to repress both promoters but is unable to support activation at P(TPCAD) in response to Hg(II), indicating that MerR undergoes a conformational change and that the required base contacts for activation are different than those for repression. Dyad domain III is tentatively defined by a mutant in the outermost base of the right palindrome arm which is unaffected in either MerR or RNA polymerase occupancy, however, a second lesion within the P(TPCAD) -10 hexamer of this mutant limits effective open complex formation. Other mutations lying solely within the -10 RNA polymerase recognition hexamer of PTPCAD are similarly competent in both MerR and RNA polymerase binding, but inadequate for open complex formation, One such mutant also affects the overlapping -10 hexamer of P(R) and results in reduced occupancy by both MerR and RNA polymerase, likely as a result of inefficient transcriptional initiation of merR mRNA. Finally, mutations affecting the -35 hexamer of P(TPCAD) bind MerR but not RNA polymerase. Dimethyl sulfate footprinting of these -35 hexamer mutants gives the first in vivo evidence for RNA polymerase contacts near the center of the interrupted dyad and also demonstrates that the Hg(II)-induced distortion in the dyad central interruption can be effected in vivo by MerR alone.	UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	University System of Georgia; University of Georgia				Summers, Anne/0000-0003-4258-9696	NIGMS NIH HHS [GM28211] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028211] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; BARRINEAU P, 1984, Journal of Molecular and Applied Genetics, V2, P601; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELTZEL A, 1987, J BACTERIOL, V169, P3379, DOI 10.1128/jb.169.7.3379-3384.1987; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HUANG JZ, 1991, J BIOL CHEM, V266, P10830; LIVRELLI V, 1993, J BIOL CHEM, V268, P2623; LUND PA, 1986, J GEN MICROBIOL, V132, P465; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J.H., 1972, EXPT MOL GENETICS; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARK SJ, 1992, J BACTERIOL, V174, P2160, DOI 10.1128/JB.174.7.2160-2171.1992; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; REZNIKOFF WS, 1992, MAXIMIZING GENE EXPR, V355, P87; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SHIH MC, 1983, CELL, V34, P941, DOI 10.1016/0092-8674(83)90551-2; SZOKE PA, 1987, BIOCHEMISTRY-US, V26, P6188, DOI 10.1021/bi00393a035; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WULFF DL, 1987, DNA PROTEIN INTERACT	27	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2632	2639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428940				2022-12-25	WOS:A1993KK81500057
J	SHAW, GC; FULCO, AJ				SHAW, GC; FULCO, AJ			INHIBITION BY BARBITURATES OF THE BINDING OF BM3R1 REPRESSOR TO ITS OPERATOR SITE ON THE BARBITURATE-INDUCIBLE CYTOCHROME-P450(BM-3) GENE OF BACILLUS-MEGATERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID MONOOXYGENASE; STRUCTURAL IDENTIFICATION; VIBRIO-HARVEYI; SYSTEM; SEQUENCE; CYTOCHROME-P-450; HYDROXYLATION; INDUCTION; OMEGA-2; BIOLUMINESCENCE	In our previous publication (Shaw, G.-C., and Fulco, A. J. (1992) J. Biol. Chem. 267, 5515-5526), we reported that Bm3R1, a protein encoded in an open reading frame just upstream from the cytochrome P450BM-3 gene, is a repressor critically involved in the barbiturate-inducible expression of this gene in Bacillus megaterium. We now describe the purification of the Bm3R1 protein from an overproducing Escherichia coli strain harboring a bm3R1 gene-carrying plasmid and report the effect of barbiturate inducers on the interaction of Bm3R1 with a fragment of B. megaterium DNA containing the bicistronic operator and promoter sequences. Gel filtration analysis revealed that, under our experimental conditions, most of the Bm3R1 protein exists in highly aggregated forms. Gel mobility shift assays showed that Bm3R1 protein bound specifically to a segment of DNA containing the promoter-operator region of the bm3R1 gene while DNase I footprinting experiments established that Bm3R1 protected a region of DNA that covers and flanks the palindromic operator sequence. The interaction between Bm3R1 repressor and its operator, in vitro, was strongly inhibited by the addition of 2 mM pentobarbital or 2 mM methohexital (strong in vivo inducers of P450BM-3) but not by the same concentration of phenobarbital (a relatively weak inducer) or by mephobarbital (a non-inducer). A detailed comparison of pentobarbital and methohexital at concentrations lower than 2 mM indicated that methohexital was 5-10 times more effective as an inhibitor of Bm3R1 binding in vitro, as compared with its 7-fold greater inducer potency in vivo. The observation that the in vitro inhibition effects of barbiturates on the interaction of Bm3R1 repressor and its operator correlate strongly with their in vivo potency as inducers of cytochrome P450BM-3 suggests a mechanism for the induction process. It seems plausible that the barbiturate inducers might bear a conformational resemblance to and mimic the mode of action of an as vet unidentified endogenous inducer(s) in B. megaterium that functions by releasing the binding of Bm3R1 repressor from its operator site.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23913] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; CAO JG, 1989, J BIOL CHEM, V264, P21670; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; FEYEREISEN R, 1989, P NATL ACAD SCI USA, V86, P1465, DOI 10.1073/pnas.86.5.1465; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HE JS, 1991, J BIOL CHEM, V266, P7864; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HY, 1991, J BIOL CHEM, V266, P11909; LUBET RA, 1992, BIOCHEM PHARMACOL, V43, P1067, DOI 10.1016/0006-2952(92)90614-O; MATSON RS, 1977, BIOCHIM BIOPHYS ACTA, V487, P487, DOI 10.1016/0005-2760(77)90218-1; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1983, BIOCHEM BIOPH RES CO, V116, P851, DOI 10.1016/S0006-291X(83)80220-4; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; RUETTINGER RT, 1984, BIOCHIM BIOPHYS ACTA, V801, P372, DOI 10.1016/0304-4165(84)90141-7; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; Sambrook J, 1989, MOL CLONING LABORATO; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEN LP, 1989, J BIOL CHEM, V264, P10996; WEN LP, 1985, MOL CELL BIOCHEM, V67, P77; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	32	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2997	3004						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428974				2022-12-25	WOS:A1993KK81500108
J	WONDISFORD, FE; STEINFELDER, HJ; NATIONS, M; RADOVICK, S				WONDISFORD, FE; STEINFELDER, HJ; NATIONS, M; RADOVICK, S			AP-1 ANTAGONIZES THYROID-HORMONE RECEPTOR ACTION ON THE THYROTROPIN BETA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; NEGATIVE REGULATION; PROTO-ONCOGENE; C-JUN; PROMOTER; ELEMENT; EXPRESSION; INHIBITION; CELLS	Thyrotropin-releasing hormone (TRH) stimulates and thyroid hormone (T3) inhibits transcription of the thyrotropin beta-subunit gene (TSH-beta). The first exon contains DNA sequences necessary for both responses and binds both AP-1 and thyroid hormone receptor (T3R). T3 did not inhibit TSH-beta gene expression in a T3R-deficient cell line. Transfection of a T3R expression vector, however, resulted in a 70% inhibition of expression by T3, which was abolished by cotransfection of c-jun and c-fos expression vectors. Mutations surrounding the transcription initiation site and DNA binding studies demonstrate both a functional and structural interaction between c-jun and T3R. Thus, TRH, acting through AP-1, may alter the set point and magnitude of thyroid hormone negative feedback of the TSH-beta gene through an interaction between AP-1 and T3R. Other regulatory pathways acting through AP-1 may alter thyroid hormone action in man.	CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-43653] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; CARR FE, 1989, MOL ENDOCRINOL, V3, P717, DOI 10.1210/mend-3-4-717; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CARR FE, 1989, 73RD P ANN M END SOC, V265, P250; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; JONAT C, 1990, SCIENCE, V62, P1189; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHUPNIK MA, 1986, J BIOL CHEM, V261, P2675; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3139; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	21	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2749	2754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428949				2022-12-25	WOS:A1993KK81500073
J	ZHAO, ZZ; BOUCHARD, P; DILTZ, CD; SHEN, SH; FISCHER, EH				ZHAO, ZZ; BOUCHARD, P; DILTZ, CD; SHEN, SH; FISCHER, EH			PURIFICATION AND CHARACTERIZATION OF A PROTEIN TYROSINE PHOSPHATASE CONTAINING SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-PLACENTA; EXPRESSION; KINASES; CLEAVAGE; HOMOLOGY; BINDING; CLONING; FAMILY	A protein tyrosine phosphatase (PTP) containing two SH2 domains (PTP1C) was purified to near homogeneity from an adenovirus expression system by a two-step chromatographic procedure with a yield of 67%. The purified enzyme behaves as a monomer of 68 kDa on gel filtration and is totally specific for phosphotyrosyl residues. Its optimal pH is around neutrality for protein substrates such as reduced, carboxamidomethylated, maleylated (RCM)-lysozyme and myelin basic protein but below 5 for low molecular weight compounds such as para-nitrophenyl phosphate (p-NPP) and phosphotyrosine. Furthermore, with the protein substrates, it displays an activity less than 1% of that obtained with other known PTPs but comparable activities toward p-NPP and phosphotyrosine. Its responsiveness toward the usual PTP activators (e.g. spermine) or inhibitors (e.g. vanadate, molybdate, heparin, or Zn2+) varied considerably with the nature of the substrates involved. Limited digestion with trypsin caused the cleavage of a C-terminal segment of the enzyme, giving rise to a 63-kDa fragment; this cleavage resulted in an approximately 20- and 10-fold activation of the enzyme toward RCM-lysozyme and myelin basic protein, respectively.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MOLEC BIOL SECT, MONTREAL H4P 2R2, QUEBEC, CANADA	National Research Council Canada	ZHAO, ZZ (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				NIDDK NIH HHS [DK0709] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK000709] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAUM G, 1991, J BIOL CHEM, V266, P12211; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FISCHER EH, 1958, BIOCHEM PREPN, V6, P68; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HUNTER T, 1986, ENZYMES, V17, P191; KHANNA NC, 1987, CELL CALCIUM, V8, P217, DOI 10.1016/0143-4160(87)90020-0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1992, J BIOL CHEM, V267, P140; POT DA, 1991, J BIOL CHEM, V266, P19688; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIMPSON RJ, 1984, BIOCHEM INT, V8, P787; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHAO ZZ, 1992, ANAL BIOCHEM, V202, P361, DOI 10.1016/0003-2697(92)90119-R	40	116	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2816	2820						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428956				2022-12-25	WOS:A1993KK81500082
J	ASPINALL, GO; MCDONALD, AG; PANG, H; KURJANCZYK, LA; PENNER, JL				ASPINALL, GO; MCDONALD, AG; PANG, H; KURJANCZYK, LA; PENNER, JL			LIPOPOLYSACCHARIDE OF CAMPYLOBACTER-COLI SEROTYPE-O-30 - FRACTIONATION AND STRUCTURE OF LIBERATED CORE OLIGOSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; MASS-SPECTROMETRY; JEJUNI; CHAIN	Lipopolysaccharide from phenol-water extraction of cells of Campylobacter coli serotype 0:30 was separated as a water-insoluble gel of low M(r) from a water-soluble antigenic polysaccharide of high M(r). Acetic acid hydrolysis of the ketosidic linkages to lipid A in the lipopolysaccharide furnished a core oligosaccharide. Structural investigations were performed using H-1 and C-13 NMR, fast atom bombardment-mass spectrometry of permethylated derivatives, and methylation linkage analysis on the core oligosaccharide and the products of two successive Smith degradations. It is concluded that the highly branched 3-deoxy-D-manno-octulosonic acid-terminated oligosaccharide chains carried at the nonreducing end disaccharide units of beta-D-Qui3NAc-(1-->2)-beta-D-Qui3NAc (where Qui3NAc represents 3-acylamino-3,6-dideoxy-D-glucose), in which N-acyl residues were either both (R)3-hydroxybutanoyl or both 3-hydroxy-2,3-dimethyl-5-oxoprolyl. The demonstration of these unusual features provides further evidence for a wide variety of structures within the core oligosaccharide region of lipopolysaccharides from Campylobacter sp.	UNIV TORONTO,DEPT MOLEC BIOL & MED GENET,CARBOHYDRATE RES CTR,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto	ASPINALL, GO (corresponding author), YORK UNIV,DEPT CHEM,N YORK M3J 1P3,ONTARIO,CANADA.							ASPINALL GO, 1992, J BACTERIOL, V174, P1324, DOI 10.1128/jb.174.4.1324-1332.1992; ASPINALL GO, 1992, CARBOHYD RES, V231, P13, DOI 10.1016/0008-6215(92)84003-B; BEER W, 1986, J BASIC MICROB, V4, P201; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELL A, 1990, CARBOHYD RES, V200, P59, DOI 10.1016/0008-6215(90)84182-T; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; KATZENELLENBOGEN E, 1991, EUR J BIOCHEM, V200, P401, DOI 10.1111/j.1432-1033.1991.tb16198.x; KHOMENKO VA, 1986, BIOORG KHIM+, V12, P1641; MANDATORI R, 1989, INFECT IMMUN, V57, P3506, DOI 10.1128/IAI.57.11.3506-3511.1989; MORAN AP, 1991, J BACTERIOL, V173, P618, DOI 10.1128/jb.173.2.618-626.1991; NABEREZHNIKH GA, 1987, BIOORG KHIM+, V13, P1428; NAESS V, 1984, J GEN MICROBIOL, V130, P2783; PENNER J L, 1988, Clinical Microbiology Reviews, V1, P157; PENNER JL, 1980, J CLIN MICROBIOL, V12, P732, DOI 10.1128/JCM.12.6.732-737.1980; PRESTON MA, 1987, INFECT IMMUN, V55, P1806, DOI 10.1128/IAI.55.8.1806-1812.1987; PRITCHARD DG, 1988, CARBOHYD RES, V173, P255, DOI 10.1016/S0008-6215(00)90821-8; SAWARDEKAR JS, 1967, ANAL CHEM, V37, P1602; SELTMANN G, 1985, J BASIC MICROB, V25, P551, DOI 10.1002/jobm.3620250823; VINOGRADOV EV, 1991, EUR J BIOCHEM, V197, P93, DOI 10.1111/j.1432-1033.1991.tb15886.x; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83	22	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6263	6268						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454598				2022-12-25	WOS:A1993KT36800031
J	BARTHELEMY, I; MARTINEAU, D; ONG, M; MATSUNAMI, R; LING, N; BENATTI, L; CAVALLARO, U; SORIA, M; LAPPI, DA				BARTHELEMY, I; MARTINEAU, D; ONG, M; MATSUNAMI, R; LING, N; BENATTI, L; CAVALLARO, U; SORIA, M; LAPPI, DA			THE EXPRESSION OF SAPORIN, A RIBOSOME-INACTIVATING PROTEIN FROM THE PLANT SAPONARIA-OFFICINALIS, IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRABILIS ANTIVIRAL PROTEIN; N-GLYCOSIDASE ACTIVITY; RICIN-A-CHAIN; DNA-SEQUENCE; EUKARYOTIC RIBOSOMES; NUCLEOTIDE-SEQUENCE; TERMINAL SEQUENCE; RNA; GENE; CDNA	We have isolated and sequenced genomic clones from the DNA of Saponaria officinalis using a cDNA probe that encodes proteins with high homology to saporin-6, one of the most potent of the ribosome-inactivating proteins that is currently used for the construction of immunotoxins and mitotoxins. Sequence differences in the clones suggest a multigene family of proteins. These data agree with observations of several different proteins with ribosome-inactivating protein activity and similar structure. Two of the genomic clones encode proteins that have identical sequences to two of the four isoforms of saporin-6. We have inserted the DNA from one genomic clone into an Escherichia coli expression system that encodes a signal sequence for export to the bacterial periplasmic space. Exportation is observed and the isolated gene product has ribosome-inactivation activity similar to the native protein. Sequence analysis shows differential processing of the remaining plant signal sequence. The majority of the expressed protein remains intracellular and this material also shows high specific activity and differential processing. Saporin as an immunotoxin in clinical trial and as a mitotoxin in experimental models has been extremely efficacious. These data indicate the ability to produce fusion proteins with saporin and cell-binding ligands for production of new reagents for further clinical and experimental use.	WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC ENDOCRINOL,LA JOLLA,CA 92037; FARMITALIA CARLO ERBA SPA,DIV BIOTECHNOL,MILAN,ITALY; WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC & CELLULAR GROWTH BIOL,LA JOLLA,CA 92037; IST SCI SAN RAFFAELE,DIPARTIMENTO BIOTECNOL,I-20132 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Cavallaro, Ugo/J-9745-2012	Cavallaro, Ugo/0000-0002-0884-6460; Higgins, Denise/0000-0002-5274-7494; Lappi, Douglas/0000-0003-4239-7387	NIDDK NIH HHS [DK-18811] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRA D, 1991, BIOTECHNOL APPL BIOC, V13, P48; Battey, 1986, BASIC METHODS MOL BI; BEITZ JG, 1992, CANCER RES, V52, P227; BENATTI L, 1989, EUR J BIOCHEM, V183, P465, DOI 10.1111/j.1432-1033.1989.tb14951.x; BENATTI L, 1991, FEBS LETT, V291, P285, DOI 10.1016/0014-5793(91)81303-P; BIANCHI MW, 1988, PLANT MOL BIOL, V11, P203, DOI 10.1007/BF00015672; BJORN MJ, 1984, BIOCHIM BIOPHYS ACTA, V790, P154, DOI 10.1016/0167-4838(84)90219-X; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHOW TP, 1990, J BIOL CHEM, V265, P8670; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ESCH FS, 1984, ANAL BIOCHEM, V136, P39, DOI 10.1016/0003-2697(84)90305-1; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FLAVELL DJ, 1991, BRIT J CANCER, V64, P274, DOI 10.1038/bjc.1991.291; FORDHAMSKELTON AP, 1990, MOL GEN GENET, V221, P134, DOI 10.1007/BF00280379; FRANKEL A, 1990, MOL CELL BIOL, V10, P6257, DOI 10.1128/MCB.10.12.6257; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HABUKA N, 1990, J BIOL CHEM, V265, P10988; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HOUSTON LL, 1983, J BIOL CHEM, V258, P9601; KATAOKA J, 1991, J BIOL CHEM, V266, P8426; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LAPPI DA, 1992, J HAND SURG-AM, V17A, P324, DOI 10.1016/0363-5023(92)90415-L; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; MARAS B, 1990, BIOCH INT, V21, P631; MONTECUCCHI PC, 1989, INT J PEPT PROT RES, V33, P263; NAKAMURA K, 1979, CELL, V18, P1109, DOI 10.1016/0092-8674(79)90224-1; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PIATAK M, 1988, J BIOL CHEM, V263, P4837; READY MP, 1988, PROTEINS, V3, P53, DOI 10.1002/prot.340030105; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; ROBERTUS JD, 1987, J BIOL CHEM, V262, P19; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SHAW PC, 1991, GENE, V97, P267, DOI 10.1016/0378-1119(91)90061-F; SIENA S, 1988, TRANSPLANTATION, V46, P747, DOI 10.1097/00007890-198811000-00023; SIENA S, 1988, BLOOD, V72, P756; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; TAZZARI PL, 1992, BRIT J HAEMATOL, V81, P203, DOI 10.1111/j.1365-2141.1992.tb08208.x; THORPE PE, 1985, J NATL CANCER I, V75, P151; WILEY RG, 1991, BRAIN RES, V562, P149, DOI 10.1016/0006-8993(91)91199-B	46	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6541	6548						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454624				2022-12-25	WOS:A1993KT36800067
J	MAUVIEL, A; CHEN, YQ; KAHARI, VM; LEDO, I; WU, M; RUDNICKA, L; UITTO, J				MAUVIEL, A; CHEN, YQ; KAHARI, VM; LEDO, I; WU, M; RUDNICKA, L; UITTO, J			HUMAN RECOMBINANT INTERLEUKIN-1-BETA UP-REGULATES ELASTIN GENE-EXPRESSION IN DERMAL FIBROBLASTS - EVIDENCE FOR TRANSCRIPTIONAL REGULATION INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; SMOOTH-MUSCLE CELLS; GROWTH FACTOR-I; 5'-FLANKING REGION; FUNCTIONAL PROMOTER; COLLAGEN PRODUCTION; TROPOELASTIN; DELINEATION; CULTURES; CLONING	The effects of human recombinant interleukin (IL)-1beta on elastin gene expression were studied in human skin fibroblast cultures by Northern hybridization and transient transfection experiments. Incubation of the cells with IL-1beta elevated the elastin mRNA stead-state levels by approximately 3- to 4-fold. A similar increase was noted at the protein level, when estimated by indirect immunofluorescence of cultured cells. This effect was independent of the on-going protein synthesis, as tested by incubation with cycloheximide. Transient transfections of the dermal fibroblasts with a human elastin promoter/chloramphenicol acetyltransferase (CAT) reporter gene construct suggested transcriptional regulation, since the CAT activity in cells incubated with IL-1beta was similarly increased approximately 3-fold. Enhancement of the human elastin promoter activity by IL-1beta was also noted in fibroblast cultures established from the skin and lungs of transgenic mice which have integrated the human promoter/CAT construct into their genome and express it in a tissue-specific manner. Furthermore, subcutaneous injection of IL-1beta to the mice resulted in a approximately 4-fold elevation of the CAT activity in the skin after a 30-h incubation, as compared to the CAT activity in the skin of control animals. Collectively, these data indicate that IL-1beta up-regulates elastin gene expression in fibroblast cultures as well as in the skin in vivo, and the activation occurs at the transcriptional level.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST,RM 450 BLSB,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University			Kähäri, Veli-Matti/E-5144-2011; Rudnicka, Lidia/L-7529-2019; MAUVIEL, Alain/F-6251-2013; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Rudnicka, Lidia/0000-0002-8308-1023; Kahari, Veli-Matti/0000-0003-2421-9368; Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [T32-AR07561, R01-AR28450] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, R01AR028450] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARRMENDARIZBORU.J, 1992, J BIOL CHEM, V267, P14316; BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FAZIO MJ, 1991, AM J HUM GENET, V48, P696; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; GIRO MG, 1985, J CLIN INVEST, V75, P672, DOI 10.1172/JCI111746; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; HSUWONG S, 1992, J INVEST DERMATOL, V98, P576; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; KAHARI VM, 1987, BIOCHIM BIOPHYS ACTA, V929, P142, DOI 10.1016/0167-4889(87)90169-8; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1988, BIOCHEM J, V252, P247, DOI 10.1042/bj2520247; MECHAM RP, 1984, J BIOL CHEM, V259, P2414; OLSEN DR, 1988, J BIOL CHEM, V263, P6465; OTANI Y, 1990, EUR J BIOCHEM, V192, P75, DOI 10.1111/j.1432-1033.1990.tb19197.x; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; PULKKINEN L, 1990, J BIOL CHEM, V265; ROSENBLOOM J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P145; Sambrook J, 1989, MOL CLONING LABORATO; UITTO J, 1991, PHYSL BIOCH MOL BIOL, P530	34	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6520	6524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454621				2022-12-25	WOS:A1993KT36800064
J	MULLER, B; ZERWES, HG; TANGEMANN, K; PETER, J; ENGEL, J				MULLER, B; ZERWES, HG; TANGEMANN, K; PETER, J; ENGEL, J			2-STEP BINDING MECHANISM OF FIBRINOGEN TO ALPHA-IIB-BETA-3 INTEGRIN RECONSTITUTED INTO PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; MEMBRANE GLYCOPROTEIN-IIB; FIBRONECTIN RECEPTOR; GPIIB-IIIA; ELECTRON-MICROSCOPY; PLATELET RECEPTOR; RECOGNITION SITE; IDENTIFICATION; AGGREGATION; LAMININ	The platelet integrin alphaIIbbeta3 binds to fibrinogen and thus mediates platelet aggregation after stimulation. This integrin was isolated from human platelets and reconstituted into lipid vesicles. As judged by electron microscopy the integrin incorporated adequately only into 1,2-dimyristoylglycero-3-phosphocholine/1,2-dimyristoylphosphatidylglycerol vesicles after removal of the detergent by adsorption to Bio-Beads. These vesicles were then used to generate planar lipid bilayers. The binding of fluorochrome labeled fibrinogen or the peptide ligand Gly-Arg-Gly-Asp-Ser-Pro-Cys (GRGDSPC) was monitored by total internal reflection fluorescence microscopy and a solid phase binding assay. Analysis of the kinetics revealed fast reversible formation of a fibrinogen/integrin precomplex (K(D) = 50 nM) followed by formation of a stable irreversible complex. This transition was monitored by measuring the fraction of precomplex which could be dissociated by addition of excess Gly-Arg-Gly-Asp-Ser (GRGDS). For the peptide, the K(D) was 1200 nM, and the rates of association and dissociation were faster than the time resolution of the method. Similar K(D) values were found by inhibition of fibrinogen binding to alphaIIbbeta3 in the immobilized receptor assay. Since the binding of fibrinogen was irreversible, K(D) values were dependent on the time period between fibrinogen incubation and peptide addition. These and results by other authors point to the biological importance of the biphasic binding process of fibrinogen to its receptor on platelets.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; SANDOZ PHARMA AG,PRECLIN RES,CH-4056 BASEL,SWITZERLAND	University of Basel; Novartis; Sandoz								Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; BULDT G, 1979, J MOL BIOL, V134, P673, DOI 10.1016/0022-2836(79)90479-0; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1991, BLOOD, V77, P75; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FRELINGER AL, 1991, J BIOL CHEM, V26, P17106; Goldberg D. E., 1989, GENETIC ALGORITHMS S; Harrick N.J., 1967, INTERNAL REFLECTION; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KALB E, 1990, BIOCHEMISTRY-US, V29, P1607, DOI 10.1021/bi00458a036; KALB E, 1991, J BIOL CHEM, V266, P19047; KELLY T, 1987, J BIOL CHEM, V262, P17189; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOUNS WC, 1992, BLOOD, V80, P2539; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; POGLITSCH CL, 1990, BIOCHEMISTRY-US, V29, P248, DOI 10.1021/bi00453a033; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	35	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6800	6808						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454652				2022-12-25	WOS:A1993KT36800103
J	ESSER, V; BRITTON, CH; WEIS, BC; FOSTER, DW; MCGARRY, JD				ESSER, V; BRITTON, CH; WEIS, BC; FOSTER, DW; MCGARRY, JD			CLONING, SEQUENCING, AND EXPRESSION OF A CDNA-ENCODING RAT-LIVER CARNITINE PALMITOYLTRANSFERASE-I - DIRECT EVIDENCE THAT A SINGLE POLYPEPTIDE IS INVOLVED IN INHIBITOR INTERACTION AND CATALYTIC FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SYSTEM; DNA; PROTEIN; ACID	We report the isolation and characterization of a full-length cDNA encoding rat liver carnitine palmitoyltransferase I (CPT I). Oligonucleotides corresponding to two tryptic peptides derived from the malonyl-CoA/etomoxir-CoA-binding protein of rat liver mitochondria (Esser, V., Kuwajima, M., Britton, C. H., Krishnan, K., Foster, D. W., and McGarry, J. D. (1993) J. Biol. Chem. 268, 5810-5816) were used to screen a rat liver cDNA library constructed in the plasmid cloning vector, pcDV. The clone obtained consisted of a 102-nucleotide 5'-untranslated region, a single open reading frame of 2,319 bases predicting a protein of 773 amino acids (M(r) = 88,150), and a 3'-untranslated segment of 1,957 nucleotides followed by the poly(A)+ tail. A 0.9-kilobase fragment of the cDNA recognized a single species of mRNA (approximately 4.7 kilobases in size) in rat liver. The identity of the cDNA was confirmed by the findings that (i) the open reading frame encoded all four peptides found in the original protein; (ii) transfection of COS cells with the cDNA subcloned into the expression vector, pCMV6, resulted in a selective and 10-20-fold induction of a malonyl-CoA- and etomoxir-CoA-sensitive CPT activity; and (iii) the overexpressed product was readily detected on Western blots by an antibody raised against the starting material. It seems likely that the de novo synthesized enzyme is targeted to the mitochondrial outer membrane via a leader peptide and that the mature protein achieves membrane anchoring through a stretch of 20 amino acids present near its amino terminus. The predicted amino acid sequence of the protein shows regions of strong identity with those of three other rat acyltransferases, namely, liver CPT II, liver carnitine octanoyltransferase, and brain choline acetyltransferase. The findings provide the first insight into the structure of a CPT I isoform. They also establish unequivocally that CPT I and CPT II are distinct proteins and that inhibitors of CPT I interact within its catalytic domain, not with an associated regulatory component.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRADY PS, 1992, BIOCHEM J, V286, P779, DOI 10.1042/bj2860779; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; BROWN NF, 1991, J BIOL CHEM, V266, P15446; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESSER V, 1993, J BIOL CHEM, V268, P5810; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; MCGARRY JD, 1992, NEW DEV FATTY ACID O, P47; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714	21	209	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5817	5822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449948				2022-12-25	WOS:A1993KR82200069
J	KELLER, PM; WAXMAN, L; ARNOLD, BA; SCHULTZ, LD; CONDRA, C; CONNOLLY, TM				KELLER, PM; WAXMAN, L; ARNOLD, BA; SCHULTZ, LD; CONDRA, C; CONNOLLY, TM			CLONING OF THE CDNA AND EXPRESSION OF MOUBATIN, AN INHIBITOR OF PLATELET-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN; ADHESION; IDENTIFICATION; PROTEINS; RECEPTOR; PEPTIDE; COMPLEX; BLOOD; YEAST	Moubatin, a new type of specific inhibitor of collagen-induced platelet aggregation, has been isolated from the soft tick Ornithodoros moubata (Waxman, L., and Connolly, T. M. (1993) J. Biol. Chem. 268, 5445-5449). A polymerase chain reaction-generated hybridization probe, produced using primers based on moubatin protein sequence, identified phage containing the entire cDNA sequence of moubatin. Analysis of the predicted amino acid sequence yielded a mature protein of 156 amino acids with a putative prepeptide of 15 amino acids. Comparison of the sequence of moubatin to that of other proteins in the Swiss PROT data base revealed no significant homology. The cDNA sequence was cloned into the yeast expression vector pKH4alpha2, producing a biologically active protein which inhibited collagen-stimulated aggregation of washed human platelets with an IC50 of about 100 nM, which is similar to the potency of native tick moubatin. A concentration of recombinant moubatin that fully inhibited collagen-stimulated aggregation did not inhibit aggregation induced by a variety of other platelet agonists, again demonstrating comparable properties of the recombinant and native proteins. Moubatin did not inhibit platelet adhesion to collagen even at a concentration up to 16 times its IC50 for the inhibition of aggregation. This specificity for inhibiting collagen-stimulated aggregation and not adhesion to collagen indicates that moubatin is unique among the natural product inhibitors of collagen stimulation of platelets. Further examination of the mechanism of moubatin-mediated inhibition of collagen-stimulated aggregation revealed that 1-6 muM moubatin diminished the second phase of aggregation induced by ADP, inhibited aggregation in response to submaximal concentrations of the thromboxane A2 mimetic U46619, and competed for the binding of a thromboxane A2 receptor antagonist to platelet membranes. Therefore, at higher concentrations, moubatin may affect more than one aspect of platelet signal transduction including the thromboxane A2 receptor. The availability of recombinant moubatin will allow further investigation of its unique activities in vitro and in vivo.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC BIOL,W POINT,PA 19486	Merck & Company; Merck & Company								BARNES MJ, 1988, COLLAGEN, V1, P275; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; CARTY CE, 1990, BIOTECHNOL LETT, V12, P879, DOI 10.1007/BF01022583; COLLER BS, 1989, BLOOD, V74, P182; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; DANIEL JL, 1987, MODERN METHODS PHARM, V4, P185; DAUGHERTY BL, 1990, DNA CELL BIOL, V9, P453, DOI 10.1089/dna.1990.9.453; DUNWIDDIE CT, 1993, IN PRESS METHODS ENZ; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; Innis MA, 1990, PCR PROTOCOLS GUIDE; JACOBSON MA, 1989, GENE, V85, P511, DOI 10.1016/0378-1119(89)90445-9; JOHNSON GJ, 1988, CIRC RES, V62, P494, DOI 10.1161/01.RES.62.3.494; KELLER PM, 1992, J BIOL CHEM, V267, P6899; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; Maniatis T., 1982, MOL CLONING; MELLOTT MJ, 1990, THROMB HAEMOSTASIS, V64, P526; MIZUNO K, 1984, NATURE, V309, P558, DOI 10.1038/309558a0; MUNRO R, 1991, BLOOD COAGUL FIBRIN, V2, P179, DOI 10.1097/00001721-199102000-00027; NEEPER MP, 1990, J BIOL CHEM, V265, P17746; PRZYSIECKI CT, 1992, PROTEIN EXPRES PURIF, V3, P185, DOI 10.1016/1046-5928(92)90014-N; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAUSSY DL, 1986, J BIOL CHEM, V261, P3025; SMITH JB, 1991, FEBS LETT, V283, P307, DOI 10.1016/0014-5793(91)80615-A; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TUSZYNSKI GP, 1991, J CLIN INVEST, V87, P1387, DOI 10.1172/JCI115144; WAXMAN L, 1993, J BIOL CHEM, V268, P5445	30	78	84	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5450	5456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449907				2022-12-25	WOS:A1993KR82200019
J	OSIPIUK, J; GEORGOPOULOS, C; ZYLICZ, M				OSIPIUK, J; GEORGOPOULOS, C; ZYLICZ, M			INITIATION OF LAMBDA-DNA REPLICATION - THE ESCHERICHIA-COLI SMALL HEAT-SHOCK PROTEINS, DNAJ AND GRPE, INCREASE DNAKS AFFINITY FOR THE LAMBDA-P PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; O-PROTEIN; ORIGIN; INVITRO; PURIFICATION; SYSTEM; ATPASE	It is known that the initiation of bacteriophage lambda replication requires the orderly assembly of the lambdaO.lambdaP.DnaB helicase protein preprimosomal complex at the orilambda DNA site. The DnaK, DnaJ, and GrpE heat shock proteins act together to destabilize the lambdaP.DnaB complex, thus freeing DnaB and allowing it to unwind lambda DNA near the orilambda site. The first step of this disassembly reaction is the binding of DnaK to the lambdaP protein. In this report, we examined the influence of the DnaJ and GrpE proteins on the stability of the lambdaP.DnaK complex. We present evidence for the existence of the following protein-protein complexes: lambdaP.DnaK, lambdaP.DnaJ, DnaJ.DnaK, DnaK.GrpE, and lambdaP.DnaK.GrpE. Our results suggest that the presence of GrpE alone destabilizes the lambdaP.DnaK complex, whereas the presence of DnaJ alone stabilizes the lambdaP.DnaK complex. Using immunoprecipitation, we show that in the presence of GrpE, DnaK exhibits a higher affinity for the lambdaP.DnaJ complex than it does alone. Using cross-linking with glutaraldehyde, we show that oligomeric forms of DnaK exhibit a higher affinity for lambdaP than monomeric DnaK. However, in the presence of GrpE, monomeric DnaK can efficiently bind lambdaP protein. These findings help explain our previous results, namely that in the GrpE-dependent lambda DNA replication system, the DnaK protein requirement can be reduced up to 10-fold.	UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,KLADKI 24,PL-80822 GDANSK,POLAND; UNIV UTAH,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; UNIV GENEVA,MED CTR,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Fahrenheit Universities; University of Gdansk; Utah System of Higher Education; University of Utah; University of Geneva					NIAID NIH HHS [AI21029] Funding Source: Medline; NIGMS NIH HHS [GM23917] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANDERL A, 1982, NUCLEIC ACIDS RES, V10, P1733, DOI 10.1093/nar/10.5.1733; ANG D, 1991, J BIOL CHEM, V266, P24233; BISWAS SB, 1987, J BIOL CHEM, V262, P7831; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; TSURIMOTO T, 1981, NUCLEIC ACIDS RES, V9, P1789, DOI 10.1093/nar/9.8.1789; TSURIMOTO T, 1982, P NATL ACAD SCI-BIOL, V79, P7639, DOI 10.1073/pnas.79.24.7639; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1984, MOL GEN GENET, V196, P401, DOI 10.1007/BF00436186; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	29	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4821	4827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444859				2022-12-25	WOS:A1993KP88400042
J	SOUNDAR, S; COLMAN, RF				SOUNDAR, S; COLMAN, RF			IDENTIFICATION OF METAL-ISOCRITRATE BINDING-SITE OF PIG-HEART NADP-SPECIFIC ISOCRITRATE DEHYDROGENASE BY AFFINITY CLEAVAGE OF THE ENZYME BY FE2+-ISOCRITRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ISOCITRATE DEHYDROGENASE; NUCLEAR MAGNETIC-RESONANCE; AMINO-ACID RESIDUES; OXIDATIVE MODIFICATION; GLUTAMINE-SYNTHETASE; MANGANOUS ION; INACTIVATION; DERIVATIVES; COMPLEXES; PROTEINS	The divalent metal-isocitrate site of pig heart NADP-specific isocitrate dehydrogenase can be located by affinity cleavage of the enzyme by Fe2+-isocitrate in the presence of O2, in analogy to the ''chemical nuclease'' action of DNA-binding drugs linked to Fe-EDTA. The enzyme is irreversibly inactivated and cleaved by Fe2+-isocitrate more rapidly than by Fe2+. Mn2+ prevents inactivation and cleavage by Fe2+-isocitrate or by Fe2+. Furthermore, other tri- or dicarboxylates (such as citrate, tricarballylate, or malate), which are not effective substrates of the enzyme, fail to promote inactivation and cleavage of the enzyme by Fe2+. These results indicate that the oxidative inactivation and cleavage reactions are specific. Two pairs of major peptides are generated during Fe2+-isocitrate inactivation: 30 + 17 kDa and 35 + 11 kDa, as compared with 46 kDa for the intact enzyme. NH2-terminal sequencing revealed that these peptides arise by a mutually exclusive cleavage at either Asp253-Met254 or His309-Gly310, suggesting Asp253 and His309 as coordination sites for Fe2+-isocitrate and, by implication, for Mn2+-isocitrate. Fe2+ alone produces peptides (32 + 15 kDa) by an alternate specific cleavage between Tyr272 and Asp273, consistent with free metal ion occupying a different site from metal-isocitrate in NADP-dependent isocitrate dehydrogenase. Affinity cleavage may be a generally useful method for locating metal and metal-substrate sites in enzymes.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware					NIDDK NIH HHS [1 R01 DK17522] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMICI A, 1989, J BIOL CHEM, V264, P3341; BACON CR, 1981, J BIOL CHEM, V256, P6593; BAILEY DB, 1980, BIOCHEMISTRY-US, V19, P591, DOI 10.1021/bi00544a031; BAILEY JM, 1987, BIOCHEMISTRY-US, V26, P4893, DOI 10.1021/bi00389a042; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; COLMAN RF, 1972, J BIOL CHEM, V247, P215; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; CREETH JM, 1983, BIOCHEM J, V211, P323, DOI 10.1042/bj2110323; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; EHRLICH RS, 1987, BIOCHEMISTRY-US, V26, P3461, DOI 10.1021/bi00386a032; EHRLICH RS, 1989, BIOCHEMISTRY-US, V28, P2058, DOI 10.1021/bi00431a014; EHRLICH RS, 1976, BIOCHEMISTRY-US, V15, P4034, DOI 10.1021/bi00663a018; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; KELLY JH, 1981, J BIOL CHEM, V256, P330; KIM K, 1985, J BIOL CHEM, V260, P5394; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LEVY RS, 1977, BIOCHEMISTRY-US, V16, P3293, DOI 10.1021/bi00634a003; MAS MT, 1984, BIOCHEMISTRY-US, V23, P1675, DOI 10.1021/bi00303a015; NORTHROP DB, 1970, FED PROC, V49, P408; RHYU GI, 1985, BIOCHEMISTRY-US, V24, P2536, DOI 10.1021/bi00331a021; SCHEPARTZ A, 1990, J AM CHEM SOC, V112, P3247, DOI 10.1021/ja00164a075; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; SOUNDAR S, 1992, 6TH S PROT SOC SAN D, P144; VILLAFRANCA JJ, 1972, J BIOL CHEM, V247, P209; VILLAFRANCA JJ, 1984, BIOCHEMISTRY-US, V13, P1152	30	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5264	5271						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444900				2022-12-25	WOS:A1993KP88400100
J	TU, CK; COUTON, JM; VANHEEKE, G; RICHARDS, NGJ; SILVERMAN, DN				TU, CK; COUTON, JM; VANHEEKE, G; RICHARDS, NGJ; SILVERMAN, DN			KINETIC-ANALYSIS OF A MUTANT (HIS(107)-]TYR) RESPONSIBLE FOR HUMAN CARBONIC ANHYDRASE-II DEFICIENCY SYNDROME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORCE-FIELD; CATALYTIC MECHANISM; NUCLEIC-ACIDS; SIMULATIONS; INHIBITION; HYDRATION; PROTEINS	The replacement His107 --> Tyr is a cause of carbonic anhydrase II deficiency syndrome in humans (Venta, P. J., Welty, R. J., Johnson, T. M., Sly, W. S., and Tashian, R. E. (1991) Am. J. Hum. Genet. 49, 1082-1090). We have prepared this mutant of human carbonic anhydrase II by site-directed mutagenesis and expressed it in Escherichia coli. The mutant was too unstable to purify; however, we were able to stabilize and store it at 4-degrees-C in cell lysates containing 1-4 mg/ml bovine serum albumin. The concentration of this mutant in the lysate was determined by titration with the tight-binding inhibitor ethoxzolamide. The stability in this preparation was sufficient to determine that this mutant of carbonic anhydrase II has k(cat/K(m) and apparent pK(a) for the hydration of CO2 equivalent to that of wild-type HCA II. The maximum velocity of CO2 hydration, which is dependent on the rate of proton transfer between enzyme and solution, was 3-fold smaller than for HCA II suggesting that the proton transfer pathway in the mutant is slightly less efficient than in wild type. Preliminary conformational energy calculations show that the replacement of His107 with the larger residue Tyr results in considerable distortion of the cavity surrounding site 107 and in the loss of at least two hydrogen bonds.	UNIV FLORIDA,CTR HLTH,DEPT PHARMACOL & THERAPEUT,BOX J-267,GAINESVILLE,FL 32610; UNIV FLORIDA,PROT EXPRESS LAB,INTERDISCIPLINARY CTR BIOTECHNOL RES,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32610; BIONEBRASKA INC,LINCOLN,NE 68504	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NIGMS NIH HHS [GM25154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; HOOPS SC, 1991, J AM CHEM SOC, V113, P8262, DOI 10.1021/ja00022a010; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; LINDSKOG S, 1991, CARBONIC ANHYDRASE, P1; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; MOHAMADI F, 1990, J COMPUT CHEM, V11, P460; Pocker Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P149; ROTH DE, 1992, P NATL ACAD SCI USA, V89, P1804, DOI 10.1073/pnas.89.5.1804; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; ROWLETT RS, 1984, J PROTEIN CHEM, V3, P369, DOI 10.1007/BF01025173; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SIMONSSON I, 1982, EUR J BIOCHEM, V123, P29, DOI 10.1111/j.1432-1033.1982.tb06494.x; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; VENTA PJ, 1991, AM J HUM GENET, V49, P1082; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	28	13	13	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4775	4779						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444854				2022-12-25	WOS:A1993KP88400036
J	YASHIRO, A; ONEIL, J; HOFF, HF				YASHIRO, A; ONEIL, J; HOFF, HF			INSOLUBLE COMPLEX-FORMATION OF LIPOPROTEIN-(A) WITH LOW-DENSITY-LIPOPROTEIN IN THE PRESENCE OF CALCIUM-IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; APO-B; ATHEROSCLEROTIC LESIONS; HEART-DISEASE; HUMAN AORTA; BINDING; LP(A); PLASMINOGEN; PLASMA; ACID	We investigated whether apolipoprotein B-containing lipoproteins could bind to the insoluble complexes of lipoprotein (a) (Lp(a)) induced by Ca2+. Lp(a), but not low density lipoprotein (LDL), very low density lipoprotein (VLDL), or high density lipoprotein3 (HDL3) formed insoluble complexes at physiologic Ca2+ concentrations. Desialylation of Lp(a) dramatically decreased the ability of Lp(a) to aggregate, suggesting that sialic acids on Lp(a) were responsible for forming Ca2+ cross-bridges. Since a reduction of only 30% of the sialic acids on Lp(a) inhibited Ca2+-induced complex formation, it appears that only a small percentage of sialic acids on Lp(a) is involved in Ca2+-induced cross-bridging of Lp(a) particles. To determine whether other lipoproteins would complex to Lp(a) in the insoluble complexes, we mixed Lp(a) with LDL, VLDL, or HDL3 in the presence of Ca2+. Although both LDL and VLDL bound to the Lp(a) in the insoluble complexes, HDL3 not only did not bind, but it also prevented Lp(a) from forming insoluble complexes. LDL bound to Lp(a) in the insoluble complexes in a concentration-dependent manner, eventually reaching saturation at a molar ratio of 5:4 (LDL to Lp(a)). The interaction between LDL and Lp(a) appeared to be ionic, since increases in the positive charge on LDL by desialylation increased this interaction, whereas decreases in positive charge on LDL reduced this interaction. At higher Ca2+ concentrations, the binding of acetyl LDL to Lp(a) in the insoluble complexes was greater than that of LDL. Since more Ca2+ was required for concentration-dependent saturation of acetyl LDL binding, it is likely that Ca2+ cross-bridging was responsible for this binding. Thus, LDL, especially its modified forms, could contribute to the formation of insoluble complex of Lp(a) with Ca2+ in atherosclerotic lesions and help explain its preferential accumulation there.	CLEVELAND CLIN FDN,RES INST,DEPT VASC CELL BIOL & ATHEROSCLEROSIS,NC1,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NHLBI NIH HHS [HL 29582, HL 43339] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043339, P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN G, 1978, CLIN GENET, V14, P115; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DURRINGTON PN, 1988, LANCET, V1, P1070; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FLESS GM, 1985, J LIPID RES, V26, P1224; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; GAUBATZ JW, 1987, J LIPID RES, V28, P69; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; JAQUES LW, 1977, J BIOL CHEM, V252, P4533; JURGENS G, 1977, ARTERY, V3, P13; KRATZIN H, 1987, BIOL CHEM H-S, V368, P1533, DOI 10.1515/bchm3.1987.368.2.1533; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; NISHIDA T, 1970, J BIOL CHEM, V245, P4689; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROESCHLAU P, 1974, Zeitschrift fuer Klinische Chemie und Klinische Biochemie, V12, P403; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; WARREN L, 1959, J BIOL CHEM, V234, P1971; YE SQ, 1988, J BIOL CHEM, V265, P6377; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	39	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4709	4715						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444846				2022-12-25	WOS:A1993KP88400026
J	GOUT, E; BLIGNY, R; PASCAL, N; DOUCE, R				GOUT, E; BLIGNY, R; PASCAL, N; DOUCE, R			C-13 NUCLEAR-MAGNETIC-RESONANCE STUDIES OF MALATE AND CITRATE SYNTHESIS AND COMPARTMENTATION IN HIGHER-PLANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRASSULACEAN ACID METABOLISM; ACER-PSEUDOPLATANUS CELLS; MAIZE ROOT-TIPS; INTRACELLULAR PH; PHOSPHOENOLPYRUVATE CARBOXYLASE; KALANCHOE-TUBIFLORA; SUCROSE DEPRIVATION; BIOCHEMICAL-CHANGES; TRANSPORT; NMR	The synthesis of malate and citrate by sycamore cells (Acer pseudoplatanus L.) perfused with (KHCO3)-C-13 was analyzed using C-13 NMR. To perform in vivo experiments, cells were compressed in a 25-mm tube and perfused with an arrangement enabling tight control of the circulating nutrient medium. An original method using paramagnetic Mn2+ that induced a complete loss of the vacuolar malate and citrate signals was developed to discriminate between cytoplasmic and vacuolar pools of malate and citrate. Our results indicated the following. (a) The accumulation of appreciable amounts of malate in sycamore cells required rather high (1 mM) concentrations of bicarbonate at all the pH values tested. (b) Malate was equally labeled at C-1 and C-4, suggesting that malate labeled at C-1 was produced by randomization of C-1 and C-4 by mitochondrial fumarase. Indeed, the separation of the intact organelles from the lysed protoplasts indicated that fumarase activity was essentially limited to the mitochondria. Similarly, citrate was equally enriched at C-1 and C-5 + C-6 carboxyls. (c) Malate appeared first in the cytoplasmic compartment; and when a threshold of cytoplasmic malate concentration was attained, malate molecules were expelled into the vacuole, where they accumulated. On the other hand, citrate accumulated steadily in the vacuole. Pulse-chase experiments demonstrated the central role played by the tonoplast in governing the vacuolar influx of citrate and the permanent exchange of malate between the cytoplasm and the vacuole.	CEN,PHYSIOL CELLULAIRE VEGETALE LAB,URA 576,85X,F-38041 GRENOBLE,FRANCE; CEN,RESONANCE MAGNET BIOL & MED LAB,F-38041 GRENOBLE,FRANCE; CEN,DEPT BIOL MOLEC & STRUCT,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)								BLIGNY R, 1977, PLANT PHYSIOL, V59, P502, DOI 10.1104/pp.59.3.502; CHANG KJ, 1989, PLANT PHYSIOL, V89, P197, DOI 10.1104/pp.89.1.197; CORNISHBOWDEN A, 1991, EUR J BIOCHEM, V195, P103, DOI 10.1111/j.1432-1033.1991.tb15681.x; DAVIES DD, 1986, PHYSIOL PLANTARUM, V67, P702, DOI 10.1111/j.1399-3054.1986.tb05081.x; Douce R., 1985, MITOCHONDRIA HIGHER; FOX GG, 1990, PLANT PHYSIOL, V93, P512, DOI 10.1104/pp.93.2.512; GENIX P, 1990, PLANT PHYSIOL, V94, P712; GOUT E, 1992, J BIOL CHEM, V267, P13903; JOURNET EP, 1986, J BIOL CHEM, V261, P3193; JOURNET EP, 1985, PLANT PHYSIOL, V79, P458, DOI 10.1104/pp.79.2.458; KALT W, 1990, PLANT PHYSIOL, V94, P826, DOI 10.1104/pp.94.2.826; KURKDJIAN A, 1989, ANNU REV PLANT PHYS, V40, P271, DOI 10.1146/annurev.pp.40.060189.001415; LATZKO E, 1983, PHYSIOL VEG, V21, P805; LEEGOOD RC, 1983, ISOLATION MEMBRANES, P185; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; LUTTGE U, 1987, NEW PHYTOL, V106, P593, DOI 10.1111/j.1469-8137.1987.tb00163.x; MARIGO G, 1988, BOT ACTA, V101, P187, DOI 10.1111/j.1438-8677.1988.tb00031.x; MARTIN JB, 1982, PLANT PHYSIOL, V70, P1156, DOI 10.1104/pp.70.4.1156; MATHIEU Y, 1986, PLANT PHYSIOL, V82, P846, DOI 10.1104/pp.82.3.846; OLEARY MH, 1982, ANNU REV PLANT PHYS, V33, P297, DOI 10.1146/annurev.pp.33.060182.001501; OSMOND CB, 1988, PLANTA, V175, P184, DOI 10.1007/BF00392426; PFEFFER PE, 1989, NUCL MAGN RESON, P3; REBEILLE F, 1985, BIOCHEM J, V226, P679, DOI 10.1042/bj2260679; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; ROBERTS JKM, 1981, BIOCHIM BIOPHYS ACTA, V639, P53, DOI 10.1016/0304-4173(81)90005-7; ROBY C, 1987, J BIOL CHEM, V262, P5000; ROBY C, 1988, BIOCHEM J, V252, P401, DOI 10.1042/bj2520401; SMITH JAC, 1987, PLANT VACUOLES THEIR, P79; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STIDHAM MA, 1983, PLANT PHYSIOL, V73, P517, DOI 10.1104/pp.73.2.517; Stryer L., 1988, BIOCHEMISTRY-US; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; WU M, 1987, J BIOL CHEM, V262, P12275	33	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3986	3992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440690				2022-12-25	WOS:A1993KN53300030
J	GUESDON, F; FRESHNEY, N; WALLER, RJ; RAWLINSON, L; SAKLATVALA, J				GUESDON, F; FRESHNEY, N; WALLER, RJ; RAWLINSON, L; SAKLATVALA, J			INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR STIMULATE 2 NOVEL PROTEIN-KINASES THAT PHOSPHORYLATE THE HEAT-SHOCK PROTEIN HSP27 AND BETA-CASEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RAPID PHOSPHORYLATION; FACTOR RECEPTOR; FACTOR-ALPHA; FIBROBLASTS; ACTIVATION; CELLS; EXPRESSION; IL-1; IDENTIFICATION	We have partially purified and characterized two protein kinases that were strongly activated by interleukin-1 (IL-1) or tumor necrosis factor (TNF) in MRC-5 fibroblasts. The kinases were separated by anion exchange chromatography of cytosolic fractions. They phosphorylated in vitro the small heat shock protein (hsp27) or beta-casein and were stimulated 3- and 4.5-fold, respectively, in cells that had been exposed to IL-1 or TNF for 10 min. They were distinct from the mitogen-activated protein kinases, whose activation by IL-1 or TNF has been reported recently. The hsp27 kinase phosphorylated its substrate on serine residues. Its molecular mass was estimated to be 45-kDa by gel filtration. It is probably involved in the increase in hsp27 phosphorylation seen in intact cells. The beta-casein kinase behaved as a 65-kDa protein. It phosphorylated its substrate on serine and threonine residues and had little activity on alpha-casein. The hsp27 and beta-casein kinases were not activated after stimulation of the cells with phorbol myristate acetate (PMA). In contrast, the MAP kinases were activated to a similar extent (2-3-fold) by the cytokines and by PMA. The hsp27- and beta-casein kinases probably correspond to novel enzymes whose mechanisms of activation may be independent of protein kinase C or MAP kinases.			GUESDON, F (corresponding author), STRANGEWAYS RES LAB,DEPT CYTOKINE,WORTS CAUSEWAY,CAMBRIDGE CB1 4RN,ENGLAND.			Freshney, Norman/0000-0002-6342-341X				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DINARELLO CA, 1991, BLOOD, V77, P1627; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1991, J BIOL CHEM, V266, P14343; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUAZON PT, 1979, EUR J BIOCHEM, V94, P497, DOI 10.1111/j.1432-1033.1979.tb12918.x; WATANABE S, 1986, EXP CELL RES, V167, P218, DOI 10.1016/0014-4827(86)90218-1; WHITNEY RM, 1976, J DAIRY SCI, V59, P795, DOI 10.3168/jds.S0022-0302(76)84280-4	45	133	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4236	4243						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440707				2022-12-25	WOS:A1993KN53300063
J	TOMAREV, SI; ZINOVIEVA, RD; GUO, K; PIATIGORSKY, J				TOMAREV, SI; ZINOVIEVA, RD; GUO, K; PIATIGORSKY, J			SQUID GLUTATHIONE-S-TRANSFERASE - RELATIONSHIPS WITH OTHER GLUTATHIONE S-TRANSFERASES AND S-CRYSTALLINS OF CEPHALOPODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININOSUCCINATE LYASE; DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; STRUCTURAL PROTEIN; MULTIGENE FAMILY; GENE-EXPRESSION; CDNA CLONE; P-GENE; RAT; LENS	Glutathione S-transferase (GST, EC 2.5.1.18) was purified from the digestive gland of the squid Ommastrephes sloani pacificus. It had high enzymatic activity for the 1-chloro-2,4-dinitrobenzene substrate and was composed of a major and a minor polypeptide band, both with molecular masses near 25 kDa on SDS-polyacrylamide gels. GST cDNA clones were derived from the digestive gland mRNA. The deduced GSTs of the longest cDNAs (pGST5 and pGST11) containing the entire coding sequence have a molecular mass near 23 kDa. Sequence comparisons showed that the squid GST is 42-44% identical to both squid and octopus S-crystallins (the major proteins of the lens), 32-34% identical to class pi and 29-32% identical to class alpha GSTs of vertebrates, and 19-23% identical to other GSTs of vertebrates and insects. Northern blot hybridization revealed that GST mRNAs were much more abundant in the digestive gland than in the testis, mantle, or lens. Analysis of a squid GST gene indicated that it has an exon-intron structure similar to that of the vertebrate class pi GST gene. An apparently novel repetitive element was identified in the 5'-flanking sequence of the squid GST gene. Our results suggest that multiple duplications of an ancestral GST gene gave rise to a family of enzymatically inactive crystallins specialized for lens refraction and one (or two) active GST enzyme expressed preferentially, but not exclusively, in the digestive gland in squids. This differs from the innovation of refractive function from a metabolic enzyme by increased expression in the lens with minimal or no gene duplication, as occurred among the enzyme-crystallins of vertebrates.			TOMAREV, SI (corresponding author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA.							ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Asaoka K, 1989, J Enzyme Inhib, V3, P77, DOI 10.3109/14756368909030366; BALLOUL JM, 1987, NATURE, V326, P149, DOI 10.1038/326149a0; BARBOSA P, 1991, J BIOL CHEM, V266, P22319; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MR, 1988, MOLLUSCA, V12; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRIS J, 1991, COMP BIOCHEM PHYS B, V98, P511, DOI 10.1016/0305-0491(91)90245-9; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LIU SX, 1992, J BIOL CHEM, V267, P4296; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; TELAKOWSKIHOPKINS CA, 1985, J BIOL CHEM, V260, P5820; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1992, BIOCHEM BIOPH RES CO, V182, P355, DOI 10.1016/S0006-291X(05)80152-4; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; WESTON K, 1989, NUCLEIC ACIDS RES, V17, P2138, DOI 10.1093/nar/17.5.2138; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729	56	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4534	4542						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440736				2022-12-25	WOS:A1993KN53300105
J	LUO, JH; KAHN, S; ODRISCOLL, K; WEINSTEIN, IB				LUO, JH; KAHN, S; ODRISCOLL, K; WEINSTEIN, IB			THE REGULATORY DOMAIN OF PROTEIN-KINASE-C BETA-1 CONTAINS PHOSPHATIDYLSERINE AND PHORBOL ESTER-DEPENDENT CALCIUM-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-TISSUES; ACTIVATION; PROENZYME; FAMILY	Certain isoforms of protein kinase C (PKC) require both Ca2+ and phospholipid for optimum activity. However, little is known about the nature of the interaction between PKC and Ca2+. The present study demonstrates that the isolated regulatory domain of PKCbeta1, when synthesized as a fusion protein in Escherichia coli, binds Ca-45(2+) with high affinity, but only in the presence of phosphatidylserine or 12-O-tetradecanoyl-phorbol-13-acetate. This binding is highly selective for Ca2+ since it is preferentially inhibited by excess non-radioactive Ca2+ when compared with the cations Mg2+, Mn2+, Na+, or K+. It appears, therefore, that the binding of Ca2+ to PKC requires a complex tertiary structure in the regulatory domain.	COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032	Columbia University	LUO, JH (corresponding author), COLUMBIA UNIV,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.				NCI NIH HHS [CA-02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCOLEO JP, 1985, CARCINOGENESIS, V6, P213, DOI 10.1093/carcin/6.2.213; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BORNER C, 1992, J BIOL CHEM, V267, P12900; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KREIBICH G, 1970, Z KREBSFORSCH KLIN O, V74, P448, DOI 10.1007/BF00531226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINSTEIN IB, 1991, ORIGINS OF HUMAN CANCER, P113	18	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3715	3719						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429046				2022-12-25	WOS:A1993KM16100104
J	WEI, Z; LIEBER, MR				WEI, Z; LIEBER, MR			LYMPHOID-V(D)J RECOMBINATION - FUNCTIONAL-ANALYSIS OF THE SPACER SEQUENCE WITHIN THE RECOMBINATION SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; LIGHT-CHAIN; SEGMENTS	The V(D)J recombination reaction is directed by a pair of signal sequences, each consisting of a palindromic heptamer, an A/T-rich nonamer, and an intervening spacer sequence of 12 or 23 base pairs. The spacer sequence previously has not been analyzed for a functional role. In this study, numerous simultaneous sequence changes have been made in the spacer of each signal to test their functional importance. All of the AT base pairs in each signal were changed to GC base pairs. This particular change is of interest because it markedly increases the energy that would be required to melt out the two strands of each signal to permit the intersignal base pairing proposed in a commonly invoked model for signal-signal interaction in V(D)J recombination. We find that changing 6 of 12 AT base pairs in the 12-signal to GC does not affect V(D)J recombination, nor does changing 11 of 23 AT base pairs in the 23-signal. Substrates with all-GC spacer sequences in both the 12- and the 23-signal also recombine at efficiencies that are not significantly reduced. These studies demonstrate that the sequences at these particular positions are not recognized by the recombinase. In addition, the data do not support models invoking signal-signal base pairing.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345	NATIONAL CANCER INSTITUTE [R01CA051105, R37CA051105] Funding Source: NIH RePORTER; NCI NIH HHS [CA51105] Funding Source: Medline; NIGMS NIH HHS [GM43236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; RAMSDEN DA, 1991, P NATL ACAD SCI USA, V88, P10721, DOI 10.1073/pnas.88.23.10721; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WATSON JD, 1987, MOL BIOL CELL, P863	14	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3180	3183						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428995				2022-12-25	WOS:A1993KM16100027
J	ZANI, ML; POURCHER, T; LEBLANC, G				ZANI, ML; POURCHER, T; LEBLANC, G			MUTAGENESIS OF ACIDIC RESIDUES IN PUTATIVE MEMBRANE-SPANNING SEGMENTS OF THE MELIBIOSE PERMEASE OF ESCHERICHIA-COLI .2. EFFECT ON CATIONIC SELECTIVITY AND COUPLING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR SPECIFICITY MUTATIONS; K+ COMPLEX PROVIDES; SOLID-STATE MODEL; TRANSPORT-SYSTEM; LACTOSE TRANSPORT; CRYSTAL-STRUCTURE; CARRIER; NA+; VESICLES; IDENTIFICATION	Individual substitution of Cys or Asn for Asp-31, Asp-51, Asp-55, or Asp-120, distributed in different membrane spanning segments of the NH2-terminal domain of melibiose (mel) permease partially or completely inactivates Na+-linked sugar transport and stimulation of sugar binding on mel permease by Na+ ions (Pourcher, T., Zani, M.-L., and Leblanc, G. (1993) J. Biol. Chem. 268, 3209-3215). To investigate further the effect of these substitutions on the cationic selectivity and coupling properties of mel permease, H+-melibiose coupled transport, coupling between H+ and melibiose movements, sugar counterflow, and zero-trans sugar efflux by the mutant permeases were analyzed. The results provide additional evidence indicating that manipulation of some of these Asp in the membrane-spanning segments of mel permease alters its cationic selectivity properties. The results also indicate that the individual mutations diversely affect mel permease-coupling properties. For example, only permease with Asn in place of Asp-31 or Cys in place of Asp-51 retains the capacity to actively transport melibiose. On the other hand, replacing Asp-55 by Cys produces uncoupling of cosubstrate flows by the carrier but does not hamper sugar translocation. These and other features of the mutant permeases are used to discuss the relative participation of Asp-31, Asp-51, Asp-55, or Asp-120 to the mel symport mechanism and to its ionic selectivity and also the existence of a possible gating mechanism that may contribute the obligatory coupling of cosubstrate flows by the symporter.	CEA,DEPT BIOL CELLULAIRE & MOLEC,LAB J MAETZ,F-06230 VILLEFRANCHE MER,FRANCE	CEA				Pourcher, Thierry/0000-0003-2839-4622				BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BEHR JP, 1982, NATURE, V295, P526, DOI 10.1038/295526a0; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1989, THESIS HARVARD MED U; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; COHN DE, 1980, BIOCHEMISTRY-US, V19, P4237, DOI 10.1021/bi00559a015; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; HANATANI M, 1984, J BIOL CHEM, V259, P1807; HILGENFELD R, 1982, TOP CURR CHEM, V101, P3; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KABACK HR, 1971, METHOD ENZYMOL, V31, P698; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1990, J BIOL CHEM, V265, P9645; LEBLANC G, 1993, IN PRESS ION COUPLED; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1990, BIOCHEMISTRY-US, V29, P690, DOI 10.1021/bi00455a014; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANDFORD C, 1983, ANN REV BIOCH, V52, P370; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P2174; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON TH, 1982, MEMBRANES TRANSPORT, P33; YAZYU H, 1984, J BIOL CHEM, V259, P4320	33	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3216	3221						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428998				2022-12-25	WOS:A1993KM16100032
J	YOSHIMURA, K; ROSENFELD, MA; SETH, P; CRYSTAL, RG				YOSHIMURA, K; ROSENFELD, MA; SETH, P; CRYSTAL, RG			ADENOVIRUS-MEDIATED AUGMENTATION OF CELL TRANSFECTION WITH UNMODIFIED PLASMID VECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; MEMBRANE-PERMEABILITY; KB-CELLS; PH; GENE; DNA; MACROMOLECULES; ENHANCEMENT; EXPRESSION; INFECTION	The present study demonstrates that the human adenovirus (Ad) can augment transfer and expression of a gene within plasmid DNA unmodified by nonspecific linkers or by linker-ligand complexes. Following the transfection of COS-7 cells with pRSVL, a luciferase expression plasmid vector directed by the Rous sarcoma virus-long terminal repeat promoter, luciferase activity in the target cells was 10(3)- to 10(4)-fold higher when the cells were also infected with Ad-CFTR, a replication-deficient recombinant Ad containing human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA. The enhancement of luciferase gene expression in COS-7 cells was also observed with Ad-dl312 (a replication-deficient E1a deletion mutant Ad with no exogenous gene) and wild type Ad5. The efficiency of cell transfection with pRSVL in the presence of an Ad was achieved in a dose-dependent fashion with progressively higher luciferase activity in cells infected by increasing amounts of Ad-CFTR, Ad-dl312, or Ad5. The augmentation by Ad-CFTR of the transfer and expression of the luciferase gene in cells was similar to that of another transfection reagent, cationic liposomes. Further, when Ad-CFTR and liposomes were used in combination, 4- to 100-fold more efficient expression of the luciferase gene was achieved than with Ad-CFTR or liposomes alone. When COS-7, HeLa, and CV-1 cells were evaluated in parallel in the presence or absence of liposomes, Ad-mediated enhancement of luciferase activity was observed in all cell lines. Thus, exposure of target cells to replication-deficient or competent human Ad will markedly augment transfer and expression of the genes within plasmid DNA in mammalian cells in vitro without modifying the plasmid with linkers or linker-ligand complexes, a strategy that should be useful for in vitro and in vivo gene transfer applications.	NHLBI,PULM BRANCH,BLDG 10,RM 6D03,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BLUMENTHAL R, 1986, BIOCHEMISTRY-US, V25, P2231, DOI 10.1021/bi00356a057; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRASCO L, 1981, VIROLOGY, V113, P623, DOI 10.1016/0042-6822(81)90190-2; CARRASCO L, 1982, VIROLOGY, V117, P62, DOI 10.1016/0042-6822(82)90507-4; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; Ginsberg HS, 1984, ADENOVIRUSES; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HORWITZ MS, 1990, VIROLOGY, P01679; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; OTERO MJ, 1987, VIROLOGY, V160, P75, DOI 10.1016/0042-6822(87)90046-8; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SETH P, 1984, J BIOL CHEM, V259, P4350; SETH P, 1984, J VIROL, V51, P650, DOI 10.1128/JVI.51.3.650-655.1984; SETH P, 1985, J BIOL CHEM, V260, P4431; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; SETH P, 1985, J BIOL CHEM, V260, P9598; SETH P, 1987, J VIROL, V61, P883, DOI 10.1128/JVI.61.3.883-888.1987; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; YAMAIZUMI M, 1979, VIROLOGY, V95, P218, DOI 10.1016/0042-6822(79)90418-5; YOSHIMURA A, 1985, CELL STRUCT FUNCT, V10, P391, DOI 10.1247/csf.10.391	30	100	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2300	2303						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428904				2022-12-25	WOS:A1993KK81500009
J	CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P				CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P			THE TRANSCRIPTIONALLY ACTIVE FACTORS MEDIATING THE EFFECT OF THE HTLV-I TAX TRANSACTIVATOR ON THE IL-2R-ALPHA KAPPA-B ENHANCER INCLUDE THE PRODUCT OF THE C-REL PROTOONCOGENE	ONCOGENE			English	Article							RECEPTOR GENE-EXPRESSION; DNA-BINDING SUBUNIT; CELLULAR PROTEINS; 65-KD SUBUNIT; ALPHA-GENE; ACTIVATION; FAMILY; HIV; POLYPEPTIDE; INHIBITION	The transactivator HTLV-1 Tax activates the promoter of the gene coding for the interleukin 2 alpha-chain receptor (IL-2Ralpha) via a kappaB site that can bind several protein species of the rel family. Tax1 strongly activates the enhancer activity of this motif, in both epithelial HeLa and lymphoid Jurkat cells. This activation was not observed in undifferentiated embryocarcinoma F9 cells. Overexpression of the p50, p65 and Rel proteins in these cells showed that significant activation of the IL-2Ralpha kappaB site was observed only with Rel and Rel plus p65. Moreover, whereas both Tax and phorbol 12-myristate 13-acetate (PMA) are able to efficiently induce the binding of NF-kappaB to the IL-2Ralpha kappaB site, PMA is functionally inactive. Using the DNA affinity precipitation assay, we observed that Tax1 is able to efficiently induce the binding of Rel, whereas PMA is not. This established a clear difference between both stimuli, indicating that Rel is the functionally active factor. We conclude from these results that the functional activity of members of the rel family is regulated by their interaction with DNA and that Rel can be a potent transcriptional activator on specific kappaB sites.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)				Philippe, Veschambre/0000-0001-6094-6795				ALEXANDRE C, 1991, J VIROL, V6, P543; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEVALLIERGRECO A, 1989, J VIROL, V63, P615, DOI 10.1128/JVI.63.2.615-623.1989; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL LK, 1991, CELL, V65, P1281; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEE JH, 1991, ONCOGENE, V6, P665; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6	45	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					867	875						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455941				2022-12-25	WOS:A1993KT22000007
J	DAVID, M; ROMERO, G; ZHANG, ZY; DIXON, JE; LARNER, AC				DAVID, M; ROMERO, G; ZHANG, ZY; DIXON, JE; LARNER, AC			INVITRO ACTIVATION OF THE TRANSCRIPTION FACTOR ISGF3 BY INTERFERON-ALPHA INVOLVES A MEMBRANE-ASSOCIATED TYROSINE PHOSPHATASE AND TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL TRANSDUCTION; RAPID ACTIVATION; BINDING; CELLS; ISOFORM; PP56LCK	Interaction of interferon alpha (IFNalpha) with its cell surface receptor rapidly activates the formation of the transcription complex ISGF3, which subsequently translocates to the nucleus and stimulates the expression of a variety of early response genes. We have recently developed a cell-free system where IFNalpha can activate the formation of ISGF3 in vitro. This system has enabled us to demonstrate that the component of the ISGF3 transcription complex which is modified by IFNalpha treatment (ISGF3alpha) is membrane-associated and that its activation involves a protein kinase. Using a combination of specific tyrosine kinase and phosphatase inhibitors and monoclonal anti-phosphotyrosine antibodies we now are able to demonstrate that IFNalpha-activated transcription involves at least a two-step process where a membrane-associated tyrosine phosphatase and a tyrosine kinase lead to modification of ISGF3alpha and subsequent formation of the complete complex. Furthermore, formation of the ISGF3 complex is specifically disrupted by protein tyrosine phosphatase and can be reversibly dissociated by the phosphotyrosine analogue phenylphosphate. The latter observation suggested that SH2 and/or SH3 domains may be required for the stable formation of this transcription complex.	CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	US Food & Drug Administration (FDA); University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					PHS HHS [18824] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA T, 1991, PROTEIN PHOSPHORYLAT, V201, P362; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BANDYOPADHYAY SK, 1992, J BIOL CHEM, V267, P6389; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	27	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6593	6599						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454630				2022-12-25	WOS:A1993KT36800075
J	LUDMERER, SW; WRIGHT, DJ; SCHIMMEL, P				LUDMERER, SW; WRIGHT, DJ; SCHIMMEL, P			PURIFICATION OF GLUTAMINE TRANSFER-RNA SYNTHETASE FROM SACCHAROMYCES-CEREVISIAE - A MONOMERIC AMINOACYL-TRANSFER RNA-SYNTHETASE WITH A LARGE AND DISPENSABLE NH2-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TERMINAL EXTENSION; MACROMOLECULAR COMPLEXES; 3-DIMENSIONAL STRUCTURE; BINDING FOLD; GLNS GENE; SEQUENCE; RESOLUTION; ENCODES; RECOGNITION	Glutamine tRNA synthetase from Saccharomyces cerevisiae has been purified to homogeneity and shown to be a monomer of 91 kDa. The size of the polypeptide agrees with that predicted from the previously reported translated DNA sequence. Mild tryptic digestion removes an amino-terminal domain and releases a fragment of 65 kDa which begins at Ser205. This tryptic fragment is similar in size and sequence to Escherichia coli glutamine tRNA synthetase and shows a modest increase from the full-length yeast enzyme in the K(m) values for glutamine and ATP and no difference in the k(cat), for aminoacylation or the K(m) for tRNA. Thus, the removal of the NH2-terminal domain appears to indirectly affect the ATP- and glutamine-binding sites in the nucleotide- binding fold domain to which the NH2-terminal domain is fused. A monoclonal antibody directed against the NH2-terminal domain of the full-length enzyme has little effect upon the aminoacylation activity. Therefore, over 200 amino acids of the NH2 terminus of the full-length enzyme form a domain that operationally has only a modest influence on the catalytic core of the protein. These studies reinforce the concept that eukaryotic synthetases have quasi-independent domains not found in their prokaryotic counterparts which may confer a function distinct from aminoacylation.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BLOW DM, 1985, BIOL MACROMOL, V2, P442; BRICK P, 1988, J MOL BIOL, V208, P83; BRUNIE S, 1987, J MOL GRAPHICS, V5, P18, DOI 10.1016/0263-7855(87)80039-5; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CHATTON B, 1988, J BIOL CHEM, V263, P52; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; HOBEN P, 1982, J BIOL CHEM, V257, P1644; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; KOHLER G, 1980, HYBRIDOMA TECHNIQUES; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; LUDMERER SW, 1985, J BACTERIOL, V163, P763, DOI 10.1128/JB.163.2.763-768.1985; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MIRANDE M, 1982, J BIOL CHEM, V257, P1056; MITCHELL AP, 1984, J BACTERIOL, V158, P530, DOI 10.1128/JB.158.2.530-534.1984; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OCONNER G, 1990, THESIS MIT; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; RISLER JL, 1981, NATURE, V292, P384, DOI 10.1038/292384a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SIVARAM P, 1988, J BIOL CHEM, V263, P18891; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; TOTH MJ, 1990, J BIOL CHEM, V265, P1000; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; YAMAO F, 1982, J BIOL CHEM, V257, P1639; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	37	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5519	5523						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449914				2022-12-25	WOS:A1993KR82200028
J	YAMASHITA, K; IDEO, H; OHKURA, T; FUKUSHIMA, K; YUASA, I; OHNO, K; TAKESHITA, K				YAMASHITA, K; IDEO, H; OHKURA, T; FUKUSHIMA, K; YUASA, I; OHNO, K; TAKESHITA, K			SUGAR CHAINS OF SERUM TRANSFERRIN FROM PATIENTS WITH CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME - EVIDENCE OF ASPARAGINE-N-LINKED OLIGOSACCHARIDE TRANSFER DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY OLIGOSACCHARIDES; ACID; GLYCOSYLATION; LECTIN	The structure of over 93% of the sugar chains of serum transferrin purified from three patients with carbohydrate-deficient glycoprotein (CDG) syndrome was Neu5Acalpha2-->6Galbeta1-->4GlcNAcbeta1-->2Manalpha1-->6 (Neu5Acalpha2-->6Galbeta1-->4GlcNAcbeta1-->2Manalpha1-->3)Manbeta1-->4GlcNAcbeta1-->4GlcNAc, similar to that in a healthy control. On chromatofocusing, CDG syndrome transferrin was separated into three major isoforms, S4, S2, and S0, containing 4, 2, and 0 sialic acids/molecule at pH 5.12 (5.16), 5.42, and 5.80, respectively. On 7.5% SDS-polyacrylamide gel electrophoresis, the molecular masses of transferrin isoforms S4, S2, and So were 80, 77, and 74 kDa, respectively. Transferrin isoforms S4 and S2 were linked to 2 and 1 mol of sialylated biantennary sugar chain/transferrin molecule, on the other hand, isoform S0 was not linked to any asparagine-N-linked oligosaccharide. Accordingly, CDG syndrome can be concluded to be an asparagine-N-linked oligosaccharide transfer deficiency, although the primary deficient enzyme has not yet been determined.	TOTTORI UNIV,SCH MED,INST NEUROL SCI,DIV CHILD NEUROL,YONAGO,TOTTORI 683,JAPAN	Tottori University	YAMASHITA, K (corresponding author), SASAKI INST,DEPT BIOCHEM,KANDA SURUGADAI,CHIYODA KU,TOKYO 101,JAPAN.							FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HASLIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761; Jaeken J, 1991, Acta Paediatr Scand Suppl, V375, P1; JAEKEN J, 1984, CLIN CHIM ACTA, V144, P245, DOI 10.1016/0009-8981(84)90059-7; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KOBATA A, 1993, PRACTICAL APPROACH G; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; OHNO K, 1992, BRAIN DEV-JPN, V14, P30, DOI 10.1016/S0387-7604(12)80276-2; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; STIBLER H, 1990, ARCH DIS CHILD, V65, P107, DOI 10.1136/adc.65.1.107; TACHIBANA Y, 1981, J BIOCHEM-TOKYO, V90, P1291, DOI 10.1093/oxfordjournals.jbchem.a133594; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; UCHIDA Y, 1974, BIOCHIM BIOPHYS ACTA, V350, P425, DOI 10.1016/0005-2744(74)90517-8; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1989, J BIOL CHEM, V264, P2415; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YAMASHITA K, 1981, J BIOL CHEM, V256, P1283; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789; YAMASHITA K, 1980, J BIOL CHEM, V254, P4820	24	148	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5783	5789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449944				2022-12-25	WOS:A1993KR82200064
J	NICHOLLS, PJ; JOHNSON, VG; ANDREW, SM; HOOGENBOOM, HR; RAUS, JCM; YOULE, RJ				NICHOLLS, PJ; JOHNSON, VG; ANDREW, SM; HOOGENBOOM, HR; RAUS, JCM; YOULE, RJ			CHARACTERIZATION OF SINGLE-CHAIN ANTIBODY (SFV)-TOXIN FUSION PROTEINS PRODUCED INVITRO IN RABBIT RETICULOCYTE LYSATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; DIPHTHERIA-TOXIN RECEPTOR; FRAGMENT D-DIMER; PSEUDOMONAS EXOTOXIN; ESCHERICHIA-COLI; RECOMBINANT IMMUNOTOXIN; GENETIC CONSTRUCTION; OVERLAP EXTENSION; VARIABLE DOMAINS; PLASMA-MEMBRANE	Chimeric proteins consisting of a fusion between binding-deficient mutants of diphtheria toxin (DT) or Pseudomonas exotoxin A (PE) and a single-chain antibody (E6 sFv) against the human transferrin receptor (TfnR) were expressed in a rabbit reticulocyte lysate system. Molecules utilizing PE40 (the carboxyl terminus 40 kDa of PE, lacking the binding domain) exhibited significant E6 sFv-mediated, cell type-specific cytotoxicity (IC50 1 x 10(-10) M) against a human erythroleukemia-derived cell line, K562. In contrast, a fusion protein between the same sFv and a DT mutant, DTM1 (containing two amino acid substitutions in the binding domain [S(508)F, S(525)F]) was not significantly cytotoxic, despite being enzymatically active. A tripartite protein in the form NH2-DTM1-E6 sFv-PE40-COOH exhibited cytotoxicity comparable to that of the PE40-sFv fusion (IC50 1 x 10(-10) M), suggesting that the deficit in activity of DTM1-sFv is not a function of misfolding of the sFv moiety or of a reduced ability to bind TfnR. In contrast to DTM1-E6 sFv, a fusion protein between a second DT mutant, CRM 107 [S(525)F], and the E6 sFv was specifically cytotoxic (IC50 1 X 10(-9) M), and toxicity could be blocked by addition of excess E6 antibody. The cell-free in vitro expression system we describe is rapid and may be used to express functional toxin-sFv fusion proteins. No protein refolding procedures are required, and the technique may be used to express proteins which, due to restrictions imposed on manipulation of toxin-encoding genes in Escherichia coli, could not be produced by more conventional methods.	US FDA,CBER,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; LIMBURGS UNIV CENTRUM,DR L WILLEMS INST,B-3610 DIEPENBEEK,BELGIUM; LIMBURGS UNIV CENTRUM,DEPT WNIF,B-3610 DIEPENBEEK,BELGIUM	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hasselt University; Hasselt University	NICHOLLS, PJ (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892, USA.							BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; GIBBS RA, 1991, P NATL ACAD SCI USA, V88, P4001, DOI 10.1073/pnas.88.9.4001; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; HEYLIGEN H, 1985, FED PROC, V44, P787; HOLVOET P, 1991, J BIOL CHEM, V266, P19717; HOOGENBOOM HR, 1990, J IMMUNOL, V144, P3211; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1989, J BIOL CHEM, V264, P17739; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREITMAN RJ, 1990, P NATL ACAD SCI USA, V87, P8291, DOI 10.1073/pnas.87.21.8291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE Y, 1991, J BIOL CHEM, V266, P16343; LIGHTFOOT HN, 1974, BIOCHEM BIOPH RES CO, V56, P351, DOI 10.1016/0006-291X(74)90849-3; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MACKOW ER, 1990, P NATL ACAD SCI USA, V87, P518, DOI 10.1073/pnas.87.2.518; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MILENIC DE, 1991, CANCER RES, V51, P6363; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; MURPHY JR, 1974, P NATL ACAD SCI USA, V71, P11, DOI 10.1073/pnas.71.1.11; NICHOLLS PJ, 1992, GENETICALLY ENG TOXI, P339; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; OLSNES S, 1989, J BIOL CHEM, V264, P12749; PRIOR TI, 1991, CANCER RES, V51, P174; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; TENMARK H, 1991, MOL MICROBIOL, V5, P595; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WILSON K, 1988, CURRENT PROTOCOLS MO; FED REG 3, V51, P16961; FED REG 3, V51, P16971	55	34	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5302	5308						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444903				2022-12-25	WOS:A1993KP88400105
J	PESECKIS, SM; DEICHAITE, I; RESH, MD				PESECKIS, SM; DEICHAITE, I; RESH, MD			IODINATED FATTY-ACIDS AS PROBES FOR MYRISTATE PROCESSING AND FUNCTION - INCORPORATION INTO PP60(V-SRC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; ROUS-SARCOMA VIRUS; MURINE LEUKEMIA-VIRUS; MEMBRANE ASSOCIATION; TRANSFORMING PROTEIN; MYRISTOYLATION; MYRISTYLATION; COA; PP60V-SRC; P60V-SRC	The myristyl group makes a critical contribution to the processing, trafficking, and function of myristylated proteins. A series of [omega-I-125]iodo-fatty acids was synthesized in order to elucidate the myristyl group's contribution to the membrane association of pp60v-src, the transforming protein of Rous sarcoma virus. In vitro translation of v-src mRNA was employed to monitor incorporation of myristyl analogs into pp60v-src polypeptide. 12-Iodododecanoic, 13-iodotridecanoic, and 14-iodotetradecanoic acids were selectively incorporated in vitro into pp60v-src. One-dimensional peptide analysis confirmed that the analogs were attached to the N terminus of pp60v-src. Upon addition of membranes, the Src proteins modified by these analogs bound to membranes at levels comparable with or slightly less than the myristyl parent. Myristyl analogs were also shown to be incorporated into pp60v-src in vivo. Fractionation of [omega-I-125]iodo-fatty acid labeled cells showed that 12-iododecanoic acid, 13-iodotridecanoic acid, and 14-iodotetradecanoic acid modified pp60v-src associated preferentially with the membrane fractions. These results demonstrate that fatty acyl groups one carbon longer or shorter than myristate can be accommodated within the membrane binding site for pp60v-src and illustrate the utility of in vitro systems for predicting analog behavior in vivo. We anticipate that iodinated fatty acids can be used as tools to aid in clarifying the role of the fatty acid in a variety of myristylated molecules.	MEM SLOAN KETTERING CANC CTR,DEPT CELL BIOL & GENET,1275 YORK AVE,BOX 143,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Deichaite, Ida/0000-0001-8839-0573; Resh, Marilyn/0000-0001-6118-9466	NCI NIH HHS [CA52405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEKSEYEV EG, 1989, KHIM FARM ZH+, V23, P879; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BARS DL, 1985, J LABELLED COMPD RAD, V22, P903; BOYLE JJ, 1962, NATURE, V196, P893, DOI 10.1038/196893a0; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; FRANKS NP, 1986, P NATL ACAD SCI USA, V83, P5116, DOI 10.1073/pnas.83.14.5116; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HELLEN CUT, 1992, VIROLOGY, V187, P391, DOI 10.1016/0042-6822(92)90440-Z; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KRAUSSLICH HG, 1990, J VIROL, V64, P2433; LEE YMH, 1992, VIROLOGY, V187, P814, DOI 10.1016/0042-6822(92)90485-8; MATSUYAMA H, 1989, J ORG CHEM, V54, P5218, DOI 10.1021/jo00283a010; MOSCUFO N, 1991, J VIROL, V65, P2372, DOI 10.1128/JVI.65.5.2372-2380.1991; OTTO CA, 1981, J LABELLED COMPD RAD, V18, P1347, DOI 10.1002/jlcr.2580180911; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1990, ONCOGENE, V5, P1437; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SCHULTZ AM, 1989, J VIROL, V63, P2370, DOI 10.1128/JVI.63.5.2370-2373.1989; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TAMURA A, 1986, BIOCHIM BIOPHYS ACTA, V855, P250, DOI 10.1016/0005-2736(86)90171-9; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591	44	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5107	5114						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444887				2022-12-25	WOS:A1993KP88400080
J	SELF, AJ; PATERSON, HF; HALL, A				SELF, AJ; PATERSON, HF; HALL, A			DIFFERENT STRUCTURAL ORGANIZATION OF RAS-EFFECTOR AND RHO-EFFECTOR DOMAINS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; TRIPHOSPHATE CONFORMATION; BINDING DOMAIN; RAS-P21 GTPASE; GAP; P21; IDENTIFICATION; TRANSFORMATION; RESIDUES	Ras regulates proliferation and differentiation signals in cells, and activation of the protein can tead to malignant transformation. Activation of the related protein, Rho, affects cell morphology, and it has been suggested that it may also have some oncogenic potential. We show here that Rho does not induce a malignant phenotype in NIH3T3 cells but instead is a potent activator of actin stress fibre formation. The limited homology between Ras and Rho has enabled us to determine the amino acids specifying their different biological activities and GTPase-activating protein (GAP) protein sensitivities using chimeras. Rho substituted with amino acids 23-46 of Ras induces transformed foci in NIH3T3 monolayers, and we conclude that Ras has a single effector domain required for downstream signalling. Although mutational analysis of Rho has revealed that residues 32-42 are also essential for its biological activity, Ras substituted with amino acids 25-48 of Rho does not induce actin stress fibre formation. On the basis of these experiments, we propose that Rho may have two effector domains: one at amino acids 32-42 and corresponding to the effector region of Ras and the second located elsewhere in the carboxy-terminal two-thirds of the molecule.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	34	93	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					655	661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437849				2022-12-25	WOS:A1993KN00800016
J	BANDI, HR; FERRARI, S; KRIEG, J; MEYER, HE; THOMAS, G				BANDI, HR; FERRARI, S; KRIEG, J; MEYER, HE; THOMAS, G			IDENTIFICATION OF 40-S RIBOSOMAL-PROTEIN S6 PHOSPHORYLATION SITES IN SWISS MOUSE 3T3 FIBROBLASTS STIMULATED WITH SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; KINASE; PHOSPHOSERINE; INITIATION; PEPTIDES; INSULIN; CELLS	All of the phosphorylation sites in 40 S ribosomal protein S6 derived from serum-stimulated Swiss mouse 3T3 cells are found within a small cyanogen bromide (CNBr) peptide derived from the carboxyl terminus, Lys218-Lys249. Further cleavage of the CNBr peptide or the intact protein with endoproteinase Lys-C (endo Lys-C) generated a single phosphorylated peptide, implying that all the sites of phosphorylation resided either between Arg231 and Lys243 or between Arg231 and Lys249 if cleavage at Lys243 was blocked by phosphorylation at a nearby residue. To discern between these possibilities and to identify the phosphorylation sites, the protein was purified from serum-stimulated cells and cleaved with endo Lys-C, and the single endo Lys-C phosphorylated peptide was isolated and sequenced following conversion of all the phosphorylated serines to S-ethylcysteine. The results show that the phosphorylated peptide extends from Arg231 to Lys249 and that the sites of phosphorylation in vivo are Ser235, Ser236, Ser240, Ser244, and Ser247.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND; RUHR UNIV BOCHUM, W-4630 BOCHUM 1, GERMANY	Friedrich Miescher Institute for Biomedical Research; Ruhr University Bochum			Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDON SD, 1991, J BIOL CHEM, V266, P380; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRANCO R, 1990, J BIOL CHEM, V265, P4321; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; PALEN E, 1987, J BIOL CHEM, V262, P3518; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	28	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4530	4533						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440735				2022-12-25	WOS:A1993KN53300104
J	KLOSE, M; SCHIMZ, KL; VANDERWOLK, J; DRIESSEN, AJM; FREUDL, R				KLOSE, M; SCHIMZ, KL; VANDERWOLK, J; DRIESSEN, AJM; FREUDL, R			LYSINE-106 OF THE PUTATIVE CATALYTIC ATP-BINDING SITE OF THE BACILLUS-SUBTILIS SECA PROTEIN IS REQUIRED FOR FUNCTIONAL COMPLEMENTATION OF ESCHERICHIA-COLI SECA MUTANTS INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; PLASMA-MEMBRANE; EXPORT; GENE; SECRETION; VECTORS; HOMOLOG; IDENTIFICATION; COMPONENT; FRAGMENTS	The SecA protein is a major component of the cellular machinery that mediates the translocation of proteins across the Escherichia coli plasma membrane. The secA gene from Bacillus subtilis was cloned and expressed in E. coli under the control of the lac or trc promoter. The temperature-sensitive growth and secretion defects of various E. coli secA mutants were complemented by the B. subtilis SecA protein, provided the protein was expressed at moderate levels. Under overproduction conditions, no complementation was observed. One of the main features of the SecA protein is the translocation ATPase activity which, together with the protonmotive force, drives the movement of proteins across the plasma membrane. A putative ATP-binding motif can be identified in the SecA protein resembling the consensus Walker A type motif. Replacement of a lysine residue at position 106, which corresponds to an invariable amino acid residue, in the consensus motif by asparagine (K106N) resulted in the loss of the ability of the B. subtilis SecA protein to complement the growth and secretion defects of E. coli secA mutants. In addition, the presence of the K106N SecA protein interfered with protein translocation, most likely at an ATP-requiring step. We conclude that lysine 106 is part of the catalytic ATP-binding site of the B. subtilis SecA protein, which is required for protein translocation in vivo.	FORSCHUNGSZENTRUM JULICH, INST BIOTECHNOL 1, POSTFACH 1913, W-5170 JULICH 1, GERMANY; UNIV GRONINGEN, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS	Helmholtz Association; Research Center Julich; University of Groningen			Driessen, Arnold J.M./D-1876-2012; Freudl, Roland/N-4179-2017	Freudl, Roland/0000-0003-0743-1279; Driessen, Arnold J.M./0000-0001-9258-9104				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; FREUDL R, 1992, J BIOTECHNOL, V23, P231, DOI 10.1016/0168-1656(92)90072-H; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; JAYARAMAN K, 1966, J MOL BIOL, V18, P339, DOI 10.1016/S0022-2836(66)80251-6; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miller J.H., 1972, EXPT MOL GENETICS; NAKAMURA K, 1990, FEBS LETT, V273, P75, DOI 10.1016/0014-5793(90)81054-R; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OVERHOFF B, 1991, MOL GEN GENET, V228, P417, DOI 10.1007/BF00260635; PRIEST FG, 1977, BACTERIOL REV, V41, P711, DOI 10.1128/MMBR.41.3.711-753.1977; SADAIE Y, 1991, GENE, V98, P101; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SUH JW, 1990, MOL MICROBIOL, V4, P305, DOI 10.1111/j.1365-2958.1990.tb00597.x; TAKAMATSU H, 1992, J BACTERIOL, V174, P4308, DOI 10.1128/JB.174.13.4308-4316.1992; TANI K, 1989, J BIOL CHEM, V264, P18582; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4504	4510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440733				2022-12-25	WOS:A1993KN53300100
J	ZAVITZ, KH; MARIANS, KJ				ZAVITZ, KH; MARIANS, KJ			HELICASE-DEFICIENT CYSTEINE TO GLYCINE SUBSTITUTION MUTANTS OF ESCHERICHIA-COLI REPLICATION PROTEIN PRIA RETAIN SINGLE-STRANDED DNA-DEPENDENT ATPASE ACTIVITY - ZN2+ STIMULATION OF MUTANT PRIA HELICASE AND PRIMOSOME ASSEMBLY ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI-X174 DNA; BINDING DOMAIN; FACTOR-Y; TRANSCRIPTION FACTOR; PRIMING REPLICATION; UNIQUE SEQUENCE; HAIRPIN REGION; ZINC; GENE; SITE	The PriA replication protein of Escherichia coli guides the ordered assembly of the primosome, the mobile, multiprotein, bidirectional, DNA replication priming/helicase complex of which it is an integral part. Although the PriA protein is not essential for viability, primosome assembly via a PriA-dependent pathway is required for normal cellular replication and growth. The PriA protein itself is multifunctional. In addition to its role in directing primosome assembly, PriA is a site-specific, single-stranded DNA-dependent ATPase (dATPase) and a 3'-->5' DNA translocase and helicase. In an attempt to assess how each individual PriA activity is related to the others (i.e. can one activity function independently of the others or are they intrinsically coupled?), a series of site-directed mutations within priA have been created. priA encodes a cysteine-rich motif, the sequence of which suggests that this region of the protein may be involved in metal binding. Biochemical characterization of three purified cysteine to glycine substitution mutant PriA proteins revealed that these mutant proteins retained their site-specific single-stranded DNA-dependent ATPase activity. However, two of the three mutant proteins were completely incapable of any helicase activity. Residual helicase activity of the third mutant PriA protein could be stimulated 3-fold by the presence of low concentrations of Zn2+ ions. Primosomes assembled with the mutant PriA proteins were also defective in both their ability to act as bidirectional helicase complexes, as well as their ability to synthesize primers for extension by the DNA polymerase III holoenzyme. The results presented here suggest that the cysteine-rich region of PriA is indeed involved in metal binding and that single cysteine to glycine substitutions within this region result in the uncoupling of the ATPase activity of PriA from both its helicase activity and its ability to interact correctly with the DNA template and the six other primosomal proteins.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM 34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAZUA P, 1984, J BIOL CHEM, V259, P14286; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; FRANKE B, 1970, VIROLOGY, V44, P168; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GAUSS P, 1987, P NATL ACAD SCI USA, V84, P8515, DOI 10.1073/pnas.84.23.8515; GREENBAUM JH, 1985, J BIOL CHEM, V260, P2266; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2595; HANAS JS, 1983, J BIOL CHEM, V258, P4120; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KABORI J, 1982, J BIOL CHEM, V257, P13770; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE MS, 1990, J BIOL CHEM, V265, P17078; LOW RL, 1982, J BIOL CHEM, V257, P6242; Maniatis T., 1982, MOL CLONING; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SOELLER W, 1984, J BIOL CHEM, V259, P4293; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	49	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4337	4346						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440719				2022-12-25	WOS:A1993KN53300077
J	LEVEILLARD, T; KASSAVETIS, GA; GEIDUSCHEK, EP				LEVEILLARD, T; KASSAVETIS, GA; GEIDUSCHEK, EP			REPRESSION AND REDIRECTION OF SACCHAROMYCES-CEREVISIAE TRANSFER-RNA SYNTHESIS FROM UPSTREAM OF THE TRANSCRIPTIONAL START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; DNA-BINDING PROTEINS; GENE; TFIIIB; U6; COMPONENTS	Derivatives of the Saccharomyces cerevisiae SUP4 tRNA(Tyr) gene with binding sites for the transcription regulatory protein GCN4 located upstream of the transcriptional start site have been constructed. The effect of GCN4 on transcription of these genes by purified RNA polymerase III and transcription factors (TF) IIIB and IIIC has been analyzed. GCN4 effectively blocks initiation of transcription only when prebound to sites that overlap with the binding site of TFIIIB. Residual GCN4-repressed transcription is significantly redirected to nearby downstream sites, the selection of which depends on the location of bound GCN4. That prebound repressing GCN4 redirects, instead of merely blocking, the TFIIIC-dependent interaction of TFIIIB with DNA has been directly demonstrated by footprinting. The effect of GCN4 on transcription persists after it has been stripped off its DNA-binding site: once it has been redirected, DNA-bound TFIIIB remains in place, a consequence of the fact that it binds extraordinarily tightly to DNA without recognizing specific DNA sequence.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Léveillard, Thierry/AAR-1804-2020	Léveillard, Thierry/0000-0001-5692-8770				BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HERNANDEZ N, 1992, TRANSCRIPTIONAL REGU, V1, P281; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1992, J MOL BIOL, V228, P1063; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARSCHALEK R, 1988, NUCLEIC ACIDS RES, V16, P6737, DOI 10.1093/nar/16.14.6737; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; STRUHL K, 1992, TRANSCRIPTIONAL REGU, V2, P833; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540	25	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3594	3603						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429036				2022-12-25	WOS:A1993KM16100087
J	LI, Y; CAMP, S; RACHINSKY, TL; BONGIORNO, C; TAYLOR, P				LI, Y; CAMP, S; RACHINSKY, TL; BONGIORNO, C; TAYLOR, P			PROMOTER ELEMENTS AND TRANSCRIPTIONAL CONTROL OF THE MOUSE ACETYLCHOLINESTERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; RECEPTOR GENES; EXPRESSION; MUSCLE; DIFFERENTIATION; BIOSYNTHESIS; MUTAGENESIS; ENHANCER; PROTEIN; REGION	The 5'-untranslated region of the mouse acetylcholinesterase gene has been characterized structurally by RNase protection, primer extension, and sequencing. Evidence has been obtained for the use of two alternative promoters in brain. Tissue-specific splicing to alternative acceptor sites in the 5'-untranslated exons occurs in brain, muscle, and erythropoietic cells. cis elements 5' of the cap site that is predominantly used in these tissues and cells have been analyzed by deletion analysis of promoter-reporter gene constructs and by site-specific mutagenesis. The cap site is found 107 base pairs (bp) 5' of the translation start site. This region is devoid of CAAT or TATA sequences; further in the 5' direction 50 and 70 bp are tandem Egr-1 sites. The putative promoter has been coupled to the open reading frame of a luciferase reporter gene. Deletion analysis shows that this region largely accounts for tissue-specific transcription seen upon transfection of neuronal and muscle cells. Mutagenesis of the Egr-1 sites results in a marked loss of reporter gene activity, further substantiating the importance of this region in the control of transcription. cis elements in the promoter differ from those found for the genes encoding the various subunits of the nicotinic acetylcholine receptor, and distinct differences in control of transcription are evident when the respective reporter genes are transfected into C2 muscle cells.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1987, CURRENT PROTOCOL MOL; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P61; EVANS S, 1987, J BIOL CHEM, V262, P4911; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; KAWASAKI E, 1989, AMPLIFICATIONS FORUM, V3, P4; KLARSFELD A, 1987, BIOCHIMIE, V69, P433, DOI 10.1016/0300-9084(87)90080-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LI Y, 1991, J BIOL CHEM, V266, P23083; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MASSOULIE J, 1988, HDB EXP PHARM, V86, P167; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MUMULA PW, 1988, DIABETES, V37, P1982; PAVLETICH NP, SCIENCE, V252, P819; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PRODY CA, 1991, J BIOL CHEM, V266, P22588; RACHINSKY TL, 1992, GENOMICS, V14, P511, DOI 10.1016/S0888-7543(05)80255-1; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V52, P7121; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER M, 1988, J BIOL CHEM, V85, P18879; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3	39	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3563	3572						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429032				2022-12-25	WOS:A1993KM16100083
J	PERRI, S; HELINSKI, DR				PERRI, S; HELINSKI, DR			DNA-SEQUENCE REQUIREMENTS FOR INTERACTION OF THE RK2 REPLICATION INITIATION PROTEIN WITH PLASMID ORIGIN REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE PLASMID-RK2; NUCLEOTIDE-SEQUENCE; BINDING-SITES; TRFA GENE; MAINTENANCE; REGION; PURIFICATION; MECHANISM; BACTERIA; INVITRO	Replication of plasmid RK2 in a variety of Gram-negative bacteria requires its origin of replication and the plasmid-encoded TrfA proteins (TrfA-33 and TrfA-44). The initiation of replication requires that the TrfA proteins bind to a series of 17-base pair (bp) direct repeats located within the RK2 origin. The conserved 17-bp repeats are arranged in tandem and are separated by less conserved spacer sequences of 4-6 bp in length. A series of plasmids containing one or two iterons, with or without the less conserved spacer sequences, were constructed to analyze the DNA sequence requirements for binding of TrfA-33 to the iterons. In addition to the analysis of TrfA binding in vitro, the plasmid constructs were examined for their ability to exert incompatibility toward an RK2 replicon in Escherichia coli. These analyses revealed that the conserved 17-bp iteron sequence itself is not sufficient for TrfA binding; the adjacent less conserved spacer sequences are also required. Site-specific mutagenesis was carried out to determine the importance of specific bases within the spacer sequence for binding activity and a consensus sequence for a TrfA-specific binding unit was determined. DNase I and methylation interference footprinting procedures were also carried out to characterize the TrfA-binding unit complex. Finally, it was shown that the binding of the TrfA-33 protein to two adjacent TrfA binding units on a DNA fragment is not substantially affected by the relative orientation or spacing between the two units.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1986, J BIOL CHEM, V261, P3548; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; Maniatis T., 1982, MOL CLONING; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASSON L, 1988, NUCLEIC ACIDS RES, V16, P413, DOI 10.1093/nar/16.2.413; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PERRI S, 1991, J BIOL CHEM, V266, P12536; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHMIDHAUSER TJ, 1985, J BACTERIOL, V164, P446, DOI 10.1128/JB.164.1.446-455.1985; SCHNEIDER GJ, 1991, J MOL BIOL, V221, P777, DOI 10.1016/0022-2836(91)80175-T; SHINGLER V, 1989, BIOCHIM BIOPHYS ACTA, V1007, P301, DOI 10.1016/0167-4781(89)90152-8; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; SUGIURA S, 1990, J BIOCHEM-TOKYO, V107, P369, DOI 10.1093/oxfordjournals.jbchem.a123052; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1984, EMBO J, V3, P57, DOI 10.1002/j.1460-2075.1984.tb01761.x; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1	28	34	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3662	3669						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429042				2022-12-25	WOS:A1993KM16100096
J	BOIVIN, D; GINGRAS, D; BELIVEAU, R				BOIVIN, D; GINGRAS, D; BELIVEAU, R			PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND PROTEIN CARBOXYL METHYLTRANSFERASE FROM RAT-KIDNEY CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ISOASPARTYL RESIDUES; ESCHERICHIA-COLI; DODECYL-SULFATE; METHYLATION; ASPARTYL; BRAIN; ISOZYMES; CARBOXYMETHYLASE; DEAMIDATION; RECOGNITION	Class II protein carboxy methyltransferases (EC 2.1.1.77) are known to exist predominantly in a soluble form in all cells studied so far. These enzymes have been purified to homogeneity from the cytosols of many mammalian tissues but not from membranes. We describe here the purification to apparent homogeneity of a membrane-associated protein carboxyl methyltransferase from the brush border membrane of rat kidney. The enzyme was purified by fast protein liquid chromatography on Superdex 75 and Mono-Q and by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis and consists of a single 27,300 poly. peptide. The purified enzyme recognizes exogenous substrate proteins such as ovalbumin and gamma-globulins as well as synthetic peptides containing a L-isoaspartyl residue but not a synthetic peptide containing a farnesylated C-terminal cysteine (S-farnesyl-LARYKC). The K(m) for S-adenosyl-L-methionine with ovalbumin as the substrate is 1.5 muM and the purified enzyme is sensitive to inhibition by S-adenosyl-L-homocysteine (K(i) = 0.3 muM). Peptide map obtained after Staphylococcus aureus V8 protease digestion of brush border membrane protein carboxyl methyltransferase showed a fragmentation pattern that was identical to that obtained for a soluble protein carboxyl methyltransferase purified according to the same procedure, indicating a high degree of homology. These results support the notion that class II protein carboxyl methyltransferases are not restricted to a cytosolic localization and show that the membrane-bound form of this enzyme shares many characteristics with known cytosolic protein carboxyl methyltransferases.	UNIV QUEBEC,DEPT CHIM BIOCHIM,RECH BIOTHERAPEUT MOLEC GRP,MEMBRANOL LAB,MONTREAL H3C 3P8,QUEBEC,CANADA	University of Quebec; University of Quebec Montreal								ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; Booth A G, 1974, Biochem J, V142, P575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN FC, 1984, BIOCHEM PHARMACOL, V33, P2921, DOI 10.1016/0006-2952(84)90217-X; CHRISTY KG, 1989, BIOTECHNIQUES, V7, P692; CLARKE S, 1981, BIOCHIM BIOPHYS ACTA, V670, P195, DOI 10.1016/0005-2795(81)90009-X; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; FU JC, 1991, J BIOL CHEM, V266, P14562; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; GINGRAS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P261, DOI 10.1016/0005-2736(91)90196-F; HAKLAI R, 1987, BIOCHEMISTRY-US, V26, P4200, DOI 10.1021/bi00388a004; INGROSSO D, 1991, BIOCHEM BIOPH RES CO, V175, P351, DOI 10.1016/S0006-291X(05)81242-2; IQBAL M, 1976, J NEUROCHEM, V27, P605, DOI 10.1111/j.1471-4159.1976.tb12289.x; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1990, PROTEIN METHYLATION, P195; KELLY MH, 1970, CLIN BIOCHEM, V3, P33, DOI 10.1016/S0009-9120(70)80053-4; KIM S, 1977, J BACTERIOL, V130, P839, DOI 10.1128/JB.130.2.839-845.1977; KIM S, 1978, ANAL BIOCHEM, V84, P415, DOI 10.1016/0003-2697(78)90059-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OTA IM, 1989, J BIOL CHEM, V264, P12879; OTA IM, 1987, J BIOL CHEM, V262, P8522; OTA IM, 1990, PROTEIN METHYLATION, P179; SELLINGER OZ, 1987, NEUROCHEM INT, V10, P155, DOI 10.1016/0197-0186(87)90122-7; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5	34	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2610	2615						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428937				2022-12-25	WOS:A1993KK81500054
J	YONEMOTO, W; MCGLONE, ML; TAYLOR, SS				YONEMOTO, W; MCGLONE, ML; TAYLOR, SS			N-MYRISTYLATION OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE CONVEYS STRUCTURAL STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATORY SUBUNIT; ACYLATED PROTEINS; ESCHERICHIA-COLI; MYRISTOYLATION; CELLS; REASSOCIATION; SPECIFICITY; EXPRESSION; MUTATION	Coexpression of the yeast N-myristyltransferase with the murine catalytic subunit of cAMP-dependent protein kinase in prokaryotic cells results in the N-myristylation of the recombinant catalytic subunit. The acylated recombinant catalytic subunit was purified following in vitro holoenzyme formation with a mutant form of the regulatory subunit and compared to the non-myristylated recombinant enzyme and to the mammalian porcine enzyme. All three enzymes are very similar in terms of their kinetic properties and their capacity to reassociate in vitro with the regulatory subunit to form holoenzyme. In contrast, the myristylated recombinant catalytic subunit is significantly more stable to thermal denaturation than the non-myristylated enzyme. Its thermal stability is now comparable to the mammalian enzyme. All three catalytic subunits are significantly more stable to thermal denaturation when they are part of the holoenzyme complex. Each shows an increase in T1/2 of 10-degrees-C. This study demonstrates that one function for the myristic acid at the NH, terminus of the catalytic subunit is to provide structural stability.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,DEPT CHEM,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego; Scripps Institution of Oceanography					NIGMS NIH HHS [GM19301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019301, R37GM019301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEE YMH, 1992, VIROLOGY, V187, P814, DOI 10.1016/0042-6822(92)90485-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NELSON NC, 1981, J BIOL CHEM, V256, P3743; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSON EN, 1985, J BIOL CHEM, V260, P3784; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	31	98	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2348	2352						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428909				2022-12-25	WOS:A1993KK81500018
J	FROST, GH; RHEE, K; THOMPSON, EA				FROST, GH; RHEE, K; THOMPSON, EA			GLUCOCORTICOID REGULATION OF THYMIDINE KINASE (TK-1) EXPRESSION IN L929 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLOGENIN MESSENGER-RNA; POST-TRANSCRIPTIONAL REGULATION; LYMPHOSARCOMA P1798 CELLS; PRO-OPIOMELANOCORTIN GENE; POLYMERASE CHAIN-REACTION; HORMONAL-REGULATION; MAMMALIAN-CELLS; RIBOSOMAL-RNA; DNA-BINDING; CYTOPLASMIC DEGRADATION	Glucocorticoids regulate the proliferation of mouse L cells. Incorporation of [H-3]thymidine is inhibited by 70-90% within 24 h after addition of 0.1 muM dexamethasone. This effect on L cells is completely reversible. The expression of the thymidine kinase gene (Tk-1) has been examined in L cells that have been treated with 0.1 muM dexamethasone for 24 h. Dexamethasone inhibits thymidine kinase activity 70-90% after 24 h. This is associated with a 90-95% decrease in Tk mRNA abundance. The decrease in Tk mRNA is not caused by a decrease in transcription of Tk-1, as shown by nuclear run-on transcription assays. Transient expression of the CAT (chloramphenicol acetyltransferase) gene, driven by the Tk-1 promoter, was not affected by dexamethasone, and transcription of stably integrated Tk minigenes in LMTk- cells was not affected by dexamethasone. This effect was observed regardless of whether Tk cDNA was fused to the simian virus 40 promoter or the mouse Tk-1 promoter region. Conversely, expression of thymidine kinase was inhibited when stable Tk+ transformants of LMTk- cells were exposed to glucocorticoids; and inhibition of expression was observed irrespective of the promoter that was used to drive transcription of the Tk minigenes. These data indicate that glucocorticoid regulation of Tk-1 in mouse L cells is, within the limits of detection of the assays used in these studies, entirely due to a posttranscriptional mechanism.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET F-45,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA24347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARBOUR KW, 1988, MOL ENDOCRINOL, V2, P78, DOI 10.1210/mend-2-1-78; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEATO M, 1987, BIOCHEM ACTION HORM, V1, P1; BERLINER DL, 1965, CANCER RES, V25, P1085; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK E, 1964, CANCER RES, V24, P841; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; CAVANAUGH AH, 1986, J BIOL CHEM, V261, P2738; CAVANAUGH AH, 1985, NUCLEIC ACIDS RES, V13, P3357, DOI 10.1093/nar/13.9.3357; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOKAL PK, 1990, J BIOL CHEM, V265, P16234; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; Gudas J. M., 1989, REGULATION PROLIFERA, P3; HACKNEY JF, 1970, MOL PHARMACOL, V6, P500; HART RP, 1982, J BIOL CHEM, V257, P1706; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KEMPER BW, 1969, MOL PHARMACOL, V5, P507; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, V1; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KNIGHT GB, 1989, JPN J CANCER RES, V80, P493, DOI 10.1111/j.1349-7006.1989.tb01664.x; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAHAJAN PB, 1987, J BIOL CHEM, V262, P16150; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MARODER M, 1990, NUCLEIC ACIDS RES, V18, P1153, DOI 10.1093/nar/18.5.1153; MCKENZIE EA, 1990, MOL ENDOCRINOL, V4, P807, DOI 10.1210/mend-4-6-807; MERRILL GF, 1984, MOL CELL BIOL, V4, P1777, DOI 10.1128/MCB.4.9.1777; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; NIELSEN DA, 1990, MOL CELL BIOL, V10, P371, DOI 10.1128/MCB.10.1.371; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PASTORI RL, 1991, MOL ENDOCRINOL, V5, P461, DOI 10.1210/mend-5-4-461; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PFAHL M, 1986, BIOCHEM ACTION HORM, V13, P325; PRATT WB, 1966, J BIOL CHEM, V241, P5244; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; RUHMANN AG, 1967, J INVEST DERMATOL, V49, P123, DOI 10.1038/jid.1967.113; RUHMANN AG, 1965, ENDOCRINOLOGY, V76, P916, DOI 10.1210/endo-76-5-916; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SEIFERT R, 1966, ACTA ENDOCRINOL-COP, V53, P189, DOI 10.1530/acta.0.0530189; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SILVER G, 1990, J BIOL CHEM, V265, P3134; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON EA, 1986, STEROID STEROL HORMO, P227; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WEINER FR, 1987, J BIOL CHEM, V262, P6955; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WOOD KM, 1984, MOL CELL BIOL, V4, P822, DOI 10.1128/MCB.4.5.822; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	76	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6748	6754						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454647				2022-12-25	WOS:A1993KT36800096
J	UMBRICHT, CB; ERDILE, LF; JABS, EW; KELLY, TJ				UMBRICHT, CB; ERDILE, LF; JABS, EW; KELLY, TJ			CLONING, OVEREXPRESSION, AND GENOMIC MAPPING OF THE 14-KDA SUBUNIT OF HUMAN REPLICATION PROTEIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; METAL CHELATE ADSORBENT; POLYMERASE-ALPHA; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; PURIFIED PROTEINS; SV40 ORIGIN; HUMAN-GENE	Replication protein A (RPA) is a three-subunit protein that plays a central role in eukaryotic DNA replication, recombination, and repair. We have previously reported the cloning and bacterial expression of the 70- and 32-kDa subunits of human RPA (hRPA). We have now cloned the 14-kDa subunit (hRPA3) from a HeLa cell cDNA library. The hRPA3 cDNA is a 692-base pair sequence that contains an open reading frame encoding a protein of 121 amino acids with a calculated molecular mass of 13.6 kDa. The deduced amino acid sequence shows only limited similarity to the small subunit of yeast RPA and is unrelated to any other protein in the current data banks. A recombinant protein containing a short histidine tag at the NH2 terminus has been purified in good yield from Escherichia coli hy metal-chelate affinity chromatography. Antibodies prepared against recombinant hRPA3 recognize the native protein and inhibit SV40 DNA replication in vitro. We have localized the genes for the 70-, 32-, and 14-kDa subunits to chromosomes 17, 1, and 7, respectively, using polymerase chain reaction amplification of genomic DNA from rodent-human hybrid cell lines. Since RPA appears to be involved in several fundamental cellular processes, the physical mapping of the RPA genes may be useful in identifying possible human genetic defects associated with RPA deficiency or dysfunction.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT & MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	UMBRICHT, CB (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.			Jabs, Ethylin/0000-0001-8983-5466	NATIONAL CANCER INSTITUTE [K11CA001469] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042780] Funding Source: NIH RePORTER; NCI NIH HHS [5 K11 CAO1469-04] Funding Source: Medline; NHGRI NIH HHS [HG00373] Funding Source: Medline; NIGMS NIH HHS [GM42780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHAGANTI RSK, 1991, ANN GENET-PARIS, V34, P206; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1991, COLD SH Q B, V56, P315; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ERDILE LF, 1991, COLD SH Q B, V56, P303; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HARLOW E, 1988, ANTIBODIES LABORATOR; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KU DH, 1989, SOMAT CELL MOLEC GEN, V15, P297, DOI 10.1007/BF01534969; KUNZE N, 1989, HUM GENET, V84, P6, DOI 10.1007/BF00210661; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; VIRSHUP DM, 1989, MOL MECHANISMS DNA R, P127; WANG TSF, 1985, P NATL ACAD SCI USA, V82, P5270, DOI 10.1073/pnas.82.16.5270; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	74	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6131	6138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454588				2022-12-25	WOS:A1993KT36800012
J	ARAI, K; SHIMAYA, A; HIRATANI, N; OHKUMA, S				ARAI, K; SHIMAYA, A; HIRATANI, N; OHKUMA, S			PURIFICATION AND CHARACTERIZATION OF LYSOSOMAL H+-ATPASE - AN ANION-SENSITIVE V-TYPE H+-ATPASE FROM RAT-LIVER LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; CHROMAFFIN GRANULE MEMBRANES; TRANSLOCATING COMPLEX; NEUROSPORA-CRASSA; BOVINE KIDNEY; PLANT-CELLS; OAT ROOTS; VACUOLAR; RECONSTITUTION; IDENTIFICATION	Lysosomal H+-ATPase was purified to homogeneity from rat liver lysosomes. It is a bafilomycin A1-sensitive Mg2+-ATPase, which reacts with antibodies against the 16- and 70-kDa subunits of vacuolar H+-ATPase (Nezu, J., Motojima, K., Tamura, H., and Ohkuma, S. (1992) J. Biochem. (Tokyo) 112, 212-219), and has been separated from both the N-ethylmaleimide (NEM)-sensitive/bafilomycin A1-insensitive Mg2+-ATPase (ATPase I) and the NEM-insensitive Mg2+/-Ca2+-ATPase (ATPase II) (Hayashi, H., Arai, K., Sato, O., Shimaya, A., Sai, Y., and Ohkuma, S. (1992) Chem. Pharm. Bull. 40, 2783-2786). The purified enzyme had the subunit structure of vacuolar H+-ATPase, consisting of 110-, 70-, 56-, 42-, 39-, 34-, (32-,) and 16-kDa proteins. It had optimal activity at a pH of 7.0-8.0, with an apparently single K(m) value for ATP of 95 muM. It hydrolyzed ATP greater-than-or-equal-to dATP >> GTP, ITP >> UTP, but not CTP, and was inhibited by ADP. It demonstrated divalent cation specificity in the order of Mg2+, Mn2+ > Fe2+, Co2+ > Ca2+. Among various anions, Cl-, Br-, and F- activated ATPase activity, whereas NO3- inhibited activity. It was inhibited not only by bafilomycin A1 but also by NEM, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, quercetin, and dicyclohexylearbodiimide. The purified enzyme was incorporated into proteoliposomes where its proton pump activity was reconstituted. This suggested that the isolated enzyme maintains its H+ translocation activity. These findings suggest that the isolated enzyme is an anion-sensitive vacuolar type H+-ATPase that functions as a lysosomal proton pump.	KANAZAWA UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, TAKARA MACHI 13-1, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University			ARAI, KUNIZO/D-8387-2015	ARAI, KUNIZO/0000-0002-8373-1137				ADACHI I, 1990, J BIOL CHEM, V265, P967; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616; BENNETT AB, 1984, PLANT PHYSIOL, V74, P538, DOI 10.1104/pp.74.3.538; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHURCHILL KA, 1983, PLANT PHYSIOL, V71, P610, DOI 10.1104/pp.71.3.610; CIDON S, 1986, J BIOL CHEM, V261, P9222; DELLANTONE P, 1988, ARCH BIOCHEM BIOPHYS, V262, P314, DOI 10.1016/0003-9861(88)90194-4; DELLANTONE P, 1979, BIOCHEM BIOPH RES CO, V86, P180, DOI 10.1016/0006-291X(79)90398-X; DSOUZA MP, 1987, P NATL ACAD SCI USA, V84, P6980, DOI 10.1073/pnas.84.20.6980; EZAKI J, 1992, J BIOCHEM, V112, P33, DOI 10.1093/oxfordjournals.jbchem.a123861; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HAYASHI H, 1992, CHEM PHARM BULL, V40, P2783, DOI 10.1248/cpb.40.2783; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MARGOLIS J, 1968, ANAL BIOCHEM, V25, P347, DOI 10.1016/0003-2697(68)90109-7; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1987, BIOCHEM BIOPH RES CO, V149, P140, DOI 10.1016/0006-291X(87)91615-9; MORIYAMA Y, 1984, J BIOCHEM-TOKYO, V95, P995, DOI 10.1093/oxfordjournals.jbchem.a134726; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; NISTOR M, 1976, Studii si Cercetari de Biologie, V28, P31; OHKUMA S, 1984, SEIKAGAKU, V56, P1499; OHKUMA S, 1990, ACTA HISTOCHEM CYTOC, V23, P41, DOI 10.1267/ahc.23.41; OHKUMA S, 1983, J BIOCHEM, V94, P1935, DOI 10.1093/oxfordjournals.jbchem.a134547; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; OHKUMA S, 1989, METHOD ENZYMOL, V174, P131; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PAZOLES CJ, 1980, J BIOL CHEM, V255, P7863; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES JP, 1984, LYSOSOM BIOL PATHOL, V7, P175; RODMAN JS, 1991, EXP CELL RES, V192, P445, DOI 10.1016/0014-4827(91)90063-Z; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHARSCHMIDT BF, 1987, ANNU REV PHYSIOL, V49, P69; SCHNEIDER DL, 1977, J MEMBRANE BIOL, V34, P247, DOI 10.1007/BF01870302; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; SCHNEIDER DL, 1988, METHOD ENZYMOL, V157, P3858; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SPANSWICK RM, 1989, ANN NY ACAD SCI, V574, P180; TSUCHIYA T, 1984, J BIOCHEM-TOKYO, V96, P1593, DOI 10.1093/oxfordjournals.jbchem.a134989; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110; WHITE MD, 1976, BIOCHIM BIOPHYS ACTA, V436, P567, DOI 10.1016/0005-2736(76)90441-7; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859; YEH HI, 1991, HEPATOLOGY, V13, P523, DOI 10.1016/0270-9139(91)90307-H; ZANG J, 1992, J BIOL CHEM, V267, P9773	68	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5649	5660						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449928				2022-12-25	WOS:A1993KR82200046
J	GRABAREK, J; WARE, JA				GRABAREK, J; WARE, JA			PROTEIN-KINASE-C ACTIVATION WITHOUT MEMBRANE CONTACT IN PLATELETS STIMULATED BY BRYOSTATIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZED CALCIUM-CONCENTRATION; ADRENAL CHROMAFFIN CELLS; PHORBOL ESTER BINDING; PLASMA-MEMBRANE; RABBIT PLATELETS; ARACHIDONIC-ACID; 2ND MESSENGERS; TRANSLOCATION; PHOSPHORYLATION; RECEPTOR	The tumor promoter phorbol myristate acetate (PMA) directly activates protein kinase C (PKC) and, in human platelets, induces aggregation, release of granular contents, mobilization of intracellular Ca2+ as detected by the photoprotein aequorin, and phosphorylation of the 47-kDa substrate (p47) of PKC. Whether PKC activation by PMA or other agonists requires translocation of PKC from the cytoplasm to the lipids of the platelet surface membrane, however, is not known. Bryostatin-1, a macrocyclic lactone that binds to PKC at or near the PMA-binding site and thus blocks PMA's proliferative effects, induced concentration-dependent p47 phosphorylation, platelet aggregation, release of dense granule contents, and a rise in cytoplasmic Ca2+ (ED50 = 2.0 nM) in intact aequorin-loaded platelets. Neither alpha-, beta-, delta-, or zeta-PKC isozymes translocated to the plasma membrane following bryostatin-1, although translocation of both alpha- and beta-PKC isozymes was seen in PMA-stimulated platelets. In a cell-free assay, bryostatin-1 activated PKC purified from platelets if the membrane-derived lipid phosphatidyl serine was present; however, if 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid or arachidonic acid, two lipid products formed in the cytoplasm of activated platelets, were present, no membrane-derived lipids were required for bryostatin-induced PKC activation. Thus, phosphorylation of PKC substrates and associated functional changes do not require isozyme translocation to the surface membrane, even when these events are induced by a direct activator of PKC.	BETH ISRAEL HOSP, DEPT MED,DIV CARDIOVASC,HARVARD THORNDIKE LAB, GZ 409,330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL38820, HL02271] Funding Source: Medline; NIDA NIH HHS [DA06306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038820, R29HL038820, K04HL002271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA006306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BELL RM, 1991, J BIOL CHEM, V266, P4661; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BOTO WMO, 1991, CELL REGUL, V2, P95, DOI 10.1091/mbc.2.2.95; Brass LF, 1991, BIOCH PLATELET ACTIV, P1176; CHANG JD, 1992, CLIN RES, V40, pA225; DALE IL, 1989, CANCER RES, V49, P3242; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DREXLER HG, 1990, EUR J IMMUNOL, V20, P119, DOI 10.1002/eji.1830200118; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FAN XT, 1990, BIOCHEM BIOPH RES CO, V169, P933, DOI 10.1016/0006-291X(90)91983-Y; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FEARON CW, 1987, J BIOL CHEM, V262, P9515; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FONLUPT P, 1991, THROMB RES, V63, P239, DOI 10.1016/0049-3848(91)90287-7; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; KIKKAWA U, 1984, ADV CYCLIC NUCL PROT, V17, P437; KISS Z, 1991, BIOCHEM J, V276, P505, DOI 10.1042/bj2760505; KRAFT AS, 1989, CANCER RES, V49, P1287; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KROLL MH, 1989, BLOOD, V74, P1181; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; MAY WS, 1987, P NATL ACAD SCI USA, V84, P8483, DOI 10.1073/pnas.84.23.8483; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; NISHIKAWA M, 1988, BIOCHEM PHARMACOL, V37, P3079, DOI 10.1016/0006-2952(88)90304-8; NISHIZUKA Y, 1988, CANCER, V10, P1892; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1991, J BIOL CHEM, V266, P8696; SAITOH M, 1992, THROMB HAEMOSTASIS, V67, P182; SALARI H, 1990, BIOCHEM J, V267, P689, DOI 10.1042/bj2670689; SHARKIS SJ, 1990, BLOOD, V76, P716; SHEARMAN MS, 1989, FEBS LETT, V243, P177, DOI 10.1016/0014-5793(89)80125-5; TALLANT EA, 1987, BIOCHIM BIOPHYS ACTA, V929, P40, DOI 10.1016/0167-4889(87)90239-4; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRENN G, 1988, J IMMUNOL, V140, P433; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; WARE JA, 1989, AM J PHYSIOL, V256, pC35, DOI 10.1152/ajpcell.1989.256.1.C35; WARE JA, 1985, BIOCHEM BIOPH RES CO, V133, P98, DOI 10.1016/0006-291X(85)91846-7; WARE JA, 1986, J CLIN INVEST, V77, P878, DOI 10.1172/JCI112385; WARREN BS, 1988, CANCER RES, V48, P5984; WATANABE M, 1988, BIOCHEM BIOPH RES CO, V152, P642, DOI 10.1016/S0006-291X(88)80087-1; WHEELERJONES CPD, 1989, BIOCHEM J, V263, P969, DOI 10.1042/bj2630969; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	51	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5543	5549						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449916				2022-12-25	WOS:A1993KR82200032
J	CERVELLA, P; SILENGO, L; PASTORE, C; ALTRUDA, F				CERVELLA, P; SILENGO, L; PASTORE, C; ALTRUDA, F			HUMAN BETA(1)-INTEGRIN GENE-EXPRESSION IS REGULATED BY 2 PROMOTER REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; PLATELET GLYCOPROTEIN-IIIA; HUMAN FIBRONECTIN RECEPTOR; TISSUE-SPECIFIC EXPRESSION; CELL-SURFACE RECEPTORS; HEMATOPOIETIC-CELLS; ADHESION RECEPTORS; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; NUCLEAR FACTOR	We report the cloning of two full-length cDNAs coding for the human beta1-integrin which diverge from each other for their 5'-untranslated sequences. Characterization of a genomic clone containing these two sequences showed that they are contiguous, spaced by 261 nucleotides, and both followed by donor splice sites. Analysis by primer extension and transient transfection in a human osteogenic sarcoma cell line (MG-63) demonstrated the existence of two independent promoters for transcription initiation. The two promoter regions are very G + C-rich, and lack both a TATA box and a CAAT box. Northern blot analysis showed that transcripts starting from the distal promoter (with respect to the first coding exon) are at least 20-fold more abundant than transcripts originating from the proximal one. The levels of both transcripts increase after transforming growth factor-beta1 induction, however, mRNAs originating from the proximal promoter increase at an higher extent. Reverse transcriptase/polymerase chain reaction analysis performed on different human tissues and cell lines revealed that, while the distal promoter is ubiquitously active, the proximal promoter is not. These findings suggest a possible complex pattern for regulation of the human beta1-integrin gene expression.	UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY	University of Turin				CERVELLA, Piero/0000-0002-0642-6059				ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DUSH MK, 1988, NUCLEIC ACIDS RES, V16, P8509, DOI 10.1093/nar/16.17.8509; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIANCOTTI FG, 1986, J CELL BIOL, V103, P429, DOI 10.1083/jcb.103.2.429; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LANZA F, 1990, J BIOL CHEM, V265, P18098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUFSON RA, 1990, J IMMUNOL, V145, P2333; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PATEL VP, 1984, SCIENCE, V224, P996, DOI 10.1126/science.6585955; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sambrook J, 1989, MOL CLONING LABORATO; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANTRUNG N, 1988, ANAL BIOCHEM, V171, P404; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	54	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5148	5155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444890				2022-12-25	WOS:A1993KP88400085
J	RINDT, H; GULICK, J; KNOTTS, S; NEUMANN, J; ROBBINS, J				RINDT, H; GULICK, J; KNOTTS, S; NEUMANN, J; ROBBINS, J			INVIVO ANALYSIS OF THE MURINE BETA-MYOSIN HEAVY-CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VENTRICULAR ALPHA-MYOSIN; MESSENGER-RNA SEQUENCES; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MULTIGENE FAMILY; SKELETAL-MUSCLE; TRANSGENIC MICE; RABBIT HEARTS; ACTIN GENE; EXPRESSION	The 5' upstream region of the murine beta-myosin heavy chain (MHC) gene has been isolated and tested for its ability to drive gene expression in transgenic mice. Three classes of transgenic mice were generated. The constructs contained approximately 5000, 2500, and 600 base pairs of beta-MHC upstream sequence fused to the chloramphenicol acetyltransferase gene and were termed beta5, beta2.5, and beta.6, respectively. Muscle-specific expression was observed with all three constructs. However, only the beta5 lines directed high levels of muscle-specific transgene expression in both pre- and postbirth mice. Expression driven by the two shorter constructs was two to three orders of magnitude lower when the chloramphenicol acetyltransferase specific activities were compared. These data suggest that a distal-positive element directs high levels of gene expression in the ventricle and in slow skeletal muscles. Analyses of transgene expression during heart maturation revealed that some of the beta5 lines were not able to respond in an appropriate manner to developmental transcriptional cues. Unlike the endogenous beta-MHC gene, which is down regulated in the ventricles around the time of birth, reporter gene expression in the majority of the lines generated was not shut off in the ventricles of the adult animals. These data indicate that high levels of muscle-specific beta-MHC gene expression are dependent upon the combinatorial interactions of a number of sequence elements that are distributed over a large region of the gene's upstream sequence.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NHLBI NIH HHS [HL41496, HL22619, HL46826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826, P01HL022619, P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHELER KR, 1992, J BIOL CHEM, V267, P12979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BUTLERBROWNE GS, 1984, DEV BIOL, V102, P324, DOI 10.1016/0012-1606(84)90197-0; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P5564; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GULICK J, 1991, J BIOL CHEM, V266, P9180; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; Hogan B, 1986, MANIPULATING MOUSE E, P89; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KROPP KE, 1987, J BIOL CHEM, V262, P16536; KURABAYASHI M, 1988, J CLIN INVEST, V82, P524, DOI 10.1172/JCI113627; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIEW CC, 1986, P NATL ACAD SCI USA, V83, P3175, DOI 10.1073/pnas.83.10.3175; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MERCADIER JJ, 1987, J AM COLL CARDIOL, V9, P1024, DOI 10.1016/S0735-1097(87)80303-0; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PARKERTHORNBURG J, 1992, DEV BIOL, V150, P99, DOI 10.1016/0012-1606(92)90010-E; ROBBINS J, 1989, GENE, V85, P541, DOI 10.1016/0378-1119(89)90449-6; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SAMUEL JL, 1986, AM J PHYSIOL, V250, pH333, DOI 10.1152/ajpheart.1986.250.3.H333; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; SINHA AM, 1984, J BIOL CHEM, V259, P6674; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TSUCHIMOCHI H, 1984, J CLIN INVEST, V74, P662, DOI 10.1172/JCI111466; Walter C A, 1989, Biotechniques, V7, P1065; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	60	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5332	5338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444907				2022-12-25	WOS:A1993KP88400109
J	WATERBORG, JH				WATERBORG, JH			HISTONE SYNTHESIS AND TURNOVER IN ALFALFA - FAST LOSS OF HIGHLY ACETYLATED REPLACEMENT HISTONE VARIANT H3.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ERYTHROCYTES; NUCLEOSOME DISSOLUTION; ACTIVE CHROMATIN; MESSENGER-RNAS; TRANSCRIPTION; GENE; CELLS; H-3; PLANTS; MAIZE	Histone synthesis in alfalfa tissue culture cells was studied by labeling with tritiated lysine, purification of histone proteins by reversed-phase high pressure liquid chromatography, and fluorography of acid/urea/Triton X-100 polyacrylamide gels. Minor histone variant H3.2 was synthesized twice as fast as major variant H3.1. The predicted difference in histone H3 variant turnover was examined during continued growth. More than 50% of newly synthesized histone H3.2 and 20% of new H3.1 were lost from chromatin over a period of 100 h. This produced a ratio between the stable remaining portions of each new histone H3 variant protein identical to that of the steady-state histone H3 variants. The labile portion of new histone H3.2 (half-life of 20 h) was rapidly lost specifically from transcriptionally active chromatin as judged by the acetylation level of nearly 1.5 acetylated lysines/histone molecule, a level 50% higher than the acetylation in histone H3.2 overall and three times that of histone H3.1. These results and the constitutive level of H3.2 gene expression identify histone H3.2 of alfalfa as a functional replacement histone variant. The extent of its preferential assembly into active chromatin nucleosomes and the rapid rate of its subsequent loss indicate significant dissolution of plant nucleosomes during gene transcription.			WATERBORG, JH (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV CELL BIOL & BIOPHYS,RM 414 BSB,5100 ROCKHILL RD,KANSAS CITY,MO 64110, USA.		Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634				ATERBORG JH, 1992, PLANT MOL BIOL, V18, P181; BAVYKIN SG, 1988, FEBS LETT, V228, P149, DOI 10.1016/0014-5793(88)80605-7; BEDOYAN J, 1992, J BIOL CHEM, V267, P5996; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; CHABOUTE ME, 1988, GENE, V71, P217, DOI 10.1016/0378-1119(88)90095-9; CHAUBET N, 1992, J MOL BIOL, V225, P569, DOI 10.1016/0022-2836(92)90943-E; CHAUBET N, 1988, NUCLEIC ACIDS RES, V16, P1295, DOI 10.1093/nar/16.4.1295; GROVE GW, 1984, BIOCHEMISTRY-US, V23, P4436, DOI 10.1021/bi00314a030; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; HOFMANN D, 1989, FEBS LETT, V256, P123, DOI 10.1016/0014-5793(89)81731-4; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KAPROS T, 1992, PLANT PHYSIOL, V98, P621, DOI 10.1104/pp.98.2.621; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LINDSEY GG, 1991, J MOL BIOL, V218, P805, DOI 10.1016/0022-2836(91)90268-B; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; MARZLUFF WF, 1989, HISTONES OTHER BASIC, P319; MOEHS CP, 1991, 3RD INT PLANT MOL BI; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFEFFER U, 1988, EXP CELL RES, V178, P25, DOI 10.1016/0014-4827(88)90374-6; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; SPIKER S, 1982, J BIOL CHEM, V257, P4250; STEIN GS, 1989, HISTONES OTHER BASIC, P269; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; TSVETKOV S, 1989, EXP CELL RES, V180, P94, DOI 10.1016/0014-4827(89)90215-2; URBAN MK, 1979, BIOCHEMISTRY-US, V18, P3952, DOI 10.1021/bi00585a017; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WALKER J, 1990, J BIOL CHEM, V265, P5736; WATERBORG JH, 1991, PLANT PHYSIOL, V96, P453, DOI 10.1104/pp.96.2.453; WATERBORG JH, 1987, ARCH BIOCHEM BIOPHYS, V256, P167, DOI 10.1016/0003-9861(87)90435-8; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006; WATERBORG JH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P324, DOI 10.1016/0167-4781(90)90105-B; WELLS D, 1991, NUCLEIC ACIDS RES, V19, P2173, DOI 10.1093/nar/19.suppl.2173; WELLS JRE, 1989, HISTONES OTHER BASIC, P253; WIDMER RM, 1984, EMBO J, V3, P1635, DOI 10.1002/j.1460-2075.1984.tb02022.x; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; WU SC, 1988, PLANT MOL BIOL, V11, P641, DOI 10.1007/BF00017464; WU SC, 1989, NUCLEIC ACIDS RES, V17, P3057, DOI 10.1093/nar/17.8.3057; WUNSCH AM, 1990, CELL DIFFER DEV, V30, P19, DOI 10.1016/0922-3371(90)90070-D; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; Zweidler A, 1984, HISTONE GENES STRUCT, P339	43	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4912	4917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444869				2022-12-25	WOS:A1993KP88400054
J	BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C				BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C			LEUKEMOGENICITY OF V-MYB-TRANSFORMED MONOBLASTS CELLS CAN BE MODULATED BY NORMAL BONE-MARROW ENVIRONMENT	ONCOGENE			English	Article							MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; BETA-GALACTOSIDASE; RECOMBINANT RETROVIRUS; MYELOMONOCYTIC CELLS; LINEAGE ANALYSIS; C-MYB; EXPRESSION; ONCOGENE; DIFFERENTIATION	The avian myeloblastosis virus (AMV) causes monoblastic leukemia in the chick. Two non-producer clones of AMV-transformed monoblasts, BM2/C3A and BM2L/A2B5, have been described (see Bottazzi et al., this issue). They differ in their growth requirements and in their ability to induce leukemia when injected into the chick embryo. We first genetically tagged these clones by retroviral infection with a vector expressing the bacterial lacZ gene. Then, we injected the lacZ-positive cells via the chorioaltantoic vein into chick embryos. With BM2L/A2B5 cells, the bone marrow of the injected birds was rapidly invaded by lacZ-positive cells. In addition, these cells rapidly overgrew cultures of bone marrow cells derived from injected animals. Conversely, the growth of BM2/C3A was inhibited in the injected animals and only a few blue cells, with the morphology of macrophages, were detected in cultures of bone marrow cells. We developed an in vitro assay to mimic in vitro the differential growth of BM2/C3A and BM2L/A2B5 observed in vivo. These data strongly suggest that BM2/C3A cells retain their ability to differentiate into macrophages in the normal bone marrow environment and that BM2L/A2B5 cells differ from BMC/C3A in the loss of this capacity.	UNIV LYON 1,INST CHIM & BIOL MOLEC & CELLULAIRE,CNRS,UA 92,F-69622 VILLEURBANNE,FRANCE; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BAGNIS, C (corresponding author), ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019	Cosset, Francois-Loic/0000-0001-8842-3726				BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COSSET FL, 1991, J VIROL, V65, P3388, DOI 10.1128/JVI.65.6.3388-3394.1991; CRAIG RW, 1984, CANCER RES, V44, P442; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MACGREEGOR JM, 1989, GENE EXPRESSION IN V; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MANIATIS T, 1983, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, CONTINUOUS LINES AMV; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY T; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STRAIR RK, 1990, NUCLEIC ACIDS RES, V18, P4759, DOI 10.1093/nar/18.16.4759; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014	32	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					737	743						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437857				2022-12-25	WOS:A1993KN00800026
J	POWERS, DD; LENTZ, BR				POWERS, DD; LENTZ, BR			SIMULATION OF PROTHROMBIN PROTEOLYSIS BY THE FULL PROTHROMBINASE ASSEMBLED ON VARIED PHOSPHOLIPID SURFACES - APPENDIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; VARYING COMPOSITION; FACTOR-XA; BINDING; VESICLES; COMPLEX; MEMBRANES; PROTEIN		UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS CB 7260,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045916] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45916] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LECOMPTE MF, 1980, BIOCHEMISTRY-US, V19, P3434, DOI 10.1021/bi00556a005; LENTZ BR, 1989, BIOCHEMISTRY-US, V28, P7459; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PEI G, 1993, J BIOL CHEM, V268, P3226; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; ROSING J, 1980, J BIOL CHEM, V255, P274; TRACY PB, 1981, J BIOL CHEM, V256, P743; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047	16	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3234	3237						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429001				2022-12-25	WOS:A1993KM16100035
J	HATTORI, A; TANAKA, E; MURASE, K; ISHIDA, N; CHATANI, Y; TSUJIMOTO, M; HAYASHI, K; KOHNO, M				HATTORI, A; TANAKA, E; MURASE, K; ISHIDA, N; CHATANI, Y; TSUJIMOTO, M; HAYASHI, K; KOHNO, M			TUMOR-NECROSIS-FACTOR STIMULATES THE SYNTHESIS AND SECRETION OF BIOLOGICALLY-ACTIVE NERVE GROWTH-FACTOR IN NONNEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ENZYME-IMMUNOASSAY; RAT SCIATIC-NERVE; MOLECULAR-CLONING; FACTOR RECEPTOR; EXPRESSION; NGF; ANTIBODIES; PROTEINS; INTERLEUKIN-1; REGENERATION	Tumor necrosis factor-alpha (TNF) markedly stimulates the synthesis and secretion of immunoreactive nerve growth factor (NGF) in quiescent mouse fibroblasts, which is a result of increase in the NGF mRNA level. NGF produced by TNF-treated fibroblasts has a molecular mass of 13 kDa on SDS-polyacrylamide gel electrophoresis, which is consistent in size with the subunit of mouse beta-NGF, and induces neurite outgrowth in paravertebral sympathetic neurons. Several peptide growth factors such as basic fibroblast growth factor (bFGF) and epidermal growth factor also stimulate NGF production in the cells, but not platelet-derived growth factor. The dose responses of TNF and bFGF to stimulate NGF production in the cells are, respectively, similar to those to induce cell proliferation. However, no correlation is observed between the ability of these growth factors to stimulate NGF production and that to induce cell proliferation. Thus, the stimulation of NGF production in the cells seems to be a specific activity of TNF and some other growth factors. TNF stimulates the synthesis and secretion of NGF also in other cells such as human glioblastoma cells. These findings suggest that TNF plays a role in regulating neuronal cell function through an indirect mechanism by which it stimulates NGF production in glial cells and fibroblasts.	GIFU PHARMACEUT UNIV, DEPT BIOL, 5-6-1 MITAHORA HIGASHI, GIFU 502, JAPAN; GIFU PHARMACEUT UNIV, DEPT MOLEC BIOL, GIFU 502, JAPAN; SUNTORY INST BIOMED RES, OSAKA 618, JAPAN	Gifu Pharmaceutical University; Gifu Pharmaceutical University; Suntory Holdings Ltd								ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FURUKAWA Y, 1984, J BIOL CHEM, V259, P1259; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; LE JM, 1987, LAB INVEST, V56, P234; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MURASE K, 1991, BIOCHEM INT, V25, P29; MURASE K, 1990, BIOCHEM INT, V22, P807; NISHIZAWA N, 1990, CELL REGUL, V1, P747, DOI 10.1091/mbc.1.10.747; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAFFER HE, 1981, ANAL BIOCHEM, V115, P113, DOI 10.1016/0003-2697(81)90533-9; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206; ULLRICH A, 1983, COLD SPRING HARB SYM, V48, P435, DOI 10.1101/SQB.1983.048.01.048; VARON S, 1972, METHODS NEUROCHEMIST, V3, P203; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VILCEK J, 1992, TUMOR NECROSIS FACTO, P269; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012	40	154	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2577	2582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428934				2022-12-25	WOS:A1993KK81500049
J	HOROWITZ, PM; BUTLER, M				HOROWITZ, PM; BUTLER, M			INTERACTIVE INTERMEDIATES ARE FORMED DURING THE UREA UNFOLDING OF RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINIUM CHLORIDE; DENATURED RHODANESE; STATE	Structural transitions have been studied on the pathway for urea denaturation of rhodanese. Unlike guanidinium hydrochloride, urea gives no visible precipitation. Increasing urea concentrations cause a transit ion in which the enzyme activity is completely lost by 4.5 M urea, and there is a shift of the intrinsic fluorescence maximum from 335 nm for the native enzyme to 350 nm. There is a maximum exposure of organized hydrophobic surfaces at 4.5 M urea as reported by the fluorescence of 1,1'-bi(4-anilino)naphthalene-5,5'-disulfonic acid. Above 4.5 M urea, this probe reports the progressive loss of organized hydrophobic surfaces. The polarization of the intrinsic fluorescence falls with increasing urea concentrations in a complex transition showing that rhodanese flexibility increases in at least two phases. Rhodanese becomes increasingly susceptible to digestion by subtilisin between 3.5 and 4.5 M urea, giving rise to large fragments. At urea concentrations >5 M, rhodanese is completely digested. There is a small increase in the rate of sulfhydryl accessibility between 3.5 and 4.5 M urea, but there is a large increase in the sulfhydryl accessibility above 4.5 M urea. Dimethyl suberimidate cross-linking shows the presence of associated species in 3-5 M urea, but there are few cross-linkable species at lower or higher urea concentrations. These results are consistent with a model i n which urea unfolding of rhodanese is associated with the initial production of a species having organized regions of structure with exposed hydrophobic surfaces separated by flexible elements.			HOROWITZ, PM (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOW SF, 1986, J BIOL CHEM, V261, P7264; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; PENSA B, 1977, BIOCHIM BIOPHYS ACTA, V484, P368, DOI 10.1016/0005-2744(77)90092-4; Ploegman J.H., 1978, NATURE, V273, P1245; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811; ZARDENETA G, 1993, IN PRESS EUR J BIOCH	24	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2500	2504						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428927				2022-12-25	WOS:A1993KK81500040
J	WESTAWAY, SK; BELFORD, HG; APOSTOL, BL; ABELSON, J; GREER, CL				WESTAWAY, SK; BELFORD, HG; APOSTOL, BL; ABELSON, J; GREER, CL			NOVEL ACTIVITY OF A YEAST LIGASE DELETION POLYPEPTIDE - EVIDENCE FOR GTP-DEPENDENT TRANSFER-RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PURIFICATION; ENDONUCLEASE; PRECURSORS; PROTEIN; GENE	Yeast tRNA ligase possesses multiple activities which are required for the joining of tRNA halves during the tRNA splicing process: cyclic phosphodiesterase, kinase, adenylylate synthetase, and ligase. A deletion polypeptide of a dihydrofolate reductase-ligase fusion protein, designated DAC, was previously shown to join tRNA halves although ATP-dependent kinase activity was not measurable in the assay used. We describe here a characterization of the mechanism of joining used by DAC and the structure of the tRNA product. DAC produces a joined tRNA and a splice junction with a structure identical to that produced by DAKC, the full-length dihydrofolate reductase-ligase fusion. Furthermore, DAC can use GTP as the sole cofactor in the joining reaction, in contrast to DAKC, which can only complete splicing in the presence of ATP. Both enzymes exhibit GTP-dependent kinase activity at 100-fold greater efficiency than with ATP. These results suggest that a potential function for the center domain of tRNA ligase (missing in DAC) is to provide structural integrity and aid in substrate interactions and specificity. They also support the hypothesis that ligase may prefer to use two different cofactors during tRNA splicing.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California Irvine; California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035955] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35955] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON J, 1991, HARVEY LECT, V85, P1; ABELSON JN, 1986, CHEM SCRIPTA, V26B, P127; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCAITH SM, 1991, J BIOL CHEM, V266, P11986; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004	23	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2435	2443						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428918				2022-12-25	WOS:A1993KK81500031
J	BAFFY, G; MIYASHITA, T; WILLIAMSON, JR; REED, JC				BAFFY, G; MIYASHITA, T; WILLIAMSON, JR; REED, JC			APOPTOSIS INDUCED BY WITHDRAWAL OF INTERLEUKIN-3 (IL-3) FROM AN IL-3-DEPENDENT HEMATOPOIETIC-CELL LINE IS ASSOCIATED WITH REPARTITIONING OF INTRACELLULAR CALCIUM AND IS BLOCKED BY ENFORCED BCL-2 ONCOPROTEIN PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE PROTEIN; T-CELLS; CA-2+; DEATH; ACTIVATION; LIVER; MITOCHONDRIA; HEPATOCYTES; POOLS	The regulation of intracellular pools of Ca2+ was investigated in an interleukin-3 (IL-3)-dependent hematopoietic cell line 32D that undergoes programmed cell death (''apoptosis'') when deprived of lymphokine. Comparisons were made with 32D cells that had bee stably transfected with a bcl-2 expression plasmid that encodes a 26-kDa intracellular integral-membrane protein known to abrogate apoptosis resulting from IL-3 withdrawal. Removal of IL-3 from cultures od 32D cells or control-transfected 32D-NEO cells for 1-2 days led to cell cycle arrest and oligonucleosomal DNA fragmentation and was associated with lower cytosolic free Ca2+ concentrations ([Ca2+]i), as measured by Indo-1 fluorescence of viable cells in Ca2+ containing media. In bcl-2-expressing 32D-BCL2 cells, IL-3 withdrawal also resulted in cessation of proliferation, but [Ca2+]i levels were not decreased and DNA fragmentation was markedly suppressed. Nonmitochondrial stores of Ca'' were also significantly diminished in IL-3-deprived 32D-NEO but not in 32D-BCL2 cells, based on measurements of Ca'' release into the cytosol following exposure of cells to thapsigargin (an inhibitor of endoplasmic reticulum Ca2+-ATPases) under Ca2+-free conditions. In contrast, estimates of mitochondrial Ca2+ stores using an uncoupler of oxidative phosphorylation 1799 (2,6-dihydroxy-1,1,1,7,7,7-he xafluoro-2,6-bis(trifluoromethyl)heptan-4-one[bis(he xafluoroacetonyl)]acetone) suggested that IL-3 deprivation leads to an increase in this intracellular pool of Ca2+ in 32D-NEO but not in 32D-BCL2 cells. Re-addition of IL-3 to factor-deprived 32D-NEO cells reversed the changes in thapsigargin- and 1799-releasable Ca2+ pools and rescued many of the cells from death. Measurements of total cellular Ca2+ revealed no difference in 32D-NEO cells before and after IL-3 withdrawal, suggesting that the observed alterations in mitochondrial and nonmitochondrial Ca2+ pools result from intracellular repartitioning of Ca2+ . Treatment of IL-3-deprived 32D-NEO cells with Ca+ ionophores blocked DNA fragmentation and prolonged cell survival, whereas addition of Ca2+ chelators to IL-3-stimulated 32D cells resulted in oligonucleosomal DNA fragmentation and cell death, suggesting that diminutions in the concentrations of Ca2+ in cytosol, endoplasmic reticulum, or other intracellular compartments either directly or indirectly regulate apoptosis in these lymphokine-dependent hematopoietic cells.	LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania; University of Pennsylvania			Baffy, Gyorgy/P-7986-2018	Baffy, Gyorgy/0000-0002-8334-0400	FIC NIH HHS [F05-TW04545] Funding Source: Medline; NCI NIH HHS [CA-47956] Funding Source: Medline; NIDDK NIH HHS [DK-15120] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004545] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015120] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOMO G, 1992, CANCER RES, V52, P1342; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P167; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIDEN TJ, 1986, J BIOL CHEM, V261, P7223; BINET A, 1985, BIOCHEM J, V228, P565, DOI 10.1042/bj2280565; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKLEWIS I, 1985, EXP HEMATOL, V13, P304; COHEN JJ, 1984, J IMMUNOL, V132, P38; Crompton T, 1991, GROWTH FACTORS, V4, P109, DOI 10.3109/08977199109000262; FULCERI R, 1991, CELL CALCIUM, V12, P431, DOI 10.1016/0143-4160(91)90069-Q; GIRARD JP, 1991, CELL CALCIUM, V12, P289, DOI 10.1016/0143-4160(91)90003-W; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUKOVSKAYA AS, 1986, EUR J BIOCHEM, V161, P249, DOI 10.1111/j.1432-1033.1986.tb10149.x; Heytler P G, 1979, Methods Enzymol, V55, P462; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, IN PRESS NATURE; JONES DP, 1989, J BIOL CHEM, V264, P6398; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KRAUSFRIEDMANN N, 1990, AM J PHYSIOL, V258, pG73, DOI 10.1152/ajpgi.1990.258.1.G73; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LUCKHOFF A, 1986, CELL CALCIUM, V7, P233, DOI 10.1016/0143-4160(86)90003-5; MAVILIO F, 1989, ONCOGENE, V4, P301; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; REED JC, 1991, CANCER RES, V51, P6529; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; RUGGIERO M, 1991, FEBS LETT, V291, P203, DOI 10.1016/0014-5793(91)81284-F; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; VANHAESEBROECK B, 1993, IN PRESS ONCOGENE; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	48	451	464	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6511	6519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454620				2022-12-25	WOS:A1993KT36800063
J	JOHNSON, BA; NAJBAUER, J; ASWAD, DW				JOHNSON, BA; NAJBAUER, J; ASWAD, DW			ACCUMULATION OF SUBSTRATES FOR PROTEIN L-ISOASPARTYL METHYLTRANSFERASE IN ADENOSINE DIALDEHYDE-TREATED PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; MURINE NEURO-BLASTOMA; MOUSE L929 CELLS; CARBOXYL METHYLTRANSFERASE; SUBCELLULAR-DISTRIBUTION; POLYACRYLAMIDE GELS; ASPARTYL RESIDUES; MEMBRANE-PROTEINS; BOVINE BRAIN; METHYLATION	Protein isoaspartyl methyltransferase is implicated in the repair of age-damaged proteins containing atypical, isoaspartyl linkages. To test the prediction that isoaspartyl proteins would accumulate during methyltransferase inhibition, rat PC12 cells were treated with the indirect methylation inhibitor, adenosine dialdehyde. We observed a marked, dose- and time-dependent, reversible accumulation of substrates for the enzyme that closely paralleled the elevation of its competitive inhibitor, S-adenosylhomocysteine. The accumulation of substrates also paralleled a cytostatic action of adenosine dialdehyde; however, 30 mum 3-deazaadenosine, another indirect methylation inhibitor, also caused an accumulation of substrates without affecting cell division, and other cytostatic agents did not affect substrate levels. Acidic gel electrophoresis revealed increased methyl-accepting capacity in a broad spectrum of proteins, with predominant increases in discrete bands of M(r) 46,000 and 110,000. A major substrate (M(r) 17,400) in untreated cells did not increase in methyl-accepting capacity during treatment. Methyl groups at the accumulated sites did not survive conventional electrophoresis, indicating the lability characteristic of isoaspartyl methyl esters in damaged proteins. These results are consistent with an involvement of the methyltransferase in the metabolism of damaged proteins, and they provide a basis for the characterization of physiological substrates for the enzyme.	UNIV CALIF IRVINE,SCH BIOL SCI,RM 2205,BIOSCI 2,IRVINE,CA 92717	University of California System; University of California Irvine				Johnson, Brett/0000-0002-9260-245X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-17269] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aswad D W, 1988, Adv Exp Med Biol, V231, P247; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V41, P1702, DOI 10.1111/j.1471-4159.1983.tb00883.x; BARTEL RL, 1984, MOL PHARMACOL, V25, P418; BARTEN DM, 1989, J NEUROCHEM, V53, P1156, DOI 10.1111/j.1471-4159.1989.tb07409.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V87, P5868; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; DORER FE, 1966, BIOCHEMISTRY-US, V5, P3236, DOI 10.1021/bi00874a025; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GURANOWSKI A, 1981, BIOCHEMISTRY-US, V20, P110, DOI 10.1021/bi00504a019; Guroff G., 1985, CELL CULTURE NEUROSC, P245, DOI 10.1007/978-1-4613-2473-7_8; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; HOFFMAN JL, 1979, TRANSMETHYLATION, P181; JAMALUDDIN M, 1975, BIOCHEMISTRY-US, V14, P694, DOI 10.1021/bi00675a008; JOHNSON BA, 1991, BIOCHEM INT, V24, P841; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1991, NEUROBIOL AGING, V12, P19, DOI 10.1016/0197-4580(91)90034-H; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1985, BIOCHEMISTRY-US, V24, P2581, DOI 10.1021/bi00331a028; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1985, J BIOL CHEM, V260, P913; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JOHNSON BA, 1985, J NEUROCHEM, V45, P1119, DOI 10.1111/j.1471-4159.1985.tb05531.x; KELLER BT, 1987, MOL PHARMACOL, V31, P485; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LI C, 1992, J BACTERIOL, V174, P355, DOI 10.1128/jb.174.2.355-361.1992; LITEPLO RG, 1986, CANCER RES, V46, P577; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MIRKIN BL, 1987, CANCER RES, V47, P3650; MURRAY ED, 1984, J BIOL CHEM, V259, P722; NAJBAUER J, 1992, ARCH BIOCHEM BIOPHYS, V293, P85, DOI 10.1016/0003-9861(92)90369-8; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; NAJBAUER J, 1990, J BIOL CHEM, V265, P12717; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OCONNOR CM, 1987, J BIOL CHEM, V262, P10404; OCONNOR CM, 1987, J BIOL CHEM, V262, P10398; OCONNOR CM, 1983, J BIOL CHEM, V258, P8485; ODEA RF, 1987, CANCER RES, V47, P3656; OHTA K, 1987, BIOCHIMIE, V69, P1227, DOI 10.1016/0300-9084(87)90150-7; PILZ RB, 1987, BLOOD, V70, P1161; SHERMAN ML, 1985, CANCER RES, V45, P5830; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TERWILLIGER TC, 1981, J BIOL CHEM, V256, P3067; ZIMMERMAN TP, 1984, J BIOL CHEM, V259, P1122	55	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6174	6181						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454593				2022-12-25	WOS:A1993KT36800018
J	KRAMER, M; SACHSENMAIER, C; HERRLICH, P; RAHMSDORF, HJ				KRAMER, M; SACHSENMAIER, C; HERRLICH, P; RAHMSDORF, HJ			UV IRRADIATION-INDUCED INTERLEUKIN-1 AND BASIC FIBROBLAST GROWTH-FACTOR SYNTHESIS AND RELEASE MEDIATE PART OF THE UV RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY VIRUS TYPE-1; MESSENGER-RNA; AUTOCRINE TRANSFORMATION; EXTRACELLULAR FACTOR; NONIRRADIATED CELLS; ESCHERICHIA-COLI; FACTOR RECEPTOR; FACTOR FAMILY; C-FOS; SURAMIN	UV irradiated cells release into the culture medium factors that induce, when given to nonirradiated cells, the transcription of several UV-inducible genes (collagenase 1, human immunodeficiency virus type 1, metallothionein IIA). We identify here the active factors released from UV-treated HeLa cells, as interleukin 1alpha and basic fibroblast growth factor. UV irradiation leads to increased mRNA levels for both factors and to their enhanced synthesis. Experiments with the drug suramin, which inhibits growth factor-growth factor receptor interactions and with antibodies directed against interleukin 1alpha and basic fibroblast growth factor, suggest that growth factors do not only transduce the UV-induced signal to nonirradiated cells but act on the producer cell thus establishing an obligatory growth factor loop for at least part of the UV response.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,POSTFACH 3640,W-7500 KARLSRUHE 1,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANSEL J, 1984, J IMMUNOL, V133, P1350; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; ELLIS SM, 1989, CANCER RES, V49, P3385; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAHRING L, 1984, P NATL ACAD SCI-BIOL, V81, P1198, DOI 10.1073/pnas.81.4.1198; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HUANG SS, 1988, J BIOL CHEM, V263, P12608; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; KRIPKE ML, 1990, PHOTOCHEM PHOTOBIOL, V52, P919, DOI 10.1111/j.1751-1097.1990.tb08703.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHER VM, 1988, DNA REPLICATION MUTA, P465; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P810; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; WINGFIELD P, 1986, EUR J BIOCHEM, V160, P491, DOI 10.1111/j.1432-1033.1986.tb10066.x; WINGFIELD P, 1987, EUR J BIOCHEM, V165, P537, DOI 10.1111/j.1432-1033.1987.tb11472.x; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	40	108	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6734	6741						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454646				2022-12-25	WOS:A1993KT36800094
J	MEADE, EA; SMITH, WL; DEWITT, DL				MEADE, EA; SMITH, WL; DEWITT, DL			DIFFERENTIAL INHIBITION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE (CYCLOOXYGENASE) ISOZYMES BY ASPIRIN AND OTHER NONSTEROIDAL ANTIINFLAMMATORY DRUGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEEP VESICULAR GLAND; BIOSYNTHESIS; PURIFICATION; SYNTHETASE; CLONING; AGENTS; ACID	Murine prostaglandin endoperoxide (PGH) synthase-1 and PGH synthase-2 expressed in cos-1 cells were found to be differentially sensitive to inhibition by common nonsteroidal anti-inflammatory drugs (NSAIDs). Aspirin completely inhibited bis-oxygenation of arachidonate by PGH synthase-1; in contrast, aspirin-treated PGH synthase-2 metabolized arachidonate primarily to 15-hydroxyeicosatetraenoic acid (15-HETE) instead of PGH2. ID50 values were determined for a panel of common NSAIDs by measuring instantaneous inhibition of cyclooxygenase activity using an oxygen electrode. Among common NSAIDs tested, indomethacin, sulindac sulfide, and piroxicam preferentially inhibited PGH synthase-1; ibuprofen, flurbiprofen, and meclofenamate inhibited both enzymes with comparable potencies; and 6-methoxy-2-naphthylacetic acid preferentially inhibited PGH synthase-2. These results demonstrate that the two PGH synthases are pharmacologically distinct and indicate that it may be possible to develop isozyme-specific cyclooxygenase inhibitors useful both for anti-inflammatory therapy and for delineating between the biological roles of the PGH synthase isozymes.	MICHIGAN STATE UNIV,DEPT BIOCHEM,510 BIOCHEM BLDG,E LANSING,MI 48824	Michigan State University					NIDDK NIH HHS [DK22042, DK42509] Funding Source: Medline; NIGMS NIH HHS [GM40713] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042, R01DK042509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040713] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1212; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER RJ, 1974, PROSTAGLANDIN SYNTHE, P9; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GOETZL EJ, 1981, BIOCHEM BIOPH RES CO, V101, P344, DOI 10.1016/0006-291X(81)91266-3; HADDOCK RE, 1984, XENOBIOTICA, V14, P327, DOI 10.3109/00498258409151419; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEADE EA, 1993, PROSTAGLANDINS THROM; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OSULLIVAN GM, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1990, STROKE, V21, P24; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VANDERHOEK JY, 1980, J BIOL CHEM, V255, P64; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; WILLARD J, 1902, NEW ENGL J MED, V327, P175; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	1204	1249	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6610	6614						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454631				2022-12-25	WOS:A1993KT36800077
J	NAKAMURA, F; MINO, T; YAMAMOTO, J; NAKA, M; TANAKA, T				NAKAMURA, F; MINO, T; YAMAMOTO, J; NAKA, M; TANAKA, T			IDENTIFICATION OF THE REGULATORY SITE IN SMOOTH-MUSCLE CALPONIN THAT IS PHOSPHORYLATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; HEAVY-MEROMYOSIN; CHICKEN GIZZARD; ATPASE ACTIVITY; 2ND MESSENGERS; MYOSIN; ACTIN; CALDESMON; ACTOMYOSIN; BINDING	F-actin and tropomyosin inhibited the phosphorylation of calponin by protein kinase C, and the phosphorylation reduced the binding of calponin to F-actin and tropomyosin. Labeled phosphate from [gamma-P-32]ATP was retained both on the chymotryptic NH2-terminal 22-kDa fragment, which contains the actin-, tropomyosin-, and calmodulin-binding regions, and on the COOH-terminal 12-kDa fragment. Fractionation of tryptic P-32-labeled peptides by high performance liquid chromatography allowed isolation of three phosphopeptides (designated T1, T2, and T3), each of which was located in three repeating amino acid motifs of calponin. Both the relative initial rates and extent of phosphorylation decreased in the order T2 > T3 > T1. Both serine and threonine residues were phosphorylated in T1 (GASQAGMTAPGTK), and only a threonine residue was phosphorylated in T2 (FASQQGMTAYGTR) and in T3 (GASQQGMTVYGLPR). As the 22-kDa fragment contained only T2, the phosphorylation site in T2 appeared to regulate the binding of calponin to F-actin and tropomyosin. The amino acid sequence of T2 indicates that protein kinase C phosphorylates Thr184. Thus Thr184 is the preferred site of phosphorylation and is functionally the most important of the sites phosphorylated by protein kinase C in smooth muscle calponin.	MIE UNIV, SCH MED, DEPT MOLEC & CELLULAR PHARMACOL, 2-174 EDOBASHI, TSU, MIE 514, JAPAN	Mie University								ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARANY M, 1991, FEBS LETT, V279, P65, DOI 10.1016/0014-5793(91)80252-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BURTNICK LD, 1986, FEBS LETT, V198, P307, DOI 10.1016/0014-5793(86)80426-4; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CHACKO S, 1977, P NATL ACAD SCI USA, V74, P129, DOI 10.1073/pnas.74.1.129; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; ENDO T, 1982, BIOCHEM BIOPH RES CO, V105, P942, DOI 10.1016/0006-291X(82)91061-0; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; HOUSE C, 1987, J BIOL CHEM, V262, P772; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KINCAID RL, 1982, J BIOL CHEM, V257, P638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; MARSTON SB, 1991, BIOCHEM J, V279, P1; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLWIN BB, 1983, METHOD ENZYMOL, V102, P148; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; POHL J, 1991, Biophysical Journal, V59, p58A; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; REES DD, 1981, J BIOL CHEM, V256, P357; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; Walsh M P, 1987, Prog Clin Biol Res, V245, P119; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	45	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6194	6201						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454594				2022-12-25	WOS:A1993KT36800021
J	OHMORI, Y; HAMILTON, TA				OHMORI, Y; HAMILTON, TA			COOPERATIVE INTERACTION BETWEEN INTERFERON (IFN) STIMULUS-RESPONSE ELEMENT AND KAPPA-B SEQUENCE MOTIFS CONTROLS IFN-GAMMA-STIMULATED AND LIPOPOLYSACCHARIDE-STIMULATED TRANSCRIPTION FROM THE MURINE IP-10 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PERITONEAL-MACROPHAGES; REGULATORY ELEMENTS; GENE-REGULATION; NUCLEAR FACTOR; SIGNAL TRANSDUCTION; INDUCIBLE ENHANCER; EXPRESSION; PROTEIN; BINDING	The transcriptional regulation of the murine IP-10 gene in lipopolysaccharide (LPS) or interferon gamma (IFN-gamma)-treated macrophages was investigated by analysis of regions of the gene that flank the transcription start site. A series of sequence fragments were placed 5' to the chloramphenicol acetyltransferase (CAT) reporter gene and ability to mediate transcription of CAT in response to IFN-gamma or LPS treatment was studied following transient transfection in the macrophage-like cell line RAW 264.7. Analysis of larger constructs identified a potential negative regulatory site for IFN-gamma response in the region between nucleotide positions -2002 and -930 and a positive regulator for LPS response in the region between bases -930 and -676. A 227-base fragment spanning positions -228 to -2 was the minimal sequence able to mediate LPS- and IFN-gamma-dependent transcription of CAT. Deletion of 24 bases, which included a highly conserved IFN stimulus response element (ISRE) from the -228 construct, abolished response to IFN-gamma. A 33-base fragment containing the IP-10 ISRE was able to confer both IFNgamma and LPS sensitivity upon a heterologous promoter. The ability of LPS to stimulate CAT via the ISRE was apparently mediated by intermediate expression of endogenous IFNalpha/beta. Elimination of bases -204 to -102 abolished sensitivity to LPS. This region contains two kappaB binding sites. Site-directed mutagenesis of key nucleotides in the ISRE and the two kappaB sites demonstrated that optimal response to IFN-gamma required both the ISRE and one of the two kappaB sites, whereas optimal response to LPS required either both kappaB sites or one kappaB site and the ISRE. IFNgamma or LPS treatment induced sequence-specific binding activity for the ISRE and the two KB sites. These results indicate that the 230 nucleotides upstream from the transcription start site are important for transcriptional control of the IP-10 gene in response to IFNgamma and LPS. The three defined regulatory elements function in distinct fashion for each of the two stimuli; optimal response to either IFN-gamma or LPS requires cooperation between at least two sites.	CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Hamilton, Thomas A/A-7756-2009	Ohmori, Yoshihiro/0000-0002-6069-357X; Hamilton, Thomas/0000-0002-9817-242X	NCI NIH HHS [CA39621, CA48919] Funding Source: Medline; NHLBI NIH HHS [HL29589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039621, P01CA048919] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ADAMS DO, 1987, INFLAMMATION BASIC P, P471; Adams Dolph O., 1992, P285; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DROUET C, 1991, J IMMUNOL, V147, P1694; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMILTON TA, 1989, J IMMUNOL, V142, P2325; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HAMILTON TA, 1992, MONONUCLEAR PHAGOCYT, P47; HAMILTON TA, 1988, IMMUNOPHARMACOLOGY, P213; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; INTRONA M, 1987, J IMMUNOL, V138, P3891; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOERNER TJ, 1987, BIOCHEM BIOPH RES CO, V149, P969, DOI 10.1016/0006-291X(87)90503-1; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NARUMI S, 1992, J IMMUNOL, V149, P529; NATHAN CF, 1985, TXB RHEUMATOLOGY, P144; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; OHMORI Y, 1992, J IMMUNOL, V148, P538; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1993, IN PRESS AM J PATHOL; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Sambrook J, 1989, MOL CLONING LABORATO; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; TANNENBAUM CS, 1989, J BIOL CHEM, V264, P4052; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; YAN C, 1991, P NATL ACAD SCI USA, V88, P144, DOI 10.1073/pnas.88.1.144	62	215	223	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6677	6688						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454640				2022-12-25	WOS:A1993KT36800086
J	KOVACS, JA; POWELL, F; EDMAN, JC; LUNDGREN, B; MARTINEZ, A; DREW, B; ANGUS, CW				KOVACS, JA; POWELL, F; EDMAN, JC; LUNDGREN, B; MARTINEZ, A; DREW, B; ANGUS, CW			MULTIPLE GENES ENCODE THE MAJOR SURFACE GLYCOPROTEIN OF PNEUMOCYSTIS-CARINII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTIGENIC VARIATION; BORRELIA-HERMSII; BINDING-PROTEIN; IDENTIFICATION; EXPRESSION; PNEUMONIA; IMMUNODEFICIENCY; PURIFICATION; RECEPTOR	The major surface antigen of Pneumocystis carinii, a life-threatening opportunistic pathogen in human immunodeficiency virus-infected patients, is an abundant glycoprotein that functions in host-organism interactions. A monoclonal antibody to this antigen is protective in animals, and thus this antigen is a good candidate for development as a vaccine to prevent or control P. carinii infection. We have cloned and sequenced seven related but unique genes encoding the major surface glycoprotein of rat P. carinii. Partial amino acid sequencing confirmed the identity of these genes. Based on Southern blot studies using chromosomal or restricted DNA, the major surface glycoproteins are the products of a multicopy family of genes. The predicted protein has an M(r) of approximately 123,000, is relatively rich in cysteine residues (5.5%) that are very strongly conserved, and contains a well conserved hydrophobic region at the carboxyl terminus. The presence of multiple related msg genes encoding the major surface glycoprotein of P. carinii suggests that antigenic variation is a possible mechanism for evading host defenses. Further characterization of this family of genes should allow the development of novel approaches to the control of this pathogen.	UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, LAB MED LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KOVACS, JA (corresponding author), NIH, CTR CLIN,DEPT CRIT CARE MED,BLDG 10,RM 7D43, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1983, J EXP MED, V158, P2127, DOI 10.1084/jem.158.6.2127; BARBOUR AG, 1991, SCAND J INFECT DIS, V77, pS88; Battey, 1986, BASIC METHODS MOL BI; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BEALS TP, 1992, J MOL BIOL, V225, P961, DOI 10.1016/0022-2836(92)90097-4; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; EDMAN U, 1989, P NATL ACAD SCI USA, V86, P6503, DOI 10.1073/pnas.86.17.6503; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIGLIOTTI F, 1988, J CLIN INVEST, V81, P1666, DOI 10.1172/JCI113503; GIGLIOTTI F, 1992, J INFECT DIS, V165, P329, DOI 10.1093/infdis/165.2.329; GIGLIOTTI F, 1988, J INFECT DIS, V158, P848, DOI 10.1093/infdis/158.4.848; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HAAS R, 1987, A VAN LEEUW J MICROB, V53, P431, DOI 10.1007/BF00415498; KOVACS JA, 1988, J IMMUNOL, V140, P2023; KOVACS JA, 1992, CLIN INFECT DIS, V14, P1005, DOI 10.1093/clinids/14.5.1005; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LINKE MJ, 1989, INFECT IMMUN, V57, P1547, DOI 10.1128/IAI.57.5.1547-1555.1989; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOW MG, 1987, BIOCHEM J, V244, P1; LUNDGREN B, 1990, INFECT IMMUN, V58, P1705, DOI 10.1128/IAI.58.6.1705-1710.1990; LUNDGREN B, 1991, J CLIN INVEST, V87, P163, DOI 10.1172/JCI114966; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; POTTRATZ ST, 1991, J CLIN INVEST, V88, P403, DOI 10.1172/JCI115318; RADDING JA, 1989, INFECT IMMUN, V57, P2149, DOI 10.1128/IAI.57.7.2149-2157.1989; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; REINITZ DM, 1992, MOL BIOCHEM PARASIT, V51, P119, DOI 10.1016/0166-6851(92)90207-Z; SAINTGIRONS I, 1991, RES MICROBIOL, V142, P711, DOI 10.1016/0923-2508(91)90085-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STRINGER SL, 1989, EXP PARASITOL, V68, P450, DOI 10.1016/0014-4894(89)90130-6; SWANSON J, 1987, J EXP MED, V165, P1344, DOI 10.1084/jem.165.5.1344; TANABE K, 1989, INFECT IMMUN, V57, P1363, DOI 10.1128/IAI.57.5.1363-1368.1989; THON G, 1990, GENE DEV, V4, P1374, DOI 10.1101/gad.4.8.1374; VAI M, 1991, J BIOL CHEM, V266, P12242; VOLPE F, 1992, GENE, V112, P213, DOI 10.1016/0378-1119(92)90378-3; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554; [No title captured]	47	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6034	6040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449961				2022-12-25	WOS:A1993KR82200099
J	WEISS, RH; MADURI, M				WEISS, RH; MADURI, M			THE MITOGENIC EFFECT OF THROMBIN IN VASCULAR SMOOTH-MUSCLE CELLS IS LARGELY DUE TO BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HAMSTER FIBROBLASTS; RECEPTOR; PDGF; ACTIVATION; BREAKDOWN; MIGRATION; PROTEINS	Mitogenesis induced by most polypeptide growth factors is mediated by either G-protein- or tyrosine kinase-linked receptor pathways. Thrombin, a potent mitogen for vascular smooth muscle cells, activates a G-protein-coupled receptor but also requires tyrosine kinase activity for its mitogenic effect (Weiss, R. H., and Nuccitelli, R. (1992) J. Biol. Chem. 267, 5608-5613). Since this growth factor elicits a synergistic effect on DNA synthesis when applied to cells concurrently with basic fibroblast growth factor (bFGF), we suspected that the two growth factors have points of convergence in their signaling pathways. We now show that when 1 unit/ml thrombin is removed after an incubation period of from 4 h to 15 min prior to 15 ng/ml bFGF addition, its synergistic effect with bFGF on mitogenesis in vascular smooth muscle cells is preserved. Furthermore, appearance of bFGF in the cellular lysate is maximal 1 h after the addition of 1 unit/ml thrombin. While monoclonal antibody to bFGF inhibits thrombin's mitogenic effect by 63% at 30 mug/ml, it lacks an inhibitory effect on platelet-derived growth factor-BB-induced mitogenesis. The inhibitory effect of bFGF antibody on thrombin's growth is completely reversed by the addition of bFGF. These data demonstrate that the presence of bFGF is essential for thrombin to exert its full mitogenic effect in vascular smooth muscle cells, providing an example of a system where a tyrosine kinase-linked growth factor receptor system can act as an essential intermediary in the mitogenic signaling pathway of a G-protein-coupled receptor.			WEISS, RH (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV NEPHROL,4301 X ST,SACRAMENTO,CA 95817, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; PARIS S, 1988, J BIOL CHEM, V263, P12893; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RIFKIN DB, 1991, ANN NY ACAD SCI, V638, P204, DOI 10.1111/j.1749-6632.1991.tb49031.x; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	22	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5724	5727						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449935				2022-12-25	WOS:A1993KR82200055
J	CUI, JS; SOMERVILLE, RL				CUI, JS; SOMERVILLE, RL			THE TYRR PROTEIN OF ESCHERICHIA-COLI, ANALYSIS BY LIMITED PROTEOLYSIS OF DOMAIN-STRUCTURE AND LIGAND-MEDIATED CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEINS; GENE; K-12; TRANSCRIPTION; EXPRESSION; REPRESSOR; ACTIVATOR; SEQUENCE; SYSTEMS; VECTORS	The TyrR protein of Escherichia coli K12 is a homodimer containing 513 amino acids/subunit. This protein is important in the transcriptional regulation of several genes whose protein products catalyze steps in aromatic amino acid biosynthesis or transport. Methods were developed for efficiently purifying the TyrR protein to apparent homogeneity. We analyzed the pattern of cleavage of the TyrR protein by trypsin, either in the absence of ligands or in the presence of saturating levels of L-tyrosine, ATP, or poly(dI-dC). At low (1:200 ratio by weight) trypsin levels, in the absence of ligands, two major digestion products accumulated. These were polypeptides of 22 and 31 kDa, shown to contain amino acid residues 1-190 and 191-467, respectively. The pattern of trypsin cleavage was unaffected by tyrosine. In the presence of ATP, an intermediate species of 53 kDa, probably containing amino acid residues 1-467, was observed. The kinetics of appearance of the 53-kDa species were consistent with a role for ATP in accelerating the hydrolysis of the R467-F468 peptide bond. The 53-kDa polypeptide underwent further tryptic hydrolysis to yield fragments of 22 and 31 kDa. When both tyrosine and ATP were present, the rate of formation of the 22- and 31-kDa fragments was more rapid than in the absence of these ligands. It appears that when both ligands are bound, the rates of hydrolysis of peptide bonds R190-Q191 and R467-F468 are both enhanced. Additional limited proteolysis experiments suggested that polypeptide segment 191-467 contains ATP binding site(s), and that the rate of cleavage of peptide bonds R190-Q191 and R467-F468 is altered when the TyrR protein interacts with poly(dI-dC), an analog of target DNA. Our results reveal the presence of two major structural domains within the TyrR protein. The first domain (amino acid residues 1-190) is extremely resistant to hydrolysis by trypsin. The second domain (residues 191-467), which is likely to contain ATP-binding site(s), is homologous to several other transcriptional activators specific for promoters responsive to the sigma54 form of RNA polymerase. The remainder of the TyrR protein (residues 468-513) contains the operator recognition elements, probably arranged in the form of a helix-turn-helix motif. This polypeptide segment was not detected as a discrete tryptic hydrolysis product.			CUI, JS (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22131] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGULO A, 1986, J BIOL CHEM, V261, P11315; ARGYROPOULOS VP, 1989, THESIS U MELBOURNE M; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMAKARIS H, 1982, J BACTERIOL, V150, P70, DOI 10.1128/JB.150.1.70-75.1982; COGGINS JR, 1986, MULTIDOMAIN PROTEINS, P1; CORNISH EC, 1986, J BIOL CHEM, V261, P403; CUI J, 1993, IN PRESS J BACTERIOL, V175; CUI JS, 1993, J BACTERIOL, V175, P303, DOI 10.1128/JB.175.1.303-306.1993; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; GOTTESMAN ME, 1968, J MOL BIOL, V31, P487, DOI 10.1016/0022-2836(68)90423-3; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; KASIAN PA, 1986, J BACTERIOL, V167, P556, DOI 10.1128/jb.167.2.556-561.1986; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSMANN MG, 1981, ANNU REV BIOCHEM, V50, P497, DOI 10.1146/annurev.bi.50.070181.002433; SAHA R, 1992, J BIOL CHEM, V267, P5862; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOMERVILLE RL, 1991, BIOCHEM BIOPH RES CO, V181, P1056, DOI 10.1016/0006-291X(91)92044-K; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; WHIPP MJ, 1977, J BACTERIOL, V132, P453, DOI 10.1128/JB.132.2.453-461.1977; WILLIAMS BG, 1979, J VIROL, V29, P555, DOI 10.1128/JVI.29.2.555-575.1979; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535	29	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5040	5047						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444880				2022-12-25	WOS:A1993KP88400071
J	KHAN, WA; BLOBE, G; HALPERN, A; TAYLOR, W; WETSEL, WC; BURNS, D; LOOMIS, C; HANNUN, YA				KHAN, WA; BLOBE, G; HALPERN, A; TAYLOR, W; WETSEL, WC; BURNS, D; LOOMIS, C; HANNUN, YA			SELECTIVE REGULATION OF PROTEIN-KINASE-C ISOENZYMES BY OLEIC-ACID IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PHORBOL ESTER; CELLULAR-REGULATION; MIXED MICELLES; ACTIVATION; INHIBITION; MEMBRANE; BINDING; PHOSPHATIDYLSERINE; DIACYLGLYCEROL	Cis-unsaturated fatty acids activate soluble protein kinase C (PKC) in vitro and in intact platelets. The following studies were conducted to determine the effects of oleate on individual isoenzymes of PKC in human platelets. Human platelets were found to contain predominantly PKC alpha, beta(I), beta(II), and delta with minor immunoreactivity for PKC epsilon, zeta, and eta. In intact platelets, sodium oleate caused a time-dependent redistribution of PKC alpha, beta(II), and delta from cytosol to membrane fractions with little effects on PKC beta(I). On the other hand, PMA and thrombin induced translocation of all four isoenzymes of PKC. In vitro, oleate partially activated (50% of V(max)) purified calcium-dependent PKC (alpha, beta(I), and beta(II) with an EC50 of 50 muM whereas it fully activated (100% of V(max)) purified calcium-independent PKC (predominantly delta) with an EC50 of 5 muM. The selective effects of oleate on PKC isoenzymes were investigated in platelet cytosol which contains endogenous PKC and its physiologic substrates. Under these conditions, oleate potently activated calcium-independent PKC causing the phosphorylation of the 40-kDa substrate. Activation of calcium-dependent isoforms occurred only at higher concentrations of oleate. Thus, oleate activates multiple isoenzymes of PKC with predominant effects on calcium-independent PKC.	DUKE UNIV, MED CTR, DEPT MED, BOX 3355, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; NIEHS, MOLEC & INTEGRATED NEUROSCI LAB, RES TRIANGLE PK, NC 27709 USA; SPHINX PHARMACEUT, DURHAM, NC 27717 USA	Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL CANCER INSTITUTE [P01CA047741] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47741] Funding Source: Medline; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DIAZGUERRA MJM, 1991, J BIOL CHEM, V266, P23568; DOOLITTLE RF, 1986, URSFSAND ORFSL PRIME; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HAGIWARA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P201, DOI 10.1016/0003-9861(90)90536-8; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KHAN W, 1991, FEBS LETT, V292, P98, DOI 10.1016/0014-5793(91)80843-R; KHAN WA, 1992, J BIOL CHEM, V267, P3605; Kitano T, 1986, Methods Enzymol, V124, P349; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEACH KL, 1985, CANCER RES, V45, P1958; MACINTYRE DE, 1984, BLOOD, V63, P848; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIKAWA M, 1988, BIOCHEM PHARMACOL, V37, P3079, DOI 10.1016/0006-2952(88)90304-8; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUNEZ D, 1990, J BIOL CHEM, V265, P18330; ONO Y, 1988, J BIOL CHEM, V263, P6927; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOLF M, 1986, J BIOL CHEM, V261, P3327	32	100	101	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5063	5068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444883				2022-12-25	WOS:A1993KP88400074
J	BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C				BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C			BM2L IS A SPONTANEOUS LEUKEMOGENIC VARIANT OF A NON-LEUKEMOGENIC V-MYB-TRANSFORMED MYELOID CELL-LINE	ONCOGENE			English	Article							C-MYB; ONCOGENE; LEUKEMIA; VIRUSES; DIFFERENTIATION; SEQUENCES	Leukemogenesis is a complex process involving an accumulation of genetic lesions affecting both growth and differentiation in cells of the hematopoietic lineage. Our laboratory has established a non-producer v-myb-transformed cell line (BM2/C3A) which, when injected into the chicken embryo, does not produce leukemia. Recently, a spontaneous variant of this cell line, called BM2L, was obtained from in vivo experiments. BM2L produces an acute monoblastic leukemia when injected into the chicken embryo. BM2L cells do not differentiate in vivo or in vitro, but continue to proliferate under conditions in culture that allow for the differentiation of BM2/C3A cells into macrophages. In addition, BM2L cells have reduced requirements for exogenous growth factors. BM2L cells contain the v-myh allele and express v-Myb protein, but leukemogenicity does not involve point mutations in v-myb. The BM2 model, consisting of two non-producer cell lines differing in vivo in their leukemogenicity, provides a novel system for identifying genes that play a role in the induction or suppression of leukemogenesis.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PATHOL,GAINESVILLE,FL 32610; VET ADM MED CTR,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32602; VET ADM MED CTR,CTR MAMMALIAN GENET,GAINESVILLE,FL 32602; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)				Bottazzi, Maria Elena/0000-0002-8429-0476	NATIONAL CANCER INSTITUTE [R01CA010697] Funding Source: NIH RePORTER; NCI NIH HHS [CA10697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER MR, 1991, ANNU REV MED, V42, P381, DOI 10.1146/annurev.me.42.020191.002121; CHEN JH, 1980, VIROLOGY, V103, P112, DOI 10.1016/0042-6822(80)90130-0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOODENOW MM, 1987, J VIROL, V61, P2489, DOI 10.1128/JVI.61.8.2489-2498.1987; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KIM WK, 1988, ONCOGENE RES, V3, P147; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSCOVICI C, 1976, VIROLOGY, V73, P181, DOI 10.1016/0042-6822(76)90072-6; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY, V1; MOSCOVICI MG, 1980, IN VIVO IN VITRO ERY, P503; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHUU RER, 1991, ONCOGENE, V6, P1409; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	25	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					731	736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437856				2022-12-25	WOS:A1993KN00800025
J	CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ				CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ			ALLELE LOSS PATTERNS ON CHROMOSOME-17Q IN 109 BREAST CARCINOMAS INDICATE AT LEAST 2 DISTINCT TARGET REGIONS	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; P53 MUTATIONS; CANCER; CARCINOGENESIS; HETEROZYGOSITY; ASSOCIATION; PROGRESSION; MECHANISMS; DELETION; PROTEIN	Loss of heterozygosity (LOH) of markers for chromosome 17 is the most frequent genetic change observed in breast cancer to date. To assess whether the location of several candidate target genes is compatible with patterns of allele losses in the individual tumors, we examined the LOH status of chromosome 17 in 109 primary breast tumors with 15 polymorphic DNA markers (three for 17p and 12 for 17q). Allelic imbalance (AI) at 17q was observed in 44 of the 97 informative cases. A significant correlation was found between Al at the long arm and Al at the short arm of chromosome 17. The patterns of Al on 17q in the tumors differed and were highly complex in some cases. A number of tumors showed AI distal to the growth hormone locus, whereas others showed Al exclusively proximal of this marker. These results indicate that there are at least two different regions of allele loss on 17q.	LEIDEN UNIV,FAC MED,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	CORNELIS, RS (corresponding author), LEIDEN UNIV,FAC MED,DEPT HUMAN GENET,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		DEVILEE, PETER/ABR-2140-2022					ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; BAKER SJ, 1990, CANCER RES, V50, P7717; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BORRESEN AL, 1991, AM J HUM GENET, V49, P44; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; DEVILEE P, 1991, ONCOGENE, V6, P311; DEVILEE P, 1990, CANCER SURV, V9, P605; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EASTON DF, 1993, IN PRESS AM J HUM GE; GELEICK D, 1990, CANCER GENET CYTOGEN, V46, P217, DOI 10.1016/0165-4608(90)90107-L; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P138; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEONE A, 1991, CANCER RES, V51, P2490; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; OSBORNE RJ, 1991, CANCER RES, V51, P6194; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; PONDER B, 1989, NATURE, V340, P264, DOI 10.1038/340264a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1990, ONCOGENE, V5, P1573; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SOLOMON E, 1991, CYTOGENET CELL GENET, V51; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1991, ONCOGENE, V6, P413; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y	44	77	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					781	785						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437862				2022-12-25	WOS:A1993KN00800031
J	REUSCH, JEB; SUSSMAN, KE; DRAZNIN, B				REUSCH, JEB; SUSSMAN, KE; DRAZNIN, B			INVERSE RELATIONSHIP BETWEEN GLUT-4 PHOSPHORYLATION AND ITS INTRINSIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; CYTOSOLIC FREE CALCIUM; RAT ADIPOSE-CELLS; PLASMA-MEMBRANES; OKADAIC ACID; INSULIN; ADIPOCYTES; ISOPROTERENOL; BASAL	In this study, we examined the effect of phosphorylation on GLUT-4 function in isolated rat adipocytes. Adipocytes labeled with P-32 for 2 h were incubated with parathyroid hormone (PTH) (20 ng/ml) for 60 min and then exposed to insulin (25 ng/ml) for an additional 30 min. P-32-GLUT-4 was immunoprecipitated from the plasma membrane and low density microsomal fractions, and its degree of phosphorylation was determined by autoradiography and densitometry. Results were expressed as P-32-GLUT-4 specific activity (phosphorylation/unit of protein). GLUT-4 intrinsic activity was measured using [C-14]2-deoxyglucose uptake in plasma membrane vesicles. PTH significantly increased GLUT-4 phosphorylation and eliminated the insulin-stimulated dephosphorylation of GLUT-4. Western blotting revealed normal distribution of GLUT-4 before and after insulin stimulation in control and PTH-treated cells, suggesting that phosphorylation of GLUT-4 does not interfere with its recruitment to the plasma membrane. In contrast, intrinsic activity of phosphorylated GLUT-4 was significantly reduced (p < 0.01). Preincubation of adipocytes with calcium channel blocker (nitrendipine) and cyclic AMP antagonist (RpcAMP) restored GLUT-4 intrinsic activity in the PTH-treated cells. In several experiments, GLUT-4 was phosphorylated in vitro in plasma membrane vesicles isolated from normal adipocytes exposed to insulin. This in vitro phosphorylation reduced GLUT-4 intrinsic activity by approximately 35% (p < 0.01). We conclude that phosphorylation of GLUT-4 significantly impairs the ability of insulin to stimulate its intrinsic activity.	VET AFFAIRS MED CTR,DEPT MED,ENDOCRINOL SECT 111H,1055 CLERMONT ST,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262; VET AFFAIRS MED CTR,RES SERV,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Reusch, Jane/0000-0001-8620-1003				BEGUM N, 1992, J CLIN INVEST, V90, P1254, DOI 10.1172/JCI115988; BEGUM N, 1992, J BIOL CHEM, V267, P5959; BEGUM N, 1992, J BIOL CHEM, V267, P3352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COVERA S, 1991, J BIOL CHEM, V266, P9271; CUSHMAN SW, 1980, J BIOL CHEM, V255, P1059; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LUDVIGSEN C, 1980, DIABETES, V29, P373, DOI 10.2337/diabetes.29.5.373; LUDVIGSEN C, 1979, J BIOL CHEM, V254, P1444; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; REUSCH JEB, 1991, ENDOCRINOLOGY, V129, P3269, DOI 10.1210/endo-129-6-3269; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TANTI JF, 1991, J BIOL CHEM, V266, P2099; Weber T. M., 1988, INSULIN RECEPTORS B, P171	21	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3348	3351						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429011				2022-12-25	WOS:A1993KM16100052
J	ANNWEILER, A; ZWILLING, S; HIPSKIND, RA; WIRTH, T				ANNWEILER, A; ZWILLING, S; HIPSKIND, RA; WIRTH, T			ANALYSIS OF TRANSCRIPTIONAL STIMULATION BY RECOMBINANT OCT PROTEINS IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; RNA POLYMERASE-II; IMMUNOGLOBULIN GENES; ACTIVATION DOMAINS; SEQUENCE ELEMENTS; GAL4 DERIVATIVES; HELA-CELLS; B-CELLS; BINDING; INVITRO	The transactivation potential of several isoforms of the lymphoid-specific transcription factor Oct2 has been analyzed using in vitro transcription. Oct2 can stimulate transcription in B-cell nuclear extracts and in HeLa nuclear extracts depleted of the ubiquitous factor Oct1 by wheat germ lectin affinity chromatography. Activity is observed from both natural and synthetic promoters containing single or multiple copies of the octamer motif ATGCAAAT. Multimerization of this motif does not result in a synergistic transcriptional stimulation, but rather leads to a linear increase in activity. To analyze the various Oct2 isoforms, they were overexpressed in HeLa cells using recombinant vaccinia virus. Although all the isoforms bind similarly to the octamer sequence, they show clear differences in their ability to transactivate transcription. This ranges from a 2-fold stimulation for Oct2.3 to the almost 20-fold effect of the most potent variant Oct2.5. In general the relative activity of the isoforms in vitro reflects that observed in vivo in cotransfection experiments. Interestingly the ubiquitous factor Oct1 is also an efficient activator of transcription in vitro, but only from promoters with multiple octamer motifs. Sarkosyl inhibition studies suggest that both Oct1 and Oct2 function in vitro by stabilizing preinitiation complexes without affecting the reinitiation rate of RNA polymerase II.	ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY; HANNOVER MED SCH,INST MOLEK BIOL,W-3000 HANNOVER 61,GERMANY	Ruprecht Karls University Heidelberg; Hannover Medical School			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CURRIE RA, 1990, NUCLEIC ACIDS RES, V18, P2987, DOI 10.1093/nar/18.10.2987; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19572; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SEN R, 1987, MOL CELL BIOL, V7, P1989, DOI 10.1128/MCB.7.5.1989; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOZA BK, 1990, MOL CELL BIOL, V10, P2145, DOI 10.1128/MCB.10.5.2145; ZELZNIKLE NJ, 1992, J BIOL CHEM, V267, P7677	44	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2525	2534						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428930				2022-12-25	WOS:A1993KK81500043
J	SVITIL, AL; CASHEL, M; ZYSKIND, JW				SVITIL, AL; CASHEL, M; ZYSKIND, JW			GUANOSINE TETRAPHOSPHATE INHIBITS PROTEIN-SYNTHESIS INVIVO - A POSSIBLE PROTECTIVE MECHANISM FOR STARVATION STRESS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCHARGED TRANSFER RNATRP; RIBOSOMAL-RNA; PPGPP; EXPRESSION; METHIONINE; TRANSPORT; MUTANTS	Guanosine 3',5'-bispyrophosphate (ppGpp) accumulates in bacteria in response to either amino acid or energy source starvation. Here we demonstrate that levels of ppGpp similar to those induced by amino acid starvation inhibit the rate of protein synthesis by 84-91%. The intracellular concentration of ppGpp is manipulated in our studies by increasing the expression of a truncated relA gene encoding a smaller but catalytically active peptide with ppGpp synthetase activity. We find that the intracellular activity of the truncated RelA peptide is insensitive to chloramphenicol, unlike the product of the wild-type relA gene, ppGpp synthetase I. Previously, this same ppGpp expression system was used (Schreiber, G., Metzger, S., Aizenman, E., Roza, S., Cashel, M., and Glaser, G. (1991) J. Biol. Chem. 226, 3760-3767) to demonstrate that increasing the ppGpp concentration inhibits growth and ribosomal RNA transcription, and they found suggestive evidence for ppGpp inhibition of protein synthesis. We further investigated the effect of ppGpp on protein synthesis and find that ppGpp is a potent inhibitor of protein synthesis as well as glycerol accumulation but has no effect on transport of methionine, the amino acid used in measuring protein synthesis rates, or on uptake of alpha-methylglucoside, a non-metabolizable analogue of glucose.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA	California State University System; San Diego State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; DIX DB, 1986, P NATL ACAD SCI USA, V83, P2027, DOI 10.1073/pnas.83.7.2027; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENTRY D, 1991, J BACTERIOL, V173, P3901, DOI 10.1128/JB.173.12.3901-3903.1991; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HAMEL E, 1974, ARCH BIOCHEM BIOPHYS, V162, P293, DOI 10.1016/0003-9861(74)90128-3; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HAYASHI SI, 1965, J MOL BIOL, V14, P515, DOI 10.1016/S0022-2836(65)80200-5; KADNER RJ, 1975, J BACTERIOL, V123, P985, DOI 10.1128/JB.123.3.985-991.1975; KADNER RJ, 1974, J BACTERIOL, V117, P232, DOI 10.1128/JB.117.1.232-241.1974; LAFFLER T, 1974, CELL, V3, P47, DOI 10.1016/0092-8674(74)90036-1; LARK KG, 1963, BIOCHIM BIOPHYS ACTA, V76, P9; LEGAULT L, 1972, FEBS LETT, V27, P71, DOI 10.1016/0014-5793(72)80412-5; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OFARRELL PH, 1978, CELL, V14, P545, DOI 10.1016/0092-8674(78)90241-6; PEDERSEN FS, 1973, NATURE-NEW BIOL, V243, P13; ROJAS AM, 1984, MOL GEN GENET, V197, P36, DOI 10.1007/BF00327920; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; ROJIANI MV, 1989, J BACTERIOL, V171, P6493, DOI 10.1128/jb.171.12.6493-6502.1989; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SOKAWA Y, 1969, BIOCHEM BIOPH RES CO, V34, P99, DOI 10.1016/0006-291X(69)90534-8; TEDIN K, 1992, J BIOL CHEM, V267, P2337; XIAO H, 1991, J BIOL CHEM, V266, P5980; YOSHIDA M, 1972, FEBS LETT, V23, P163, DOI 10.1016/0014-5793(72)80331-4	29	153	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2307	2311						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428905				2022-12-25	WOS:A1993KK81500011
J	WAHLE, E; LUSTIG, A; JENO, P; MAURER, P				WAHLE, E; LUSTIG, A; JENO, P; MAURER, P			MAMMALIAN POLY(A)-BINDING PROTEIN-II - PHYSICAL-PROPERTIES AND BINDING TO POLYNUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLY(A) POLYMERASE; CYTOPLASMIC POLY(A)-RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN-PARTICLES; TRANSLATION INITIATION; REPEATING STRUCTURE; POLYADENYLATION; CLEAVAGE; EXPRESSION; PURIFICATION	The 49-kDa poly(A)-binding protein II (PAB II) was purified to homogeneity from calf thymus. The 70-kDa poly(A)-binding protein I (PAB I) was obtained in different fractions of the same preparation. Whereas PAB II stimulated poly(A) polymerase, PAB I was an inhibitor. In analytical ultracentrifugation, the predominant form of PAB II was a monomer of 50.3 kDa. A sedimentation constant of only 2.2 S indicated a distinctly non-spherical shape. Binding was specific for single-stranded purine polyribonucleotides. The dependence of the dissociation constant on the length of oligoriboadenylate indicated a binding site size of 12 nucleotides. A single site was bound with a K(D) of 2 x 10(-9) M, as determined by nitrocellulose filter binding assays. From fluorescence quenching and gel retardation experiments, the packing ratio on poly(A) was estimated as 23 nucleotides/protein monomer.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND	University of Basel; University of Basel	WAHLE, E (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Bock R. M., 1967, METHODS ENZYMOLOGY A, V12, P218; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P549; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFRERE V, 1990, GENE, V96, P219, DOI 10.1016/0378-1119(90)90256-Q; LINGNER J, 1991, J BIOL CHEM, V266, P8741; PEATTIE DA, 1983, METHODS DNA RNA SEQU, P261; PINGOUD A, 1975, EUR J BIOCHEM, V56, P617, DOI 10.1111/j.1432-1033.1975.tb02269.x; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; Schachman H.K., 1959, ULTRACENTRIFUGATION; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; Stone K. L., 1988, MACROMOLECULAR SEQUE, P7; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, BIOESSAYS, V14, P113, DOI 10.1002/bies.950140208; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WERNER M, 1991, BIOCHEMISTRY-US, V30, P5832, DOI 10.1021/bi00238a004; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	45	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2937	2945						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428968				2022-12-25	WOS:A1993KK81500100
J	WAND, GS; DIEHL, AM; LEVINE, MA; WOLFGANG, D; SAMY, S				WAND, GS; DIEHL, AM; LEVINE, MA; WOLFGANG, D; SAMY, S			CHRONIC ETHANOL TREATMENT INCREASES EXPRESSION OF INHIBITORY G-PROTEINS AND REDUCES ADENYLYLCYCLASE ACTIVITY IN THE CENTRAL-NERVOUS-SYSTEM OF 2 LINES OF ETHANOL-SENSITIVE MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE ACTIVITY; INDUCED HETEROLOGOUS DESENSITIZATION; MOUSE CEREBRAL-CORTEX; REGULATES G-PROTEINS; BINDING-PROTEINS; ENZYME-ACTIVITY; MESSENGER-RNA; NEURAL CELLS; ADENOSINE	The possibility that a 7-day period of ethanol exposure could regulate expression of specific GTP-binding regulatory proteins was investigated in two distinct brain regions from two different lines of ethanol-sensitive mice. Following ethanol treatment, plasma membranes were prepared from cerebellum and pons of short and long sleep mice. Studies of membranes were performed to assess hormone-sensitive adenylylcyclase activity and to quantify expression of G-protein subunits. Immunoblot analysis showed that levels of G(i)alpha(1) and G(i)alpha(2) were markedly increased in cerebellar and pons membranes from ethanol-exposed mice compared to controls. Treatment of short sleep mice with ethanol enhanced ADP-ribosylation of both a 41- and a 39-40 kDa protein catalyzed by pertussis toxin. Ethanol did not alter expression of G(s)alpha as assessed by immunoblot analysis, cholera toxin-dependent ADP-ribosylation, or by the ability of detergent extracted G(s)alpha to reconstitute a functional adenylylcyclase in membranes from S49 cyc- murine lymphoma cells, a cell line which genetically lacks G(s)alpha. Moreover, ethanol exposure did not influence levels of G(o)alpha or Gbeta35-36 in either cerebellar or pons membranes. Cerebellar and pons membranes from ethanol-exposed short sleep mice demonstrated significantly less adenylylcyclase activity following stimulation with GTP, GTPgammaS, AlF, forskolin, and stimulatory ligands for three distinct receptors which couple to G(s)alpha. Pretreatment of membranes with pertussis toxin reversed the ethanol-induced inhibition in adenylylcyclase activity. These observations were not limited to one line of mice but were also documented in a second line of ethanol-sensitive mice (e.g. long sleep). We conclude that ethanol exposure enhances expression of G(i)alpha(1) and G(i)alpha(2) in ethanol-sensitive mice, and is associated with decreased adenylylcyclase activity. Enhanced expression of G(i)alpha(1) and G(i)alpha(2) may contribute to impaired signal transduction in the central nervous system, and reduce the efficacy of neurotransmitters which signal through the adenylylcyclase system.	JOHNS HOPKINS UNIV,SCH MED,DIV GASTROENTEROL,BALTIMORE,MD 21205	Johns Hopkins University	WAND, GS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL,720 RUTLAND AVE,ROSS BLDG,ROOM 1032,BALTIMORE,MD 21205, USA.			Levine, Michael/0000-0003-0036-7809	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009000, R29AA007384] Funding Source: NIH RePORTER; NIAAA NIH HHS [R29AA07384, R29AA-01260, R01-AA09000] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BODE DC, 1988, J PHARMACOL EXP THER, V246, P1040; CHARNESS ME, 1986, J BIOL CHEM, V261, P3164; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; CHUNG CT, 1989, J PHARMACOL EXP THER, V249, P16; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; DOWNS RW, 1985, J CLIN ENDOCR METAB, V61, P351, DOI 10.1210/jcem-61-2-351; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; GOWLER D, 1987, NATURE, V327, P229; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; HYNIE S, 1980, ACTA PHARMACOL TOX, V47, P58; JAFFEY K, 1988, NEUROSCI LETT, V84, P317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1983, J CLIN INVEST, V72, P316, DOI 10.1172/JCI110971; LEVINE MA, 1990, J BIOL CHEM, V265, P3553; LI PP, 1991, EUR J PHARM-MOLEC PH, V206, P165, DOI 10.1016/0922-4106(91)90027-F; LUCCHI L, 1983, NEUROSCI LETT, V40, P187, DOI 10.1016/0304-3940(83)90300-2; MILLER BA, 1991, BLOOD, V77, P486; MOCHLYROSEN D, 1988, NATURE, V33, P848; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NAGY LE, 1988, P NATL ACAD SCI USA, V85, P6973, DOI 10.1073/pnas.85.18.6973; RABE CS, 1990, BIOCHEM PHARMACOL, V40, P565, DOI 10.1016/0006-2952(90)90557-2; RABIN RA, 1990, J PHARMACOL EXP THER, V252, P1021; RABIN RA, 1983, J PHARMACOL EXP THER, V227, P551; ROS M, 1988, J BIOL CHEM, V263, P4362; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3906, DOI 10.1073/pnas.86.10.3906; SAITO T, 1987, J NEUROCHEM, V48, P1817, DOI 10.1111/j.1471-4159.1987.tb05741.x; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STENSTROM S, 1982, J PHARMACOL EXP THER, V221, P334; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; TABAKOFF B, 1979, J PHARMACOL EXP THER, V208, P216; TABAKOFF B, 1988, T AM SOC NEUROCHEM, V19, P144; VALVERIUS P, 1987, MOL PHARMACOL, V32, P217; VALVERIUS P, 1989, J NEUROCHEM, V52, P492, DOI 10.1111/j.1471-4159.1989.tb09147.x; WALTMAN C, IN PRESS ALCOHOL CLI; WAND GS, 1989, ENDOCRINOLOGY, V124, P518, DOI 10.1210/endo-124-1-518; WAND GS, 1991, ALCOHOL CLIN EXP RES, V15, P705, DOI 10.1111/j.1530-0277.1991.tb00583.x; WHELAND J P, 1991, Alcoholism Clinical and Experimental Research, V15, P333	42	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2595	2601						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428935				2022-12-25	WOS:A1993KK81500052
J	BROWN, PJ; SCHONBRUNN, A				BROWN, PJ; SCHONBRUNN, A			AFFINITY PURIFICATION OF A SOMATOSTATIN RECEPTOR-G-PROTEIN COMPLEX DEMONSTRATES SPECIFICITY IN RECEPTOR-G-PROTEIN COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; PITUITARY CELL-MEMBRANES; RAT-BRAIN; MOLECULAR CHARACTERIZATION; K+ CHANNELS; SOLUBILIZATION; LINE; IDENTIFICATION; INHIBITION; ANALOGS	The inhibitory neuropeptide somatostatin (SRIF) initiates many of its physiological effects by binding to membrane receptors which are coupled to pertussis toxin-sensitive G-protein(s). We have solubilized such a SRIF receptor-G-protein complex and purified it using a biotinylated SRIF analog and guanine nucleotide-dependent affinity chromatography. Following [I-125-Tyr11]SRIF binding to membranes from AR4-2J pancreatic acinar cells, only two detergents, dodecyl-beta-D-maltoside (DbetaM) and sucrose monolaureate, extracted greater than 70% of the prebound peptide in association with receptor. The DbetaM-solubilized ligand-receptor complex was extremely stable: the half-time (t1/2) for dissociation was 11 days at 4-degrees-C. However, guanosine 5'-3-O-(thio)triphosphate (10 muM) elicited rapid dissociation of the [I-125-Tyr11]SRIF-receptor complex (t1/2 < 30 s), and this effect was concentration-dependent (ED50 = 4.0 + 0.3 nM). [I-125-Tyr11]SRIF dissociation was also stimulated by GDP (ED50 = 4.1 +/- 0.3 muM), and the potency of GDP was increased 4-fold by 30 muM AlF-4. Thus, the solubilized receptor was functionally associated with G-proteins. Cross-linking of the soluble [I-125-Tyr11]SRIF-receptor complex resulted in the covalent labeling of a 70-90-kDa band, the same band that was specifically labeled in membranes. Affinity purification of the SRIF receptor-G-protein complex was accomplished by prebinding a biotinylated SRIF analog, [N-biotinyl-Leu8,D-Trp22,Tyr25]SRIF28, to membranes followed by solubilization of the ligand-receptor-G-protein complex, adsorption to streptavidin-agarose, and specific elution with 100 muM GDP, 30 muM AlF4-. G-proteins were identified in the eluate by immunoblotting with specific antipeptide antisera. Using this protocol, the G-protein subunits alpha(i)-1, alpha(i)-3, and beta36 were shown to be specifically associated with the AR4-2J cell SRIF receptor. Thus, we have developed a new, generally applicable, procedure for the efficient solubilization and affinity purification of a stable SRIF receptor-G-protein complex and have characterized the specific G-protein subunits associated with pancreatic SRIF receptors.	UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225	University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032234] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; BROWN PJ, 1992, P AM SOC BIOCH MOL B; BROWN PJ, 1992, 74TH P M END SOC; CREMO CR, 1981, ANAL BIOCHEM, V115, P331, DOI 10.1016/0003-2697(81)90014-2; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; HAGA T, 1990, RECEPTOR BIOCH PRACT, P1; HE HT, 1989, P NATL ACAD SCI USA, V86, P1480, DOI 10.1073/pnas.86.5.1480; HE HT, 1990, MOL PHARMACOL, V37, P614; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KNUHTSEN S, 1988, BIOCHEM J, V254, P641, DOI 10.1042/bj2540641; KNUHTSEN S, 1990, J BIOL CHEM, V265, P1129; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; MARIE JC, 1989, EUR J BIOCHEM, V186, P181, DOI 10.1111/j.1432-1033.1989.tb15193.x; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1990, METAB CLIN EXP S2, V39; PHILLIPS WJ, 1989, MOL PHARMACOL, V35, P533; PRESKY DH, 1988, MOL PHARMACOL, V34, P651; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; REUBI JC, 1984, NEUROSCI LETT, V49, P259, DOI 10.1016/0304-3940(84)90299-4; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHONBRUNN A, 1993, ENDOCRINOLOGY, V132, P146, DOI 10.1210/en.132.1.146; SCHONBRUNN A, 1990, METABOLISM, V39, P96, DOI 10.1016/0026-0495(90)90221-W; SCHONBRUNN A, 1991, 73RD P M END SOC WAS, P354; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUSINI C, 1986, J BIOL CHEM, V261, P6738; THERMOS K, 1988, MOL PHARMACOL, V33, P370; THERMOS K, 1989, NEUROSCIENCE, V31, P131, DOI 10.1016/0306-4522(89)90035-3; TRAN VT, 1985, SCIENCE, V228, P492, DOI 10.1126/science.2858917; VIGUERIE N, 1988, AM J PHYSIOL, V255, pG113, DOI 10.1152/ajpgi.1988.255.1.G113; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; Yamada T, 1989, HDB PHYSL 6, P431; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283; ZEGGARI M, 1987, EUR J BIOCHEM, V164, P667, DOI 10.1111/j.1432-1033.1987.tb11178.x	49	58	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6668	6676						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454639				2022-12-25	WOS:A1993KT36800085
J	ROOS, DS				ROOS, DS			PRIMARY STRUCTURE OF THE DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE GENE FROM TOXOPLASMA-GONDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; LACTOBACILLUS-CASEI; SACCHAROMYCES-CEREVISIAE; PLASMODIUM-FALCIPARUM; PNEUMOCYSTIS-CARINII; MOLECULAR CHARACTERIZATION; BIFUNCTIONAL POLYPEPTIDE	We have determined the primary genomic and cDNA sequences encoding the bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) enzyme of the protozoan parasite Toxoplasma gondii (dihydrofolate reductase, EC 1.5.1.3; thymidylate synthase EC 2.1.1.45). The DHFR-TS gene of T. gondii (strain RH) spans more than 6 kilobases of genomic DNA. Unlike the DHFR-TS genes of other protists, sequences encoding the Toxoplasma protein are interrupted by numerous intervening sequences. Analysis of processed T. gondii DHFR-TS cDNAs reveals a single open reading frame of 1830 nucleotides, predicting a 610-amino acid protein of molecular mass of 69 kilodaltons. Because its nucleotide composition and codon usage are roughly comparable to those observed in ''higher'' eukaryotes, the Toxoplasma DHFR-TS sequence is particularly useful for assessing evolutionary relationships between eukaryotic species. The predicted amino acid sequence for the DHFR-TS protein shows conservation of the major structural features identified in other DHFR and TS enzymes, while revealing certain differences which may be exploited for the design of novel antifolates for treatment of toxoplasmosis associated with AIDS.			ROOS, DS (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.			Roos, David Siker/0000-0001-6725-4089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028724, R01AI028724] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28724] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPLEMAN JR, 1990, J BIOL CHEM, V265, P5579; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARBEHENN EK, 1980, J BIOL CHEM, V255, P1978; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; BELLISARIO RL, 1976, P NATL ACAD SCI USA, V73, P1848, DOI 10.1073/pnas.73.6.1848; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Brooks R. G., 1987, Antimicrobial Agents Annual, V2, P297; BURG JL, 1988, J IMMUNOL, V141, P3584; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CELLA R, 1988, PLANT MOL BIOL, V10, P331, DOI 10.1007/BF00029883; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COWMAN AF, 1989, MOL CELL BIOL, V9, P5182, DOI 10.1128/MCB.9.11.5182; DAVIES JF, 1990, BIOCHEMISTRY-US, V29, P9467, DOI 10.1021/bi00492a021; DENG T, 1986, J BIOL CHEM, V261, P6000; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; EDMAN U, 1989, P NATL ACAD SCI USA, V86, P6503, DOI 10.1073/pnas.86.17.6503; FERONE R, 1980, P NATL ACAD SCI-BIOL, V77, P5802, DOI 10.1073/pnas.77.10.5802; FILMAN DJ, 1982, J BIOL CHEM, V257, P13663; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; FLING ME, 1988, GENE, V63, P165, DOI 10.1016/0378-1119(88)90522-7; FREISHEIM JH, 1978, J BIOL CHEM, V253, P6437; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HUGHES DE, 1989, MOL BIOCHEM PARASIT, V34, P155, DOI 10.1016/0166-6851(89)90007-8; HUYNH TV, 1984, DNA CLONING TECHNIQU, P49; HYDE JE, 1990, PHARMACOL THERAPEUT, V48, P45, DOI 10.1016/0163-7258(90)90017-V; HYDE JE, 1987, GENE, V61, P177, DOI 10.1016/0378-1119(87)90112-0; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; IWAKURA M, 1988, GENE, V64, P9, DOI 10.1016/0378-1119(88)90476-3; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JOHNSON AM, 1990, J MOL EVOL, V30, P383, DOI 10.1007/BF02101892; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEWIN B, 1990, GENES, V4; LUFT BJ, 1987, J INFECT DIS, V57, P1; MALEY GF, 1979, J BIOL CHEM, V254, P1301; MALEY GF, 1982, ARCH BIOCHEM BIOPHYS, V216, P551, DOI 10.1016/0003-9861(82)90244-2; Maniatis T., 1982, MOL CLONING; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MASTERS JN, 1983, GENE, V21, P59, DOI 10.1016/0378-1119(83)90147-6; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MELERA PW, 1988, J BIOL CHEM, V263, P1978; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; NAGEL SD, 1988, MOL BIOCHEM PARASIT, V29, P261, DOI 10.1016/0166-6851(88)90081-3; NELSON K, 1990, NUCLEIC ACIDS RES, V18, P2819, DOI 10.1093/nar/18.9.2819; OEFINER C, 1988, EUR J BIOCHEM, V174, P377; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PERRYMAN SM, 1986, MOL BIOL EVOL, V3, P313; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; REMINGTON JS, 1989, INFECT DIS, P89; SCHWARTZMAN JD, 1981, J PARASITOL, V67, P150, DOI 10.2307/3280627; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH DR, 1980, NUCLEIC ACIDS RES, V8, P2255, DOI 10.1093/nar/8.10.2255; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P218, DOI 10.1021/bi00116a031; STONE D, 1979, J BIOL CHEM, V254, P480; TAKEISHI K, 1985, NUCLEIC ACIDS RES, V13, P2035, DOI 10.1093/nar/13.6.2035; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TAYLOR GR, 1987, J BIOL CHEM, V262, P5298; TOTH I, 1987, EMBO J, V6, P1853, DOI 10.1002/j.1460-2075.1987.tb02443.x; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; [No title captured]	77	87	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6269	6280						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454599				2022-12-25	WOS:A1993KT36800032
J	ARAUJO, H; DANZIGER, N; CORDIER, J; GLOWINSKI, J; CHNEIWEISS, H				ARAUJO, H; DANZIGER, N; CORDIER, J; GLOWINSKI, J; CHNEIWEISS, H			CHARACTERIZATION OF PEA-15, A MAJOR SUBSTRATE FOR PROTEIN-KINASE-C IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIAL-CELLS; STRIATAL ASTROCYTES; CULTURED ASTROGLIA; ADENYLATE-CYCLASE; PHORBOL ESTER; PHOSPHORYLATION; MOUSE; ACTIVATION; BRAIN; NEUROTRANSMITTERS	Astrocytes in the central nervous system are involved in a variety of functions including storage of glycogen, maintenance of the extracellular ionic equilibrium, and support for the migration and the differentiation of neurons. Astrocytes express membrane receptors allowing them to respond to extracellular signals. Activation of receptors induces a cascade of events, such as stimulation of protein kinases and subsequent phosphorylation of target proteins. To understand the regulatory processes underlying neuroglial interactions, attempts were made to identify major phosphorylated proteins in striatal astrocytes, grown in primary culture and labeled with [P-32]phosphate. Two-dimensional gel electrophoresis revealed a major doublet, Pa and Pb, of highly labeled spots, with a low molecular weight (M(r) = 15,000) and acidic pI (pI = 5.2 and 5.3, respectively). Using an enriched, heat-stable, cytosolic fraction, Pa and Pb were eluted from semi-preparative two-dimensional gels and subjected to a limited proteolysis and partial microsequencing. The same sequences were obtained within Pa and Pb and had no homology with other known protein. Antibodies raised against corresponding synthetic peptides confirm that the doublet represents two isoelectric variants of the same protein, which also exists under a nonphosphorylated form, N. We propose to name this protein PEA-15, for Phosphoprotein Enriched in Astrocytes-15 kDa, according to its large enrichment in these cells. Treatment of intact astrocytes with 12-O-tetradecanoylphorbol-13-acetate (TPA), which stimulates protein kinase C (PKC), increased the phosphorylation of the more acidic spot (Pb) while decreasing Pa intensity. Stimulations of astrocytes known to increase PKC activity, i.e. noradrenaline, or its inhibition by decreasing extracellular calcium concentrations, staurosporine, or desensitization following long term treatment with TPA, induced a phosphorylation or a dephosphorylation of PEA-15, respectively. Using purified PKC, PEA-15 appeared to be a good substrate in vitro. Two-dimensional peptide mapping revealed that the phosphorylation site in intact cells was identical with the site phosphorylated by PKC in vitro. Mapping the phosphopeptides by HPLC following endolysine C treatment lead to the identification of a sequence, phosphorylated in intact astrocytes and in vitro by PKC, containing a consensus site for PKC: LTRIPSAKK. Antibodies raised against a synthetic peptide derived from this sequence recognized N and Pa in control conditions and Pb after its dephosphorylation. Thus, PEA-15 is an endogenous substrate for PKC, the kinase mediating the transition from Pa to Pb.	COLL FRANCE,INSERM,U114,CHAIRE NEUROPHARMACOL,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			herve, chneiweiss/Q-6818-2019; Araujo, Helena M/D-7149-2013; Araujo, Helena/AAP-2530-2021	herve, chneiweiss/0000-0001-7675-5061; Araujo, Helena M/0000-0003-0371-9523; Araujo, Helena/0000-0003-0371-9523				BARRES BA, 1991, J NEUROSCI, V11, P3685; BERETTA L, 1989, ENDOCRINOLOGY, V125, P1358, DOI 10.1210/endo-125-3-1358; BIRMAN S, 1989, NEUROCHEM INT, V14, P25, DOI 10.1016/0197-0186(89)90005-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CAMBRAYDEAKIN M, 1988, J NEUROCHEM, V51, P1852, DOI 10.1111/j.1471-4159.1988.tb01168.x; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHNEIWEISS H, 1985, J NEUROCHEM, V44, P1825, DOI 10.1111/j.1471-4159.1985.tb07175.x; CHNEIWEISS H, 1985, J NEUROCHEM, V44, P779, DOI 10.1111/j.1471-4159.1985.tb12883.x; CHNEIWEISS H, 1991, SOC NEUR ABSTR, V17; DENISDONINI S, 1984, NATURE, V307, P641, DOI 10.1038/307641a0; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GIAUME C, 1991, P NATL ACAD SCI USA, V88, P5577, DOI 10.1073/pnas.88.13.5577; GUILLAUME D, 1990, J NEUROCHEM, V54, P130, DOI 10.1111/j.1471-4159.1990.tb13292.x; HARRISON BC, 1990, J NEUROSCI RES, V25, P71, DOI 10.1002/jnr.490250109; HARRISON BC, 1989, J NEUROCHEM, V53, P1245, DOI 10.1111/j.1471-4159.1989.tb07421.x; HARRISON BC, 1992, J NEUROCHEM, V58, P320, DOI 10.1111/j.1471-4159.1992.tb09313.x; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HOF PR, 1988, J NEUROSCI, V8, P1922; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MCCARTHY KD, 1985, J NEUROCHEM, V44, P723, DOI 10.1111/j.1471-4159.1985.tb12875.x; MCCARTHY KD, 1988, GLIAL CELL RECEPTORS; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; NEARY JT, 1988, J NEUROCHEM, V50, P1179, DOI 10.1111/j.1471-4159.1988.tb10590.x; NEWMAN EA, 1991, J NEUROSCI, V11, P3972; NOETZEL MJ, 1990, J NEUROSCI RES, V27, P184, DOI 10.1002/jnr.490270208; POLLENZ RS, 1986, J NEUROCHEM, V47, P9; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; TAPSCOTT SJ, 1988, SCIENCE, V242, P404; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	40	137	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5911	5920						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449955				2022-12-25	WOS:A1993KR82200084
J	KUJUBU, DA; REDDY, ST; FLETCHER, BS; HERSCHMAN, HR				KUJUBU, DA; REDDY, ST; FLETCHER, BS; HERSCHMAN, HR			EXPRESSION OF THE PROTEIN PRODUCT OF THE PROSTAGLANDIN SYNTHASE-2/TIS10 GENE IN MITOGEN-STIMULATED SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEEP VESICULAR GLAND; MESSENGER-RNA; GROWTH-FACTOR; H SYNTHASE; CYCLOOXYGENASE; SYNTHETASE; IMMUNOCYTOCHEMISTRY; INTERLEUKIN-1; BIOSYNTHESIS; FIBROBLASTS	TIS10/PGS-2 encodes a prostaglandin synthase (PGS) distinct from the previously described enzyme PGS-1 (EC 1.14.99.1). We have now generated antipeptide antisera, directed to an amino acid sequence unique to the murine TIS10/PGS-2 protein, which specifically recognize the TIS10/PGS-2 antigen. TIS10/PGS-2 protein was undetectable in quiescent Swiss 3T3 cells. The level of TIS10/PGS-2 protein peaked between 6 and 8 h following phorbol ester stimulation of cells, then declined to basal levels after 18-24 h. Synthesis of TIS10/PGS-2 protein was dramatically increased in the second hour following mitogen stimulation and remained elevated for several hours. The half-life of the TIS10/PGS-2 protein was 4 h. Immunofluorescence studies demonstrated a perinuclear and cytoplasmic localization of the TIS10/PGS-2 antigen. As expected, detection of induced TIS10/PGS-2 antigen was dependent on protein synthesis. Metabolically labeled TIS10/PGS-2 protein migrated as a 71/73-kDa doublet following immunoprecipitation. Dexamethasone blocked both the TPA- and serum-induced appearance of TIS10/PGS-2 antigen. These studies demonstrate the existence of a mitogen-inducible, glucocorticoid-inhibitable, immunologically distinct prostaglandin synthase protein.	UNIV CALIF LOS ANGELES, SCH MED,BIOMED & ENVIRONM SCI LAB,WARREN HALL, 900 VET AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV NEPHROL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [M24797, 1K11 01815] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIAZ A, 1992, J BIOL CHEM, V267, P10816; EGAN RW, 1976, J BIOL CHEM, V251, P7329; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FU JY, 1990, J BIOL CHEM, V265, P16737; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HELIN L, 1987, ENDOCRINOLOGY, V121, P722; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIM RW, 1987, ONCOGENE, V1, P263; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; QURESHI SA, 1991, ONCOGENE, V6, P995; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1982, METHOD ENZYMOL, V86, P213; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	32	183	184	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5425	5430						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449903				2022-12-25	WOS:A1993KR82200015
J	SOSSIN, WS; DIAZARRASTIA, R; SCHWARTZ, JH				SOSSIN, WS; DIAZARRASTIA, R; SCHWARTZ, JH			CHARACTERIZATION OF 2 ISOFORMS OF PROTEIN-KINASE-C IN THE NERVOUS-SYSTEM OF APLYSIA-CALIFORNICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC FACILITATION; SENSORY NEURONS; PHOSPHORYLATION; TRANSLOCATION; CALMODULIN; ACTIVATION; FAMILY; GENE; DISHABITUATION; EXPRESSION	By molecular cloning Kruger et al. (Kruger, K. E., Sossin, W. S., Sacktor, T. C., Bergold, P. J., Beushausen, S., and Schwartz, J. H. (1991) J. Neurosci. 11, 2303-2313) provided evidence for three isoforms of protein kinase C (PKC) in Aplysia, two of which, Apl I and Apl II, are expressed abundantly in the nervous system. We resolve two major kinase activities from nervous tissue by column chromatography on DEAE-cellulose and hydroxylapatite (HAP), one Ca2+-activated and the other Ca+-independent. We show that these two activities correspond to the previously cloned Apl I and II. These two isoforms appear to be the only major PKCs present in nervous tissue. The Apl I kinase is strongly activated by cis-fatty acids but only in the presence of Ca2+. Thus functionally, Apl I is more like the alpha and beta isoforms of vertebrate PKC, than to the vertebrate neural gamma isoform. The Apl II kinase is Ca2+-independent and resembles vertebrate PKCepsilon. The simplicity of the PKC isoform distribution in Aplysia makes this mollusc an attractive animal for understanding the differential regulation and physiological activities of Ca2+-activated and Ca2+-independent PKCs.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032	Columbia University			Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029255, R01NS029255] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-48850] Funding Source: Medline; NINDS NIH HHS [NS-29255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; CHOI KW, 1991, J BIOL CHEM, V266, P15999; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DERIEMER SA, 1984, J NEUROSCI, V4, P1618; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; EPPLER CM, 1982, J NEUROSCI, V2, P1692; GHIRARDI M, 1992, NEURON, V9, P1; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; KRUGER KE, 1991, J NEUROSCI, V11, P2303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MURIKAMI K, 1985, FEBS LETT, V192, P189; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODA T, 1991, J NEUROCHEM, V56, P1363; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARFITT K D, 1991, Society for Neuroscience Abstracts, V17, P1487; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; SACKTOR TC, 1990, P NATL ACAD SCI USA, V87, P2036, DOI 10.1073/pnas.87.5.2036; SACKTOR TC, 1988, J PHYSIOL-PARIS, V83, P224; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P277; SHEARMAN MS, 1987, BIOCHEM BIOPH RES CO, V147, P911, DOI 10.1016/S0006-291X(87)80157-2; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; SUGITA S, 1992, J NEUROPHYSIOL, V68, P643, DOI 10.1152/jn.1992.68.2.643; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	35	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5763	5768						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449941				2022-12-25	WOS:A1993KR82200061
J	BROMME, D; BONNEAU, PR; LACHANCE, P; WIEDERANDERS, B; KIRSCHKE, H; PETERS, C; THOMAS, DY; STORER, AC; VERNET, T				BROMME, D; BONNEAU, PR; LACHANCE, P; WIEDERANDERS, B; KIRSCHKE, H; PETERS, C; THOMAS, DY; STORER, AC; VERNET, T			FUNCTIONAL EXPRESSION OF HUMAN CATHEPSIN-S IN SACCHAROMYCES-CEREVISIAE - PURIFICATION AND CHARACTERIZATION OF THE RECOMBINANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS PROTEINS; CYSTEINE PROTEINASE; PAPAIN PRECURSOR; BOVINE SPLEEN; MECHANISM; SECRETION; MUTAGENESIS; CLEAVAGE; REGION; CELLS	A cDNA encoding the human lysosomal cysteine proteinase cathepsin S precursor has been expressed in yeast using the pVT100-U expression vector containing the alpha-factor promoter. The procathepsin S gene was expressed either as a fusion protein with the pre-region or with the prepro-region of the yeast alpha-factor precursor gene. Following in vitro processing both constructs gave an identical active mature enzyme with a molecular weight of 24,000. After prolonged cultivation of the cells the recombinant protein is also found as an active proteinase in the culture supernatant. The precursor can be activated in vitro at pH 4.5 and 40-degrees-C under reducing conditions. The in vitro activated enzyme has a 6-amino acid NH2-terminal extension when compared with the native bovine enzyme. The purified enzyme displays a bell-shaped pH activity profile with a pH optimum of 6.5 and pK values of 4.5 and 7.8. The isoelectric point of the recombinant human cathepsin S is between 8.3 and 8.6 and about 1.5 pH units higher than for the bovine enzyme. The kinetic data for several synthetic substrates and inhibitors reveal a preference for smaller amino acid residues in the binding subsites S2 and S3 of cathepsin S. Like the bovine enzyme, the recombinant human cathepsin S is characterized by a broader range of pH stability (pH 5-7.5) than cathepsins B and L.	MARTIN LUTHER UNIV, INST BIOCHEM, O-4020 HALLE, GERMANY; UNIV GOTTINGEN, INST BIOCHEM 2, W-3400 GOTTINGEN, GERMANY	Martin Luther University Halle Wittenberg; University of Gottingen	BROMME, D (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MOLEC BIOL SECTOR, MONTREAL H4P 2R2, PQ, CANADA.		Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ABRAHAMSON M, 1988, SCAND J CLIN LAB INV, V48, P21; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; BROMME D, 1989, BIOCHEM J, V264, P475; ERNST JF, 1988, DNA-J MOLEC CELL BIO, V7, P355, DOI 10.1089/dna.1.1988.7.355; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KARGEL HJ, 1980, FEBS LETT, V114, P257, DOI 10.1016/0014-5793(80)81128-8; KATSUNUMA N, 1987, EXP MED, V5, P926; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KIRSCHKE H, 1981, CHEM LYSOSOMAL PROTE, P193; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZIFITTER; LEE X, 1990, J BIOL CHEM, V265, P5950; MASON RW, 1985, INTRACELLULAR PROTEI, P217; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; MENARD R, 1991, PROTEIN ENG, V4, P307; RITONJA A, 1991, FEBS LETT, V283, P329, DOI 10.1016/0014-5793(91)80620-I; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEAHAN K, 1989, CANCER RES, V49, P3809; SHI GP, 1992, J BIOL CHEM, V267, P7258; SLOANE BF, 1991, BIOMED BIOCHIM ACTA, V50, P549; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TSAI PK, 1984, J BIOL CHEM, V259, P3805; van der Stappen J W, 1991, Biochem Soc Trans, V19, p362S; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1990, J BIOL CHEM, V265, P16661; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VERNET T, 1993, IN PRESS PROTEIN ENG; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5	39	160	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4832	4838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444861				2022-12-25	WOS:A1993KP88400044
J	HUANG, CH; REID, ME; BLUMENFELD, OO				HUANG, CH; REID, ME; BLUMENFELD, OO			EXON SKIPPING CAUSED BY DNA RECOMBINATION THAT INTRODUCES A DEFECTIVE DONOR SPLICE SITE INTO THE HUMAN GLYCOPHORIN-A GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; MESSENGER-RNA; HEREDITARY ELLIPTOCYTOSIS; MOLECULAR ANALYSIS; EXPRESSION; IDENTIFICATION; SEQUENCES; DELETION; MUTATION; VARIANT	We report here the pre-mRNA splicing of the human glycophorin M(z) (HGpM(z)) gene altered by a defective donor splice site introduced into the third intron via the mechanism of gene conversion. We found that the directional transfer from HGpB(delta) to HGpA(alpha) of a 145-base pair silent homologous segment had resulted in HGpM(z) as an alpha-delta-alpha hybrid gene with a G-T transversion in the consensus GT motif of the 5'-donor splice site. Transcript analysis showed the presence in the M(z) reticulocytes of three major glycophorin cDNA species of which two occurred as the shortened and aberrantly spliced products of HGpM(z) pre-mRNA lacking the sequences encoded by one and two exons, respectively. The skipping of exon III results in one HGpM(z) protein with 99 amino acids that bears the M and St(a) blood group antigens, whereas the coincident skipping of both exon III and exon IV leads to the expression of a minor HGpM(z) protein with 86 amino acids. These results indicate that the translocated defective donor splice site not only causes uniform skipping of the upstream exon but also affects the processing of the downstream exon. Complementing our previous studies, the finding that the active and inactive splice sites can be transposed by DNA recombination and alternatively used to construct new glycophorin alleles reveals a novel mechanism for sequence diversification in human genes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	Yeshiva University; Albert Einstein College of Medicine; New York Blood Center					NCI NIH HHS [5P30 CA13330] Funding Source: Medline; NIGMS NIH HHS [R01 GM 16389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AKLI S, 1990, J BIOL CHEM, V265, P7324; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; CHIODO AA, 1992, J BIOL CHEM, V267, P6361; DAHR W, 1990, BIOL CHEM H-S, V371, P403, DOI 10.1515/bchm3.1990.371.1.403; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; Goossens M, 1981, Methods Enzymol, V76, P805; GOTODA T, 1991, J BIOL CHEM, V266, P24757; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1988, P NATL ACAD SCI USA, V85, P9640, DOI 10.1073/pnas.85.24.9640; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1989, BLOOD, V74, P836; HUANG CH, 1992, BLOOD, V80, P2379; HUANG CH, 1992, J BIOL CHEM, V267, P3336; HUANG CH, 1992, BLOOD, V80, P257; HUANG CH, 1991, BLOOD, V77, P1813; HUANG CH, 1991, J BIOL CHEM, V266, P7248; HUANG CH, 1991, J BIOL CHEM, V266, P23306; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUIVANIEMI H, 1990, J BIOL CHEM, V265, P12067; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LOSSI AM, 1989, FEBS LETT, V256, P163, DOI 10.1016/0014-5793(89)81740-5; LU YQ, 1987, BLOOD, V69, P618; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; ORKIN SH, 1984, ANNU REV GENET, V18, P131; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAHUEL C, 1988, EUR J BIOCHEM, V177, P605, DOI 10.1111/j.1432-1033.1988.tb14413.x; REARDEN A, 1990, J BIOL CHEM, V265, P9259; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TACCHINICOTTIER FM, 1988, J IMMUNOL, V141, P3647; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; YOON SH, 1991, J BIOL CHEM, V266, P8490	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4945	4952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444872				2022-12-25	WOS:A1993KP88400059
J	DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD				DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD			AN IMMEDIATE EARLY HUMAN GENE ENCODES AN ID-LIKE HELIX LOOP HELIX PROTEIN AND IS REGULATED BY PROTEIN-KINASE-C ACTIVATION IN DIVERSE CELL-TYPES	ONCOGENE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; MURINE HOMOLOG; SARCOMA-VIRUS; 3T3 CELLS; MYC; EXPRESSION; FIBROBLASTS; SEQUENCE; MUSCLE	Transcription factors characterized by the presence of a helix-loop-helix (HLH) domain play a central role in the regulation of cell growth/differentiation and tumorigenesis. We report here the cDNA sequence of a human early-response gene, designated HLH 1R21, encoding a 15-kDa HLH protein that lacks a basic, DNA-binding domain and which by a number of criteria appears to be the human homologue of mouse HLH 462. Like its murine counterpart, HLH 1R21 protein functions as an Id (inhibitor of DNA binding) transcription factor by inhibiting the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer oligonucleotide in vitro. However HLH 1R21 does not inhibit the binding of HLH Max protein to a Max-binding oligonucleotide in vitro, indicating that it has limited promiscuity in its ability to antagonize the function of other HLH transcription factors. In addition, HLH 1R21 mRNA transcripts are regulated by phorbol ester treatment of a diverse range of human cell lines and, when overexpressed in mouse NIH3T3 cells, HLH 1R21 induces a morphologically transformed phenotype.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT GENE REGULAT,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT CANC GENET,MANCHESTER M20 9BX,ENGLAND; KINGS COLL,IMMUNOL SECT,LONDON W8 7AH,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of London; King's College London			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153				BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GOLDFARB M, 1991, ONCOGENE, V6, P65; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSAIO WL, 1989, MOL CELL BIOL, V9, P2641; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MILLER AD, 1984, CELL, V36, P51; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTON JD, 1984, J VIROL, V50, P439, DOI 10.1128/JVI.50.2.439-444.1984; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VLODAVSKY GM, 1980, CELL, V19, P606; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	36	105	107	2	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					599	607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437843				2022-12-25	WOS:A1993KN00800010
J	MAHER, DW; STRAWN, LM; DONOGHUE, DJ				MAHER, DW; STRAWN, LM; DONOGHUE, DJ			ALANINE MUTAGENESIS OF CONSERVED RESIDUES IN THE PLATELET-DERIVED GROWTH-FACTOR FAMILY - IDENTIFICATION OF RESIDUES NECESSARY FOR DIMERIZATION AND TRANSFORMATION	ONCOGENE			English	Article							V-SIS GENE; ENDOTHELIAL-CELL MITOGEN; TERMINAL CODING REGION; PDGF-B-CHAIN; BOVINE PAPILLOMAVIRUS; AMINO-ACIDS; RECEPTOR; PROTEIN; BINDING; AUTOPHOSPHORYLATION	Platelet-derived growth factor (PDGF) and vascular endothelial growth factor define a family of dimeric proteins characterized by eight conserved cysteine residues involved in disulfide bonds. Thirteen non-cysteine residues conserved among the platelet-derived/vascular endothelial growth factors were individually mutated to alanine in v-sis/PDGF-B. In addition, five other residues flanking F148 were also mutated to alanine. The resulting mutants were assayed for transformation of NIH3T3 cells, and the mutant proteins were assayed for their ability to dimerize. Four residues were found to be crucial for disulfide-linked dimer formation: P152 and (;162 were mandatory, while R159 and H205 also contributed to efficient dimerization. Four of the mutant proteins (at residues N147, F148, L149 and K185) dimerized efficiently yet exhibited less than 50% transforming activity compared with wild-type v-sis. Two mutants (at residues D142 and F148) were located in a region important for PDGF receptor interaction and were further studied with regard to secretion and PDGF receptor autophosphorylation. A series of substitutions at residue F148 revealed a strong preference for aromatic amino acids. One mutant from this series (F148G) dimerized but was completely inactive for transformation. This study thus identifies four residues in v-sis/PDGF-B important for dimerization and also identifies additional residues critical for full activation of PDGF receptors. The E5 oncoprotein encoded by bovine papillomavirus type I exhibits two short regions of amino acid similarity when compared with the minimal transforming region of v-sis/PDGF-B. Several of the v-sis mutants discussed in this work affect residues that are also present in the E5 oncoprotein, including F148, L149 and H205.	UNIV CALIF SAN DIEGO,DEPT CHEM,DIV BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA040573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAINES EW, 1984, P NATL ACAD SCI USA, V81, P3423; RAMACHANDRAN GN, 1966, BIOPHYS J, V6, P849, DOI 10.1016/S0006-3495(66)86699-7; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; SAUER MK, 1986, J VIROL, V59, P292, DOI 10.1128/JVI.59.2.292-300.1986; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011	36	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					533	541						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437840				2022-12-25	WOS:A1993KN00800002
J	SZWEDA, LI; UCHIDA, K; TSAI, L; STADTMAN, ER				SZWEDA, LI; UCHIDA, K; TSAI, L; STADTMAN, ER			INACTIVATION OF GLUCOSE-6-PHOSPHATE-DEHYDROGENASE BY 4-HYDROXY-2-NONENAL - SELECTIVE MODIFICATION OF AN ACTIVE-SITE LYSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCTS; ASCITES TUMOR-CELLS; LEUCONOSTOC-MESENTEROIDES; LIVER; ALDEHYDES; SEQUENCE; ACIDS	Incubation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides with 4-hydroxy-2-nonenal (HNE) results in a pseudo first-order loss of enzyme activity. The pH dependence of the inactivation rate exhibits an inflection around pH 10, and the enzyme is protected from inactivation by glucose 6-phosphate. Loss of enzyme activity corresponds with the formation of one carbonyl function per enzyme subunit and the appearance of a lysine-HNE adduct. The data presented in this paper are consistent with the view that the epsilon-amino group of a lysine residue in the glucose beta-phosphate-binding site reacts with the double bond (C3) of HNE, resulting in the formation of a stable secondary amine derivative and loss of enzyme activity. We have described a mechanism by which HNE may, in part, mediate free radical damage. In addition, a method for the detection of the lysine-HNE adduct is introduced.	NHLBI,BIOCHEM LAB,BLDG 3,RM 222,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Uchida, Koji/0000-0003-3894-5299				BENEDETTI A, 1982, BIOCHIM BIOPHYS ACTA, V711, P345, DOI 10.1016/0005-2760(82)90044-3; BENEDETTI A, 1986, BIOCHIM BIOPHYS ACTA, V876, P658, DOI 10.1016/0005-2760(86)90055-X; CHURCH FC, 1985, ANAL BIOCHEM, V146, P343, DOI 10.1016/0003-2697(85)90549-4; DEMONTARBY L, 1989, B SOC CHIM FR, P419; ESTERBAUER H, 1989, FREE RADICAL BIO MED, V7, P197, DOI 10.1016/0891-5849(89)90015-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; HAGHIGHI B, 1982, BIOCHEMISTRY-US, V21, P6415, DOI 10.1021/bi00268a015; ISHAQUE A, 1974, BIOCHEM BIOPH RES CO, V59, P894, DOI 10.1016/S0006-291X(74)80063-X; LEE WT, 1991, J BIOL CHEM, V266, P13028; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LICHTENSTEIN IE, 1966, J FRANKLIN I, V281, P481, DOI 10.1016/0016-0032(66)90435-2; MILHAUSEN M, 1975, EUR J BIOCHEM, V50, P453, DOI 10.1111/j.1432-1033.1975.tb09823.x; OLIVE C, 1971, J BIOL CHEM, V246, P2047; SHAUENSTEIN E, 1979, CIBA F SERIES, V67, P225; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P5611, DOI 10.1073/pnas.89.12.5611; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P232, DOI 10.1016/0005-2760(84)90122-X; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8	19	273	276	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3342	3347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429010				2022-12-25	WOS:A1993KM16100051
J	CHEN, GG; JAGENDORF, AT				CHEN, GG; JAGENDORF, AT			IMPORT AND ASSEMBLY OF THE BETA-SUBUNIT OF CHLOROPLAST COUPLING FACTOR-I (CF(1)) INTO ISOLATED INTACT CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; ATP SYNTHASE; FACTOR-I; POLYPHENOL OXIDASE; MEMBRANE-PROTEINS; INVITRO SYNTHESIS; FOREIGN PROTEIN; TRANSIT PEPTIDE; TRANSPORT; TENTOXIN	The transit peptide gene of the small subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase from Nicotiana plumbaginifolia was fused to the tentoxin-resistant beta-subunit gene of chloroplast coupling factor 1 (CF1) from Nicotiana tabacum via a linker sequence. The consequent fusion gene encodes the entire gene sequences of both the transit peptide and the beta-subunit of CF1 without a single change of amino acid residues. The fusion gene was in vitro expressed in a coupled transcription-translation system as a 62-kDa precursor and was imported into isolated intact chloroplasts of Nicotiana longiflora. The imported precursor was found to be processed to the expected mature beta-subunit size. Evidence is presented that radioactively labeled beta-subunit was incorporated into mature CF1 and not just nonspecifically associated with the thylakoid membranes. Since the fusion protein containing only the transit peptide sequence was imported and apparently correctly processed, it may not be necessary to include N-terminal amino acids of the mature small subunit for correct proteolytic cleavage in the chloroplast stroma.	CORNELL UNIV, PLANT BIOL SECT, PLANT SCI BLDG, ITHACA, NY 14853 USA	Cornell University								AVNI A, 1991, J BIOL CHEM, V266, P7317; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BHAYA D, 1985, ARCH BIOCHEM BIOPHYS, V237, P217, DOI 10.1016/0003-9861(85)90272-3; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CASHMORE A, 1985, BIO-TECHNOL, V3, P803, DOI 10.1038/nbt0985-803; CHEN GG, 1989, THESIS CORNELL U; CLINE K, 1986, J BIOL CHEM, V261, P4804; DANIELL H, 1990, P NATL ACAD SCI USA, V87, P88, DOI 10.1073/pnas.87.1.88; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DOBBERSTEIN B, 1977, P NATL ACAD SCI USA, V74, P1082, DOI 10.1073/pnas.74.3.1082; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; GATENBY AA, 1988, EMBO J, V7, P1307, DOI 10.1002/j.1460-2075.1988.tb02945.x; HERRIN D, 1985, ARCH BIOCHEM BIOPHYS, V237, P224, DOI 10.1016/0003-9861(85)90273-5; HUDSON GS, 1988, PHOTOSYNTH RES, V18, P205, DOI 10.1007/BF00042985; JAGENDORF AT, 1991, CELL CULTURE SOMATIC, P225; JOSHI RL, 1991, FEBS LETT, V281, P1, DOI 10.1016/0014-5793(91)80346-5; KASAMO K, 1989, PLANT CELL PHYSIOL, V30, P729; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KLOTZ MG, 1988, PHYSIOL PLANTARUM, V74, P575, DOI 10.1111/j.1399-3054.1988.tb02021.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEU S, 1990, FEBS LETT, V269, P41, DOI 10.1016/0014-5793(90)81114-4; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARGULIES MM, 1983, EUR J BIOCHEM, V137, P241, DOI 10.1111/j.1432-1033.1983.tb07821.x; MEYER WL, 1975, J AM CHEM SOC, V97, P3802, DOI 10.1021/ja00846a041; NAGLEY P, 1989, TRENDS BIOCHEM SCI, V14, P31, DOI 10.1016/0968-0004(89)90087-X; PEACOCK J, 1992, NATURE, V357, P358, DOI 10.1038/357358a0; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; POULSEN C, 1986, MOL GEN GENET, V205, P193, DOI 10.1007/BF00430426; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; SHINOHARA K, 1988, ARCH BIOCHEM BIOPHYS, V260, P452, DOI 10.1016/0003-9861(88)90469-9; Shinozaki K., 1986, PLANT MOL BIOL REP, V4, P111, DOI DOI 10.1007/BF02669253; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VAUGHN KC, 1984, PHYSIOL PLANTARUM, V60, P257, DOI 10.1111/j.1399-3054.1984.tb04574.x; VAUGHN KC, 1981, PHYSIOL PLANTARUM, V53, P421, DOI 10.1111/j.1399-3054.1981.tb02725.x; VAUGHN KC, 1982, PHYSIOL PLANTARUM, V11, P48; WALDEN R, 1990, EUR J BIOCHEM, V192, P563, DOI 10.1111/j.1432-1033.1990.tb19262.x; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; YE GN, 1990, PLANT MOL BIOL, V15, P808	45	4	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2363	2367						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428910				2022-12-25	WOS:A1993KK81500020
J	FERNANDEZCHECA, JC; YI, JR; GARCIARUIZ, C; KNEZIC, Z; TAHARA, SM; KAPLOWITZ, N				FERNANDEZCHECA, JC; YI, JR; GARCIARUIZ, C; KNEZIC, Z; TAHARA, SM; KAPLOWITZ, N			EXPRESSION OF RAT-LIVER REDUCED GLUTATHIONE TRANSPORT IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFLUX; HEPATOCYTES; INHIBITION; SYSTEM; METHIONINE; KINETICS; MEMBRANE; CLONING	We have studied the expression of the hepatic GSH transport system in Xenopus laevis oocytes. Injection of rat liver poly(A)+ RNA resulted in the functional expression of the GSH transport system determined as GSH efflux from GSH loaded oocytes. Expression required 3-5 days to process the liver mRNA. Methionine, cystathionine, and sulfobromophthalein (BSP)-GSH inhibited the efflux of GSH from liver mRNA-injected oocytes according to their known cis or transactions on hepatocytes, namely BSP-GSH from inside and methionine and cystathionine from outside. The expressed hepatic GSH transport system also mediated the uptake of intact GSH into the oocyte, consistent with the bidirectional operation of this facilitative transporter. The uptake of GSH into mRNA-injected oocytes was inhibited by BSP-GSH in chloride-free conditions. Finally, two different mRNA size fractions encoded for hepatic GSH transport activity (uptake or efflux): a 2.0-2.5-kilobase size class, which expressed GSH transport (uptake or efflux) completely inhibited by BSP-GSH (compatible with sinusoidal GSH transport), and a 3.5-4.0-kilobase size class, which expressed GSH transport (uptake or efflux) not inhibited by BSP-GSH. These results demonstrate that hepatic GSH transport can be expressed in Xenopus oocytes and mRNA of two distinct sizes encode for GSH transporters.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990; Tahara, Stanley/0000-0001-5097-0927	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030312, R37DK030312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1984, J BIOL CHEM, V259, P9355; BOORER KJ, 1992, FEBS LETT, V302, P166, DOI 10.1016/0014-5793(92)80431-F; COLMAN A, 1986, TRANSCRIPTION TRANSL, P271; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; MANIATIS T, 1982, MOL CLONING LABORATO, P461; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; WEBER WM, 1989, J MEMBRANE BIOL, V111, P93, DOI 10.1007/BF01869212; WHELAN G, 1970, J LAB CLIN MED, V75, P542; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946	24	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2324	2328						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428906				2022-12-25	WOS:A1993KK81500014
J	MOLKENTIN, JD; BROGAN, RS; JOBE, SM; MARKHAM, BE				MOLKENTIN, JD; BROGAN, RS; JOBE, SM; MARKHAM, BE			EXPRESSION OF THE ALPHA-MYOSIN HEAVY-CHAIN GENE IN THE HEART IS REGULATED IN PART BY AN E-BOX-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART; BINDING-FACTOR; MUSCLE-CELLS; FUSION GENE; TRANSCRIPTION; PROMOTER; FIBROBLASTS; MYOBLASTS; MYOD; IDENTIFICATION	Proximal regulatory element B (PRE-B), located from positions -318 to -284 in the a-myosin heavy chain (MHC) promoter, stimulated expression from an otherwise weak alpha-MHC promoter fragment in primary rat neonatal cardiomyocytes but not in the C2C12 myogenic cell line. PRE-B interacted with alpha-MHC binding factor 2 (BF-2), a protein found in nuclear extracts from several neonatal rat tissues and cell types including cardiomyocytes. BF-2 DNA binding activity was greatly reduced in adult versus neonatal tissues. Methylation interference footprints indicated that BF-2 bound to an element that included an E-box consensus sequence. Site-directed mutations in the BF-2-binding site, that abolish BF-2 binding, reduced expression from the full-length alpha-MHC promoter by 70%. A BF-2-like protein interacts within the HF-1a element of the myosin light chain-2 (MLC-2) promoter suggesting that one of the proteins that regulates the alpha-MHC and MLC-2 genes is identical or closely related. Analysis of binding by competition gel shift experiments indicated that both BF-2 and HF-1a are E-box-binding proteins. The alpha-MHC and MLC-2 genes encode contractile proteins which are precursors of myosin. Regulation by the same transcription factor might indicate that the expression of alpha-MHC and MLC-2 is coordinately controlled.	MED COLL WISCONSIN, CARDIOVASC RES CTR, DEPT PHYSIOL, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, MOLEC & CELLULAR BIOL TRAINING PROGRAM, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, MED SCIENTIST TRAINING PROGRAM, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin				Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043662] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43662] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BURT JM, 1982, J MEMBRANE BIOL, V68, P227, DOI 10.1007/BF01872267; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JACKOWSKI G, 1980, BIOCHEM J, V188, P363, DOI 10.1042/bj1880363; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MARKHAM BE, 1987, J BIOL CHEM, V262, P12856; Maxam A M, 1980, Methods Enzymol, V65, P499; MORKIN E, 1989, CELLULAR MOL BIOL MU, P381; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OJAMAA K, 1991, BIOCHEM BIOPH RES CO, V179, P1269, DOI 10.1016/0006-291X(91)91710-T; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMEDA PK, 1986, MOL BIOL MUSCLE DEV, P808; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	40	39	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2602	2609						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428936				2022-12-25	WOS:A1993KK81500053
J	PEREZ, HD; HOLMES, R; VILANDER, LR; ADAMS, RR; MANZANA, W; JOLLEY, D; ANDREWS, WH				PEREZ, HD; HOLMES, R; VILANDER, LR; ADAMS, RR; MANZANA, W; JOLLEY, D; ANDREWS, WH			FORMYL PEPTIDE RECEPTOR CHIMERAS DEFINE DOMAINS INVOLVED IN LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN	We have begun to study the structural requirements for the binding of formyl peptides to their specific receptors. As an initial approach, we constructed C5a-formyl peptide receptor chimeras. Unique (and identical) restriction sites were introduced within the transmembrane domains of these receptors that allowed for the exchange of specific areas. Four types of chimeric receptors were generated. 1) The C5a receptor was progressively substituted by the formyl peptide receptor. 2) The formyl peptide receptor was progressively substituted by the C5a receptor. 3) Specific domains of the C5a receptor were substituted by the corresponding domain of the formyl peptide receptor. 4) Specific domains of the formyl peptide receptor were replaced by the same corresponding domain of the C5a receptor. Wild type and chimeric receptors were transfected into COS 7 cells and their ability to bind formyl peptide determined, taking into account efficiency of transfection and expression of chimeric protein. Based on these results, a ligand binding model is presented in which the second, third, and fourth extracellular (and/or their transmembrane) domains together with the first transmembrane domain form a ligand binding pocket for formyl peptides. It is proposed that the amino-terminal domain plays a role by presumably providing a ''lid'' to the pocket. The carboxyl-terminal cytoplasmic tail appears to modulate ligand binding by regulating receptor affinity.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PEREZ, HD (corresponding author), BERLEX BIOSCI INC,213 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM028566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028290] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-28566] Funding Source: Medline; NIAID NIH HHS [AI-28290] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOMMAKANTI RK, 1992, CLIN RES, V40, pA352; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; KUNZ D, 1992, J BIOL CHEM, V267, P9101; PEREZ HD, 1992, J BIOL CHEM, V267, P358; PEREZ HD, 1992, BIOCHEMISTRY-US, V31, P11595, DOI 10.1021/bi00161a044; PEREZ HD, 1992, GENE, V118, P303, DOI 10.1016/0378-1119(92)90208-7; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; PROSSNITZ E, 1992, FASEB J, V6, pA2058; QUEHENBERGER O, 1992, FASEB J, V6, pA2056; RADEL SJ, 1991, BIOCHEM INT, V25, P745; SCHREIBER RE, 1992, FASEB J, V6, pA2056	13	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2292	2295						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428903				2022-12-25	WOS:A1993KK81500007
J	MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK				MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK			DNA-BINDING BY N-MYC AND L-MYC PROTEINS	ONCOGENE			English	Note							LOOP-HELIX PROTEIN; LEUCINE-ZIPPER REGION; C-MYC; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; TRANSGENIC MICE; ENHANCER; MYOD; OLIGOMERIZATION; EXPRESSION	N- and L-Myc, like c-Myc, contain adjacent basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) motifs, which characterize a family of DNA-binding proteins. We have used a polymerase chain reaction (PCR)-based binding site selection technique to demonstrate that the most highly preferred binding site for both N- and L-Myc fusion proteins contains a CACGTG motif, the core binding sequence previously identified for c-Myc. Further analysis identified other N-Myc binding sequences, including asymmetric sequences such as CATGTG. N-Myc, like c-Myc, preferentially forms heterodimeric DNA-binding complexes with Max protein. Mutational analyses of N-Myc basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) regions revealed that all three regions are necessary for DNA binding by N-Myc-Max complexes, and that dimerization requires both HLH and LZ motifs, while BR sequences are needed only for DNA binding. Our findings support the notion that the LZ motif is a critical element in dimer formation by bHLH-LZ proteins.	CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center			Moroy, Tarik/D-9923-2011		NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALOZENETIS T, 1992, SCIENCE, V255, P464; HALOZENETIS T, 1991, P NATL ACAD SCI USA, V88, P6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA H, 1989, ONCOGENE, V4, P999; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	39	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1093	1098						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455937				2022-12-25	WOS:A1993KT22000036
J	BELLELLI, A; BRANCACCIO, A; BRUNORI, M				BELLELLI, A; BRANCACCIO, A; BRUNORI, M			HYDRATION AND ALLOSTERIC TRANSITIONS IN HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOHYDRIC ALCOHOLS; OXYGEN-AFFINITY; RESOLUTION; WATER	Sucrose and other neutral solutes reduce the oxygen affinity of human hemoglobin. This effect was attributed by Colombo et al. (Colombo, M. F., Rau, D. C., and Parsegian, V. A. (1992) Science 256, 655-659) to a stabilization of the deoxy-T quaternary state of hemoglobin A, via a reduction of the activity coefficient of water. This was correlated to crystallographic results which showed that a significant surface area at the alpha1beta2 interface, which is exposed to the solvent in the oxy-R state, is buried in the deoxy-T state. We show that sucrose has no effect on the oxygen affinity of trout hemoglobin I, which is cooperative in oxygen binding but lacks heterotropic effects, and that in spite of the large buried surface exposed to solvent upon dissociation of human hemoglobin into alphabeta dimers, sucrose leads either to an increased dissociation of hemoglobin A-CO into dimers or to no effect at all (in the presence of inositol hexakisphosphate). These results may demand a reconsideration of the hypothesis extensively discussed by Colombo et al.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM,PALE A MORO 5,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Bellelli, Andrea/D-2785-2009; Brancaccio, Andrea/C-5876-2009	Brancaccio, Andrea/0000-0003-4690-8826; Brunori, Maurizio/0000-0002-7795-1635				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; Brunori M, 1975, Curr Top Cell Regul, V9, P1; BULONE D, 1991, J CHEM PHYS, V94, P6816, DOI 10.1063/1.460260; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; CORDONE L, 1981, BIOPOLYMERS, V20, P53, DOI 10.1002/bip.1981.360200105; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FERMMI G, 1981, HAEMOGLOBIN MYOGLOBI, V2; GIBSON QH, 1967, J BIOL CHEM, V242, P4678; HAIRE RN, 1983, BIOCHEMISTRY-US, V22, P327, DOI 10.1021/bi00271a015; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; 1937, INT ANN TABLES CONST	19	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4742	4744						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444850				2022-12-25	WOS:A1993KP88400031
J	SOLOMON, WB; LIN, CH; PALMA, J; GAO, XY; WU, SL				SOLOMON, WB; LIN, CH; PALMA, J; GAO, XY; WU, SL			SUPPRESSION OF A CELLULAR-DIFFERENTIATION PROGRAM BY PHORBOL ESTERS COINCIDES WITH INHIBITION OF BINDING OF A CELL-SPECIFIC TRANSCRIPTION FACTOR (NF-E2) TO AN ENHANCER ELEMENT REQUIRED FOR EXPRESSION OF AN ERYTHROID-SPECIFIC GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; PROTEIN DNA INTERACTIONS; INDUCIBLE ENHANCER; GLOBIN GENES; FACTOR AP-1; LINE K562; C-JUN; SITES; INVIVO; LOCUS	Induction by hemin increases, while induction with 12-O-tetradecanoylphorbol-13-acetate (TPA) represses, erythroid-specific gene expression in the human cell line K562. We analyzed the effects of hemin or TPA induction on the binding and activity of transcription factors at a regulatory element found within the transcriptional regulatory sequences of many erythroid-specific genes. TPA induction increases the binding of ubiquitous AP-1 factors to this element. TPA induction inhibits the binding of the lineage limited transcription factor NF-E2 to this transcriptional control element. Hemin induction of K562 cells does not facilitate the binding of NF-E2 to its recognition site. Hemin induction appears to nonspecifically increase the expression of transiently transfected genes in K562 cells. Beyond this nonspecific increase in gene expression, hemin induction acts to increase the activity of the lineage limited transcription factor NF-E2. The divergent effects of hemin and TPA on gene expression in K562 cells are mediated, in part, by their contrasting effects on the transcription factor NF-E2.	SUNY HSC,MORSE INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	SOLOMON, WB (corresponding author), SUNY HSC,DEPT MED,DIV HEMATOL & ONCOL,BOX 44,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.				NIDDK NIH HHS [DK 39566] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039566] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; Maxam A M, 1980, Methods Enzymol, V65, P499; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Siebert P D, 1985, Prog Clin Biol Res, V191, P233; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5089	5096						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444885				2022-12-25	WOS:A1993KP88400078
J	TOMASKA, L; RESNICK, RJ				TOMASKA, L; RESNICK, RJ			SUPPRESSION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TYROSINE KINASE-ACTIVITY BY UNSATURATED FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; PHYSICAL ASSOCIATION; POTASSIUM CHANNELS; ADENYLATE CYCLASE; BINDING PROTEINS	Treatment of cells with platelet-derived growth factor (PDGF) was previously shown to increase the release of unesterified fatty acids from phospholipids. In view of these observations we examined the effect of various fatty acids on PDGF receptor activity. Unsaturated (oleic, linoleic, linolenic, and arachidonic) but not saturated (stearic and arachidic) fatty acids significantly inhibited the tyrosine kinase activity of the PDGF receptor in intact cells and membrane preparations. Half-maximal inhibition (IC50) was observed between 60 and 100 muM and maximal inhibition between 170 and 200 muM. Lysophospholipids and phospholipids had no effect on receptor activity. Activation of endogenous phospholipase A2 by mellitin in vivo or hydrolysis of phosphatidylcholine by purified phospholipase A2 in vitro inhibited PDGF receptor autophosphorylation similar to that of purified fatty acids. Dimerization of PDGF receptors in vivo was significantly reduced by concentrations of arachidonic acid inhibitory for receptor kinase activity while the binding of PDGF was only marginally affected. These data suggest a possible feedback mechanism resulting in the reduction of PDGF receptor activity by unsaturated fatty acids generated downstream within the PDGF-dependent signal transduction pathway and this effect may be as a direct result of decreased receptor dimerization and/or kinase activity.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University			Tomaska, Lubomir/I-3071-2014	Tomaska, Lubomir/0000-0003-4886-1910	NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BISHAYEE S, 1989, J BIOL CHEM, V264, P11688; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FAIN JN, 1975, J BIOL CHEM, V250, P6586; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT I H, 1991, Cellular Physiology and Biochemistry, V1, P177, DOI 10.1159/000154605; LEVINE L, 1979, HORMONES CELL CULTUR, P623; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LOPEZRIVAS A, 1984, EMBO J, V3, P939, DOI 10.1002/j.1460-2075.1984.tb01911.x; MALGIERI JA, 1975, J BIOL CHEM, V250, P6593; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORLY J, 1975, P NATL ACAD SCI USA, V72, P3433, DOI 10.1073/pnas.72.9.3433; PAWSON T, 1988, ONCOGENE, V3, P491; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCROEDER E, 1971, EXPERIENTIA, V15, P764; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SPEIZER LA, 1991, AM J PHYSIOL, V261, P109; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WALLACH D, 1976, J BIOL CHEM, V251, P5802; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	81	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5317	5322						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444905				2022-12-25	WOS:A1993KP88400107
J	WANG, JT; GROSSMAN, L				WANG, JT; GROSSMAN, L			MUTATIONS IN THE HELIX-TURN-HELIX MOTIF OF THE ESCHERICHIA-COLI UVRA PROTEIN ELIMINATE ITS SPECIFICITY FOR UV-DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; NUCLEOTIDE EXCISION REPAIR; T4 ENDONUCLEASE-V; BACTERIOPHAGE-LAMBDA; CRYSTAL-STRUCTURE; ZINC FINGERS; BINDING; COMPLEX; RECOGNITION; REPRESSOR	The Escherichia coli UvrA protein possesses a stretch of amino acids, 494 to 513, that matches the consensus sequence of the helix-turn-helix motif of many sequence-specific DNA binding proteins. It also has two zinc finger motif regions and two ATP binding sites. To study the potential roles of both helix-turn-helix and zinc finger motifs in the functioning of UvrA protein, random mutations were created in these motif regions by degenerate oligonucleotide-directed mutagenesis. Using this method, 12 single substitution mutants (eight in the helix-turn-helix motif region, one in the N-terminal zinc finger region, and three in the C-terminal zinc finger region) were isolated that failed to confer UV resistance in the E. coli strain deleted of the uvrA gene. One ''hyper'' UV-resistant mutant, G275A, was identified that conferred significantly more UV resistance than the wild type in the MH1-DELTAA strain. To further investigate the mechanism of failure of these mutant UvrA proteins to support nucleotide excision repair, two mutant UvrA proteins, G502D and V508D, were selected for purification and characterization, since they carry mutations at the positions offered as the putative constellation for the helix-turn-helix motif. The binding affinity of these two mutants for nonirradiated plasmid DNA was unaffected by the mutations. Both mutant proteins exhibited substantial ATPase activity, and together with the UvrB protein, they were capable of generating positively supercoiled plasmid DNA from the relaxed form in the presence of ATP and bacterial topoisomerase I. However, both mutant proteins failed to respond to UV damage in the filter binding assay and were incapable of forming 2 x SSC-resistant nucleoprotein complexes with UvrB protein on UV-irradiated plasmid DNA. Taking these properties together, it appears that the mutations in the helix-turn-helix motif region impaired the UvrA protein's ability to recognize UV damage, while its other activities were largely unaffected. Interestingly, ERCC-3, a human DNA repair protein, also has a similar helix-turn-helix motif. Given the highly conserved nature of repair proteins in general, this observation raises the possibility that both procaryotes and eucaryotes might use similar mechanisms to recognize damaged sites in their genomes.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,615 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM31110, GM 22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM031110, R01GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; DICKSTEIN R, 1988, MUTAT RES, V193, P75, DOI 10.1016/0167-8817(88)90009-0; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12738; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; JENCKS WP, 1982, MEMBRANES TRANSPORT, V1, P515; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1988, UCLA S MOL CELL BIOL, V83, P87; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PORTER SD, 1986, NATURE, V320, P766, DOI 10.1038/320766a0; REDEMANN N, 1988, NATURE, V332, P90, DOI 10.1038/332090a0; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; VANHOUTEN B, 1987, J BACTERIOL, V169, P540, DOI 10.1128/jb.169.2.540-545.1987; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5323	5331						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444906				2022-12-25	WOS:A1993KP88400108
J	GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J				GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J			THE 12S-ADENOVIRAL E1A-PROTEIN IMMORTALIZES AVIAN CELLS AND INTERACTS WITH THE AVIAN RB-PRODUCT	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; REGION 1A PROTEINS; EPITHELIAL-CELLS; GENE-PRODUCT; GROWTH; LINE; ESTABLISHMENT; ASSOCIATION; ONCOGENE	Quail cells were immortalized for the first time by using retroviruses expressing the 12S adenoviral E1A gene. In these cells, interaction between the 12S E1A product and the quail RB protein was shown, suggesting that the 12S adenoviral E1A product works in avian cells through similar biochemical pathways as in mammalian cells by interacting and inactivating host cellular proteins, including the RB product. These results confirm that the RB product exhibits a universal function among higher vertebrates in controlling cellular growth and tumor progression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INRA,UNITE BIOL CELLULAIRE & MICROSCOPIE ELECTR,F-78350 JOUY EN JOSAS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, J CELL PHYSL S, V1, P195; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIEHLE RD, 1990, ONCOGENE, V5, P787	29	13	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					619	624						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437845				2022-12-25	WOS:A1993KN00800012
J	RUSINOL, A; VERKADE, H; VANCE, JE				RUSINOL, A; VERKADE, H; VANCE, JE			ASSEMBLY OF RAT HEPATIC VERY LOW-DENSITY LIPOPROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; APOLIPOPROTEIN-B; GOLGI-APPARATUS; HEPG2 CELLS; LIVER; SECRETION; PLASMA; FRACTIONS; HEPATOCYTES; MEMBRANE	The intracellular site of assembly of hepatic very low density lipoproteins has been investigated. Two endoplasmic reticulum fractions and Golgi vesicles (relatively free from endosomal contamination) were isolated from rat liver and the luminal contents were released. The apoB-containing entities were separated from the lumen of the endoplasmic reticulum and Golgi vesicles by an immunoaffinity isolation procedure. The amount of each lipid moiety (triacylglycerols, cholesterol plus cholesteryl esters and phospholipids) associated with a unit mass of apoB was shown to be very similar in the luminal contents isolated from each of the three fractions. Moreover, the apoB-containing particles that were isolated from the endoplasmic reticulum and Golgi were mainly present in a fraction of density <1.02 g/ml. The average diameter of these lipoprotein particles was shown by negative staining electron microscopy to be in the size range of very low density lipoproteins and low density lipoproteins. The size and composition of the intracellular lipoproteins were very similar to those of both very low density lipoproteins isolated from the culture medium from rat hepatocytes and plasma very low density lipoproteins. The conclusion from this study is that the full complement of lipids associate with apoB at an early stage during the secretory pathway, in the endoplasmic reticulum.	UNIV ALBERTA, LIPID & LIPOPROT GRP, 315 HERITAGE MED RES CTR, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA	University of Alberta; University of Alberta; University of Alberta				Verkade, Henkjan J/0000-0002-7034-2861				ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSON LJ, 1989, J LIPID RES, V30, P1819; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ELOVSON J, 1988, J LIPID RES, V29, P1461; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAMILTON RL, 1991, J LIPID RES, V32, P529; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P90; JANERO DR, 1983, J BIOL CHEM, V258, P4496; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; NESTRUCK AC, 1976, CAN J BIOCHEM CELL B, V54, P617, DOI 10.1139/o76-091; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REITHMEIER RAF, 1991, BIOCH LIPIDS LIPOPRO, P525; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; TANIGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V273, P197, DOI 10.1016/0003-9861(89)90179-3; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNEMITSU M, 1990, ARTERIOSCLEROSIS, V10, P386, DOI 10.1161/01.ATV.10.3.386; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU AL, 1979, J BIOL CHEM, V254, P7316; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1989, J BIOL CHEM, V264, P11373	37	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3555	3562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429031				2022-12-25	WOS:A1993KM16100082
J	SCHAFFER, L; KJELDSEN, T; ANDERSEN, AS; WIBERG, FC; LARSEN, UD; CARA, JF; MIRMIRA, RG; NAKAGAWA, SH; TAGER, HS				SCHAFFER, L; KJELDSEN, T; ANDERSEN, AS; WIBERG, FC; LARSEN, UD; CARA, JF; MIRMIRA, RG; NAKAGAWA, SH; TAGER, HS			INTERACTIONS OF A HYBRID INSULIN INSULIN-LIKE GROWTH FACTOR-I ANALOG WITH CHIMERIC INSULIN TYPE-I INSULIN-LIKE GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING-SPECIFICITY; STRUCTURAL ANALOGS; REDUCED AFFINITY; FACTOR (IGF)-I; DETERMINANTS; REGIONS; CELLS	We have examined, by use of a hybrid insulin/insulin-like growth factor-I analog and chimeric insulin/type I insulin-like growth factor receptors, the interplay between ligand and receptor structure in determining the affinity and specificity of hormone-receptor interactions in the insulin and insulin-like growth factor-I systems. Our findings, obtained through the study of radiolabeled peptide binding to detergent-solubilized full-length receptors and to soluble truncated receptors, show that (a) the two-chain hybrid analog exhibits significant cross-reactivity with both receptor systems, (b) the exchange of appropriate domains in chimeric receptors enhances the receptor binding affinity of the analog by 3.5-21-fold, and (c) the affinity of the hybrid analog for the chimeric receptors actually exceeds that of either natural insulin or natural insulin-like growth factor-I. We conclude that the specificity-conferring domains of the insulin and type I insulin-like growth factor receptors reside in different regions of a common binding site, and that the exchange of domains between pairs of related hormones and between pairs of related receptors can yield new ligand-receptor systems with significantly altered affinities and selectivities.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; NOVO NORDISK AS,DEPT DIABET RES,DK-2880 BAGSVAERD,DENMARK; NOVO NORDISK AS,DEPT PHARMACEUT RES,DK-2880 BAGSVAERD,DENMARK	University of Chicago; University of Chicago; Novo Nordisk; Novo Nordisk			Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075; Kjeldsen, Thomas/0000-0003-0094-9286	NIDDK NIH HHS [DK 43702, DK 20595] Funding Source: Medline; NIGMS NIH HHS [GM 07281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK043702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; CARA JF, 1990, J BIOL CHEM, V265, P17820; CARA JF, 1988, ENDOCRINOLOGY, V122, P2881, DOI 10.1210/endo-122-6-2881; CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3229, DOI 10.1021/bi00409a016; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DREJER K, 1991, DIABETES, V40, P1488, DOI 10.2337/diabetes.40.11.1488; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217	17	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3044	3047						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428981				2022-12-25	WOS:A1993KM16100008
J	ESTEBAN, JA; SALAS, M; BLANCO, L				ESTEBAN, JA; SALAS, M; BLANCO, L			FIDELITY OF PHI-29 DNA-POLYMERASE - COMPARISON BETWEEN PROTEIN-PRIMED INITIATION AND DNA POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MANGANESE MUTAGENESIS; REPLICATION FIDELITY; KINETIC MECHANISM; TERMINAL PROTEIN; INVITRO; ENZYME; ALPHA; FRAGMENT; MUTANTS	Phi29 DNA polymerase is able to catalyze two different synthetic reactions: protein-primed initiation and DNA polymerization. We have studied the fidelity of phi29 DNA polymerase when carrying out these two reactions. Global fidelity was dissected into three steps: insertion discrimination, mismatch elongation, and proofreading. The insertion discrimination of phi29 DNA polymerase in DNA polymerization ranged from 10(4) to 10(6). The efficiency of mismatch elongation was 10(5)-10(6)-fold lower than that of a properly paired primer terminus. These factors indicate that DNA polymerization catalyzed by phi29 DNA polymerase is a highly accurate process. Conversely, the insertion fidelity of protein-primed initiation was quite low, the insertion discrimination factor being about 10(2). Mismatch elongation discrimination was also rather low: mismatched terminal protein (TP).dNMP complexes were elongated from 2- to 6-fold more slowly than the correct TP.dNMP complex. Even more, the 3' --> 5' exonuclease activity of phi29 DNA polymerase was unable to act on the TP.dNMP initiation complex, precluding the possibility that a wrong dNMP covalently linked to TP could be excised and corrected. Therefore, protein-primed initiation can be predicted as a quite inaccurate reaction. The problem of maintaining the sequence at the DNA ends is discussed in the context of a recently described model for protein-primed initiation.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTOBLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Esteban, Jose/L-4944-2014; Salas, Margarita/J-9873-2014; Blanco, Luis/I-1848-2015	Esteban, Jose/0000-0002-3759-3300; Salas, Margarita/0000-0001-5939-3441; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ELDEIRY WS, 1988, BIOCHEMISTRY-US, V27, P546, DOI 10.1021/bi00402a007; ELDEIRY WS, 1984, P NATL ACAD SCI-BIOL, V81, P7378, DOI 10.1073/pnas.81.23.7378; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GOODMAN MF, 1983, J BIOL CHEM, V258, P3469; HIBNER U, 1980, NATURE, V285, P300, DOI 10.1038/285300a0; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; MAKI H, 1991, J BIOL CHEM, V266, P5055; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MURRAY MJ, 1976, BIOCHIM BIOPHYS ACTA, V425, P256, DOI 10.1016/0005-2787(76)90032-0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	39	206	232	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2719	2726						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428945				2022-12-25	WOS:A1993KK81500069
J	YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R			GENE REARRANGEMENT AND TRUNCATED MESSENGER-RNA IN CELL-LINES WITH 11Q23 TRANSLOCATION	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOME; BREAKPOINT; LYMPHOMA; FUSION; T(4-11)(Q21-Q23); AMPLIFICATION; HETEROGENEITY; NEOPLASIA; T(11-14)	We have previously demonstrated that the breakpoints of t(11;19)(q23;p13) leukemias are within 360 kb of the CD3 gene. One of the phage clones, 6n, which was isolated from the yeast artificial chromosome clone yB22B2 containing CD3, was found to be within 60 kb of t(11;19) breakpoints. In this study, gene walking was conducted and two phage clones (lambdaHp8-3 and lambdaHp23-13) were isolated from a human placenta genomic library. Southern blot analysis with a genomic probe from lambdaHp8-3 detected gene rearrangements in t(4;11) and t(11;19) cell lines with BamHI digestion. Subsequently, using reiterated sequence-free probes from both ends of 6n that detected transcriptional units in various hematopoietic cells, we isolated cDNA clones. These cDNA clones were classified into two groups (designated MLL-a and MLL-b), which do not hybridize to each other. Northern blot analysis with MLL-a cDNA detected 15-, 14- and 12-kb mRNAs, while MLL-b detected the additional 9.7- and 5-kb mRNAs in peripheral blood lymphocytes. MLL-b cDNA detected a truncated form of 12.5-kb mRNA in t(4;11) cell lines and a truncated form of 10-kb or 9.2-kb mRNA in t(11;19) cell lines. MLL-a did not demonstrate a truncated form of mRNA, but the stronger 14-kb signal was noted in t(4;11) cells, while this signal was very weak in t(11;19) cells. By Southern blot analysis, MLL-b cDNA detected gene rearrangement in cell lines with t(4;11) and t(11;19), whereas MLL-a did not. Furthermore, chimeric cDNA clones were isolated from cDNA libraries of t(4;11) and t(11;19) cell lines with a MLL-b cDNA probe. These results indicate that the MLL-b cDNA is derived from the common target gene involved in 11q23 translocation with 4q21 or 19p13.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; YAMANASHI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 684,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; University of Yamanashi; Tottori University; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; ABE T, 1990, JPN J CLIN HEMATOL, V31, P1304; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1991, CANCER RES, V51, P6712; COTTER FE, 1991, GENE CHROMOSOME CANC, V3, P8, DOI 10.1002/gcc.2870030103; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	27	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					479	485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426751				2022-12-25	WOS:A1993KN00600027
J	ARIAS, HR; VALENZUELA, CF; JOHNSON, DA				ARIAS, HR; VALENZUELA, CF; JOHNSON, DA			TRANSVERSE LOCALIZATION OF THE QUINACRINE BINDING-SITE ON THE TORPEDO ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 CHLORPROMAZINE; NONCOMPETITIVE BLOCKERS; ALPHA-SUBUNIT; DELTA-SUBUNIT; ION CHANNEL; CHOLINERGIC RECEPTOR; GAMMA-SUBUNIT; AMINO-ACIDS; CALIFORNICA; LABELS	We demonstrated previously that a phencyclidine-displaceable quinacrine binding site exists at the lipid-protein interface of the Torpedo acetylcholine receptor (AcChR) (Valenzuela, C. F., Kerr, J. A., and Johnson, D. A. (1992) J. Biol. Chem. 267, 8238-8244). In this manuscript, we assess (1) the transverse position of this site in the lipid bilayer by examining the ability of a series of paramagnetic n-doxyl stearates (n-SALs) and iodide to quench receptor-bound quinacrine and membrane-partitioned octadecyl rhodamine B (C18-Rho) fluorescence and (2) the stoichiometry of histrionicotoxin- or phencyclidine-displaceable quinacrine binding. Initial experiments established what fraction of the n-doxyl stearates partitioned into the membranes and that the n-doxyl stearates do not interfere with quinacrine binding to the receptor at the concentrations used in the quenching studies. The n-doxyl stearate quenching experiments indicated relatively small (<2) differences between the n-doxyl stearates to quench receptor-bound quinacrine fluorescence, with a rank order of 7-SAL greater-than-or-equal-to 5-SAL > 12-SAL > 16-SAL. This contrasts with the n-doxyl stearate quenching of the membrane-partitioned C18-Rho which showed as much as an 8.6-fold difference between the various isomers with a rank order of quenching efficiencies of 5-SAL > 7-SAL > 12-SAL greater-than-or-equal-to 16-SAL. Iodide quenching measurements indicated significant solute accessibility to membrane-partitioned C18-Rho but not to receptor-bound quinacrine. The ratios of the bimolecular quenching rate constants for free to bound quinacrine and for free rhodamine B to membrane-partitioned C18-Rho were 53.4 and 6.6, respectively. Direct titration of quinacrine into suspensions of a high concentration of AcChR- associated membranes yielded an upper limit to the binding stoichiometry of 1.4 HTX- or PCP-displaceable quinacrine binding sites/AcChR functional units. The results suggest that there is a single phencyclidine- or histrionicotoxin-displaceable quinacrine binding site located at or somewhat below the level of the C5-C-7 in the phospholipid acyl chains at the lipid-protein interface.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT NEUROSCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								ADAMS PR, 1980, J PHYSIOL-LONDON, V306, P261, DOI 10.1113/jphysiol.1980.sp013396; ADAMS PR, 1980, J PHYSIOL-LONDON, V306, P283, DOI 10.1113/jphysiol.1980.sp013397; ANDREASEN TJ, 1980, BIOCHEMISTRY-US, V19, P4719, DOI 10.1021/bi00561a027; [Anonymous], 1959, CHEM ENG PROG; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; BLATT E, 1984, PHOTOCHEM PHOTOBIOL, V39, P477; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; CHARNET P, 1990, NEURON, V2, P87; CHRISTIE WW, 1987, HPLC LIPIDS; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DREYER EB, 1986, J BIOL CHEM, V261, P3727; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JOHNSON DA, 1985, BIOPHYS J, V48, P949, DOI 10.1016/S0006-3495(85)83858-3; KARLIN A, 1991, HARVEY LECT, V85, P71; KOSMAN DJ, 1981, SPECTROSCOPY BIOCH, V2, P57; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LONDON E, 1982, MOL CELL BIOCHEM, V45, P181; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SUGIYAMA H, 1976, J MOL BIOL, V106, P485, DOI 10.1016/0022-2836(76)90248-5; TAYLOR P, 1991, ANN NY ACAD SCI, V265, P568; TSAI MC, 1979, MOL PHARMACOL, V16, P382; VALENZUELA CF, 1992, J BIOL CHEM, V267, P8238; WEILAND G, 1977, J BIOL CHEM, V252, P7648; Yguerabide J, 1972, Methods Enzymol, V26, P498	43	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6348	6355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454605				2022-12-25	WOS:A1993KT36800042
J	FERRO, FE; KOZAK, SL; HOATLIN, ME; KABAT, D				FERRO, FE; KOZAK, SL; HOATLIN, ME; KABAT, D			CELL-SURFACE SITE FOR MITOGENIC INTERACTION OF ERYTHROPOIETIN RECEPTORS WITH THE MEMBRANE GLYCOPROTEIN ENCODED BY FRIEND-ERYTHROLEUKEMIA VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; REVERTANT VIRUSES; ENVELOPE PROTEIN; GENE; MUTANT; GP55; ACTIVATION; METABOLISM; MUTATIONS; GROWTH	The membrane glycoprotein (gp55) encoded by the env gene of Friend spleen focus-forming virus (SFFV) causes mitogenesis of infected erythroblasts and is inefficiently (3-5%) processed from the rough endoplasmic reticulum (RER) to plasma membranes. Recent evidence suggested that gp55 binds to erythropoietin receptors (EpoR) in the RER, and it was proposed that this intracellular interaction causes mitogenesis (Li, J.-P., D'Andrea, A. D., Lodish, H. F., and Baltimore, D. (1990) Nature 343, 762-764). Other evidence has indicated that the plasma membrane component (gp55P) can also complex with EpoR. To identify the site of functional complexes and to study the factors that control their formation, we analyzed eight SFFV env mutants that contain in-frame deletions or linker insertions. The three nonpathogenic mutants encode gp55s that fail to leave the RER, whereas the five pathogenic mutants encode glycoproteins that occur on cell surfaces. Although BaF3 hematopoietic cells are interleukin 3 (IL-3)-dependent, a cellular derivative BaF3/EpoR that contains EpoR survives and grows in either IL-3 or erythropoietin (Epo). The five pathogenic SFFV env mutants converted BaF3/EpoR but not BaF3 cells to growth factor independence, whereas the nonpathogenic mutants did not eliminate growth factor requirements of any cells. Studies using I-125-Epo and the covalent cross-linking reagent disuccinimidyl suberate provided unambiguous evidence for ternary complexes of I-125-Epo.EpoR.gp55P on surfaces of all factor-independent cells. Size of the cell surface complex was correspondingly reduced in the case of a newly isolated SFFV mutant that encodes a severely truncated (M(r) approximately 41,000) but mitogenically active env glycoprotein. Our results support the hypothesis that activation of EpoR by the SFFV env glycoprotein occurs exclusively on cell surfaces.	OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University					NATIONAL CANCER INSTITUTE [R01CA054149, R01CA025810] Funding Source: NIH RePORTER; NCI NIH HHS [CA25810, CA54149] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; GLINIAK BC, 1989, J VIROL, V63, P3561, DOI 10.1128/JVI.63.9.3561-3568.1989; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; HANKINS WD, 1980, CELL, V22, P693; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; LI JP, 1986, J VIROL, V57, P534, DOI 10.1128/JVI.57.2.534-538.1986; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MACHIDA CA, 1984, J VIROL, V49, P394, DOI 10.1128/JVI.49.2.394-402.1984; MACHIDA CA, 1985, VIROLOGY, V144, P158, DOI 10.1016/0042-6822(85)90314-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; PINTER A, 1985, VIROLOGY, V143, P646, DOI 10.1016/0042-6822(85)90406-4; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; RUTA M, 1982, J BIOL CHEM, V257, P126; SPIRO C, 1989, J VIROL, V63, P4434, DOI 10.1128/JVI.63.10.4434-4437.1989; WOLFF L, 1983, P NATL ACAD SCI-BIOL, V80, P4718, DOI 10.1073/pnas.80.15.4718; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5741	5747						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449938				2022-12-25	WOS:A1993KR82200058
J	GUYCAFFEY, JK; WEBSTER, RE				GUYCAFFEY, JK; WEBSTER, RE			THE MEMBRANE DOMAIN OF A BACTERIOPHAGE ASSEMBLY PROTEIN - TRANSMEMBRANE-DIRECTED PROTEOLYSIS OF A MEMBRANE-SPANNING FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ALKALINE-PHOSPHATASE; AMINO-ACID-SEQUENCE; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; ASPARTATE RECEPTOR; LEADER PEPTIDASE; OUTER MEMBRANES; RNA-POLYMERASE; CELL-ENVELOPE	A tripartite fusion construct encoding the amino-terminal half of EcoRI endonuclease followed by amino acids 217-299 of the filamentous bacteriophage gene I protein (pI) attached to the enzymatic portion of alkaline phosphatase results in the production of two proteins. The larger protein, pI(f), is the complete tripartite fusion protein while the smaller protein, pI(f)*, results from internal initiation of translation at pI methionine 241. Both pI(f) and pI(f)* span the Escherichia coli inner membrane via a 20-amino-acid hydrophobic stretch of pI with their amino termini in the cytoplasm and their carboxyl-terminal alkaline phosphatase domains in the periplasm. The alkaline phosphatase moiety of approximately 70% of pI(f) is released into the periplasm by in vivo proteolysis, but only about 10% of p(I)f* is cleaved. Neither DegP, OmpT, nor protease III are responsible for the cleavage in vivo, and leader peptidase is unable to cleave the fusion protein in vitro. Deletion and substitution analyses demonstrate that the degree of periplasmic cleavage depends on the sequence of the cytoplasmic domain of the fusion proteins. Possible mechanisms for this transmembrane-directed cleavage event are compared to proposed models for signal transduction.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018305] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BRISSETTE JL, 1990, J MOL BIOL, V211, P565, DOI 10.1016/0022-2836(90)90266-O; DAHL MK, 1989, J BACTERIOL, V171, P2361, DOI 10.1128/jb.171.5.2361-2371.1989; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HORABIN JI, 1988, J BIOL CHEM, V263, P11575; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; LOPEZ J, 1985, J BACTERIOL, V163, P1270, DOI 10.1128/JB.163.3.1270-1274.1985; LOPILATO JE, 1984, J BACTERIOL, V158, P665, DOI 10.1128/JB.158.2.665-673.1984; LYONS LB, 1972, VIROLOGY, V49, P45, DOI 10.1016/S0042-6822(72)80006-0; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MCCRACKEN S, 1980, J BIOL CHEM, V255, P2396; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; Model P., 1988, BACTERIOPHAGES, P375; NEWMAN AK, 1981, J BIOL CHEM, V256, P2131; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; PAKULA A, 1992, NATURE, V355, P496, DOI 10.1038/355496a0; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YEN TSB, 1981, J BIOL CHEM, V256, P1259; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5488	5495						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449911				2022-12-25	WOS:A1993KR82200024
J	KLEMSZ, MJ; MAKI, RA; PAPAYANNOPOULOU, T; MOORE, J; HROMAS, R				KLEMSZ, MJ; MAKI, RA; PAPAYANNOPOULOU, T; MOORE, J; HROMAS, R			CHARACTERIZATION OF THE ETS ONCOGENE FAMILY MEMBER, FLI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GENE; EXPRESSION; VIRUS; ERYTHROLEUKEMIA; ACTIVATION; PROTEINS; SEQUENCE; COMPLEX; CELLS	The recently cloned fli-1 gene is a member of the ets oncogene family that is preferentially expressed in hematopoietic cells. It is a target of dysregulation by Friend leukemia virus insertion and translocation in Ewing's sarcoma and neuroepithelioma. In this report, we have studied the function and regulation of both murine and human fli-1. Analysis of the human and mouse fli-I proteins showed that fli-1 binds to specific DNA sequences highly related to m-ets-2 binding sites. Methylation protection experiments showed that fli-1 and m-ets-2 contacted the same nucleotides in two different binding sites. The fli-1 protein was shown to be a transcriptional activator in co-transfection studies. Stimulation of murine bone marrow macrophages by mediators of inflammation, such as lipopolysaccharide, phorbol 12-myristate 13-acetate, interleukin-1, and interferon-gamma resulted in the reduced expression of fli-1 mRNA. fli-1 was only expressed in a defined subset of human erythroleukemia cell lines.	INDIANA UNIV,MED CTR,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; INDIANA UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,DEPT BIOCHEM,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; University of Washington; University of Washington Seattle; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	KLEMSZ, MJ (corresponding author), INDIANA UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,INDIANAPOLIS,IN 46202, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048914, R29HL048914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48914-01] Funding Source: Medline; NIAID NIH HHS [AI30656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CELADA A, 1989, EUR J IMMUNOL, V19, P205, DOI 10.1002/eji.1830190134; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1004; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ M, 1990, CELL, V61, P133; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1990, ONCOGENE, V5, P663; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	23	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5769	5773						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449942				2022-12-25	WOS:A1993KR82200062
J	NGHIEM, P; SAATI, SM; MARTENS, CL; GARDNER, P; SCHULMAN, H				NGHIEM, P; SAATI, SM; MARTENS, CL; GARDNER, P; SCHULMAN, H			CLONING AND ANALYSIS OF 2 NEW ISOFORMS OF MULTIFUNCTIONAL CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE - EXPRESSION IN MULTIPLE HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; AUTONOMOUS ENZYME; CYSTIC-FIBROSIS; CALMODULIN; BRAIN; CALCIUM; AUTOPHOSPHORYLATION; ACTIVATION; CELLS; DNA	Multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) is a mediator of calcium signals in diverse signaling pathways. In human lymphocytes and epithelial tissues, CaM kinase activates a chloride channel via a Ca2+-dependent pathway which is preserved in cystic fibrosis. To characterize the CaM kinase present in these tissues we have cloned an isoform of this kinase from human T lymphocytes. We show the cDNA structure of two variants of this human CaM kinase, gamma(B) and gamma(C), which are predicted to translate to 518 and 495 amino acids, respectively. Amino acid differences between these isoforms and the rat brain gamma isoform (which we refer to as gamma(A)) are localized to the variable domain. We used RNase protection of this variable region to reveal the level of expression of gamma(B) and gamma(C) CaM kinase mRNAs in nine human tissues and cell lines. When transfected into Jurkat T cells, the gamma(B) cDNA encoded a functional kinase which cosedimented on sucrose gradients with endogenous T cell CaM kinase activity and formed a large multimeric enzyme. The recombinant gamma(B) isoform displayed two phases of autophosphorylation characteristic of CaM kinases, including the phase which converts it to a partially Ca2+-independent species. Site-directed mutagenesis of the predicted autoinhibitory domain yielded a mutant which was approximately 37% active in the absence of Ca2+/calmodulin, confirming the region as critical for autoregulation, and suggesting this mutant as a tool for studying the role of CaM kinase in nonneuronal tissues.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NCI NIH HHS [CA09302] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KARLS U, 1992, MOL CELL BIOL, V12, P3644, DOI 10.1128/MCB.12.8.3644; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; NAKAYAMA T, 1992, SCIENCE, V257, P96, DOI 10.1126/science.1621102; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; ROSS RA, 1983, J NATL CANCER I, V71, P741; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; TAKAISHI T, 1992, J NEUROCHEM, V58, P1971, DOI 10.1111/j.1471-4159.1992.tb10079.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; THURSTON JH, 1975, J BIOL CHEM, V250, P1751; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	56	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5471	5479						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449910				2022-12-25	WOS:A1993KR82200022
J	BARCIA, MG; CASTRO, JM; JULLIEN, CD; FREIRE, M				BARCIA, MG; CASTRO, JM; JULLIEN, CD; FREIRE, M			PROTHYMOSIN-ALPHA IS PHOSPHORYLATED IN PROLIFERATING STIMULATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; RAT THYMUS; PROTEIN; GENE; EXPRESSION; THYMOSIN; PARATHYMOSIN; DIVISION; TISSUES; CDNA	Prothymosin alpha is a widely distributed polypeptide whose function, though unknown, seems to be related to cell proliferation. In vitro, it is a substrate for casein kinase-2. In this work, extracts of mitogenically stimulated murine splenic lymphocytes labeled with [P-32] orthophosphate were found to contain [P-32]prothymosin alpha. Phosphorylation activity was highly dependent on mitogenic activation with concanavalin A plus interleukin-2. While cells remained viable, phosphorylation increased with stimulation time in the presence of [P-32]orthophosphate. Structural analysis showed that prothymosin alpha was phosphorylated at Thr residues located among its first 14 amino acids, whereas its in vitro phosphorylation by casein kinase-2 affects both Ser and Thr residues in this fragment, apparently in similar proportions. Thus, casein kinase-2 seems not to be responsible for the phosphorylation of prothymosin alpha in vivo. Prothymosin alpha was also found to be phosphorylated in proliferating murine thymocytes and HeLa cells; the phosphorylation sites were the same as in splenic lymphocytes, but the rate of phosphorylation was about 5 times lower. In thymocytes and subconfluent HeLa cells, the [P-32]prothymosin alpha concentrations of the cytosolic and nuclear fractions were similar; in splenic lymphocytes, [P-32]prothymosin alpha was found mostly in cytosol.	UNIV SANTIAGO,FAC BIOL,DEPT BIOQUIM & BIOL MOLEC,GALICIA,SPAIN	Universidade de Santiago de Compostela			Diaz-Jullien, Cristina/L-4575-2018	Diaz-Jullien, Cristina/0000-0002-4307-8129				BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CALDARELLA J, 1983, P NATL ACAD SCI-BIOL, V80, P7424, DOI 10.1073/pnas.80.24.7424; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRANCO FJ, 1989, IMMUNOLOGY, V67, P263; FRANCO FJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P43, DOI 10.1016/0167-4838(92)90422-A; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P85; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; GUASCH MD, 1986, BIOCHEM J, V234, P523, DOI 10.1042/bj2340523; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW TLK, 1990, FEBS LETT, V273, P1, DOI 10.1016/0014-5793(90)81037-O; MAKAROVA T, 1989, FEBS LETT, V257, P247, DOI 10.1016/0014-5793(89)81544-3; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MCCLURE JE, 1982, J IMMUNOL, V128, P368; PAN LX, 1986, ARCH BIOCHEM BIOPHYS, V250, P197, DOI 10.1016/0003-9861(86)90717-4; PANNEERSELVAM C, 1988, ARCH BIOCHEM BIOPHYS, V265, P454, DOI 10.1016/0003-9861(88)90149-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROSON E, 1990, HISTOCHEMISTRY, V94, P597; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6	32	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4704	4708						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444845				2022-12-25	WOS:A1993KP88400025
J	ROBBINS, DJ; ZHEN, EZ; OWAKI, H; VANDERBILT, CA; EBERT, D; GEPPERT, TD; COBB, MH				ROBBINS, DJ; ZHEN, EZ; OWAKI, H; VANDERBILT, CA; EBERT, D; GEPPERT, TD; COBB, MH			REGULATION AND PROPERTIES OF EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE-1 AND KINASE-2 INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERINE THREONINE KINASES; ACTIVATED MAP KINASE; SWISS 3T3-CELLS; FACTOR RECEPTOR; PEPTIDE KINASE; PC12 CELLS; S6 KINASE; INSULIN; PHOSPHORYLATION	Extracellular signal-regulated protein kinases (ERK) 1 and 2 and mutants of each were expressed in bacteria with a hexahistidine tag and purified using nickel-chelate chromatography. Basal activity of wild type ERK2 was approximately 2 nmol/min/mg. Self-catalyzed phosphorylation occurred in vitro on the major physiological site of tyrosine phosphorylation in an intramolecular reaction. Rabbit muscle ERK activator activated ERK2 500-1000-fold up to a specific activity (approximately 2 mumol/min/mg) approximating that of ERK1 purified from stimulated cells (Boulton, T. G., Gregory, J. S., and Cobb, M. H. (1991) Biochemistry 30, 278-286). ERK1 could also be activated by the ERK activator to the same extent. Mutants lacking the major site of tyrosine phosphorylation were autophosphorylated at a greatly reduced rate and were no longer highly activated by the ERK kinase. Mutants lacking the major site of threonine phosphorylation were autophosphorylated at the same or an enhanced rate, but the kinase activity of these mutants depended on the residue used to replace the threonine. Replacement by glutamate rendered the kinase capable of being activated by ERK activator, while replacement by alanine did not. Thus, the carboxyl group of glutamate can provide at least some of the features introduced by phosphothreonine in activated ERKs.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; HAROLD SIMMONS ARTHRITIS RES CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ROBBINS, DJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001918, R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128, DK01918] Funding Source: Medline; NIGMS NIH HHS [GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSHI M, 1988, J BIOL CHEM, V263, P5396; ITOH H, 1991, J BIOL CHEM, V266, P16226; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEVERS SJ, 1992, EMBO J, V11, P569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1990, MOL CELL BIOL, V10, P549, DOI 10.1128/MCB.10.2.549; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TSAO H, 1990, J BIOL CHEM, V265, P15471; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	52	454	464	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5097	5106						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444886				2022-12-25	WOS:A1993KP88400079
J	ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK				ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK			T1, AN IMMUNOGLOBULIN SUPERFAMILY MEMBER, IS EXPRESSED IN H-RAS-DEPENDENT EPITHELIAL TUMORS OF MAMMARY CELLS	ONCOGENE			English	Article							ANTIGEN GENE FAMILY; CARCINOEMBRYONIC ANTIGEN; ONCOGENE EXPRESSION; TRANSGENIC MICE; INDUCTION; GLAND; TRANSCRIPTION; TRANSFORMATION; EMBRYOGENESIS; INVASION	T1 is a glycosylated protein in the carcinoembryonic antigen (CEA) family of tumour marker molecules. It was originally identified by virtue of its transient induction after the expression of p21H-ras in NIH3T3 fibroblasts. Here we show that the T1 gene is activated in mammary adenocarcinomas of transgenic mice harbouring an H-ras transgene under the control of the mammary-specific whey acidic protein (WAP) promoter. By contrast, T1 mRNA was not, or only faintly, detectable in mammary carcinomas of transgenic mice bearing a WAP-myc transgene. Thus, T1 overexpression does not appear to be a general tumour-specific phenomenon. A dependence of T1 gene expression on the action of p21H-ras is suggested by the observation of T1 mRNA in nude mouse tumours generated from H-ras-transformed cultured mammary epithelial cells. Interestingly, activation of the T1 gene is also found during the maturation of the mammary gland (3-4 weeks after birth), whereas it is absent during its terminal differentiation in pregnancy and lactation. This expression pattern suggests a role for the secreted T1 glycoprotein in the phase of epithelial proliferation of the mammary gland. It appears that p21H-ras-induced transformation of mammary epithelial cells mimicks the situation occurring in puberty. In both developmental stages the T1 glycoprotein might affect celt interactions of the proliferating epithelial cells with the surrounding stroma. It might thus promote ductal outgrowth in gland maturation as well as invasive growth of p21H-ras-transformed mammary epithelial cells.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,DEPT CELL CHEM,INGOLST LANDSTR 1,W-8042 NEUHERBERG,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST PATHOL,W-8042 NEUHERBERG,GERMANY; UNIV BERN,INST CLIN CANC RES,CH-3004 BERN,SWITZERLAND; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bern; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ANDRES AC, 1991, ONCOGENE, V6, P771; BEAUCHEMIN N, 1989, CANCER RES, V49, P2017; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; COURNOYER D, 1988, CANCER RES, V48, P3153; GO VLW, 1982, CANCER PHILA S, V30, P2618; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HUANG JQ, 1990, DEVELOPMENT, V110, P573; INAGUMA Y, 1988, DEV BIOL, V128, P245, DOI 10.1016/0012-1606(88)90288-6; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KODELJA V, 1989, J BIOL CHEM, V264, P6906; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; THOMPSON J, 1988, TUMOR BIOL, V9, P63, DOI 10.1159/000217547; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; ZIMMERMANN W, 1988, CANCER RES, V48, P2500	28	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					609	617						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437844				2022-12-25	WOS:A1993KN00800011
J	GILLESPIE, W; PAULSON, JC; KELM, S; PANG, M; BAUM, LG				GILLESPIE, W; PAULSON, JC; KELM, S; PANG, M; BAUM, LG			REGULATION OF ALPHA-2,3-SIALYLTRANSFERASE EXPRESSION CORRELATES WITH CONVERSION OF PEANUT AGGLUTININ (PNA)+ TO PNA- PHENOTYPE IN DEVELOPING THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; CARBOHYDRATE DIFFERENTIATION ANTIGENS; MOUSE THYMOCYTES; SIALIC ACIDS; CELLS; SIALYLTRANSFERASE; IDENTIFICATION; GLYCOPROTEINS; GLYCOSYLATION; BIOSYNTHESIS	Staining of thymus tissue with the plant lectin peanut agglutinin (PNA) is a classic technique for defining the cortical (PNA+) and medullary (PNA-) regions of this tissue. These two regions are primarily composed of immature and mature thymocytes, respectively. Conversion of the PNA+ to the PNA- phenotype has been attributed to masking of the cell surface carbohydrate receptors of PNA by sialic acid during the intrathymic maturation of these cells. We present evidence that the regulated expression of a single glycosyltransferase, a Galbeta1,3GalNAc alpha2,3-sialyltransferase, can account for this glycosylation change. This enzyme sialylates the preferred ligand of PNA, Galbeta1,3GalNAc, forming the sequence NeuAcalpha2,3Galbeta1,3GalNAc, thus masking PNA binding sites. Expression of the enzyme is inversely proportional to expression of the PNA receptor, as evidenced by analysis of T-lymphoblastoid cell lines and by in situ hybridization experiments in human thymic tissue.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, 10833 LECONTE AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM & MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV KIEL, INST BIOCHEM, W-2300 KIEL 1, GERMANY	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Scripps Research Institute; University of Kiel			Kelm, Soerge/C-5403-2013; Paulson, James/AAG-3565-2019	Kelm, Soerge/0000-0001-5277-9421; 	NCI NIH HHS [CA-16042] Funding Source: Medline; NICHD NIH HHS [HD-07201] Funding Source: Medline; NIGMS NIH HHS [GM-27904] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER MA, 1987, CANCER RES, V47, P2763; BAKER MA, 1984, BLOOD, V63, P1194; BEYER TA, 1979, J BIOL CHEM, V254, P2531; CONZELMANN A, 1988, J EXP MED, V167, P119, DOI 10.1084/jem.167.1.119; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEMAIO A, 1986, FEBS LETT, V194, P28, DOI 10.1016/0014-5793(86)80045-X; DESPONT JP, 1975, CELL IMMUNOL, V17, P487, DOI 10.1016/S0008-8749(75)80052-9; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; KANANI A, 1990, CANCER RES, V50, P5003; LEFRANCOIS L, 1985, J EXP MED, V162, P1275, DOI 10.1084/jem.162.4.1275; LEFRANCOIS L, 1987, J IMMUNOL, V139, P2220; LEVI G, 1983, IMMUNOL LETT, V7, P35, DOI 10.1016/0165-2478(83)90052-4; LOTAN R, 1975, J BIOL CHEM, V250, P8518; PERIERA MEA, 1976, CARBOHYD RES, V51, P107; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1988, J BIOL CHEM, V263, P15146; POWELL LD, 1987, J IMMUNOL, V139, P262; REARICK JI, 1979, J BIOL CHEM, V254, P444; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; Reutter W., 1982, CELL BIOL MONOGR, V10, P263; SADLER JE, 1984, BIOL CARBOHYDRATES, V2, P87; SASAKI R, 1982, CLIN EXP IMMUNOL, V47, P381; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SHARON N, 1983, ADV IMMUNOL, V34, P213, DOI 10.1016/S0065-2776(08)60380-6; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TOPOROWICZ A, 1986, CELL IMMUNOL, V100, P10, DOI 10.1016/0008-8749(86)90002-X; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WHITEHEART SW, 1990, CELL IMMUNOL, V125, P337, DOI 10.1016/0008-8749(90)90089-A	31	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3801	3804						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440675				2022-12-25	WOS:A1993KN53300002
J	SPEICHER, DW; DESILVA, TM; SPEICHER, KD; URSITTI, JA; HEMBACH, P; WEGLARZ, L				SPEICHER, DW; DESILVA, TM; SPEICHER, KD; URSITTI, JA; HEMBACH, P; WEGLARZ, L			LOCATION OF THE HUMAN RED-CELL SPECTRIN TETRAMER BINDING-SITE AND DETECTION OF A RELATED CLOSED HAIRPIN LOOP DIMER USING PROTEOLYTIC FOOTPRINTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-I DOMAIN; HUMAN-ERYTHROCYTE SPECTRIN; CODON CHANGE ARG; HEREDITARY ELLIPTOCYTOSIS; BETA-SPECTRIN; SELF-ASSOCIATION; FUNCTIONAL DOMAINS; MOLECULAR DEFECT; TRYPTIC PEPTIDE; MUTATION	Head-to-head association of two spectrin alphabeta heterodimers to form tetramers involves the formation of two equivalent alpha-beta complexes. The sites on the alpha subunit N-terminal region and beta subunit C-terminal region that form these alphabeta complexes have been identified using protease footprinting and direct binding assays. The existence of a similar previously hypothesized internal head-to-head alphabeta interaction in dimers was also demonstrated. The discrete regions of both subunits that are protected from proteolysis in tetramers and dimers are not due to the laterally associated subunit since head-to-head complexes of a univalent alpha peptide with a univalent beta peptide show similar protection of the same sites. These sites are unshielded immediately after monomers assemble side-to-side to form heterodimers, demonstrating that reconstituted dimers are initially in an ''open'' conformation. Conversion of open dimers to a closed form through formation of the internal head-to-head alphabeta association, as demonstrated by restoration of protease protection, occurred on a time scale of hours at 0-degrees-C. Analysis of peptide binding affinities as well as isolation and sequence analysis of head-to-head alphabeta noncovalent complexes further defined the regions required for association on both subunits. These regions are homologous to the 106-residue repetitive motif that comprises most of both chains. An algorithm designed to improve prediction accuracy of multiple homologous motifs was used to model the conformation of spectrin repetitive motifs as well as the contact regions. In this model, the separate alpha and beta binding sites are incomplete complementary parts of a triple stranded folding unit. Formation of the alphabeta head-to-head complex produces a triple stranded conformational unit that is slightly different from other homologous motifs in the protein. Most hemolytic anemia mutations that are known to disrupt tetramer association are located in the mapped regions, including several mutations that induce a conformational change in the paired subunit.			SPEICHER, DW (corresponding author), WISTAR INST, 3601 SPRUCE ST, RM C102, PHILADELPHIA, PA 19104 USA.			Weglarz, Ludmila/0000-0003-4217-5274	NCI NIH HHS [CA10815] Funding Source: Medline; NHLBI NIH HHS [HL38794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKMAN L, 1991, J BIOL CHEM, V266, P3835; BAKLOUTI F, 1992, BLOOD, V79, P2464; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; CALVERT R, 1980, EUR J BIOCHEM, V107, P363; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; EBER SW, 1988, J CLIN INVEST, V81, P523, DOI 10.1172/JCI113350; FLOYD PB, 1991, BLOOD, V78, P1364; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; GALLAGHER PG, 1992, J CLIN INVEST, V89, P892, DOI 10.1172/JCI115669; GARBARZ M, 1991, J CLIN INVEST, V88, P76, DOI 10.1172/JCI115307; GARBARZ M, 1990, BLOOD, V75, P1691; KAM Z, 1977, BIOCHEMISTRY-US, V16, P5568, DOI 10.1021/bi00644a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE MC, 1989, BLOOD, V74, P1126; LECOMTE MC, 1990, BRIT J HAEMATOL, V76, P406, DOI 10.1111/j.1365-2141.1990.tb06376.x; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; MARCHESI SL, 1987, J CLIN INVEST, V80, P191, DOI 10.1172/JCI113047; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MCGUIRE M, 1988, Hematologic Pathology, V2, P1; MORLE L, 1990, J CLIN INVEST, V86, P548, DOI 10.1172/JCI114743; MORLE L, 1989, BLOOD, V74, P828; MORRIS M, 1989, BIOCHEMISTRY-US, V28, P8561, DOI 10.1021/bi00447a044; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALEK J, 1990, SEMIN HEMATOL, V27, P290; POTHIER B, 1990, BLOOD, V75, P2061; REIM DF, 1992, TECHNIQUES PROTEIN C, V3, P53; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROUX AF, 1989, BLOOD, V73, P2196; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAHR KE, 1989, J CLIN INVEST, V84, P1243, DOI 10.1172/JCI114291; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YOON SH, 1991, J BIOL CHEM, V266, P8490	49	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4227	4235						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440706				2022-12-25	WOS:A1993KN53300062
J	PEARSON, AM; RICH, A; KRIEGER, M				PEARSON, AM; RICH, A; KRIEGER, M			POLYNUCLEOTIDE BINDING TO MACROPHAGE SCAVENGER RECEPTORS DEPENDS ON THE FORMATION OF BASE-QUARTET-STABILIZED 4-STRANDED HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DNA TOPOISOMERASE-II; ALKALI-METAL IONS; TELOMERIC DNA; POLYINOSINIC ACID; CHOLESTEROL DEPOSITION; MEDIATED ENDOCYTOSIS; CIRCULAR-DICHROISM; POLYGUANYLIC ACID; CELLS	Macrophage scavenger receptors exhibit unusually broad, but circumscribed, polyanionic ligand-binding specificity. For example, the polyribonucleotides poly(I) and poly(G) are ligands but poly(A) and poly(C) are not. To further investigate the molecular basis of this polynucleotide-binding specificity, we tested the capacity of various oligodeoxyribonucleic acids to inhibit the scavenger receptor-mediated degradation of I-125-labeled acetylated low density lipoprotein by Chinese hamster ovary cells expressing the type I bovine scavenger receptor. A series of short oligodeoxyriboguanines (dG(n), where 5 less-than-or-equal-to n less-than-or-equal-to 37) were effective inhibitors. The dG6, dG12, and dA5G37 members of this series were shown by circular dichroism and UV spectroscopy to be assembled into four-stranded helices stabilized by G-quartets. [P-32]dA5G37 bound directly to scavenger receptors. Partial or complete denaturation of the quadruplex structures of these oligonucleotides by boiling destroyed their inhibitory activity. Receptor activity was also inhibited by d(T4G4)4, a telomere-like oligonucleotide which forms an intramolecular quadruplex. In addition, conversion of the four-stranded potassium salt of poly(I) to the single-stranded lithium salt dramatically reduced its inhibitory activity. Addition of KCl to the Li+ salt resulted in the reformation of poly(I)'s quadruplex structure and restoration of its inhibitory activity. A variety of single-stranded and double-stranded oligo- and polydeoxyribonucleotides (e.g. dA37, HaeIII restriction fragments of PHIX174) exhibited very little or no inhibitory activity. Thus, a base-quartet-stabilized four-stranded helix appears to be a necessary structural determinant for polynucleotide binding to and inhibition of scavenger receptors. This conformational requirement accounts for the previously unexplained polyribonucleotide-binding specificity of scavenger receptors. The spatial distribution of the negatively charged phosphates in polynucleotide quadruplexes may form a charged surface which is complementary to the positively charged surface of the collagenous ligand-binding domain of the scavenger receptor.	MIT, DEPT BIOL, RM E25-236, CAMBRIDGE, MA 02139 USA						NHLBI NIH HHS [HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON S, 1993, J BIOL CHEM, V268, P3530; ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BONAZZI S, 1991, J AM CHEM SOC, V113, P5809, DOI 10.1021/ja00015a040; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; CHEN FM, 1992, BIOCHEMISTRY-US, V31, P3769, DOI 10.1021/bi00130a006; CHOU CH, 1977, NUCLEIC ACIDS RES, V4, P2407, DOI 10.1093/nar/4.7.2407; CHUNG IK, 1991, J BIOL CHEM, V266, P9508; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P178; FRANKKAMENETSKII M, 1989, NATURE, V342, P737, DOI 10.1038/342737a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAY DM, 1974, BIOPOLYMERS, V13, P2087, DOI 10.1002/bip.1974.360131011; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; GUO Q, 1992, BIOCHEMISTRY-US, V31, P2451, DOI 10.1021/bi00124a002; GUO Q, 1992, J BIOL CHEM, V267, P15293; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOWARD FB, 1982, BIOCHEMISTRY-US, V21, P6736, DOI 10.1021/bi00269a019; HOWARD FB, 1977, BIOPOLYMERS, V16, P791, DOI 10.1002/bip.1977.360160407; HOWARD FB, 1982, BIOPOLYMERS, V21, P147, DOI 10.1002/bip.360210112; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1991, CIRCULATION, V84, P229; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, IN PRESS J BIOL CHEM, V268; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MILES HT, 1978, J AM CHEM SOC, V100, P8037, DOI 10.1021/ja00493a058; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; POCHON F, 1965, P NATL ACAD SCI USA, V53, P1425, DOI 10.1073/pnas.53.6.1425; RAEPPLE E, 1976, IMMUNOCHEMISTRY, V13, P251, DOI 10.1016/0019-2791(76)90223-8; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; RALPH RK, 1962, J AM CHEM SOC, V84, P2265, DOI 10.1021/ja00870a055; RESNICK D, 1993, J BIOL CHEM, V268, P3538; RICH A, 1958, BIOCHIM BIOPHYS ACTA, V29, P502, DOI 10.1016/0006-3002(58)90005-2; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROY KB, 1979, BIOPOLYMERS, V18, P3077, DOI 10.1002/bip.1979.360181213; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; Sambrook J, 1989, MOL CLONING LABORATO; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	70	192	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3546	3554						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429030				2022-12-25	WOS:A1993KM16100081
J	CORBETT, JA; SWEETLAND, MA; LANCASTER, JR; MCDANIEL, ML				CORBETT, JA; SWEETLAND, MA; LANCASTER, JR; MCDANIEL, ML			A 1-HOUR PULSE WITH IL-1-BETA INDUCES FORMATION OF NITRIC-OXIDE AND INHIBITS INSULIN-SECRETION BY RAT ISLETS OF LANGERHANS - EVIDENCE FOR A TYROSINE KINASE SIGNALING MECHANISM	FASEB JOURNAL			English	Note						NITRIC OXIDE; INTERLEUKIN-1; ISLET; IRONNITROSYL COMPLEX; TYROSINE KINASE	TUMOR-NECROSIS-FACTOR; REQUIRES GENE-TRANSCRIPTION; L-ARGININE; PANCREATIC-ISLETS; ACTIVATED MACROPHAGES; BETA-CELLS; INTERFERON-GAMMA; INTERLEUKIN-1; PROTEIN; COMPLEXES	Nitric oxide has been implicated as the effector molecule that mediates interleukin-1beta (IL-1beta)-induced inhibition of glucose-stimulated insulin secretion by rat islets. Brief exposures of islets (1 h) to IL-1beta have been shown to inhibit glucose-stimulated insulin secretion at 8 or 18 h after removal of this cytokine. The purpose of this investigation was to determine if brief exposures of islets to IL-1beta are sufficient to induce the formation of nitric oxide and to examine the signaling process associated with IL-1beta-induced expression of nitric oxide synthase. We demonstrate that a 1-h pretreatment of islets with IL-1beta followed by an 8-h incubation in the absence of this cytokine results in inhibition of glucose-stimulated insulin secretion (50%), which is completely prevented by pretreatment of islets with the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (NMMA). The production of nitric oxide by islets under the se pulse conditions is demonstrated by IL-1beta-induced nitrite and electron paramagnetic resonance-detectable iron-nitrosyl complex formation, both of which are prevented by NMMA. IL-1beta initiates a signal transduction process resulting in the expression of nitric oxide synthase. The signaling process appears to require the activation of a tyrosine kinase, since the tyrosine kinase inhibitor genistein prevents both IL-1beta-induced inhibition of insulin secretion by islets and formation of nitric oxide by the insulinoma cell line RINm5F. These results show that short exposures of islets to IL-1beta are sufficient to induce the formation of nitric oxide resulting in inhibition of glucose-stimulated insulin secretion and that a tyrosine kinase may participate in the early signaling events required for IL-1beta to induce the expression of nitric oxide synthase.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, BOX 8118, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; UTAH STATE UNIV, DEPT CHEM & BIOCHEM, LOGAN, UT 84322 USA	Washington University (WUSTL); Utah System of Higher Education; Utah State University					NIDDK NIH HHS [DK-06181, DK-08748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK006181, F32DK008748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BERGMANN L, 1992, FEBS LETT, V299, P103, DOI 10.1016/0014-5793(92)80110-3; CHEDID M, 1989, J IMMUNOL, V142, P4301; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DOBSON PRM, 1989, J MOL ENDOCRINOL, V2, pR5, DOI 10.1677/jme.0.002R005; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; EIZIRIK DL, 1991, DIABETOLOGIA, V34, P445, DOI 10.1007/BF00403185; EIZIRIK DL, 1992, AUTOIMMUNITY, V12, P127, DOI 10.3109/08916939209150319; FRENCH JF, 1991, J PHARMACOL EXP THER, V259, P260; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAMMONDS P, 1990, FEBS LETT, V261, P97, DOI 10.1016/0014-5793(90)80645-Y; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HIBBS JB, 1990, INT CONGR SER, V897, P189; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; HUGHES JH, 1990, FEBS LETT, V266, P33, DOI 10.1016/0014-5793(90)81499-E; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; MANDRUPPOULSEN T, 1986, ALLERGY, V41, P250, DOI 10.1111/j.1398-9995.1986.tb02025.x; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1988, DIABETES, V37, P1311, DOI 10.2337/diabetes.37.10.1311; MONCADA S, 1991, PHARMACOL REV, V43, P109; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167	42	79	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					369	374		10.1096/fasebj.7.2.8440413	http://dx.doi.org/10.1096/fasebj.7.2.8440413			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440413				2022-12-25	WOS:A1993KN88500012
J	JHON, DY; LEE, HH; PARK, DG; LEE, CW; LEE, KH; YOO, OJ; RHEE, SG				JHON, DY; LEE, HH; PARK, DG; LEE, CW; LEE, KH; YOO, OJ; RHEE, SG			CLONING, SEQUENCING, PURIFICATION, AND GQ-DEPENDENT ACTIVATION OF PHOSPHOLIPASE-C-BETA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; G-PROTEINS; SIGNAL TRANSDUCTION; BETA-1 ISOZYME; COMPLETE CDNA; C ISOZYMES; GENE; DROSOPHILA; DIVERSITY; BINDING	Six mammalian phospholipase C isozymes (PLC-beta1, PLC-beta2, PLC-gamma1, PLC-gamma2, PLC-delta1, and PLC-delta2) have been identified at both protein and DNA levels. Here, cDNAs corresponding to a previously unidentified PLC isozyme were isolated from a rat thyroid cell FRTL cDNA library. Comparison of the predicted amino acid sequence of this new PLC with other known PLC isozymes revealed a high degree of overall similarity with PLC-beta1 and PLC-beta2. Thus, the new PLC was named PLC-beta3. Comparison with PLC-beta1 and PLC-Beta2 also revealed that the deduced amino-terminal sequence of PLC-beta3 was incomplete by 10-20 amino acids. With the use of antibodies raised against synthetic peptides corresponding to PLC-beta3-specific amino acid sequences, we purified PLC-beta3 from a rat brain particulate fraction. The purified enzyme exhibited an apparent molecular mass of 152 kDa on SDS-polyacrylamide gels, as compared with 150 and 140 kDa for PLC-beta1 and PLC-beta2, respectively. Studies of the activation of PLC-beta isozymes by three alpha subunits of G(q) class G proteins, alpha(q), all, and alpha1 in the presence of guanosine 5-O-(3-thiotriphosphate) (GTPgammaS) revealed that the extent of activation decreased in the order of PLC-beta1 greater-than-or-equal-to PLC-beta3 >> PLC-beta2 for all three alpha subunits, suggesting a certain degree of specificity in the interaction of G(q)alpha subunits with different PLC-beta isozymes.	KOREA ADV INST SCI & TECHNOL, DEPT LIFE SCI, DAEDOK 305701, SOUTH KOREA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Yoo, Ook Joon/C-1860-2011					BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; EMORI Y, 1989, J BIOL CHEM, V264, P21885; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; LITOSCH I, 1989, BIOCHEM J, V261, P245, DOI 10.1042/bj2610245; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK D, 1992, J BIOL CHEM, V267, P16048; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1992, J BIOL CHEM, V267, P1811	37	205	211	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6654	6661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454637				2022-12-25	WOS:A1993KT36800083
J	PARK, JH; KAUSHANSKY, K; LEVITT, L				PARK, JH; KAUSHANSKY, K; LEVITT, L			TRANSCRIPTIONAL REGULATION OF INTERLEUKIN-3 (IL3) IN PRIMARY HUMAN T-LYMPHOCYTES - ROLE OF AP-1-BINDING AND OCTAMER-BINDING PROTEINS IN CONTROL OF IL3 GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE-C; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; MESSENGER-RNA; ACTIVATION; INDUCTION; PROMOTER; IDENTIFICATION	We have investigated the molecular and biochemical basis for activation of interleukin 3 (IL3) gene expression in primary human T lymphocytes following CD3 and CD2 receptor stimulation or activation by phytohemagglutinin plus phorbol 12-myristate 13-acetate. Using transfection and reporter gene assays specifically designed for primary T lymphocytes in conjunction with gel retardation assays, Western blot analyses and UV cross-linking studies, we found that c-Jun, c-Fos, and octamer-binding proteins play a major role in transcriptional activation of the IL3 gene via their interaction with two specific regions contained within the IL3 5'-flanking sequence. Additionally, the region between bases -107 and -59 of the IL3 promoter containing putative AP-2 and Spl binding motifs appears necessary for basal level expression of the IL3 gene. The data also indicate that CD2 receptor activation and phytohemagglutinin plus phorbol 12-myristate 13-acetate stimulation augment T cell IL3 gene expression through the same cis- and trans-activating signals. These results should contribute to a better understanding of the regulation of IL3 gene expression in human T lymphocytes.	STANFORD UNIV,MED CTR,DEPT MED,DIV INNERE MED,ROOM S-161,STANFORD,CA 94305; UNIV WASHINGTON,DEPT MED,DIV INNERE MED,SEATTLE,WA 98195	Stanford University; University of Washington; University of Washington Seattle					NCI NIH HHS [CA 31615] Funding Source: Medline; NHLBI NIH HHS [R01 HL 35774, 5 T32 HL 07093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035774, T32HL007093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BERRY N, 1989, J IMMUNOL, V143, P1407; CANN AJ, 1988, ONCOGENE, V3, P123; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FARRAR WL, 1986, J IMMUNOL, V136, P1266; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; HANEKOM C, 1989, BIOCHEM J, V262, P449, DOI 10.1042/bj2620449; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEL AE, 1990, J IMMUNOL, V144, P2683; NIEMEYER CM, 1989, BLOOD, V73, P945; OTSUKA T, 1988, J IMMUNOL, V140, P2288; RYAN GR, 1991, BLOOD, V77, P1195; Sambrook J, 1989, MOL CLONING LABORATO; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6299	6308						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454603				2022-12-25	WOS:A1993KT36800036
J	LUTHIN, DR; EPPLER, CM; LINDEN, J				LUTHIN, DR; EPPLER, CM; LINDEN, J			IDENTIFICATION AND QUANTIFICATION OF G(I)-TYPE GTP-BINDING PROTEINS THAT COPURIFY WITH A PITUITARY SOMATOSTATIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN BLOCKS; PANCREATIC BETA-CELL; ANTERIOR-PITUITARY; GROWTH-HORMONE; BOVINE BRAIN; TUMOR-CELLS; SECRETION; INHIBITION; SUBTYPES; SUBUNITS	Somatostatin (SRIF) receptors of GH4C1 cells occupied with biotinyl-NH-[Leu8,D-Trp22, Tyr25] somatostatin28 (bio-S28) have been affinity purified over streptavidin affinity columns (Eppler, C. M., Zysk, J. R., Corbett, M., and Shieh, H.-M. (1992) J. Biol. Chem. 267, 15603-15612). This procedure results in the copurification of a single subtype of SRIF receptor (SSTR2) and associated guanine nucleotide-binding proteins (G proteins) that are coupled to these receptors. For accurate quantification it was necessary to: (i) use homogenous recombinant standards; (ii) accurately assess the purity of standards; (iii) determine recovery of G proteins during sample preparation and Western blotting; and (iv) account for cross-reactivity among antisera. Four pertussis toxin-sensitive G proteins were quantified with previously characterized polyclonal antisera. G(ialpha1) also was measured with a novel, more sensitive monoclonal antibody (7H7). G(oalpha) and G(ialpha2) but not G(ialpha1) and G(ialpha3) were detected in membrane extracts prepared from GH4C1 cells. In contrast, the G proteins copurified with SSTR2 receptors were predominantly G(ialpha2) (50% of total G protein) and G(ialpha3) (36% of total G protein), whereas G(oalpha) and G(ialpha1) were negligible. G(beta) subunits also were detected. Silver staining confirmed the absence of a 39-kDa protein, corresponding to the M(r) of G(oalpha) associated with purified SRIF receptor-G protein complexes. These data suggest that SRIF receptors selectively couple to two G proteins, one of which is sparsely expressed in GH4C1 cells; the data conform to the notion that SRIF receptors discriminate between similar pertussis toxin-sensitive G proteins.	UNIV VIRGINIA, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT INTERNAL MED CARDIOL, CHARLOTTESVILLE, VA 22908 USA; AMER CYANAMID CO, DIV AGR RES, MOLEC GENET SCREEN DESIGN & BIOCHEM GRP, PRINCETON, NJ 08543 USA	University of Virginia; University of Virginia; American Cyanamid Company					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037942, T32HL007284] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07284, R01-HL37942] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BROWN M, 1981, ENDOCRINOLOGY, V108, P2391, DOI 10.1210/endo-108-6-2391; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; CARTY DJ, 1991, METHOD ENZYMOL, V195, P302; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CRONIN MJ, 1983, ENDOCRINOLOGY, V113, P209, DOI 10.1210/endo-113-1-209; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; EPPLER CM, 1992, J BIOL CHEM, V267, P15603; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HULMES JD, 1992, BIOCHEM BIOPH RES CO, V184, P131, DOI 10.1016/0006-291X(92)91168-P; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KIMURA N, 1989, J BIOL CHEM, V264, P7033; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1992, MOL PHARMACOL, V42, P398; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MAHY N, 1988, J PHARMACOL EXP THER, V246, P779; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MOREL A, 1983, J BIOL CHEM, V258, P8273; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATEL A, 1988, MOL PHARMACOL, V33, P585; PATEL YC, 1986, ANNU REV PHYSIOL, V48, P551; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; SRIKANT CB, 1992, ENDOCRINOLOGY, V130, P2937, DOI 10.1210/en.130.5.2937; TALLENT M, 1992, MOL PHARMACOL, V41, P452; THERMOS K, 1988, MOL PHARMACOL, V33, P370; THERMOS K, 1990, AM J PHYSIOL, V259, pE216, DOI 10.1152/ajpendo.1990.259.2.E216; VALE W, 1974, ENDOCRINOLOGY, V95, P968, DOI 10.1210/endo-95-4-968; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; WESSEL D, 1984, ANAL BIOCHEM, V185, P324; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YATANI A, 1990, METABOLISM, V39, P91, DOI 10.1016/0026-0495(90)90220-7	54	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5990	5996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449959				2022-12-25	WOS:A1993KR82200094
J	BAIER, G; TELFORD, D; GIAMPA, L; COGGESHALL, KM; BAIERBITTERLICH, G; ISAKOV, N; ALTMAN, A				BAIER, G; TELFORD, D; GIAMPA, L; COGGESHALL, KM; BAIERBITTERLICH, G; ISAKOV, N; ALTMAN, A			MOLECULAR-CLONING AND CHARACTERIZATION OF PKC-THETA, A NOVEL MEMBER OF THE PROTEIN-KINASE-C (PKC) GENE FAMILY EXPRESSED PREDOMINANTLY IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; HUMAN LYMPHOCYTES-T; RAT-BRAIN; IDENTIFICATION; HETEROGENEITY; INHIBITION; ACTIVATION; MULTIPLE; SEQUENCE; ANTIGEN	Members of the protein kinase C (PKC) family of serine/threonine kinases play a key role in regulating the differentiation and growth of diverse cell types and, to date, the cloning of seven mammalian PKC genes encoding eight distinct isoforms has been reported. Here we describe the molecular cloning and deduced primary structure of a cDNA encoding a novel PKC isoform, termed PKCtheta, which was isolated in the course of attempts to identify PKC genes that are expressed selectively in hematopoietic cells. Degenerate oligonucleotide primers corresponding to conserved sequence motifs, which distinguish the PKC family from other protein kinases, were employed in polymerase chain reactions (PCR) to amplify partial core sequences of putative PKC genes from a human peripheral blood lymphocyte-derived cDNA library. DNA sequencing of selected clones revealed several PKC-related sequences, including one that, on the basis of sequence comparison with known PKC isoforms, represented a novel PKC isoform. The complete cDNA sequence was determined by anchored PCR cloning and sequencing the entire coding sequence, using cDNA derived from a human leukemic T cell line (Jurkat). Included within this approximately 2.7-kilobase pair cDNA is an open reading frame of 2,118 nucleotides encoding a putative 82-kDa protein. The deduced primary structure contains consensus sequences characteristic of protein kinase catalytic domains and, based on its amino acid sequence and domain structure, is a member of the PKC family. PKCtheta displays the highest homology to PKCdelta, lacks the Ca2+ binding C2 domain and, thus, belongs to the subfamily of Ca2+-independent PKC enzymes which also includes the delta, epsilon, zeta, and eta isoforms. RNase protection assays and semiquantitative PCR analysis indicated that, although PKCtheta transcripts are expressed ubiquitously, the highest levels are found in hematopoietic tissues and cell lines, including T cells and thymocytes. In contrast, the expression levels in the brain and testes are considerably lower, and no transcripts were detected in several human carcinoma cell lines. A rabbit antiserum raised against a unique (V3 domain) bacterially expressed PKCtheta fragment immunoprecipitated specifically an 82-kDa protein from Jurkat cell lysates. Thus, PKCtheta represents an additional member of the PKC family, and its predominant expression in hematopoietic cells suggests that it may play a role in signal transduction and growth regulatory pathways unique to these cells.	BEN GURION UNIV NEGEV, DEPT MICROBIOL & IMMUNOL, IL-84105 BEER SHEVA, ISRAEL	Ben Gurion University	BAIER, G (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA.		Baier, Gottfried/E-8755-2012; ISAKOV, NOAH/F-1659-2012	Baier, Gottfried/0000-0002-2085-8325; Isakov, Noah/0000-0002-1412-0957	NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ALTMAN A, 1992, IMMUNOLOGY, V76, P465; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BEYERS AD, 1988, J IMMUNOL, V141, P3463; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUBBARD SR, 1991, SCIENCE, V254, P1776; ISAKOV N, 1992, MOL IMMUNOL, V29, P927, DOI 10.1016/0161-5890(92)90131-G; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; JUSZCZAK RJ, 1989, J BIOL CHEM, V264, P810; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUGER KE, 1991, J NEUROSCI, V11, P2303; KURTH JH, 1990, AMPLIFICATIONS, V5, P18; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NEL AE, 1987, J IMMUNOL, V139, P2230; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; OVERBAUGH J, 1990, TECHNIQUES HIV RES, P139; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATEL MD, 1987, J BIOL CHEM, V262, P5831; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHEARMAN MS, 1988, FEBS LETT, V234, P387, DOI 10.1016/0014-5793(88)80122-4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X	50	277	284	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4997	5004						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444877				2022-12-25	WOS:A1993KP88400066
J	HAUER, CR; REBRIN, I; THONY, B; NEUHEISER, F; CURTIUS, HC; HUNZIKER, P; BLAU, N; GHISLA, S; HEIZMANN, CW				HAUER, CR; REBRIN, I; THONY, B; NEUHEISER, F; CURTIUS, HC; HUNZIKER, P; BLAU, N; GHISLA, S; HEIZMANN, CW			PHENYLALANINE HYDROXYLASE-STIMULATING PROTEIN PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE FROM RAT AND HUMAN LIVER - PURIFICATION, CHARACTERIZATION, AND COMPLETE AMINO-ACID-SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; 7-SUBSTITUTED PTERINS; HYPERPHENYLALANINEMIA; 4A-CARBINOLAMINE; ACTIVATION; OXYGEN	Phenylalanine hydroxylase-stimulating protein, also known as pterin-4alpha-carbinolamine dehydratase (PHS/PCD), was purified from rat and, for the first time, from human liver. We obtained their complete protein primary sequence using a combination of liquid secondary ionization mass spectrometry/tandem quadrupole mass spectrometry, electrospray ionization mass spectrometry, and Edman microsequence analysis. The amino acid sequences of human and rat PHS/PCD were found to be identical. Surprisingly, the primary structure of PHS/PCD is also essentially identical to a protein of the cell nucleus, named dimerization cofactor of hepatocyte nuclear factor 1alpha, recently reported to be involved in transcription (Mendel, D. M., Khavari, P. A., Conley, P. B., Graves, M. K., Hansen, L. P., Admon, A., and Crabtree, G. R. (1991) Science 254, 1762-1767).	UNIV ZURICH, DEPT PEDIAT, DIV CLIN CHEM, CH-8032 ZURICH, SWITZERLAND; ERNST MORITZ ARNDT UNIV, INST MED GENET, O-2200 GREIFSWALD, GERMANY; UNIV ZURICH, INST BIOCHEM, CH-8057 ZURICH, SWITZERLAND; UNIV CONSTANCE, DEPT BIOL, W-7750 CONSTANCE, GERMANY	University of Zurich; Ernst Moritz Arndt Universitat Greifswald; University of Zurich; University of Konstanz				Hauer, Christoph/0000-0001-8704-2198; Blau, Nenad/0000-0003-4347-3230				ADLER C, 1992, EUR J BIOCHEM, V208, P139, DOI 10.1111/j.1432-1033.1992.tb17167.x; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BLASKOVICS M, 1988, NEW ENGL J MED, V319, P1611; CURTIUS HC, 1988, BIOCHEM BIOPH RES CO, V153, P715, DOI 10.1016/S0006-291X(88)81153-7; CURTIUS HC, 1990, BIOCHEM BIOPH RES CO, V172, P1060, DOI 10.1016/0006-291X(90)91554-6; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DHONDT JL, 1988, EUR J PEDIATR, V147, P153, DOI 10.1007/BF00442213; DIX TA, 1985, BIOCHEMISTRY-US, V24, P2955, DOI 10.1021/bi00333a022; DIX TA, 1987, BIOCHEMISTRY-US, V26, P3354, DOI 10.1021/bi00386a016; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; HAUER CR, 1992, BIOCHEM BIOPH RES CO, V182, P953, DOI 10.1016/0006-291X(92)91824-A; HUANG CY, 1973, J BIOL CHEM, V248, P4235; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KUSTER T, 1991, BIOCHEMISTRY-US, V30, P8812, DOI 10.1021/bi00100a012; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LAZARUS RA, 1982, J AM CHEM SOC, V104, P6869, DOI 10.1021/ja00388a105; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; PARNIAK MA, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P656; PEMBER SO, 1986, BIOCHEMISTRY-US, V25, P6611, DOI 10.1021/bi00369a042; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; [No title captured]	23	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4828	4831						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444860				2022-12-25	WOS:A1993KP88400043
J	HERWIG, S; KRUFT, V; ECKART, K; WITTMANNLIEBOLD, B				HERWIG, S; KRUFT, V; ECKART, K; WITTMANNLIEBOLD, B			CROSS-LINKED AMINO-ACIDS IN THE PROTEIN PAIRS L3-L19 AND L23-L29 OF BACILLUS-STEAROTHERMOPHILUS RIBOSOMES AFTER TREATMENT WITH DIEPOXYBUTANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; HALOBACTERIUM-MARISMORTUI; GEL-ELECTROPHORESIS; LINKING TECHNIQUES; SUBUNITS; RNA; PEPTIDE; L23; IDENTIFICATION; NITROCELLULOSE	Treatment of native 50 S ribosomal subunits of Bacillus stearothermophilus with the homobifunctional cross-linking reagent diepoxybutane generated two cross-linked protein pairs, L3-L19 and L23-L29, which were isolated and identified. The analysis of the cross-linking sites at the amino acid level in both protein pairs is presented. Using a combination of sequence analysis and mass spectrometry it could be demonstrated that His-28 in protein L3 and the N-terminal amino acids Met-1, His-2, and His-3 in protein L19 are involved in forming the cross-link L3-L19. Within the pair L23-L29 Met-1 in protein L23 and Lys-4 in protein L29 were identified as cross-linking sites employing a similar approach. Comparison of our data with results derived from other cross-linking experiments showed that in general the structural organization of the ribosomes in eubacteria (the Gram-positive B. stearothermophilus and the Gram-negative Escherichia coli) has been conserved to quite an extent during evolution but that the fine structures differ slightly. By mass spectrometry the specificity of diepoxybutane and its cleaving mechanism using sodium periodate could be examined. In addition the complete amino acid sequence of protein L19 of B. stearothermophilus has been determined and revealed 58% identical amino acid residues to the homologous E. coli protein L19.	MAX PLANCK INST MOLEC GENET, WITTMANN ABT, W-1000 BERLIN 33, GERMANY	Max Planck Society								ALLEN G, 1979, J BIOL CHEM, V256, P9800; ARNDT E, 1991, BIOCHIMIE, V73, P657, DOI 10.1016/0300-9084(91)90045-3; BAUMERT HG, 1978, EUR J BIOCHEM, V89, P353, DOI 10.1111/j.1432-1033.1978.tb12536.x; BAUMERT HG, 1989, METHOD ENZYMOL, V172, P584; BERGMANN U, 1991, THESIS FREIE U BERLI; BRIMACOMBE R, 1990, BIOCHIM BIOPHYS ACTA, V1050, P8, DOI 10.1016/0167-4781(90)90133-M; BROCKMOLLER J, 1986, BIOL CHEM H-S, V367, P925, DOI 10.1515/bchm3.1986.367.2.925; BROCKMOLLER J, 1988, BIOCHEMISTRY-US, V27, P3372, DOI 10.1021/bi00409a038; BROSIUS J, 1978, BIOCHEMISTRY-US, V17, P508, DOI 10.1021/bi00596a021; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CHANG JY, 1978, FEBS LETT, V91, P63, DOI 10.1016/0014-5793(78)80018-0; CHOLI T, 1990, ELECTROPHORESIS, V11, P562, DOI 10.1002/elps.1150110706; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; HACKL W, 1988, EUR J BIOCHEM, V174, P431, DOI 10.1111/j.1432-1033.1988.tb14116.x; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HERFURTH E, 1991, BIOL CHEM H-S, V372, P955, DOI 10.1515/bchm3.1991.372.2.955; HERFURTH E, 1991, BIOL CHEM H-S, V372, P351, DOI 10.1515/bchm3.1991.372.1.351; HERWIG S, 1990, CHROMATOGRAPHIA, V30, P696, DOI 10.1007/BF02269746; HERWIG S, 1992, EUR J BIOCHEM, V207, P877, DOI 10.1111/j.1432-1033.1992.tb17119.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JI TH, 1983, METHOD ENZYMOL, V91, P580; KAMP RM, 1988, MODERN METHODS PROTE, V3, P275; KIMURA M, 1985, EUR J BIOCHEM, V150, P491, DOI 10.1111/j.1432-1033.1985.tb09049.x; KRUFT V, 1991, BIOCHIMIE, V73, P855, DOI 10.1016/0300-9084(91)90126-L; LEFFERS H, 1988, J MOL BIOL, V204, P507, DOI 10.1016/0022-2836(88)90351-8; LUTTER LC, 1974, FEBS LETT, V48, P288, DOI 10.1016/0014-5793(74)80488-6; MAASSEN JA, 1981, BIOCHEMISTRY-US, V20, P1020, DOI 10.1021/bi00507a057; MAKOWSKI I, 1987, J MOL BIOL, V193, P819, DOI 10.1016/0022-2836(87)90362-7; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NOWOTNY V, 1986, STRUCTURE FUNCTION G, P101; POHL T, 1988, J BIOL CHEM, V263, P4293; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; TRAUT RR, 1980, STRUCTURE FUNCTION G, P89; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WALLEZEK J, 1989, BIOCHEMISTRY-US, V28, P4094; WEITZMANN CJ, 1990, BIOCHEMISTRY-US, V29, P3458, DOI 10.1021/bi00466a006; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOWER I, 1981, NUCLEIC ACIDS RES, V9, P4285, DOI 10.1093/nar/9.17.4285; YAMASAKI RB, 1982, ANAL BIOCHEM, V126, P183, DOI 10.1016/0003-2697(82)90127-0; YONATH A, 1990, RIBOSOME, P134; YONATH AE, 1980, BIOCHEM INT, V1, P428	47	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4643	4650						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444837				2022-12-25	WOS:A1993KP88400016
J	LEROY, A; TOOHILL, KLH; FRUCHART, JC; JONAS, A				LEROY, A; TOOHILL, KLH; FRUCHART, JC; JONAS, A			STRUCTURAL-PROPERTIES OF HIGH-DENSITY-LIPOPROTEIN SUBCLASSES HOMOGENEOUS IN PROTEIN-COMPOSITION AND SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; GUANIDINE-HYDROCHLORIDE; HUMAN-SERUM; IMMUNOAFFINITY CHROMATOGRAPHY; MICELLAR COMPLEXES; PARTICLES; LECITHIN; SUBPOPULATIONS	We isolated native high density lipoprotein (HDL) subclasses homogeneous in size and in their protein content with the objective of investigating the differences and similarities in their apolipoprotein AI (apoA-I) structures. Defined particles were isolated from ultracentrifugally prepared HDL by immunoaffinity and gel-filtration chromatography. The isolated 88-angstrom LpAI, 106-angstrom LpAI, 96-angstrom LpAI/AII particles (LpAI, particles contain only apoA-I; LpAI/AII, particles contain apoA-I and apoA-II), together with a 93-angstrom reconstituted HDL were analyzed for purity, composition, and content of apolipoprotein molecules per particle, and were examined by far and near circular dichroism and intrinsic fluorescence spectroscopic methods, as well as by reaction kinetics with lecithin:cholesterol acyltransferase. The spectroscopic analyses indicated that the secondary structures and three-dimensional arrangements of apoA-I in all these particles are remarkably similar: their tryptophan residues are located in similar nonpolar environments and become exposed to increasing concentrations of guanidine hydrochloride in comparable denaturation steps; the 60-65% alpha-helical structures in apoA-I are denatured in similar patterns with 0-5 M denaturant concentrations. However, increasing surface lipid contents and the presence of apoA-II stabilize apoA-I on the HDL particles. The reaction kinetics with lecithin:cholesterol acyltransferase are similar and slow for the isolated HDL particles, reflecting product inhibition, and/or an apoA-I conformation that is unfavorable for the activation of the lecithin:cholesterol acyltransferase reaction.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,506 S MATHEWS AVE,URBANA,IL 61801; INST PASTEUR,SERV RECH LIPOPROT,F-59019 LILLE,FRANCE	University of Illinois System; University of Illinois Urbana-Champaign; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16059] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVI.P, 1972, BIOCHIM BIOPHYS ACTA, V260, P689, DOI 10.1016/0005-2760(72)90018-5; ALBERS JJ, 1976, BIOCHEMISTRY-US, V15, P1084, DOI 10.1021/bi00650a020; ATMEH RF, 1983, BIOCHIM BIOPHYS ACTA, V751, P175, DOI 10.1016/0005-2760(83)90172-8; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BETARD C, 1987, J CLIN CHEM CLIN BIO, V25, P893; BEYCHOK S, 1965, P NATL ACAD SCI USA, V53, P999, DOI 10.1073/pnas.53.5.999; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1988, J LIPID RES, V29, P15; CHEUNG MC, 1989, J LIPID RES, V30, P499; CHEUNG MC, 1987, J LIPID RES, V28, P913; EDELHOCH H, 1968, J BIOL CHEM, V243, P4799; EDELSTEIN C, 1972, J BIOL CHEM, V247, P5842; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; FRUCHART JC, 1985, METHOD ENZYMAT AN, V8, P26; HEIDER JG, 1978, J LIPID RES, V19, P514; JAMES RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P292, DOI 10.1016/0005-2760(89)90343-3; JAMES RW, 1988, J LIPID RES, V29, P1557; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1993, IN PRESS BIOCH BIOPH; JONAS A, 1993, IN PRESS J BIOL CHEM; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, J BIOL CHEM, V247, P2598; MARCEL YL, 1980, P NATL ACAD SCI-BIOL, V77, P2969, DOI 10.1073/pnas.77.5.2969; MASSEY JB, 1989, BIOCHIM BIOPHYS ACTA, V999, P111, DOI 10.1016/0167-4838(89)90207-0; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; NICHOLS AV, 1985, CIRCULATION, V72, P364; NICHOLS AV, 1991, BIOCHIM BIOPHYS ACTA, V1085, P306, DOI 10.1016/0005-2760(91)90134-4; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; NORFELDT PIP, 1981, EUR J BIOCHEM, V118, P1, DOI 10.1111/j.1432-1033.1981.tb05478.x; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; RADER DJ, 1991, J LIPID RES, V32, P1849; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P431; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STOFFEL W, 1979, H-S Z PHYSIOL CHEM, V360, P691, DOI 10.1515/bchm2.1979.360.1.691; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; STRICKLA.EH, 1969, BIOCHEMISTRY-US, V8, P3205, DOI 10.1021/bi00836a012; STRICKLAND EH, 1970, J BIOL CHEM, V245, P4168; TALUSSOT C, 1991, BIOCHIMIE, V73, P1173, DOI 10.1016/0300-9084(91)90001-H; WALD JH, 1990, J BIOL CHEM, V265, P20037	53	41	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4798	4805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444856				2022-12-25	WOS:A1993KP88400039
J	LI, ZM; GLIBOWICKA, M; JOENSSON, C; DEBER, CM				LI, ZM; GLIBOWICKA, M; JOENSSON, C; DEBER, CM			CONFORMATIONAL STATES OF MUTANT-M13 COAT PROTEINS ARE REGULATED BY TRANSMEMBRANE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MEMBRANE; BACTERIOPHAGE; DNA; MUTAGENESIS; M13; MUTATIONS; SEQUENCE; DYNAMICS; FD	Mutational and structural analysis of the 28 viable bacteriophage M13 mutants obtained by randomized mutagenesis of the effective transmembrane (TM) segment of the 50-residue major coat (gene VIII) protein (residues 21-39) demonstrated that M13 coat protein functionality, as reflected by phage viability, is incompatible with an increase in Gly + beta-branched residue content in its TM core. SDS-polyacrylamide gel electrophoresis and circular dichroism spectroscopy performed in membrane environments on purified mutant coat proteins revealed that these proteins exist in a range of state(s), identified as helical monomers and dimers and polymeric (alpha-helical and/or beta-sheet) species, of which relative populations, and thermally induced conformational transitions, were dependent uniquely upon mutation type and locus. Mutations to relatively polar residues (eg. G23D, Y24D, Y24H, A27E, I32T, and T36S) stabilized principally monomeric species, while mutants with decreased beta-branched content in the protein TM hydrophobic core (e.g. V29A, V30A, V31A, V31L, and V33A) displayed mainly dimeric species. Mutation of Ile37 --> Thr within a ''Sternberg-Gullick'' consensus sequence of the coat protein TM segment led to a highly oligomerized/polymerized protein. The overall results suggest that TM residues in M13 coat protein are not universal components of a hydrophobic anchor segment per se, but are further selected (i) to impart conformational flexibility to the TM segment through helix destabilization and (ii) to retain the capacity to regulate protein-protein association and packing motifs within membranes.	HOSP SICK CHILDREN,RES INST,DIV BIOCHEM RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BANNER DW, 1981, NATURE, V289, P814, DOI 10.1038/289814a0; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAY LA, 1988, ANNU REV BIOPHYS BIO, V17, P509; DEBER CM, 1992, J BIOL CHEM, V267, P5296; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; DUNKER AK, 1991, FEBS LETT, V292, P271, DOI 10.1016/0014-5793(91)80882-4; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HENRY GD, 1992, BIOCHEMISTRY-US, V31, P5284, DOI 10.1021/bi00138a007; HENRY GD, 1990, BIOCHEM CELL BIOL, V68, P318, DOI 10.1139/o90-044; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HUBNER P, 1988, GENE, V73, P319, DOI 10.1016/0378-1119(88)90496-9; HUNTER GJ, 1987, NATURE, V327, P252, DOI 10.1038/327252a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LI ZM, 1991, BIOCHEM BIOPH RES CO, V180, P687; NOZAKI Y, 1976, NATURE, V259, P335, DOI 10.1038/259335a0; OPELLA SJ, 1987, Q REV BIOPHYS, V19, P1; PUTTERMAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P699, DOI 10.1073/pnas.81.3.699; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; SPRUIJT RB, 1991, BIOCHEMISTRY-US, V30, P11147, DOI 10.1021/bi00110a018; SPRUIJT RB, 1989, BIOCHEMISTRY-US, V28, P9158, DOI 10.1021/bi00449a030; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS GJ, 1981, P NATL ACAD SCI-BIOL, V78, P2962, DOI 10.1073/pnas.78.5.2962; TZAGOLOFF H, 1964, VIROLOGY, V24, P372, DOI 10.1016/0042-6822(64)90174-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	34	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4584	4587						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444834				2022-12-25	WOS:A1993KP88400005
J	NISHIYAMA, M; BIRKTOFT, JJ; BEPPU, T				NISHIYAMA, M; BIRKTOFT, JJ; BEPPU, T			ALTERATION OF COENZYME SPECIFICITY OF MALATE-DEHYDROGENASE FROM THERMUS-FLAVUS BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; SEQUENCE; NADP; CLONING	On the basis of the crystal structure of the NAD-dependent cytoplasmic malate dehydrogenase (MDH) and its alignment with NADP-dependent counterparts, the loop region between beta-strand B and alpha-helix C in the dinucleotide-binding fold was predicted as a principal determinant for the coenzyme specificity. Two mutants, EX7 and EX3, of NAD-dependent MDH from Thermus flavus were constructed. In the EX7 mutant, the seven loop amino acids in positions 41-47, Glu-Ile-Pro-Gln-Ala-Met-Lys, were replaced by the corresponding loop residues in the NADP-dependent MDH from chloroplasts, Gly-Ser-Glu-Arg-Ser-Phe-Gln. In the EX3 mutant, Glu-41, Ile-42, and Ala-45 were substituted with the corresponding 3 amino acids in the NADP-dependent chloroplast MDH. In both mutations the coenzyme specificity was altered from NAD to NADP. Especially, the EX7 mutation resulted in a more than 1000-fold improvement in overall catalytic efficiency with NADPH and a 600-fold decrease in the efficiency with NADH as cofactors. Consequently, EX7 mutant was 132 times more efficient with NADPH than NADH without a large decrease in turnover number.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	NISHIYAMA, M (corresponding author), UNIV TOKYO,FAC AGR,DEPT AGR CHEM,YAYOI 1-1-1,BUNKYO KU,TOKYO 113,JAPAN.			Nishiyama, Makoto/0000-0001-8143-8052				BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1987, BIOCHEMISTRY-US, V26, P2722, DOI 10.1021/bi00384a011; BIRKTOFT JJ, 1984, PEPT PROTEIN REV, V4, P1; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; Cleland W W, 1979, Methods Enzymol, V63, P103; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; FICKENSCHER K, 1987, EUR J BIOCHEM, V168, P653, DOI 10.1111/j.1432-1033.1987.tb13466.x; JOH T, 1987, J BIOL CHEM, V262, P15127; KELLY CA, 1991, J MOL BIOL, V221, P383, DOI 10.1016/0022-2836(91)80060-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; METZLER MC, 1989, PLANT MOL BIOL, V12, P713, DOI 10.1007/BF00044162; NISHIYAMA M, 1991, J BIOL CHEM, V266, P14294; NISHIYAMA M, 1986, J BIOL CHEM, V261, P14178; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0	17	69	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4656	4660						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444839				2022-12-25	WOS:A1993KP88400018
J	POULIN, R; COWARD, JK; LAKANEN, JR; PEGG, AE				POULIN, R; COWARD, JK; LAKANEN, JR; PEGG, AE			ENHANCEMENT OF THE SPERMIDINE UPTAKE SYSTEM AND LETHAL EFFECTS OF SPERMIDINE OVERACCUMULATION IN ORNITHINE DECARBOXYLASE-OVERPRODUCING L1210 CELLS UNDER HYPOSMOTIC STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE TRANSPORT-SYSTEM; ALPHA-DIFLUOROMETHYLORNITHINE; NEUROSPORA-CRASSA; MAMMALIAN-CELLS; LEUKEMIA-CELLS; LUNG-CARCINOMA; AMINO-ACIDS; MOUSE; GROWTH; METABOLISM	The D-R cell subline, an ornithine decarboxylase-overproducing variant of L1210 mouse leukemia cells, shows a growth advantage at low osmolality due to its high putrescine content. We tested the ability of spermidine to fulfill the role of putrescine under hyposmotic conditions. Although spermidine (1-30 muM) had no effect on growth under normosmotic conditions (325 mosm/kg), it was strongly inhibitory to D-R cell proliferation at 150 mosm/kg in a concentration-dependent manner. Hypotonic shock greatly increased the rate of spermidine uptake in D-R cells. The increased spermidine content enhanced total putrescine synthesis through a large induction of cytosolic spermidine/spermine N1-acetyltransferase activity but also promoted the excretion of most of the putrescine synthesized by the cells. Delaying the addition of spermidine until 24 h after hypotonic shock resulted in a much sharper decrease in D-R cell viability and strongly depressed polyamine contents. These lethal effects occurred between 8 and 24 h after spermidine addition and followed a dramatic increase in the rate and extent of spermidine accumulation which overrode the metabolic capacity of the N1-acetyltransferase/polyamine oxidase (PAO) pathway. Inhibition of PAO partly reversed the effect of spermidine on growth when the polyamine was added at the time of hypotonic shock, but not 24 h later. Similar experiments performed with alpha-methylspermidine, a metabolically resistant analog, which can completely fulfill cellular requirements for spermidine in normosmotic media, suggested that the lethal effect of a delayed spermidine addition is caused predominantly by excessive accumulation with a minor contribution resulting from stress due to polyamine oxidase activity. In contrast, in hypotonically shocked L1210 cells, spermidine stimulated cell proliferation (albeit less effectively than putrescine), there was no lethal effect of a delayed addition of alpha-methylspermidine, and there was no time-dependent increase in the rate of alpha-methylspermidine uptake. Thus, the spermidine transport system is strongly enhanced by hyposmotic shock in D-R cells, which can result in extensive cell death from overaccumulation of the polyamine and, to a lesser extent, from stress related to the PAO-catalyzed degradation of N1-acetylspermidine. The absence of these effects in parental L1210 cells indicates that the acquisition of an ornithine decarboxylase-overproducing phenotype also involves major modifications in the expression and/or regulation of polyamine transport.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MED CHEM,ANN ARBOR,MI 48109	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [U01CA037606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37606] Funding Source: Medline; NIGMS NIH HHS [GM-26290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JC, 1979, EUR J BIOCHEM, V102, P153, DOI 10.1111/j.1432-1033.1979.tb06275.x; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; BODE BP, 1991, J BIOL CHEM, V266, P7376; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNTON VG, 1991, BIOCHEM J, V280, P193, DOI 10.1042/bj2800193; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CHANG BK, 1988, BIOCHEM BIOPH RES CO, V157, P264, DOI 10.1016/S0006-291X(88)80042-1; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; COX DR, 1988, CYTOGENET CELL GENET, V48, P92, DOI 10.1159/000132597; DAVIS RH, 1991, ARCH BIOCHEM BIOPHYS, V285, P297, DOI 10.1016/0003-9861(91)90363-N; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; FLORES HE, 1982, SCIENCE, V217, P1259, DOI 10.1126/science.217.4566.1259; GRAMZINSKI RA, 1990, DIFFERENTIATION, V43, P59, DOI 10.1111/j.1432-0436.1990.tb00430.x; GUARINO LA, 1979, P NATL ACAD SCI USA, V76, P3184, DOI 10.1073/pnas.76.7.3184; GUARNIERI C, 1982, BIOCHIM BIOPHYS ACTA, V718, P157, DOI 10.1016/0304-4165(82)90214-8; HARARI PM, 1989, INT J RADIAT ONCOL, V16, P451, DOI 10.1016/0360-3016(89)90341-6; HAUSSINGER D, 1991, BIOCHEM CELL BIOL, V69, P1; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HIRVONEN A, 1989, BIOCHEM J, V258, P709, DOI 10.1042/bj2580709; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JANNE J, 1971, J BIOL CHEM, V246, P1725; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAPYAHO K, 1982, BIOCHIM BIOPHYS ACTA, V714, P93, DOI 10.1016/0304-4165(82)90130-1; KHAN NA, 1990, CELL MOL BIOL, V36, P345; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; KUMAGAI J, 1989, AM J PHYSIOL, V256, pG905, DOI 10.1152/ajpgi.1989.256.5.G905; LAKANEN JR, 1992, J MED CHEM, V35, P724, DOI 10.1021/jm00082a013; LUNDGREN DW, 1988, J CELL PHYSIOL, V137, P469, DOI 10.1002/jcp.1041370311; LUNDGREN DW, 1992, J BIOL CHEM, V267, P6841; MCCORMACK SA, 1989, AM J PHYSIOL, V256, pG838; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; MITCHELL JLA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P136, DOI 10.1016/0167-4889(92)90248-A; MORGAN DML, 1987, BIOCHEM J, V242, P347, DOI 10.1042/bj2420347; MORGAN DML, 1981, ADV POLYAMINE RES, V3, P65; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; MUNRO GF, 1975, BIOCHIM BIOPHYS ACTA, V411, P263, DOI 10.1016/0304-4165(75)90306-2; MUNRO GF, 1973, J BACTERIOL, V116, P488, DOI 10.1128/JB.116.1.488-490.1973; PADMANABHAN S, 1991, BIOCHEMISTRY-US, V30, P7550, DOI 10.1021/bi00244a026; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1988, CANCER RES, V48, P2678; PERRY JW, 1980, BIOCHIM BIOPHYS ACTA, V629, P24, DOI 10.1016/0304-4165(80)90261-5; PORTER CW, 1984, CANCER RES, V44, P126; POULIN R, 1991, J BIOL CHEM, V266, P6142; POULIN R, 1990, J BIOL CHEM, V265, P4025; RINEHART CA, 1984, J BIOL CHEM, V259, P4750; RINEHART CA, 1985, P NATL ACAD SCI USA, V82, P4365, DOI 10.1073/pnas.82.13.4365; SCHUBER F, 1989, BIOCHEM J, V260, P1; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Seiler N., 1987, INHIBITION POLYAMINE, P49; TOHYAMA Y, 1991, EUR J BIOCHEM, V202, P1327, DOI 10.1111/j.1432-1033.1991.tb16507.x; TONIN PN, 1989, ONCOGENE, V4, P1117; WATSON PA, 1989, J BIOL CHEM, V264, P14735; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383; ZURETTI MF, 1983, BIOCHIM BIOPHYS ACTA, V742, P269, DOI 10.1016/0167-4838(83)90311-4	63	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4690	4698						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444843				2022-12-25	WOS:A1993KP88400023
J	PANG, JH; CHEN, KY				PANG, JH; CHEN, KY			A SPECIFIC CCAAT-BINDING PROTEIN, CBP/TK, MAY BE INVOLVED IN THE REGULATION OF THYMIDINE KINASE GENE-EXPRESSION IN HUMAN IMR-90 DIPLOID FIBROBLASTS DURING SENESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT GENES; CELL-CYCLE; MESSENGER-RNA; TRANSCRIPTION INITIATION; MOUSE FIBROBLASTS; FACTORS INTERACT; PROMOTER; SEQUENCE; AGE; BOX	The aging of IMR-90 human diploid fibroblasts in culture is accompanied by a 5-7-fold decrease in the level of thymidine kinase (TK) mRNA and TK activity (Chang, Z. F., and Chen, K. Y. (1988) J. Biol. Chem. 263, 11431-11435). We have employed a gel mobility shift analysis to investigate the molecular basis of the age-dependent attenuation of TK gene expression. Several cis-elements including two inverted CCAAT boxes, located at base pairs (bp) -36 and -67, and GC-rich Sp1 binding sites have been identified in the TK promoter. A 28-bp (-91 to -64) fragment containing the distal inverted CCAAT element was excised from the TK promoter to examine possible differences in nuclear protein binding between young and old IMR-90 cells. A prominent DNA-protein complex was identified in serum-stimulated young cells by a gel mobility shift assay. Competition analysis indicated that the binding was highly specific. The nuclear protein responsible for the complex formation was named CBP/tk (CCAAT Binding Protein for TK gene) since methylation interference assay showed that the inverted CCAAT box was involved in binding. The appearance of the CBP/tk-28-bp complex in IMR-90 cells was (i) serum-dependent, becoming prominent 12-24 h after serum stimulation, and (ii) age-dependent, prominent only in young but not in old IMR-90 cells. Similar serum- and age-dependent complex formations were also observed using a 67-bp fragment (-63 to +4) containing the proximal CCAAT element and a TATA box. In contrast, the binding activities for the Sp1 sequence were the same in young and old cells and appeared to be serum-independent. CBP/tk binding activity in nuclear extracts was abolished by heat (60-degrees-C, 5 min) or treatment with proteinase K (0.1 mug/ml) and sodium dodecyl sulfate (0.005%), but not by Nonidet P-40 or Triton X-100. Treatment of nuclear extracts with alkaline phosphatase or lectins (concanavalin A and wheat germ agglutinin) did not affect the binding activity. Metal chelators such as 1,10-orthophenanthroline (0.5 mM) inhibited the CBP/tk binding activity. Cycloheximide added to the serum-stimulated cultures at an early or mid-G, phase inhibited the CBP/tk binding activity. The half-life of the serum-induced CBP/tk binding activity was estimated to be less than 1 h. These data suggested that CBP/tk is a unique CCAAT-binding protein and that it may play a key role in the cell cycle- and age-dependent regulation of TK gene expression in human IMR-90 cells.	RUTGERS STATE UNIV,DEPT CHEM,WRIGHT CHEM LAB,POB 939,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick				Chen, Kuang Yu/0000-0002-5629-7785	NATIONAL INSTITUTE ON AGING [R01AG003578] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG03578] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARCOT SS, 1989, J BIOL CHEM, V264, P2343; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CHANG CD, 1991, J BIOL CHEM, V266, P8663; CHANG ZF, 1988, J BIOL CHEM, V263, P11431; CHEN KY, 1989, EXP GERONTOL, V24, P523; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOI HS, 1990, J BIOL CHEM, V265, P18005; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1979, J INVEST DERMATOL, V73, P8, DOI 10.1111/1523-1747.ep12532752; HENDRICKSON SL, 1980, P NATL ACAD SCI-BIOL, V77, P5140, DOI 10.1073/pnas.77.9.5140; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; JOHNSON LF, 1982, EXP CELL RES, V138, P76; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KIM YK, 1992, J BIOL CHEM, V267, P2723; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P1551; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIU HT, 1985, J BIOL CHEM, V260, P3269; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARTIN GM, 1977, AM J PATHOL, V89, P484; MARTIN GM, 1970, LAB INVEST, V23, P86; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; PANG JH, 1992, FASEB J, V6, pA4894; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265	55	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2909	2916						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428965				2022-12-25	WOS:A1993KK81500096
J	TOHKIN, M; KISHINO, J; ISHIZAKI, J; ARITA, H				TOHKIN, M; KISHINO, J; ISHIZAKI, J; ARITA, H			PANCREATIC-TYPE PHOSPHOLIPASE-A(2) STIMULATES PROSTAGLANDIN SYNTHESIS IN MOUSE OSTEOBLASTIC CELLS (MC3T3-E1) VIA A SPECIFIC BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; EPIDERMAL GROWTH-FACTOR; FATTY-ACID CYCLOOXYGENASE; BONE-RESORPTION INVITRO; MESSENGER-RNA SYNTHESIS; SMOOTH-MUSCLE CELLS; PARATHYROID-HORMONE; PORCINE PANCREAS; RAT; LINE	Previously, we have reported a novel proliferative action of pancreatic group I phospholipase A2 (PLA2-I) via a specific binding site in Swiss 3T3 fibroblasts, vascular smooth muscle cells, and chondrocytes. In this study, we characterized the PLA2-I specific binding site in osteoblastic cell line (MC3T3-E1 cells) with an equilibrium binding constant (K(d)) value of 1.13 nM and maximum binding capacity of 40.1 fmol/10(6) cells. PLA2-I stimulated prostaglandin E2 (PGE2) production in a concentration-dependent manner in MC3T3-E1 cells, and its EC50 value was similar to the K(d) value for PLA2-I binding. This effect of PLA2-I was type-specific and did not depend on its hydrolytic activity. PLA2-I increased the activity of prostaglandin endoperoxide synthase (PES), and PLA2-I-stimulated PGE2 synthesis was inhibited by cycloheximide. Northern blot analysis showed the increase in both type-1 and type-2 PES mRNAs. These findings indicated that PLA2-I Stimulated PGE2 synthesis by induction of PES via a specific binding site in osteoblastic cells.	SHIONOGI & CO LTD,SHIONOGI RES LAB,12-4 SAGISU 5-CHOME,FUKUSHIMA KU,OSAKA 553,JAPAN	Shionogi & Company Limited								ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ARITA H, 1991, J BIOL CHEM, V266, P19139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETRICH JW, 1975, PROSTAG OTH LIPID M, V10, P231; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; HAKEDA Y, 1985, BIOCHEM BIOPH RES CO, V126, P340, DOI 10.1016/0006-291X(85)90611-4; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; IKEDA E, 1988, CALCIFIED TISSUE INT, V43, P162, DOI 10.1007/BF02571314; IRVINE RF, 1982, BIOCHEM J, V204, P153; KAMEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUMEGAWA M, 1983, CALCIFIED TISSUE INT, V35, P542, DOI 10.1007/BF02405091; KUMEGAWA M, 1984, CALCIFIED TISSUE INT, V36, P72, DOI 10.1007/BF02405296; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LORENZO JA, 1988, ENDOCRINOLOGY, V123, P2194, DOI 10.1210/endo-123-5-2194; LORENZO JA, 1986, J CLIN INVEST, V77, P1897, DOI 10.1172/JCI112517; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NEFUSSI JR, 1985, ANAT REC, V211, P9, DOI 10.1002/ar.1092110103; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OHARA O, 1990, NUCLEIC ACIDS RES, V18, P6997, DOI 10.1093/nar/18.23.6997; OKA S, 1991, J BIOL CHEM, V266, P9956; ONO T, 1984, J BIOCHEM-TOKYO, V101, P625; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1076, DOI 10.1210/endo-126-2-1076; RAISZ LG, 1977, NATURE, V267, P532, DOI 10.1038/267532a0; RAPUANO BE, 1991, BIOCHIM BIOPHYS ACTA, V1091, P374, DOI 10.1016/0167-4889(91)90203-A; RAZ A, 1988, J BIOL CHEM, V263, P3022; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1986, LAB INVEST, V55, P391; WU KK, 1988, J BIOL CHEM, V263, P19043; YANAGA F, 1992, J BIOL CHEM, V267, P5114; YANAGA F, 1991, BIOCHIM BIOPHYS ACTA, V1094, P139; YASUDA T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P189, DOI 10.1016/0005-2760(90)90188-4; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	53	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2865	2871						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428961				2022-12-25	WOS:A1993KK81500089
J	BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH				BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH			SEQUENCE AND BIOLOGICAL-ACTIVITY OF CHICKEN SNON CDNA CLONES	ONCOGENE			English	Article							V-SKI ONCOGENE; RETROVIRUS VECTORS; CELLS; GENE; VIRUSES; MUSCLE	cDNA clones of the ski-related gene, sno, were isolated from a chicken cDNA library and sequenced. In contrast to the human system, from which two forms of sno cDNAs have been isolated, we obtained only one type of chicken sno cDNA, that encoding snoN. The coding region for chicken snoN was inserted into the retroviral vectors RCAS(A) and RCASBP(A) and introduced into chicken embryo fibroblasts (CEFs) or quail embryo cells (QECs). Like the various forms of ski, snoN appears to be localized in the nucleus, and high levels of snoN expression cause transformation of CEFs and muscle differentiation of QECs. In contrast to ski however, low-level expression of snoN cannot induce transformation, and is only weakly myogenic.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Maniatis T., 1982, MOL CLONING; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462	13	88	93	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					457	466						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426750				2022-12-25	WOS:A1993KN00600025
J	OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T			CPG METHYLATION INACTIVATES THE PROMOTER ACTIVITY OF THE HUMAN RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							DNA METHYLATION; TRANSCRIPTIONAL ACTIVATION; TUMORIGENIC EXPRESSION; CYTOSINE METHYLATION; HUMAN CHROMOSOME-11; HUMAN NEOPLASIA; FACTOR BINDING; HUMAN CANCERS; SP1; HYPOMETHYLATION	Cytosine methylation of CpG sites in the promoter region of eucaryotic genes is involved in the inactivation of expression of certain genes. Given that methylation can lead to reduced transcription, it is possible that expression of tumor-suppressor genes is also inactivated by hypermethylation, thereby contributing to the etiology of cancer. Recently we found five sporadic retinoblastoma tumors (16% of all unilateral cases) with hypermethylation of the 5' end of the retinoblastoma gene without detecting any structural abnormalities. However, it is unclear whether the promoter of the retinoblastoma gene is actually inactivated by its hypermethylation. Here we show that specific hypermethylation in the promoter region of the retinoblastoma gene reduces its expression to only 8% of the unmethylated control. Furthermore, we have found that two transcription factors important for the promoter activity, an activating transcription factor (ATF)-like factor and the retinoblastoma binding factor 1, do not bind when their recognition sequences are CpG methylated. These results in vitro strongly support the hypothesis that CpG methylation of the human tumor-suppressor gene can result in the inactivation of the gene and thus lead to oncogenesis.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Kyoto Prefectural University of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1986, CANCER RES, V46, P461; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	27	288	298	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1063	1067						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455933				2022-12-25	WOS:A1993KT22000031
J	SELSTED, ME; TANG, YQ; MORRIS, WL; MCGUIRE, PA; NOVOTNY, MJ; SMITH, W; HENSCHEN, AH; CULLOR, JS				SELSTED, ME; TANG, YQ; MORRIS, WL; MCGUIRE, PA; NOVOTNY, MJ; SMITH, W; HENSCHEN, AH; CULLOR, JS			PURIFICATION, PRIMARY STRUCTURES, AND ANTIBACTERIAL ACTIVITIES OF BETA-DEFENSINS, A NEW FAMILY OF ANTIMICROBIAL PEPTIDES FROM BOVINE NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IDENTIFICATION; BACTENECINS; GRANULES	A new family of cysteine-rich antimicrobial peptides from bovine neutrophils was isolated and characterized. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. The complete sequences of the peptides were determined by a combination of enzymatic digestion, Edman degradation, and additional biochemical characterization of the carboxyl termini. The peptides are characterized by a highly cationic 38-42-residue chain which includes 6 invariantly spaced cysteines which form three disulfides. They share a highly conserved consensus sequence which is also found in a recently described epithelial antimicrobial peptide from bovine trachea. The in vitro antibacterial activities of the 13 neutrophil peptides, determined in assays using Staphylococcus aureus and Escherichia coli as test organisms, demonstrated that each peptide possessed antimicrobial activity, and that several were as active as the most potent neutrophil defensin, rabbit NP-1. Though the structural and functional attributes of the bovine neutrophil peptides are similar to those of defensins, the two peptide families are distinguished by their unique consensus sequences and additionally by differing tridisulfide motifs. We therefore propose that this new defensin-like antimicrobial peptide family be named beta-defensins.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV CALIF DAVIS,SCH VET MED,DEPT PATHOL,DAVIS,CA 95616; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Irvine; University of California System; University of California Davis; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SELSTED, ME (corresponding author), UNIV CALIF IRVINE,COLL MED,DEPT PATHOL,IRVINE,CA 92717, USA.				NIAID NIH HHS [UO1-AI31696, AI22931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931, U01AI031696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambler R P, 1972, Methods Enzymol, V25, P143, DOI 10.1016/S0076-6879(72)25012-1; AMREIN PC, 1980, BLOOD, V56, P442; BAGGIOLINI M, 1985, LAB INVEST, V52, P151; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENHAUER P, 1990, INFECT IMMUN, V58, P3899, DOI 10.1128/IAI.58.12.3899-3902.1990; EISENHAUER PB, 1989, INFECT IMMUN, V57, P2021, DOI 10.1128/IAI.57.7.2021-2027.1989; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GENNARO R, 1983, J CELL BIOL, V96, P1651, DOI 10.1083/jcb.96.6.1651; GENNARO R, 1983, INFECT IMMUN, V40, P684, DOI 10.1128/IAI.40.2.684-690.1983; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; GENNARO R, 1991, BLOOD CELL BIOCH, V3, P335; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; Klemm P, 1984, Methods Mol Biol, V1, P243, DOI 10.1385/0-89603-062-8:243; LEHHRER RI, 1991, J IMMUNOL METHODS, V137, P167; LEHRER RI, 1990, BLOOD, V76, P2169; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SPITZNAGEL JK, 1990, J CLIN INVEST, V86, P1381, DOI 10.1172/JCI114851; TANG YQ, 1993, J BIOL CHEM, V268, P6649; YAMASHITA T, 1989, INFECT IMMUN, V57, P2405, DOI 10.1128/IAI.57.8.2405-2409.1989	35	361	419	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6641	6648						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454635				2022-12-25	WOS:A1993KT36800081
J	GHIRARDI, ML; MAHAJAN, S; SOPORY, SK; EDELMAN, M; MATTOO, AK				GHIRARDI, ML; MAHAJAN, S; SOPORY, SK; EDELMAN, M; MATTOO, AK			PHOTOSYSTEM-II REACTION CENTER PARTICLE FROM SPIRODELLA STROMA LAMELLAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REACTION CENTER COMPLEX; PHOTOSYNTHETIC ELECTRON-TRANSPORT; CHLAMYDOMONAS-REINHARDTII; THYLAKOID MEMBRANES; ANTENNA SIZE; PHOTOCHEMICAL APPARATUS; CHLOROPLAST MEMBRANES; SPECTRAL PROPERTIES; PROTEIN-SYNTHESIS; BETA	A Photosystem II (PSII) reaction center particle from the stroma lamellae of Spirodela oligorrhiza has been isolated. The stroma lamellar PSII reaction center contained the same proteins found in granal PSII reaction centers, namely D1, D2, and cytochrome b559; however, the cytochrome b559 content was half of that in the granal centers. The pigment composition, 77 K fluorescence emission, and excitation spectra of the stroma lamellar reaction centers were determined. Our results indicate a fully functional PSII particle in the stromal lamellae.	USDA ARS,BELTSVILLE AGR RES CTR,PLANT MOLEC BIOL LAB,BELTSVILLE AGR RES CTR W,BLDG 106,BELTSVILLE,MD 20705; JAWAHARLAL NEHRU UNIV,SCH LIFE SCI,NEW DELHI 110067,INDIA; WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL	United States Department of Agriculture (USDA); Jawaharlal Nehru University, New Delhi; Weizmann Institute of Science			Mattoo, Autar/G-9863-2011; Mattoo, Autar/U-9751-2019	Mattoo, Autar/0000-0001-9226-7164				ADIR N, 1990, J BIOL CHEM, V265, P12563; ALBERTSSON PA, 1988, BIOCHIM BIOPHYS ACTA, V936, P215, DOI 10.1016/0005-2728(88)90238-1; ANDERSON JM, 1983, P NATL ACAD SCI-BIOL, V80, P745, DOI 10.1073/pnas.80.3.745; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; ANDREASSON E, 1988, BIOCHIM BIOPHYS ACTA, V936, P339, DOI 10.1016/0005-2728(88)90010-2; ARMOND PA, 1977, PLANT PHYSIOL, V59, P398, DOI 10.1104/pp.59.3.398; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BRAUN P, 1990, BIOCHEMISTRY-US, V29, P10376, DOI 10.1021/bi00497a012; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; CHYLLA RA, 1987, BIOCHIM BIOPHYS ACTA, V894, P562, DOI 10.1016/0005-2728(87)90136-8; DENG XW, 1986, PHOTOBIOCH PHOTOBIOP, V13, P41; EAGLESHAM AR, 1974, BIOCHIM BIOPHYS ACTA, V335, P396, DOI 10.1016/0005-2787(74)90162-2; EDELMAN M, 1984, CHLOROPLAST BIOGENES, P282; GHIRARDI ML, 1986, BIOCHIM BIOPHYS ACTA, V851, P331, DOI 10.1016/0005-2728(86)90069-1; GHIRARDI ML, 1988, BIOCHIM BIOPHYS ACTA, V932, P130, DOI 10.1016/0005-2728(88)90147-8; GHIRARDI ML, 1990, CURRENT RES PHOTOSYN, V2, P733; GRAAN T, 1986, BIOCHIM BIOPHYS ACTA, V852, P320, DOI 10.1016/0005-2728(86)90238-0; GREBANIER AE, 1979, PLANT PHYSIOL, V63, P436, DOI 10.1104/pp.63.3.436; GREENE BA, 1988, PLANT PHYSIOL, V87, P365, DOI 10.1104/pp.87.2.365; GUENTHER JE, 1990, PHOTOSYNTH RES, V24, P35, DOI 10.1007/BF00032642; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P195, DOI 10.1007/BF00035010; HAEHNEL W, 1984, ANNU REV PLANT PHYS, V35, P659, DOI 10.1146/annurev.pp.35.060184.003303; HENRYSSON T, 1990, PHOTOSYNTH RES, V25, P107, DOI 10.1007/BF00035459; HOLZWARTH AR, 1985, BIOCHIM BIOPHYS ACTA, V807, P155, DOI 10.1016/0005-2728(85)90119-7; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; KYLE DJ, 1982, BIOCHIM BIOPHYS ACTA, V680, P336, DOI 10.1016/0005-2728(82)90147-5; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P59, DOI 10.1016/0005-2728(87)90212-X; LAVERGNE J, 1982, PHOTOBIOCH PHOTOBIOP, V3, P257; LETO KJ, 1985, EMBO J, V4, P1645, DOI 10.1002/j.1460-2075.1985.tb03832.x; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MARDER JB, 1988, BIOCHIM BIOPHYS ACTA, V932, P363; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MCTAVISH H, 1989, PLANT PHYSIOL, V89, P452, DOI 10.1104/pp.89.2.452; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; MELIS A, 1985, BIOCHIM BIOPHYS ACTA, V808, P334, DOI 10.1016/0005-2728(85)90017-9; MELIS A, 1976, PHOTOCHEM PHOTOBIOL, V23, P343, DOI 10.1111/j.1751-1097.1976.tb07259.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEALE PJ, 1990, PLANT PHYSIOL, V92, P1196, DOI 10.1104/pp.92.4.1196; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; REISFELD A, 1978, CHLOROPLAST DEV, P641; SEIBERT M, 1988, PLANT PHYSIOL, V87, P303, DOI 10.1104/pp.87.2.303; SHUVALOV VA, 1989, FEBS LETT, V258, P27, DOI 10.1016/0014-5793(89)81607-2; SUNDBY C, 1986, BIOCHIM BIOPHYS ACTA, V851, P475, DOI 10.1016/0005-2728(86)90084-8; SVENSSON P, 1991, BIOCHIM BIOPHYS ACTA, V1060, P45, DOI 10.1016/S0005-2728(05)80117-3; TANG XS, 1990, FEBS LETT, V273, P257, DOI 10.1016/0014-5793(90)81098-9; TETENKIN VL, 1989, FEBS LETT, V250, P459, DOI 10.1016/0014-5793(89)80776-8; THIELEN APGM, 1981, BIOCHIM BIOPHYS ACTA, V635, P111, DOI 10.1016/0005-2728(81)90012-8; VALLON O, 1987, CARLSBERG RES COMMUN, V52, P405, DOI 10.1007/BF02907528; VALLON O, 1986, PHOTOBIOCH PHOTOBIOP, V12, P203; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8	52	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5357	5360						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449899				2022-12-25	WOS:A1993KR82200005
J	JOHNSON, JL; RAJAGOPALAN, KV; MUKUND, S; ADAMS, MWW				JOHNSON, JL; RAJAGOPALAN, KV; MUKUND, S; ADAMS, MWW			IDENTIFICATION OF MOLYBDOPTERIN AS THE ORGANIC-COMPONENT OF THE TUNGSTEN COFACTOR IN 4 ENZYMES FROM HYPERTHERMOPHILIC ARCHAEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLIC-ACID REDUCTASE; IRON-SULFUR PROTEIN; MOLYBDENUM COFACTOR; PYROCOCCUS-FURIOSUS; XANTHINE-OXIDASE; SULFITE OXIDASE; GUANINE DINUCLEOTIDE; FORMYLMETHANOFURAN DEHYDROGENASE; FORMATE DEHYDROGENASE; BIOLOGICAL FUNCTION	The hyperthermophilic Archaea represent some of the most ancient organisms on earth. A study of enzymatic cofactors in these organisms could provide basic information on the origins of related cofactors in man and other more recently evolved organisms. To this end, the nature of the tungsten cofactor in aldehyde ferredoxin oxidoreductases from Pyrococcus furiosus and ES-4 and in formaldehyde ferredoxin oxidoreductases from P. furiosus and Thermococcus litoralis has been investigated. All four proteins contain molybdopterin, previously characterized as the organic component of the molybdenum cofactor in a large number of molybdoenzymes. Molybdopterin was identified by conversion to the dicarboxamidomethyl derivative by alkylation of the vicinal sulfhydryl groups on the pterin side chain and by conversion to the oxidized fluorescent derivative, Form A. The pterin of the tungsten cofactor in the four enzymes was examined for the presence of appended GMP, CMP, AMP, or IMP previously observed in molybdenum cofactors of some molybdoenzymes. No evidence for the presence of a molybdopterin dinucleotide or other modified form of molybdopterin was obtained. These results further document the essential nature of molybdopterin for the function of molybdenum and tungsten enzymes in diverse life forms.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR MET ENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	JOHNSON, JL (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.			Adams, Michael/0000-0002-9796-5014	NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; ADAMS MWW, 1992, BIOCATALYSIS EXTREME; BLAKE PR, 1992, IN PRESS PROTEIN SCI; BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; DAY MW, 1992, IN PRESS PROTEIN SCI; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; GEORGE GN, 1992, J AM CHEM SOC, V114, P3521, DOI 10.1021/ja00035a055; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; JOHNSON JL, 1974, J BIOL CHEM, V249, P859; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1974, J BIOL CHEM, V249, P5056; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1991, BIOFACTORS, V3, P103; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1976, J BIOL CHEM, V251, P5505; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KELLY RM, 1988, BIOTECHNOL PROGR, V4, P47, DOI 10.1002/btpr.5420040202; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; NEUNER A, 1990, ARCH MICROBIOL, V153, P205, DOI 10.1007/BF00247822; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; PLEDGER RJ, 1991, J GEN MICROBIOL, V137, P203, DOI 10.1099/00221287-137-1-203; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STROBL G, 1992, BIOL CHEM H-S, V373, P123, DOI 10.1515/bchm3.1992.373.1.123; TAYLOR EC, 1989, J AM CHEM SOC, V111, P7664, DOI 10.1021/ja00201a084; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; WHITE H, 1991, BIOL CHEM H-S, V372, P999, DOI 10.1515/bchm3.1991.372.2.999; WHITE RH, 1991, J BACTERIOL, V173, P1987, DOI 10.1128/jb.173.6.1987-1991.1991; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826	36	65	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4848	4852						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444863				2022-12-25	WOS:A1993KP88400046
J	ZVYAGA, TA; MIN, KC; BECK, M; SAKMAR, TP				ZVYAGA, TA; MIN, KC; BECK, M; SAKMAR, TP			MOVEMENT OF THE RETINYLIDENE SCHIFF-BASE COUNTERION IN RHODOPSIN BY ONE HELIX TURN REVERSES THE PH-DEPENDENCE OF THE METARHODOPSIN-I TO METARHODOPSIN-II TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; CYSTEINE RESIDUE-110; DISK MEMBRANE; BACTERIORHODOPSIN; ACTIVATION; TRANSDUCIN; MUTANTS; GENE; SUBSTITUTION; ABSORBENCY	The environment of the retinylidene Schiff base in bovine rhodopsin has been studied by movement of its carboxylic acid counterion from position 113 to position 117 by site-specific mutagenesis. Replacement of the counterion at position 113 by a neutral amino acid residue has been shown to produce a lowering of the Schiff base acidity constant (pK(a) from > 8.5 to about 6. The aim of the present work was to change the position of the counterion without causing a significant effect on the Schiff base pK(a). A triple replacement mutant (Glu113 --> Ala/Ala117 --> Glu/Glu122 --> Gln) was designed to move the position of the counterion by one helix turn in the third putative transmembrane helix (helix C). The mutant bound 11-cis-retinal to form a chromophore with a visible absorbance maximum (lambda(max)) of 490 nm which was independent of pH in the range of about 5-8.5. Upon illumination under conditions in which rhodopsin was converted to the active metarhodopsin II (MII) photoproduct, the mutant was converted to a metarhodopsin I (MI)-like species (lambda(max) = 475 nm). Furthermore, the effect of pH on the photobleaching behavior of the mutant was the reverse of that reported for rhodopsin. In the mutant, acidic pH favored the formation of the MI-like photoproduct, and basic pH favored the formation of an MII-like photo-product (lambda(max) = 380 nm). The MII-like photoproduct of the mutant pigment was able to activate the guanine nucleotide-binding protein, transducin. We conclude that the Schiff base counterion in rhodopsin can be repositioned to form a pigment with an apparently unperturbed Schiff base pK(a). Furthermore, a specific amino acid residue that acts as a Schiff base proton acceptor is not strictly required for photoconversion of rhodopsin to its active MII form.	ROCKEFELLER UNIV,BOX 284,1230 YORK AVE,NEW YORK,NY 10021; HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007739, 5-T32-GM-O7739] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; CHAN T, 1992, J BIOL CHEM, V267, P9478; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; EMELS D, 1982, FEBS LETT, V143, P29; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LIN SW, 1992, BIOCHEMISTRY-US, V31, P5105, DOI 10.1021/bi00137a003; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P2583, DOI 10.1073/pnas.88.6.2583; WALD G, 1955, J GEN PHYSIOL, V38, P623, DOI 10.1085/jgp.38.5.623; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1982, FEBS LETT, V31, P10400	36	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4661	4667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444840				2022-12-25	WOS:A1993KP88400019
J	MANAK, JR; PRYWES, R				MANAK, JR; PRYWES, R			PHOSPHORYLATION OF SERUM RESPONSE FACTOR BY CASEIN KINASE .2. EVIDENCE AGAINST A ROLE IN GROWTH-FACTOR REGULATION OF FOS-EXPRESSION	ONCOGENE			English	Article							TERNARY COMPLEX-FORMATION; DNA-BINDING ACTIVITY; C-FOS; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; ELEMENT; PROTEIN; SEQUENCES; P67SRF; CELLS	Serum response factor (SRF) is a transcription factor involved in the serum and growth factor regulation of the c-fos gene. SRF is phosphorylated by casein kinase II (CKII), which causes a large increase in its DNA-binding activity. CKII activity has been shown to be stimulated by growth factors and serum. Since c-fos transcription is induced by a number of the same agents that stimulate CKII activity, and sincefos activation and CKII stimulation demonstrate similar rapid kinetics, a role was proposed for CKII in regulating fos expression via its phosphorylation of SRF. In this report, we provide evidence against this hypothesis by using several different strategies. First, by immunoprecipitation of SRF from cells, we show that the phosphorylation state of SRF does not change upon growth factor treatment. Second, by two-dimensional electrophoresis of lysates from a cell line that overexpresses SRF, we show that, although SRF exists in the cell in several different isoforms, there is no change in their relative amounts upon serum stimulation. Third, we tested the activity of an SRF mutant that binds DNA at constitutively high levels irrespective of CKII phosphorylation. If phosphorylation is regulatory, this mutant would be expected to consitutitively activate (or repress) fos expression. However, when overexpressed stably in cetls this mutant had no effect on endogenous c-fos expression, suggesting that CKII phosphorylation of SRF is not the limiting event for fos activation.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Manak, John/0000-0002-6562-7694	NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50329-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15873; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LUO K, 1990, ONCOGENE, V5, P921; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	54	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					703	711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437853				2022-12-25	WOS:A1993KN00800022
J	NOMURA, N; ZU, YL; MAEKAWA, T; TABATA, S; AKIYAMA, T; ISHII, S				NOMURA, N; ZU, YL; MAEKAWA, T; TABATA, S; AKIYAMA, T; ISHII, S			ISOLATION AND CHARACTERIZATION OF A NOVEL MEMBER OF THE GENE FAMILY ENCODING THE CAMP RESPONSE ELEMENT-BINDING PROTEIN CRE-BP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN CLEAVAGE ENZYME; POL II PROMOTERS; ATF CDNA CLONES; CYCLIC-AMP; TRANSCRIPTION FACTOR; ADENOVIRUS-E1A PROTEIN; SOMATOSTATIN GENE; DNA; EXPRESSION; ACTIVATION	Among multiple CRE (cyclic AMP response element)-binding proteins, CRE-BP1 (also designated ATF-2) has two unique characteristics: it mediates the adenovirus E1A-induced trans-activation and forms a heterodimer with c-Jun. Two structures, a putative metal finger and a leucine zipper, in CRE-BP1 are responsible for these capacities. As a new member of a CRE-BP1 family that has similar metal finger and leucine zipper structures, we have isolated cDNA clones of CRE-BPa by cross-hybridization with CRE-BP1 cDNA. CRE-BPa protein consists of 508 amino acids and has a molecular weight of 56,840. CRE-BPa protein is highly homologous with CRE-BP1 in four regions: two of them are the regions containing the putative metal finger or the DNA-binding domain consisting of the basic amino acid cluster and the leucine zipper. Like CRE-BP1, CRE-BPa binds to CRE with higher affinity than to the 12-O-tetradecanoylphorbol-13-acetate response element as a homodimer or a CRE-BPa/c-Jun or CRE-BPa/CRE-BP1 heterodimer. However, using the c-Myb-CRE-BPa fusion protein, it was show that CRE-BPa could not mediate the E1A-induced transactivation. Expression of CRE-BPa mRNA was found in a limited number of cell lines, and multiple sizes of CRE-BPa mRNA species were detected in some cell lines and tissues. CRE-BPa will be useful to clarify the mechanism of CRE-mediated transcriptional activation by E1A or c-Jun.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KANAGAWA 211,JAPAN; FAC SCI NAGOYA,DEPT BIOL,NAGOYA,AICHI 464,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN	RIKEN; Nippon Medical School; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GILARDI P, 1986, NUCLEIC ACIDS RES, V14, P9035, DOI 10.1093/nar/14.22.9035; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4143; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAGREGOR PF, 1990, ONCOGENE, V5, P451; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKEDA J, 1991, ONCOGENE, V6, P1009; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; YOSHIMURA T, 1990, EMBO J, V9, P2535; ZU YL, 1991, J BIOL CHEM, V266, P24134	42	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4259	4266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440710				2022-12-25	WOS:A1993KN53300066
J	ARAI, H; NAKAO, K; TAKAYA, K; HOSODA, K; OGAWA, Y; NAKANISHI, S; IMURA, H				ARAI, H; NAKAO, K; TAKAYA, K; HOSODA, K; OGAWA, Y; NAKANISHI, S; IMURA, H			THE HUMAN ENDOTHELIN-B-RECEPTOR GENE - STRUCTURAL ORGANIZATION AND CHROMOSOMAL ASSIGNMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MESSENGER-RNA; CDNA; EXPRESSION; SEQUENCE; PROMOTER; PROTEINS; DNA; TRANSCRIPTION; POLYMERASE	The gene encoding the human endothelin-B receptor (hET-BR) has been isolated, and its structural organization and chromosomal assignment have been determined. Southern blot analysis demonstrated a single copy of the hET-BR gene in the human genome. The hET-BR gene spans 24 kilobases and consists of seven exons and six introns. The size range for exons is 109-2855 base pairs, although that for introns is 0.2-14.5 kilobases. Every intron occurs near the border of the putative transmembrane domain in the coding region. The major transcription initiation sites were mapped to the positions 258 and 229 base pairs upstream of the ATG initiation codon by primer extension and nuclease S1 protection experiments. The 5'-flanking region of the hET-BR gene lacks conventional TATA and CCAAT boxes but contains a sequence of potential Sp1 binding sites upstream of the transcription initiation sites. There are some canonical consensus sequences of cis-elements including GATA motif, acute phase reactant regulatory element, and E box. Using human-rodent somatic hybrid cell lines, the hET-BR gene was assigned to human chromosome 13. The present study will lead to a better understanding of the mechanism for the transcriptional regulation of the hET-BR gene and will give a clue as to how to search for possible genetic disorders of hET-BR.	KYOTO UNIV,SCH MED,DEPT MED,DIV 2,54 SHOGOIN KAWAHARA CHO,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LEE ME, 1990, J BIOL CHEM, V265, P10446; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKAMUTA M, 1991, BIOCHEM BIOPH RES CO, V177, P34, DOI 10.1016/0006-291X(91)91944-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; OGAWA Y, 1992, HYPERTENSION, V19, P809, DOI 10.1161/01.HYP.19.6.809; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; REPASKE R, 1985, J VIROL, V54, P764, DOI 10.1128/JVI.54.3.764-772.1985; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	37	148	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3463	3470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429023				2022-12-25	WOS:A1993KM16100069
J	ARORA, N; LEPPLA, SH				ARORA, N; LEPPLA, SH			RESIDUES-1-254 OF ANTHRAX TOXIN LETHAL FACTOR ARE SUFFICIENT TO CAUSE CELLULAR UPTAKE OF FUSED POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; PSEUDOMONAS EXOTOXIN; LIVING CELLS; TERMINAL END; EXPRESSION; PROTEINS; PURIFICATION	Anthrax lethal toxin is a complex of protective antigen (PA, 735 amino acids) and lethal factor (LF, 776 amino acids) that lyses certain eukaryotic cells. LF interacts with PA to gain access to the cytosol to assert its toxicity. The internalization of LF requires that PA bind to a specific membrane receptor and be cleaved by a cell-surface protease (probably furin), so as to expose a site on PA to which LF binds with high affinity. To localize LF functional domains, amino, carboxyl, and internal deletions of LF were made. Toxicity was eliminated by deletion of 40 and 47 residues from the amino and carboxyl termini, respectively. Similarly, deleting the first of the four imperfect repeats of 19 amino acids located at residues 308-383 made LF non-toxic, showing that this region is also essential for activity. To identify the minimum region of LF which is required for binding to PA, varying amino-terminal portions of LF were fused to the ADP-ribosylation domain of Pseudomonas exotoxin A. Fusion proteins containing residues 1-254 of LF were toxic when administered with PA, while those having only residues 1-198 of LF were inactive, showing that the PA-binding domain of LF lies within residues 1-254.	NIDR, MICROBIAL ECOL LAB, BLDG 30, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ARORA N, 1992, J BIOL CHEM, V267, P15542; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1989, J BIOL CHEM, V264, P14792; GRAZIADEI L, 1991, ANAL BIOCHEM, V194, P198, DOI 10.1016/0003-2697(91)90168-S; GUIDIRONTANI C, 1992, MOL MICROBIOL, V6, P1281, DOI 10.1111/j.1365-2958.1992.tb00849.x; HAMBLETON P, 1984, Vaccine, V2, P125, DOI 10.1016/0264-410X(84)90003-3; HARRISSMITH PW, 1958, J GEN MICROBIOL, V19, P91, DOI 10.1099/00221287-19-1-91; IVINS BE, 1988, EUR J EPIDEMIOL, V4, P12, DOI 10.1007/BF00152686; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; LEPPLA SH, 1991, METHOD ENZYMOL, V195, P153; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1986, BACTERIAL PROTEIN TO, P275; LEPPLA SH, 1990, SALISBURY MED B S, V68, P41; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LITTLE SF, 1990, INFECT IMMUN, V58, P1606, DOI 10.1128/IAI.58.6.1606-1613.1990; MADSHUS IH, 1992, INFECT IMMUN, V60, P3296, DOI 10.1128/IAI.60.8.3296-3302.1992; MCNEIL PL, 1989, METHOD CELL BIOL, V29, P153; MILNE JC, 1991, J CELL BIOL, V115; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; QUINN CP, 1991, J BIOL CHEM, V266, P20124; RECHSTEINER M, 1987, METHOD ENZYMOL, V149, P42; ROBERTSON DL, 1986, GENE, V44, P71, DOI 10.1016/0378-1119(86)90044-2; Schlegel R A, 1978, Methods Cell Biol, V20, P341, DOI 10.1016/S0091-679X(08)62026-9; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1991, J BIOL CHEM, V266, P15493; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Singh Y, 1990, SALISBURY MED B, V68, P46; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; Stephen J., 1986, Pharmacology of bacterial toxins, P381; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TURNBULL PCB, 1991, VACCINE, V9, P533, DOI 10.1016/0264-410X(91)90237-Z	50	145	184	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3334	3341						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429009				2022-12-25	WOS:A1993KM16100050
J	ROHER, AE; LOWENSON, JD; CLARKE, S; WOLKOW, C; WANG, R; COTTER, RJ; REARDON, IM; ZURCHERNEELY, HA; HEINRIKSON, RL; BALL, MJ; GREENBERG, BD				ROHER, AE; LOWENSON, JD; CLARKE, S; WOLKOW, C; WANG, R; COTTER, RJ; REARDON, IM; ZURCHERNEELY, HA; HEINRIKSON, RL; BALL, MJ; GREENBERG, BD			STRUCTURAL ALTERATIONS IN THE PEPTIDE BACKBONE OF BETA-AMYLOID CORE PROTEIN MAY ACCOUNT FOR ITS DEPOSITION AND STABILITY IN ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ISOASPARTYL METHYLTRANSFERASE; PRECURSOR PROTEIN; SENILE PLAQUES; ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASES; NEUROFIBRILLARY TANGLES; HUMAN-ERYTHROCYTES; NEURONAL ORIGIN; CLEAVAGE SITE; ACID	The structure of beta-amyloid (betaA) from Alzheimer disease brains was examined to determine if post-translational modifications might be linked to the abnormal deposition of this peptide in the diseased tissue. The betaA peptides were isolated from the compact amyloid cores of neuritic plaques and separated from minor glycoprotein components by size-exclusion high-pressure liquid chromatography (HPLC). This parenchymal betaA has a maximal length of 42 residues, but shorter forms with ''ragged'' NH2 termini are also present. Tryptic peptide analysis revealed heterogeneity in the betaA1-5 and betaA6-16 peptides, each of which eluted as four peaks on reverse phase HPLC. Amino acid composition and sequence analyses, mass spectrometry, enzymatic methylation, and stereoisomer determinations revealed that these multiple peptide forms resulted from structural rearrangements of the aspartyl residues at betaA positions 1 and 7. The L-isoaspartyl form predominates at each of these positions, whereas the D-isoaspartyl, L-aspartyl, and D-aspartyl forms are present in lesser amounts. BetaA purified from the leptomeningeal microvasculature contains the same structural alterations as parenchymal, betaA, but is 2 residues shorter at its COOH terminus. Using two different purification protocols, and using a synthetic betaA1-42 peptide as a control, we show that these modifications arose endogenously and were not caused by the experimental manipulations. The abundance of structurally altered aspartyl residues may profoundly affect the conformation of the betaA protein within plaque cores and thus significantly impact normal catabolic processes designed to limit its deposition. These alterations may therefore contribute to the production and stability of beta-amyloid deposits in Alzheimer brain tissue.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, MIDDLE ATLANTIC MASS SPECTROMETRY LAB, BALTIMORE, MD 21205 USA; UPJOHN CO, LABS, CNS RES, KALAMAZOO, MI 49001 USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Johns Hopkins University; Pfizer; Oregon Health & Science University; Oregon Health & Science University	ROHER, AE (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, 540 E CANFIELD AVE, DETROIT, MI 48201 USA.		Lowenson, Jonathan/AAN-6768-2020; Wang, Rong/A-8721-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER; NIA NIH HHS [P30-AG08017] Funding Source: Medline; NIGMS NIH HHS [GM-26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; Ball M J, 1988, Alzheimer Dis Assoc Disord, V2, P29, DOI 10.1097/00002093-198802010-00004; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COTTER RJ, 1988, ANAL CHEM, V60, pA781, DOI 10.1021/ac00164a002; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; CRAS P, 1990, AM J PATHOL, V137, P241; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; DEWJI NN, 1990, J MOL NEUROSCI, V2, P19, DOI 10.1007/BF02896922; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EIKELENBOOM P, 1989, VIRCHOWS ARCH B, V56, P259; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FISHER GH, 1992, BRAIN RES BULL, V28, P127, DOI 10.1016/0361-9230(92)90239-T; GALLETTI P, 1989, INT J PEPT PROT RES, V33, P397; GEIGER T, 1987, J BIOL CHEM, V262, P785; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG BD, 1991, ANNU REP MED CHEM, V26, P229; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; JOACHIM C, 1991, AM J PATHOL, V138, P373; JOHNSON BA, 1991, NEUROBIOL AGING, V12, P19, DOI 10.1016/0197-4580(91)90034-H; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1990, BIOCHEMISTRY-US, V29, P4373, DOI 10.1021/bi00470a017; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KAWAI M, 1992, AM J PATHOL, V140, P947; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KLUNK WE, 1990, J NEUROCHEM, V54, P2050, DOI 10.1111/j.1471-4159.1990.tb04910.x; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MACLAREN DC, 1992, IN PRESS GENOMICS; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1991, BRAIN RES, V544, P315, DOI 10.1016/0006-8993(91)90071-3; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MORI H, 1992, J BIOL CHEM, V267, P17082; MURPHY GM, 1991, NEUROSCI LETT, V131, P100, DOI 10.1016/0304-3940(91)90346-U; MURRAY ED, 1984, J BIOL CHEM, V259, P722; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ORLANDO R, 1992, BIOCHEM BIOPH RES CO, V184, P686, DOI 10.1016/0006-291X(92)90644-Z; OTA IM, 1988, BIOCHEM BIOPH RES CO, V151, P1136, DOI 10.1016/S0006-291X(88)80484-4; PARDRIDGE WM, 1987, J NEUROCHEM, V49, P1394, DOI 10.1111/j.1471-4159.1987.tb01005.x; PAYAN IL, 1992, NEUROCHEM RES, V17, P187, DOI 10.1007/BF00966798; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PETSKO GA, 1992, SCIENCE, V256, P1403, DOI 10.1126/science.1604313; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRELLI F, 1988, BIOCHEM BIOPH RES CO, V151, P1150, DOI 10.1016/S0006-291X(88)80486-8; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SEKOE DJ, 1988, J NEUROCHEM, V46, P1820; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMYTH DG, 1962, J BIOL CHEM, V237, P1845; SNOW AD, 1988, AM J PATHOL, V133, P456; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TORGERSON DF, 1974, BIOCHEM BIOPH RES CO, V60, P616, DOI 10.1016/0006-291X(74)90285-X; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; WANG R, 1991, J BIOL CHEM, V266, P16960; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210	81	713	732	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3072	3083						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428986				2022-12-25	WOS:A1993KM16100013
J	YANG, LJ; CAMORATTO, AM; BAFFY, G; RAJ, S; MANNING, DR; WILLIAMSON, JR				YANG, LJ; CAMORATTO, AM; BAFFY, G; RAJ, S; MANNING, DR; WILLIAMSON, JR			EPIDERMAL GROWTH FACTOR-MEDIATED SIGNALING OF GI-PROTEIN TO ACTIVATION OF PHOSPHOLIPASES IN RAT-CULTURED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PERTUSSIS TOXIN; FACTOR RECEPTOR; C-GAMMA; TYROSINE PHOSPHORYLATION; DNA-SYNTHESIS; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHOINOSITIDE HYDROLYSIS; INOSITOL PHOSPHATES; PHORBOL ESTERS	Hepatocytes were established in tissue culture in order to study the effects of pertussis toxin (PT) on epidermal growth factor (EGF)-mediated cellular responses under in vitro conditions. EGF caused a 3-fold increase of myo-inositol 1,4,5-trisphosphate (Ins-1,4,5-P3) mass and a 50% increase of diacylglycerol mass within the first minute, with the change of diacylglycerol content being 100-fold greater than that of Ins-1,4,5-P3. Diacylglycerol, but not Ins-1,4,5-P3, continued to accumulate over several hours, indicating that EGF increased the hydrolysis of lipids other than phosphatidylinositol 4,5-bisphosphate (PIP2). EGF increased phosphoinositide-specific phospholipase C-gamma (PLC-gamma) tyrosine phosphorylation within 1 min, but no effect was observed with vasopressin, insulin, or glucagon after 5 min. EGF also caused a rapid, tyrosine kinase-dependent association of G(i)alpha with PLC-gamma, which was maximal within 10 min. In contrast to our previous data on fresh hepatocytes, PT had no effect on the EGF-induced tyrosine phosphorylation of PLC-gamma, although Ins-1,4,5-P3 and diacylglycerol production were inhibited. The role of G-proteins in EGF signaling was investigated further by microinjection of Galpha antibodies into single fura-2-loaded hepatocytes. Anti-G(i)alpha (common) antibodies prevented EGF-induced but not vasopressin-induced Ca2+ transients. These results strengthen previous observations that a PT-sensitive G-protein is involved in EGF-mediated phospholipid metabolism in hepatocytes and show that tyrosine phosphorylation of PLC-gamma is an insufficient signal for activation of PIP2 hydrolysis.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,601 GODDARD LAB,37TH & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Baffy, Gyorgy/P-7986-2018	Baffy, Gyorgy/0000-0002-8334-0400	NCI NIH HHS [CA-39712] Funding Source: Medline; NIDDK NIH HHS [DK-19525, DK-15120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK015120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CATTANEO MG, 1989, BIOCHEM J, V262, P665, DOI 10.1042/bj2620665; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUJINAGA Y, 1989, FEBS LETT, V245, P117, DOI 10.1016/0014-5793(89)80203-0; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HEPLER JR, 1990, BIOCHEM J, V270, P337, DOI 10.1042/bj2700337; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; LIANG M, 1991, J BIOL CHEM, V266, P13342; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MEIJER AJ, 1975, J BIOL CHEM, V250, P7728; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MONCK JR, 1988, J BIOL CHEM, V263, P4569; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHI YE, 1989, CANCER RES, V49, P3574; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR CW, 1988, BIOCHEM J, V249, P917, DOI 10.1042/bj2490917; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TEITELBAUM I, 1990, J CLIN INVEST, V85, P1044, DOI 10.1172/JCI114534; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VERHEIJDEN GF, 1991, CELL REGUL, V1, P615; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WU DQ, 1992, J BIOL CHEM, V267, P1811; YANG LJ, 1991, J BIOL CHEM, V266, P22451; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZHANG Y, 1991, CELL CALCIUM, V12, P559, DOI 10.1016/0143-4160(91)90075-P	64	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3739	3746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429049				2022-12-25	WOS:A1993KM16100108
J	LORENZ, P; PEPPERKOK, R; ANSORGE, W; PYERIN, W				LORENZ, P; PEPPERKOK, R; ANSORGE, W; PYERIN, W			CELL BIOLOGICAL STUDIES WITH MONOCLONAL AND POLYCLONAL ANTIBODIES AGAINST HUMAN CASEIN KINASE-II SUBUNIT-BETA DEMONSTRATE PARTICIPATION OF THE KINASE IN MITOGENIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; ALPHA; MICROINJECTION; TRANSCRIPTION	Casein kinase II (CKII) is a highly conserved ubiquitous serine/threonine kinase composed of two catalytically active (alpha and/or alpha') and two regulatory (beta) subunits. It has been suspected that, among numerous other cellular functions, CKII might play a role in the control of mitogenic signaling. To test for such a role and its mechanism in intact cells, monoclonal antibodies (mAbs) were generated against CKIIbeta using a recombinant protein containing amino acids 20-200 of human CKIIbeta. The CKIIbeta-specific mAb with the highest reactivity, mAb IVG6 (classified as IgG1 with kappa light chains), was purified to homogeneity. It recognized a CKIIbeta epitope comprising the amino acids 140-156, a basic and highly conserved region. In addition, polyclonal antibodies (pAbs) were raised and made monospecific by affinity purification. pAbs-mediated quantitative immunofluorescence microscopy of human IMR-90 fibroblasts and/or Western blots of cell fractions revealed (i) CKIIbeta was present in exponentially growing cells at a 2-3-fold higher level than in quiescent cells, (ii) CKIIbeta was localized predominantly in the nucleus of cells (3-15-fold cytoplasmic level depending on cellular state and assay used), and (iii) the nuclear/cytoplasmic ratio of CKIIbeta was higher by a factor of 2 in exponentially growing cells. Consequently, mitogenic stimulation of quiescent cells by fetal calf serum doubled the nuclear/cytoplasmic ratio of CKIIbeta. The increase occurred within the 1st h of stimulation. The translocation of CKIIbeta into the nucleus was inhibited when mAb IVG6 was injected into the cytoplasm at the time of mitogenic stimulation. This microinjection also significantly inhibited the cell proliferation. The data imply that cytoplasmic CKII participates in the transmission of mitogenic signals by translocation into the nucleus.	GERMAN CANC RES CTR, W-6900 HEIDELBERG, GERMANY; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020	Lorenz, Peter A./0000-0001-7925-1002				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, J BIOL CHEM, V258, P1403; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P5367; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KATNIK I, 1987, J IMMUNOL METHODS, V102, P279, DOI 10.1016/0022-1759(87)90087-1; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefkovits I, 1979, IMMUNOLOGICAL METHOD, V1, P355; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; Maniatis T., 1982, MOL CLONING; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MOLINA E, 1991, BIOCHEM J, V277, P811, DOI 10.1042/bj2770811; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYERIN W, 1988, BIOL CHEM H-S, V369, P896; PYERIN W, 1992, RECENT ADV CELL MOL, V4, P86; PYERIN W, 1992, IN PRESS ANN NY ACAD; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SCHNEPPENHEIM R, 1987, EUR J CLIN MICROBIOL, V6, P49, DOI 10.1007/BF02097190; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SONDERGARDANDERSEN J, 1990, J IMMUNOL METHODS, V131, P99, DOI 10.1016/0022-1759(90)90238-Q; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; WESTERWOUDT RJ, 1986, METHOD ENZYMOL, V121, P3; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	56	132	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2733	2739						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428947				2022-12-25	WOS:A1993KK81500071
J	STROUS, GJ; VAN KERKHOF, P; VAN MEER, G; RIJNBOUTT, S; STOORVOGEL, W				STROUS, GJ; VAN KERKHOF, P; VAN MEER, G; RIJNBOUTT, S; STOORVOGEL, W			DIFFERENTIAL-EFFECTS OF BREFELDIN-A ON TRANSPORT OF SECRETORY AND LYSOSOMAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; CELL-SURFACE; NETWORK; OLIGOMERIZATION; SPHINGOMYELIN; ACCUMULATION; CISTERNAE; APPARATUS; ENDOSOMES	Brefeldin A (BFA) rapidly blocks anterograde exocytotic transport through the Golgi complex. Sustained retrograde traffic induced by brefeldin A causes redistribution of constituents of the Golgi, but not the trans-Golgi network (TGN), to the endoplasmic reticulum (ER). In the present study on HepG2 cells, we have observed a differential effect of BFA on transport from the TGN of two soluble proteins: alpha1-antitrypsin as a representative of secretory proteins and cathepsin D as a prototype of lysosomal enzymes. The Golgi complex of HepG2 cells is sensitive to BFA, as within minutes after its addition nearly all activity of three resident Golgi enzymes was recovered in the ER as monitored by cell fractionation on sucrose density gradients. In accordance with this, ''high mannose''-glycosylated alpha1-antitrypsin was retained in or transported back to the ER. ''Complex''-glycosylated al-antitrypsin was neither secreted into the medium nor transported back to the ER. Most of it was retained in vesicles with the buoyant density of Golgi. These vesicles contained the fluid phase endocytotic marker horseradish peroxidase when this was added to the culture medium prior to the BFA, suggesting that the vesicles derived from the TGN. After BFA addition, the compartment became inaccessible to endocytosed horseradish peroxidase. In contrast to blocking transport of complex alpha1-antitrypsin, BFA did not affect processing of newly synthesized complex-glycosylated procathepsin D (53 kDa) to the mature 31-kDa form. Neither did it interfere with processing of endocytosed procathepsin D. That the mature cathepsin D had indeed reached the lysosomes was verified by Percoll density gradient fractionation. In conclusion, in HepG2 cells, BFA induces two blocks in the secretory pathway: one at the level of the ER-Golgi juncture and the other in the TGN. In contrast, transport from the Golgi complex to the lysosomes and from the plasma membrane to the lysosomes continued.			STROUS, GJ (corresponding author), UNIV UTRECHT, AZU,DEPT CELL BIOL,CELL BIOL LAB, HEIDELBERGLAAN 100, ROOM H02314, 3584 CX UTRECHT, NETHERLANDS.		van Meer, Gerrit/AAH-1560-2021	van Kerkhof, Peter/0000-0002-8954-2230; van Meer, Gerrit/0000-0002-5976-6436				BRAULKE T, 1988, BIOL CHEM H-S, V369, P441, DOI 10.1515/bchm3.1988.369.1.441; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DEMKE H, 1991, J BIOL CHEM, V266, P24829; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; NILSSON B, 1979, J BIOL CHEM, V254, P4545; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	35	73	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2341	2347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428908				2022-12-25	WOS:A1993KK81500017
J	FILMUS, J; SHI, W; SPENCER, T				FILMUS, J; SHI, W; SPENCER, T			ROLE OF TRANSFORMING GROWTH FACTOR-ALPHA (TGF-ALPHA) IN THE TRANSFORMATION OF RAS-TRANSFECTED RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON; FACTOR-RECEPTOR; AUTOCRINE GROWTH; HA-RAS; CARCINOMA-CELLS; TRANSGENIC MICE; EXPRESSION; CANCER; GENE; INDUCTION	Most intestinal tumors express transforming growth factor alpha (TGF-alpha) while normal immature crypt cells, the targets for tumor initiation, do not. We have used a rat intestinal cell line derived from immature epithelial crypt cells (IEC-18) to investigate the role of this growth factor in intestinal tumorigenesis. ras transformation of IEC-18 cells induces expression and secretion of TGF-alpha. By studying several independently derived IEC-ras clones, we have established that the amount of TGF-alpha secreted is proportional to the level of activated ras expressed by each clone. The growth of all ras-transformed IEC clones is significantly inhibited by neutralizing antibodies against TGF-alpha and by an antisense TGF-alpha expression vector, indicating a mitogenic role for this growth factor through an autocrine loop. To determine whether TGF-alpha itself can transform intestinal cells, IEC-18 clones transfected with TGF-alpha expression vectors were isolated and characterized. None of the TGF-alpha-expressing clones show any signs of tumorigenic transformation even when they secrete as much TGF-alpha as the IEC-ras clones. It seems, therefore, that TGF-alpha per se does not have the capacity to transform rat epithelial intestinal cells and that its role is mostly related to autocrine growth stimulation.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR,DIV CANC RES,REICHMANN RES BLDG,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.							ANZANO MA, 1989, CANCER RES, V49, P2898; BARNARD JA, 1991, AM J PHYSIOL, V261, pC994, DOI 10.1152/ajpcell.1991.261.6.C994; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1989, FEBS LETT, V250, P474, DOI 10.1016/0014-5793(89)80779-3; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COLLETTA G, 1991, ONCOGENE, V6, P583; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DERNYCK R, 1992, ADV CANCER RES, V58, P27; DIMARCO E, 1989, ONCOGENE, V4, P831; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HOFER DR, 1991, CANCER RES, V51, P2780; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MORISHIGE K, 1991, CANCER RES, V51, P5951; MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120; QUARONI A, 1981, J NATL CANCER I, V67, P1353; REISS M, 1991, CANCER RES, V51, P6254; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA S, 1991, AM J PATHOL, V139, P123; THOMAS DM, 1992, GUT, V33, P628, DOI 10.1136/gut.33.5.628; TRICOLI JV, 1986, CANCER RES, V46, P6169; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; YASUI W, 1988, CANCER RES, V48, P137; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	48	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1017	1022						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455929				2022-12-25	WOS:A1993KT22000025
J	DEVOS, R; GUISEZ, Y; CORNELIS, S; VERHEE, A; VANDERHEYDEN, J; MANNEBERG, M; LAHM, HW; FIERS, W; TAVERNIER, J; PLAETINCK, G				DEVOS, R; GUISEZ, Y; CORNELIS, S; VERHEE, A; VANDERHEYDEN, J; MANNEBERG, M; LAHM, HW; FIERS, W; TAVERNIER, J; PLAETINCK, G			RECOMBINANT SOLUBLE HUMAN INTERLEUKIN-5 (HIL-5) RECEPTOR MOLECULES - CROSS-LINKING AND STOICHIOMETRY OF BINDING TO IL-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; GM-CSF; EOSINOPHILIA; PROTEIN; MICE; BETA; EXPRESSION; SYSTEMS; CELLS; BLOOD	Recombinant soluble human interleukin-5 receptor alpha (shIL-5Ralpha) has been expressed in COS-1 cells and in baculovirus-infected cells. The protein was purified from the supernatant by chromatography on concanavalin A-Sepharose, MonoQ, and a final gel filtration step. A chimeric fusion receptor protein (hIL-5Ralpha-hgamma3) was constructed by fusion of the cDNA corresponding to the shIL-5Ralpha to the cDNA corresponding to the Fe part of the human IgG Cgamma3 chain, and was expressed in baculovirus-infected insect cells. The chimeric receptor was secreted as a disulfide-linked homodimer, and was purified by protein G affinity chromatography. In a solid-phase binding assay the shIL-5Ralpha and the bivalent hIL-5Ralpha-hgamma3 were found to bind hIL-5 with a similar affinity, corresponding to the membrane-bound, low affinity hIL-5Ralpha. SDS-polyacrylamide gel electrophoresis of shIL-5Ralpha cross-linked to radiolabeled hIL-5, suggested that one shIL-5Ralpha molecule binds to one hIL-5 homodimer molecule. Gel filtration studies of the complex formed between the shIL-5Ralpha and hIL-5 pointed toward the same stoichiometry of binding. The formation of such a complex could be observed by electrophoresis in native gels. Immunoaffinity chromatography using a non-neutralizing monoclonal antibody directed against hIL-5, followed by size column chromatography, allowed the purification of the complex. The data obtained from the amino acid analysis of the constituents of the complex blotted from an SDS-polyacrylamide gel, and from the amino acid composition of the complex blotted from a native polyacrylamide gel, provided direct evidence that the shIL-5Ralpha binds the hIL-5 dimer in a 1:1 ratio.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Roche Holding	DEVOS, R (corresponding author), F HOFFMANN LA ROCHE & CO LTD,ROCHE RES GENT,PLATEAUSTR 22,B-9000 GHENT,BELGIUM.		Tavernier, Jan/AAG-3636-2019					ANTONI G, 1989, ANAL BIOCHEM, V179, P158, DOI 10.1016/0003-2697(89)90217-0; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DIPERSIO JF, 1991, J BIOL CHEM, V266, P279; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MALISZEWSKI CR, 1992, CELL IMMUNOL, V143, P434, DOI 10.1016/0008-8749(92)90038-Q; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; PROUDFOOT AEI, 1991, FEBS LETT, V283, P61, DOI 10.1016/0014-5793(91)80553-F; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1990, INT J CELL CLONING, V8, P147, DOI 10.1002/stem.5530080713; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; WANG F, 1991, ANAL BIOCHEM, V198, P285, DOI 10.1016/0003-2697(91)90426-T	30	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6581	6587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454628				2022-12-25	WOS:A1993KT36800073
J	GONZALEZ, A; NICOVANI, S; JUICA, F				GONZALEZ, A; NICOVANI, S; JUICA, F			APICAL SECRETION OF HEPATITIS-B SURFACE-ANTIGEN FROM TRANSFECTED MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; VIRAL GLYCOPROTEINS; CYTOPLASMIC DOMAIN; INTRACELLULAR-TRANSPORT; ENVELOPE PROTEINS; MAMMALIAN-CELLS	Hepatitis B surface antigen (HBsAg), the major envelope component of human hepatitis B virus, during infection drives the assembly and basolateral secretion from hepatocytes of both virions and subviral lipoprotein particles into the bloodstream. We studied the sorting behavior of HBsAg in the heterologous epithelial Madin-Darby canine kidney cells permanently transformed with the hepatitis B virus S gene. These cells, forming tightly packed monolayers in permeable supports, secreted HBsAg apically through a mechanism not involving transcytosis. This suggests that molecular features acting as apical addressing information, seemingly unfunctional or less efficiently used by the exocytic machinery of hepatocytes, could be contained in short hydrophilic regions of HBsAg. Lipids also could play a role in this asymmetric sorting because HBsAg is known to be secreted by forming macromolecular lipoprotein complexes rather than as a soluble protein. Together with available data, our results would imply not only the existence of tissue-specific variations in handling constitutively secreted proteins but also that these variations are strikingly dependent on the kind of protein examined. On the other hand, pulse-chase experiments with tunicamycin showed that the expression of apical information in HBsAg particles does not require N-linked glycosylation, contrasting with the known gp80 Madin-Darby canine kidney-endogenous apical secretory marker. This is the first experimental evidence that carbohydrate moieties in secretory proteins do not hold domain-specific sorting signals, a fact previously shown exclusively for membrane proteins. Thus, HBsAg provides a novel model system for the analysis of the molecular mechanisms of constitutive apical secretion.	PONTIFICIA UNIV CATOLICA CHILE, FAC CIENCIAS BIOL, DEPT BIOL CELULAR & MOLEC, SANTIAGO, CHILE	Pontificia Universidad Catolica de Chile	GONZALEZ, A (corresponding author), PONTIFICIA UNIV CATOLICA CHILE, FAC MED, DEPT INMUNOL CLIN & REUMATOL, CASILLA 114-D, SANTIAGO, CHILE.							BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BLUM HE, 1983, P NATL ACAD SCI-BIOL, V80, P6685, DOI 10.1073/pnas.80.21.6685; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BOXALL E, 1975, LANCET, V2, P1211; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; DEJEAN A, 1984, J GEN VIROL, V65, P651, DOI 10.1099/0022-1317-65-3-651; EBLE BE, 1986, MOL CELL BIOL, V6, P1454, DOI 10.1128/MCB.6.5.1454; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAVILANES F, 1982, J BIOL CHEM, V257, P7770; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; HALPERN MS, 1983, P NATL ACAD SCI-BIOL, V80, P4865, DOI 10.1073/pnas.80.15.4865; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HOEFS JC, 1980, GASTROENTEROLOGY, V79, P191, DOI 10.1016/0016-5085(80)90129-8; HUGHSON EJ, 1989, J CELL SCI, V94, P327; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KLOPPEL TM, 1986, HEPATOLOGY, V6, P587, DOI 10.1002/hep.1840060407; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; PATZER EJ, 1986, J VIROL, V58, P884, DOI 10.1128/JVI.58.3.884-892.1986; PATZER EJ, 1984, J VIROL, V51, P346, DOI 10.1128/JVI.51.2.346-353.1984; PETERSON DL, 1982, J BIOL CHEM, V257, P414; PETERSON DL, 1981, J BIOL CHEM, V256, P6975; POWELL SK, 1991, AM J PHYSIOL, V260, pC715, DOI 10.1152/ajpcell.1991.260.4.C715; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; ROTH MG, 1979, P NATL ACAD SCI USA, V76, P6430, DOI 10.1073/pnas.76.12.6430; Sambrook J, 1989, MOL CLONING LABORATO; SAUCAN L, 1992, HEPATOLOGY, V15, P714, DOI 10.1002/hep.1840150427; SHIMODA T, 1981, GASTROENTEROLOGY, V81, P998; SHOREY J, 1980, GASTROENTEROLOGY, V79, P391; SIMON K, 1988, J CELL BIOL, V107, P2163, DOI 10.1083/jcb.107.6.2163; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STANDRING DN, 1986, PROG LIVER DIS, V8, P311; STEPHENS EB, 1988, ANNU REV MICROBIOL, V42, P489; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0; VALENZUELA P, 1984, HEPATITIS B VIRUS DI; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551; [No title captured]	69	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6662	6667						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454638				2022-12-25	WOS:A1993KT36800084
J	KRISTIE, TM; SHARP, PA				KRISTIE, TM; SHARP, PA			PURIFICATION OF THE CELLULAR-C1 FACTOR REQUIRED FOR THE STABLE RECOGNITION OF THE OCT-1 HOMEODOMAIN BY THE HERPES-SIMPLEX VIRUS ALPHA-TRANS-INDUCTION FACTOR (VP16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; NUCLEAR FACTOR-III; RNA POLYMERASE-II; HISTONE H2B GENE; OCTAMER-BINDING PROTEINS; TUMOR SUPPRESSOR GENES; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYOS; PROMOTER INVITRO; POU DOMAIN	The assembly of specific multiprotein complexes on the herpes simplex virus alpha/IE (immediate early) enhancer elements requires the interactions of the Oct-1 POU homeodomain, the viral alphaTIF (alpha-trans-induction factor) (VP16), and at least one additional cellular factor, the C1 factor. The C1 factor interacts directly with alphaTIF, likely forming an intermediate protein complex that recognizes the Oct-1 homeodomain-DNA complex. The biochemical purification of the mammalian C1 factor suggests that it is composed of multiple subunits of related, but heterogeneous, polypeptides. The interaction of a subset of these polypeptides with alphaTIF is stimulated by post-translational modifications of the C1 proteins, suggesting that this factor may be a critical target for the regulation of the herpes simplex virus alpha/IE transcription.	MIT,CTR CANC RES,40 AMES ST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD R, 1989, PRACTICAL GUIDE PEPT, P73; Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BZIK DJ, 1986, NUCLEIC ACIDS RES, V14, P929, DOI 10.1093/nar/14.2.929; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P17; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7862; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KATN M, 1990, NUCLEIC ACIDS RES, V18, P6871; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1988, J VIROL, V62, P1145, DOI 10.1128/JVI.62.4.1145-1157.1988; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MACKEM S, 1982, P NATL ACAD SCI-BIOL, V79, P4917, DOI 10.1073/pnas.79.16.4917; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MCKNIGHT JLC, 1986, CANCER CELL CONTROL, V4, P163; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; ONEILL EA, 1988, J BIOL CHEM, V263, P931; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; Roizman B., 1985, VIROLOGY, P497; ROIZMAN B, 1974, COMPREHENSIVE VIROLO, P299; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; SPECTOR D, 1991, J VIROL, V65, P3504, DOI 10.1128/JVI.65.7.3504-3513.1991; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x	87	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6525	6534						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454622				2022-12-25	WOS:A1993KT36800065
J	SHISHEVA, A; SHECHTER, Y				SHISHEVA, A; SHECHTER, Y			ROLE OF CYTOSOLIC TYROSINE KINASE IN MEDIATING INSULIN-LIKE ACTIONS OF VANADATE IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; GLUCOSE-TRANSPORT; RECEPTOR KINASE; PROTEIN-KINASE; BLOOD-GLUCOSE; PHOSPHORYLATION; STIMULATION; INHIBITOR; INVIVO; PHOSPHOTYROSINE	In previous studies we have identified a cytosolic protein tyrosine kinase (CytPTK) in rat adipocytes that is largely activated in vanadate-pretreated cells (Shisheva, A., and Shechter, Y. (1992) FEBS Lett. 300, 93-96). We report here that staurosporine and its analog K-252a are highly potent (ID50 = 3 and 100 nM, respectively) in inhibiting CytPTK activity of crude cell extract or partially purified enzyme preparations. Staurosporine and K-252a were less effective by more than 2 and 1 orders of magnitude, respectively, in inhibiting insulin receptor-catalyzed PolyGlu4Tyr phosphorylation in cell-free experiments. Preincubation of rat adipocytes with either staurosporine or K-252a selectively blocked the action of vanadate in activating glucose incorporation into lipids and its oxidation. Thus, staurosporine inhibited vanadate-stimulated lipogenesis and glucose oxidation (via glycolysis and the pentose phosphate pathway) in a concentration-dependent manner with ID50 of 75 and 300 nM, respectively. Insulin-stimulated bioeffects were not inhibited at this low range of staurosporine concentration. Staurosporine had no effect on vanadate-stimulated hexose uptake or on vanadate's antilipolytic action. Using staurosporine, we probed those insulinomimetic agents which facilitate their biological activity via the insulin receptor kinase (insulin, wheat germ agglutinin, concanavalin A, and pervanadate) or via CytPTK (vanadate and to a certain degree Mn2+ and Zn2+). These results suggest that (a) vanadate facilitates its insulin-like actions on glucose utilization via the cytosolic tyrosine kinase and (b) this enzyme does not participate in vanadate effects in stimulating hexose uptake and in inhibiting lipolysis. These findings explain further vanadate's post-insulin receptor actions and raise possible application in the management of glucose metabolism in insulin-independent fashion in pathological conditions.	WEIZMANN INST SCI, DEPT HORMONE RES, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ANDERSEN PH, 1988, BIOCHEM BIOPH RES CO, V154, P171, DOI 10.1016/0006-291X(88)90666-3; BELFRAGE P, 1986, MECHANISMS INSULIN A, P323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Corbin J D, 1974, Methods Enzymol, V38, P287; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KIRSCH D, 1985, BIOCHEM BIOPH RES CO, V128, P824, DOI 10.1016/0006-291X(85)90121-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MEYEROVITCH J, 1990, BIOCHEMISTRY-US, V29, P3654, DOI 10.1021/bi00467a010; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SHECHTER Y, 1983, ENDOCRINOLOGY, V113, P1921, DOI 10.1210/endo-113-6-1921; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; SHECHTER Y, 1982, ENDOCRINOLOGY, V110, P1579, DOI 10.1210/endo-110-5-1579; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SHISHEVA A, 1991, J BIOCHEM BIOPH METH, V23, P307, DOI 10.1016/0165-022X(91)90006-I; SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014-5793(92)80171-C; SHISHEVA A, 1992, DIABETES, V41, P982, DOI 10.2337/diabetes.41.8.982; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; SHOELSON SE, 1989, MOL CELLULAR BIOL DI, V2, P23; SRIVASTAVA AK, 1990, INT J BIOCHEM, V22, P1229, DOI 10.1016/0020-711X(90)90303-K; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VENKATESAN N, 1991, DIABETES, V40, P492, DOI 10.2337/diabetes.40.4.492; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; WITTERS LA, 1985, NATURE, V315, P777, DOI 10.1038/315777a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	45	103	104	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6463	6469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454619				2022-12-25	WOS:A1993KT36800057
J	HALLAHAN, DE; GIUS, D; KUCHIBHOTLA, J; SUKHATME, V; KUFE, DW; WEICHSELBAUM, RR				HALLAHAN, DE; GIUS, D; KUCHIBHOTLA, J; SUKHATME, V; KUFE, DW; WEICHSELBAUM, RR			RADIATION SIGNALING MEDIATED BY JUN ACTIVATION FOLLOWING DISSOCIATION FROM A CELL TYPE-SPECIFIC REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IONIZING-RADIATION; BINDING-PROTEINS; GENE-EXPRESSION; FOS-PROTEIN; KAPPA-B; INHIBITOR; PHOSPHORYLATION; DOMAIN	The promoter regions of several radiation-inducible genes contain AP-1 cis-acting regulatory elements that are dependent upon protein kinase C signaling. We analyzed nuclear protein from irradiated human tumor cell lines for binding to the AP-1 consensus sequence. The increase in nuclear protein binding following irradiation was specific for the AP-1 sequence and was reduced by antibodies to c-Jun and c-Fos. The AP-1 DNA binding sequence was found to regulate transcription in irradiated cells and mutation of the AP-1 site within the c-jun promoter abolished transcriptional induction by radiation. The gene encoding the chimeric transcription factor Gal4-Jun5-253, which includes the DNA binding region of Gal4 and the transcriptional regulatory region of c-Jun, was cotransfected with the reporter plasmid with Gal4 binding sequences (G5B-CAT). Transfection of RIT-3 and HeLa cells revealed that the regulatory region of Jun was sufficient to activate transcription following irradiation. Conversely, Hep G2 cells, which do not contain the cell type-specific Jun repressor, were not responsive to radiation-induced Jun activation. The c-Jun repressor was found to regulate Jun activation by experiments using the expression vector CMV-jun, which competes for Jun inhibitor and eliminates radiation-induction of Jun. We propose transcription factor dissociation from inhibitor proteins may participate in the initiation of cellular responses to ionizing radiation.	MICHAEL REESE MED CTR,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115	Michael Reese Hospital & Medical Center; University of Chicago; University of Chicago; University of Chicago; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	HALLAHAN, DE (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,5841 S MARYLAND AVE,BOX 442,CHICAGO,IL 60637, USA.		Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA037435, R01CA042596, R01CA041068] Funding Source: NIH RePORTER; NCI NIH HHS [CA42596, CA41068, CA37435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHILES TC, 1991, J IMMUNOL, V146, P1730; COWAN JM, 1990, CANCER GENET CYTOGEN, V50, P125, DOI 10.1016/0165-4608(90)90246-7; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2152; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Oshima Y., 1982, REGULATORY CIRCUITS, P159; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEICHSELBAUM RR, 1992, PHYSICAL BIOL BASIS	33	54	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4903	4907						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444868				2022-12-25	WOS:A1993KP88400052
J	YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G				YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-14 OCCURS IN ADVANCED COLORECTAL CARCINOMAS	ONCOGENE			English	Article							NEURO-BLASTOMA; DNA; GENE; IDENTIFICATION; DEFICIENCY; PATHOLOGY; LOCATION; CLONING	The current model for colorectal tumorigenesis defines four specific mutations (activation of a ras proto-oncogene and inactivation of the APC, p53 and DCC tumor-suppressor genes) that accumulate in a colonic epithelial cell as it progresses towards a carcinoma. However, further mutations must be needed for progression to malignancy because advanced adenomas have been observed with all four of these mutations. Loss of heterozygosity (LOH) for 11 loci spanning the distal portion of the long arm of chromosome 14 was studied in 89 sporadic colorectal adenocarcinomas and 25 adenomas. The overall rate of LOH in carcinomas was 53% (46/86 informative carcinomas). The smatlest region of overlap (SRO) of deletions includes the markers D14SI9 to D14S20. No LOH was seen in the 18 informative adenomas examined. There was a significant trend towards higher levels of LOH within the SRO in advanced Dukes' stages (P = 0.016). Since frequent loss of heterozygosity in a specific region of a chromosome may reflect the inactivation of a tumor-suppressor gene located there, these data suggest that a gene involved in the progression of colonic neoplasia may reside on the distal portion of the long arm of chromosome 14, and that its inactivation may be a critical event in this process.	UNIV QUEENSLAND,QUEENSLAND INST MED RES,BRISBANE,QLD 4000,AUSTRALIA; ROYAL BRISBANE HOSP FDN,BANCROFT CTR,GLAXO GASTROENTEROL RES LAB,BRISBANE,QLD,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland	YOUNG, J (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES UNIT,HERSTON RD,BRISBANE,QLD 4006,AUSTRALIA.		Leggett, Barbara A/D-3579-2011; Young, Joanne P/H-7774-2014	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380				BAIRD M, 1986, AM J HUM GENET, V39, P489; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKHSHI A, 1983, NEW ENGL J MED, V309, P826, DOI 10.1056/NEJM198310063091404; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; COX DW, 1985, NATURE, V316, P79, DOI 10.1038/316079a0; COX DW, 1989, HUMAN GENOME MAPPING, V10; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEDMAN EA, 1985, CANCER INVEST, V3, P453, DOI 10.3109/07357908509039806; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P380, DOI 10.1093/nar/16.1.380; HOFF M, 1988, NUCLEIC ACIDS RES, V16, P10400, DOI 10.1093/nar/16.21.10400; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KELSEY GD, 1988, J MED GENET, V25, P361, DOI 10.1136/jmg.25.6.361; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONSTANTINOVA LN, 1991, HUM GENET, V86, P491; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P5220, DOI 10.1093/nar/16.11.5220; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; NAKAMURA Y, 1988, AM J HUM GENET, V43, P854; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3593, DOI 10.1093/nar/16.8.3593; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; RABIN M, 1986, SOMAT CELL MOLEC GEN, V12, P209, DOI 10.1007/BF01560668; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SASAKI M, 1989, CANCER RES, V49, P4402; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOUNG J, 1992, CANCER RES, V52, P285; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	33	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					671	675						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437850				2022-12-25	WOS:A1993KN00800018
J	WEINER, JH; SHAW, G; TURNER, RJ; TRIEBER, CA				WEINER, JH; SHAW, G; TURNER, RJ; TRIEBER, CA			THE TOPOLOGY OF THE ANCHOR SUBUNIT OF DIMETHYL-SULFOXIDE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; TERMINAL OXIDASE COMPLEX; PROTEIN EXPORT SIGNALS; MEMBRANE-PROTEIN; INVIVO COMPLEMENTATION; BETA-LACTAMASE; GENE FUSIONS; SEQUENCE; PERMEASE; OPERON	The terminal electron transfer enzyme Me2SO reductase of Escherichia coli is a heterotrimeric enzyme composed of a membrane extrinsic catalytic dimer (DmsAB) and a membrane intrinsic polytopic anchor subunit (DmsC). The topology of DmsC has been studied using phoA (alkaline phosphatase) and blaM (beta-lactamase) gene fusions. The results of analyzing the properties of proteins produced by the fusions suggests a structure with eight transmembrane helices. Both the amino and carboxyl termini are exposed to the periplasm. The entire DmsC polypeptide is necessary to anchor DmsAB to the membrane as fusions with truncated DmsC were not functional and soluble DmsAB accumulated in the cytoplasm. A dmsC-phoA fusion in the termination codon of dmsC generated a chimeric enzyme with functional Me2SO reductase and alkaline phosphatase activity. Quantitation of the minimal inhibitory concentration of ampicillin for the dmsC-blaM fusions indicated that different transmembrane helices had differing signal sequence activity.			WEINER, JH (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA.		Turner, Raymond J./M-3961-2015	Turner, Raymond J./0000-0002-9263-0776; Trieber, Catharine/0000-0002-1336-1126				AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CONDON C, 1988, MOL MICROBIOL, V2, P43, DOI 10.1111/j.1365-2958.1988.tb00005.x; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; ESPOSTI MD, 1990, EUR J BIOCHEM, V190, P201; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTIERREZ C, 1987, J MOL BIOL, V195, P289, DOI 10.1016/0022-2836(87)90650-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller J.H., 1972, EXPT MOL GENETICS; NEWTON G, 1991, MOL MICROBIOL, V5, P2511, DOI 10.1111/j.1365-2958.1991.tb02097.x; NILSSON I, 1991, CELL, V62, P1135; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J, 1989, MOL CLONING LABORATO; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WU JH, 1992, J BIOL CHEM, V267, P12570; YUN CH, 1991, J BIOL CHEM, V266, P10967; ZHANG Y, 1990, MOL MICROBIOL, V3, P1361	34	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3238	3244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429002				2022-12-25	WOS:A1993KM16100036
J	BHAMIDIPATI, SP; HAMILTON, JA				BHAMIDIPATI, SP; HAMILTON, JA			NMR-STUDIES OF PHOSPHOLIPASE-C HYDROLYSIS OF PHOSPHATIDYLCHOLINE IN MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-PLASMA LECITHIN; APOLIPOPROTEIN-A-I; CHOLESTEROL ACYLTRANSFERASE; C-13 NMR; SIGNAL TRANSDUCTION; SPECIFICITY; BILAYERS; DIACYLGLYCEROLS; SOLUBILIZATION	Hydrolysis of phospholipids in biological membranes by phospholipase C (PLC) produces an important second messenger molecule, 1,2-diacylglycerol (DAG), that is essential for the activation of protein kinase C (PKC). While the effects of DAG on model membranes have been investigated earlier, studies on physical properties of DAG introduced into phospholipid bilayers by PLC have been lacking. We present an NMR approach for studying structural and kinetic aspects of PLC-mediated hydrolysis of 13 carbonyl-enriched phospholipids in model membranes (small unilamellar vesicles). The product DAG is readily detected by C-13 NMR, and its structural properties as well as those of the model membrane can be monitored continuously. PLC hydrolysis was limited to a low proportion of the model membrane by incorporating a small amount of ester phospholipid into a nonhydrolyzable ether-linked phospholipid matrix. Under these conditions, PLC (Bacillus cereus) hydrolyzed only the monolayer of phosphatidylcholine to which it was exposed (the outer monolayer). The 1,2-DAG product remained associated with the membrane bilayer and did not alter bilayer structure in any detectable way. From the chemical shift data, it is inferred that the DAG has an interfacial conformation similar to that of phosphatidylcholine. These results show that DAG could activate PKC by direct interaction with the enzyme rather than by perturbation of the membrane bilayer.	BOSTON UNIV,SCH MED,HOUSMAN MED RES CTR,DEPT BIOPHYS,80 E CONCORD ST,BOSTON,MA 02118	Boston University				Hamilton, James/0000-0002-4747-7071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [1PO1 HL26335] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERDEN JA, 1974, FEBS LETT, V46, P55, DOI 10.1016/0014-5793(74)80333-9; BHAMIDIPATI SP, 1989, BIOCHEMISTRY-US, V28, P6667, DOI 10.1021/bi00442a020; BURNS RA, 1981, BIOCHEMISTRY-US, V20, P5945, DOI 10.1021/bi00524a004; DEBOECK H, 1989, BIOCHEMISTRY-US, V28, P7439, DOI 10.1021/bi00444a043; DEMANT EJF, 1979, EUR J BIOCHEM, V95, P613, DOI 10.1111/j.1432-1033.1979.tb13002.x; ELSAYED MY, 1985, BIOCHIM BIOPHYS ACTA, V837, P325, DOI 10.1016/0005-2760(85)90056-6; EPAND RM, 1990, TRENDS PHARMACOL SCI, V11, P317, DOI 10.1016/0165-6147(90)90234-Y; EXTON JH, 1990, J BIOL CHEM, V265, P1; GEORGE R, 1990, BIOCHEM CELL BIOL, V68, P161, DOI 10.1139/o90-022; GOLDFINE H, 1982, BIOCHEM BIOPH RES CO, V108, P1502, DOI 10.1016/S0006-291X(82)80077-6; HAMILTON JA, 1991, BIOCHEMISTRY-US, V30, P2894, DOI 10.1021/bi00225a024; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; HAMILTON JA, 1974, J BIOL CHEM, V249, P4872; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; KODALI DR, 1990, CHEM PHYS LIPIDS, V52, P163, DOI 10.1016/0009-3084(90)90111-4; MASSEY JB, 1985, J BIOL CHEM, V260, P1719; MCKEONE BJ, 1986, BIOCHEMISTRY-US, V25, P7711, DOI 10.1021/bi00371a064; Merrill AH, 1991, CURR OPIN STRUC BIOL, V1, P516, DOI 10.1016/S0959-440X(05)80071-5; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; POWNALL HJ, 1985, BIOCHIM BIOPHYS ACTA, V833, P456, DOI 10.1016/0005-2760(85)90103-1; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P5010, DOI 10.1021/bi00438a016; SMITH SO, 1992, BIOCHEMISTRY-US, V31, P11660, DOI 10.1021/bi00161a054; SUNDLER R, 1978, J BIOL CHEM, V253, P5299; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	29	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2431	2434						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428917				2022-12-25	WOS:A1993KK81500030
J	MISCHAK, H; GOODNIGHT, J; KOLCH, W; MARTINYBARON, G; SCHAECHTLE, C; KAZANIETZ, MG; BLUMBERG, PM; PIERCE, JH; MUSHINSKI, JF				MISCHAK, H; GOODNIGHT, J; KOLCH, W; MARTINYBARON, G; SCHAECHTLE, C; KAZANIETZ, MG; BLUMBERG, PM; PIERCE, JH; MUSHINSKI, JF			OVEREXPRESSION OF PROTEIN KINASE-C-DELTA AND KINASE-EPSILON IN NIH 3T3 CELLS INDUCES OPPOSITE EFFECTS ON GROWTH, MORPHOLOGY, ANCHORAGE DEPENDENCE, AND TUMORIGENICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; PHORBOL ESTERS; EXPRESSION; FAMILY; FIBROBLASTS; NPKC; CDNA; PKC; DIFFERENTIATION; PURIFICATION	We have determined the patterns of mRNA and protein expression of 7 protein kinase C (PKC) isozymes in NIH 3T3 cells. Only PKC-alpha is expressed abundantly in NIH 3T3 cells; endogenous levels of the other 6 PKC isozymes are low or undetectable. We have overexpressed PKC-delta and -epsilon in these cells to observe activation/translocation of these two isozymes and the biological consequences of overexpression. Both PKC-delta and epsilon, but not PKC-alpha, are partially associated with the insoluble fraction even in the absence of phorbol 12-myristate 13-acetate (PMA). Upon PMA stimulation, both PKC-delta and -epsilon translocate to the insoluble fraction of cell homogenates, as can be observed with the endogenous PKC-alpha. Overexpression of PKC-delta induces significant changes in morphology and causes the cells to grow more slowly and to a decreased cell density in confluent cultures. These changes are accentuated by treatment with PMA. Overexpression of PKC-epsilon does not lead to morphological changes, but causes increased growth rates and higher cell densities in monolayers. None of the PKC-delta overexpressers grow in soft agar with or without PMA, but all the cell lines that overexpress PKC-E grow in soft agar in the absence of PMA, but not in its presence. NIH 3T3 cells that overexpress PKC-epsilon also form tumors in nude mice with 100% incidence. This indicates that high expression of PKC-epsilon contributes to neoplastic transformation.	NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA; NCI, GENET LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011; Kolch, Walter/ABF-2102-2021	Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; ISHIZUKA T, 1992, BIOCHEM BIOPH RES CO, V183, P814, DOI 10.1016/0006-291X(92)90556-Z; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SHARKEY NA, 1985, CANCER RES, V45, P19; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799	35	570	587	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6090	6096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454583				2022-12-25	WOS:A1993KT36800006
J	SANZ, JM; GARCIA, JL; LAYNEZ, J; USOBIAGA, P; MENENDEZ, M				SANZ, JM; GARCIA, JL; LAYNEZ, J; USOBIAGA, P; MENENDEZ, M			THERMAL-STABILITY AND COOPERATIVE DOMAINS OF CPL1 LYSOZYME AND ITS NH2-TERMINAL AND COOH-TERMINAL MODULES - DEPENDENCE ON CHOLINE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATISTICAL MECHANICAL DECONVOLUTION; LYTIC ENZYMES; STREPTOCOCCUS-PNEUMONIAE; CLOSTRIDIUM-ACETOBUTYLICUM; PROTEIN-STRUCTURE; TRANSITIONS; MACROMOLECULES; BACTERIOPHAGES; EVOLUTION	Differential scanning calorimetry (DSC) has been employed to characterize the thermal denaturation of CPL1 lysozyme and its isolated fragments in the absence and presence of choline. The heat capacity function of CPL1 lysozyme shows two peaks with T(m) values of 43.5 and 51.4-degrees-C. At saturating concentrations of choline the second transition disappears, and the T(m) is shifted to higher temperatures. The DSC thermogram of the C-CPL1 protein corresponding to the carboxyl-terminal domain of CPL1 lysozyme has a single peak with a T(m) of 42.9-degrees-C. The effect of choline is very similar to that observed for the whole CPL1 lysozyme. The NH2-terminal fragment obtained by proteolytic digestion shows a T(m) of 52-degrees-C, close to that of 51.4-degrees-C found for the second transition of CPL1, and choline does not affect the T(m) nor the denaturation enthalpy. These data suggest that choline is bound to the COOH-terminal domain of the protein. Deconvolution of the excess heat capacity curve of the CPL1 lysozyme shows that the data can be fitted to two two-state independent transitions. The analysis of the DSC curves showed that the NH2-terminal unfolding enthalpy steadily decreases with increasing concentrations of choline. These results indicate that, under saturating concentrations of choline, whole CPL1 could unfold as a single cooperative unit.	CSIC, INST QUIM FIS ROCASOLANO, SERRANO 119, E-28006 MADRID, SPAIN; CSIC, CTR INVEST BIOL, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Sanz, Jesus M/B-2244-2008; Menendez, Margarita/M-1795-2014; Garcia Lopez, Jose Luis/G-9139-2015	Sanz, Jesus M/0000-0002-4421-9376; Menendez, Margarita/0000-0002-3267-4443; Garcia Lopez, Jose Luis/0000-0002-9238-2485				CROUX C, 1991, GENE, V104, P25, DOI 10.1016/0378-1119(91)90460-S; DIAZ E, 1991, J BIOL CHEM, V266, P5464; DIAZ E, 1990, P NATL ACAD SCI USA, V87, P8125, DOI 10.1073/pnas.87.20.8125; FASMAN GD, 1976, HDB BIOCH MOL BIOL, V3; FREIRE E, 1978, BIOPOLYMERS, V17, P481, DOI 10.1002/bip.1978.360170213; FREIRE E, 1978, BIOPOLYMERS, V17, P497, DOI 10.1002/bip.1978.360170214; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1988, FEMS MICROBIOL LETT, V52, P133; GARCIA JL, 1987, J VIROL, V61, P2573; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; HU CQ, 1987, BIOCHEMISTRY-US, V26, P178, DOI 10.1021/bi00375a025; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KILPPERBALZ R, 1985, INT J SYST BACTERIOL, V35, P482, DOI 10.1099/00207713-35-4-482; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ R, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P77; MAYORGA OL, 1987, BIOPHYS CHEM, V27, P87, DOI 10.1016/0301-4622(87)80049-2; MONK P, 1968, ACTA CHEM SCAND, V22, P1842, DOI 10.3891/acta.chem.scand.22-1842; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANZ JM, 1990, EUR J BIOCHEM, V187, P409, DOI 10.1111/j.1432-1033.1990.tb15319.x; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; TEERI T, 1992, J BIOTECHNOL, V24, P169, DOI 10.1016/0168-1656(92)90120-X; TOMASZ A, 1981, REV INFECT DIS, V3, P190	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6125	6130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454587				2022-12-25	WOS:A1993KT36800011
J	YANG, SY				YANG, SY			ASSOCIATION OF BOTH ENOYL COENZYME-A HYDRATASE AND 3-HYDROXYACYL COENZYME A EPIMERASE WITH AN ACTIVE-SITE IN THE AMINO-TERMINAL DOMAIN OF THE MULTIFUNCTIONAL FATTY-ACID OXIDATION PROTEIN FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; BETA-OXIDATION; MULTIENZYME COMPLEX; LARGE SUBUNIT; BIFUNCTIONAL ENZYME; COA HYDRATASE; FADBA OPERON; PURIFICATION; SEQUENCE; CLONING	An Escherichia coli mutant multienzyme complex of fatty acid oxidation, composed of two 41-kDa beta-subunits and two 79-kDa mutant alpha-subunits with the alpha/Gly116-->Phe substitution, has been overproduced and purified. The catalytic properties of 3-ketoacyl-coenzyme A (CoA) thiolase and L-3-hydroxyacyl-CoA dehydrogenase were found to be virtually identical with those of the wild type, whereas both enoyl-CoA hydratase and 3-hydroxyacyl-CoA epimerase activities were eliminated by the alpha/Gly116-->Phe mutation. DELTA3-cis-DELTA2-trans-Enoyl-CoA isomerase was only slightly affected by the mutation. The results of this study, together with the sequence analysis of the large alpha-subunit of the E. coli complex (Yang, X.-Y. H., Schulz, H., Elzinga, M., and Yang, S.-Y. (1991) Biochemistry 30, 6788-6795) and a demonstration of the epimerization of D-3-hyroxyacyl-CoAs in E. coli via a dehydration/hydration mechanism (Smeland, T. E., Cuebas, D., and Schulz, H. (1991) J. Biol. Chem. 266,23904-23908), lead to the conclusion that enoyl-CoA hydratase and 3-hydroxyacyl-CoA epimerase are associated with a common active site in the amino-terminal domain of the multifunctional fatty acid oxidation protein. Thus the E. coli hydratase and epimerase activities represent two functions of a unique crotonase that converts both L- and D-3-hydroxyacyl-CoAs to 2-trans-enoyl-CoAs. Moreover, the results suggest that the aminoterminal domain of the large alpha-subunit is also involved in the isomerase activity but the key residue(s) required for catalyzing the isomerization is distinct from the crotonase.			YANG, SY (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABILIT, NEUROBIOCHEM LAB, STATEN ISL, NY 10314 USA.							BAHNSON BJ, 1991, BIOCHEMISTRY-US, V30, P5894, DOI 10.1021/bi00238a013; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER K, 1992, BIOCHEM BIOPH RES CO, V183, P443, DOI 10.1016/0006-291X(92)90501-B; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CUNNINGHAM PR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P18, DOI 10.1016/0167-4781(90)90135-O; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; Higuchi R., 1989, PCR TECHNOLOGY, P61; IMAMURA S, 1990, J BIOCHEM, V107, P184, DOI 10.1093/oxfordjournals.jbchem.a123023; ISHII N, 1987, J BIOL CHEM, V262, P8144; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JX, 1990, J BIOL CHEM, V265, P13629; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; PALOSAARI PM, 1991, J BIOL CHEM, V266; PAWAR S, 1981, J BIOL CHEM, V256, P3894; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS; SEUBERT W, 1960, BIOCHEM PREP, V7, P80; SMELAND TE, 1991, J BIOL CHEM, V266, P23904; SPRATT SK, 1984, J BACTERIOL, V158, P535, DOI 10.1128/JB.158.2.535-542.1984; STAACK H, 1978, J BIOL CHEM, V253, P1827; Steinman H M, 1975, Methods Enzymol, V35, P136, DOI 10.1016/0076-6879(75)35149-5; STERN JR, 1961, ENZYMES, V5, P511; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VOLGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615; WAKIL SJ, 1956, BIOCHIM BIOPHYS ACTA, V19, P497, DOI 10.1016/0006-3002(56)90473-5; WEEKS G, 1968, J BIOL CHEM, V243, P1180; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANG SY, 1983, J BIOL CHEM, V258, P9780; YANG SY, 1985, J BIOL CHEM, V260, P2862; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; YANG SY, 1986, J BIOL CHEM, V261, P5390; YANG SY, 1992, PROG CLIN BIOL RES, V375, P183; YANG SY, 1991, J BACTERIOL, V173, P7405, DOI 10.1128/jb.173.23.7405-7406.1991; YANG SY, 1991, J BIOL CHEM, V30, P6788	42	37	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6588	6592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454629				2022-12-25	WOS:A1993KT36800074
J	BHAUMIK, D; MEDIN, J; GATHY, K; COLEMAN, MS				BHAUMIK, D; MEDIN, J; GATHY, K; COLEMAN, MS			MUTATIONAL ANALYSIS OF ACTIVE-SITE RESIDUES OF HUMAN ADENOSINE-DEAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; TRANSITION-STATE STABILIZATION; ANALOG INHIBITORS; ESCHERICHIA-COLI; DEFICIENCY; QUANTITATION; EXPRESSION; BINDING; DEOXYNUCLEOTIDES; IDENTIFICATION	Adenosine deaminase was overexpressed in a baculovirus system. The pure recombinant and native enzymes were identical in size, Zn2+ content, and activity. Five amino acids, in proximity to the active site, were replaced by mutagenesis. The altered enzymes were purified to homogeneity and compared to wild-type adenosine deaminase with respect to zinc content, enzymatic activity, and kinetic parameters. All but one of the alterations produced significant activity perturbations. Replacement of Cys262 produced a protein that retained at least 30-40% of wild-type activity. In contrast, replacements of His17, His214, His238, and Glu217 resulted in dramatic losses of enzyme activity. None of these mutants exhibited large variations in K(m). The proteins produced from alterations of amino acids implicated in metal coordination were slightly activated by inclusion of Zn2+ throughout purification. These experiments confirm that in the active enzyme Zn2+ plays a critical role in catalysis, that a histidine or glutamate residue plays a mechanistic role in the hydrolytic deamination step, and that cysteine is not involved in the catalytic mechanism of adenosine deaminase. These data support the roles for these amino acid residues suggested from the x-ray structure of murine adenosine deaminase (Wilson, D. K., Rudolf, F. B., and Quicho, F. A. (1991) Science 252, 1278-1284).	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA026391] Funding Source: NIH RePORTER; NCI NIH HHS [CA26391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULD DS, 1988, METHOD ENZYMOL, V158, P13, DOI 10.1016/0076-6879(88)58043-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; COLEMAN MS, 1975, BIOCHEM MED METAB B, V13, P46, DOI 10.1016/0006-2944(75)90139-8; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; COLEMAN MS, 1983, BIOSCIENCE, V33, P707, DOI 10.2307/1309351; COSSACK ZT, 1991, INT J VITAM NUTR RES, V61, P51; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; EVANS BE, 1973, BIOCHEMISTRY-US, V12, P392, DOI 10.1021/bi00727a005; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GIBLETT ER, 1972, LANCET, V2, P1067; INGOLIA DE, 1985, J BIOL CHEM, V260, P3261; JONES W, 1989, BIOCHEMISTRY-US, V28, P1242, DOI 10.1021/bi00429a043; KATI WM, 1989, BIOCHEMISTRY-US, V28, P7919, DOI 10.1021/bi00445a055; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P8450, DOI 10.1021/bi00399a063; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; MEDIN JA, 1990, P NATL ACAD SCI USA, V87, P2760, DOI 10.1073/pnas.87.7.2760; MEDIN JA, 1993, METHODS MOL BIOL; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P24; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P3386, DOI 10.1021/bi00768a011; PHILIPS AV, 1987, BIOCHEMISTRY-US, V26, P2893, DOI 10.1021/bi00384a034; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SCHRADER WP, 1977, J BIOL CHEM, V252, P6409; SELLIN S, 1984, J BIOL CHEM, V259, P1426; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P8977; WIGINTON DA, 1984, NUCLEIC ACIDS RES, V12, P2439, DOI 10.1093/nar/12.5.2439; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004; WOLFENDEN R, 1967, J BIOL CHEM, V242, P977; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V8, P2412, DOI 10.1021/bi00834a024; WRAY W, 1981, ANAL BIOCHEM, V72, P248; ZIELKE CL, 1971, ENZYMES, V4, P47	39	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5464	5470						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449909				2022-12-25	WOS:A1993KR82200021
J	LUBIN, IM; CABAN, R; RUNGE, MS				LUBIN, IM; CABAN, R; RUNGE, MS			THE TISSUE PLASMINOGEN-ACTIVATOR FINGER DOMAIN CONFERS FIBRIN-DEPENDENT ENHANCEMENT OF CATALYTIC ACTIVITY TO SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; STRUCTURAL DOMAINS; KRINGLE-2 DOMAIN; PRO-UROKINASE; PURIFICATION; EXPRESSION; VARIANTS; DUPLICATION; KINETICS	To determine whether the fibrin-binding domains of tissue plasminogen activator (tPA) can confer enhanced catalytic activity to single-chain urokinase-type plasminogen activator (scuPA), we constructed, expressed, and characterized the kinetics of five recombinant tPA/scuPA hybrid molecules. The hybrid molecules are 1) tPA3-50 (tPA finger)/scuPA138-411, 2) tPA177-256 (tPA kringle2)/scuPA140-411(scuPA catalytic), 3) tPA3-50/tPA177-256/scuPA140-411, 4) scuPA1-47 (scuPA growth factor)/tPA177-256/scuPA140-411, and 5) scuPA1-138 (scuPA growth factor and kringle)tPA127-256/scuPA139-411. The amidolytic activity of all hybrids was comparable, as were the kinetics for conversion from single-chain to two-chain plasminogen activator. We found that 1) the lag time prior to achieving maximal velocity among these hybrids varied, 2) hybrids 2, 3, 4, and 5 were 2-134-fold more potent (by k(cat)/K(m)) than hybrid 1, and 3) those hybrid proteins containing the tPA finger domain (hybrids 1 and 3) gave a 2-fold increase in catalytic efficiency in the presence of DESAFIB (reptilase-digested fibrinogen). These kinetic differences are likely mediated by changes in the tertiary structure of the scuPA catalytic domain resulting from interactions between catalytic and non-catalytic domains in the presence of fibrin.	EMORY UNIV, SCH MED, DIV CARDIOL, DRAWER LL, ATLANTA, GA 30322 USA	Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008439, K04HL002414, R01HL044307] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02414, HL08439-01, HL44307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; COLLEN D, 1991, CIRCULATION, V84, P1216, DOI 10.1161/01.CIR.84.3.1216; COLLEN D, 1986, J BIOL CHEM, V261, P1259; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GHEYSEN D, 1987, J BIOL CHEM, V262, P11779; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LEE SG, 1988, J BIOL CHEM, V263, P2917; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; NOVAKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; RUNGE MS, 1991, MOL BIOL MED, V8, P245; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STUMP DC, 1986, J BIOL CHEM, V261, P1274; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x	25	4	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5550	5556						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449917				2022-12-25	WOS:A1993KR82200033
J	ISHIHARA, M; TYRRELL, DJ; STAUBER, GB; BROWN, S; COUSENS, LS; STACK, RJ				ISHIHARA, M; TYRRELL, DJ; STAUBER, GB; BROWN, S; COUSENS, LS; STACK, RJ			PREPARATION OF AFFINITY-FRACTIONATED, HEPARIN-DERIVED OLIGOSACCHARIDES AND THEIR EFFECTS ON SELECTED BIOLOGICAL-ACTIVITIES MEDIATED BY BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SULFATE METABOLISM; FACTOR RECEPTOR; BINDING; INHIBITOR; IDENTIFICATION; PROTEOGLYCAN; CHLORATE	Homogeneously sized, heparin-derived oligosaccharides were prepared from heparin following partial depolymerization with nitrous acid, reduction with sodium borohydride, and fractionation by gel permeation chromatography. The resulting pools of di-, tetra-, hexa-, octa-, and decasaccharides were sequentially applied to an affinity column of human recombinant basic fibroblast growth factor (bFGF) covalently attached to Sepharose 4B and further fractionated into subpools based on their elution from this column in response to gradients of sodium chloride. In general, pools of smaller heparin-derived oligosaccharides required relatively lower salt concentration for complete elution, and pools of larger oligosaccharides required higher salt concentration. The homogeneously sized pools and affinity-fractionated subpools of heparin-derived oligosaccharides were quantitatively assessed as inhibitors or enhancers of specific bFGF-mediated biological activities in five separate assay systems as follows: assay 1, to compete with human lymphoblastoid cells expressing syndecan (RO-12 UC cells) for binding to bFGF-coated wells (Ishihara, M., Tyrrell, D. J., Kiefer, M. C., Barr, P. J., and Swiedler, S. J. (1992) Anal. Biochem. 202, 310-315); assay 2, to inhibit I-125-bFGF binding to ''low affinity sites'' of adrenocortical endothelial (ACE) cells; assay 3, to inhibit bFGF-induced proliferation of ACE cells; assay 4, to support mitogenic activity of bFGF in a growth stimulation assay of chlorate-treated ACE cells; and assay 5, to enhance the in vitro interaction between I-125-bFGF and the recombinant extracellular domain of FGF high affinity receptor. The data derived from the five assay systems demonstrated that heparin-derived hexa- and octasaccharides inhibited the interaction between cell surface heparan sulfate proteoglycan and bFGF (assays 1 and 2) and bFGF-induced proliferation of ACE cells (assay 3) but were unable to enhance the binding of bFGF to its high affinity receptor in vitro (assay 5) or to support bFGF-induced mitogenesis in ACE cells (assay 4). These two activities required at least a decasaccharide with high affinity for bFGF.	CHIRON CORP, EMERYVILLE, CA 94608 USA	Novartis	ISHIHARA, M (corresponding author), GLYCOMED INC, 860 ATLANTIC AVE, ALAMEDA, CA 94501 USA.							BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BARR PJ, 1988, J BIOL CHEM, V263, P16471; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOSPODAROWICZ D, 1991, ANN NY ACAD SCI, V638, P1, DOI 10.1111/j.1749-6632.1991.tb49012.x; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIEFER MC, 1991, ANN NY ACAD SCI, V638, P167, DOI 10.1111/j.1749-6632.1991.tb49027.x; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KOSAKAI M, 1979, ANAL BIOCHEM, V93, P295, DOI 10.1016/S0003-2697(79)80083-4; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WRIGHT TC, 1989, J BIOL CHEM, V264, P1534; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	36	148	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4675	4683						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444841				2022-12-25	WOS:A1993KP88400021
J	CHANG, YY; WANG, AY; CRONAN, JE				CHANG, YY; WANG, AY; CRONAN, JE			MOLECULAR-CLONING, DNA SEQUENCING, AND BIOCHEMICAL ANALYSES OF ESCHERICHIA-COLI GLYOXYLATE CARBOLIGASE - AN ENZYME OF THE ACETOHYDROXY ACID SYNTHASE-PYRUVATE OXIDASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; IDENTIFICATION; OPERON; MUTAGENESIS; CHROMOSOME; FRAGMENTS; STRAINS; PATHWAY; K-12; SITE	Glyoxylate carboligase (Gcl) (EC 4.1.1.47) of Escherichia coli catalyzes the condensation of two molecules of glyoxylate to give tartronic semialdehyde, a key intermediate in glyoxylate catabolism. We report the cloning, genomic location, and DNA sequence of the gene (called gcl) encoding E. coli Gcl and isolation of mutants lacking the enzyme. Gcl is a protein of 593 amino acid residues (64,738 Da) that has a high level (30%) of sequence similarity to the acetohydroxy acid synthases (AHAS) of branched chain amino acid synthetic pathway. Significant sequence identity (26%) was also observed with E. coli pyruvate oxidase, a redox flavoprotein, previously shown to be related to the AHAS enzymes (Chang, Y.-Y., and Cronan, J. E., Jr. (1988) J. Bacteriol. 170, 3937-3945). Consistent with a grouping of Gcl with the AHAS and pyruvate oxidase enzymes, Gcl contains a quinone binding site as well as binding site for thiamine pyrophosphate and FAD. We also found that a gene (orf258) immediately downstream of the gcl gene encoded a protein (Orf258) of 258 residues. Although the gene organization of gcl and orf258 is analogous to that of the ilv gene operons which encode the E. coli AHAS isozyme large and small subunits, Orf258 does not function as a Gcl subunit. Moreover, disruption of the chromosomal copy of orf258 did not affect growth on glyoxylate or glycolate.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	CHANG, YY (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019	WANG, AI-YU/0000-0002-8485-602X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHANG YY, 1983, J BACTERIOL, V154, P756, DOI 10.1128/JB.154.2.756-762.1983; CHANG YY, 1986, J BACTERIOL, V167, P312, DOI 10.1128/jb.167.1.312-318.1986; CHANG YY, 1982, J BACTERIOL, V151, P1279, DOI 10.1128/JB.151.3.1279-1289.1982; CHANG YY, 1992, EVOLUTION METABOLIC, P81; CROMARTIE TH, 1976, J BIOL CHEM, V251, P329; DEVEAUX LC, 1986, J BACTERIOL, V167, P920, DOI 10.1128/jb.167.3.920-927.1986; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GUPTA NK, 1966, ARCH BIOCHEM BIOPHYS, V113, P255, DOI 10.1016/0003-9861(66)90185-8; GUPTA NK, 1964, J BIOL CHEM, V239, P3787; HANSEN RW, 1962, J BACTERIOL, V83, P679, DOI 10.1128/JB.83.3.679-687.1962; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HOHEISEL J, 1986, NUCLEIC ACIDS RES, V14, P3605, DOI 10.1093/nar/14.8.3605; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG HL, 1961, ADV ENZYMOL REL S BI, V23, P401; LAGO CT, 1985, BIOCHIM BIOPHYS ACTA, V824, P74, DOI 10.1016/0167-4781(85)90031-4; LORD JM, 1972, BIOCHIM BIOPHYS ACTA, V267, P227, DOI 10.1016/0005-2728(72)90111-9; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; Miller J.H., 1972, EXPT MOL GENETICS; MURRAY A, 1952, J AM CHEM SOC, V74, P2405, DOI 10.1021/ja01129a068; ORNSTON LN, 1969, J BACTERIOL, V98, P1098, DOI 10.1128/JB.98.3.1098-1108.1969; RESNIK E, 1991, GENE, V107, P19, DOI 10.1016/0378-1119(91)90292-J; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SCHLOSS JV, 1988, NATURE, V331, P360, DOI 10.1038/331360a0; SINGER M, 1989, MICROBIOL REV, V53, P1; SWOFFORD DL, 1990, PAUP PHYLOGENETIC AN; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; Umbarger HE, 1987, ESCHERICHIA COLI SAL, P352; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WEK RC, 1985, NUCLEIC ACIDS RES, V13, P3995, DOI 10.1093/nar/13.11.3995; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	33	61	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3911	3919						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440684				2022-12-25	WOS:A1993KN53300021
J	CHUNG, CD; BIEBER, LL				CHUNG, CD; BIEBER, LL			PROPERTIES OF THE MEDIUM CHAIN LONG-CHAIN CARNITINE ACYLTRANSFERASE PURIFIED FROM RAT-LIVER MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; SEQUENCE-ANALYSIS; PALMITOYLTRANSFERASE; OXIDATION; CLONING; ENZYME; OCTANOYLTRANSFERASE; MITOCHONDRIAL	Carnitine octanoyltransferase (COT) purified from rat liver microsomes has K0.5 values between 1.0 and 4.0 muM for saturated 6-carbon to 16-carbon length acyl-CoAs, with little differences in V(max) values. The reaction rate is linear with time in the forward direction (acyl-CoA --> acylcarnitine), but it increases with time when assayed in the reverse direction (acylcarnitine --> acyl-CoA). The K0.5 for decanoylcarnitine and CoASH are 0.3 mM for CoASH and between 1.0 and 4.0 mM for decanoylcarnitine. The kinetic data indicate that the enzyme functions in the direction of acylcarnitine formation. It is moderately inhibited by aminocarnitine, and D-carnitine and etomoxiryl-CoA are weak inhibitors; malonyl-CoA does not inhibit the enzyme. The enzyme has little, if any, capacity to use valproylcarnitine, 3-methylglutarylcarnitine, or pivaloylcarnitine as a substrate. Polyclonal antibodies prepared against COT give a positive Western blot against the purified enzyme and against a protein in microsomes having the molecular mass of COT (53 kDA). Antimitochondrial CPT and antiperoxisomal CAT did not show appreciable cross-reactivity with purified microsomal COT. The inhibitor data, the kinetic data, the molecular masses, and the Western blotting profiles all show that the enzyme purified from rat liver microsomes is a different carnitine acyltransferase than those previously purified from other organelles.	MICHIGAN STATE UNIV,DEPT BIOCHEM,BIOCHEM BLDG,RM 224,E LANSING,MI 48824	Michigan State University					NIDDK NIH HHS [DK-18427] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018427] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BIEBER LL, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P7; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; Chung C, 1991, Protein Expr Purif, V2, P426, DOI 10.1016/1046-5928(91)90104-Q; FARRELL SO, 1984, J BIOL CHEM, V259, P13088; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KERNER J, 1990, BIOCHEMISTRY-US, V29, P4326, DOI 10.1021/bi00470a010; LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; LILLY K, 1990, BIOCH LIFE SCI ADV, V9, P79; LYSAIAK W, 1986, J BIOL CHEM, V261, P13698; MARKWELL MA, 1973, J BIOL CHEM, V248, P3426; MARKWELL MAK, 1977, BIOCHEM PHARMACOL, V26, P1697, DOI 10.1016/0006-2952(77)90147-2; MCGARRY JD, 1978, J BIOL CHEM, V253, P8294; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; MCMILLIN JB, 1992, J MOL CELL CARDIOL, V24, P259, DOI 10.1016/0022-2828(92)93163-E; MIYAZAWA S, 1983, J BIOCHEM, V94, P529, DOI 10.1093/oxfordjournals.jbchem.a134384; MURTHY MSR, 1992, PROTEIN EXPRES PURIF, V3, P75, DOI 10.1016/1046-5928(92)90059-6; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720	20	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4519	4524						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440734				2022-12-25	WOS:A1993KN53300102
J	GOODMAN, DW; ISAKSON, PC				GOODMAN, DW; ISAKSON, PC			MITOGEN ACTIVATION OF RESTING LYMPHOCYTES EXPOSES CRYPTIC INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; CULTURED HUMAN-LYMPHOCYTES; TYROSINE KINASE; SEQUENTIAL EXPRESSION; CELL DIFFERENTIATION; T ACTIVATION; BETA-SUBUNIT; RNA LEVELS; PHOSPHORYLATION; PROTEIN	Mitogen activation of resting lymphocytes induces expression of high affinity insulin receptors on the plasma membrane. The mechanism underlying this effect on insulin receptor expression was examined by comparing levels of insulin receptor mRNA and protein in resting and mitogen-activated rodent lymphocytes. Analysis of RNA levels indicated that resting and concanavalin A-activated lymphocytes contained equivalent amounts of insulin receptor mRNA with predominant transcripts of 7.9 and 9.5 kilobases. Although little or no insulin binding was detectable on intact resting lymphocytes, detergent solubilization of these cells resulted in the appearance of readily detectable insulin binding activity that could be immunoprecipitated with anti-insulin receptor antibodies. Detergent-solubilized resting and mitogen-activated lymphocytes expressed equivalent amounts of insulin receptors that bound insulin with similar affinity (K(D) = 90 pM) and migrated on reduced SDS-polyacrylamide gels with apparent masses of approximately 130 and approximately 95 kDa. Insulin receptors from resting lymphocytes appeared to be associated with the plasma membrane since I-125 labeling of intact lymphocytes radiolabeled the insulin receptor, insulin binding activity was detected in membrane fractions of hypotonically lysed cells, and trypsin treatment of intact cells destroyed >90% of the insulin binding activity in detergent extracts. These results suggest that resting lymphocytes express insulin receptor mRNA and protein and that mitogen activation exposes cryptic insulin receptors present in the plasma membrane of resting lymphocytes.	SEARLE RES & DEV,IMMUNOINFLAMMATORY DIS RES,ST LOUIS,MO 63198; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Pfizer; University of Virginia					NIAID NIH HHS [AI-29976] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029976] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRKELAND ML, 1987, J EXP MED, V166, P506, DOI 10.1084/jem.166.2.506; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BRACIALE VL, 1982, J EXP MED, V156, P664, DOI 10.1084/jem.156.2.664; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTI A, 1989, J CLIN INVEST, V83, P192, DOI 10.1172/JCI113858; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRANK BH, 1983, J CHROMATOGR, V266, P239, DOI 10.1016/S0021-9673(01)90897-0; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; HELDERMAN JH, 1977, J CLIN INVEST, V59, P338, DOI 10.1172/JCI108646; HELDERMAN JH, 1978, NATURE, V274, P62, DOI 10.1038/274062a0; HELDERMAN JH, 1979, J BIOL CHEM, V254, P7203; JETT M, 1977, J BIOL CHEM, V252, P2134; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KNUTSON VP, 1991, FASEB J, V5, P2130, DOI 10.1096/fasebj.5.8.2022311; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUG U, 1972, P NATL ACAD SCI USA, V69, P2604, DOI 10.1073/pnas.69.9.2604; KUMAGAI J, 1981, J IMMUNOL, V126, P1249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1981, J EXP MED, V153, P310, DOI 10.1084/jem.153.2.310; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LORD JM, 1988, J MOL ENDOCRINOL, V1, P197, DOI 10.1677/jme.0.0010197; MARQUEZ C, 1989, J IMMUNOL, V142, P3187; Mishell B.B., 1980, SELECTED METHODS CEL, P23; OLSEN T, 1988, J BIOL CHEM, V263, P7342; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PARKER CW, 1987, METHOD ENZYMOL, V150, P29; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROHILLA AMK, 1991, BIOCHEM BIOPH RES CO, V175, P520, DOI 10.1016/0006-291X(91)91595-4; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; ROUILLER DG, 1987, P NATL ACAD SCI USA, V84, P126, DOI 10.1073/pnas.84.1.126; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; Snow E.C., 1985, J IMMUNOL, V135, P776; SNOW EC, 1980, J IMMUNOL, V124, P739; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TOROSSIAN K, 1988, J BIOL CHEM, V263, P9353	52	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4207	4215						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440705				2022-12-25	WOS:A1993KN53300060
J	KONDO, T; KONISHI, F; INUI, H; INAGAMI, T				KONDO, T; KONISHI, F; INUI, H; INAGAMI, T			DIFFERING SIGNAL TRANSDUCTIONS ELICITED BY 3 ISOFORMS OF PLATELET-DERIVED GROWTH-FACTOR IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; FACTOR PDGF; B-CHAIN; A-CHAIN; INOSITOL 1,4,5-TRISPHOSPHATE; TYROSINE PHOSPHORYLATION; DNA-SYNTHESIS; DIACYLGLYCEROL; MITOGENESIS; RECEPTOR	The differing signal transductions elicited by three isoforms of platelet-derived growth factor (PDGF) were studied in cultured rat vascular smooth muscle cells (VSMC), which show different mitogenic responses to the three PDGF isoforms. PDGF-BB elicited a variety of cellular signals, including the phosphorylation on tyrosine of phospholipase C-gamma1 (PLC-gamma1) and the PDGF receptor, formation of inositol 1,4,5-trisphosphate and diacylglycerol, degradation of phosphoinositides (phosphatidylinositol, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-bisphosphate) and elevation of intracellular calcium ([Ca2+]i). However, PDGF-AB failed to show some of these signals, although it stimulated [H-3]thymidine incorporation to almost the same extent as PDGF-BB. Importantly, phosphorylation on tyrosine of the PLC-gamma1 was far less (<6.25%) in the case of PDGF-AB than that of PDGF-BB when assessed by immunoblotting. On the other hand, calcium ion entry from the extracellular medium was comparable in PDGF-AB- and PDGF-BB- stimulated VSMC. PDGF-AA, which did not stimulate [H-3]thymidine incorporation, failed to show any of these effects with the exception of diacylglycerol formation. These observations suggest that the three PDGF isoforms stimulate different signal transduction pathways and that calcium ion entry, but not tyrosine phosphorylation of PLC-gamma1, is essential for PDGF-induced mitogenesis in VSMC.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University			Inui, Hiroshi/C-7721-2011		NHLBI NIH HHS [HL-35323, HL-14192] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014192, R01HL035323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8799; DEUEL TF, 1983, CURR TOP CELL REGUL, V26, P51; EICHNER W, 1989, EUR J BIOCHEM, V185, P135, DOI 10.1111/j.1432-1033.1989.tb15094.x; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HMMACHER A, 1988, EUR J BIOCHEM, V176, P179; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; NILSSON J, 1985, ATHEROSCLEROSIS, V58, P109, DOI 10.1016/0021-9150(85)90059-0; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1990, FEBS LETT, V275, P95, DOI 10.1016/0014-5793(90)81447-V; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SHULTZ PJ, 1990, HYPERTENSION S1, V15, P176; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; THYBERG J, 1987, BIOL CELL, V60, P125, DOI 10.1111/j.1768-322X.1987.tb00552.x; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	44	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4458	4464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440728				2022-12-25	WOS:A1993KN53300093
J	WEERS, PMM; VANMARREWIJK, WJA; BEENAKKERS, AMT; VANDERHORST, DJ				WEERS, PMM; VANMARREWIJK, WJA; BEENAKKERS, AMT; VANDERHORST, DJ			BIOSYNTHESIS OF LOCUST LIPOPHORIN - APOLIPOPHORIN-I AND APOLIPOPHORIN-II ORIGINATE FROM A COMMON PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SOUTHWESTERN CORN-BORER; MANDUCA-SEXTA; MOSQUITO VITELLOGENIN; INSECT APOLIPOPROTEIN; MONOCLONAL-ANTIBODIES; DIATRAEA-GRANDIOSELLA; MIGRATORY LOCUST; TOBACCO HORNWORM; LIPID TRANSPORT	Biosynthesis of apolipophorins of high density lipophorin of the locust Locusta migratoria was studied in vitro. Analysis of immunoprecipitates from homogenates of in vitro labeled fat body revealed a common precursor for apolipophorin I (apoLp-I, M(r) 220,000) and apolipophorin II (apoLp-II, M(r) 72,000) with a molecular mass of approximately 280 kDa. Pulse-chase experiments showed that this high molecular mass precursor is cleaved into apoLp-I and apoLp-II which subsequently are secreted as high density lipophorin from the fat body. The time required for the complete synthesis and secretion was estimated to be approximately 35 min. Both apolipophorins are glycoproteins as demonstrated by the incorporation of [H-3]mannose. Treatment of [H-3]mannose-labeled apolipophorin with endoglycosidase H resulted in the complete removal of the incorporated [H-3]mannose. Endoglycosidase H treatment of [H-3]leucine-labeled apolipophorins caused a reduction in molecular mass of approximately 3 kDa for apoLp-I and 3.5 kDa for apoLp-II, suggesting the N-linked carbohydrate content to be 1-2 and 5%, respectively. Incubation of fat body tissue in the presence of low concentrations of tunicamycin led to the synthesis and release of nonglycosylated apolipophorins.			WEERS, PMM (corresponding author), UNIV UTRECHT,DEPT EXPTL ZOOL,BIOCHEM PHYSIOL RES GRP,8 PADUALAAN,3508 TB UTRECHT,NETHERLANDS.							BEENAKKERS AMT, 1985, PROG LIPID RES, V24, P19; BOSE SG, 1988, BIOCHEM BIOPH RES CO, V155, P436, DOI 10.1016/S0006-291X(88)81105-7; CHINO H, 1986, J LIPID RES, V27, P377; CHINO H, 1981, J LIPID RES, V22, P1042; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; COLE KD, 1987, J BIOL CHEM, V262, P11794; DELLACIOPPA G, 1987, INSECT BIOCHEM, V17, P401, DOI 10.1016/0020-1790(87)90002-3; DHADIALLA TS, 1990, J BIOL CHEM, V265, P9924; KANOST MR, 1988, J BIOL CHEM, V263, P10568; KASHIWAZAKI Y, 1985, ARCH BIOCHEM BIOPHYS, V237, P160, DOI 10.1016/0003-9861(85)90265-6; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; NAGAO E, 1987, J LIPID RES, V28, P450; NAGAO E, 1987, INSECT BIOCHEM, V17, P531, DOI 10.1016/0020-1790(87)90051-5; OSIR EO, 1986, ARCH INSECT BIOCHEM, V3, P217, DOI 10.1002/arch.940030302; PRASAD SV, 1986, J BIOL CHEM, V261, P7174; RAIKHEL AS, 1986, J INSECT PHYSIOL, V32, P879, DOI 10.1016/0022-1910(86)90103-4; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1990, INSECT BIOCHEM, V20, P127, DOI 10.1016/0020-1790(90)90004-E; RYAN RO, 1984, ARCH INSECT BIOCHEM, V1, P375, DOI 10.1002/arch.940010408; SCHULZ TKF, 1987, ARCH INSECT BIOCHEM, V6, P97, DOI 10.1002/arch.940060204; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHAPIRO JP, 1984, J BIOL CHEM, V259, P3680; SHELBY KS, 1990, INSECT BIOCHEM, V20, P517, DOI 10.1016/0020-1790(90)90034-R; SHELBYKS, 1991, ARCH INSECT BIOCH PH, V18, P203; SURHOLT B, 1992, BIOL CHEM H-S, V373, P13, DOI 10.1515/bchm3.1992.373.1.13; VANDERHORST DJ, 1991, EUR J BIOCHEM, V196, P509; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; VANDERHORST DJ, 1987, INSECT BIOCHEM, V17, P799, DOI 10.1016/0020-1790(87)90014-X; VANHEUSDEN MC, 1987, INSECT BIOCHEM, V17, P771, DOI 10.1016/0020-1790(87)90048-5; VENKATESH K, 1987, INSECT BIOCHEM, V17, P1173, DOI 10.1016/0020-1790(87)90090-4; WEERS PMM, 1992, J LIPID RES, V33, P485; WYATT GR, 1988, CAN J ZOOL, V66, P2600, DOI 10.1139/z88-384	32	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4300	4303						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440714				2022-12-25	WOS:A1993KN53300071
J	WHINNA, HC; CHOI, HU; ROSENBERG, LC; CHURCH, FC				WHINNA, HC; CHOI, HU; ROSENBERG, LC; CHURCH, FC			INTERACTION OF HEPARIN COFACTOR-II WITH BIGLYCAN AND DECORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; ARTICULAR-CARTILAGE; FIBRILLAR COLLAGEN; ENDOTHELIAL-CELLS; ANTITHROMBIN-III; BOVINE; FIBRONECTIN; THROMBIN; FIBROBLASTS; ACTIVATION	Two small interstitial dermatan sulfate-containing proteoglycans, biglycan and decorin, are present in extracellular matrices of skin, tendon, ligament, and cartilage. We investigated the effects of biglycan and decorin on the inhibition of alpha-thrombin by the serine proteinase inhibitor heparin cofactor II. In solution, heparin cofactor II inhibition of thrombin is accelerated by intact biglycan or decorin and by the dermatan sulfate-containing glycosaminoglycan (GAG) chains prepared from the proteoglycans, while core protein from cartilage biglycan had no effect. L-Iduronic acid-rich skin decorin and GAG chains had a greater accelerating effect than proteoglycan and GAG chains from cartilage that had lower L-iduronic acid content. Treatment of skin decorin and GAG chains with chondroitinase ABC totally eliminated the ability of these compounds to accelerate thrombin inhibition by heparin cofactor II suggesting that dermatan sulfate was responsible for this action. Both biglycan and decorin bound to type V collagen in a saturable and specific manner. Biglycan, decorin, and core protein from biglycan competed for decorin binding to the type V collagen, while only the intact proteoglycans competed for biglycan binding. When bound to type V collagen, both biglycan and decorin accelerated the heparin cofactor II/thrombin inhibition reaction as efficiently as the proteoglycans in solution. Our results demonstrate that heparin cofactor II in the presence of biglycan or decorin bound to type V collagen provides a ''thromboresistant surface,'' further suggesting a physiological function for these proteins in regulating the extravascular activities of thrombin.	UNIV N CAROLINA, SCH MED,DEPT PATHOL,DIV HEMATOL,CAMPUS BOX 7035, 416 BURNETT WOMACK, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA; MONTEFIORE MED CTR, ORTHOPED RES LABS, BRONX, NY 10467 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM021498] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32656] Funding Source: Medline; NIADDK NIH HHS [AM HD-21498] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREW M, 1992, J CLIN INVEST, V89, P321, DOI 10.1172/JCI115579; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHURCH FC, 1991, J BIOL CHEM, V266, P704; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Fessler J.H., 1987, TYPE 5 COLLAGEN, P81; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOFFMAN M, 1989, BLOOD, V73, P1682; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10	29	106	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3920	3924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440685				2022-12-25	WOS:A1993KN53300022
J	MAZZORANA, M; GRUFFAT, H; SERGEANT, A; VANDERREST, M				MAZZORANA, M; GRUFFAT, H; SERGEANT, A; VANDERREST, M			MECHANISMS OF COLLAGEN TRIMER FORMATION - CONSTRUCTION AND EXPRESSION OF A RECOMBINANT MINIGENE IN HELA-CELLS REVEALS A DIRECT EFFECT OF PROLYL HYDROXYLATION ON CHAIN ASSEMBLY OF TYPE-XII COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROCOLLAGEN-MESSENGER-RNA; TRIPLE-HELIX; TRANS ISOMERIZATION; ASCORBIC-ACID; PEPTIDE-BONDS; II COLLAGEN; IX COLLAGEN; CARTILAGE; STIMULATION; INCELLULO	Collagen types IX, XII, and XIV are characterized by the presence of a highly conserved region comprising the most C-terminal triple helical domain (COL1, approximately 100 residues/chain) and 2 cysteines separated by 4 amino acid residues at the junction between this COL1 domain and the C-terminal non-triple helical domain (NC1). In order to better understand the functions of this conserved domain, we have constructed a recombinant minigene, comprising the sequence coding for an unrelated signal peptide and for the COL1 and NC1 domains of type XII collagen. This construct was placed under the control of the cytomegalovirus promoter and transfected into HeLa cells. The cells expressed the transfected minigene and the secreted chain, called alpha1(mini XII), could be detected by immunotransfer with an anti-peptide antibody recognizing an epitope found in the NC 1 domain. Under conditions preventing the hydroxylation of prolyl residues (absence of ascorbate or presence of alphaalpha'-dipyridyl), interchain disulfide bridges did not form, while in the presence of ascorbate, disulfide-bonded (alpha1(mini XII))3 molecules were secreted. The collagenous nature and triple helical conformation of the trimeric molecule were ascertained by the differential resistances of the COL1 and NC1 domains to trypsin and collagenase digestions, respectively. Our data demonstrate that the NC1 and COL1 domains of type XII collagen contain the information necessary for trimer formation and that, contrary to the fibrillar collagen types, posttranslational modification of the triple helical domain is essential for assembly and disulfide bonding of the chains.	ECOLE NORMAL SUPER LYON,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)	MAZZORANA, M (corresponding author), INST BIOL & CHIM PROT,PASSAGE DU VERCORS,F-69367 LYON 07,FRANCE.		Gruffat, Henri/I-2407-2016	Gruffat, Henri/0000-0002-4735-6894; MAZZORANA, Marlene/0000-0002-3956-4319				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; CHOJKIER M, 1989, J BIOL CHEM, V264, P16957; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUBLET B, 1987, J BIOL CHEM, V262, P17724; DUBLET B, 1988, FEBS LETT, V233, P177, DOI 10.1016/0014-5793(88)81379-6; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FURTH JJ, 1991, EXP CELL RES, V192, P118, DOI 10.1016/0014-4827(91)90165-Q; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; GORDON MK, 1990, ANN NY ACAD SCI, V508, P8; GORDON MK, 1989, J BIOL CHEM, V264; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; OLSEN BR, 1989, COLLAGEN BIOCH BIOTE, P1; SCHWARZ RI, 1978, J CELL BIOL, V79, P672, DOI 10.1083/jcb.79.3.672; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SUGRUE SP, 1989, INVEST OPHTH VIS SCI, V32, P1876; TAJIMA S, 1982, BIOCHEM BIOPH RES CO, V106, P632, DOI 10.1016/0006-291X(82)91157-3; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	30	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3029	3032						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428977				2022-12-25	WOS:A1993KM16100004
J	SINHA, U; WOLF, DL				SINHA, U; WOLF, DL			CARBOHYDRATE RESIDUES MODULATE THE ACTIVATION OF COAGULATION FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE FACTOR-X; BLOOD-COAGULATION	Factor X is a plasma protein involved in both the intrinsic and extrinsic pathways of blood coagulation. Post-translational modifications of the protein involve gamna-carboxylation of specific glutamic acid residues, beta-hydroxylation of one aspartic acid residue, and N- and O-linked glycosylation. Even though it is known that gamma-carboxylation is instrumental in regulating biological activity, the role of glycosylation in the function and properties of factor X has not been previously investigated. We utilized lectin binding and glycosidase treatment to investigate the functional role of carbohydrates on the activation peptide of factor X. Sambucus nigra agglutinin, a lectin that binds to sialic acid terminally linked alpha(2-6) to galactose or N-acetyl-galactosamine inhibits activation of human factor X in a dose-dependent manner. Inhibition of activation was observed for both intrinsic (factor IXa/VIIIa) and extrinsic (factor VIIa/tissue factor) pathway complexes. In accordance with this, selective removal of sialic acid residues on the activation peptide of factor X by neuraminidase also results in a drastic reduction of activation of the zymogen by these complexes. Corresponding reduction of activity in classical clotting assays (activated partial thromboplastin time and prothrombin time) also agrees with this observation. These results suggest a possible role of N-linked carbohydrates in the activation of factor X.			SINHA, U (corresponding author), COR THERAPEUT INC,256 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P250; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; MORITA T, 1986, J BIOL CHEM, V261, P4015; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1972, J BIOL CHEM, V247, P8160; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WOLF DL, 1991, J BIOL CHEM, V266, P13726	13	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3048	3051						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428982				2022-12-25	WOS:A1993KM16100009
J	RON, D; BOTTARO, DP; FINCH, PW; MORRIS, D; RUBIN, JS; AARONSON, SA				RON, D; BOTTARO, DP; FINCH, PW; MORRIS, D; RUBIN, JS; AARONSON, SA			EXPRESSION OF BIOLOGICALLY-ACTIVE RECOMBINANT KERATINOCYTE GROWTH-FACTOR - STRUCTURE-FUNCTION ANALYSIS OF AMINO-TERMINAL TRUNCATION MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HEPARIN-BINDING; ENZYMATIC AMPLIFICATION; 3-DIMENSIONAL STRUCTURE; RECEPTOR-BINDING; FACTOR-I; FIBROBLAST; POLYMERASE; PROTEINS; AFFINITY	Keratinocyte growth factor (KGF) is a newly identified member of the fibroblast growth factor (FGF) family (FGF-7). KGF is expressed by stromal fibroblasts and acts on epithelial cells in a paracrine mode. To facilitate structure/function studies, we utilized the T7 prokaryotic expression system to synthesize this growth factor. Recombinant KGF (rKGF) was mitogenic with a specific activity around 10-fold higher than native KGF. By in vitro mutagenesis, we generated a series of KGF mutants with sequential deletions of the amino-terminal domain, the most divergent region among different FGF members. Mutant proteins, produced in bacteria, were tested for their ability to bind heparin, bind and activate the KGF receptor, and induce DNA synthesis. Heparin binding properties were preserved with deletion of up to 28 amino-terminal residues of the mature KGF but lost by the deletion of an additional 10 residues. Biological activity of mutants with deletions of up to 10 residues was comparable to that of rKGF. However, deletion of 29 residues resulted in significantly reduced ability to stimulate KGF receptor tyrosine-kinase activity and DNA synthesis, although this mutant bound the receptor at high affinity. These characteristics of a partial agonist may be useful in the development of competitive antagonists of KGF action.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; GOSPODAROWICZ D, 1990, J CELL PHYSIOL, V142, P325, DOI 10.1002/jcp.1041420215; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; MANIATIS T, 1982, MOL CLONING LABORATO, pA2; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PASQUALE DB, 1988, MOL CELL BIOL, V8, P2933; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	31	102	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2984	2988						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428972				2022-12-25	WOS:A1993KK81500106
J	YEPIZPLASCENCIA, GM; HO, CM; MARTEL, RR; LAW, JH				YEPIZPLASCENCIA, GM; HO, CM; MARTEL, RR; LAW, JH			MOLECULAR-CLONING AND SEQUENCE OF A NOVEL OMMOCHROME-BINDING PROTEIN CDNA FROM AN INSECT, MANDUCA-SEXTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM; DNA; SIMILARITY; PROGRAMS; ACID	An ommochrome-binding protein (OBP) from the hemolymph of Manduca sexta has recently been purified and characterized. A cDNA clone was isolated from a fifth instar larval cDNA expression library utilizing antiserum against OBP. Northern blot analysis of total fat body RNA detected a transcript of approximately 1.2 kilobases in fifth instar wandering larvae RNA. The complete nucleotide sequence of the 905-base pair cDNA insert was determined by the dideoxy chain termination method. The OBP cDNA encodes a polypeptide of 274 residues with a predicted molecular weight of 30,580 and with one consensus N-linked glycosylation site. Comparison of the NH2-terminal sequence of the mature protein and the cDNA sequence revealed a typical signal peptide of 18 amino acids. In wandering stage larvae, the OBP transcript appeared to be at least 250-fold less abundant than ribosomal RNA.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; NATL YANG MING MED COLL,DEPT PARASITOL,TAIPEI 11221,TAIWAN	University of Arizona; University of Arizona; National Yang Ming Chiao Tung University			Yepiz, Gloria/ABE-1101-2020	Yepiz-Plascencia, Gloria/0000-0001-5730-4011	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29238] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTFELD NS, 1990, J BIOL CHEM, V265, P21684; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOURNEY RM, 1987, FOCUS, V10, P5; GALE K, 1989, EUR J BIOCHEM, V185, P311, DOI 10.1111/j.1432-1033.1989.tb15117.x; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Kayser H., 1985, P367; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MARTEL RR, 1992, INSECT BIOCHEM MOLEC, V22, P561, DOI 10.1016/0965-1748(92)90033-B; MARTEL RR, 1991, J BIOL CHEM, V266, P21392; MARTEL RR, 1991, THESIS U ARIZONA; MOUNT DW, 1986, NUCLEIC ACIDS RES, V14, P443, DOI 10.1093/nar/14.1.443; PRASAD SV, 1986, J BIOL CHEM, V261, P7174; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WANG X, 1988, J BIOL CHEM, V263, P8851	21	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2337	2340						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428907				2022-12-25	WOS:A1993KK81500016
J	RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW				RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW			P53 CONFERS A SELECTIVE ADVANTAGE ON TRANSFECTED HELA-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; CDNA CLONE; TRANSFORMATION; GROWTH; GENE; EXPRESSION; ANTIGEN; MOUSE	The p53 gene, which is frequently mutated in various tumors, encodes a phosphoprotein thought to have a key role in the regulation of cell proliferation. To explore their biological effects, the HeLa carcinoma line, which does not express p53, was co-transfected with plasmid constructs expressing wild-type or mutant p53 proteins, or unrelated proteins, along with a plasmid conferring resistance to a neomycin-kanamycin antibiotic analog (G418). Both wild-type and mutant forms of p53 stimulated the number of G418-resistant colonies between 5- and 36-fold. Further investigation of colony development revealed that p53 enhanced cell survival, leading to increased colony numbers, but did not stimulate cell growth. Nonetheless, we suggest that an initial slowing of cell growth caused by expression of the unintegrated p53 plasmids renders the transfectants resistant to selection with G418, thus causing a higher frequency of G418-resistant colonies. p53 constructs were found to be expressed transiently in HeLa cells as expected, but the G418-resistant colonies frequently failed to express p53. This loss of p53 expression may be due to negative regulatory effects of p53 on the cytomegalovirus promoter that drives the selection marker.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHOHAT O, 1987, ONCOGENE, V1, P277; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	29	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1069	1074						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455934				2022-12-25	WOS:A1993KT22000032
J	GRAVES, PR; HAAS, DW; HAGEDORN, CH; DEPAOLIROACH, AA; ROACH, PJ				GRAVES, PR; HAAS, DW; HAGEDORN, CH; DEPAOLIROACH, AA; ROACH, PJ			MOLECULAR-CLONING, EXPRESSION, AND CHARACTERIZATION OF A 49-KILODALTON CASEIN KINASE-I ISOFORM FROM RAT TESTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GLYCOGEN-SYNTHASE; SUBSTRATE DETERMINANTS; NUCLEAR-LOCALIZATION; PURIFICATION; DNA; YEAST; RNA; PHOSPHORYLATE; INHIBITION	We report the molecular cloning and characterization of a 49-kDa form of casein kinase I from rat testis. A cDNA clone encoding the enzyme, designated casein kinase I delta, contained an open reading frame of 1284 nucleotides that predicts a polypeptide of 428 amino acids with a M(r) of 49,121. The predicted amino acid sequence shares 76% identity with casein kinase I alpha, a 37-kDa form recently cloned from bovine brain (Rowles, J., Slaughter, C., Moomaw, C., Hsu, J., and Cobb, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9548-9552), and 65% identity with HRR25, a 57-kDa form of casein kinase I from yeast shown to be involved in DNA repair (Hoekstra, M. F., Liskay, R. M., Ou, A. C., DeMaggio, A. J., Burbee, D. G., and Heffron, F. (1991) Science 253, 1031-1034). Northern analysis of rat or rabbit RNA revealed three hybridizing species of 3.5-4.1, 2.2, and 1.9 kilobase pairs (kb). The largest message was detected in all tissues examined, whereas the 1.9- and 2.2-kb species were found predominantly in testis. A probe corresponding to the 3'-untranslated region of the casein kinase I delta cDNA hybridized only to the 1.9-kb transcript. Expression of the casein kinase I delta cDNA in Escherichia coli resulted in active enzyme that phosphorylated casein, phosvitin, and the peptide substrate DDDDVASLPGLRRR. Enzyme activity was associated with a predominant polypeptide of 55-kDa, although COOH-terminal degradation products of 50 and 42 kDa were also present in partially purified enzyme. Recombinant casein kinase I delta was inhibited by the specific casein kinase I inhibitor, CKI-7, half-maximally at 12 muM. Heparin inhibited recombinant casein kinase I delta when phosvitin was the substrate, with half-maximal inhibition at 11.5 mug/ml. However, if the peptide substrate was used, heparin activated recombinant casein kinase I delta 4-5-fold, with half-maximal activation at 9.5 mug/ml. A truncated form of casein kinase I delta, lacking the COOH-terminal 111 amino acids, was no longer activated by heparin. Casein kinase I delta therefore represents a separate member of the casein kinase I family distinguished by its larger size and unique kinetic behavior with respect to heparin.	VET ADM MED CTR, NASHVILLE, TN 37203 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University; Vanderbilt University	GRAVES, PR (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.				NIDDK NIH HHS [DK27221, DK36569] Funding Source: Medline; NIGMS NIH HHS [GM 40219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK036569, R01DK027221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; AHMAD Z, 1982, J BIOL CHEM, V257, P8348; AHMAD Z, 1984, J BIOL CHEM, V259, P3420; BAYDOUN H, 1982, J BIOL CHEM, V257, P1032; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPECH M, 1986, EUR J BIOCHEM, V160, P333, DOI 10.1111/j.1432-1033.1986.tb09976.x; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DESJARDINS PR, 1972, CAN J BIOCHEM CELL B, V50, P1249, DOI 10.1139/o72-170; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE K, 1989, J NEUROSCI, V9, P1883; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; PINNA LA, 1989, PEPTIDES PROTEIN PHO, P145; PINNA LA, 1991, NATO ASI SER H, V56, P179; RIKANS LE, 1976, BIOCHIM BIOPHYS ACTA, V422, P73, DOI 10.1016/0005-2744(76)90009-7; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SINGH TJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P661, DOI 10.1016/0003-9861(88)90495-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THORNBURG W, 1978, J BIOL CHEM, V253, P4638; TRAKTMAN P, 1989, J BIOL CHEM, V264, P21458; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275	43	125	132	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6394	6401						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454611				2022-12-25	WOS:A1993KT36800048
J	PACKARD, BZ; KOMORIYA, A				PACKARD, BZ; KOMORIYA, A			A 36-KILODALTON TUMOR-DERIVED FACTOR WITH MYELOID IMMUNOMODULATORY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CANCER-THERAPY; IMMUNOLOGICAL SURVEILLANCE; CELLS; DEHYDROGENASE; CYTOKINES; DIFFERENTIATION; IMMUNOTHERAPY; CARCINOGENESIS; MACROPHAGES	The conditioned medium from the epidermal carcinoma cell line A431 is shown to inhibit the growth of three human myeloid leukemic cell lines. We have purified to homogeneity from this conditioned medium a 36-kDa protein, as measured hy sodium dodecyl sulfate-polyacrylamide gel electrophoresis, which inhibits [H-3]thymidine incorporation into the DNA and induces cell surface expression of CD11b, the alpha chain of the adhesion receptor MAC-1, on the human promyelocytic leukemic cell line HL-60. This factor was purified by sequential anion exchange, hydrophobic interaction, and gel permeation chromatography. Amino acid sequence analysis of two tryptic fragments of the purified material showed greater than 95% homology with sequences 179-194 and 319-328 of the M chain of human L-lactate dehydrogenase. Although the tetrameric L-lactate dehydrogenase alone exhibits no activities associated with the purified 36-kDa protein, brief acid treatment which has been shown to yield predominantly monomeric lactate dehydrogenase-M, results in about 50% of the maximal antiproliferative activity of that induced by this factor. The role of soluble factors of tumor origin in modulating myeloid function as part of an immunosurveillance network is discussed.			PACKARD, BZ (corresponding author), US FDA,CBER,DCB,BLDG 29A,ROOM 3B22,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALLISON AC, 1977, CANCER IMMUNOL IMMUN, V2, P151; ARNAOUT MA, 1990, BLOOD, V75, P1037; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BOLHUIS RLH, 1991, CANCER IMMUNOL IMMUN, V34, P1, DOI 10.1007/BF01741317; BOYKINS RA, 1982, J BIOCHEM BIOPH METH, V7, P55, DOI 10.1016/0165-022X(82)90036-7; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; BURNET FM, 1957, BRIT MED J, V1, P844; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DANA N, 1986, J IMMUNOL, V137, P3259; DENOTTER W, 1986, CANCER IMMUNOL IMMUN, V21, P85, DOI 10.1007/BF00199854; DIMOPOULOS MA, 1991, ANN INTERN MED, V115, P931, DOI 10.7326/0003-4819-115-12-931; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; EBERLEIN TJ, 1991, SURGERY, V110, P459; EDWARDS YH, 1977, ISOZYMES CURRENT TOP, V1, P19; EHRLICH P, 1957, COLLECTED PAPERS P E, P500; FREITAS I, 1990, ANTICANCER RES, V10, P613; GOLDENBERG DM, 1989, SEMIN NUCL MED, V19, P332, DOI 10.1016/S0001-2998(89)80025-X; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HIBBS JB, 1972, SCIENCE, V177, P998, DOI 10.1126/science.177.4053.998; IOANNIDES CG, 1989, ANTICANCER RES, V9, P535; JACOBS EL, 1991, CURR PROB CANCER, V15, P299; JAENICKE R, 1974, EUR J BIOCHEM, V46, P149, DOI 10.1111/j.1432-1033.1974.tb03607.x; KRIPKE ML, 1988, JNCI-J NATL CANCER I, V80, P722, DOI 10.1093/jnci/80.10.722; LOTEM J, 1989, ANN NY ACAD SCI, V557, P417; MAKISHIMA M, 1991, LEUKEMIA RES, V15, P701, DOI 10.1016/0145-2126(91)90072-2; MAKISHIMA M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P1, DOI 10.1016/0167-4889(91)90019-T; MARKERT CL, 1968, ANN NY ACAD SCI, V151, P14, DOI 10.1111/j.1749-6632.1968.tb11876.x; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MORIKAWA K, 1989, J BIOL RESP MODIF, V8, P206; NISHIKAWA A, 1991, BRIT J CANCER, V63, P819, DOI 10.1038/bjc.1991.181; OETTGEN HF, 1991, CURR OPIN IMMUNOL, V3, P699, DOI 10.1016/0952-7915(91)90099-M; OETTGEN HF, 1990, J CANCER RES CLIN, V116, P116, DOI 10.1007/BF01612653; PACKARD B, 1989, TRENDS BIOTECHNOL, V7, P78, DOI 10.1016/0167-7799(89)90002-4; PACKARD B, 1985, TRENDS BIOCHEM SCI, V10, P378, DOI 10.1016/0968-0004(85)90057-X; PACKARD BS, 1990, P NATL ACAD SCI USA, V87, P4058, DOI 10.1073/pnas.87.11.4058; PACKARD BS, 1990, PROGR REGIONAL CANCE, P293; PACKARD BZ, 1992, FASEB J, V6, pA1695; PREHN RT, 1987, INT J CANCER, V39, P106, DOI 10.1002/ijc.2910390119; Quesada J R, 1989, Tex Med, V85, P42; REIZENSTEIN P, 1985, BIOMED PHARMACOTHER, V39, P1; ROSENBERG SA, 1989, CANCER TREAT REV, V16, P115, DOI 10.1016/0305-7372(89)90031-5; ROSS GD, 1985, J IMMUNOL, V134, P3307; SCHWARTZ MK, 1992, CLIN CHIM ACTA, V206, P77, DOI 10.1016/0009-8981(92)90008-E; SIKORA K, 1991, BRIT MED BULL, V47, P209, DOI 10.1093/oxfordjournals.bmb.a072456; SONDEL PM, 1989, CRIT REV ONCOL HEMAT, V9, P125, DOI 10.1016/S1040-8428(89)80008-3; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TAKAHASHI N, 1989, J BIOL CHEM, V264, P15624; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; THOMAS L, 1959, CELLULAR HUMORAL ASP, P519; TSUJIBO H, 1985, EUR J BIOCHEM, V147, P9, DOI 10.1111/j.1432-1033.1985.tb08711.x; URBAN JL, 1988, PROG EXP TUMOR RES, V32, P17; VALLEE RB, 1975, BIOCHEMISTRY-US, V14, P2574, DOI 10.1021/bi00683a003; WERTHAMER S, 1973, CLIN CHIM ACTA, V45, P5, DOI 10.1016/0009-8981(73)90137-X; WONG JH, 1989, SEMIN SURG ONCOL, V5, P448, DOI 10.1002/ssu.2980050612; YARBRO JW, 1991, SEMIN SURG ONCOL, V7, P183, DOI 10.1002/ssu.2980070403	57	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6356	6363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454606				2022-12-25	WOS:A1993KT36800043
J	CHEN, YH; BOGENHAGEN, DF				CHEN, YH; BOGENHAGEN, DF			EFFECTS OF DNA LESIONS ON TRANSCRIPTION ELONGATION BY T7 RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR MECHANICS CALCULATIONS; PSORALEN CROSS-LINK; MUTATION HOT-SPOT; ESCHERICHIA-COLI; ABASIC SITE; TRANSLESION SYNTHESIS; IONIZING-RADIATION; PROTON NMR; INVITRO; AMINOFLUORENE	T7 phage RNA polymerase was used to transcribe a series of DNA templates bearing any of several precisely localized lesions. Lesions were positioned downstream of the T7 promoter on either strand of the DNA template to investigate the effects of these lesions on elongation of transcription. The following four types of DNA modifications were studied: 1) 3-hydroxy-2-hydroxymethyltetrahydrofuran (tetrahydrofuran), a synthetic apurinic/apyrimidinic site; 2) 8-oxoguanine (8-oxodG), an oxidized derivative of guanine; 3) N-acetyl-2-aminofluorene (AAF) modified guanine; 4) 2-aminofluorene (AF) modified guanine. None of these lesions blocked transcription elongation when they were located on the non-template strand. Lesions on the template strand blocked elongation with varied efficiency. The series of AAF-dG, AF-dG, and tetrahydrofuran lesions showed a progressively decreasing ability to block elongation, while 8-oxo-dG caused little, if any, premature termination. T7 RNA polymerase was able to read through all of the lesions with sufficient efficiency to permit chain termination sequencing using the read-through products as templates. AAF-dG and AF-dG adducts did not induce detectable misreading. Adenine and, more rarely, cytosine were incorporated opposite 8-oxo-dG, as observed for translesional synthesis by DNA polymerases. Adenine was most commonly inserted opposite the non-instructional abasic site analogue, although a minor fraction of guanine was incorporated.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04068] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BELGUISEVALLADIER P, 1991, BIOCHEMISTRY-US, V30, P10091, DOI 10.1021/bi00106a005; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; Chamberlin M., 1982, ENZYMES, V15, P87; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; CUNIASSE P, 1989, BIOCHEMISTRY-US, V28, P2018, DOI 10.1021/bi00431a009; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FLOYD RA, 1989, ARCH BIOCHEM BIOPHYS, V273, P106, DOI 10.1016/0003-9861(89)90167-7; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GRUNBERGER D, 1982, MECHANISMS CHEM CARC, P155; GUPTA PK, 1989, J BIOL CHEM, V264, P20120; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KOHDA K, 1990, CHEM PHARM BULL, V38, P3072, DOI 10.1248/cpb.38.3072; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAELS ML, 1991, CARCINOGENESIS, V12, P1641, DOI 10.1093/carcin/12.9.1641; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; MOORE PD, 1982, P NATL ACAD SCI-BIOL, V79, P7166, DOI 10.1073/pnas.79.23.7166; MOORE PD, 1980, NUCLEIC ACIDS RES, V8, P4474; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NATH ST, 1991, CARCINOGENESIS, V12, P973, DOI 10.1093/carcin/12.6.973; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAHM J, 1989, BIOCHEMISTRY-US, V28, P2836, DOI 10.1021/bi00433a014; SASTRY SS, 1991, J MOL BIOL, V221, P1111, DOI 10.1016/0022-2836(91)80115-B; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SHI YB, 1988, J BIOL CHEM, V263, P527; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	47	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5849	5855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449951				2022-12-25	WOS:A1993KR82200074
J	ESCALANTE, C; YANG, DCH				ESCALANTE, C; YANG, DCH			EXPRESSION OF HUMAN ASPARTYL-TRANSFER RNA-SYNTHETASE IN ESCHERICHIA-COLI - FUNCTIONAL-ANALYSIS OF THE N-TERMINAL PUTATIVE AMPHIPHILIC HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSYL-TRANSFER RNA; MOLECULAR-WEIGHT COMPLEXES; RAT-LIVER; SHEEP LIVER; DIADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE; NH2-TERMINAL EXTENSION; MULTIENZYME COMPLEX; PURIFICATION; YEAST; PROTEOLYSIS	Mammalian aspartyl-tRNA synthetase occurs in the multienzyme complex of aminoacyl-tRNA synthetases, while bacterial and yeast aspartyl-tRNA synthetases exist as free soluble enzymes. Cloning and sequencing of mammalian aspartyl-tRNA synthetase revealed a newly evolved N-terminal 32-amino-acid sequence, which contains a putative amphiphilic helix (Jacobo-Molina, A., Peterson, R., and Yang, D. C. H. (1989) J. Biol. Chem. 264, 16608-16612). Human aspartyl-tRNA synthetase (hDRS) and an N-terminal 32-residue truncated form of human aspartyl-tRNA synthetase (hDRSDELTA32) were expressed in Escherichia coli under the control of the inducible tac promoter as glutathione-S-transferase (GST) fusion proteins linked through a thrombin cleavage site. The GST-hDRS fusion protein and the GST-hDRSDELTA32 were purified by affinity chromatography on glutathione-agarose and were fully active in aspartylation of mammalian tRNA. After cleavage of GST from the fusion proteins by thrombin, hDRS and hDRSDELTA32 were purified by affinity chromatography on tRNA-Sepharose. Both hDRS and hDRSDELTA32 were present as a mixture of monomeric and dimeric forms. GST-hDRS formed high molecular weight aggregates while GST-hDRSDELTA32 was a dimeric protein. Both hDRS and hDRSDELTA32 bound to hydrophobic interaction gels such as aminohexyl-agarose. In the absence of propylene glycol, hDRS bound to aminohexyl-agarose weaker than hDRSDELTA32, but, in the presence of 50% propylene glycol, hDRS bound tighter than hDRSDELTA32. Both hDRS and hDRSDELTA32 were fully active in aspartylation of mammalian tRNA and ATP-PP(i) exchange. In comparison to the N-terminal truncated form, the full-length enzyme showed greater thermal stability and ATP-PP(i) exchange activity but lower aminoacylation activity. The catalytic constant of hDRSDELTA32 for aminoacylation of tRNA was 2-fold higher than that of hDRS. The Michaelis-Menten constants for aspartic acid and tRNA(Asp) were 302 muM and 13 nm for hDRS, and 29 muM and 130 nM for hDRSDELTA32, respectively. These results suggest that the newly evolved N-terminal peptide in hDRS may modulate the enzymatic activity, the stability, and the chromatographic behavior of hDRS. The structure and function of the N-terminal peptide in aspartyl-tRNA synthetase and in the synthetase complex will be discussed.	GEORGETOWN UNIV, DEPT CHEM, WASHINGTON, DC 20057 USA	Georgetown University			Yang, David/A-7294-2009		NIGMS NIH HHS [GM-25848] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS PF, 1976, P NATL ACAD SCI USA, V73, P3857, DOI 10.1073/pnas.73.11.3857; BANDYOPADHYAY AK, 1973, J MOL BIOL, V74, P257, DOI 10.1016/0022-2836(73)90112-5; Bose K K, 1974, Methods Enzymol, V29, P522; BREVET A, 1982, J BIOL CHEM, V257, P4613; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; DANG CV, 1985, BIOCHIM BIOPHYS ACTA, V829, P319, DOI 10.1016/0167-4838(85)90239-0; DANG CV, 1982, INT J BIOCHEM, V14, P539, DOI 10.1016/0020-711X(82)90030-1; DANG CV, 1979, J BIOL CHEM, V254, P5350; DANG CV, 1982, BIOCHEMISTRY-US, V21, P4891; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ESCALANTE C, 1991, FASEB J, V5, pA1200; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; HUANG ST, 1991, BIOCHEM BIOPH RES CO, V180, P702, DOI 10.1016/S0006-291X(05)81122-2; JACOBOMOLINA A, 1988, FEBS LETT, V232, P65, DOI 10.1016/0014-5793(88)80387-9; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JOHNSON DL, 1980, J BIOL CHEM, V255, P4362; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; KELLERMANN O, 1978, EUR J BIOCHEM, V88, P197, DOI 10.1111/j.1432-1033.1978.tb12438.x; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOORE PA, 1977, J BIOL CHEM, V252, P7427; PAILLIEZ JP, 1984, J BIOL CHEM, V259, P5491; PREVOST G, 1989, EUR J BIOCHEM, V180, P351, DOI 10.1111/j.1432-1033.1989.tb14655.x; REMY P, 1972, FEBS LETT, V27, P134, DOI 10.1016/0014-5793(72)80426-5; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARISKY V, 1991, BIOCHEM BIOPH RES CO, V177, P757, DOI 10.1016/0006-291X(91)91853-5; SAXHOLM HJK, 1979, BIOCHIM BIOPHYS ACTA, V562, P386, DOI 10.1016/0005-2787(79)90103-5; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SELLAMI M, 1985, GENE, V40, P349, DOI 10.1016/0378-1119(85)90060-5; SIDDIQUI FA, 1985, BIOCHIM BIOPHYS ACTA, V828, P177, DOI 10.1016/0167-4838(85)90055-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TING SM, 1992, J BIOL CHEM, V267, P17701; VELLEKAMP G, 1987, J BIOL CHEM, V262, P9927; VELLEKAMP GJ, 1983, J BIOL CHEM, V258, P8195; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; WAHAB SZ, 1985, J BIOL CHEM, V260, P5286; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5	49	25	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6014	6023						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449960				2022-12-25	WOS:A1993KR82200097
J	KASPI, CI; SIEDOW, JN				KASPI, CI; SIEDOW, JN			CROSS-LINKING OF THE CMS-T MAIZE MITOCHONDRIAL PORE-FORMING PROTEIN URF13 BY N,N'-DICYCLOHEXYLCARBODIIMIDE AND ITS EFFECT ON URF13 SENSITIVITY TO FUNGAL TOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAYDIS RACE-T; MALE-STERILE CYTOPLASM; SUSCEPTIBLE CORN MITOCHONDRIA; ESCHERICHIA-COLI; MAYS L; METHOMYL; DICYCLOHEXYLCARBODIIMIDE; MEMBRANES; ZEA	URF13 is a membrane protein unique to mitochondria from maize having the Texas male-sterile cytoplasm (cms-T), which is capable of permeabilizing biological membranes in the presence of a family of pathotoxins (T-toxins) produced by certain fungi or the insecticide methomyl. The carboxylate-specific reagent dicyclohexylcarbodiimide has been shown previously to protect URF13-containing membranes against the permeabilizing effects of added T-toxin or methomyl. Dicyclohexylcarbodiimide was found to covalently cross-link URF13 into higher order oligomers, including dimers, trimers, and tetramers, in isolated cms-T mitochondria and Escherichia coli cells expressing URF13. In intact E. coli cells and isolated spheroplasts, the observed protection against the effects of methomyl was not associated with the appearance of dimers but was correlated with the appearance of cross-linked trimers and tetramers. Following treatment of E. coli cells expressing URF13 with dicyclohexylcarbodiimide, the specific binding of tritiated T-toxin was reduced by 50% and all binding cooperativity was lost. A similar decrease in the level of T-toxin binding and loss of binding cooperativity were observed with site-directed, T-toxin-insensitive URF13 mutants at aspartate 39, the residue known to undergo reaction with dicyclohexylcarbodiimide. When coupled with a postulated three membrane-spanning helical model of URF13, these results provide initial insights into the intermolecular interactions involved in URF13 oligomer formation.	DUKE UNIV,DEPT BOT,BOX 90338,DURHAM,NC 27708	Duke University								ALBER T, 1989, PREDICTION PROTEIN S, P161; BEDNARSKI MA, 1977, PLANT PHYSIOL, V59, P540, DOI 10.1104/pp.59.4.540; BERVILLE A, 1984, PLANT PHYSIOL, V76, P508, DOI 10.1104/pp.76.2.508; BOUTHYETTE PY, 1985, J EXP BOT, V36, P511, DOI 10.1093/jxb/36.3.511; BRAUN CJ, 1990, PLANT CELL, V2, P153, DOI 10.1105/tpc.2.2.153; BRAUN CJ, 1989, P NATL ACAD SCI USA, V86, P4435, DOI 10.1073/pnas.86.12.4435; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CRAMER WA, 1983, BIOCHIM BIOPHYS ACTA, V737, P173, DOI 10.1016/0304-4157(83)90016-3; DAVIDSON VL, 1984, J MEMBRANE BIOL, V79, P105, DOI 10.1007/BF01872115; DEWEY RE, 1987, P NATL ACAD SCI USA, V84, P5374, DOI 10.1073/pnas.84.15.5374; DEWEY RE, 1988, SCIENCE, V239, P293, DOI 10.1126/science.3276005; DEWEY RE, 1986, CELL, V44, P439, DOI 10.1016/0092-8674(86)90465-4; FORDE BG, 1980, P NATL ACAD SCI-BIOL, V77, P418, DOI 10.1073/pnas.77.1.418; FORDE BG, 1978, P NATL ACAD SCI USA, V75, P3841, DOI 10.1073/pnas.75.8.3841; HACK E, 1991, PLANT PHYSIOL, V95, P861, DOI 10.1104/pp.95.3.861; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLDEN MJ, 1989, PLANT PHYSIOL, V91, P1296, DOI 10.1104/pp.91.4.1296; HOLDEN MJ, 1984, PLANT PHYSIOL, V75, P235, DOI 10.1104/pp.75.1.235; HOLDEN MJ, 1987, PLANT MITOCHONDRIA S, P305; HUMAYDAN HS, 1977, HORTSCIENCE, V12, P312; KLEIN RR, 1985, PLANT PHYSIOL, V77, P912, DOI 10.1104/pp.77.4.912; KORTH KL, 1991, P NATL ACAD SCI USA, V88, P10865, DOI 10.1073/pnas.88.23.10865; LEVINGS CS, 1990, SCIENCE, V250, P942, DOI 10.1126/science.250.4983.942; LEVINGS CS, 1992, PLANT MOL BIOL, V19, P134; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS DE, 1979, PLANT PHYSIOL, V63, P1149, DOI 10.1104/pp.63.6.1149; NALECZ MJ, 1986, METHOD ENZYMOL, V125, P86; SPACH G, 1983, PHYSICAL CHEM TRANSM, P375; STEGINK SJ, 1986, PLANT PHYSIOL, V80, P196, DOI 10.1104/pp.80.1.196; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5828	5833						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449949				2022-12-25	WOS:A1993KR82200071
J	BU, X; HAAS, DW; HAGEDORN, CH				BU, X; HAAS, DW; HAGEDORN, CH			NOVEL PHOSPHORYLATION SITES OF EUKARYOTIC INITIATION FACTOR-4F AND EVIDENCE THAT PHOSPHORYLATION STABILIZES INTERACTIONS OF THE P25 AND P220 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA CAP; STIMULATES PHOSPHORYLATION; TRANSLATIONAL INITIATION; GROWTH-FACTOR; FACTOR 4E; KINASE-C; EIF-4F; POLYPEPTIDE; COMPLEX	Only serine phosphorylation of eukaryotic initiation factor-4E (eIF-4E) has been previously reported in intact cells. We found that treatment of HepG2 cells with okadaic acid resulted in as much as 20% of eukaryotic initiation factor (eIF)-4E phosphorylation occurring on threonine residues and that tryptic phosphopeptide maps showed several previously unrecognized phosphopeptides. Analysis of p220 from control and okadaic acid-treated cells demonstrated serine and threonine phosphorylation under both conditions. However, a unique pattern of phosphopeptides in okadaic acid-treated cells was observed. The most notable finding was that hyperphosphorylation of eIF-4E and p220 increased binding of p220 but not eIF-4E to the m7GTP cap structure. We suggest that phosphorylation of eIF-4E is more complicated than previously recognized and that hyperphosphorylation of eIF-4E and p220 recruits more p220 into the protein complex that associates with mRNA caps. A better understanding of these protein-protein and protein-mRNA interactions may aid the design of anti-sense directed chemistries that disrupt such interactions for a specific target mRNA (Baker, B. F., Miraglia, L., and Hagedorn, C. H. (1992) J. Biol. Chem. 267, 11495-11499).	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; VET ADM MED CTR,NASHVILLE,TN 37203	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BF, 1992, J BIOL CHEM, V267, P11495; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P85; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P340, DOI 10.1016/S0006-291X(88)81228-2; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P925; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; TUAZON PT, 1989, J BIOL CHEM, V264, P2773	22	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4975	4978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444875				2022-12-25	WOS:A1993KP88400063
J	DING, HF; WINKLER, HH				DING, HF; WINKLER, HH			CHARACTERIZATION OF THE DNA-MELTING FUNCTION OF THE RICKETTSIA-PROWAZEKII RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRATE SYNTHASE GENE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; NUCLEOTIDE-SEQUENCE; ABORTIVE INITIATION; SIGMA-SUBUNIT; PURIFICATION; EXPRESSION; BACTERIAL	In vitro specific transcription by the Rickettsia prowazekii RNA polymerase was investigated. The purified rickettsial RNA polymerase, in striking contrast to that of Escherichia coli, could specifically transcribe two R. prowazekii genes (ATP/ADP translocase and citrate synthase genes) and one E. coli gene (RNA-I) on negative supercoiled plasmids but not the same genes on linear plasmids. Following the specific binding of the rickettsial RNA polymerase to the translocase gene promoter on a linear plasmid, there was no detectable open complex formation. Both the E. coli and the R. prowazekii RNA polymerases worked well when poly(dA-dT).poly(dA-dT) or poly(dI-dC).poly(dI-dC) was used as template for generalized transcription. However, the rickettsial RNA polymerase, in contrast to the E. coli enzyme, had little activity on poly(dG-dC).poly(dG-dC), a template with a larger number of hydrogen bonds. These data indicate that the rickettsial RNA polymerase is weak, at least relative to E. coli, in the function required for the opening of DNA duplex. It appears that this operation in R. prowazekii is aided by the negative supercoiling and the high 72% AT composition of the rickettsial genome.	UNIV SO ALABAMA,COLL MED,DEPT MICROBIOL & IMMUNOL,MOLEC BIOL LAB,MOBILE,AL 36688	University of South Alabama				Ding, Han-Fei/0000-0001-5702-3439	NIAID NIH HHS [AI-15035] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOROWIEC JA, 1987, J MOL BIOL, V195, P89, DOI 10.1016/0022-2836(87)90329-9; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; DASCH GA, 1977, INFECT IMMUN, V15, P280, DOI 10.1128/IAI.15.1.280-286.1977; DING HF, 1990, J BACTERIOL, V172, P5624, DOI 10.1128/jb.172.10.5624-5630.1990; FUTCHER B, 1988, TRENDS GENET, V4, P271, DOI 10.1016/0168-9525(88)90166-7; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HANSON BA, 1981, INFECT IMMUN, V34, P596, DOI 10.1128/IAI.34.2.596-604.1981; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; ISHIHAMA A, 1971, MOL GEN GENET, V111, P66, DOI 10.1007/BF00286555; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; KINSELLA L, 1982, BIOCHEMISTRY-US, V21, P2719, DOI 10.1021/bi00540a022; KRAUSE DC, 1985, P NATL ACAD SCI USA, V82, P3015, DOI 10.1073/pnas.82.9.3015; LEVINE AD, 1978, MICROBIOLOGY 1978, P163; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MARKS GL, 1992, GENE, V121, P155, DOI 10.1016/0378-1119(92)90175-O; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEISS E, 1973, BACTERIOL REV, V37, P259, DOI 10.1128/MMBR.37.3.259-283.1973; WILLIAMSON LR, 1989, GENE, V80, P269, DOI 10.1016/0378-1119(89)90291-6; WINKLER HH, 1976, J BIOL CHEM, V251, P389; WINKLER HH, 1990, ANNU REV MICROBIOL, V44, P131, DOI 10.1146/annurev.mi.44.100190.001023; WOOD DC, 1984, J BIOL CHEM, V259, P1184; WOOD DO, 1987, J BACTERIOL, V169, P3564, DOI 10.1128/jb.169.8.3564-3572.1987; WOOD DO, 1983, J BACTERIOL, V155, P412, DOI 10.1128/JB.155.1.412-416.1983; WYATT GR, 1952, NATURE, V170, P846, DOI 10.1038/170846a0; YANOFSKY C, 1982, ANNU REV GENET, V16, P113	47	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3897	3902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440683				2022-12-25	WOS:A1993KN53300019
J	MAHER, PA				MAHER, PA			INHIBITION OF THE TYROSINE KINASE-ACTIVITY OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR BY THE METHYLTRANSFERASE INHIBITOR 5'-METHYLTHIOADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHORYLATION; BINDING; CELL; PROTEINS; METHYLATION; DOMAIN; PHOSPHOTYROSINE	Stimulation of fibroblasts with basic fibroblast growth factor (bFGF) led to the rapid tyrosine phosphorylation of a number of cellular proteins, including a major substrate of 90 kDa. The methyltransferase inhibitor 5'-methylthioadenosine (MTA) was found to be a specific inhibitor of bFGF-stimulated protein tyrosine phosphorylation in fibroblasts, blocking both receptor autophosphorylation and substrate phosphorylation. MTA had no effect on either epidermal growth factor- or platelet-derived growth factor-stimulated protein tyrosine phosphorylation in fibroblasts. MTA also inhibited both bFGF-stimulated protein tyrosine phosphorylation and neurite outgrowth in PC12 cells. MTA was a specific inhibitor of bFGF-stimulated protein tyrosine phosphorylation only in intact cells. MTA delayed and reduced, but did not inhibit, bFGF internalization and processing. The effects of MTA on bFGF-stimulated tyrosine phosphorylation required only a brief pretreatment with the agent and were readily reversible.			MAHER, PA (corresponding author), WHITTIER INST DIABET & ENDOCRINOL, DEPT MOLEC & CELLULAR GROWTH BIOL, LA JOLLA, CA 92037 USA.				NIDDK NIH HHS [DK18811] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BORCHARDT RT, 1979, BIOCHEM BIOPH RES CO, V89, P919, DOI 10.1016/0006-291X(79)91866-7; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COOPER JA, 1986, BIOESSAYS, V4, P9, DOI 10.1002/bies.950040104; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUERRE JA, 1985, BIOCHEMISTRY-US, V24, P6848, DOI 10.1021/bi00345a017; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; EK B, 1984, J BIOL CHEM, V259, P1145; ENOUF J, 1979, CANCER RES, V39, P4497; ENRIGHT WJ, 1991, FOCUS, V13, P79; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFFMAN T, 1981, P NATL ACAD SCI-BIOL, V78, P3839, DOI 10.1073/pnas.78.6.3839; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIN PH, 1991, METHOD ENZYMOL, V198, P251; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAHER PA, 1993, IN PRESS J CELL PHYS, V154; Moenner M, 1989, GROWTH FACTORS, V1, P115, DOI 10.3109/08977198909029121; ODEA RF, 1987, CANCER RES, V47, P3656; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SEELEY PJ, 1984, J CELL BIOL, V98, P417, DOI 10.1083/jcb.98.2.417; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; TOGARI A, 1985, J NEUROSCI, V5, P307; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4244	4249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440708				2022-12-25	WOS:A1993KN53300064
J	CERNEUS, DP; UEFFING, E; POSTHUMA, G; STROUS, GJ; VANDERENDE, A				CERNEUS, DP; UEFFING, E; POSTHUMA, G; STROUS, GJ; VANDERENDE, A			DETERGENT INSOLUBILITY OF ALKALINE-PHOSPHATASE DURING BIOSYNTHETIC TRANSPORT AND ENDOCYTOSIS - ROLE OF CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-GLYCAN; HUMAN-FIBROBLASTS; PLASMA-MEMBRANES; CANCER-CELLS; COATED PITS; PROTEINS; 5'-NUCLEOTIDASE; SPHINGOMYELIN; LOCALIZATION; ANTIBODIES	Alkaline phosphatase is anchored to the outer leaflet of the plasma membrane by a covalently attached glycosyl-phosphatidylinositol anchor. We have studied the biosynthetic. transport and endocytosis of alkaline phosphatase in the choriocarcinoma cell line BeWo, which endogenously expresses this protein. It was demonstrated that the protein was synthesized as a Triton X-100-soluble precursor. During transport to the cell surface the enzyme was converted in a mature form, which was insoluble in Triton X-100 at 0-degrees-C. Once at the cell surface 85% of alkaline phosphatase remained in the detergent-insoluble form. Under steady state conditions 15% of alkaline phosphatase was endocytosed. Most interestingly, this fraction of internalized alkaline phosphatase was completely soluble in Triton X-100 at 0-degrees-C. After depletion of membrane cholesterol by saponin, alkaline phosphatase became completely soluble in Triton X-100 at 0-degrees-C, suggesting that cholesterol plays a critical role in the formation and maintenance of Triton X-100-resistant membrane domains.	UNIV UTRECHT,SCH MED,DEPT CELL BIOL,HEIDELBERGLAAN 100,H02314,3584 CX UTRECHT,NETHERLANDS	Utrecht University			van der Ende, Arie/A-4346-2012					ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1991, J CELL BIOL, V114, P1149, DOI 10.1083/jcb.114.6.1149; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; JEMMERSON R, 1985, FEBS LETT, V179, P316, DOI 10.1016/0014-5793(85)80542-1; JEMMERSON R, 1985, J HISTOCHEM CYTOCHEM, V33, P1227, DOI 10.1177/33.12.4067276; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOWE ME, 1990, CANCER RES, V50, P3956; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MATSUURA S, 1984, J CELL BIOL, V99, P166, DOI 10.1083/jcb.99.1.166; McComb Jr RB, 1979, ALKALINE PHOSPHATASE, DOI 10.1007/978-1-4613-2970-1_4; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MILLAN JL, 1990, ISOZYMES STRUCTURE F, P453; OGATA S, 1988, J BIOL CHEM, V263, P10489; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHLOSSER E, 1969, Z NATURFORSCH PT B, VB 24, P1284; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; TAKAMI N, 1988, J BIOL CHEM, V263, P3016; TOKUYASU KT, 1976, J CELL BIOL, V71, P894, DOI 10.1083/jcb.71.3.894; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x; VANDERENDE A, 1987, J BIOL CHEM, V262, P8910; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WEBB PD, 1988, EUR J BIOCHEM, V172, P647, DOI 10.1111/j.1432-1033.1988.tb13938.x; YANDOUZI EHE, 1992, BIOCHEMISTRY-US, V31, P547; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	48	152	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3150	3155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428991				2022-12-25	WOS:A1993KM16100023
J	CHU, FF; DOROSHOW, JH; ESWORTHY, RS				CHU, FF; DOROSHOW, JH; ESWORTHY, RS			EXPRESSION, CHARACTERIZATION, AND TISSUE DISTRIBUTION OF A NEW CELLULAR SELENIUM-DEPENDENT GLUTATHIONE-PEROXIDASE, GSHPX-GI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN-PLASMA; EUKARYOTIC CELLS; ACTIVE-SITE; GENE; CDNA; PROTEINS; ENZYME; SELENOCYSTEINE; DISTINCT	We have characterized a new selenium-dependent glutathione peroxidase, GSHPx-GI, by expressing a GSHPx-GI cDNA isolated from human hepatoma HepG2 cells in human mammary carcinoma MCF-7 cells, which have virtually undetectable expression of either the classical cellular enzyme, GSHPx-1, or GSHPx-GI at the protein level. One of the G418-resistant clones, neo-D1, expresses the transfected GSHPx-GI cDNA. This is based on 1) the presence of an additional GSHPx-GI DNA restriction fragment detected by Southern analysis; 2) the presence of a 1.9-kilobase (kb) GSHPx-GI mRNA in addition to the 1.0-kb endogenous mRNA by Northern analysis; and 3) the appearance of a 22-kDa Se-75-labeled protein which is absent in parental MCF-7 cells revealed by SDS-polyacrylamide gel electrophoresis. GSHPx-GI expressed in neo-D1 is a tetrameric protein localized in cytosol. GSHPx-GI does not cross-react with antisera against human GSHPx-1 or human plasma glutathione peroxidase (GSHPx-P). Similar substrate specificities are found for GSHPx-1 and GSHPx-GI; they both catalyze the reduction of H2O2, tert-butyl hydroperoxide, cumene hydroperoxide, and linoleic acid hydroperoxide with glutathione, but not of phosphatidylcholine hydroperoxide. GSHPx-GI mRNA was readily detected in human liver and colon, and occasionally in human breast samples, but not other human tissues including kidney, heart, lung, placenta, or uterus. In rodent tissues, GSHPx-GI mRNA is only detected in the gastrointestinal tract, and not in other tissues including liver. In fact, GSHPx-GI appears to be the major glutathione-dependent peroxidase activity in rodent GI tract. This finding suggests that GSHPx-GI could play a major role in protecting mammals from the toxicity of ingested lipid hydroperoxides. In conclusion, we have demonstrated that GSHPx-GI is the fourth member in the selenium-dependent glutathione peroxidase family, in addition to GSHPx-1, GSHPx-P, and phospholipid hydroperoxide glutathione peroxidase (PHGPX).	CITY HOPE NATL MED CTR,DEPT MED ONCOL & THERAPEUT RES,DUARTE,CA 91010	City of Hope				Esworthy, Steve/0000-0002-4111-3349	NCI NIH HHS [CA 33572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKASAKA M, 1990, NUCLEIC ACIDS RES, V18, P4619, DOI 10.1093/nar/18.15.4619; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHAMBERS I, 1988, OXYRADICALS MOL BIOL, P289; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1992, BLOOD, V79, P3233; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; CHU FF, 1988, P AM ASSOC CANC RES, V29, P440; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; FAURE J, 1991, BIOL REPROD, V44, P13, DOI 10.1095/biolreprod44.1.13; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HILL RE, 1985, MOL CELL BIOL, V5, P2144; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MCBRIDE O W, 1988, Biofactors, V1, P285; MILLS GC, 1957, J BIOL CHEM, V229, P189; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLIGAN RC, 1979, NATURE, V277, P108, DOI 10.1038/277108a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; ROVERI A, 1992, J BIOL CHEM, V267, P6142; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SINET P M, 1975, Biochemical and Biophysical Research Communications, V67, P910, DOI 10.1016/0006-291X(75)90763-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; THOMAS JP, 1990, J BIOL CHEM, V265, P454; VILAS NN, 1976, J NUTR, V106, P589, DOI 10.1093/jn/106.5.589; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	37	453	479	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2571	2576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428933				2022-12-25	WOS:A1993KK81500048
J	KAN, WM; TAI, HH				KAN, WM; TAI, HH			MONOCLONAL ANTIIDIOTYPIC ANTIBODY TO A POTENT THROMBOXANE-A2 RECEPTOR ANTAGONIST AND ITS INTERACTION WITH THROMBOXANE-A2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; BINDING; PURIFICATION; BRAIN	A monoclonal anti-idiotypic antibody that interacts with thromboxane A2 receptor was generated using an anti-idiotypic approach. Idiotypic antibodies against a potent receptor antagonist, HS-145, were generated in rabbit. The idiotypic antibodies were then selected by an affinity procedure using SQ29,548-Affi-Gel-102 matrix. The selected idiotypic antibodies were used as surrogate receptor for anti-idiotypic antibody generation. A mouse monoclonal antibody, 3D-9E-12, was generated. It was shown to displace I-125-HS-145 from affinity-purified idiotypic antibodies. It also inhibits I-125-IS-145 binding to thromboxane A2 receptor in human platelet membranes in a dose-dependent manner. Furthermore, it attenuated U46,619-induced increase in [S-35]guanosine 5'-O-(thiotriphosphate) binding and GTPase activity in human platelet membranes. Finally, it inhibited U46,619- but not PAF-induced platelet aggregation. These results indicate that 3D-9E-12 acts as a specific antagonist in the thromboxane A2 receptor.	UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536	University of Kentucky								ABOOD LG, 1987, P NATL ACAD SCI USA, V84, P6587, DOI 10.1073/pnas.84.18.6587; BARTELS E, 1971, P NATL ACAD SCI USA, V68, P1820, DOI 10.1073/pnas.68.8.1820; BURCH RM, 1985, BIOCHEM BIOPH RES CO, V132, P961, DOI 10.1016/0006-291X(85)91901-1; CAYANIS E, 1986, J BIOL CHEM, V261, P5094; COURAUD JY, 1985, J BIOL CHEM, V260, P9461; ELAZAR Z, 1988, LIFE SCI, V42, P5853; ERLANGER BF, 1980, TRENDS BIOCHEM SCI, V5, P110, DOI 10.1016/0968-0004(80)90262-5; FARID NR, 1982, J CELL BIOCHEM, V19, P305, DOI 10.1002/jcb.240190402; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; GRAMSCH C, 1988, J BIOL CHEM, V263, P5853; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HEDBERG A, 1988, J PHARMACOL EXP THER, V245, P786; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRSH P D, 1981, New England Journal of Medicine, V304, P685, DOI 10.1056/NEJM198103193041201; HOMCY CJ, 1982, J CLIN INVEST, V69, P1147, DOI 10.1172/JCI110550; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAN WM, 1993, IN PRESS CHEM PHYS L; KERINS DM, 1988, CIRCULATION, V77, P142; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KU HH, 1987, J IMMUNOL, V139, P2376; LOMBES M, 1989, J BIOL CHEM, V264, P2528; MILSTEIN C, 1980, SCI AM, V243, P66, DOI 10.1038/scientificamerican1080-66; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NAISASA M, 1988, J MED CHEM, V31, P1847; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2445; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; WANG CJ, 1991, J BIOL CHEM, V266, P12372	28	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6364	6370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454607				2022-12-25	WOS:A1993KT36800044
J	CHAKRAVARTI, D; MAITI, T; MAITRA, U				CHAKRAVARTI, D; MAITI, T; MAITRA, U			ISOLATION AND IMMUNOCHEMICAL CHARACTERIZATION OF EUKARYOTIC TRANSLATION INITIATION FACTOR-5 FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTES; PROTEIN-SYNTHESIS; FACTOR-II; POLYACRYLAMIDE GELS; PURIFICATION; SUBUNIT	Eukaryotic translation initiation factor 5 (eIF-5), which catalyzes the hydrolysis of GTP bound to the 40 S ribosomal initiation complex has been purified from yeast cell lysates. The purified factor eluted from gel filtration columns as a protein of apparent M(r) = 45,000-50,000. However, when the purified preparation was analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate, two distinct polypeptides of apparent M(r) = 54,000 and 56,000 were observed. Each of the two polypeptides individually was found to contain eIF-5 activity, and they were immunologically related to each other. In less pure preparations of yeast eIF-5, however, a significant proportion of eIF-5 activity eluted from gel filtration columns as a protein of M(r) > 140,000. Immunochemical methods were therefore employed to determine the molecular structure of eIF-5 in crude yeast cell lysates. Antisera against purified yeast eIF-5 were prepared in rabbits and shown to be highly potent in inhibiting eIF-5-mediated 80 S initiation complex formation. When crude eIF-5 preparations, as well as yeast cells that were lysed directly into a denaturing buffer containing 3% sodium dodecyl sulfate, were analyzed by Western blots probed with affinity-purified anti-eIF-5 antibodies, a major immunoreactive polypeptide (apparent M(r) = 54,000) and a minor band (apparent M(r) = 56,000) were observed. No precursor forms of molecular weight higher than 56,000 were detected in any preparations. These results suggest that yeast eIF-5 is a monomeric protein of apparent M(r) = 50,000-56,000.			CHAKRAVARTI, D (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,DIV BIOL SCI,BRONX,NY 10461, USA.			Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD MF, 1985, J BIOL CHEM, V260, P6955; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BAUERLE PA, 1988, CELL, V53, P211; BENNE R, 1978, J BIOL CHEM, V253, P3070; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAUDHURI A, 1981, J BIOL CHEM, V256, P3988; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DUBNOFF J S, 1972, Journal of Biological Chemistry, V247, P2876; DUBNOFF JS, 1971, METHOD ENZYMOL, V20, P248; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GILLAM IC, 1971, METHOD ENZYMOL, V20, P55; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KERWAR SS, 1970, BIOCHEM BIOPH RES CO, V41, P78, DOI 10.1016/0006-291X(70)90471-7; KOZAK M, 1983, MICROBIOL REV, V47, P1; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MEYER LJ, 1981, J BIOL CHEM, V256, P351; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD P, 1970, BIOCHEMISTRY-US, V9, P1694, DOI 10.1021/bi00810a007; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; Torano A, 1974, Methods Enzymol, V30, P254; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7	34	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5754	5762						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449940				2022-12-25	WOS:A1993KR82200060
J	ELLIS, V; DANO, K				ELLIS, V; DANO, K			POTENTIATION OF PLASMINOGEN ACTIVATION BY AN ANTI-UROKINASE MONOCLONAL-ANTIBODY DUE TO TERNARY COMPLEX-FORMATION - A MECHANISTIC MODEL FOR RECEPTOR-MEDIATED PLASMINOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PRO-UROKINASE; BOVINE TRYPSINOGEN; CELLULAR RECEPTOR; BOUND UROKINASE; BINDING; CELLS; PURIFICATION; PROENZYME; FORM	We have observed that a murine IgG1 monoclonal antibody directed against human urokinase-type plasminogen activator (uPA) greatly potentiates pro-uPA-mediated plasminogen activation. This effect was dependent on the interaction between the immunoglobulin and the kringle domain of pro-uPA and could be competed efficiently by kringle-containing proteolytic fragments of uPA. In addition, the potentiation could also be competed by the lysine analog 6-aminohexanoic acid, an antagonist of plasminogen binding. This unexpected plasminogen binding dependence was found to be due to a carboxyl-terminal lysine residue on the immunoglobulin gamma chain, which by analogy with other proteins represents a potential binding site for plasminogen. Removal of this residue with carboxypeptidase B resulted in a complete abolition of the potentiation. It appears therefore that the potentiatory effect involves a novel mechanism wih the antibody acting to provide a specific template for the assembly of a ternary complex involving pro-uPA/uPA and plasminogen, enabling them to interact in a catalytically favorable manner. This interpretation was confirmed by studying the kinetics of plasminogen activation by the complex between active, two-chain uPA and the antibody, which resulted in an overall 50-fold increase in reaction efficiency (k(cat)/K(m)), primarily due to a reduction in K(m) from 20 to 0.1 muM. Pro-uPA activation by plasmin was also accelerated, although to a lesser extent. The potentiation due to complex formation also provides a mechanism for the initiation of this system, dependent only on the low intrinsic proteolytic activity of the zymogen forms. The effects observed here, mediated by ternary complex formation, simulate the effects we have previously observed on assembly of the uPA receptor-mediated cellular plasminogen activation system and may therefore represent a mechanistic model for both its activity and initiation.			ELLIS, V (corresponding author), RIGSHOSP,FINSEN INST,STRANDBLVD 49,DK-2100 COPENHAGEN,DENMARK.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNNER G, 1990, FEBS LETT, V260, P141, DOI 10.1016/0014-5793(90)80087-Y; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; COLLEN D, 1986, J BIOL CHEM, V261, P1259; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EATON DL, 1984, J BIOL CHEM, V259, P6241; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; ELLIS V, 1990, J BIOL CHEM, V265, P990; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HALL SW, 1991, J BIOL CHEM, V266, P12329; HORTIN GL, 1989, THROMB RES, V54, P621, DOI 10.1016/0049-3848(89)90128-X; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KALTOFT K, 1982, P NATL ACAD SCI-BIOL, V79, P3720, DOI 10.1073/pnas.79.12.3720; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; LEARMONTH MP, 1992, FIBRINOLYSIS, V6, P113; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MARKUS G, 1978, J BIOL CHEM, V253, P727; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; MYOHANEN H, 1992, FIBRINOLYSIS S2, V6; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; NEURATH H, 1975, PROTEASES BIOL CONTR, V2, P51; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NIELSEN LS, 1983, EMBO J, V2, P115, DOI 10.1002/j.1460-2075.1983.tb01391.x; PANNELL R, 1986, BLOOD, V67, P1215; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; TAPIOVARA H, 1992, FIBRINOLYSIS S2, V6; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WUN TC, 1982, J BIOL CHEM, V257, P7262	55	75	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4806	4813						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444857				2022-12-25	WOS:A1993KP88400040
J	HASSANAIN, HH; CHON, SY; GUPTA, SL				HASSANAIN, HH; CHON, SY; GUPTA, SL			DIFFERENTIAL REGULATION OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE GENE-EXPRESSION BY INTERFERON-GAMMA AND INTERFERON-ALPHA - ANALYSIS OF THE REGULATORY REGION OF THE GENE AND IDENTIFICATION OF AN INTERFERON-GAMMA-INDUCIBLE DNA-BINDING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; TRANSCRIPTIONAL INDUCTION; CYTOPLASMIC ACTIVATION; TRYPTOPHAN CATABOLISM; RESPONSIVE ELEMENT; BETA-INTERFERON; CELLS; PROMOTER; MECHANISM; ENHANCER	The induction of indoleamine 2,3-dioxygenase (IDO) activity has been implicated in the antiproliferative action of interferon (IFN)-gamma on tumor cells and the inhibition of intracellular pathogens. Earlier studies have demonstrated that the expression of the IDO gene is induced strongly by IFN-gamma, but very poorly by IFN-alpha despite the presence of a sequence highly homologous to the IFN-alpha-responsive sequence element (interferon-stimulated response element (ISRE)) in its IFN-gamma-responsive control region. In addition, a sequence with a partial homology to the IFN-gamma-responsive sequence (GAS) identified by Lew et al. (Lew, D. J., Decker, T., Strehlow, I., and Darnell, J. E., Jr. (1991) Mol. Cell. Biol. 11, 182-191) in a human gene for a guanylate-binding protein and to the X box sequence found in all major histocompatibility complex class II genes was found. Deletion experiments have indicated that the ISRE homolog (but not the GAS-related or the X box-related sequence) was essential for an inducibility by IFN-gamma. To investigate the lack of inducibility by IFN-alpha despite the presence of an ISRE homolog, the binding of this ISRE homolog to the IFN-alpha-stimulated gene factor 3 (ISGF3) was examined. Gel mobility shift experiments and competition experiments indicated that this ISRE homolog did not form a stable complex with ISGF3. This may account for a poor inducibility by IFN-alpha. This inability to bind ISGF3 appears to be (at least in part) due to minor differences between the nucleotide sequence of the ISRE homolog present in the IDO gene promoter and the ISRE consensus sequence found in IFN-alpha-inducible genes. An IFN-gamma-inducible DNA-binding factor was identified with characteristics different from ISGF3: (i) the IFN-gamma-inducible factor was detected in the nuclear extracts, but not in the cytoplasmic extracts; and (ii) the appearance of this DNA-binding factor required new protein synthesis, which could explain the dependence on new protein synthesis for the induction of IDO by IFN-gamma.	HIPPLE CANC RES CTR,4100 S KETTERING BLVD,DAYTON,OH 45439						NCI NIH HHS [CA-29991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Baron S, 1992, INTERFERON PRINCIPLE; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; DAI W, 1990, J BIOL CHEM, V265, P19871; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DELAMAZA LM, 1988, CANCER RES, V48, P346; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; GORMAN CM, 1982, MOL CELL BIOL, V2, P1051; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KARA CJ, 1991, CURR OPIN IMMUNOL, V3, P16, DOI 10.1016/0952-7915(91)90070-H; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; PFEFFERKORN ER, 1986, MOL BIOCHEM PARASIT, V20, P215, DOI 10.1016/0166-6851(86)90101-5; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Rosa F M, 1986, Interferon, V7, P47; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1991, HORMONAL CONTROL GEN, P349; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STRUNK RC, 1985, J BIOL CHEM, V260, P5280; SUGAWARA M, 1991, P NATL ACAD SCI USA, V88, P10347, DOI 10.1073/pnas.88.22.10347; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WERNER ER, 1990, J BIOL CHEM, V265, P3189; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	52	106	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5077	5084						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444884				2022-12-25	WOS:A1993KP88400076
J	RINDRESS, D; LEI, X; AHLUWALIA, JPS; CAMERON, PH; FAZEL, A; POSNER, BI; BERGERON, JJM				RINDRESS, D; LEI, X; AHLUWALIA, JPS; CAMERON, PH; FAZEL, A; POSNER, BI; BERGERON, JJM			ORGANELLE-SPECIFIC PHOSPHORYLATION - IDENTIFICATION OF UNIQUE MEMBRANE PHOSPHOPROTEINS OF THE ENDOPLASMIC-RETICULUM AND ENDOSOMAL APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GOLGI FRACTIONS; PRELYSOSOMAL COMPARTMENT; LYSOSOMAL MEMBRANE; BINDING-PROTEINS; RECEPTOR KINASE; INSULIN; ANTIBODIES; INVIVO; CELLS	Highly purified endoplasmic reticulum fractions from rat liver and dog pancreas harbor membrane-associated kinases that phosphorylate integral membrane proteins of 90, 56, 35, and 15 kDa with [gamma-P-32] GTP and of 90, 56, and 35 kDa with [gamma-P32]ATP. Of these, only the 35-kDa phosphoprotein was N-glycosylated. Screening of Golgi fractions, endosomes, plasma membranes, lysosomes, and mitochondria revealed phosphoproteins unique to each organelle. In particular, endosomes were found to harbor a 48-kDa extrinsic membrane protein and two or more integral membrane phosphoproteins of 30-35 kDa. None of these were N-glycosylated as judged by their insensitivity to digestion by N-glycosidase F and a lack of binding to concanavalin A or wheat germ agglutinin. Since the 30-35-kDa membrane phosphoproteins present in Golgi-free endosomal fractions were not detected in endosome-free, highly purified Golgi fractions and were found exclusively in horseradish peroxidase-containing endosomes as determined by the diaminobenzidine shift protocol, then these membrane phosphoproteins are unique to endosomes. Since membrane phosphoproteins unique to the endoplasmic reticulum have been shown to have important functional significance in calcium binding and as a membrane chaperone(s) (Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J.-J., II, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610; Ahluwalia, N., Bergeron, J. J. M., Wada, I., Degen, E., and Williams, D. B. (1992) J. Biol. Chem. 267, 10914-10918), then the unique endosomal phosphoproteins may serve equally important functions in addition to serving as novel markers for the organelle.	MCGILL UNIV, DEPT MED, MONTREAL H3A 2B2, QUEBEC, CANADA	McGill University	RINDRESS, D (corresponding author), MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL H3A 2B2, QUEBEC, CANADA.		Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021					AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BERGERON JJM, 1979, BIOCHIM BIOPHYS ACTA, V555, P493, DOI 10.1016/0005-2736(79)90402-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BERGERON JJM, 1988, CELL FREE ANAL MEMBR, P391; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1985, J BIOL CHEM, V260, P4879; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DAWSON AP, 1986, BIOCHEM J, V234, P311, DOI 10.1042/bj2340311; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRIFFITHS G, 1990, J CELL SCI, V95, P441; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; JOSEFSBERG Z, 1979, J BIOL CHEM, V254, P209; KAY DG, 1984, BIOCHEM BIOPH RES CO, V123, P1144, DOI 10.1016/S0006-291X(84)80252-1; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1982, J BIOL CHEM, V257, P5969; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUCOCQ J, 1991, J CELL SCI, V100, P753; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; OU WJ, 1992, J BIOL CHEM, V267, P23789; PAIEMENT J, 1983, J CELL BIOL, V96, P1791, DOI 10.1083/jcb.96.6.1791; PARK JE, 1991, J CELL BIOL, V112, P245, DOI 10.1083/jcb.112.2.245; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIEDIMONTE G, 1988, J CELL BIOCHEM, V36, P91, DOI 10.1002/jcb.240360110; PIEDIMONTE G, 1986, J CELL BIOCHEM, V32, P113, DOI 10.1002/jcb.240320204; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; REGGIO H, 1984, J CELL BIOL, V99, P1511, DOI 10.1083/jcb.99.4.1511; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Schacht J, 1981, Methods Enzymol, V72, P626; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SHORE GC, 1983, METHOD ENZYMOL, V97, P396; Tartakoff A M, 1974, Methods Enzymol, V31, P41; TOUGARD C, 1985, J CELL BIOL, V100, P786, DOI 10.1083/jcb.100.3.786; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILSON JM, 1987, J CELL BIOL, V105, P691, DOI 10.1083/jcb.105.2.691	51	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5139	5147						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444889				2022-12-25	WOS:A1993KP88400084
J	TYRRELL, DJ; ISHIHARA, M; RAO, N; HORNE, A; KIEFER, MC; STAUBER, GB; LAM, LH; STACK, RJ				TYRRELL, DJ; ISHIHARA, M; RAO, N; HORNE, A; KIEFER, MC; STAUBER, GB; LAM, LH; STACK, RJ			STRUCTURE AND BIOLOGICAL-ACTIVITIES OF A HEPARIN-DERIVED HEXASACCHARIDE WITH HIGH-AFFINITY FOR BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ENDOTHELIAL-CELLS; BINDING DOMAINS; RECEPTOR; OLIGOSACCHARIDES; DEPOLYMERIZATION; PROTECTS; SULFATE; MATRIX	We demonstrated previously that heparin-derived hexasaccharides are the smallest fragments of the polysaccharide with comparable basic fibroblast growth factor (bFGF)-modulating activity in vitro (Ishihara, M., Tyrrell, D. J., Stauber, G. B., Brown, S., Cousens, L., and Stack, R. J. (1993) J. Biol. Chem. 268, 4675-4683. In this report, a specific hexasaccharide having high affinity for recombinant human bFGF was isolated and its structure deduced by analysis of its reduced disaccharide products after treatment with nitrous acid at pH 1. 5, and by H-1 NMR spectroscopy. The hexasaccharide has the structure [IdoA(2-OSO3)alpha1-4GlcNSO3(6-OSO3)alpha1-4]2IdoA(2-OSO3)alpha1-4AMan(R) (6-OSO3). The hexasaccharide effectively inhibits the binding of syndecan-transfected RO-12 UC cells to bFGF-coated wells (Ishihara, M., Tyrrell, D. J., Kiefer, M. C., Barr, P. J., and Swiedler, S. J. (1992) Anal. Biochem. 202, 310-315), prevents the binding of I-125-bFGF to confluent monolayers of adrenocortical endothelial (ACE) cells, and inhibits the bFGF-dependent proliferation of ACE cells. Unlike the heparin from which it was derived, however, the hexasaccharide cannot promote the binding of I-125-bFGF to a recombinant high affinity bFGF receptor (flg) or restore the bFGF-dependent proliferative response to ACE cells grown in the presence of 5 mm sodium chlorate. Collectively, these data indicate that a hexasaccharide can be as effective as heparin as an antagonist of bFGF-mediated cell mitogenesis.	CHIRON CORP,EMERYVILLE,CA 94608	Novartis	TYRRELL, DJ (corresponding author), GLYCOMED INC,860 ATLANTIC AVE,ALAMEDA,CA 94501, USA.							BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARR PJ, 1988, J BIOL CHEM, V263, P16471; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; DABORA JM, 1991, J BIOL CHEM, V266, P23637; DAVIS DG, 1985, J AM CHEM SOC, V107, P7197, DOI 10.1021/ja00310a085; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GATTI G, 1978, BIOCHEM BIOPH RES CO, V85, P14, DOI 10.1016/S0006-291X(78)80004-7; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X; KUROKAWA M, 1989, J BIOL CHEM, V264, P7686; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	38	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4684	4689						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444842				2022-12-25	WOS:A1993KP88400022
J	JAUHIAINEN, M; METSO, J; PAHLMAN, R; BLOMQVIST, S; VANTOL, A; EHNHOLM, C				JAUHIAINEN, M; METSO, J; PAHLMAN, R; BLOMQVIST, S; VANTOL, A; EHNHOLM, C			HUMAN PLASMA PHOSPHOLIPID TRANSFER PROTEIN CAUSES HIGH-DENSITY-LIPOPROTEIN CONVERSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; PARTICLE-SIZE; IMMUNOAFFINITY CHROMATOGRAPHY; LIPID TRANSFERS; HEPATIC LIPASE; A-I; APOLIPOPROTEIN; COMPLEXES; SERUM	The effect of human plasma phospholipid transfer protein (PLTP) on the particle size distribution of human high density lipoprotein (HDL) was studied by incubating human HDL3 (particle diameter, 8.7 nm) together with PLTP in vitro. Incubation of HDL3 with highly purified preparations of PLTP, devoid of cholesterol ester transfer protein (CETP), induced a conversion of the homogenous population of HDL particles into two main populations of particles, one larger, particle diameter 10.9 nm, and one smaller, particle diameter 7.8 nm, than the original HDL3. These size changes were evident as analyzed by gradient gel electrophoresis and by high resolution gel filtration. The degree of the conversion was dependent on the amount of PLTP added to the incubation and on incubation time. An inhibitory monoclonal antibody (TP-1) directed against CETP had no effect on the HDL conversion. The PLTP used was purified to homogeneity from human plasma using ultracentrifugation and a combination of hydrophobic, cation-exchange, heparin-Sepharose-, anion-exchange, and gel filtration chromatographies. The monoclonal anti-CETP antibody (TP-1), which inhibits lipid transfer catalyzed by CETP, did not react with PLTP or inhibit its activity. The estimated molecular weight of PLTP is 75,000. The present study demonstrates that PLTP can act like the putative conversion factor and has the ability to convert HDL3 into populations of larger and smaller HDL particles. The mechanism(s) involved in this process and its physiological relevance remain to be established.	NATL PUBL HLTH INST,DEPT BIOCHEM,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND; ERASMUS UNIV,DEPT BIOCHEM,3000 DR ROTTERDAM,NETHERLANDS	Finland National Institute for Health & Welfare; Erasmus University Rotterdam								ATMEH RF, 1983, BIOCHIM BIOPHYS ACTA, V751, P175, DOI 10.1016/0005-2760(83)90172-8; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BERGMEYER HU, 1985, METHOD ENZYMAT AN, P1; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; CALABRESI L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P195, DOI 10.1016/0005-2760(92)90098-G; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1987, J LIPID RES, V28, P913; DAERR WH, 1982, BIOCHIM BIOPHYS ACTA, V710, P128, DOI 10.1016/0005-2760(82)90142-4; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; EISENBERG S, 1984, J LIPID RES, V25, P1017; GAMBERT P, 1982, BIOCHIM BIOPHYS ACTA, V713, P1, DOI 10.1016/0005-2760(82)90159-X; GLOMSET JA, 1968, J LIPID RES, V9, P155; GROENER JEM, 1986, CLIN CHEM, V32, P283; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOPKINS GJ, 1986, J LIPID RES, V27, P1265; HOPKINS GJ, 1985, J LIPID RES, V26, P218; IHM J, 1980, BIOCHEM BIOPH RES CO, V93, P1114, DOI 10.1016/0006-291X(80)90604-X; JONAS A, 1988, J LIPID RES, V29, P1349; KOSTNER GM, 1981, HIGH DENSITY LIPOPRO, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1126, P143, DOI 10.1016/0005-2760(92)90284-3; LAGROST L, 1990, J LIPID RES, V31, P1569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P124, DOI 10.1016/0005-2760(85)90038-4; MILLER GJ, 1975, LANCET, V1, P16; NESTRUCK AC, 1983, BIOCHIM BIOPHYS ACTA, V753, P65, DOI 10.1016/0005-2760(83)90099-1; NICHOLS AV, 1985, BIOCHIM BIOPHYS ACTA, V834, P285, DOI 10.1016/0005-2760(85)90001-3; NISHIDA HI, 1992, FASEB J, V6, P2136; OHNISHI T, 1990, J LIPID RES, V31, P397; PATSCH JR, 1978, P NATL ACAD SCI USA, V75, P4519, DOI 10.1073/pnas.75.9.4519; RAJARAM OV, 1986, BIOCHIM BIOPHYS ACTA, V877, P406, DOI 10.1016/0005-2760(86)90206-7; RIEPPONEN P, 1987, SCAND J CLIN LAB INV, V47, P739; RYE KA, 1984, BIOCHIM BIOPHYS ACTA, V795, P230, DOI 10.1016/0005-2760(84)90070-5; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1992, J LIPID RES, V33, P215; RYE KA, 1986, BIOCHIM BIOPHYS ACTA, V875, P429, DOI 10.1016/0005-2760(86)90062-7; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; SWEENY SA, 1985, BIOCHIM BIOPHYS ACTA, V835, P279, DOI 10.1016/0005-2760(85)90283-8; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1983, J LIPID RES, V24, P277; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112	48	322	329	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4032	4036						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440695				2022-12-25	WOS:A1993KN53300037
J	MITCHELL, GA; ROBERT, MF; HRUZ, PW; WANG, S; FONTAINE, G; BEHNKE, CE; MENDEMUELLER, LM; SCHAPPERT, K; LEE, C; GIBSON, KM; MIZIORKO, HM				MITCHELL, GA; ROBERT, MF; HRUZ, PW; WANG, S; FONTAINE, G; BEHNKE, CE; MENDEMUELLER, LM; SCHAPPERT, K; LEE, C; GIBSON, KM; MIZIORKO, HM			3-HYDROXY-3-METHYLGLUTARYL COENZYME-A LYASE (HL) - CLONING OF HUMAN AND CHICKEN LIVER HL CDNAS AND CHARACTERIZATION OF A MUTATION CAUSING HUMAN HL DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; GENE	3-Hydroxy-3-methylglutaryl coenzyme A lyase (HL) catalyzes the final step of ketogenesis, an important pathway of mammalian energy metabolism. HL deficiency is an autosomal recessive inborn error in man leading to episodes of hypoglycemia and coma. Using the N-terminal peptide sequence of purified chicken liver HL, we designed degenerate sequence primers and amplified an 89-base pair (bp) chicken liver HL cDNA fragment. Longer cDNA clones for chicken (1384 bp) and human (1575 bp) HL were obtained by library screening. The peptide sequence predicted from the chicken clone contains two peptides from purified chicken HL. Mature human and chicken HL are 298-residue peptides. The sequence of the human clone predicts a 27-residue mitochondrial leader and a 31.6-kDa mature HL peptide. Human fibroblast and liver RNA contain a single 1.7-kilobase HL message. Two Acadian French-Canadian siblings with HL deficiency were homozygous for a 2-base pair deletion within the Ser-69 codon (S69fs(-2)), predicted to result in a truncated nonfunctional HL peptide lacking a complete active site. S69fs(-2) was not present in 12 other HL-deficient patients of 10 other ethnic origins, showing that HL deficiency is genetically heterogeneous.	HOP ST JUSTINE,CTR RECH,CANADIAN HUMAN GENET CTR EXCELLENCE,MONTREAL H3T 1C5,QUEBEC,CANADA; HOSP SICK CHILDREN,DEPT MED GENET,CANADIAN HUMAN GENET CTR EXCELLENCE,TORONTO M5G 1X8,ONTARIO,CANADA; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; BAYLOR RES INST,DALLAS,TX 75226	Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Medical College of Wisconsin; Baylor Scott & White Health; Baylor University Medical Center	MITCHELL, GA (corresponding author), HOP ST JUSTINE,GENET MED SECT,3175 COTE STE CATHERINE,MONTREAL H3T 1C5,QUEBEC,CANADA.			Hruz, Paul/0000-0002-1478-3355	NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; Atkins RC., 1973, DR ATKINSDIET REVOLU; BACHHAWAT BK, 1955, J BIOL CHEM, V216, P727; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BRODY LC, 1992, J BIOL CHEM, V267, P3302; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; DECAUX JF, 1988, FEBS LETT, V232, P156, DOI 10.1016/0014-5793(88)80407-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DW, 1989, ENDOCRINOLOGY, P1439; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; GIBSON KM, 1988, J INHERIT METAB DIS, V11, P76, DOI 10.1007/BF01800058; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MITCHELL GA, 1991, AM J HUM GENET, V49, P101; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; OZAND PT, 1992, J CHILD NEUROL S, V7, pS4; PAUL HS, 1992, J BIOL CHEM, V267, P11208; RIBES A, 1990, J INHERIT METAB DIS, V13, P752, DOI 10.1007/BF01799579; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; ROBINSON BH, 1980, NEUROLOGY, V30, P714, DOI 10.1212/WNL.30.7.714; Sambrook J, 1989, MOL CLONING LABORATO; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SWAIMAN KF, 1989, PEDIATR NEUROL, P421; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353; [No title captured]	34	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4376	4381						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440722				2022-12-25	WOS:A1993KN53300082
J	VANTHOF, R; VANKLOMPENBURG, W; PILON, M; KOZUBEK, A; DEKORTEKOOL, G; DEMEL, RA; WEISBEEK, PJ; DEKRUIJFF, B				VANTHOF, R; VANKLOMPENBURG, W; PILON, M; KOZUBEK, A; DEKORTEKOOL, G; DEMEL, RA; WEISBEEK, PJ; DEKRUIJFF, B			THE TRANSIT SEQUENCE MEDIATES THE SPECIFIC INTERACTION OF THE PRECURSOR OF FERREDOXIN WITH CHLOROPLAST ENVELOPE MEMBRANE-LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SMALL SUBUNIT; MITOCHONDRIAL PROTEIN; BINDING; OUTER; TRANSLOCATION; PEPTIDE; PURIFICATION; TRANSPORT	The interaction of the precursor of the chloroplast protein ferredoxin with membrane lipids was studied in monolayer experiments in order to investigate the possible involvement of membrane lipids in the protein translocation process. The precursor efficiently and specifically inserts into a total lipid extract of its biological target the outer envelope membrane of chloroplasts. This interaction is mediated by the transit sequence as it can also be observed for the chemically prepared transit peptide of ferredoxin but neither for the ferredoxin apoprotein nor holoprotein. Interactions with the individual chloroplast lipids, monogalactosyl-diacylglycerol, sulfoquinovosyl-diacylglycerol, and phosphatidylglycerol are predominantly involved which corresponds to the results obtained for transit peptide fragments of the small subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (van't Hof, R., Demel, R. A., Keegstra, K., and De Kruijff, B. (1991) FEBS Lett. 291, 350-354). No efficient interaction was obtained with digalactosyl-diacylglycerol and phosphatidylcholine, suggesting that a loose lipid headgroup packing due to small lipid headgroups and/or electrostatic repulsions facilitates efficient insertion. The observed preferences for interaction of the precursor and transit peptide of ferredoxin for the chloroplast outer envelope membrane lipid extract and the presequence of cytochrome c oxidase subunit IV for the mitochondrial outer membrane lipid extract indicate that targeting sequence-lipid interactions contribute to organelle-specific protein targeting.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University	VANTHOF, R (corresponding author), UNIV UTRECHT,DEPT BIOCHEM MEMBRANES,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS.		Kozubek, Arkadiusz/B-6316-2008	Kozubek, Arkadiusz/0000-0002-0033-3863				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BILLECOCQ A, 1974, BIOCHIM BIOPHYS ACTA, V352, P245, DOI 10.1016/0005-2736(74)90215-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKERHOFF H, 1974, LIPIDS, V9, P645, DOI 10.1007/BF02532169; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1985, J BIOL CHEM, V260, P3691; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEMEL RA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P151, DOI 10.1016/0005-2760(92)90091-9; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Douce R, 1984, Subcell Biochem, V10, P1; ENDO T, 1992, EUR J BIOCHEM, V270, P671; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HUISMAN JG, 1978, BIOCHEM BIOPH RES CO, V82, P1121, DOI 10.1016/0006-291X(78)90303-0; JOYARD J, 1989, ENDOCRYTOBIOLOGIE, V4, P527; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KERBER B, 1992, FEBS LETT, V306, P71, DOI 10.1016/0014-5793(92)80840-D; MORSE PD, 1973, BIOCHIM BIOPHYS ACTA, V298, P769, DOI 10.1016/0005-2736(73)90381-7; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAGANI S, 1984, EUR J BIOCHEM, V142, P361, DOI 10.1111/j.1432-1033.1984.tb08295.x; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1992, J BIOL CHEM, V267, P19907; REIS B, 1978, MOL GEN GENET, V209, P116; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SMEEKENS J, 1989, MOL GEN GENET, V261, P178; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SMEEKENS S, 1986, CELL, V46, P356; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P168; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WEBB MS, 1991, BIOCHIM BIOPHYS ACTA, V1060, P133, DOI 10.1016/S0005-2728(09)91002-7; WIESLANDER A, 1978, BIOCHIM BIOPHYS ACTA, V512, P241, DOI 10.1016/0005-2736(78)90250-X	52	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4037	4042						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440696				2022-12-25	WOS:A1993KN53300038
J	RIPLEY, CR; FANT, J; BIENKOWSKI, RS				RIPLEY, CR; FANT, J; BIENKOWSKI, RS			BREFELDIN-A INHIBITS DEGRADATION AS WELL AS PRODUCTION AND SECRETION OF COLLAGEN IN HUMAN LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; INTRACELLULAR DEGRADATION; ENVELOPE GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; DEFECTIVE COLLAGEN; GOLGI-APPARATUS; PROTEINS; MECHANISM	Brefeldin A (BFA) inhibits protein secretion, collapses the Golgi complex into the endoplasmic reticulum (ER), causes redistribution of processing enzymes normally resident in the Golgi to the ER, and uncouples the proximal and distal regions of the secretory pathway. We used BFA to determine where intracellular degradation of newly synthesized collagen degradation occurs. In normal human fetal lung fibroblasts, BFA (50 ng/ml) completely blocked collagen secretion and reduced collagen production by two-thirds. In cells synthesizing collagen under normal conditions, intracellular degradation was about 16%; BFA (50 ng/ml) reduced degradation to less than 5%. In cells induced to synthesize structurally abnormal collagen (by incubation with the proline analog cis-hydroxyproline), degradation was approximately 33%; BFA reduced this level to less than 10%. When the y axes were scaled appropriately, the dose-response curves for collagen degradation +/- cis-hydroxyproline versus BFA concentration coincided. A pulse-chase experiment demonstrated that BFA did not inhibit hydroxylation of prolyl residues, a major posttranslational modification of collagen that occurs in the ER, and that inhibition of degradation was independent of inhibition of collagen synthesis. Immunofluorescence examination revealed that BFA redistributed Golgi glycoproteins to the ER. At the ultrastructural level, Golgi complex could not be found in fibroblasts exposed to BFA for 1 h; however, clusters of small vesicles were observed. A different structure, comprising one or two lamellae and resembling a partial Golgi complex, was observed in cells incubated with BFA for 6 h. This structure was adjacent to ER but far from the nucleus. In addition, the ER was devoid of ribosomes. The inhibition of intracellular collagen degradation by BFA indicates that collagen degradation does not occur in the ER. Rather, it suggests that collagen degradation occurs beyond the BFA block, perhaps in the trans-Golgi network.	LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,PEDIAT RES CTR,NEW HYDE PK,NY 11042; CUNY QUEENS COLL,DEPT BIOL,FLUSHING,NY 11367; YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR ANALYT ULTRASTRUCT,BRONX,NY 10461	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; City University of New York (CUNY) System; Queens College NY (CUNY); Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BARILE FA, 1989, ARCH BIOCHEM BIOPHYS, V270, P294, DOI 10.1016/0003-9861(89)90031-3; BARILE FA, 1990, ARCH BIOCHEM BIOPHYS, V276, P125, DOI 10.1016/0003-9861(90)90018-T; BERG RA, 1984, BIOCHEMISTRY-US, V23, P2134, DOI 10.1021/bi00305a005; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1981, ANAL BIOCHEM, V116, P414, DOI 10.1016/0003-2697(81)90382-1; BIENKOWSKI RS, 1983, BIOCHEM J, V214, P1; BIENKOWSKI RS, 1990, BIOCHEM BIOPH RES CO, V168, P479, DOI 10.1016/0006-291X(90)92346-2; BIENKOWSKI RS, 1989, CURRENT TRENDS STUDY, P423; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; PAL R, 1991, AIDS RES HUM RETROV, V7, P707, DOI 10.1089/aid.1991.7.707; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PETERKOFSKY B, 1982, IMMUNOCHEMISTRY EXTR, V2, P19; SATO R, 1990, J BIOL CHEM, V265, P11880; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1991, J BIOL CHEM, V266, P9173; UTANI A, 1990, LAB INVEST, V63, P181; VIRTANEN I, 1990, HISTOCHEMISTRY, V94, P397	30	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3677	3682						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429043				2022-12-25	WOS:A1993KM16100098
J	BELFORD, HG; WESTAWAY, SK; ABELSON, J; GREER, CL				BELFORD, HG; WESTAWAY, SK; ABELSON, J; GREER, CL			MULTIPLE NUCLEOTIDE COFACTOR USE BY YEAST LIGASE IN TRANSFER-RNA SPLICING - EVIDENCE FOR INDEPENDENT ATP-BINDING AND GTP-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE; ENZYME; GENE	We have examined multiple cofactor usage by yeast tRNA ligase in splicing in vitro. The ligase mechanism of action requires expenditure of two molar equivalents of nucleotide cofactor per mole of tRNA product. Recent evidence (Westaway, S. K., Belford, H. G., Apostol, B. L., Abelson, J., and Greer, C. L. (1993) J. Biol. Chem. 268, 2435-2443) demonstrated that the ligase-associated kinase activity is more efficient with GTP as cofactor than with ATP. Employing a ligase fusion construct with dihydrofolate reductase (Apostol, B. L., Westaway, S. K., Abelson, J., and Greer, C. L. (1991) J. Biol. Chem. 266, 7445-7455) for purposes of enzyme purification, we performed joining assays demonstrating that ATP and GTP are the most effective combination of cofactors. ATP was essential to the joining reaction, while UTP, CTP, or ATP replaced GTP inefficiently.,Specific and functionally independent binding sites were confirmed for ATP and GTP by direct binding measurement. A third site was implicated in UTP- and CTP-ligase interactions. Comparison of binding constants with K(app) values determined for nucleotide-dependent joining suggested both that nucleotide triphosphate binding may be limiting in tRNA joining and that tRNA ligation occurs most efficiently using GTP for the kinase reaction and ATP as the adenylylate synthetase cofactor.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California Irvine; California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035955] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35955] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON J, 1991, HARVEY LECT, V85, P1; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; APOSTOL BL, 1991, NUCLEIC ACIDS RES, V19, P1853, DOI 10.1093/nar/19.8.1853; BURRIDGE PW, 1977, CAN J BIOCHEM CELL B, V55, P935, DOI 10.1139/o77-140; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004	18	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2444	2450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428919				2022-12-25	WOS:A1993KK81500032
J	CALA, SE; ULBRIGHT, C; KELLEY, JS; JONES, LR				CALA, SE; ULBRIGHT, C; KELLEY, JS; JONES, LR			PURIFICATION OF A 90-KDA PROTEIN (BAND-VII) FROM CARDIAC SARCOPLASMIC-RETICULUM - IDENTIFICATION AS CALNEXIN AND LOCALIZATION OF CASEIN KINASE-II PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MOLECULAR-CLONING; CDNA CLONING; RAT-LIVER; CALSEQUESTRIN; VESICLES; GLYCOPROTEIN; 53,000-DALTON; SPECIFICITY; EXPRESSION	Purification and sequencing of proteins from cardiac sarcoplasmic reticulum (SR) vesicles have provided a framework for the study of SR function. Included among the SR proteins so far investigated are a collection of intralumenal proteins that stain blue with the protein dye Stains-All in sodium dodecyl sulfate-polyacrylamide gels. A single prominent blue staining SR protein of apparent M(r) = 90,000 (Band VII), however, has remained uncharacterized. In the work described here, purification of Band VII from dog cardiac SR vesicles, along with amino acid sequencing and cDNA cloning, identified this protein as calnexin, a homologue of calreticulin recently described in dog pancreatic microsomes. Using ryanodine-mediated calcium oxalate loading of SR vesicles followed by density gradient centrifugation, we have shown that calnexin is a bona fide SR protein and an integral constituent of both junctional and free SR vesicles. Calnexin was found to be a substrate for casein kinase II and was phosphorylated at two distinct sites localized to the carboxyl- and amino-terminal ends of the molecule. Enrichment of calnexin in cardiac SR vesicles indicates a role for calnexin involving the specialized function of the SR membrane.	INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	CALA, SE (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28556, HL06308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALLEN G, 1989, SEQUENCING PROTEINS; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA S E, 1991, Biophysical Journal, V59, p249A; CALA SE, 1983, J BIOL CHEM, V258, P1932; CALA SE, 1992, BIOCHIM BIOPHYS ACTA, V1118, P277, DOI 10.1016/0167-4838(92)90285-L; CALA SE, 1991, J BIOL CHEM, V266, P391; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUZIKI Y, 1982, J CELL BIOL, V93, P97; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOFMANN SL, 1989, J BIOL CHEM, V264, P8260; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; JONES LR, 1979, J BIOL CHEM, V254, P530; JONES LR, 1981, J BIOL CHEM, V256, P1809; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; Maniatis T., 1982, MOL CLONING; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SEILER S, 1984, J BIOL CHEM, V259, P8550; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; VAN PN, 1989, J BIOL CHEM, V264, P17494; WADA I, 1991, J BIOL CHEM, V266, P19599; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	37	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2969	2975						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428970				2022-12-25	WOS:A1993KK81500104
J	MCGUIRE, MJ; LIPSKY, PE; THIELE, DL				MCGUIRE, MJ; LIPSKY, PE; THIELE, DL			GENERATION OF ACTIVE MYELOID AND LYMPHOID GRANULE SERINE PROTEASES REQUIRES PROCESSING BY THE GRANULE THIOL PROTEASE DIPEPTIDYL PEPTIDASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE METHYL-ESTER; CYTO-TOXIC LYMPHOCYTES; NATURAL-KILLER CELLS; MAST-CELL; CYTOTOXIC LYMPHOCYTES; NEUTROPHIL ELASTASE; MONOCLONAL-ANTIBODY; DIAZOMETHYL KETONES; ZYMOGEN ACTIVATION; MOLECULAR-CLONING	The proenzyme activation peptides predicted from cDNAs encoding each of the granule serine proteases synthesized by cytotoxic lymphocytes and myeloid and mast cells are composed of 2 residues. The mechanism by which these amino-terminal dipeptides are cleaved to generate the active enzymes has not been elucidated. The comparable distribution of dipeptidyl peptidase I (DPPI) and serine proteases and the ability of DPPI to hydrolyze relevant dipeptide sequences suggested a role for DPPI in the processing and activation of granule serine proteases. This study demonstrates that inhibition of DPPI activity is associated with impairment of the generation of granule serine protease activity in CD8(+) T cells, lymphokine-activated killer cells, P815 mastocytoma cells, and U-937 myeloid cells. Inhibition of DPPI resulted in impairment of the generation of cathepsin G enzymatic activity without reduction in the amount of immunoreactive cathepsin G produced. In U-937 cells pulsed with [H-3]isoleucine, inhibition of DPPI activity was associated with the accumulation of the inactive proenzyme form of cathepsin G bearing an amino-terminal dipeptide extension to the isoleucine residue that normally occupies the amino terminus of the enzymatically active protein. These results indicate that DPPI plays a requisite role in the post-translational processing and activation of members of the family of granule serine proteases expressed in bone marrow-derived effector cells.			MCGUIRE, MJ (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI024639, R01AI024639] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24639] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BLEACKLEY RC, 1989, CURR TOP MICROBIOL, V140, P67; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FRUTON JS, 1960, ENZYMES, V4, P233; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; HENKART PA, 1987, J IMMUNOL, V139, P2398; HSIUNG HM, 1987, METHOD ENZYMOL, V153, P390; HUBER R, 1977, REGULATORY PROTEOLYT, P15; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOGDBERG L, 1985, CELL IMMUNOL, V94, P299, DOI 10.1016/0008-8749(85)90254-0; MAGNUSSON S, 1971, ENZYMES, V3, P277; MCDONALD JK, 1969, J BIOL CHEM, V244, P6199; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCDONALD JK, 1970, TISSUE PROTEINASES, P69; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; OKANO K, 1990, BIOCHEM BIOPH RES CO, V167, P1326, DOI 10.1016/0006-291X(90)90668-D; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; PURCELL GM, 1963, BIOCHIM BIOPHYS ACTA, V78, P800, DOI 10.1016/0006-3002(63)91067-9; RAFF RF, 1988, TRANSPLANTATION, V46, P655, DOI 10.1097/00007890-198811000-00005; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; ROBINSON NC, 1973, BIOCHEMISTRY-US, V12, P420, DOI 10.1021/bi00727a010; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SCHICK B, 1990, IMMUNOLOGY, V69, P423; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHAW E, 1981, METHOD ENZYMOL, V80, P820; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS RL, 1989, CURR TOP MICROBIOL, V140, P93; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; STROUD RM, 1975, PROTEASES BIOL CONTR, P13; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TAKAYAMA H, 1987, J IMMUNOL, V138, P566; THIELE DL, 1987, J IMMUNOL, V138, P51; THIELE DL, 1990, J EXP MED, V172, P183, DOI 10.1084/jem.172.1.183; THIELE DL, 1985, P NATL ACAD SCI USA, V82, P2468, DOI 10.1073/pnas.82.8.2468; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; THIELE DL, 1986, J IMMUNOL, V136, P1038; THIELE DL, 1992, TRANSPLANTATION, V53, P1334, DOI 10.1097/00007890-199206000-00030; Tubbs P.K., 1969, METHODS ENZYMOL, V13, P535, DOI [10.1016/0076-6879(69)13079-7, DOI 10.1016/0076-6879(69)13079-7]; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VIVIER I, 1991, J IMMUNOL, V147, P447; WATANABE T, 1982, BIOCHIM BIOPHYS ACTA, V717, P439, DOI 10.1016/0304-4165(82)90285-9; WILDE CG, 1990, J BIOL CHEM, V265, P2038; Worthington C.C, 1988, WORTHINGTON ENZYME M, P199; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	64	189	197	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2458	2467						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428921				2022-12-25	WOS:A1993KK81500034
J	NELSON, JE; KRAWETZ, SA				NELSON, JE; KRAWETZ, SA			LINKAGE OF HUMAN SPERMATID-SPECIFIC BASIC NUCLEAR-PROTEIN GENES - DEFINITION AND EVOLUTION OF THE P1-]P2-]TP2 LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION PROTEIN-1; PROTAMINE GENES; CHROMOSOMAL LOCALIZATION; NUCLEOTIDE-SEQUENCE; PRM1; HYBRIDIZATION; ASSIGNMENT; CHAIN; TNP2; TP1	Protamines and transition proteins are highly basic sperm-specific nuclear proteins that serve to compact the DNA within the condensing spermatid nucleus. It has been proposed that the genes for protamine P1 and P2 and transition protein 2 may be clustered at a single loci. This may have marked implications for their evolution and coordinate developmental regulation. The cloning of a contiguous segment encompassing this region would directly address these issues. We have utilized a cloned segment of the human protamine P1 gene to isolate a human cosmid clone which contains the genes for protamines P1 and P2 and transition protein TP2. Sequence and hybridization analysis of this cosmid showed that the TP2 gene resided 3' of the P2 gene at a distance of approximately 7 kilobases (kb). This establishes the order of this gene cluster within a 13-kb region of 16pl3.13-16pl3.2 to be P1-->P2-->TP2. Similar to their spatial order, comparative computer-assisted sequence analysis predicts an identical relative rank order of emergence. Accordingly we propose that this gene cluster may have arisen from the P1 gene through a series of gene duplication events.	WAYNE STATE UNIV,SCH MED,CS MOTT CTR HUMAN GROWTH & DEV 253,DEPT OBSTET & GYNECOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CS MOTT CTR HUMAN GROWTH & DEV,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201	Wayne State University; Wayne State University			krawetz, stephen/GQQ-3308-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504] Funding Source: NIH RePORTER; NICHD NIH HHS [1RO1HD2850401A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADHAM IM, 1991, CYTOGENET CELL GENET, V57, P47, DOI 10.1159/000133113; AKAMA K, 1990, BIOCHIM BIOPHYS ACTA, V1041, P264, DOI 10.1016/0167-4838(90)90282-K; Balhorn R., 1989, P366; BALHORN R, 1982, J CELL BIOL, V93, P298, DOI 10.1083/jcb.93.2.298; BELLVE AR, 1988, BIOCHEMISTRY-US, V27, P2890, DOI 10.1021/bi00408a034; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; DIXON GH, 1986, CHROMOSOMAL PROTEINS, P287; DOMENJOUD L, 1990, GENOMICS, V8, P127, DOI 10.1016/0888-7543(90)90234-L; DUPRESSOIR T, 1985, EXP CELL RES, V161, P63, DOI 10.1016/0014-4827(85)90490-2; Goldberg ML, 1979, SEQUENCE ANAL DROSOP; HARLOW P, 1988, J MOL EVOL, V27, P56, DOI 10.1007/BF02099730; Hecht N.B., 1989, P396; Hecht NB, 1989, HISTONES OTHER BASIC, P347; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HEIDARAN MA, 1989, GENE, V75, P39, DOI 10.1016/0378-1119(89)90381-8; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KEIME S, 1992, BIOL CHEM H-S, V373, P261, DOI 10.1515/bchm3.1992.373.1.261; KLEENE KC, 1990, GENE, V95, P301, DOI 10.1016/0378-1119(90)90376-3; KRAWETZ SA, 1989, GENOMICS, V5, P639, DOI 10.1016/0888-7543(89)90036-0; KRAWETZ SA, 1988, J MOL EVOL, V27, P291, DOI 10.1007/BF02101190; KRAWETZ SA, 1988, J BIOL CHEM, V263, P321; KRAWETZ SA, 1988, BIOTECHNIQUES, V5, P620; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1981, BIOREGULATORS REPROD, P151; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON JE, 1992, IN PRESS ANAL BIOCH, V207; Oliva R., 1991, PROGR NUCL ACID RES, P26; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINHART N, 1991, BIOL CHEM H-S, V372, P431, DOI 10.1515/bchm3.1991.372.1.431; RICHARDS RI, 1991, GENOMICS, V10, P1047, DOI 10.1016/0888-7543(91)90197-M; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SCHLUTER G, 1992, GENOMICS, V14, P377, DOI 10.1016/S0888-7543(05)80229-0; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; VIGUIE F, 1990, HUM GENET, V85, P171; YELICK PC, 1991, GENOMICS, V11, P687, DOI 10.1016/0888-7543(91)90076-Q	39	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2932	2936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428967				2022-12-25	WOS:A1993KK81500099
J	OSAWA, Y; DARBYSHIRE, JF; STEINBACH, PJ; BROOKS, BR				OSAWA, Y; DARBYSHIRE, JF; STEINBACH, PJ; BROOKS, BR			METABOLISM-BASED TRANSFORMATION OF MYOGLOBIN TO AN OXIDASE BY BRCCL3 AND MOLECULAR MODELING OF THE OXIDASE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; CYTOCHROME-P-450 HEME; CRYSTAL-STRUCTURE; PROSTHETIC HEME; PROTEIN ADDUCTS; IRON RELEASE; DEGRADATION; HEMOGLOBIN; DYNAMICS; INACTIVATION	The stoichiometric reductive debromination of BrCCl3 to a trichloromethyl radical by myoglobin caused the prosthetic heme to become covalently cross-linked to the protein moiety and transformed myoglobin from an oxygen storage protein to an oxidase. This was shown in experiments in which oxygen consumption was measured during redox cycling of the altered myoglobin in the presence of ascorbate or an enzymatic reducing system containing diaphorase and NADH. Redox cycling eventually led to loss of the protein-bound heme adduct and oxidase activity of myoglobin. We have used molecular modeling and the known structure of the protein-bound heme adduct to identify probable mechanisms for transformation of myoglobin to an oxidase. Based on these modeling studies, the most likely structure of the experimentally observed adduct involves ligation to the heme iron of the epsilon-nitrogen atom of histidine 97 and/or that of histidine 64. The model structures revealed access of solvent to the heme active site, which could facilitate oxygen reduction. The transformation of myoglobins and perhaps other hemoproteins to oxidases may have toxicological importance in causing the tissue damage resulting from exposure to various xenobiotics and endogenous chemicals as well as explaining how hemoproteins are inactivated during catalysis.	NIH, DIV COMP RES & TECHNOL, MOLEC GRAPH & SIMULAT LAB, BETHESDA, MD 20892 USA		OSAWA, Y (corresponding author), NHLBI, CHEM PATHOL LAB, BLDG 10, RM 8N110, BETHESDA, MD 20892 USA.							ANTONINI E, 1964, BIOCHIM BIOPHYS ACTA, V79, P284; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; DAVIES HW, 1986, CHEM-BIOL INTERACT, V58, P345, DOI 10.1016/S0009-2797(86)80108-9; DEMONTELLANO PRO, 1990, PHARMACOL THERAPEUT, V48, P95, DOI 10.1016/0163-7258(90)90020-3; DEMONTELLANO PRO, 1983, ANNU REV PHARMACOL, V23, P481; EDMUNDSO.AB, 1965, NATURE, V205, P883, DOI 10.1038/205883a0; FERRALI M, 1989, BIOCHEM PHARMACOL, V38, P1819, DOI 10.1016/0006-2952(89)90417-6; GUENGERICH FP, 1986, BIOCHEM BIOPH RES CO, V138, P193, DOI 10.1016/0006-291X(86)90265-2; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; OSAWA Y, 1992, SYNTHESIS AND APPLICATIONS OF ISOTOPICALLY LABELLED COMPOUNDS 1991, P415; PERUTZ MF, 1989, TRENDS BIOCHEM SCI, V14, P42, DOI 10.1016/0968-0004(89)90039-X; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PRASAD MR, 1989, BIOCHEM J, V263, P731, DOI 10.1042/bj2630731; PUPPO A, 1988, FREE RADICAL RES COM, V4, P415, DOI 10.3109/10715768809066910; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; REDDY BR, 1989, FREE RADICAL BIO MED, V7, P45; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STEINBACH PJ, 1991, CHEM PHYS, V158, P383, DOI 10.1016/0301-0104(91)87078-A; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TROTTA RJ, 1983, BIOCHEM J, V212, P759, DOI 10.1042/bj2120759; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966	33	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2953	2959						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428969				2022-12-25	WOS:A1993KK81500102
J	ZHANG, YY; LIND, B; RADMARK, O; SAMUELSSON, B				ZHANG, YY; LIND, B; RADMARK, O; SAMUELSSON, B			IRON CONTENT OF HUMAN 5-LIPOXYGENASE, EFFECTS OF MUTATIONS REGARDING CONSERVED HISTIDINE-RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN 5-LIPOXYGENASE; SOYBEAN LIPOXYGENASE; ARACHIDONATE 12-LIPOXYGENASE; PORCINE LEUKOCYTES; LEUKOTRIENES; ENVIRONMENT; PATHWAY; ENZYME; ACIDS; PROBE	Recombinant human 5-lipoxygenase was expressed in Escherichia coli and purified to more than 95% homogeneity by ammonium sulfate precipitation and agarose-ATP column chromatography. The specific activity of the purified enzyme was 21-28 mumol/mg, as assessed by the generation of 5-hydro(pero)xyeicosatetraenoic acid. The iron content was analyzed by graphite furnace atomic absorption spectrophotometry for six preparations of the enzyme. The average value of the iron content was 0.86 mol/mol (iron/protein) with a range of 0.74-1.15 mol/mol. All lipoxygenases that have been sequenced contain 6 conserved histidine residues. Mutants of 5-lipoxygenase, with substitutions of these 6 conserved histidines, were purified and analyzed. Mutants H372Q and H550Q had no detectable enzyme activity and were also practically devoid of iron. Three mutants regarding His367 (H367Q, H367N, and H367S) were all inactive but had partial iron contents (0.5, 0.2, and 0.5 mol/mol, respectively). Finally, the mutated proteins H362Q, H390Q, and H399Q displayed reduced enzyme activity but contained similar amounts of iron as non-mutated 5-lipoxygenase. We conclude that histidines 372 and 550 constitute two of the iron ligands in 5-lipoxygenase. Also His367 is necessary for the enzyme activity, but this residue is not crucial for binding of iron.	KAROLINSKA INST, INST ENVIRONM MED, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet	ZHANG, YY (corresponding author), KAROLINSKA INST, DEPT PHYSIOL CHEM 2, S-10401 STOCKHOLM 60, SWEDEN.							CHAN HWS, 1973, BIOCHIM BIOPHYS ACTA, V327, P32, DOI 10.1016/0005-2744(73)90100-9; COOKE ST, 1991, LIPOXYGENASES THEIR; COREY EJ, 1987, J AM CHEM SOC, V109, P8107, DOI 10.1021/ja00260a038; DEMARZO N, 1992, LUNG CELL MOL PHYSL, V6, pL198; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FEITERS MC, 1990, RECL TRAV CHIM PAY B, V109, P133; FURUKAWA M, 1984, BIOCHIM BIOPHYS ACTA, V795, P458; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2; KRONECK PMH, 1991, FEBS LETT, V287, P105, DOI 10.1016/0014-5793(91)80026-Y; MATSUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1084, P202; MATSUMOTO T, 1991, 27 P YAM C INT S OXY, P51; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; PISTORIUS EK, 1974, J BIOL CHEM, V249, P3183; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROZA M, 1973, BIOCHIM BIOPHYS ACTA, V327, P24, DOI 10.1016/0005-2744(73)90099-5; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHIBATA D, 1991, PLANT MOL BIOL, V16, P353, DOI 10.1007/BF00020569; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; Veldink G A, 1984, Adv Inorg Biochem, V6, P139; WHITTAKER JW, 1986, J AM CHEM SOC, V108, P835, DOI 10.1021/ja00264a045; WIESNER R, 1983, BIOMED BIOCHIM ACTA, V42, P431; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; ZHANG Y, 1991, J AM CHEM SOC, V113, P5162, DOI 10.1021/ja00014a004; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	34	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2535	2541						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428931				2022-12-25	WOS:A1993KK81500044
J	WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H				WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H			ACTIVATION OF C-MOS ONCOGENE BY INTEGRATION OF AN ENDOGENOUS LONG TERMINAL REPEAT ELEMENT DURING TRANSFECTION OF GENOMIC DNA FROM MOUSE SKIN TUMOR-CELLS	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; PROTO-ONCOGENE; CELLULAR ONCOGENE; EXPRESSION; LTR; REARRANGEMENT; TRANSCRIPTS; JUNCTIONS	An activated c-mos oncogene was identified in a transformed clone of golden hamster embryo cells transfected with DNA extracted from cells cultured from a UV-induced mouse skin tumor. Southern blot hybridization with a v-mos oncogene probe showed that the mos oncogene was amplified in the primary and secondary transformed cells but not in the original tumor cells. Expression of the mos oncogene was very high in the primary and secondary transformants, but mos mRNA was undetectable in the original tumor cells. A genomic DNA fragment containing the activated mos oncogene was cloned and sequenced. The upstream mouse sequence of the mos oncogene, which functions as the transcription terminator, was lost and replaced by a mouse endogenous long terminal repeat (LTR) element that provides the promoter sequence, resulting in high expression of the gene. The rearrangement apparently occurred during transfection, since the polymerase chain reaction (PCR) product encompassing the junction region was present in the primary and secondary transformants but not in the original tumor cells. The LTR element is likely to have been amplified during the skin tumor development caused by UV irradiation. Southern blot hybridization showed that the copy number of LTR in the tumor cells was significantly higher than that in normal skin cells. The amplification of the LTR in the cells may have increased the chance of recombination between the LTR and c-mos gene during the DNA transfection.	KYOTO UNIV,FAC MED,DEPT DERMATOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	WANG, SM (corresponding author), KYOTO UNIV,FAC MED,DEPT EXPTL RADIOL,SAKYO KU,KYOTO 606,JAPAN.							BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coffin J.M., 1984, RNA TUMOR VIRUSES, P1109; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DHAR R, 1980, P NATL ACAD SCI-BIOL, V77, P3937, DOI 10.1073/pnas.77.7.3937; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAO CL, 1988, ONCOGENE, V3, P267; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HOUSEY GM, 1985, BIOCHEM BIOPH RES CO, V127, P391, DOI 10.1016/S0006-291X(85)80172-8; KIRSCHMEIER P, 1982, P NATL ACAD SCI-BIOL, V79, P2773, DOI 10.1073/pnas.79.9.2773; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILSON JH, 1982, MOL CELL BIOL, V2, P1258, DOI 10.1128/MCB.2.10.1258; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	37	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1009	1016						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455928				2022-12-25	WOS:A1993KT22000024
J	CHIN, JE; DICKENS, M; TAVARE, JM; ROTH, RA				CHIN, JE; DICKENS, M; TAVARE, JM; ROTH, RA			OVEREXPRESSION OF PROTEIN-KINASE-C ISOENZYMES-ALPHA, BETA-I, GAMMA, AND EPSILON IN CELLS OVEREXPRESSING THE INSULIN-RECEPTOR - EFFECTS ON RECEPTOR PHOSPHORYLATION AND SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; GROWTH FACTOR-I; TYROSINE KINASE; STIMULATED SERINE; PHORBOL ESTER; THREONINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; AUTOPHOSPHORYLATION; ACTIVATION; EXPRESSION	Chinese hamster ovary cells overexpressing the human insulin receptor were transfected with cDNAs encoding protein kinase C isoenzymes alpha, betaI, gamma, and epsilon as well as an inactive alpha. Overexpression of these protein kinase Cs did not affect expression of the insulin receptor or insulin-stimulated tyrosine phosphorylation of the receptor. However, in response to phorbol esters, cells overexpressing isoenzymes alpha, betaI, and gamma, but not epsilon or inactive alpha, exhibited 3-4-fold higher levels of insulin receptor phosphorylation. This increased phosphorylation occurred exclusively on serines and threonine. Tryptic peptide maps indicated that this phosphorylation was primarily on serines 1305/1306 and threonine 1348 as well as several other unidentified sites. This phorbol ester-stimulated phosphorylation did not inhibit activation of the insulin receptor kinase when the receptor was activated in situ but assayed in vitro. However, in cells overexpressing protein kinase Calpha, it did inhibit an in vivo monitor of the activation of the insulin receptor kinase, the insulin-stimulated increase in anti-phosphotyrosine-precipitable phosphatidylinositol 3-kinase activity. These results indicate that increased protein kinase Calpha activity can inhibit insulin-stimulated responses and support the hypothesis that excessive protein kinase Calpha is involved in the insulin resistance observed in non-insulin-dependent diabetics.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	Stanford University; University of Bristol			Dickens, Martin/B-2001-2012		NIDDK NIH HHS [DK08577] Funding Source: Medline; PHS HHS [41765, 34962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKITA Y, 1990, J BIOL CHEM, V265, P354; ANDERSON CM, 1991, J BIOL CHEM, V266; AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BRILLON DJ, 1989, DIABETES, V38, P397, DOI 10.2337/diabetes.38.3.397; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DELALUNA S, 1988, GENE, V62, P121; DURONIO V, 1990, ENDOCRINOLOGY, V127, P481, DOI 10.1210/endo-127-1-481; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GRUNBERGER G, 1991, CELL SIGNAL, V3, P171, DOI 10.1016/0898-6568(91)90042-S; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HARING HU, 1991, DIABETOLOGIA, V34, P848, DOI 10.1007/BF00400192; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; JACOBS S, 1986, J BIOL CHEM, V261, P934; KARASIK A, 1990, J BIOL CHEM, V265, P10226; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KOVACINA K, 1993, IN PRESS ATHEROSCLER, V25; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LEE TS, 1989, J CLIN INVEST, V83, P90, DOI 10.1172/JCI113889; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PILLAY TS, 1991, BIOCHEM BIOPH RES CO, V179, P962, DOI 10.1016/0006-291X(91)91912-V; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SMITH DM, 1988, BIOCHEM J, V250, P509, DOI 10.1042/bj2500509; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; THAKKER JK, 1989, J BIOL CHEM, V264, P7169; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG B, 1992, J BIOL CHEM, V267, P18320	58	169	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6338	6347						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454604				2022-12-25	WOS:A1993KT36800041
J	LEE, TH; KLAMPFER, L; SHOWS, TB; VILCEK, J				LEE, TH; KLAMPFER, L; SHOWS, TB; VILCEK, J			TRANSCRIPTIONAL REGULATION OF TSG6, A TUMOR NECROSIS FACTOR-1-INDUCIBLE AND INTERLEUKIN-1-INDUCIBLE PRIMARY RESPONSE GENE CODING FOR A SECRETED HYALURONAN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; NUCLEAR FACTOR; HUMAN-FIBROBLASTS; FACTOR-ALPHA; EUKARYOTIC PROMOTERS; LINK PROTEINS; EXPRESSION; ACTIVATION; INDUCTION; CYTOKINES	TSG6 was originally identified as a tumor necrosis factor (TNF)-inducible gene in human fibroblasts. Earlier we showed that the secretory TSG6 protein is a member of a family of hyaluronan-binding proteins that includes cartilage link protein, proteoglycan core protein, and the adhesion receptor CD44. In the present study we have used Southern blot analysis to demonstrate that TSG6 is a single-copy gene in the human and murine species. With the aid of a somatic cell hybrid mapping panel, TSG6 was assigned to human chromosome 2. Nuclear run-on analysis revealed that TNF produced a rapid, primary transcriptional activation of the TSG6 gene in normal human FS-4 fibroblasts. In order to learn more about the regulation of TSG6 gene expression, we cloned the TSG6 gene from a genomic library of human white blood cells. Sequencing of a 1.3-kilobase fragment of the 5'-flanking region of the TSG6 gene identified TATA-like and CAAT sequences near the transcription start site. In addition, potential binding sites for NF-IL-6, AP-1, interferon regulatory factors (IRF)-l and -2, and glucocorticoid response elements were identified in the 5'-flanking region. A single transcription start site was identified by primer extension. Deletion analysis of the 5'-flanking region of the TSG6 DNA linked to the chloramphenicol acetyltransferase reporter gene revealed that a construct containing TSG6 DNA from positions-165 to +78 could be transcriptionally activated by interleukin(IL)-1, and to a lesser extent by TNF, upon transfection into FS-4 fibroblasts. The region that imparts inducibility by IL-1 or TNF (positions -165 to -58) contains potential binding sites for IRF- 1 and -2, AP-1, and NF-IL-6. A region mediating transcriptional silencing was localized further upstream (between positions -332 and -165). The results suggest that TSG6 gene expression is regulated by an interplay of positively and negatively acting transactivating factors.	ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14263; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Roswell Park Cancer Institute; New York University; New York University	LEE, TH (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.				NCI NIH HHS [R35CA49731] Funding Source: Medline; NHGRI NIH HHS [HG00333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, INTERLEUKINS MOL BIO, P299; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LE JM, 1987, LAB INVEST, V56, P234; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LEE TH, 1993, TUMOR NECROSIS FACTO; LIN JX, 1987, J BIOL CHEM, V262, P11908; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NETA R, 1992, TUMOR NECROSIS FACTO, P499; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WISNIEWSKI HG, 1992, PHYSL PATHOPHYSIOLOG, P149; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	35	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6154	6160						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454591				2022-12-25	WOS:A1993KT36800015
J	STOTT, K; SAITO, K; THIELE, DJ; MASSEY, V				STOTT, K; SAITO, K; THIELE, DJ; MASSEY, V			OLD YELLOW ENZYME - THE DISCOVERY OF MULTIPLE ISOZYMES AND A FAMILY OF RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CARLSBERGENSIS; CLONING; YEAST; TRANSFORMATION; GENE; ACID	Using fast protein liquid chromatography, we have separated native Old Yellow Enzyme from Brewer's Bottom Yeast into three distinct fractions. Two of these fractions are homodimeric forms of the enzyme while the third is the corresponding heterodimeric form. One of these homodimeric fractions is identical in every respect to OYE1, originally cloned from Brewer's Bottom Yeast (Saito, K., Thiele, D. J., Davio, M., Lockridge, O., and Massey, V. (1991) J. Biol. Chem. 266, 20720-20724). We have cloned, sequenced, and expressed a second Old Yellow Enzyme gene from Saccharomyces cerevisiae, showing close similarity, but not identity, with OYE1. Native Old Yellow Enzyme samples were also affinity-purified from a strain of S. cerevisiae and an OYE deletion mutant constructed from it. A total of at least seven isozymes of Old Yellow Enzyme have been discovered, each having slightly different characteristics ranging from surface charge to NADPH dehydrogenase activities with different electron acceptors, as well as N-terminal amino acid sequence. In addition, both recombinant enzymes showed considerable similarity to two proteins in the GenBank/EMBL data bank, a 60,000-dalton bile acid-inducible polypeptide in Eubacterium sp. (Mallonee, D. H., White, W. B., and Hylemon, P. B. (1990) J. Lipid Res. 172, 7011-7019) and a 72,000-dalton NADH oxidase in Thermoanaerobium brockii.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; CASEY GP, 1988, CARLSBERG RES COMMUN, V53, P209, DOI 10.1007/BF02904408; DUBY A, 1987, CURRENT PROTOCOLS MO, V1; HYLEMON PB, 1980, AM J CLIN NUTR, V33, P2507, DOI 10.1093/ajcn/33.11.2507; HYLEMON PB, 1991, J LIPID RES, V32, P89; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P901, DOI 10.1093/oxfordjournals.jbchem.a135551; PARKS LW, 1978, CR CRIT REV MICROBIO, V6, P300; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAITO K, 1991, J BIOL CHEM, V266, P20720; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOPFER LM, 1991, STUDY ENZYMES, V2, P247; SHERMAN F, 1991, METHOD ENZYMOL, V194, P15; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Theorell H, 1935, BIOCHEM Z, V275, P344; Warburg O, 1933, BIOCHEM Z, V266, P377	23	135	145	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6097	6106						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454584				2022-12-25	WOS:A1993KT36800007
J	FISHBURN, CS; BELLELI, D; DAVID, C; CARMON, S; FUCHS, S				FISHBURN, CS; BELLELI, D; DAVID, C; CARMON, S; FUCHS, S			A NOVEL SHORT ISOFORM OF THE D3 DOPAMINE RECEPTOR GENERATED BY ALTERNATIVE SPLICING IN THE 3RD CYTOPLASMIC LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ACETYLCHOLINE-RECEPTOR; MOLECULAR-CLONING; DIFFERENTIAL EXPRESSION; D2-DOPAMINE RECEPTOR; ALPHA-SUBUNIT; RAT; GENE; D1; SPECIFICITY	The mouse D3 dopamine receptor has been cloned from olfactory tubercle cDNA using polymerase chain reaction and has been found to exist in two alternatively spliced forms. These two mRNA isoforms differ by the presence or absence of 63 base pairs (bp), which encode 21 amino acids in the putative third cytoplasmic loop of the receptor. The longer form corresponds to the previously reported rat D3 dopamine receptor, to which it bears sequence homology of 94%. Northern blot analysis shows the mouse D3 receptor to be most abundant in the olfactory tubercle. Expression studies show the novel short D3 isoform to bind dopaminergic ligands with a D3-like pharmacological profile. Polymerase chain reaction analysis on different mouse brain regions shows the long and short D3 receptors to be present in the same tissues, the longer form invariably being the predominant one. Analysis of the gene for the mouse D3 dopamine receptor shows that no separate exon encodes the 63-bp stretch and reveals the presence of a consensus sequence for an acceptor site at the 3' end of the 63-bp stretch. This suggests that an internal acceptor site in the exon coding for the distal part of the third cytoplasmic loop directs alternative splicing of the D3 dopamine receptor.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; ASHER O, 1988, FEBS LETT, V233, P277, DOI 10.1016/0014-5793(88)80442-3; BOUTHENET ML, 1991, BRAIN RES, V564, P203, DOI 10.1016/0006-8993(91)91456-B; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHIO CL, 1990, NATURE, V343, P266, DOI 10.1038/343266a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVELLI O, 1991, EUR J PHARM-MOLEC PH, V207, P277, DOI 10.1016/0922-4106(91)90001-X; CREESE I, 1983, ANNU REV NEUROSCI, V6, P43, DOI 10.1146/annurev.ne.06.030183.000355; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; ELAZAR Z, 1989, EMBO J, V8, P2353, DOI 10.1002/j.1460-2075.1989.tb08363.x; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FISHBURN CS, 1991, 3RD IBRO WORLD C NEU, P278; GIROS B, 1991, BIOCHEM BIOPH RES CO, V176, P1584, DOI 10.1016/0006-291X(91)90469-N; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; ISRAEL JM, 1985, ENDOCRINOLOGY, V117, P1448, DOI 10.1210/endo-117-4-1448; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; NIZNIK HB, 1987, MOL CELL ENDOCRINOL, V54, P1, DOI 10.1016/0303-7207(87)90134-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHARA K, 1988, MOL PHARMACOL, V33, P290; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SNYDER LA, 1991, BIOCHEM BIOPH RES CO, V180, P1031, DOI 10.1016/S0006-291X(05)81169-6; SNYDER LA, 1991, NEUROSCI LETT, V122, P37, DOI 10.1016/0304-3940(91)90187-X; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TARASKEVICH PS, 1978, NATURE, V276, P832, DOI 10.1038/276832a0; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	43	93	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5872	5878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449953				2022-12-25	WOS:A1993KR82200078
J	LI, Y; CAMP, S; TAYLOR, P				LI, Y; CAMP, S; TAYLOR, P			TISSUE-SPECIFIC EXPRESSION AND ALTERNATIVE MESSENGER-RNA PROCESSING OF THE MAMMALIAN ACETYLCHOLINESTERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPASE-C; MOLECULAR-FORMS; ELECTRIC ORGAN; DIMERIC FORM; MUSCLE; CELLS; CHOLINESTERASES; BIOSYNTHESIS; MUTAGENESIS	This study examines the tissue specificity and the gene products arising from alternative mRNA processing of the mammalian acetylcholinesterase gene. By splicing either alternative exons 5 or 6 in the mouse and human genes directly to the invariant exons (exons 2, 3, and 4), we show that the acetylcholinesterase species expressed by transfected recombinant DNA have the properties expected for the respective enzyme forms found in tissue. Antisense mRNA derived from these cDNAs has been employed to examine differential splicing in various tissues. In most cells, the hydrophilic form of AChE encoded by the exon 4 to exon 6 splice to form the mRNA is the predominant species. However, splicing of exon 4 to exon 5, yielding a mRNA encoding the glycophospholipid-linked form of acetylcholinesterase, is seen primarily in erythroid and to a lesser extent in AtT-20 cells. Only small amounts of this mRNA species appear in some other cells in culture. A novel third mRNA species, which arises from an extension of exon 4 without splicing to a downstream exon, is seen in mouse erythroid but not in human erythroid cells. A cDNA encoding this species when expressed in COS cells gives rise to a unique hydrophilic, secreted form of acetylcholinesterase. Transfection of a human genomic clone into mouse erythroleukemia cells does not result in the appearance of a mRNA species with an extension of exon 4 as seen with the endogenous mouse gene. Hence, differential splicing between the mouse and human genes appears intrinsic to the coding sequence and is not dependent solely on specific factors in the mouse erythroleukemia cell.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24437, GM 18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel F.M., 1987, CURRENT PROTOCOL MOL; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; BUONASSISI V, 1962, P NATL ACAD SCI USA, V48, P1184, DOI 10.1073/pnas.48.7.1184; BURSTEIN SA, 1985, J CELL PHYSIOL, V122, P159, DOI 10.1002/jcp.1041220124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FUENTES ME, 1988, MOL CELL BIOCHEM, V81, P53; GANAOVASMUNOZ MD, 1990, BIOCHIM BIOPHYS ACTA, V1039, P323; GARCIA L, 1988, NEUROCHEM INT, V13, P327, DOI 10.1016/0197-0186(88)90005-8; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; GREENFIELD SA, 1991, CELL MOL NEUROBIOL, V11, P55, DOI 10.1007/BF00712800; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI Y, 1991, J BIOL CHEM, V266, P23083; LI Y, 1993, IN PRESS J BIOL CHEM; MACDONALD ME, 1978, J CELL PHYSIOL, V96, P291, DOI 10.1002/jcp.1040960304; MASSOULIE J, 1988, HDB EXP PHARM, V86, P167; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; PAULUS JM, 1981, BLOOD, V58, P1100; PRIETO AL, 1989, J NEUROSCI RES, V24, P169, DOI 10.1002/jnr.490240207; RACHINSKY TL, 1992, GENOMICS, V14, P511, DOI 10.1016/S0888-7543(05)80255-1; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V52, P7121; Sambrook J, 1989, MOL CLONING LABORATO; SCHUMACHER M, 1988, J BIOL CHEM, V85, P18879; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; STIEGER S, 1989, EUR J BIOCHEM, V181, P633, DOI 10.1111/j.1432-1033.1989.tb14770.x; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VELAN B, 1991, J BIOL CHEM, V266, P23977; [No title captured]	42	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5790	5797						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449945				2022-12-25	WOS:A1993KR82200065
J	HORAZDOVSKY, BF; EMR, SD				HORAZDOVSKY, BF; EMR, SD			THE VPS16 GENE-PRODUCT ASSOCIATES WITH A SEDIMENTABLE PROTEIN COMPLEX AND IS ESSENTIAL FOR VACUOLAR PROTEIN SORTING IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; LYSOSOMAL-ENZYMES; SECRETORY PATHWAY; BIOGENESIS; TRANSPORT; TRANSFORMATION; HYDROLASES; PROPEPTIDE; RECEPTORS	The Saccharomyces cerevisiae vacuolar protein sorting mutant, vps16, exhibits pleiotropic defects in vacuolar protein targeting and vacuole morphology. To understand the role of the VPS16 gene in vacuolar protein sorting and organelle assembly, a vps16 ts mutant was used to clone the wild-type gene. DNA sequence analysis identified a single open reading frame within a vps16 complementing DNA fragment, capable of encoding a protein of 92,000 Da. Hydrophobicity analysis indicates that the Vps16 protein (Vps16p) is hydrophilic and contains no obvious signal sequence or membrane spanning domains. Gene disruption experiments have shown that VPS16 is not essential. DELTAvps16 cells exhibit, 1) a severe defect in vacuolar protein sorting; 2) a ts growth defect; 3) a grossly abnormal vacuole morphology, no normal vacuole compartment(s) is present; and 4) a defect in alpha-factor processing. A trpE-Vps16 fusion protein has been used to generate polyclonal antiserum. This anti-serum detects an unglycosylated protein of 90,000 Da. Subcellular fractionation studies indicate that the vast majority of the VPS16 gene product is associated with a particulate cell fraction. This association is resistant to detergent and salt extractions, but Vps16p can be extracted with 6 M urea and alkali buffer. In addition, overexpression of Vps16p appears to saturate the association sites available in this sedimentable structure. These data indicate that Vps16p may be specifically associated with a large protein complex, or with a limited number of sites on cytoskeletal elements of the cell.	CALTECH, DIV BIOL 14775, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32703, GM-12848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FEDDE KN, 1985, BIOCHEM BIOPH RES CO, V133, P614, DOI 10.1016/0006-291X(85)90949-0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; Neufeld EF, 1983, METABOLIC BASIS INHE, P778; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; VOLGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WOOLFORD CA, 1990, GENETICS, V125, P739	50	102	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4953	4962						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444873				2022-12-25	WOS:A1993KP88400060
J	WALKER, B; KRISHNASASTRY, M; BAYLEY, H				WALKER, B; KRISHNASASTRY, M; BAYLEY, H			FUNCTIONAL COMPLEMENTATION OF STAPHYLOCOCCAL ALPHA-HEMOLYSIN FRAGMENTS - OVERLAPS, NICKS, AND GAPS IN THE GLYCINE-RICH LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE DAMAGE; TOXIN; AUREUS; PROTEIN; BACTERIORHODOPSIN; MECHANISM; CHANNEL; BINDING; SITE; INACTIVATION	The final steps in assembly of the lytic pore formed by staphylococcal alpha-hemolysin (alphaHL) involve the formation of a nonlytic oligomeric pore precursor, followed by the formation of a transmembrane channel. In this study, truncation mutants of alphaHL encompassing the NH2-terminal or COOH-terminal half of the polypeptide chain and all, part, or none of the central glycine-rich loop were obtained by in vitro, coupled transcription and translation of mutant plasmid DNAs. These polypeptides were unable to oligomerize upon or cause lysis of rabbit erythrocytes (rRBCs). Twenty-one pairs of the same truncation mutants constituting discontinuous alphaHL chains with overlaps, nicks, and gaps in the central loop were obtained by cotranslation. When incubated with rRBCs, many of the pairs were able to form hetero-oligomers with wild-type alpha-hemolysin (s-alphaHL) and most of these formed homo-oligomers in the absence of s-alphaHL. However, only members of a subset of these pairs were able to lyse the cells. The lytic combinations contained overlaps, nicks, or gaps, but only two pairs, with nicks between amino acid residues 128 and 129 and between 131 and 132 had hemolytic activities approaching that of the wild-type polypeptide. Active combinations could also be obtained by separately translating NH2- and COOH-terminal truncation mutants and then combining them. These findings suggest that the integrity of the central loop is of little significance for oligomer formation but that it is more important for the final step in pore assembly or alternatively for determining the correct structure of the conductive channel. Our findings disagree with previous reports of NH2- and COOH-terminal fragments with hemolytic activity and of the prevention of hemolysis by proteolytic cleavage in the central loop. This discord is attributed to experimental and interpretative ambiguities in the earlier protein chemistry. For example, we show that loss of hemolytic activity after treatment with trypsin is not due to cleavage after Lys-131, as previously proposed, but to the removal of a small NH2-terminal peptide through cleavage after Lys-8.			WALKER, B (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.			Bayley, Hagan/0000-0003-2499-6116				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BHAKDI S, 1983, TRENDS BIOCHEM SCI, V8, P134, DOI 10.1016/0968-0004(83)90237-2; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BLOMQVIST L, 1987, FEBS LETT, V211, P127, DOI 10.1016/0014-5793(87)81422-9; BLOMQVIST L, 1986, ACTA PATH MICRO IM B, V94, P277; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; EDER J, 1992, BIOCHEMISTRY-US, V31, P3617, DOI 10.1021/bi00129a010; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG KS, 1982, J BIOL CHEM, V257, P8596; HUANG KS, 1981, J BIOL CHEM, V256, P3802; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; KATO I, 1980, TOXICON, V18, P361, DOI 10.1016/0041-0101(80)90018-5; KRASILNIKOV OV, 1988, GEN PHYSIOL BIOPHYS, V7, P467; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; OLOFSSON A, 1991, J STRUCT BIOL, V106, P199, DOI 10.1016/1047-8477(91)90069-9; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; POPOT JL, 1989, J MOL BIOL, V210, P829, DOI 10.1016/0022-2836(89)90111-3; RICHARDS FM, 1958, P NATL ACAD SCI USA, V44, P162, DOI 10.1073/pnas.44.2.162; ROTHSCHILD KJ, 1982, J BIOL CHEM, V257, P8592; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TERNOVSKY VI, 1991, BIOL MEMBRANY, V8, P271; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WATANABE M, 1978, BIOCHIM BIOPHYS ACTA, V535, P388, DOI 10.1016/0005-2795(78)90104-6; ZABIN I, 1975, ANNU REV BIOCHEM, V44, P295, DOI 10.1146/annurev.bi.44.070175.001455; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	44	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5285	5292						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444902				2022-12-25	WOS:A1993KP88400103
J	WATERBORG, JH				WATERBORG, JH			DYNAMIC METHYLATION OF ALFALFA HISTONE H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; PATTERNS; CELLS	Dynamic lysine methylation of histone H3 in alfalfa tissue culture cells was studied by labeling with tritiated methionine, purification of variants H3.1 and H3.2 by reversed-phase high pressure liquid chromatography and amino acid analysis. Mono- and dimethyl-L-lysine were the major labeled amino acids. Within 100 h of continued growth conversion from Nepsilon-monomethyl-L-lysine (MML) to Nepsilon-dimethyl-L-lysine (DML) and Nepsilon-trimethyl-L-lysine (TML) was observed, consistent with steady-state histone methylation. During the same time 20% of the methylation label was lost from major variant H3.1 protein and more than 50% from the more highly labeled minor variant H3.2. A similar pattern of label incorporation and loss was observed during a study of histone synthesis and turnover. This conforms with the general observation in animal cells that lysine methylation is limited to newly synthesized histone. Increased methylation of the more highly acetylated forms of histone H3 protein indicates limited accessibility of chromatin for histone methylation. After loss of the labile fraction of newly synthesized H3 variants, stably methylated proteins with 30% of the label in MML, 40% in DML, and 25% in TML remain. Turnover of methyl modification groups independent of histone turnover was not detected.			WATERBORG, JH (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV CELL BIOL & BIOPHYS,RM 414 BSB,5100 ROCKHILL RD,KANSAS CITY,MO 64110, USA.		Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634				CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DESROSIERS R, 1989, BIOCHEM BIOPH RES CO, V162, P1037, DOI 10.1016/0006-291X(89)90778-X; DUERRE JA, 1990, PROTEIN METHYLATION, P125; GLAZER AN, 1975, LABORATORY TECHNIQUE; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HEMPEL K, 1979, H-S Z PHYSIOL CHEM, V360, P869, DOI 10.1515/bchm2.1979.360.2.869; HENDZEL MJ, 1992, BIOCHEM BIOPH RES CO, V185, P414, DOI 10.1016/S0006-291X(05)81001-0; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; HOOGERHEIDE JG, 1992, ANAL BIOCHEM, V201, P146, DOI 10.1016/0003-2697(92)90187-C; KAPROS T, 1992, PLANT PHYSIOL, V98, P621, DOI 10.1104/pp.98.2.621; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; RENEKER J, 1991, BIOCHEMISTRY-US, V30, P8402, DOI 10.1021/bi00098a018; Tanguay R. M., 1990, PROTEIN METHYLATION, P139; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; WATERBORG JH, 1983, BIOCHEMISTRY-US, V22, P1489, DOI 10.1021/bi00275a025; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006; WATERBORG JH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P324, DOI 10.1016/0167-4781(90)90105-B	19	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4918	4921						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444870				2022-12-25	WOS:A1993KP88400055
J	WEEKS, BS; DESAI, K; LOEWENSTEIN, PM; KLOTMAN, ME; KLOTMAN, PE; GREEN, M; KLEINMAN, HK				WEEKS, BS; DESAI, K; LOEWENSTEIN, PM; KLOTMAN, ME; KLOTMAN, PE; GREEN, M; KLEINMAN, HK			IDENTIFICATION OF A NOVEL CELL ATTACHMENT DOMAIN IN THE HIV-1 TAT PROTEIN AND ITS 90-KDA CELL-SURFACE BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ARG-GLY-ASP; GROWTH-FACTOR; RECEPTORS; INTEGRINS; ADHESION; TERMINI; RGD	The HIV-1 transactivator protein Tat is essential for viral gene expression and replication. Tat is taken up by cells and transactivates the HIV-LTR promoter in the cell nucleus. The present studies show that cells adhere to both synthetic and recombinant Tat, and, using synthetic peptides, we localize the binding site to a region spanning amino acid residues 49-57 (peptide Tat49-57). Tat49-57 also inhibited cell attachment to solid phase full-length Tat peptide and to recombinant Tat protein. Using Tat peptide affinity chromatography, we identified a 90-kDa cell surface protein that binds to Tat. The 90-kDa protein could be eluted from the Tat column using the Tat49-57 peptide. A 90-kDa cell surface Tat binding protein was also identified by co-precipitation with Tat after incubation with radiolabeled cell membrane preparations. Co-precipitation of the 90-kDa protein was inhibited by competition with a Tat49-65 peptide, but not with Tat55-86. Our findings suggest that cellular attachment to Tat is mediated through a 90-kDa cell surface protein that binds to a Tat domain between amino acids 49 and 57.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WEEKS, BS (corresponding author), NIDR,DEV BIOL LAB,BETHESDA,MD 20892, USA.		klotman, mary e/A-1921-2016	Weeks, Benjamin/0000-0002-8361-0677	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028201, K06AI004739] Funding Source: NIH RePORTER; NIAID NIH HHS [5 K06 AI04739, AI28201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLEBE RJ, 1974, NATURE, V250, P248, DOI 10.1038/250248a0; LEW AM, 1986, P NATL ACAD SCI USA, V83, P6084, DOI 10.1073/pnas.83.16.6084; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROY S, 1990, SCIENCE, V247, P245; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3	17	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5279	5284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444901				2022-12-25	WOS:A1993KP88400102
J	HOLTZMAN, EJ; KINANE, TB; WEST, K; SOPER, BW; KARGA, H; AUSIELLO, DA; ERCOLANI, L				HOLTZMAN, EJ; KINANE, TB; WEST, K; SOPER, BW; KARGA, H; AUSIELLO, DA; ERCOLANI, L			TRANSCRIPTIONAL REGULATION OF G-PROTEIN-ALPHA-I SUBUNIT GENES IN LLC-PK1 RENAL-CELLS AND CHARACTERIZATION OF THE PORCINE G-ALPHA-I-3 GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SARCOMA-VIRUS; MESSENGER-RNA LEVELS; GTP-BINDING PROTEIN; PERTUSSIS TOXIN; MAMMALIAN-CELLS; SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; EPITHELIAL-CELLS; DNA METHYLATION; NA+ CHANNELS	Heterotrimeric guanine nucleotide-binding proteins (G-proteins) function as signal transducers for a variety of hormone-coupled enzyme and ion transport systems in eukaryotic cells. The expression of pertussis toxin-sensitive G-proteins (G(i)) which couple their cognate receptors and effectors are regulated by cell cycle-dependent events in porcine LLC-PK1 renal epithelial cells. Galpha(i-2) and Galpha(i-3) isoforms are detected in these cells, and like Galpha(i-2) (Holtzman, E. J., Soper, B. W., Stow, L. L., Ausiello, D. A., and Ercolani, L. (1991) J. Biol. Chem. 266, 1763-1771), we now demonstrate that Galpha(i-3) mRNA and protein is coordinately expressed in these cells during differentiation. To gain further insights into these events, the porcine Galpha(i-3) gene minimal promoter was characterized and found 67 base pairs upstream from the major transcription start site. The 56-base pair minimal promoter lacked TATAAA and GC boxes but did contain a sequence GGAAGTG conserved in both the human and porcine gene that could potentially bind an adenovirus E4TF1 transcription factor. In cells stably transfected with Galpha(i-2) or Galpha(i-3) gene 5'-flanking sequences fused to firefly luciferase cDNA reporter, temporal 10-15-fold transcriptional activation of both genes occurred before cellular polarization. Utilizing mobility shift assays which compared nuclear extracts from cells before and after cell polarization, a motif in the 5' region of the gene promoter GTACTTCCGCT was identified that bound an induced nuclear protein complex during transcriptional activation. In polarized cells complemented with the human glucocorticoid receptor, dexamethasone decreased Galpha(i-2) but increased Galpha(i-3) basal transcription and mRNA content 3-fold. These studies demonstrate that both Galpha(i) genes are dynamically regulated in LLC-PK1 cells by both growth, differentiation, and hormone signals.	MASSACHUSETTS GEN HOSP E, RENAL UNIT, 8TH FLOOR, 149 13TH ST, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 42543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; CUI Z, 1991, J BIOL CHEM, V266, P20276; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN A, 1990, J BIOL CHEM, V265, P5206; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LEE RT, 1989, FEBS LETT, V249, P139, DOI 10.1016/0014-5793(89)80610-6; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MISSALE C, 1991, J BIOL CHEM, V266, P23392; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PLATT SG, 1987, ANAL BIOCHEM, V162, P529, DOI 10.1016/0003-2697(87)90429-5; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RAPIEJKO PJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P348, DOI 10.1016/0167-4889(90)90233-4; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; RIBEIRONETO F, 1987, MOL ENDOCRINOL, V1, P472, DOI 10.1210/mend-1-7-472; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SHINAR D, 1989, DIFFERENTIATION, V41, P116, DOI 10.1111/j.1432-0436.1989.tb00739.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SKORECKI KL, 1987, BIOCHEMISTRY-US, V26, P639, DOI 10.1021/bi00376a040; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; WEISS ER, 1985, ANN NY ACAD SCI, V456, P420, DOI 10.1111/j.1749-6632.1985.tb14894.x	70	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3964	3975						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440688				2022-12-25	WOS:A1993KN53300027
J	PARK, DG; JHON, DY; LEE, CW; RYU, SH; RHEE, SG				PARK, DG; JHON, DY; LEE, CW; RYU, SH; RHEE, SG			REMOVAL OF THE CARBOXYL-TERMINAL REGION OF PHOSPHOLIPASE-C-BETA-1 BY CALPAIN ABOLISHES ACTIVATION BY G-ALPHA-Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; G-PROTEINS; BETA-1 ISOZYME; RAT-BRAIN; PURIFICATION; FORMS	The 150-kDa phospholipase C (PLC)-beta1 and three immunologically related proteins with molecular sizes of 140, 100, and 45 kDa were purified from bovine brain extracts. Determination of the amino-terminal amino acid sequence of the 45-kDa protein and immunoblots of the purified proteins with sequence-specific antibodies to peptides corresponding to three different regions of PLC-beta1 suggest that a single cleavage at the linkage between amino acid residues 880 and 881 of PLC-beta1 generates the 100- and 45-kDa proteins, which correspond to the amino-terminal and carboxyl-terminal portions, respectively, of PLC-beta1. The Ca2+-dependent protease calpain appears to be responsible for the cleavage of PLC-beta1; the PLC-beta1 amino acid sequence contains PEST sequences which are common to proteins susceptible to calpain, and limited proteolysis of purified PLC-beta1 by calpain generated a 100-kDa protein and a 40-kDa protein that contains the same amino-terminal sequence as the 45-kDa protein. The 140-kDa protein lacks the carboxyl-terminal-most region of PLC-beta1, but there is no evidence it is derived from PLC-beta1 by proteolysis. Cleavage of PLC-beta1 by calpain had no significant effect on catalytic activity measured in the absence of the alpha subunit of the Galphaq but completely abrogated the stimulatory effect of Galphaq. On the other hand, Galphaq activated the 140-kDa enzyme. These results suggest that the region between residue 881 and the most carboxyl-terminal 10 kDa of PLC-beta1 contains the Galphaq interaction site.	NHLBI, BIOCHEM LAB, BLDG 3, RM 122, BETHESDA, MD 20892 USA; POHANG INST SCI & TECHNOL, DEPT LIFE SCI, POHANG 790600, SOUTH KOREA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pohang University of Science & Technology (POSTECH)				Ryu, Sung Ho/0000-0003-0913-3048				BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GERFEN CR, 1988, P NATL ACAD SCI USA, V85, P3208, DOI 10.1073/pnas.85.9.3208; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; PARK D, 1992, J BIOL CHEM, V267, P16048; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WU DQ, 1993, J BIOL CHEM, V268, P3704; ZIMMERMAN UJP, 1984, J BIOL CHEM, V259, P3210	22	132	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3710	3714						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429045				2022-12-25	WOS:A1993KM16100103
J	PHILLIPS, JE; SHIRK, RA; WHINNA, HC; HENRIKSEN, RA; CHURCH, FC				PHILLIPS, JE; SHIRK, RA; WHINNA, HC; HENRIKSEN, RA; CHURCH, FC			INHIBITION OF DYSTHROMBINS QUICK-I AND QUICK-II BY HEPARIN COFACTOR-II AND ANTITHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; CONGENITAL DYSTHROMBIN; CRYSTAL-STRUCTURE; REACTIVE SITE; PROTEIN-C; IDENTIFICATION; BINDING; HIRUDIN; THROMBOMODULIN; GLYCOSAMINOGLYCANS	Heparin cofactor II and antithrombin are plasma serine proteinase inhibitors whose ability to inhibit alpha-thrombin is accelerated by glycosaminoglycans. Dysfunctional thrombin mutants Quick I (Arg67 --> Cys) and Quick II (Gly226 --> Val) were used to further compare heparin cofactor II and antithrombin interactions. Quick I, Quick II, and alpha-thrombin were eluted at the same salt concentration from heparin-Sepharose suggesting that the putative heparin-binding site (also termed anion binding exosite-II) is functional. Antithrombin yielded similar inhibition rates for Quick I and alpha-thrombin in the absence or presence of various amounts of heparin. Also, Quick I was inhibited similarly to alpha-thrombin by heparin cofactor II in the absence of glycosaminoglycan. In contrast, glycosaminoglycan-accelerated Quick I inhibition by heparin cofactor II was greatly reduced indicating that anion binding exosite-I (where the mutation occurs in Quick I) is critical for increased inhibition by heparin cofactor II. We also found that heparin cofactor II formed a SDS-resistant bimolecular complex with Quick II and alpha-thrombin at similar rates and the rate of complex formation was accelerated in the presence of glycosaminoglycans. A three-dimensional molecular model of the Quick II active site compared to alpha-thrombin suggested that the heparin cofactor II Leu-Ser-reactive site sequence (P1-P1') is a compatible ''pseudosubstrate'' in contrast to the Arg-Ser sequence found in antithrombin. The importance of heparin cofactor II as a thrombin regulator will depend upon its ability to interact with glycosaminoglycans and the functional availability of thrombin exosites.	UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; E CAROLINA UNIV, SCH MED, DEPT MED, GREENVILLE, NC 27858 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; East Carolina University	PHILLIPS, JE (corresponding author), UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, 435 BURNETT WOMACK, CB 7015, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008413, R29HL045194, R01HL032656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32656, F32-HL08413, HL45194] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HENRIKSEN RA, 1980, J CLIN INVEST, V66, P934, DOI 10.1172/JCI109961; HENRIKSEN RA, 1983, J BIOL CHEM, V258, P3717; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HENRIKSEN RA, 1987, J BIOL CHEM, V262, P4664; HENRIKSEN RA, 1989, BIOCHEMISTRY-US, V28, P2078, DOI 10.1021/bi00431a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; NESHEIM M, 1986, J BIOL CHEM, V260, P3214; NOE G, 1988, J BIOL CHEM, V263, P11729; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; PRATT CW, 1990, J BIOL CHEM, V265, P6092; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; RAGG H, 1986, NUCLEIC ACIDS RES, V14, P1073, DOI 10.1093/nar/14.2.1073; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STONE SR, 1991, BIOCHEMISTRY-US, V30, P6392, DOI 10.1021/bi00240a007; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	39	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3321	3327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429008				2022-12-25	WOS:A1993KM16100048
J	SLACK, J; MCMAHAN, CJ; WAUGH, S; SCHOOLEY, K; SPRIGGS, MK; SIMS, JE; DOWER, SK				SLACK, J; MCMAHAN, CJ; WAUGH, S; SCHOOLEY, K; SPRIGGS, MK; SIMS, JE; DOWER, SK			INDEPENDENT BINDING OF INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA TO TYPE-I AND TYPE-II INTERLEUKIN-1 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MULTIVALENT IMMUNE-COMPLEXES; GROWTH-FACTOR-RECEPTOR; MURINE B-CELL; IL-1 RECEPTOR; HIGH-AFFINITY; T-CELLS; SIGNAL TRANSDUCTION; EXPRESSION CLONING; ESCHERICHIA-COLI	Interleukin (IL)-1 refers to a group of three polypeptide hormones with a wide range of cellular targets. Two types of IL-1 receptor have been identified and characterized by cDNA cloning. Both human type I and type II IL-1 receptors contain extracellular domains of approximately 310 residues and a single membrane-spanning region. The type I receptor contains a cytoplasmic domain of 213 residues. The cytoplasmic region of the type II receptor is 29 residues in length. It has been found recently that a number of cells express both forms of receptor. By analogy with other cytokine receptor systems, the two IL-1 receptors might be expected to form a heterodimeric complex, the type II receptor being an alpha-chain-like structure, functioning only to bind ligand, and associating with the type I receptor (a beta-chain-like structure) which would transduce signals. In this report we show that this is not the case, but rather that IL-1, when complexed to type II receptor, cannot bind type I receptors, and vice versa. These data show that the complex patterns often observed for IL-1 binding to cells cannot be accounted for by the same type of mechanism that underlies the behavior of, for example, the IL-2 system.	IMMUNEX RES & DEV CORP,DEPT BIOCHEM,IMMUNEX BLDG,51 UNIV ST,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROC DEV,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,HYBRIDOMA LAB,SEATTLE,WA 98101					Sims, John/0000-0002-5667-9185; dower, steve/0000-0002-4675-4225				Arend W P, 1991, Br J Rheumatol, V30 Suppl 2, P49; AREND WP, 1989, J IMMUNOL, V143, P1851; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BENJAMIN D, 1990, BLOOD, V75, P2017; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BENSIMON C, 1989, J IMMUNOL, V143, P1168; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COCHET C, 1988, J BIOL CHEM, V263, P3290; CONCA W, 1991, J BIOL CHEM, V266, P16265; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; DELISI C, 1981, NATURE, V289, P322, DOI 10.1038/289322a0; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6326, DOI 10.1021/bi00525a007; DOWER SK, 1989, J IMMUNOL, V142, P4314; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6335, DOI 10.1021/bi00525a008; DOWER SK, 1989, INTERLEUKIN 1 INFLAM, P63; DOWER SK, 1991, INTERLEUKINS MOL BIO, P33; DOWER SK, 1989, LYMPHOKINE RECEPTOR, P17; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KILIAN PL, 1990, PROG CLIN BIOL RES, V349, P251; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KRONHEIM SR, 1986, BIO-TECHNOL, V4, P1078, DOI 10.1038/nbt1286-1078; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MELTON LB, 1989, CLIN IMMUNOL IMMUNOP, V50, P171, DOI 10.1016/0090-1229(89)90126-8; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; PARK LS, 1989, J BIOL CHEM, V264, P5420; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1989, BIOTECHNIQUES, V7, P1132; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; URDAL DL, 1988, J BIOL CHEM, V263, P2870; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	62	107	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2513	2524						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428929				2022-12-25	WOS:A1993KK81500042
J	TAGAYA, M; WILSON, DW; BRUNNER, M; ARANGO, N; ROTHMAN, JE				TAGAYA, M; WILSON, DW; BRUNNER, M; ARANGO, N; ROTHMAN, JE			DOMAIN-STRUCTURE OF AN N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN INVOLVED IN VESICULAR TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI STACK; YEAST; GENE; REQUIRES; FAMILY; NSF; PURIFICATION; ENDOCYTOSIS; EXPRESSION; COMPONENT	N-Ethylmaleimide-sensitive fusion protein (NSF) is an essential component for protein transport between Golgi cisternae. Sequence analysis and proteolytic dissection reveal that NSF contains two tandem ''ATP domains,'' each containing the consensus sequence for the binding of nucleotide. When Escherichia coli-produced Chinese hamster ovary NSF is purified, it exhibits a low, but significant, ATPase activity. The ATPase activity of NSF is sensitive to N-ethylmaleimide and influenced by monoclonal antibodies against recombinant NSF.	SLOAN KETTERING INST CANC RES,ROCKEFELLER RES LAB,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Brunner, Michael/0000-0001-9798-3047	NIDDK NIH HHS [DK 27044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	27	169	169	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2662	2666						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428942				2022-12-25	WOS:A1993KK81500061
J	CAMP, LA; CHAUHAN, P; FARRAR, JD; LEHRMAN, MA				CAMP, LA; CHAUHAN, P; FARRAR, JD; LEHRMAN, MA			DEFECTIVE MANNOSYLATION OF GLYCOSYLPHOSPHATIDYLINOSITOL IN LEC35 CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; ENDOPLASMIC-RETICULUM; LINKED GLYCOSYLATION; PHOSPHOLIPASE-C; BIOSYNTHESIS; MANNOSE; MUTANTS; MANNOSYLPHOSPHORYLDOLICHOL	The Lec35 mutation (previously designated PIR) of Chinese hamster ovary cells is a recessive mutation that affects the participation of mannose-P-dolichol (MPD) in dolichol-P-P-oligosaccharide biosynthesis in vivo, even though MPD and the respective MPD-dependent mannosyltransferases are present. The Lec35 phenotype can be partially corrected by disrupting Lec35 cells and performing the transferase reactions in vitro, suggesting that the defect may be related to mislocalization of MPD. In this study, we examined the effect of the Lec35 mutation on glycosylphosphatidylinositol (GPI) lipid biosynthesis, another pathway that requires MPD. Our data indicate that the first mannosylation reaction of GPI lipid biosynthesis is defective in Lec35 cells, with the accumulation of glucosaminylphosphatidylinositol having a fatty acyl group on inositol and a base-resistant alkyl group attached to glycerol. The same intermediate accumulates in Lec15 (MPD synthase-defective) cells. The defective mannosylation reaction of Lec35 cells was corrected in vitro and shown to require MPD. These results demonstrate that the Lec35 gene governs a general aspect of MPD metabolism affecting both GPI lipid and dolichol-P-P-oligosaccharide biosynthesis. To provide additional insight into the role of the Lec35 gene, we give evidence for an inefficient pool of MPD in Lec35 membranes.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KANG MS, 1978, J BIOL CHEM, V253, P8860; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; TURCO SJ, 1981, ANAL BIOCHEM, V118, P278, DOI 10.1016/0003-2697(81)90582-0; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; ZENG YC, 1990, J BIOL CHEM, V265, P2296; ZHU XY, 1992, J BIOL CHEM, V267, P8895	32	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6721	6728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454644				2022-12-25	WOS:A1993KT36800092
J	SCHUBERT, J; SCHMIDT, RE; MEDOF, ME				SCHUBERT, J; SCHMIDT, RE; MEDOF, ME			REGULATION OF GLYCOINOSITOL PHOSPHOLIPID ANCHOR ASSEMBLY IN HUMAN-LYMPHOCYTES - ABSENT MANNOLIPID SYNTHESIS IN AFFECTED T-CELL AND NATURAL-KILLER-CELL LINES FROM PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA PATIENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; PERIPHERAL-BLOOD; BIOSYNTHESIS; GLYCOSYLPHOSPHATIDYLINOSITOL; DEFICIENCY; ACTIVATION; PROTEIN; MUTANTS; THY-1	Glycoinositol phospholipid (GPI) anchor structures derive from sequentially glycosylated inositol phospholipid precursors assembled in the endoplasmic reticulum. To characterize GPI biosynthesis in non-transformed human lymphocytes and to define the GPI synthetic defect underlying deficient expression of GPI-anchored proteins by paroxysmal nocturnal hemoglobinuria (PNH) cells, putative intracellular GPI intermediates were analyzed following [H-3]Man labeling of normal and affected lymphocytes. In unstimulated normal peripheral blood lymphocytes, [H-3]Man incorporation into GPIs was minimally detectable but after phytohemagglutinin (PHA), allogeneic cell, or anti-CD3 stimulation, assembly of [H-3]Man-labeled GPIs markedly increased. Expression of GPIs by prestimulated quiescent PHA blasts could be efficiently induced by phorbol 12-myristate 13-acetate (PMA) and increased by the Ca2+ ionophore A23187 independently of new protein synthesis. Utilizing allogeneically stimulated cells in conjunction with PMA induction, products deriving from [H-3]Man labeling of affected CD48- T and natural killer lymphocyte cell lines from five PNH patients were compared to those deriving from unaffected CD48+ cell lines from the same patients or controls. In contrast to unaffected paired control cells, affected cells of all of the patients exhibited a common abnormality in which they assembled dolichol-phosphoryl-Man but failed to express [H-3]Man-containing GPIs. These data indicate that 1) significant GPI production in lymphocytes is dependent on prior stimulation of the cells, 2) exposure of lymphocytes to agents which activate protein kinase C induces GPI synthesis, and 3) in five PNH patients affected lymphocytes are uniformly defective in an early GPI biosynthetic step which undermines expression of GPI mannolipids.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; HANNOVER MED SCH,IMMUNOL & TRANSFUS MED ABT,W-3000 HANNOVER 61,GERMANY	Case Western Reserve University; Hannover Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAROTHERS DJ, 1990, J CLIN INVEST, V85, P47, DOI 10.1172/JCI114432; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18581; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HERCEND T, 1982, J IMMUNOL, V129, P1299; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; ISAKOV N, 1987, J IMMUNOL, V138, P3100; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; NICHOLSONWELLER A, 1985, NEW ENGL J MED, V312, P1091, DOI 10.1056/NEJM198504253121704; OKADA N, 1989, J IMMUNOL, V143, P2262; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; PANGBURN MK, 1983, J EXP MED, V157, P1971, DOI 10.1084/jem.157.6.1971; SCHMIDT RE, 1986, J EXP MED, V164, P351, DOI 10.1084/jem.164.1.351; SCHUBERT J, 1992, J IMMUNOL, V148, P3814; SCHUBERT J, 1990, BLOOD, V76, P1181; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YOMTOVIAN R, 1993, IN PRESS TRANSFUSION, V33	33	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6281	6287						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454600				2022-12-25	WOS:A1993KT36800033
J	ADAMSKA, I; KLOPPSTECH, K; OHAD, I				ADAMSKA, I; KLOPPSTECH, K; OHAD, I			EARLY LIGHT-INDUCIBLE PROTEIN IN PEA IS STABLE DURING LIGHT STRESS BUT IS DEGRADED DURING RECOVERY AT LOW LIGHT-INTENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PISUM-SATIVUM-L; CHLOROPLAST PROTEIN; XANTHOPHYLL CYCLE; PHOTOSYSTEM-II; MESSENGER-RNAS; GENE; PHOTOINHIBITION; PHOTOSYNTHESIS; ACCUMULATION; CAROTENOIDS	The nuclear-encoded, thylakoid-bound early light-inducible protein (ELIP) reported to be related to the initial stages of chloroplast differentiation is synthesized in substantial amounts in leaves of mature plants exposed to light stress conditions (Adamska, I., Ohad, I., and Kloppstech, K. (1992b) Proc. Natl. Acad. Sci. U. S. A. 89, 2610-2613). Increase in ELIP content correlates with the photoinactivation of PSII, degradation of D1 protein, and changes in the level of pigments. Inhibition of phytoene desaturase and/or zeta-carotene desaturase during light stress drastically increases accumulation of the protein. ELIP mRNA is short-lived (t1/2 = 1 h). The thylakoid bound protein is stable in high light exposed leaves and is degraded only during recovery from light stress at low light intensity (40 muE/m2s). The lifetime of the protein during the recovery process increases with the extent of initial light stress condition. We propose that ELIP synthesis and degradation is related to the process of the plant response to light stress and recovery from photoinhibition.	HEBREW UNIV JERUSALEM,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	ADAMSKA, I (corresponding author), UNIV HANNOVER,INST BOT,HERRENHAUSER STR 2,W-3000 HANNOVER 21,GERMANY.							ADAMSKA I, 1991, PLANT MOL BIOL, V16, P209, DOI 10.1007/BF00020553; ADAMSKA I, 1992, J BIOL CHEM, V267, P24732; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAIMA S, 1991, J PHOTOCH PHOTOBIO B, V11, P107, DOI 10.1016/1011-1344(91)80253-E; BILGER W, 1989, PLANT PHYSIOL, V91, P542, DOI 10.1104/pp.91.2.542; CHAMOVITZ D, 1990, Z NATURFORSCH C, V45, P482; CHOLLET R, 1990, Pesticide Science, V30, P326; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V138, P201; HAVAUX M, 1991, PHOTOCHEM PHOTOBIOL, V3, P361; HUMBECK K, 1989, PLANTA, V179, P242, DOI 10.1007/BF00393695; KLOPPSTECH K, 1985, PLANTA, V165, P502, DOI 10.1007/BF00398095; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MEYER G, 1984, EUR J BIOCHEM, V167, P493; OTTO B, 1988, PLANT PHYSIOL, V88, P21, DOI 10.1104/pp.88.1.21; PEMBERTON RE, 1975, ANAL BIOCHEM, V66, P18, DOI 10.1016/0003-2697(75)90720-4; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; RAU W, 1980, BLUE LIGHT SYNDROME, P283; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; SAGAR AD, 1988, PLANT PHYSIOL, V88, P340, DOI 10.1104/pp.88.2.340; SANDMANN G, 1990, Z NATURFORSCH C, V45, P487; SCHARNHORST C, 1985, PLANT MOL BIOL, V4, P241, DOI 10.1007/BF02418242; SCHUSTER G, 1988, EMBO J, V7, P1; SIMPSON J, 1986, SCIENCE, V233, P34, DOI 10.1126/science.233.4759.34; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	32	70	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5438	5444						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449905				2022-12-25	WOS:A1993KR82200017
J	MORI, H; TANIZAWA, K; FUKUI, T				MORI, H; TANIZAWA, K; FUKUI, T			A CHIMERIC ALPHA-GLUCAN PHOSPHORYLASE OF PLANT TYPE-L AND TYPE-H ISOZYMES - FUNCTIONAL-ROLE OF 78-RESIDUE INSERTION IN TYPE-L ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-PHOSPHORYLASE; POTATO PHOSPHORYLASE; AFFINITY ELECTROPHORESIS; DISSOCIATION-CONSTANTS; MOLECULAR-CLONING; SPINACH; LOCALIZATION; ISOENZYMES; SEQUENCE; BINDING	Higher plant tissues such as potato tuber and leaf contain two alpha-glucan phosphorylase isozymes designated types L and H. Although the sequences of the two isozymes are highly conserved except for a 78-residue insertion found uniquely in the type L isozyme, they differ strikingly in affinities for substrates. To examine whether the insertion in the type L isozyme plays a role in enzymic functions, particularly in substrate specificities, we have constructed a chimeric enzyme, in which a 189-residue sequence of the type L isozyme including the insertion and its flanking regions is replaced by the corresponding sequence (112 residues) of the type H isozyme lacking the insertion. The gene for the chimeric enzyme as well as the cDNA for the type L isozyme were expressed at a low temperature in Escherichia coli cells under the control of the strong T7 RNA polymerase promoter. The purified chimeric phosphorylase was five times less active than the parent type L isozyme, but its affinity for glycogen was much higher than that of the type L isozyme and only slightly lower than that of the type H isozyme. The Michaelis constants of the chimeric enzyme for small oligosaccharides were comparable with those of the type L isozyme. These results provide evidence for the role of the 78-residue insertion in the type L isozyme, lowering the affinity of the enzyme for large, branched substrates probably through steric hindrance. It is also assumed that the corresponding region in the type H isozyme contains a high affinity site like the glycogen storage site occurring in the animal enzyme.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University								BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; Cleland W W, 1979, Methods Enzymol, V63, P103; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLETTERICK RJ, 1982, ACCOUNTS CHEM RES, V15, P361, DOI 10.1021/ar00083a004; FUKUI T, 1987, BIOCH VITAMIN B6, P267; GERBRANDY SJ, 1972, PHYTOCHEMISTRY, V11, P2403, DOI 10.1016/S0031-9422(00)88506-4; GERBRANDY SJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P410, DOI 10.1016/0005-2744(74)90102-8; GERBRANDY SJ, 1975, PHYTOCHEMISTRY, V14, P2331, DOI 10.1016/0031-9422(75)80338-4; GOLD AM, 1971, J BIOL CHEM, V246, P3444; HOREJSI V, 1977, BIOCHIM BIOPHYS ACTA, V499, P290, DOI 10.1016/0304-4165(77)90011-3; IWATA S, 1973, FEBS LETT, V36, P222, DOI 10.1016/0014-5793(73)80373-4; JOHNSON LN, 1990, J BIOL CHEM, V265, P2409; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORI H, 1991, J BIOL CHEM, V266, P18446; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P691, DOI 10.1093/oxfordjournals.jbchem.a122918; NAKANO K, 1986, J BIOL CHEM, V261, P8230; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OKITA TW, 1979, PLANT PHYSIOL, V64, P187, DOI 10.1104/pp.64.2.187; SCHNEIDER EM, 1979, H-S Z PHYSIOL CHEM, V360, P369; SHIMOMURA S, 1982, J BIOCHEM-TOKYO, V91, P703, DOI 10.1093/oxfordjournals.jbchem.a133743; SHIMOMURA S, 1980, BIOCHEMISTRY-US, V19, P2287, DOI 10.1021/bi00552a001; SMITH EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P380, DOI 10.1016/0003-9861(71)90140-8; STEUP M, 1979, PLANTA, V145, P69, DOI 10.1007/BF00379929; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEO K, 1972, ARCH BIOCHEM BIOPHYS, V153, P1, DOI 10.1016/0003-9861(72)90413-4; WILLNECKER J, 1991, ENZYMES DEPENDENT PY, P393	28	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5574	5581						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449920				2022-12-25	WOS:A1993KR82200036
J	SHENG, SJ; SCHUSTER, SM				SHENG, SJ; SCHUSTER, SM			PURIFICATION AND CHARACTERIZATION OF SACCHAROMYCES-CEREVISIAE DNA DAMAGE-RESPONSIVE PROTEIN-48 (DDRP-48)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE POLYACRYLAMIDE-GEL; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; ASPARAGINE SYNTHETASE; INDUCIBLE REPAIR; SMALL SUBUNIT; GENES; IDENTIFICATION; MUTAGENESIS; EXPRESSION	A yeast protein was purified from wild type Saccharomyces cerevisiae (S. cerevisiae) to near homogeneity using an ethanolamine affinity chromatography procedure. The N-terminal amino acid sequencing and the amino acid composition analyses identified this protein as the product of the second open reading frame of S. cerevisiae DNA Damage-responsive gene 48 (DDR 48) (Treger, J. M., and McEntee, K. (1990) Mol. Cell. Biol. 10, 3174-3184) The first methionine residue encoded by the translation starting codon was not present in the mature protein which is designated as DDRP 48. DDRP 48 was found to be a negatively charged and highly hydrophilic glycoprotein. The glycosidase cleavage analyses suggested that DDRP 48 was mainly N-link-glycosylated. The apparent molecular mass of DDRP 48 was estimated to be approximately 65 kilo-daltons. DDRP 48 was found able to hydrolyze ATP and GTP yielding PP(i). The K(m) values for ATP and GTP are 0.29 mM and 0.58 mM, respectively. The Western blot analysis demonstrated that DDRP 48 was expressed to various concentrations in different S. cerevisiae strains. Increased DDRP 48 abundance was observed after yeast cells carrying the wild type RAD 52 gene were exposed to either ethylmethane sulfonate or heat shock treatments. After similar DNA-damaging treatments, however, no significant inductions of DDRP 48 were found in a rad 52 mutant strain. These observations are consistent with the predictions resulting from previous studies on transcriptional regulation of the DDR 48 gene (Maga, J. A., McClanahan, T. A., and McEntee, K. (1986) Mol. & Gen. Genet. 205, 276-284; McClanahan, T., and McEntee, K. (1986) Mol. Cell. Biol. 6, 90-96)	UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; ANGULO JF, 1985, MOL GEN GENET, V201, P20, DOI 10.1007/BF00397980; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns J, 1981, Prog Nucleic Acid Res Mol Biol, V26, P237, DOI 10.1016/S0079-6603(08)60408-0; Cleland W W, 1979, Methods Enzymol, V63, P103; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; ELLEDGE SJ, 1983, J MOL BIOL, V164, P175, DOI 10.1016/0022-2836(83)90074-8; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; FOGLIANO M, 1981, NATURE, V289, P196, DOI 10.1038/289196a0; HAMES BD, 1981, GEL ELECTROPHORESIS, P17; HUISMAN O, 1980, MOL GEN GENET, V177, P629; HURD HK, 1987, MOL CELL BIOL, V7, P3673, DOI 10.1128/MCB.7.10.3673; KENYON CJ, 1981, NATURE, V289, P808, DOI 10.1038/289808a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUEHR CA, 1980, J BIOCHEM BIOPH METH, V3, P151, DOI 10.1016/0165-022X(80)90014-7; MAGA JA, 1986, MOL GEN GENET, V205, P276, DOI 10.1007/BF00430439; MAGA JA, 1986, MOL GEN GENET, V200, P313; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCLANAHAN T, 1986, MOL CELL BIOL, V6, P90, DOI 10.1128/MCB.6.1.90; NAKAGAWA S, 1989, ANAL BIOCHEM, V181, P75, DOI 10.1016/0003-2697(89)90395-3; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; PATTERSON MK, 1968, J BIOL CHEM, V243, P376; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; RUBY SW, 1983, METHOD ENZYMOL, V101, P253; RUBY SW, 1985, MOL CELL BIOL, V5, P75, DOI 10.1128/MCB.5.1.75; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHENG SJ, 1992, BIOTECHNIQUES, V13, P704; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; STEDLER D, 1981, GENETICS, V98, P763; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VANHEEKE G, 1990, PROTEIN ENG, V3, P739, DOI 10.1093/protein/3.8.739; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	41	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4752	4758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444852				2022-12-25	WOS:A1993KP88400033
J	WEITZHANDLER, M; KADLECEK, D; AVDALOVIC, N; FORTE, JG; CHOW, D; TOWNSEND, RR				WEITZHANDLER, M; KADLECEK, D; AVDALOVIC, N; FORTE, JG; CHOW, D; TOWNSEND, RR			MONOSACCHARIDE AND OLIGOSACCHARIDE ANALYSIS OF PROTEINS TRANSFERRED TO POLYVINYLIDENE FLUORIDE MEMBRANES AFTER SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL-ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PULSED AMPEROMETRIC DETECTION; TISSUE PLASMINOGEN-ACTIVATOR; HAMSTER OVARY CELLS; AMINO-ACID ANALYSIS; RECOMBINANT ERYTHROPOIETIN; NITROCELLULOSE SHEETS; DIFLUORIDE MEMBRANES; PICOMOLE QUANTITIES; GLYCOPROTEIN FETUIN	We have developed an intermediate method toward the complete carbohydrate analysis of proteins, which should be universally applicable to all proteins and independent of sample matrix. Using only Coomassie Blue-stained proteins which have been electroblotted onto polyvinylidene fluoride membranes, we report a strategy for: (i) determining unequivocally whether a protein is glycosylated; (ii) obtaining a complete monosaccharide composition; (iii) oligosaccharide mapping which separates most forms according to size, charge and isomerity; and (iv) sequentially releasing and analyzing specific classes of oligosaccharides with endoglycosidases. The method was shown to be applicable to a variety of well characterized soluble glycoproteins and to the membrane-bound protein, the gastric H+,K+-ATPase. The monosaccharide composition of the H+,K+-ATPase revealed the absence of N-acetylneuraminic or N-glycolylneuraminic acids and a monosaccharide composition which indicated O-linked sugar chains. Oligomannosidic/hybrid and biantennary oligosaccharides were sequentially released and analyzed from one electroblotted band of recombinant tissue plasminogen activator using endo-beta-N-acetylglucosaminidase H and endo-beta-N-acetylglucosaminidase F2, respectively. Sialylated polylactosamine structures were identified and quantified by analyzing high performance liquid chromatography profiles of oligosaccharides first released by peptide-N4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase and then treated with endo-beta-galactosidase, using a single, stained band of recombinant erythropoietin. This recombinant erythropoietin was found to contain eight times more tetrasialylated oligosaccharides than previously reported (Sasaki, H., Bothner, B., Dell, A., and Fukuda, M. (1987) J. Biol. Chem. 262, 12059-12076); 47% of released oligosaccharides were identified as polylactosamine structures.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; DIONEX CHEM CORP,SUNNYVALE,CA 94088; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California San Francisco; Thermo Fisher Scientific; Dionex Corporation; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031376, R01DK038972] Funding Source: NIH RePORTER; NIDDK NIH HHS [DDK31376, DDK38972] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BENDIAK B, 1989, BIOCHEMISTRY-US, V28, P6491, DOI 10.1021/bi00441a050; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CUMMING DA, 1989, BIOCHEMISTRY-US, V28, P6500, DOI 10.1021/bi00441a051; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; ECKHARDT AE, 1976, ANAL BIOCHEM, V73, P192, DOI 10.1016/0003-2697(76)90154-8; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; FORTE JG, 1977, GASTROENTEROLOGY, V73, P921; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA MN, 1989, BLOOD, V73, P84; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HERMENTIN P, 1992, ANAL BIOCHEM, V202, P281; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laine RA, 1972, METHOD ENZYMOL, V28, P159, DOI [10.1016/0076-6879(72)28012-0, DOI 10.1016/0076-6879(72)28012-0]; LEONARDS KS, 1985, BIOCHEMISTRY-US, V24, P4876, DOI 10.1021/bi00339a023; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MARTIN BM, 1991, TECHNIQUES PROTEIN C, V2, P191; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKAGAWA S, 1989, ANAL BIOCHEM, V181, P75, DOI 10.1016/0003-2697(89)90395-3; OGAWA H, 1990, ANAL BIOCHEM, V190, P165, DOI 10.1016/0003-2697(90)90175-9; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PETERS T, 1975, PLASMA PROTEINS, P133; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REENSTRA WW, 1990, METHOD ENZYMOL, V192, P151; ROHRINGER R, 1985, ANAL BIOCHEM, V144, P118, DOI 10.1016/0003-2697(85)90092-2; ROSENBERG A, 1976, BIOL ROLES SIALIC AC, P43; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SASAKI H, 1988, BIOCHEMISTRY-US, V27, P8618, DOI 10.1021/bi00423a017; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TOUS GI, 1989, ANAL BIOCHEM, V179, P50, DOI 10.1016/0003-2697(89)90198-X; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND R R, 1991, Glycobiology, V1, P139, DOI 10.1093/glycob/1.2.139; TOWNSEND RR, 1993, HPLC GLYCOCONJUGATES; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x	54	73	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5121	5130						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444888				2022-12-25	WOS:A1993KP88400082
J	YAMADA, SH; YOSHIDA, K; SUGIURA, M; SUGAHARA, K; KHOO, KH; MORRIS, HR; DELL, A				YAMADA, SH; YOSHIDA, K; SUGIURA, M; SUGAHARA, K; KHOO, KH; MORRIS, HR; DELL, A			STRUCTURAL STUDIES ON THE BACTERIAL LYASE-RESISTANT TETRASACCHARIDES DERIVED FROM THE ANTITHROMBIN-III-BINDING SITE OF PORCINE INTESTINAL HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAMS ANOMALOCARDIA-BRASILIANA; BOMBARDMENT MASS-SPECTROMETRY; CELL-GROWTH FACTOR; SUBSTRATE-SPECIFICITY; ENDOTHELIAL-CELLS; TIVELA-MACTROIDES; SEQUENCE; SULFATE; AFFINITY; SPECTROSCOPY	Three discrete tetrasaccharide structures which are resistant to Flavobacterium heparinase and heparitinases I and II were isolated from porcine intestinal heparin after exhaustive digestion with a mixture of all the above enzymes, and the tri-, tetra-, and pentasulfated structures were determined by negative ion mode fast atom bombardment mass spectrometry and 500-MHz H-1 NMR analysis as DELTA4,5GlcAbeta1-4GlcNAc (6-sulfate)alpha1-4GlcAbeta1-4GlcN(N,3-disulfate), DELTA4,5 GlcAbeta1-4GlcNAc(6-sulfate)alpha1-4GlcAbeta1-4GlcN (N,3,6-trisulfate), and DELTA4,5GlcAbeta1-4GlcN (N,6-disulfate)alpha1-4GlcAbeta1-4GlcN(N,3,6-trisulfate). The three components share the 3-O-sulfated reducing GlcN and the 6-O-sulfated internal GlcN, indicating that they are structural variants derived from the nonreducing portion of the minimal pentasaccharide sequence required for binding to antithrombin III. Isolation of the pentasulfated component has never been reported. Their unexpected resistance to heparitinases I and II indicates that 3-O-sulfation of the reducing GlcN contributes to the resistant nature of these tetrasaccharides to the enzymes. The present study demonstrates that the nonreducing trisaccharide portion of the structural variants of the antithrombin III-binding pentasaccharide sequence can be isolated in tetrasaccharides resistant to heparinase/heparitinases I and II, while the rest of the repeating region is degraded into disaccharide units. The lyase treatment is applicable to evaluation of heparin/heparan sulfate preparations in terms of the presence or absence of the specific structure containing the 3-O-sulfated GlcN representing biosynthetic precursors, intermediates or final products of the binding site.	KOBE WOMENS COLL PHARM,DEPT PHYSIOL CHEM,KOBE 658,JAPAN; KOBE WOMENS COLL PHARM,NUCL MAGNET RESONANCE LAB,KOBE 658,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,TOKYO 189,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND	Kobe Pharmaceutical University; Kobe Pharmaceutical University; Seikagaku Corporation; Imperial College London			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DELL A, 1988, CARBOHYD RES, V179, P7, DOI 10.1016/0008-6215(88)84105-3; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FOLKMAN J, 1989, HEPARIN, P317; GETTINS P, 1992, CARBOHYD RES, V223, P81, DOI 10.1016/0008-6215(92)80008-O; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HORNE A, 1991, CARBOHYD RES, V225, P43; JORDAN RE, 1986, ARCH BIOCHEM BIOPHYS, V248, P690, DOI 10.1016/0003-9861(86)90524-2; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; LANE DA, 1986, J BIOL CHEM, V261, P3980; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1986, J BIOL CHEM, V261, P4448; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MALLIS LM, 1989, ANAL CHEM, V61, P1453, DOI 10.1021/ac00188a030; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; NADER HB, 1990, J BIOL CHEM, V265, P16807; OTOOTANI N, 1982, BIOCHEM J, V205, P23; OTOTANI N, 1981, J BIOCHEM-TOKYO, V90, P1553, DOI 10.1093/oxfordjournals.jbchem.a133625; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1987, J BIOL CHEM, V262, P5036; REINHOLD VN, 1987, CARBOHYD RES, V161, P305, DOI 10.1016/S0008-6215(00)90088-0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1992, 16TH INT CARB S PAR, P515; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	47	88	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4780	4787						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444855				2022-12-25	WOS:A1993KP88400037
J	MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N				MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N			P53-GENE MUTATIONS IN HUMAN EPITHELIAL SKIN CANCERS	ONCOGENE			English	Article							RAS GENE; ONCOGENE; HETEROZYGOSITY; AMPLIFICATION; PROGRESSION; SPECIFICITY; CARCINOMAS; CELLS	In the present study we analysed 38 epithelial skin cancers, 19 basal cell carcinomas (BCCs), 13 squamous cell carcinomas (SCCs) and six Bowen diseases (BwDs), using a combination of polymerase chain reaction (PCR) and single-stranded conformation polymorphism (SSCP) techniques for the presence of p53 and RAS gene mutations. Whereas 48% (9/19) of the BCCs tested presented a mutated p53 gene, the frequency was lower (15%, 2/13) in our series of SCCs and negatve in the BwDs. Nine of the 11 characterized mutations were single-nucleotide substitutions and, interestingly, seven of these involved CC dimers, where a C was changed into a T or a G (three C-->T transitions and four C-->G transversions). This mutational pattern, added to the fact that all the mutated tumors occurred at sun-exposed body sites, implicates UV light in their genesis. Furthermore, we observed two internal deletions of 6 and 24 bp whose flanking sequences contained two or three Cs on either strand. In addition to molecular detection, we searched for p53 protein accumulation, by immunocytochemical staining, in a subset of 23 epithelial skin tumors (nine bearing a mutation, 14 which scored negative in our assay). Three commercially available anti-p53 antibodies (PAb CM1, mAbs DO7 and 1801) were used, and 3/23 (all showing a mutated p53 gene) presented specific nuclear staining. In contrast to other reported data we could not detect any activating RAS gene mutation in our series of human skin cancers.	CNRS,CRBM,DERMATOL MOLEC LAB,BP 5051,ROUTE DE MENDE,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Theillet, Charles/O-7634-2018; Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1989, ONCOGENE, V4, P1389; BENNETT WP, 1991, ONCOGENE, V6, P1779; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Brash D., 1991, P NATL ACAD SCI USA, V88, P1012; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS PA, 1991, ONCOGENE, V6, P2363; CARBONE D, 1991, NUCLEIC ACIDS RES, V6, P1691; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PORTIER M, 1992, IN PRESS ONCOGENE; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504	29	194	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					583	588						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437842				2022-12-25	WOS:A1993KN00800008
J	QIAN, DP; GRISWOLDPRENNER, I; ROSNER, MR; FITCH, FW				QIAN, DP; GRISWOLDPRENNER, I; ROSNER, MR; FITCH, FW			MULTIPLE COMPONENTS OF THE T-CELL ANTIGEN RECEPTOR COMPLEX BECOME TYROSINE-PHOSPHORYLATED UPON ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-CHAIN; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; INOSITOL PHOSPHATES; MOLECULAR-CLONING; ETA-CHAIN; PROTEINS; KINASE; IDENTIFICATION; STIMULATION	Triggering of the multicomponent T cell antigen receptor (TCR) complex results in several biochemical processes which are critical for the functional activation of T lymphocytes. One common process is the tyrosine phosphorylation of several proteins, including the TCRzeta chain. Here we show that in addition to TCRzeta, other subunits (CD3gamma, CD3delta, and CD3epsilon) of the TCR complex can also be tyrosine-phosphorylated in response to antigen receptor stimulation. This rapid phosphorylation was detected in several mature murine T cell subsets, including CD4+ type 1 and 2 helper cells (T(H)1 and T(H)2). Therefore, tyrosine phosphorylation of multiple TCR components in addition to TCRzeta may be an important event during the initiation of the signaling cascade leading to T cell activation.	UNIV CHICAGO, BEN MAY INST, 5841 S MARYLAND AVE, MC3084, CHICAGO, IL 60637 USA; UNIV CHICAGO, COMM IMMUNOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago					NATIONAL CANCER INSTITUTE [R35CA044372, R01CA035541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007197] Funding Source: NIH RePORTER; NCI NIH HHS [CA44372, CA35541] Funding Source: Medline; NIGMS NIH HHS [GM07197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIES AA, 1987, J BIOL CHEM, V262, P10918; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PATEL MD, 1987, J BIOL CHEM, V262, P5831; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377	52	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4488	4493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440731				2022-12-25	WOS:A1993KN53300097
J	SEIFERT, RA; VANKOPPEN, A; BOWENPOPE, DF				SEIFERT, RA; VANKOPPEN, A; BOWENPOPE, DF			PDGF-AB REQUIRES PDGF RECEPTOR ALPHA-SUBUNITS FOR HIGH-AFFINITY, BUT NOT FOR LOW-AFFINITY, BINDING AND SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DIFFERENT DIMERIC FORMS; SMOOTH-MUSCLE CELLS; DIFFERENT ISOFORMS; KINASE ACTIVATION; HUMAN-FIBROBLASTS; HUMAN-PLATELETS; LIGAND-BINDING; B-CHAIN; DIMERIZATION	There are two PDGF receptor proteins (PDGFRalpha and PDGFRbeta) which are proposed to function as subunits to form a high-affinity dimeric PDGF receptor. One aspect of this model about which there is still disagreement is whether PDGF-AB can bind to cells that express only PDGFRbeta and, if so, whether PDGF-AB can act as an agonist or an antagonist. To address this question, we derived 3T3 cell lines from Patch mutant mouse embryos in which the PDGFRalpha gene is deleted but which express normal levels of PDGFRbeta. Comparison between the binding and response properties of mutant and wild type 3T3 cell lines allowed us to define the contribution that PDGFRalpha makes to the ability of a cell to bind, and respond to, PDGF-AB. We found that PDGF-AB binds to PDGFRalpha-negative 3T3 cells and can induce DNA synthesis, PDGFRbeta dimerization, and phosphorylation on tyrosine. In addition we found that PDGF-AB binding and stimulation of these activities is strongly temperature-dependent, whereas PDGF-AB binding and activation of PDGFRbeta in the presence of PDGFRalpha is not. However, 3T3 cells that do not express PDGFRalpha require for activation PDGF-AB concentrations that were nearly 100-fold greater than for cells that do express PDGFRalpha These results suggest that neither PDGF-AA nor PDGF-AB are likely to be physiologically significant activators of cells unless the cells express PDGFRalpha.	UNIV WASHINGTON,DEPT PATHOL SJ60,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL-18645] Funding Source: Medline; NIGMS NIH HHS [GM-35501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; GRONTENDORST GR, 1991, J CELL PHYSL, V149, P235; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1983, J BIOL CHEM, V258, P54; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAJ S, 1992, BIOCHEMISTRY-US, V31, P1774, DOI 10.1021/bi00121a027; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STROOBANT P, 1984, EMBO J, V12, P2963; TODARO GJ, 1990, MOL CELL BIOL, V10, P6781; WELSH CJ, 1991, IN VITRO CELL DEV B, V27, P425; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4473	4480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440729				2022-12-25	WOS:A1993KN53300095
J	STEPHENS, L; RADENBERG, T; THIEL, U; VOGEL, G; KHOO, KH; DELL, A; JACKSON, TR; HAWKINS, PT; MAYR, GW				STEPHENS, L; RADENBERG, T; THIEL, U; VOGEL, G; KHOO, KH; DELL, A; JACKSON, TR; HAWKINS, PT; MAYR, GW			THE DETECTION, PURIFICATION, STRUCTURAL CHARACTERIZATION, AND METABOLISM OF DIPHOSPHOINOSITOL PENTAKISPHOSPHATE(S) AND BISDIPHOSPHOINOSITOL TETRAKISPHOSPHATE(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; INOSITOL PHOSPHATES; AVIAN ERYTHROCYTES; PHYTIC ACID; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; SULFATED OLIGOSACCHARIDES; RECEPTOR ACTIVATION; ACINAR-CELLS; P-31 NMR; HEXAKISPHOSPHATE	A new class of inositol phosphates containing energy-rich pyrophosphoryl residues has been characterized. D/L-1-Diphosphoinositol pentakisphosphate(s) and D/L-bis-(1,4)-diphosphoinositol tetrakisphosphate(s) are present as soluble ionic species in the cytosol of amoebae (Dictyostelium discoideum) at concentrations in the range of 0.05-0.25 mM. These compounds are rapidly metabolized in intact cells and can be synthesized in cell lysates from myo-inositol hexakisphosphate in the presence of ATP. Their phosphomonoester groups have predicted C-O-P bond energies of between 3.3 and 4 kcal mol-1; however, the bond energies of the P-O-P links in their diphosphate moieties are 6.6 kcal mol-1 and hence similar to the equivalent bonds in ADP, indicating a potential role for these compounds as phosphate donors in phosphotransferase reactions. Compounds with similar chromatographic properties are found in a variety of mammalian cell types.	RUHR UNIV BOCHUM,FAK MED,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY; UNIV GESAMTHSCH WUPPERTAL,FACHBEREICH CHEM,BIOCHEM ABT,W-5600 WUPPERTAL,GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND	Ruhr University Bochum; University of Wuppertal; Imperial College London	STEPHENS, L (corresponding author), INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.		Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X; Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATKINSON MR, 1960, COMP BIOCHEM, V2, P1; BARTLETT GR, 1980, AM ZOOL, V20, P103; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BERRIDGE MJ, 1984, NATURE, V312, P325; BISWAS S, 1978, ARCH BIOCHEM BIOPHYS, V185, P557, DOI 10.1016/0003-9861(78)90201-1; BITTET D, 1989, J BIOL CHEM, V264, P18489; BOWNES CP, 1985, MOL MECHANISMS TRANS, P2; CAMPBELL ID, 1978, METHOD BIOCHEM ANAL, V25, P1; CARR SA, 1984, J CARBOHYD CHEM, V3, P381, DOI 10.1080/07328308408057904; COSGROVE DJ, 1966, REV PURE APPL CHEM, V16, P209; DELL A, 1988, CARBOHYD RES, V179, P7, DOI 10.1016/0008-6215(88)84105-3; EMSLEY J, 1981, PHOSPHORUS SULFUR, V10, P401, DOI 10.1080/03086648108077394; EUROPEFINNER GN, 1991, BIOCHEM BIOPH RES CO, V181, P191, DOI 10.1016/S0006-291X(05)81400-7; FRENCH PJ, 1988, BIOCHEM SOC T, V16, P985, DOI 10.1042/bst0160985; GALLA T, 1989, J BIOL CHEM, V264, P13605; GRAF E, 1987, J BIOL CHEM, V262, P11647; GRAF E, 1983, ANAL BIOCHEM, V131, P351, DOI 10.1016/0003-2697(83)90182-3; GUMBER SC, 1986, BIOCHEM J, V235, P617, DOI 10.1042/bj2350617; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; JOHNSON LF, 1969, CAN J CHEMISTRY, V47, P63, DOI 10.1139/v69-008; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; MALLIS LM, 1989, ANAL CHEM, V61, P1453, DOI 10.1021/ac00188a030; MAYR GW, 1987, FEBS LETT, V213, P278, DOI 10.1016/0014-5793(87)81505-3; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; PHILLIPPY BQ, 1988, ANAL BIOCHEM, V175, P162, DOI 10.1016/0003-2697(88)90374-0; SCHOLZ P, 1990, METHODS INOSITIDE RE, P65; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; STEPHENS LR, 1990, BIOCHEM J, V272, P201, DOI 10.1042/bj2720201; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; WILLIAMS SG, 1970, PLANT PHYSIOL, V45, P376, DOI 10.1104/pp.45.4.376	42	165	178	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4009	4015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440693				2022-12-25	WOS:A1993KN53300033
J	SUBRAMANIAM, A; GULICK, J; NEUMANN, J; KNOTTS, S; ROBBINS, J				SUBRAMANIAM, A; GULICK, J; NEUMANN, J; KNOTTS, S; ROBBINS, J			TRANSGENIC ANALYSIS OF THE THYROID-RESPONSIVE ELEMENTS IN THE ALPHA-CARDIAC MYOSIN HEAVY-CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE REGULATES EXPRESSION; RAT-HEART; RETINOIC ACID; FUSION GENE; ACTIN GENE; RECEPTOR; PROTEIN; FETAL; TRANSCRIPTION; MUSCLE	The role of two putative, cis-acting thyroid hormone-responsive elements, TRE1 and TRE2, located at -129 to -149 and -102 to -120, respectively, on the murine alpha-myosin heavy chain (MHC) gene, has been investigated in transgenic mice. These motifs are present in a 4.5-kilobase fragment lying upstream of the transcriptional start site of the mouse alpha-MHC gene: this fragment directs appropriate expression of a reporter gene in transgenic mice (Subramaniam, A., Jones, W. K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1991) J. Biol. Chem. 266, 24613-24620). Here, we independently mutate the TRE1 and TRE2 elements by base substitution. The mice were analyzed for transgene expression in different muscle and non-muscle tissues including the atria and ventricles. Normal levels of transgene expression were observed in euthyroid mice carrying a mutation in TRE1. In contrast to these results, mice in which TRE2 was mutated showed reduced levels of CAT activity in both the atria and ventricles, suggesting a previously undefined role for this element in the constitutive up-regulation of the alpha-MHC gene. In hypothyroid mice carrying either of these mutations, the complete cessation of ventricular expression of the chloramphenicol acetyltransferase transcripts that takes place in the alpha-5.5 (wild type) animals did not occur.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P01HL046826, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496, HL46826, HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P5564; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FRIEDMAN DJ, 1984, P NATL ACAD SCI-BIOL, V81, P3044, DOI 10.1073/pnas.81.10.3044; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GULICK J, 1991, J BIOL CHEM, V266, P9180; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIEW CC, 1986, P NATL ACAD SCI USA, V83, P3175, DOI 10.1073/pnas.83.10.3175; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; MAHDAVI V, 1989, UCLA S MOL CELL BIOL, V93, P369; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MARKHAM BE, 1987, J BIOL CHEM, V262, P12856; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OJAMAA K, 1991, BIOCHEM BIOPH RES CO, V179, P1269, DOI 10.1016/0006-291X(91)91710-T; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; SAMUEL JL, 1986, AM J PHYSIOL, V250, pH333, DOI 10.1152/ajpheart.1986.250.3.H333; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; SUBRAMANIAM A, 1990, J BIOL CHEM, V265, P13986; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Walter C A, 1989, Biotechniques, V7, P1065; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG WG, 1992, J BIOL CHEM, V267, P15056; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	54	80	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4331	4336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440718				2022-12-25	WOS:A1993KN53300076
J	BRANDT, R; LEE, G				BRANDT, R; LEE, G			FUNCTIONAL-ORGANIZATION OF MICROTUBULE-ASSOCIATED PROTEIN-TAU - IDENTIFICATION OF REGIONS WHICH AFFECT MICROTUBULE GROWTH, NUCLEATION, AND BUNDLE FORMATION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ANTISENSE OLIGONUCLEOTIDES; DYNAMIC INSTABILITY; NERVOUS-SYSTEM; BINDING DOMAIN; BOVINE BRAIN; TUBULIN; PHOSPHORYLATION; POLYMERIZATION; KINASE	Tau protein is a microtubule-associated protein that is almost exclusively expressed in the brain and is enriched in the axon. Determination of tau's sequence has revealed three to four tandem repeats that have been shown to constitute the microtubule binding site. In order to study the functional organization of tau, we prepared a series of truncated tau fragments using an Escherichia coli expression system. We assayed each fragment's activity in promoting growth of microtubules and in nucleating free microtubules. We found that tau's ability to nucleate microtubules requires the presence of additional sequence amino-terminal to that required for growth. We demonstrate that tau's carboxyl and amino termini differentially affect microtubule growth and nucleation. Finally, we show that in vitro microtubule bundle formation occurs when tubulin is assembled in the presence of an amino- and carboxyl-terminally truncated tau protein, whereas almost no bundling is observed in the presence of full-length tau or tau fragments that contain the amino terminus in addition to the repeat domain. We conclude that although the presence of the repeat domain promotes the growth of microtubules, the structural requirements for nucleation activity are more stringent. The differentiation between the growth promoting and nucleation activities on the structural level makes it possible for the two activities to be differentially regulated in vivo.			BRANDT, R (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115, USA.		Lee, Gloria/F-5965-2011	Lee, Gloria/0000-0002-8633-1534; Brandt, Roland/0000-0003-0101-1257	NIGMS NIH HHS [GM39300] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1991, J BIOL CHEM, V266, P9841; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; Amos LA, 1991, MOL CYTOSKELETON; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BRION JP, 1988, NEUROSCIENCE, V25, P139, DOI 10.1016/0306-4522(88)90013-9; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE G, 1992, J CELL SCI, V102, P227; LEWIS SA, 1990, NATURE, V345, P674, DOI 10.1038/345674a0; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MARECK A, 1980, NATURE, V284, P353, DOI 10.1038/284353a0; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; RODER HM, 1991, J NEUROSCI, V11, P3325; ROZDZIAL MM, 1990, EUR J CELL BIOL, V52, P27; SANDOVAL IV, 1981, J BIOL CHEM, V256, P8795; SCOTT CW, 1991, J NEUROSCI RES, V30, P154, DOI 10.1002/jnr.490300116; SOMERS M, 1990, EUR BIOPHYS J, V18, P239, DOI 10.1007/BF00183377; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; TUCKER RP, 1990, BRAIN RES REV, V15, P201; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WITMAN GB, 1976, P NATL ACAD SCI USA, V73, P4070, DOI 10.1073/pnas.73.11.4070	58	196	202	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3414	3419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429017				2022-12-25	WOS:A1993KM16100062
J	HICKEY, MJ; ROTH, GJ				HICKEY, MJ; ROTH, GJ			CHARACTERIZATION OF THE GENE ENCODING HUMAN PLATELET GLYCOPROTEIN-IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE GLYCOPROTEINS; BERNARD-SOULIER PLATELETS; LEUKEMIA-CELL-LINE; VONWILLEBRAND-FACTOR; GEL-ELECTROPHORESIS; CHROMOSOMAL LOCALIZATION; DECREASED ADHESION; GLOBIN EXPRESSION; ALPHA-CHAIN; FACTOR-IV	Glycoprotein IX is a relatively small (M(r) 20,000) surface glycoprotein of human platelets; one of three (Ibalpha, Ibbeta, IX) polypeptide chains present in the glycoprotein Ib-IX complex that functions as the von Willebrand factor receptor and mediates platelet adhesion in the arterial circulation. Using a cDNA for human glycoprotein IX as the probe, clones were isolated from a human genomic library, and the genomic sequence for glycoprotein IX (3.2 kilobases) was determined. The transcriptional start site was located by RNase protection and primer extension experiments. The gene includes three exons and two introns within 1.6 kilobases of DNA, and the entire open reading frame for glycoprotein IX is included within the third exon. The genes for glycoproteins IX and Ibalpha share similar exon sequences on the 5' side of their ATG start codons, and both genes possess introns in this region. The glycoprotein IX gene contains two consensus regulatory sequences (GATA and ACTTCCT [ets]) in its promoter region (5' flank, within 67 bases of the start site) that are also present in similar sites in the previously described ''megakaryocyte-platelet'' genes (glycoprotein IIb, platelet factor 4, beta-thromboglobulin: human and rat). Thus, the glycoprotein IX gene shares structural features with other megakaryocyte-platelet genes and contains at least two consensus cis-acting regulatory elements that may govern gene expression.	VET ADM MED CTR,MED SERV,HEMATOL SECT,SEATTLE,WA 98108; VET ADM MED CTR,RES SERV,SEATTLE,WA 98108; SEATTLE INST BIOMED & CLIN RES,SEATTLE,WA; UNIV WASHINGTON,SEATTLE,WA 98108	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Center for Infectious Disease Research; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 39947] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039947] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNARD J, 1948, Sem Hop, V24, P3217; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; COLLINS SJ, 1987, BLOOD, V70, P1233; CRABTREE GR, 1985, J MOL BIOL, V185, P1, DOI 10.1016/0022-2836(85)90179-2; DAVIE EW, 1990, HEMOSTASIS THROMBOSI, P242; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; EISMAN R, 1990, BLOOD, V76, P336; EISMAN R, 1990, BLOOD S1, V76, P1455; FAVALORO EJ, 1990, BRIT J HAEMATOL, V74, P385, DOI 10.1111/j.1365-2141.1990.tb06324.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENBERG SM, 1988, BLOOD, V72, P1968; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1990, FEBS LETT, V274, P189, DOI 10.1016/0014-5793(90)81361-Q; HOWARD MA, 1973, BRIT MED J, V2, P586, DOI 10.1136/bmj.2.5866.586; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; NURDEN AT, 1981, J CLIN INVEST, V67, P1431, DOI 10.1172/JCI110172; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; PONCZ M, 1990, BLOOD, V75, P1282; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTH GJ, 1989, BIOCHEM BIOPH RES CO, V160, P705, DOI 10.1016/0006-291X(89)92490-X; SAMBROOK J, 1989, MOL CLONING LAB MANU, P779; TAKEHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; UZAN G, 1991, J BIOL CHEM, V266, P8932; VICENTE V, 1990, J BIOL CHEM, V265, P274; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WENGER RH, 1989, GENE, V85, P517, DOI 10.1016/0378-1119(89)90446-0; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x	52	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3438	3443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429020				2022-12-25	WOS:A1993KM16100065
J	PEI, G; POWERS, DD; LENTZ, BR				PEI, G; POWERS, DD; LENTZ, BR			SPECIFIC CONTRIBUTION OF DIFFERENT PHOSPHOLIPID SURFACES TO THE ACTIVATION OF PROTHROMBIN BY THE FULLY ASSEMBLED PROTHROMBINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA; CATALYZED ACTIVATION; COMPLEX; MEMBRANES; THROMBIN; VESICLES; BINDING; EXPRESSION; INHIBITOR; MECHANISM	This paper addresses, in thermodynamic and kinetic terms, the reasons for the acidic lipid specificity of the human prothrombinase complex. We obtained, from the measured lipid titrations of the initial rates of prothrombin activation, the empirical binding constants for prothrombinase assembly on different membranes. These favored assembly on phosphatidylserine (PS)- as opposed to phosphatidylglycerol (PG)-containing membranes. In addition, we have used full time courses of prothrombin activation, in conjunction with a calculation of the equilibrium distribution of factor Xa between four enzymatic forms, to obtain the intrinsic kinetic constants of the prothrombinase assembled on PS- or PG-containing membranes. The resulting values of k(cat), K(m), and k(cat)/K(m) increased as acidic lipid content increased, and k(cat)/K(m) reached a plateau at 12 mol % PS and 50 mol % PG. Using the measured assembly and kinetic constants, the observed shapes of the phospholipid titration curves of human prothrombin activation were interpreted. We conclude that the difference in activity of prothrombinase assembled on PS- versus PG-containing membranes results both from the different binding properties of factors Xa and Va to these surfaces and from the different intrinsic activities of the prothrombinase when assembled on different membranes.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CB 7260,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL45916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045916] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN PS, 1956, J BIOL CHEM, V252, P1756; CRAWFORD N, 1985, ADV EXP MED BIOL, V192, P1; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; JACKSON CM, 1974, THROMB DIATH HAEMO, V17, P273; Jesty J, 1976, Methods Enzymol, V45, P95; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; KISIEL W, 1981, METHOD ENZYMOL, V80, P275; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LENTZ BR, 1982, BIOCHEMISTRY-US, V21, P4212, DOI 10.1021/bi00261a004; LENTZ BR, 1991, BIOPHYS J, V60, P942, DOI 10.1016/S0006-3495(91)82128-2; LENTZ BR, 1980, BIOCHEMISTRY-US, V19, P4475; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOU.D, 1962, P SOC EXP BIOL MED, V111, P412; POWERS DD, 1993, J BIOL CHEM, V268, P3234; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1980, J BIOL CHEM, V255, P274; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P335; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; Segel IH, 1975, ENZYME KINETICS, P54; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WU JR, 1991, BIOPHYS J, V60, P76	38	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3226	3233						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429000				2022-12-25	WOS:A1993KM16100034
J	PONSIN, G; PULCINI, T; SPARROW, JT; GOTTO, AM; POWNALL, HJ				PONSIN, G; PULCINI, T; SPARROW, JT; GOTTO, AM; POWNALL, HJ			HIGH-DENSITY-LIPOPROTEIN INTERCONVERSIONS IN RAT AND MAN AS ASSESSED WITH A NOVEL NONTRANSFERABLE APOLIPOPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; LIPID TRANSFER PROTEINS; ESTER TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; CHOLESTEROL ACYLTRANSFERASE; POSTPRANDIAL LIPEMIA; HEPATIC LIPASE; METABOLISM; KINETICS; PHOSPHATIDYLCHOLINES	A nontransferable peptide analog of a plasma apolipoprotein diacyl lipid-associating peptide (diLAP) incorporates into model reassembled high density lipoproteins (R-HDL). In whole plasma in vitro, diLAP irreversibly transfers to native rat HDL2 and human HDL3, but not to rat HDL1 or human HDL2. The rate of transfer is dependent on the physical state of the lipid in the R-HDL. Exogenous cholesterol promotes the formation of larger HDL. When diLAP-labeled R-HDL were injected into rats, the diLAP that initially associated with HDL2 transferred to HDL1 over a period of 48 h. The rate of clearance of diLAP-labeled HDL was slower than that of apoA-I. The liver was the preferred site for diLAP-labeled HDL1 uptake. In contrast, diLAP-labeled HDL2 were associated with liver, ovaries, and adrenal glands, with the adrenal grands exhibiting the highest specific association. DiLAP was not found in the kidneys. These data show that 1) rat HDL is cleared more slowly than rat apoA-I; 2) HDL is removed from the plasma compartment as a particle; 3) there are tissue-specific differences in the removal of rat HDL1 and HDL2; 4) HDL2 is a precursor to HDL1; and 5) cholesterol and the activity of lecithin:cholesterol acyltransferase are essential to HDL remodeling.	METHODIST HOSP,MAIL STN A601,6565 FANNIN ST,HOUSTON,TX 77030; HOP ANTIQUAILLE,METAB LIPIDES LAB,F-69321 LYON 5,FRANCE; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	The Methodist Hospital System; The Methodist Hospital - Houston; CHU Lyon; Baylor College of Medicine				Pownall, Henry/0000-0001-8412-506X				BARTER PJ, 1987, AM HEART J, V113, P538, DOI 10.1016/0002-8703(87)90628-4; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; EDELSTEIN C, 1979, J LIPID RES, V20, P143; EISENBERG S, 1984, J LIPID RES, V25, P121; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GAVISH D, 1987, J LIPID RES, V28, P257; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GORDON V, 1983, J BIOL CHEM, V258, P6202; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HICKSONBICK D, 1988, BIOCHEMISTRY-US, V27, P7881, DOI 10.1021/bi00420a045; HINZ H, 1972, J BIOL CHEM, V247, P6071; JARNAGIN AS, 1987, P NATL ACAD SCI USA, V84, P1854, DOI 10.1073/pnas.84.7.1854; KOO C, 1985, J BIOL CHEM, V260, P1934; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCKEONE BJ, 1988, BIOCHEMISTRY-US, V27, P4500, DOI 10.1021/bi00412a042; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; OSCHRY Y, 1982, J LIPID RES, V23, P1099; Patsch J R, 1986, Methods Enzymol, V129, P3; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PATSCH JR, 1984, J CLIN INVEST, V74, P2017, DOI 10.1172/JCI111624; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PONSIN G, 1986, J CLIN INVEST, V77, P559, DOI 10.1172/JCI112337; PONSIN G, 1985, J THEOR BIOL, V112, P183, DOI 10.1016/S0022-5193(85)80123-5; PONSIN G, 1984, BIOCHEMISTRY-US, V23, P5337, DOI 10.1021/bi00317a036; PONSIN G, 1985, BIOCHEM BIOPH RES CO, V133, P856, DOI 10.1016/0006-291X(85)91213-6; POWNALL HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3154, DOI 10.1073/pnas.77.6.3154; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RETZINGER GS, 1985, ANAL BIOCHEM, V150, P131, DOI 10.1016/0003-2697(85)90451-8; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCHWARTZ CC, 1982, J CLIN INVEST, V70, P105, DOI 10.1172/JCI110582; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SHEPHERD J, 1978, EUR J CLIN INVEST, V8, P115, DOI 10.1111/j.1365-2362.1978.tb00823.x; STEIN Y, 1966, BIOCHIM BIOPHYS ACTA, V116, P95, DOI 10.1016/0005-2760(66)90095-6; TALL AR, 1986, J LIPID RES, V27, P361	39	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3114	3119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428990				2022-12-25	WOS:A1993KM16100018
J	MOSS, J; STANLEY, SJ; VAUGHAN, M; TSUJI, T				MOSS, J; STANLEY, SJ; VAUGHAN, M; TSUJI, T			INTERACTION OF ADP-RIBOSYLATION FACTOR WITH ESCHERICHIA-COLI ENTEROTOXIN THAT CONTAINS AN INACTIVATING LYSINE-112 SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; CHOLERA-TOXIN; DIPHTHERIA-TOXIN; RIBOSYLTRANSFERASE ACTIVITY; PERTUSSIS TOXIN; NAD; ACTIVATION; SUBUNIT; IDENTIFICATION; EXPRESSION	Cholera toxin and Escherichia coli heat-labile enterotoxin (LT) exert their effects on cells through ADP-ribosylation of guanine nucleotide-binding proteins. Both toxins consist of one A subunit, which is an ADP-ribosyltransferase, and five B (or binding) subunits. Their enzymatic activities are latent; activation requires reduction and proteolysis, resulting in a catalytically active A1 protein and a much smaller A2 protein. These ADP-ribosyltransferases are activated by GTP-dependent 20-kDa ADP-ribosylation factors or ARFs. To determine if proteolysis plus reduction is required for appearance of the ARF allosteric site as well as for catalytic activity, an inactive mutant of LT, LT(E112K), with replacement of glutamate by lysine at position 112 of its A subunit, was utilized as a competitor in cholera toxin ADP-ribosyltransferase assays containing limiting amounts of ARF. LT(E112K) required trypsinization and reduction to become a potent, concentration-dependent inhibitor. Inhibition was reversed by increasing concentrations of ARF. Reduction or trypsinization alone did not generate an inhibitory form of LT(E112K). These studies are consistent with the conclusion that the ARF site is not expressed in the latent toxin. Both trypsinization and reduction are required for expression of a functional ARF binding site as well as for catalytic activity.	FUJITA HLTH UNIV,SCH MED,DEPT MICROBIOL,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University	MOSS, J (corresponding author), NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892, USA.							BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; COCKLE SA, 1989, FEBS LETT, V249, P329, DOI 10.1016/0014-5793(89)80652-0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KUNZ BC, 1990, FASEB J, V4, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CM, 1992, J BIOL CHEM, V267, P9028; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1981, P NATL ACAD SCI-BIOL, V78, P4809, DOI 10.1073/pnas.78.8.4809; MOSS J, 1981, J BIOL CHEM, V256, P2861; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NODA M, 1989, BIOCHEMISTRY-US, V28, P7936, DOI 10.1021/bi00445a057; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; TSUJI T, 1990, J BIOL CHEM, V265, P22520; TWETEN RK, 1985, J BIOL CHEM, V260, P392; WEISS O, 1989, J BIOL CHEM, V264, P21066; [No title captured]	32	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6383	6387						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454609				2022-12-25	WOS:A1993KT36800046
J	PODOLSKY, DK; LYNCHDEVANEY, K; STOW, JL; OATES, P; MURGUE, B; DEBEAUMONT, M; SANDS, BE; MAHIDA, YR				PODOLSKY, DK; LYNCHDEVANEY, K; STOW, JL; OATES, P; MURGUE, B; DEBEAUMONT, M; SANDS, BE; MAHIDA, YR			IDENTIFICATION OF HUMAN INTESTINAL TREFOIL FACTOR - GOBLET CELL-SPECIFIC EXPRESSION OF A PEPTIDE TARGETED FOR APICAL SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; STOMACH MUCOSA; PSP; DIFFERENTIATION; LINE; RAT; PROTEIN; PS2-PROTEIN; CARCINOMA	Trefoil peptides are a recently recognized group of small peptides abundantly produced at mucosal surfaces that offer the opportunity to define mechanisms of mucosal cell-specific differentiation and to illuminate new mechanisms for the preservation of mucosal integrity. We report the cDNA cloning of a 75-amino acid human trefoil factor expressed in small and large intestinal mucosas that is highly homologous to the intestinal trefoil factor, with 70% identity at the amino acid level of the predicted mature protein. This human intestinal trefoil factor is also homologous, although to a lesser extent, to trefoil peptides expressed at other sites in the gastrointestinal tract in man, exhibiting absolute conservation of the P domain motif (CX9CX9CX4CCX9WCF) that defines this family of peptides. These findings indicate a high degree of evolutionary conservation of organ/region-specific members of this peptide family. In situ hybridization of intestinal trefoil factor demonstrates a high degree of expression in mature small intestine villus and colonic epithelial goblet cells. Immunogold staining demonstrates high concentrations of intestinal trefoil factor in the rough endoplasmic reticulum and theca of goblet cells as well as throughout the mucosal surface, consistent with vectorial secretion of this factor by goblet cells onto the intestinal luminal surface. In addition, intestinal trefoil factor was also localized within columnar epithelial cells by immunogold labeling despite the absence of mRNA. These observations suggest that peptide secreted by goblet cells might be taken up from the luminal surface and transcytosed by enterocytes. Human intestinal trefoil factor expression was also detected in the HT-29N2 and HT-29H2 subclones in conjunction with the emergence of the goblet cell phenotype, but not in the CaCO2 cell line that exhibits enterocytic phenotype. In summary, these findings confirm the existence of a highly conserved family of peptides that are abundantly expressed in distinctive regions throughout the gastrointestinal tract in a highly cell-specific pattern reflecting a goblet cell differentiation pathway. They form one of the more abundant constituents of the interface between the mucosa and ''outside' environment and may provide a new paradigm of regulation of the integrity of epithelial surfaces as well as a previously unrecognized dimension of goblet cell function.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,NEW ENGLAND REG PRIMATE RES CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	PODOLSKY, DK (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114, USA.		Sands, Bruce/R-7887-2019; Stow, Jennifer/I-4723-2013	Sands, Bruce/0000-0001-5762-5042; Stow, Jennifer/0000-0002-5409-9101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034422, P30DK043351, T32DK007191] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07191, DK34422, DK43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1967, J BIOL CHEM, V242, P5617; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANDSEN EK, 1986, REGUL PEPTIDES, V16, P291, DOI 10.1016/0167-0115(86)90028-5; HAUSER F, 1991, J BIOL CHEM, V266, P21306; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HOOSEIN NM, 1989, FEBS LETT, V247, P303, DOI 10.1016/0014-5793(89)81357-2; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; JORGENSEN KH, 1982, REGUL PEPTIDES, V3, P207, DOI 10.1016/0167-0115(82)90126-4; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Neutra M, 1989, FUNCTIONAL EPITHELIA, P363; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1251, DOI 10.1172/JCI112428; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SUSSMAN NL, 1989, AM J PHYSIOL, V257, pG14, DOI 10.1152/ajpgi.1989.257.1.G14; THIM L, 1988, BIOCHEM J, V253, P309; THIM L, 1982, REGUL PEPTIDES, V3, P221, DOI 10.1016/0167-0115(82)90127-6; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	36	264	277	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6694	6702						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454642				2022-12-25	WOS:A1993KT36800088
J	RAO, R; SLAYMAN, CW				RAO, R; SLAYMAN, CW			MUTAGENESIS OF CONSERVED RESIDUES IN THE PHOSPHORYLATION DOMAIN OF THE YEAST PLASMA-MEMBRANE H+-ATPASE - EFFECTS ON STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-TRANSPORTING ATPASES; NUCLEOTIDE-BINDING DOMAIN; AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; SECRETORY VESICLES; CONSEQUENCES; CA-2+-ATPASE; CELLS	A diagnostic feature of P-ATPases is a phosphorylation motif (DKTGTLT), located in the hydrophilic center of the polypeptide chain, within which the beta-aspartyl-phosphate reaction intermediate is formed. The roles of four invariant residues (Lys379, Thr380, Thr382, and Thr384) in this region of the yeast plasma membrane H+-ATPase have been analyzed by site-directed mutagenesis. In addition, a set of six insertion mutants was generated containing a single glycine residue at each of the indicated sites: C(del)S(del)D(del)K(del)T(del)GT(del)LT to examine spatial arrangements within this highly conserved domain. In order to minimize toxic effects of the mutations on cell growth, the defective ATPases were expressed behind an inducible heat shock promoter and targeted to an intracellular pool of secretory vesicles, while wild-type ATPase was maintained in the plasma membrane where it is required for viability. Secretory vesicles containing mutant ATPase were isolated as described previously (Nakamoto, R. K., Rao, R., and Slayman, C. W. (1991) J. Biol. Chem. 266, 7940-7949) and assayed for the amount of ATPase polypeptide and for rates of ATP hydrolysis and H+ pumping. All of the insertion mutations led to biosynthetic arrest of the defective enzyme, with no ATPase appearing in the secretory vesicles. Nonconservative amino acid substitutions (Lys --> Gln, Thr --> Ala) inactivated the ATPase, whereas conservative substitutions (Lys --> Arg, Thr --> Ser) retained partial activity which has been characterized in detail. There was little or no change in the K(m) for ATP or the pH optimum in any of the mutant enzymes. Strikingly, however, all displayed an increase in resistance to vanadate, consistent with the idea that the residues in question contribute to a phosphate/vanadate binding site or that they affect the equilibrium between E1 and E2 conformations of the enzyme.			RAO, R (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CID A, 1988, J BIOL CHEM, V263, P14134; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, STRUCTURE FUNCTION S, P91; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PARDO JP, 1989, J BIOL CHEM, V264, P9373; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; RAO R, 1992, BIOPHYS J, V62, P228, DOI 10.1016/S0006-3495(92)81808-8; RAO R, 1989, ION TRANSPORT, P35; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH RL, 1980, J BIOL CHEM, V255, P9852; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; VANDYCK L, 1990, EUR J BIOCHEM, V194, P785; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V101, P377	40	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6708	6713						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454643				2022-12-25	WOS:A1993KT36800090
J	DELLACQUA, ML; CARROLL, RC; PERALTA, EG				DELLACQUA, ML; CARROLL, RC; PERALTA, EG			TRANSFECTED M2 MUSCARINIC ACETYLCHOLINE-RECEPTORS COUPLE TO G-ALPHA-I2 AND G-ALPHA-I3 IN CHINESE-HAMSTER OVARY CELLS - ACTIVATION AND DESENSITIZATION OF THE PHOSPHOLIPASE-C SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ADENYLYL CYCLASE; ADRENERGIC-RECEPTOR; ALPHA-SUBUNITS; BIOCHEMICAL-PROPERTIES; ADP-RIBOSYLATION; BETA-1 ISOZYME; GQ CLASS; IDENTIFICATION; EXPRESSION	Muscarinic acetylcholine receptor subtypes (m1-m5) differentially regulate phosphoinositide-specific phospholipase (PLC) through the activation of distinct guanine nucleotide-binding (G) proteins which can be distinguished on the basis of their sensitivity to inhibition by pertussis toxin (PTX). In transfected Chinese hamster ovary cells, the m2 receptor subtype regulates the stimulation of PLC and inhibition of adenylyl cyclase (AC) through PTX-sensitive G proteins. In this study, we utilized the ability of cholera toxin (CTX) to ADP-ribosylate PTX-sensitive alpha subunits as part of the ternary complex formed by heterotrimeric G proteins and agonist-bound receptors to detect and characterize the interactions between transfected m2 receptors and endogenous G proteins in Chinese hamster ovary cells. In membranes derived from cells expressing the m2, but not the m3 receptor, the cholinergic agonist carbachol stimulated CTX modification of a 40-kDa species (G(alpha40)). Importantly, similar carbachol dose dependence values and PTX dose sensitivities were observed for m2 receptor-mediated PLC signaling and G(alpha40)-CTX modification. High resolution urea-SDS-polyacrylamide gel electrophoresis analysis revealed that G(alphai2) (40 kDa) and G(alphai3) (41 kDa) were components of the G(alpha40) identified by m2 receptor-dependent CTX modification. Furthermore, the sensitivities of G(alphai2) and G(alphai3) to PTX modification were determined to be the same as those for PTX inhibition of G(alpha40) labeling by CTX and m2 receptor-mediated PLC signaling. Similarly, agonist-induced desensitization of m2 receptor-G protein signaling required doses of agonist associated with stimulation of PLC. Desensitization involved receptor sequestration and down-regulation of G(alphai3); however, only the reduction of G(alphai3) required prior activation PLC signaling. Finally, desensitization of m2-G protein coupling could be partially mimicked by treatment with thapsigargin, an inducer of intracellular Ca2+ release, without altering the number of cell surface receptors or G protein levels. These results demonstrate that m2 receptors couple to both G(alphai2) and G(alphai3) in vivo and that this interaction is integral to both positive and negative regulatory pathways leading to activation of PLC and desensitization of receptor signaling.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University				Dell'Acqua, Mark/0000-0003-3798-3461				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUFF RM, 1985, J BIOL CHEM, V260, P864; IIRI T, 1992, J BIOL CHEM, V267, P1020; IIRI T, 1989, J BIOL CHEM, V264, P21394; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MASA M, 1991, NATURE, V349, P760; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MUMBY S, 1988, J BIOL CHEM, V263, P2020; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	46	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5676	5685						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449930				2022-12-25	WOS:A1993KR82200049
J	IMAI, E; MINER, JN; MITCHELL, JA; YAMAMOTO, KR; GRANNER, DK				IMAI, E; MINER, JN; MITCHELL, JA; YAMAMOTO, KR; GRANNER, DK			GLUCOCORTICOID RECEPTOR-CAMP RESPONSE ELEMENT-BINDING PROTEIN-INTERACTION AND THE RESPONSE OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE TO GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN OSTEOCALCIN GENE; CYCLIC-AMP; RETINOIC ACID; FOS-JUN; NEGATIVE REGULATION; DNA-BINDING; C-JUN; TRANSCRIPTION; PROMOTER; IDENTIFICATION	The phosphoenolpyruvate carboxykinase (PEPCK) gene encodes the rate-limiting enzyme in gluconeogenesis. Glucocorticoids enhance PEPCK gene expression through a multicomponent regulatory complex. We show that a full response to glucocorticoids requires two DNA segments: 1) a glucocorticoid response unit (GRU), centered at about position -400, which contains two accessory factor elements (AF1 and AF2) and two glucocorticoid receptor binding sites (GR1 and GR2), and 2) a basal promoter/cyclic AMP response element (E/CRE) at about position -90, which binds the transcription factor CREB. A protein-protein interaction was observed in vitro between GR and CREB that might account for the role of the E/CRE in the glucocorticoid response of the PEPCK gene.	VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Vanderbilt University; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA020535, R37CA020535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, R01DK035107] Funding Source: NIH RePORTER; NCI NIH HHS [CA20535] Funding Source: Medline; NIDDK NIH HHS [DK35107, DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FOREST CF, 1990, MOL ENDOCRINOL, V249, P1302; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRANNER DK, 1979, GLUCOCORTICOID HORMO, V12, P593; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; SASAKI K, 1984, J BIOL CHEM, V259, P15424; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	34	267	270	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5353	5356						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449898				2022-12-25	WOS:A1993KR82200004
J	KOPP, M; MULLER, H; HOLZER, H				KOPP, M; MULLER, H; HOLZER, H			MOLECULAR ANALYSIS OF THE NEUTRAL TREHALASE GENE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREHALOSE-6-PHOSPHATE SYNTHASE; TRANSCRIPTION TERMINATION; DNA-SEQUENCE; YEAST; PROTEIN; ACID; FRUCTOSE-1,6-BISPHOSPHATASE; PURIFICATION; PHOSPHATASE; REPRESSION	Neutral trehalase (EC 3.2.1.28) is a trehalose hydrolyzing enzyme of the Yeast Saccharomyces cerevisiae (App, H., and Holzer, H. (1989) J. Biol. Chem. 264, 17583-17588). The gene of neutral trehalase was cloned by complementation of a neutral trehalase-deficient yeast mutant which was obtained by ethylmethanesulfonate mutagenesis. Three mutants without detectable neutral trehalase activity were obtained and characterized by tetrad analysis and found to belong to the same complementation group. The mutants were transformed with a S. cerevisiae genomic library in YEp24. Two overlapping plasmids were isolated, containing the neutral trehalase gene NTH1 with an open reading frame of 2079 base pairs (bp), encoding a protein of 693 amino acids, corresponding to a molecular mass of 79,569 Da. Several putative TATA boxes were found in the 5'-nontranslated region of the NTH1 gene. In positions -652 to -641 a possible binding sequence for the MIG1 protein, a multicopy inhibitor of the GAL1 promotor, which also binds to the promotor sequences of the SUC2 and the FBP1 gene, was found. The start codon of the neutral trehalase is located about 2500 bp upstream of the centromere 4 consensus sequence elements I, II, and III (Mann, C., and Davis, R. W. (1986) Mol. Cell. Biol. 6, 241-245). Vicinity to a centromere is known to have a depressing influence on the number of plasmid copies per cell. This probably explains why transformation with pNTH does not lead to overexpression of neutral trehalase. The four consensus sequences AATAAA contained in the centromeric elements and reconfirmed by our sequencing data might be polyadenylation signals for NTH1-mRNA transcription termination. Northern blot analysis yielded a single mRNA species of approximately 2.3 kilobase(s). The neutral trehalase protein has a putative cAMP-dependent phosphorylation consensus sequence RRGS from amino acid positions 22-25. Therefore, the previously described activation of neutral trehalase by cAMP-dependent phosphorylation is probably due to phosphorylation of serine 25. Three potential N-glycosylation sites (Asn-X-Ser/Thr) occur in the open reading frame of the neutral trehalase gene. However, no evidence for glycosylation could be detected by Western blotting. The amino acid sequence of neutral trehalase from S. cerevisiae points to significant similarity in three domains with the osmoregulated treA gene encoding the periplasmic trehalase from E. coli K12 (Gutierrez, C., Ardourel, M., Bremer, E., Middendorf, A., Boos, W., and Ehmann, U. (1989) Mol. Gen. Genet. 217, 347-354) and in four domains to the trehalase gene of rabbit small intestine (Ruf, J., Wacker, H., James, P., Maffia, M., Seiler, P., Galand, G., Kiekebusch, A. V., Semenza, G., and Mantei, N. (1990) J. Biol. Chem. 265, 15034-15039). These domains might be part of the catalytic center of these trehalases. In order to study the biological function of the neutral trehalase, an isogenic disruption mutant, with the URA3 gene inserted, was constructed. It could be shown, that the steady state concentration of trehalose in the exponentially growing disruption mutant is three times higher than in the wild-type and that trehalose, accumulated at heat stress in the wild-type, must be degraded at return to normal growth temperature by neutral trehalase, not by acid trehalase.	UNIV FREIBURG, INST BIOCHEM, HERMANN HERDER STR 7, W-7800 FREIBURG, GERMANY	University of Freiburg								ALBIG W, 1988, GENE, V73, P141, DOI 10.1016/0378-1119(88)90320-4; APP H, 1989, J BIOL CHEM, V264, P17583; ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; AUSUBEL FM, CURR PROTOCOLS MOL B, V2; BACON JSD, 1965, BIOCHEM J, V94, P175, DOI 10.1042/bj0940175; Battey, 1986, BASIC METHODS MOL BI; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOURQUELOT MEM, 1893, CR HEBD ACAD SCI, V116, P826; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Elbein A D, 1974, Adv Carbohydr Chem Biochem, V30, P227, DOI 10.1016/S0065-2318(08)60266-8; ENTIAN KD, 1988, FEBS LETT, V236, P195, DOI 10.1016/0014-5793(88)80313-2; FELIX H, 1982, ANAL BIOCHEM, V120, P211, DOI 10.1016/0003-2697(82)90340-2; FERNANDEZ E, 1992, EUR J BIOCHEM, V204, P983, DOI 10.1111/j.1432-1033.1992.tb16720.x; Fischer E, 1895, BERICHTE DTSCH CHEM, V28, P1429, DOI [10.1002/CBER.18950280243, DOI 10.1002/CBER.18950280243]; FRANCOIS J, 1991, YEAST, V7, P575, DOI 10.1002/yea.320070605; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P41; GUTIERREZ C, 1989, MOL GEN GENET, V217, P347, DOI 10.1007/BF02464903; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; ITO H, 1984, AGR BIOL CHEM TOKYO, V48, P341, DOI 10.1080/00021369.1984.10866161; KELLER F, 1982, ARCH MICROBIOL, V131, P298, DOI 10.1007/BF00411175; KOHALMI SE, 1988, J MOL BIOL, V204, P561, DOI 10.1016/0022-2836(88)90355-5; KOPETZKI E, 1987, BIOCHIM BIOPHYS ACTA, V912, P398, DOI 10.1016/0167-4838(87)90044-6; KOPP M, 1993, THESIS U FREIBURG GE; LONDESBOROUGH J, 1984, BIOCHEM J, V219, P511, DOI 10.1042/bj2190511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN C, 1986, MOL CELL BIOL, V6, P241, DOI 10.1128/MCB.6.1.241; MERCADO JJ, 1991, FEBS LETT, V291, P97, DOI 10.1016/0014-5793(91)81112-L; MITTENBUHLER K, 1988, J BIOL CHEM, V263, P8537; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; ORITZ CH, 1983, J BACTERIOL, V153, P644, DOI 10.1128/JB.153.2.644-651.1983; PANEK AC, 1987, CURR GENET, V11, P459, DOI 10.1007/BF00384607; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; RUF J, 1990, J BIOL CHEM, V265, P15034; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SAMBROOK F, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TYLER DD, 1979, BIOCHEM J, V178, P289, DOI 10.1042/bj1780289; UNO I, 1983, J BIOL CHEM, V258, P867; VANDERCAMMEN A, 1989, EUR J BIOCHEM, V182, P613, DOI 10.1111/j.1432-1033.1989.tb14870.x; VANSOLINGEN P, 1975, BIOCHEM BIOPH RES CO, V62, P553, DOI 10.1016/0006-291X(75)90434-9; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; WIEMKEN A, 1982, FEBS LETT, V150, P329, DOI 10.1016/0014-5793(82)80762-X; Wiggers HAL., 1832, ANN PHARM, V1, P129, DOI [10.1002/jlac.18320010202, DOI 10.1002/JLAC.18320010202]; WINKLER K, 1991, FEBS LETT, V291, P269, DOI 10.1016/0014-5793(91)81299-N; WOLSKAMITASZKO B, 1981, ANAL BIOCHEM, V116, P241, DOI 10.1016/0003-2697(81)90351-1; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	57	121	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4766	4774						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444853				2022-12-25	WOS:A1993KP88400035
J	LAHERTY, CD; PERKINS, ND; DIXIT, VM				LAHERTY, CD; PERKINS, ND; DIXIT, VM			HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX AND PHORBOL 12-MYRISTATE 13-ACETATE INDUCE EXPRESSION OF THE A20 ZINC FINGER PROTEIN BY DISTINCT MECHANISMS INVOLVING NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; CD3/T-CELL RECEPTOR COMPLEX; ENHANCER-BINDING PROTEINS; FACTOR-ALPHA; DNA-BINDING; IMMATURE THYMOCYTES; LYMPHOCYTES-T; GENE; APOPTOSIS	A20 was originally identified as a primary tumor necrosis factor alpha (TNF)-responsive gene, which encodes a 790-amino acid zinc finger protein. A20 is expressed in a wide variety of cell lines, including fibroblasts, in which A20 expression protects cells from TNF cytotoxicity. An analysis of A20 expression in lymphocytic and monocytic cells lines revealed that A20 protein expression correlates with lymphocyte activation and monocyte differentiation. A20 expression was also induced in Jurkat T cells expressing the human T cell leukemia virus type I Tax protein. Transient transfection studies demonstrated that stimulation of A20 transcription by TNF, phorbol 12-myristate 13-acetate (PMA), and Tax was mediated by two kappaB elements within the A20 promoter. Accordingly, DNA electrophoretic mobility shift assays confirmed inducible binding of nuclear factor kappaB (NF-kappaB) to a promoter fragment containing both A20kappaB elements. Analysis of individual A20 kappaB sites revealed that both kappaB sites were required for TNF or PMA activation of the A20 promoter; however, Tax activation required only one kappaB site. Overexpression of NF-kappaB subunits activated the wild type A20 promoter, but did not activate mutated forms containing single kappaB sites. Thus, Tax activation of A20 transcription occurs through a mechanism distinct from PMA and TNF, possibly due to differential activation of NF-kappaB complexes or transcriptional cofactors.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, BOX 0602, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, CELLULAR & MOLEC BIOL PROGRAM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45351] Funding Source: Medline; NIAMS NIH HHS [AR 20557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLLINS M, 1991, CURR BIOL, V3, P140; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; ROBAYE B, 1991, AM J PATHOL, V138, P447; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UCKER DS, 1989, J IMMUNOL, V143, P3461; UCKER DS, 1991, NEW BIOL, V3, P103; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	59	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5032	5039						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444879				2022-12-25	WOS:A1993KP88400070
J	WEDLER, FC; LEY, BW				WEDLER, FC; LEY, BW			KINETIC AND REGULATORY MECHANISMS FOR (ESCHERICHIA-COLI) HOMOSERINE DEHYDROGENASE-I - EQUILIBRIUM ISOTOPE EXCHANGE KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTATION; ASPARTATE-TRANSCARBAMYLASE; COMPUTER-SIMULATION; CATALYTIC CHAIN; ASPARTOKINASE; TYR240->PHE; SUBSTRATE; PATTERNS; BINDING; SYSTEM	Isotope exchange kinetics at chemical equilibrium were used to probe the mechanisms of substrate binding and regulatory behavior of homoserine dehydrogenase-I from Escherichia coli. At pH 9.0, 37-degrees-C, K(eq) = 100 (+/-20) for the catalyzed reaction: L-aspartate-beta-semialdehyde + NADPH + H+ = L-homoserine + NADP+. Saturation curves for the exchange reactions, [C-14]L-homoserine reversible L-aspartate-beta-semialdehyde and [H-3]NADP+ reversible NADPH were observed as a function of different reactant-product pairs, varied in constant ratio at equilibrium. The NADP+ reversible NADPH exchange rate was inhibited upon variation of pairs involving L-aspartate-beta-semialdehyde and L-homoserine, consistent with preferred order random binding of cofactors before amino acids. Optimal rate constants, derived by simulations of equilibrium isotope exchange kinetics data with the ISOBI program, indicate faster dissociation of amino acids than cofactors from the central complexes but nearly equal rates for association of cofactors and amino acids to free enzyme. Rate limitation of net turnover in both directions is determined by dissociation of cofactor from the E-cofactor complex. The allosteric modifier, L-threonine, produces distinctive perturbations of the saturation curves for isotope exchange, which were analyzed systematically with the ISOBI program. The best fit to the data was obtained by L-threonine inhibiting catalysis between the central complexes without altering substrate association-dissociation rates. Simulations also showed that rate-limiting catalysis suppresses the kinetic inhibition effects that are characteristic of preferred order substrate binding, producing patterns typical for a (rapid equilibrium) random kinetic scheme.			WEDLER, FC (corresponding author), PENN STATE UNIV, DEPT MOLEC & CELL BIOL, BIOCHEM PROGRAM, UNIV PK, PA 16802 USA.							ANDERSSON P, 1984, EUR J BIOCHEM, V139, P519, DOI 10.1111/j.1432-1033.1984.tb08036.x; ANGELES TS, 1990, ARCH BIOCHEM BIOPHYS, V283, P96, DOI 10.1016/0003-9861(90)90617-8; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEARER CF, 1978, BIOCHEMISTRY-US, V17, P3517, DOI 10.1021/bi00610a015; BEARER CF, 1978, BIOCHEMISTRY-US, V17, P3523, DOI 10.1021/bi00610a016; BEARER CF, 1978, BIOCHEMISTRY-US, V17, P3512, DOI 10.1021/bi00610a014; BLACK S, 1962, METHOD ENZYMOL, V5, P820, DOI 10.1016/S0076-6879(62)05320-3; BLACK S, 1955, J BIOL CHEM, V213, P39; BOYER PD, 1959, ARCH BIOCHEM BIOPHYS, V82, P387, DOI 10.1016/0003-9861(59)90136-5; BOYER PD, 1978, ACCOUNTS CHEM RES, V11, P218, DOI 10.1021/ar50125a007; COHEN GN, 1965, BIOCHEM BIOPH RES CO, V19, P546, DOI 10.1016/0006-291X(65)90160-9; COHEN GN, 1980, MULTIFUNCTIONAL PROT, P49; COSTREJEAN JM, 1977, J BIOL CHEM, V252, P5332; COWIE DB, 1973, BIOCHEM BIOPH RES CO, V53, P188, DOI 10.1016/0006-291X(73)91418-6; EHRLICH RS, 1973, BIOCHEMISTRY-US, V12, P4309, DOI 10.1021/bi00746a002; FUNKHOUSER JD, 1974, J BIOL CHEM, V249, P7580; HECK HD, 1972, BIOCHEMISTRY-US, V11, P4421, DOI 10.1021/bi00774a001; HECK HD, 1970, BIOCHEMISTRY-US, V9, P2776, DOI 10.1021/bi00816a004; HIRTH CG, 1975, EUR J BIOCHEM, V50, P425, DOI 10.1111/j.1432-1033.1975.tb09819.x; HSUANYU Y, 1988, J BIOL CHEM, V263, P4172; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; JANIN J, 1969, EUR J BIOCHEM, V11, P520, DOI 10.1111/j.1432-1033.1969.tb00804.x; JANIN J, 1969, EUR J BIOCHEM, V11, P530, DOI 10.1111/j.1432-1033.1969.tb00805.x; JANIN J, 1969, EUR J BIOCHEM, V8, P128, DOI 10.1111/j.1432-1033.1969.tb00505.x; LOWRY OH, 1961, J BIOL CHEM, V236, P2756; OGILVIE JW, 1975, J BIOL CHEM, V250, P1242; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; PATTE JC, 1963, BIOCHIM BIOPHYS ACTA, V67, P16; PATTE JC, 1964, CR HEBD ACAD SCI, V259, P1255; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; SHAMES SL, 1984, J BIOL CHEM, V259, P5331; SHAW J, 1977, J BIOL CHEM, V252, P5304; SILVERSTEIN E, 1974, BIOCHEMISTRY-US, V13, P1815, DOI 10.1021/bi00706a006; SILVERSTEIN E, 1969, BIOCHEMISTRY-US, V8, P2543, DOI 10.1021/bi00834a042; STADTMAN ER, 1961, J BIOL CHEM, V236, P2033; TAKAHASHI M, 1971, BIOCHEMISTRY-US, V10, P1700, DOI 10.1021/bi00785a030; TRUFABAC.P, 1968, EUR J BIOCHEM, V5, P73, DOI 10.1111/j.1432-1033.1968.tb00339.x; TRUFFA-BACHI P, 1974, Critical Reviews in Biochemistry, V2, P379, DOI 10.3109/10409237409105452; TRUFFABACHI P, 1970, METHODS ENZYMOLOGY A, V17, P694; WAMPLER DE, 1968, BIOCHEMISTRY-US, V7, P1661, DOI 10.1021/bi00845a007; WEDLER FC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P247, DOI 10.1016/0167-4838(92)90209-V; WEDLER FC, 1982, METHOD ENZYMOL, V87, P647; WEDLER FC, 1972, J BIOL CHEM, V247, P993; WEDLER FC, 1973, J THEOR BIOL, V38, P539, DOI 10.1016/0022-5193(73)90255-5; WEDLER FC, 1974, ARCH BIOCHEM BIOPHYS, V163, P57, DOI 10.1016/0003-9861(74)90454-8; WEDLER FC, 1978, PHYSIOL CHEM PHYS M, V10, P97; WEDLER FC, 1989, J BIOL CHEM, V264, P17266; WEDLER FC, 1989, ANAL BIOCHEM, V177, P268, DOI 10.1016/0003-2697(89)90051-1	49	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4880	4888						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444866				2022-12-25	WOS:A1993KP88400050
J	COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA				COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA			E1A-ONCOGENE EXPRESSION LEVEL IN SARCOMA-CELLS - AN INDEPENDENT DETERMINANT OF CYTOLYTIC SUSCEPTIBILITY AND TUMOR REJECTION	ONCOGENE			English	Article							NATURAL-KILLER CELLS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR GENE-EXPRESSION; E1A ONCOGENE; ACTIVATED MACROPHAGES; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; NK SENSITIVITY; H-RAS; C-MYC	Ad2/5 E1A oncogene expression induces cytolytic susceptibility of rodent cells to natural killer lymphocytes. To determine whether the requisite thresholds of E1A oncoprotein expression differ for induction of cytolytic susceptibility as compared with other. E1A-related activities, sarcoma cells expressing low or normal levels of E1A oncoproteins were compared for differences in morphological transformation, transactivation of viral genes, cytolytic susceptibility and tumorigenicity. Low-level E1A expression transformed sarcoma cells and transactivated the Ad5 E2A gene but did not induce the increased cytolytic susceptibility observed with normal levels of E1A expression. Furthermore, low-level E1A expressers retained the tumorigenicity of parental cells, whereas normal-level expressers were non-tumorigenic in hosts with intact natural killer (NK)-cell responses. In contrast to E1A, E1B oncogene expression caused no changes in morphological, cytolytic or tumorigenic phenotypes in these sarcoma cells. These data define an expression threshold for E1A-induced cytolytic susceptibility and associated NK-cell-dependent tumor rejection. The results suggest that the cellular mechanisms involved in E1A induction of cytolytic susceptibility differ from those involved in E1A-mediated cellular transformation and viral gene transactivation.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL IMMUNOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	COOK, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL, DENVER, CO 80206 USA.				NCI NIH HHS [CA 41387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA041387, R01CA041387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1989, MOL IMMUNOL, V26, P985, DOI 10.1016/0161-5890(89)90117-X; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1983, P NATL ACAD SCI-BIOL, V80, P5995, DOI 10.1073/pnas.80.19.5995; COOK JL, 1979, CANCER RES, V39, P1455; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EDDY BE, 1964, PROG EXP TUMOR RES, V4, P1; FRESA KL, 1987, J IMMUNOL, V138, P1215; GOTLIEBSTEMATSK.T, 1964, VIROLOGY, V22, P314, DOI 10.1016/0042-6822(64)90022-4; GREENBERG AH, 1987, CELL IMMUNOL, V109, P444, DOI 10.1016/0008-8749(87)90327-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JOHNSON PW, 1987, J IMMUNOL, V138, P3996; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANZA LA, 1986, J IMMUNOL, V137, P2716; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; ORTALDO JR, 1986, PATHOL IMMUNOPATH R, V5, P203, DOI 10.1159/000157014; PHILLIPS B, 1991, J VIROL, V65, P5680, DOI 10.1128/JVI.65.11.5680-5692.1991; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; POPE JH, 1964, J EXP MED, V120, P121, DOI 10.1084/jem.120.2.121; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1985, CANCER CELLS 3 GROWT, P257; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SATYABHAMA S, 1988, DNA-J MOLEC CELL BIO, V7, P203, DOI 10.1089/dna.1988.7.203; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHEIL JM, 1984, J IMMUNOL, V132, P1578; SHENK T, 1991, ADV CANCER RES, V57, P47; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; ZAJCHOWSKI DA, 1988, J VIROL, V62, P1762, DOI 10.1128/JVI.62.5.1762-1767.1988; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	61	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					625	635						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437846				2022-12-25	WOS:A1993KN00800013
J	BERR, F; MEIER, PJ; STIEGER, B				BERR, F; MEIER, PJ; STIEGER, B			EVIDENCE FOR THE PRESENCE OF A PHOSPHATIDYLCHOLINE TRANSLOCATOR IN ISOLATED RAT-LIVER CANALICULAR PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BILIARY LIPIDS; BILE; SECRETION; PHOSPHOLIPIDS; CHOLESTEROL; BILAYER	In the present study we used the water-soluble short chain phosphatidylcholine analogue L-alpha-dibutyroyl-glycero-3-phosphatidylcholine (diC4PC) to investigate the mechanism involved in the canalicular secretion of phospholipids in rat liver. Uptake of C-14-labeled diC4PC was studied in isolated microsomes as well as in basolateral (sinusoidal) and canalicular plasma membrane vesicles. Saturable uptake of diC4PC into an osmotically active space was observed in microsomes and canalicular membrane vesicles. In contrast, diC4PC uptake into basolateral membrane vesicles could be accounted for by cross-contamination with endoplasmic reticulum and canalicular membrane vesicles. Whereas the K(m) values for diC4PC uptake (37-degrees-C) were similar in microsomes (7.4 +/- 2.6 mM) and canalicular membrane vesicles (8.2 +/- 2.0 mM), the V(max) values were approximately 2-fold higher in canalicular membrane vesicles (29.6 +/- 2.7 nmol/mg of protein x min) than in microsomes (16.7 +/- 2.1 nmol/mg of protein x min). Furthermore, Pronase treatment of the membrane vesicles reduced diC4PC uptake by 34-54% in both subfractions, whereas the D-[C-14]glucose-accessible water space was only reduced by approximately 20%. These data provide direct evidence for the presence of a protein-mediated phosphatidylcholine translocating activity in the canalicular membrane of rat hepatocytes. This canalicular ''flippase'' has kinetic properties similar to those described previously in microsomes and provides a potential pathway for the translocation of bile salt dissolvable biliary phospholipids to the exoplasmic leaflet of the canalicular membrane.	UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	BERR, F (corresponding author), UNIV MUNICH,HOSP GROSSHADERN,DEPT MED 2,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.		Stieger, Bruno/U-6323-2017	Stieger, Bruno/0000-0002-7190-5785				BARTLETT GR, 1959, J BIOL CHEM, V234, P469; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; CHANUSSOT F, 1990, BIOCHEM J, V270, P691, DOI 10.1042/bj2700691; COHEN DE, 1990, J LIPID RES, V31, P55; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; COLEMAN R, 1989, BIOCHEM J, V258, P17, DOI 10.1042/bj2580017; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAY DW, 1990, HEPATOLOGY, V12, pS6; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HIGGINS JA, 1978, BIOCHEM J, V174, P563, DOI 10.1042/bj1740563; HOLZBACH RT, 1990, HEPATOLOGY, V12, pS106; LOWE PJ, 1984, BIOCHEM J, V222, P631, DOI 10.1042/bj2220631; MARZOLO MP, 1990, HEPATOLOGY, V12, pS134; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247	23	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3976	3979						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440689				2022-12-25	WOS:A1993KN53300028
J	FARRAR, YJK; LUKAS, TJ; CRAIG, TA; WATTERSON, DM; CARLSON, GM				FARRAR, YJK; LUKAS, TJ; CRAIG, TA; WATTERSON, DM; CARLSON, GM			FEATURES OF CALMODULIN THAT ARE IMPORTANT IN THE ACTIVATION OF THE CATALYTIC SUBUNIT OF PHOSPHORYLASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; DEPENDENT PROTEIN-KINASE; SITE-SPECIFIC MUTAGENESIS; RABBIT SKELETAL-MUSCLE; CA2+-DEPENDENT MODULATOR PROTEIN; AMINO-ACID SUBSTITUTIONS; GAMMA-SUBUNIT; MUTANT CALMODULINS; BINDING DOMAINS; MYOSIN	Calmodulin (CaM) is an integral subunit, called delta, of the phosphorylase kinase hexadecamer, and the activity of the isolated catalytic gamma-subunit of the kinase is stimulated by CaM. We report here the first analysis of functionally important features of CaM for activation of the gamma-subunit. A set of genetically engineered CaMs, in which acidic residues in each of the four E-helices of the ''EF-hands'' were changed to basic lysine residues, was used to probe the relative importance of charge features in each domain of CaM. The maximal activation of the isolated gamma-subunit was diminished by all of the charge reversal mutations. The gamma-subunit was especially sensitive to reversals in the second and third E-helix of CaM (residues 45-47 and 82-84), the latter being present in the central helix. The results suggest the functional importance of electrostatics in the interactions between the delta-subunit (CaM) and the catalytic gamma-subunit of phosphorylase kinase, which is similar to results obtained with CaM-dependent myosin light chain kinase (MLCK) from chicken gizzard and CaM-dependent protein kinase II (CaMPK-II). However, novel features of the interaction between CaM and the gamma-subunit of phosphorylase kinase are the significant contribution of electrostatics throughout the CaM molecule, including residues in both halves and on more than one face of CaM, and the lack of a major effect of the CaM mutations on substrate kinetic parameters, unlike the effects observed with MLCK and CaMPK-II. These results are consistent with a model in which the delta-subunit (CaM) of phosphorylase kinase interacts with an extended region or multiple regions of the gamma-subunit and suggest that the mechanism of CaM activation of the gamma-subunit may have features that are distinct from those of MLCK and CaMPK-II.	UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163; VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232	University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University				Watterson, Daniel/0000-0001-7605-5866	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32953] Funding Source: Medline; NIGMS NIH HHS [GM-30861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHABBERT M, 1991, BIOCHEMISTRY-US, V30, P7615, DOI 10.1021/bi00244a034; Cleland W W, 1979, Methods Enzymol, V63, P103; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; FOSTER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P616, DOI 10.1016/0003-9861(86)90371-1; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HERRING BP, 1991, J BIOL CHEM, V266, P11838; KEE SM, 1986, J BIOL CHEM, V261, P4732; KEE SM, 1991, J BIOL CHEM, V266, P7087; KOSKKOSICKA D, 1991, BIOCHEMISTRY-US, V30, P65, DOI 10.1021/bi00215a010; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; LUKAS TJ, 1985, BIOCHEMISTRY-US, V24, P151, DOI 10.1021/bi00322a021; MASSOM LR, 1991, BIOCHEMISTRY-US, V30, P663, DOI 10.1021/bi00217a011; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SLAUGHTER GR, 1985, BIOCHEM BIOPH RES CO, V126, P295, DOI 10.1016/0006-291X(85)90605-9; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VILLARPALASI C, 1983, BIOCHIM BIOPHYS ACTA, V757, P40, DOI 10.1016/0304-4165(83)90150-2; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WAXHAM MN, 1989, J BIOL CHEM, V264, P7477; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107	39	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4120	4125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440701				2022-12-25	WOS:A1993KN53300050
J	NIKKOLA, M; GLEASON, FK; EKLUND, H				NIKKOLA, M; GLEASON, FK; EKLUND, H			REDUCTION OF MUTANT PHAGE-T4 GLUTAREDOXINS BY ESCHERICHIA-COLI THIOREDOXIN REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; REDUCED FORM; SUBSTITUTION; PURIFICATION; TITRATION; STABILITY; PKA	Fifteen mutant T4 glutaredoxins (previously T4 thioredoxin) have been assayed for activity with Escherichia coli thioredoxin reductase. The mutations include substitutions in the region of the active site, in the 2 cysteines, and in the 2 residues between the cysteines forming the active-site disulfide bridge. Mutant thioredoxins where substitutions have been made in charged residues around the active site show the biggest differences in activity. The positive residues Lys-13 and Lys-21 were found to be important for efficient binding to thioredoxin reductase. Substitution of the aspartic acid at position 80 with a serine produced a glutaredoxin with superior activity. This mutant glutaredoxin has earlier been shown to be more efficient than the wild type in thiol transferase activity (Nikkola, M., Gleason, F. K., Saarinen, M., Joelson, T., Bjornberg, O., and Eklund, H. (1991) J. Biol. Chem. 266, 16105-16112). Even the glutaredoxin P66A, where the active-site cis-proline has been substituted, could be efficiently reduced by thioredoxin reductase. Glutaredoxins lacking one or both cysteines were not active.	UNIV MINNESOTA,DEPT PLANT BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities	NIKKOLA, M (corresponding author), SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN.							BERGLUND O, 1975, J BIOL CHEM, V250, P2778; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; GLEASON FK, 1992, J BACTERIOL, V174, P2592, DOI 10.1128/jb.174.8.2592-2598.1992; HOLMGREN A, 1981, J BIOL CHEM, V256, P3118; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JOELSON T, 1988, THESIS SWEDISH AGR U; JOELSON T, 1990, J BIOL CHEM, V265, P183; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEY RF, 1987, BIOCHEMISTRY-US, V26, P6765, DOI 10.1021/bi00395a028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LIM CJ, 1986, J BACTERIOL, V168, P1258, DOI 10.1128/jb.168.3.1258-1264.1986; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; NAVARRO JA, 1991, BIOCHEMISTRY-US, V30, P2192, DOI 10.1021/bi00222a024; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; PIGIET VP, 1977, J BIOL CHEM, V252, P6367; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SJOBERG BM, 1976, J MOL BIOL, V100, P415, DOI 10.1016/S0022-2836(76)80072-1; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; THELANDER L, 1967, J BIOL CHEM, V242, P852; TOLLIN G, 1986, BIOCHIM BIOPHYS ACTA, V853, P29, DOI 10.1016/0304-4173(86)90003-0; WELLS WW, 1990, J BIOL CHEM, V265, P15361	36	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3845	3849						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440680				2022-12-25	WOS:A1993KN53300012
J	CANNONS, AC; BARBER, MJ; SOLOMONSON, LP				CANNONS, AC; BARBER, MJ; SOLOMONSON, LP			EXPRESSION AND CHARACTERIZATION OF THE HEME-BINDING DOMAIN OF CHLORELLA NITRATE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DOMAINS; ASSIMILATORY NADH; SEQUENCE; FLAVIN	A recombinant protein corresponding to the putative heme-binding domain of assimilatory NADH:nitrate reductase from Chlorella vulgaris has been expressed and purified from transformed Escherichia coli BL21 cells. The recombinant protein, exhibited a subunit molecular mass of approximately 10 kDa with a N-terminal sequence beginning with the residues PAGA in agreement with that predicted by cDNA analysis. The UV-visible spectrum of the protein confirmed the incorporation of heme with maxima at 413 nm and 423, 528, and 557 nm for the oxidized and reduced forms, respectively. Circular dichroism spectra indicated the environment of the heme chromophore was very similar to that of the native enzyme. Potentiometric titrations of the recombinant heme domain yielded a midpoint potential of +16 mV (n = 1, pH 7), substantially higher than the values of -160 mV obtained for the native enzyme and -28 mV obtained for a previously expressed recombinant heme domain that contained part of the Mo-pterin domain. These results indicate that portions of the amino acid sequence that are involved in the formation of the Mo-pterin domain of Chlorella nitrate reductase influence the redox potential of the heme prosthetic group.			CANNONS, AC (corresponding author), UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNT CE, 1992, BIOCHEM J, V283, P87, DOI 10.1042/bj2830087; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAMPBELL WH, 1992, PLANT PHYSIOL, V99, P693, DOI 10.1104/pp.99.2.693; CANNONS AC, 1991, BIOCHEM J, V278, P203, DOI 10.1042/bj2780203; CAPEILLEREBLANDIN C, 1986, BIOCHEM J, V238, P745, DOI 10.1042/bj2380745; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DELAROSA MA, 1980, EUR J BIOCHEM, V106, P249; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HOWARD WD, 1982, J BIOL CHEM, V257, P243; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; KAY CJ, 1990, BIOCHEM J, V272, P545, DOI 10.1042/bj2720545; KAY CJ, 1986, J BIOL CHEM, V261, P5799; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1989, BIOCHEM J, V263, P285, DOI 10.1042/bj2630285; KAY CJ, 1986, J BIOL CHEM, V261, P14125; KUBO Y, 1988, J BIOL CHEM, V263, P19684; MATTHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; Sambrook J, 1989, MOL CLONING LABORATO; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; SOLOMONSON LP, 1987, J BIOL CHEM, V262, P8934; TRUONG HN, 1991, BIOCHEM J, V278, P393, DOI 10.1042/bj2780393; Vega JM., 1980, METHODS ENZYMOL, V69, P255, DOI [10.1016/S0076-6879(80)69025-9, DOI 10.1016/S0076-6879(80)69025-9]	24	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3268	3271						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429004				2022-12-25	WOS:A1993KM16100040
J	JOHNSON, VG; NICHOLLS, PJ; HABIG, WH; YOULE, RJ				JOHNSON, VG; NICHOLLS, PJ; HABIG, WH; YOULE, RJ			THE ROLE OF PROLINE-345 IN DIPHTHERIA-TOXIN TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; NUCLEOTIDE-SEQUENCE; PROLYL ISOMERASE; FRAGMENT-B; LOW PH; MEMBRANE TRANSLOCATION; PROTEIN TRANSLOCATION; OVERLAP EXTENSION; VERO CELLS; GENE	Diphtheria toxin (DT) can translocate across endosomal membranes in response to low pH. Buried hydrophobic domains localized in the 37-kDa toxin B chain become exposed in response to acidic conditions and are thought to participate in the membrane translocation process. The crystal structure of DT has revealed a structurally distinct translocation domain composed of nine alpha-helices with their interconnecting loops (Choe, S., Bennett, M., Fujii, G., Curmi, P., Kantardjieff, K., Collier, R., and Eisenberg, D. (1992) Nature 357, 216-222). Two of these alpha-helices, TH8 and TH9, are unusually apolar and constitute the central core of the translocation domain. It has been proposed that these domains and the highly charged interconnecting loop undergo a conformation change under acidic conditions producing a dagger-like structure capable of inserting into the membrane thus initiating the translocation process. Proline 345 occupies a strategic location at the end of the TH8 alpha-helix. Proline residues have the ability to undergo a cis-trans isomerization reaction and because of this have been proposed to play a role in the conformational change that is a prerequisite for toxin translocation. The role of the proline at position 345 in membrane translocation was investigated. Pro was mutagenized to Glu and to Gly using a two-step recombinant polymerase chain reaction procedure, and the mutant proteins were expressed in vitro. Glu, an alpha-helix former, and Gly, an alpha-helix breaker, were selected for mutagenesis to distinguish between a structural role for Pro as an alpha-helix breaker and alternative roles, perhaps involving cistrans isomerization-related conformational changes. Replacing Pro at position 345 with Glu or Gly resulted in a 99% reduction in toxicity to Vero cells. The enzymatic and binding activity of the toxin were not altered by the mutations. Instead, the reduction in toxicity is due to decreased translocation ability, suggesting that the Pro at position 345 plays a specific role in toxin membrane translocation.	NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	JOHNSON, VG (corresponding author), US FDA,CBER,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BLDG 29,RM 103,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BOQUET P, 1976, J BIOL CHEM, V251, P5770; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DEBER CM, 1990, BIOPOLYMERS, V29, P149, DOI 10.1002/bip.360290120; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DELLARCIPRETE L, 1988, J IMMUNOL, V140, P2466; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; DUNKER AK, 1982, J THEOR BIOL, V97, P95, DOI 10.1016/0022-5193(82)90281-8; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FALMAGNE P, 1985, BIOCHIM BIOPHYS ACTA, V827, P45, DOI 10.1016/0167-4838(85)90099-8; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; HONJO T, 1968, J BIOL CHEM, V243, P3553; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1989, J BIOL CHEM, V264, P17739; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KACZOREK M, 1983, SCIENCE, V221, P855, DOI 10.1126/science.6348945; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAYSER G, 1981, BIOCHEM BIOPH RES CO, V99, P358, DOI 10.1016/0006-291X(81)91753-8; KIM K, 1965, J BACTERIOL, V90, P1557, DOI 10.1128/JB.90.6.1557-1562.1965; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOTTE P, 1980, J CELL BIOL, V87, P837, DOI 10.1083/jcb.87.3.837; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OLSNES S, 1989, J BIOL CHEM, V264, P12749; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RATTI G, 1983, NUCLEIC ACIDS RES, V11, P6589, DOI 10.1093/nar/11.19.6589; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROBINSON A, 1987, BIOCHEM J, V246, P249, DOI 10.1042/bj2460249; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SPIK G, 1991, J BIOL CHEM, V266, P10735; TOPSCHUG M, 1990, NATURE, V346, P674; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; WOOLFSON DN, 1991, BIOCHEM BIOPH RES CO, V175, P733, DOI 10.1016/0006-291X(91)91627-O; ZIMMERMAN SS, 1976, MACROMOLECULES, V9, P408, DOI 10.1021/ma60051a005; FED REG 3, V51, P16961	66	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3514	3519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429026				2022-12-25	WOS:A1993KM16100076
J	SHIH, DM; WALL, RJ; SHAPIRO, SG				SHIH, DM; WALL, RJ; SHAPIRO, SG			A 5' CONTROL REGION OF THE HUMAN EPSILON-GLOBIN GENE IS SUFFICIENT FOR EMBRYONIC SPECIFICITY IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-GAMMA-GLOBIN; GREEK HEREDITARY PERSISTENCE; LOCUS ACTIVATION REGION; ERYTHROID-SPECIFIC EXPRESSION; STAGE-SPECIFIC EXPRESSION; BETA-GLOBIN; FETAL HEMOGLOBIN; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE; 5'-FLANKING REGION	When introduced as part of DNA constructions containing the human beta-globin locus control region (LCR), the human embryonic beta-globin gene, epsilon, is expressed in primitive but not definitive erythroid cells of recipient transgenic mice. In contrast to this pattern, the hu an fetal, beta-globin gene, gamma, has been shown to be expressed in both primitive and definitive erythroid cells of transgenic mice when introduced in similar LCR-containing constructions. To begin to identify the minimal sequence(s) necessary for the epsilon expression pattern, we have fused a DNA fragment that contains the human epsilon-globin gene promoter region, and 13.7-kilobase (kb) of contiguous upstream flanking sequence containing super-hypersensitive (HS) sites 5'HS-2 and 5'HS-1 of the globin LCR, to the structural portion and near 3'-flanking region of the human gamma-globin gene. This construction, and one containing an intact human gamma-globin gene with the same 3'-flanking sequence and 383 base pairs of 5'-flanking sequence linked to LCR DNA from -0.86 to -13.7 kb upstream of epsilon, were each microinjected to produce transgenic mice. While the construction containing the intact gamma-globin gene is transcriptionally active in primitive and definitive erythroid cells of the transgenic mice, the fusion construction, in which the gamma-globin gene promoter and promoter proximal region is essentially replaced by that of epsilon, is not active in definitive erythroid cells and expresses with the same pattern as an intact epsilon gene. These results indicate that the promoter and near 5'-flanking region of epsilon, when linked to the LCR, is sufficient for embryonic-specific expression in transgenic mice. The level of expression of the fusion construction in primitive erythroid cells of transgenic mice is similar to that previously observed for the intact epsilon gene when identically cloned. This suggests that the epsilon 5'-region of the fusion construction also contains all the sequence necessary for the LCR-dependent activation of epsilon in transgenic mice.	UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742; UNIV MARYLAND,PROGRAM MOLEC & CELL BIOL,COLLEGE PK,MD 20742; USDA ARS,BELTSVILLE AGR RES CTR,GENE EVALUAT & MAPPING LAB,BELTSVILLE,MD 20705	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; United States Department of Agriculture (USDA)								BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FANTONI A, 1967, SCIENCE, V157, P1327, DOI 10.1126/science.157.3794.1327; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUTMAN PD, 1992, GENE, V110, P197, DOI 10.1016/0378-1119(92)90648-9; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HANSEN JN, 1982, J BIOL CHEM, V257, P1048; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KIOUSSIS D, 1985, EMBO J, V4, P927, DOI 10.1002/j.1460-2075.1985.tb03720.x; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LIN HJ, 1987, J CLIN INVEST, V80, P374, DOI 10.1172/JCI113082; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; LUSE DS, 1981, NUCLEIC ACIDS RES, V9, P4339, DOI 10.1093/nar/9.17.4339; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; OTTOLENGHI S, 1988, BLOOD, V71, P815; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SURREY S, 1988, BLOOD, V71, P807; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; YU CY, 1991, J BIOL CHEM, V266, P8907	43	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3066	3071						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428985				2022-12-25	WOS:A1993KM16100012
J	HAMILTON, JA; STEINRAUF, LK; BRADEN, BC; LIEPNIEKS, J; BENSON, MD; HOLMGREN, G; SANDGREN, O; STEEN, L				HAMILTON, JA; STEINRAUF, LK; BRADEN, BC; LIEPNIEKS, J; BENSON, MD; HOLMGREN, G; SANDGREN, O; STEEN, L			THE X-RAY CRYSTAL-STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL-30-]MET VARIANT TO 1.7-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMA PREALBUMIN; AMINO-ACID-SEQUENCE; PRE-ALBUMIN; THYROXINE-BINDING; MACROMOLECULAR STRUCTURES; CHOROID-PLEXUS; PROTEIN; POLYNEUROPATHY; BRAIN; GENE	The x-ray crystal structures of normal human transthyretin (prealbumin) and the amyloidogenic Val-30-Met variant have been refined at 1.7-angstrom resolution to R-values of 0.168 and 0.179, respectively, for 19,882 and 20,362 reflections (F(obs) > 2.0sigma). Standard deviations for stereochemical parameters are 0.018 and 0.022 angstrom for bond distances, 0.030 and 0.038 angstrom for angle distances, and 0.035 and 0.070 A for planar 14 distances. The newly refined normal structure shows improvement over the original structure of Blake and Swan (Blake, C. C. F., and Swan, I. D. A. (1971) J. Mol. Biol. 61, 217-224) in stereochemistry and in the conformation of the loop regions. Residues Arg-103, Thr-123, Asn-124, and Pro-125 have now been resolved, and residues 1-9 and 126-127 have been modeled with the aid of simulated annealing refinement. The functional form of transthyretin is a tetramer, having a cylindrical cavity which will bind thyroxine and an exterior binding site for the complex of retinol with retinol-binding protein. The monomer is a beta barrel flattened to become more like a sandwich with residue 30 in the interior. The methionyl for valyl substitution forces the beta sheets of the monomer as much as 1 angstrom apart, resulting in a distortion of the thyroxine-binding cavity, in agreement with the independent observations that the Met-30 variant has low affinity for thyroxine.	INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; UMEA UNIV,DEPT CLIN GENET,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT OPHTHALMOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT CLIN MED,S-90187 UMEA,SWEDEN	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Umea University; Umea University; Umea University	HAMILTON, JA (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.			Hamilton, James/0000-0002-4747-7071	NCRR NIH HHS [RR-00750] Funding Source: Medline; NIDDK NIH HHS [NIDDK-34881, NIDDK-42111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034881, R01DK042111] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENSON MD, 1981, J CLIN INVEST, V67, P1035, DOI 10.1172/JCI110114; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BLAKE CCF, 1971, J MOL BIOL, V61, P217, DOI 10.1016/0022-2836(71)90218-X; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; COHEN AS, 1959, NATURE, V183, P1202, DOI 10.1038/1831202a0; COSTA PP, 1978, P NATL ACAD SCI USA, V75, P4499, DOI 10.1073/pnas.75.9.4499; CRUICKSHANK DWJ, 1949, ACTA CRYSTALLOGR, V2, P65, DOI 10.1107/S0365110X49000175; DICKSON PW, 1985, BIOCHEM BIOPH RES CO, V127, P890, DOI 10.1016/S0006-291X(85)80027-9; DICKSON PW, 1985, J BIOL CHEM, V260, P8214; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; DWULET FE, 1984, P NATL ACAD SCI-BIOL, V81, P694, DOI 10.1073/pnas.81.3.694; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; FELDING P, 1982, BIOCHIM BIOPHYS ACTA, V716, P446, DOI 10.1016/0304-4165(82)90040-X; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; HAMILTON JA, 1992, BIOCHIM BIOPHYS ACTA, V1139, P9, DOI 10.1016/0925-4439(92)90075-X; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES AL, 1992, 2ND P INT S FAM AM P, P61; JONES TA, 1982, COMPUTATIONAL CRYSTA, P3303; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KANDA Y, 1974, J BIOL CHEM, V249, P6796; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MITA S, 1986, NEUROLOGY, V36, P298, DOI 10.1212/WNL.36.2.298; MITA S, 1986, J BIOCHEM-TOKYO, V100, P1215, DOI 10.1093/oxfordjournals.jbchem.a121826; REFETOFF S, 1986, J CLIN ENDOCR METAB, V63, P1432, DOI 10.1210/jcem-63-6-1432; ROBBINS J, 1960, PHYSIOL REV, V40, P415, DOI 10.1152/physrev.1960.40.3.415; SARAIVA MJM, 1991, AMYLOID AND AMYLOIDOSIS 1990, P569; SHIRAHAMA T, 1967, J CELL BIOL, V33, P679, DOI 10.1083/jcb.33.3.679; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; STEINRAUF LK, 1991, BIOCHEM BIOPH RES CO, V179, P804, DOI 10.1016/0006-291X(91)91888-J; SUNDELIN J, 1985, J BIOL CHEM, V260, P6481; TSUZUKI T, 1985, J BIOL CHEM, V260, P2224; WAKASUGI S, 1985, J BIOCHEM-TOKYO, V98, P1707, DOI 10.1093/oxfordjournals.jbchem.a135442; WAKASUGI S, 1986, J BIOCHEM-TOKYO, V100, P49, DOI 10.1093/oxfordjournals.jbchem.a121705	38	221	224	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2416	2424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428915				2022-12-25	WOS:A1993KK81500028
J	HEEB, MJ; MESTERS, RM; TANS, G; ROSING, J; GRIFFIN, JH				HEEB, MJ; MESTERS, RM; TANS, G; ROSING, J; GRIFFIN, JH			BINDING OF PROTEIN-S TO FACTOR VA ASSOCIATED WITH INHIBITION OF PROTHROMBINASE THAT IS INDEPENDENT OF ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XA; VENOUS THROMBOEMBOLISM; ANTICOAGULANT ACTIVITY; MONOCLONAL-ANTIBODIES; C4B-BINDING PROTEIN; DEFICIENCY; INACTIVATION; PLASMA; PLATELETS; IDENTIFICATION	Since plasma protein S serves an anticoagulant function by mechanisms which are not completely understood, its possible interaction with Factor Va was investigated. Human protein S bound to immobilized human Factor Va in a calcium-dependent, saturable, and reversible manner and Factor Va bound similarly to immobilized protein S. Binding of protein S to immobilized Factor V was greatly enhanced by pretreatment of the surface-bound Factor V with increasing doses of thrombin up to 1 unit/ml. Binding of protein S to Factor Va was also demonstrated in fluid phase with a K(d) of 33 +/- 9 nM. Biotin-labeled heavy chain of Factor Va bound to immobilized protein S, and this binding was reversed by a 17-fold molar excess of intact unlabeled Factor Va. Protein S competed efficiently with prothrombin for binding to immobilized Factor Va. The prothrombinase activity in a reaction mixture of purified clotting factors was inhibited by protein S and exhibited a pattern of mixed inhibition. The concentration of protein S needed for 50% inhibition of the prothrombinase activity of a mixture containing 1 nm Factor Xa, 20 pm Factor Va, and 50 muM phospholipids was about 16 nM. Since not all protein S preparations exhibited this degree of prothrombinase inhibitory activity, extensive control experiments were performed to verify that the inhibitory activity was associated with protein S during immunoaffinity chromatography and was not caused by traces of activated protein C in the protein S preparations. These data show that protein S has an anticoagulant function which is independent of activated protein C and, at least in part, that this is because of its competition with prothrombin for direct binding to Factor Va.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, BCR-5, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV LIMBURG, DEPT BIOCHEM, 6229 MAASTRICHT, NETHERLANDS	Scripps Research Institute; Scripps Research Institute; Maastricht University				Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTINA RM, 1985, HAEMOSTASIS, V15, P241; BROEKMANS AW, 1985, THROMB HAEMOSTASIS, V53, P273; CLEZARDIN P, 1985, J CHROMATOGR, V319, P67, DOI 10.1016/S0021-9673(01)90540-0; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GARDINER JE, 1984, CIRCULATION, V70, P205; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; GRUBER A, 1989, BLOOD, V73, P639; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HARRIS KW, 1985, J BIOL CHEM, V260, P2007; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HILLARP A, 1991, THROMB HAEMOSTASIS, V65, P710; JANE SM, 1991, BLOOD COAGUL FIBRIN, V2, P723, DOI 10.1097/00001721-199112000-00005; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANNUCCI PM, 1986, THROMB HAEMOSTASIS, V55, P440; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MITCHELL CA, 1988, J CLIN INVEST, V82, P2142, DOI 10.1172/JCI113836; MITCHELL CA, 1988, THROMB HAEMOSTASIS, V60, P298; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21794; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1985, BLOOD, V66, P1452; SCHWARZ HP, 1986, THROMB HAEMOSTASIS, V56, P382; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STENFLO J, 1979, FEBS LETT, V101, P377, DOI 10.1016/0014-5793(79)81048-0; STERN DM, 1986, J BIOL CHEM, V261, P713; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; TANS G, 1991, BLOOD, V77, P2641; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; WALKER FJ, 1986, J BIOL CHEM, V261, P941; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521	37	214	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2872	2877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428962				2022-12-25	WOS:A1993KK81500090
J	LIVRELLI, V; LEE, IW; SUMMERS, AO				LIVRELLI, V; LEE, IW; SUMMERS, AO			INVIVO DNA-PROTEIN INTERACTIONS AT THE DIVERGENT MERCURY RESISTANCE (MER) PROMOTERS .1. METALLOREGULATORY PROTEIN MERR MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; TRANSCRIPTIONAL ACTIVATION; REGULATORY PROTEIN; RNA-POLYMERASE; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; RECEPTOR-SITE; BINDING; COMPLEX; REPRESSION	Regulation of transcriptional initiation of the Tn21 mercury resistance (mer) operon occurs at the diver gent promoter region lying between the structural genes (merTPCAD) and a regulatory gene (merR). During repression, both promoters are negatively regulated by MerR bound to a dyadic operator located between the -10 and -35 hexamers of P(TPCAD). Upon Hg(II) induction, MerR activates transcription only from P(TPCAD) and continues to repress transcription from P(R). Using in vivo dimethyl sulfate and KMnO4 footprinting of the merOP region of strains carrying wild-type MerR or MerR mutants, we have dissected the steps in MerR-mediated positive and negative regulation of the divergent mer promoters. The greater sensitivity of primer extension footprinting allowed the resolution of details previously undetectable in vivo. Two MerR mutants unable to bind merOP DNA allow RNA polymerase to form an open complex preferentially at P(R). The intensity of the P(R) open complex is considerably less than that which occurs upon MerR-Hg(II) activation of P(TPCAD) and considerably greater than that which occurs at P(TPCAD) when MerR is deleted; this is the first in vivo estimate of the relative strengths of these two promoters. Although retaining the wild-type capacity to sequester RNA polymerase in the closed complex, the four MerR mutants defective in Hg(II) binding do not distort the dyad DNA or foster open complex formation when the inducer is added. Two activation-defective MerR mutants foster closed complex formation as well as wild-type, but they do not distort the dyad DNA or foster open complex formation when the inducer is added, although they are also able to bind Hg(II). Two semiconstitutive inducible MerR mutants differ from each other in that one (which lies nearer the COOH terminus) does distort the dyad center upon Hg(II) induction, whereas the other (which lies in near the center of merR) exhibits no dyad distortion upon induction. Paradoxically, despite their relatively strong semiconstitutive expression of mer-lac transcriptional fusions, neither of these mutants has a detectable open complex in the absence of added Hg(II).	UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia				Summers, Anne/0000-0003-4258-9696	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028211] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28211] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CROSA JH, 1981, MANUAL METHODS GENER; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELMANN JD, 1989, J BACTERIOL, V171, P222, DOI 10.1128/jb.171.1.222-229.1989; HELTZEL A, 1987, J BACTERIOL, V169, P3379, DOI 10.1128/jb.169.7.3379-3384.1987; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LADDAGA RA, 1987, P NATL ACAD SCI USA, V84, P5106, DOI 10.1073/pnas.84.15.5106; LEE IW, 1989, J BACTERIOL, V171, P2222, DOI 10.1128/jb.171.4.2222-2225.1989; LEE IW, 1993, J BIOL CHEM, V268, P2632; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LUND P, 1989, NUCLEIC ACIDS RES, V17, P5517, DOI 10.1093/nar/17.14.5517; LUND PA, 1986, J GEN MICROBIOL, V132, P465; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MINCHIN SD, 1989, EMBO J, V8, P3491, DOI 10.1002/j.1460-2075.1989.tb08514.x; MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MUKHOPADHYAY D, 1991, J BIOL CHEM, V266, P18538; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARK SJ, 1992, J BACTERIOL, V174, P2160, DOI 10.1128/JB.174.7.2160-2171.1992; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2331, DOI 10.1021/bi00431a052; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SUMEMRS AO, 1992, J BACTERIOL, V174, P3097; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	40	29	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2623	2631						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428939				2022-12-25	WOS:A1993KK81500056
J	WILKISON, WO; SPIEGELMAN, BM				WILKISON, WO; SPIEGELMAN, BM			BIOSYNTHESIS OF THE VASOACTIVE LIPID MONOBUTYRIN - CENTRAL ROLE OF DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; RAT ADIPOSE-TISSUE; PROTEIN KINASE-C; 3T3 ADIPOCYTES; CELLS; ANGIOGENESIS; STIMULATION; SPECIFICITY; METABOLISM; MECHANISM	Monobutyrin (1-butyrylglycerol) is a simple lipid secreted by adipocytes that stimulates both angiogenesis and vasodilation of microvascular beds. While monobutyrin production is increased during lipolysis, little is known about the biosynthetic pathway of this short chain monoacylglycerol. We show here that diacylglycerol, an intermediate in the lipolytic pathway, can stimulate monobutyrin synthesis from an adipocyte particulate fraction and does so by acting as a substrate. The biosynthetic route involves the acylation of diacylglycerol with butyryl-CoA to form a transient triacylglycerol intermediate. This intermediate is then hydrolyzed by a lipase(s) with specificity for long chain fatty acyl groups to form monobutyrin. Based on this information, a novel pathway for the synthesis of monobutyrin is proposed. Preliminary characterization of these enzymatic activities with respect to their cell-type specificity indicates that the acyltransferase activity is found in several cell types, albeit at lower levels than in adipocytes. The lipase activity appears to be two distinct steps, with both steps being adipocyte differentiation-dependent. These results indicate the likely biochemical basis for the restriction of monobutyrin synthesis to fat cells and also suggests a molecular basis for the close linkage between lipolysis, monobutyrin synthesis, and vasodilation.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	WILKISON, WO (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042420, F32DK008277] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42420, DK08277] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDINEJAD A, 1981, ARCH BIOCHEM BIOPHYS, V208, P135, DOI 10.1016/0003-9861(81)90132-6; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BOWERY B, 1973, BRIT J PHARMACOL, V47, P305, DOI 10.1111/j.1476-5381.1973.tb08328.x; BUGAUT M, 1989, LIPIDS, V24, P193, DOI 10.1007/BF02535234; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; CASTELLOT JJ, 1986, J CELL PHYSIOL, V127, P323, DOI 10.1002/jcp.1041270221; CASTELLOT JJ, 1980, P NATL ACAD SCI-BIOL, V77, P6007, DOI 10.1073/pnas.77.10.6007; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; DALTON C, 1974, PROSTAG OTH LIPID M, V6, P227, DOI 10.1016/S0090-6980(74)80050-X; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fleischer S, 1974, Methods Enzymol, V31, P6; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; FREDRIKSON G, 1983, J BIOL CHEM, V258, P4253; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GANONG BR, 1986, CELL MEMBRANES METHO; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HANSEN JK, 1980, BIOCHEM J, V186, P287, DOI 10.1042/bj1860287; KRAEMER FB, 1991, J LIPID RES, V32, P1303; MARSHALL MO, 1979, EUR J BIOCHEM, V94, P93, DOI 10.1111/j.1432-1033.1979.tb12875.x; MARSHALL MO, 1977, EUR J BIOCHEM, V81, P259, DOI 10.1111/j.1432-1033.1977.tb11947.x; MICHELL RH, 1988, PHILOS T ROY SOC B, V320, P239, DOI 10.1098/rstb.1988.0074; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIZACK MA, 1961, J BIOL CHEM, V236, P657; ROSELL S, 1979, PHYSIOL REV, V59, P1078, DOI 10.1152/physrev.1979.59.4.1078; SCHUTE HR, 1975, BIOCHIM BIOPHYS ACTA, V409, P283; SHULZ H, 1990, FATTY ACID OXIDATION, P23; THIDINH KLK, 1990, LIPIDS, V25, P278, DOI 10.1007/BF02544388; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87; WILKISON WO, 1991, J BIOL CHEM, V266, P16886; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N; ZINDER O, 1973, J BIOL CHEM, V248, P7673	35	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2844	2849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428959				2022-12-25	WOS:A1993KK81500086
J	WADHWA, R; KAUL, SC; IKAWA, Y; SUGIMOTO, Y				WADHWA, R; KAUL, SC; IKAWA, Y; SUGIMOTO, Y			IDENTIFICATION OF A NOVEL MEMBER OF MOUSE HSP70 FAMILY - ITS ASSOCIATION WITH CELLULAR MORTAL PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENT HUMAN-FIBROBLASTS; TUMOR SUPPRESSOR GENES; INDEFINITE DIVISION; SENSITIVE METHOD; HUMAN-CELLS; PROTEIN; EXPRESSION; PROLIFERATION; INDUCTION; ANTIBODY	A novel 66-kDa protein, named p66mot-1, is identified to be associated with cellular mortality by virtue of its presence in cytosolic fractions of serially passaged mouse embryonic fibroblasts (MEF) and the mortal hybrids obtained by the fusion of mortal (MEF) and immortal (MN48-1, derivative of NIH 3T3) cells. Immortal cells lack this protein in their cytosolic fractions. cDNA cloning and homology search placed it in the heat shock protein 70 (hsp70) family. Microinjection of anti-p66 antibody to senescent MEF could transiently stimulate their cell division, which supports the cellular mortality-related function of p66mot-1.	AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, TSUKUBA, IBARAKI 305, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); RIKEN	WADHWA, R (corresponding author), INST PHYS & CHEM RES, AGING PROC RES LAB, TSUKUBA, IBARAKI 305, JAPAN.		Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUMURA T, 1980, EXP CELL RES, V125, P453, DOI 10.1016/0014-4827(80)90139-1; NING Y, 1991, MUTAT RES, V256, P303, DOI 10.1016/0921-8734(91)90021-3; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; PARDEE AB, 1987, J CELL PHYSIOL, P107; PECHAN PM, 1991, FEBS LETT, V280, P1, DOI 10.1016/0014-5793(91)80190-E; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925	37	181	189	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6615	6621						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454632				2022-12-25	WOS:A1993KT36800078
J	PRONK, GJ; MCGLADE, J; PELICCI, G; PAWSON, T; BOS, JL				PRONK, GJ; MCGLADE, J; PELICCI, G; PAWSON, T; BOS, JL			INSULIN-INDUCED PHOSPHORYLATION OF THE 46-KDA AND 52-KDA SHC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOTYROSINE-CONTAINING PROTEINS; RECEPTOR TYROSINE KINASES; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ONCOGENE PRODUCTS; GROWTH-FACTOR; CLONING	The products of the shc gene appear to be substrates for activated oncogenic tyrosine kinases, such as v-Src and v-Fps and activated tyrosine kinase receptors like the epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors. We investigated whether the She proteins are targets for the activated insulin receptor tyrosine kinase. Here we show that the 46- and 52-kDa Shc proteins are rapidly phosphorylated upon insulin receptor activation in fibroblasts expressing elevated levels of human insulin receptors. Furthermore, we observed insulin-induced association of a 23-kDa protein with the Shc proteins. These effects on Shc proteins are similar to those observed after EGF and PDGF treatment. In contrast to the observed Shc-EGF receptor association, we did not detect association between the Shc proteins and the insulin receptor. We conclude that the Shc proteins are common elements in a signal transduction pathway that is shared by EGF, PDGF, and insulin.	UNIV UTRECHT, PHYSIOL CHEM LAB, VONDELLAAN 24A, 3521 GG UTRECHT, NETHERLANDS; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV PERUGIA, POLICLIN MONTELUCE, INST CLIN MED 1, I-06100 PERUGIA, ITALY	Utrecht University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Perugia			Pawson, Tony J/E-4578-2013; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1992, ONCOGENE, V7, P389; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	42	305	311	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5748	5753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449939				2022-12-25	WOS:A1993KR82200059
J	ZHANG, ZY; TARONE, G; TURNER, DC				ZHANG, ZY; TARONE, G; TURNER, DC			EXPRESSION OF INTEGRIN-ALPHA-1-BETA-1 IS REGULATED BY NERVE GROWTH-FACTOR AND DEXAMETHASONE IN PC12 CELLS - FUNCTIONAL CONSEQUENCES FOR ADHESION AND NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERENCE CONTRAST MICROSCOPY; PHEOCHROMOCYTOMA CELLS; NEURONAL DIFFERENTIATION; ALPHA-1-BETA-1 INTEGRIN; GENE-EXPRESSION; COLLAGEN; LAMININ; RECEPTOR; CONE; MOLECULES	PC12 cells respond to nerve growth factor by differentiating into sympathetic neuron-like cells that employ the integrin alpha1beta1 to attach to, and extend neurites on, substrata coated with collagen or laminin. In one PC12 subline, PC12i, prolonged treatment with nerve growth factor results in a marked increase in synthesis of alpha1 subunits and in the level of alpha1 mRNA, with a corresponding increase in alpha1beta1 expressed on the cell surface. These changes are accompanied by substantial increases in initial cell attachment to collagen and in the fraction of neurite-bearing cells and average neurite length. Integrin beta1-subunits are constitutively expressed, so that alpha1 synthesis controls the amount of alpha1beta1 heterodimer expressed on PC12i cells. Acidic fibroblast growth factor also induces alpha1beta1 in PC12i cells, with consequent enhancement of neurite outgrowth; treatment with epidermal growth factor or dibutyryl cyclic AMP does not have these effects. Another subline, PC12c, expresses high levels of alpha1 mRNA and alpha1 protein constitutively. With or without nerve growth factor pretreatment, these cells adhere well to collagen and a majority extend neurites when replated in the presence of nerve growth factor. Dexamethasone treatment of PC12c cells reduces expression of alpha1 mRNA and alpha1 protein, with consequent reduction in attachment to collagen. In both sublines, then, there is a direct relationship between the level of a specific matrix receptor and cell-matrix adhesion. Moreover, our results suggest that induced expression of this matrix receptor is an essential aspect of the regulation of neurite extension by nerve growth factor in PC12i cells.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, 750 E ADAMS ST, SYRACUSE, NY 13210 USA; UNIV TURIN, DIPARTIMENTO GENET BIOL & CHIM MED, I-10126 TURIN, ITALY	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Turin				Tarone, Guido/0000-0003-4805-086X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027409] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27409] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALETTA JM, 1988, J NEUROSCI, V8, P1425; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHANDLER CE, 1980, J CELL PHYSIOL, V105, P275, DOI 10.1002/jcp.1041050211; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLYMAN RI, 1990, ARTERIOSCLEROSIS, V10, P402, DOI 10.1161/01.ATV.10.3.402; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GOLDBERG DJ, 1989, TRENDS NEUROSCI, V12, P503, DOI 10.1016/0166-2236(89)90110-0; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1991, CULTURING NERVE CELL, P207; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P243; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; LANDER AD, 1987, MOL NEUROBIOL, V1, P213, DOI 10.1007/BF02936609; LEIN PJ, 1991, J CELL BIOL, V113, P417, DOI 10.1083/jcb.113.2.417; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RIVAS RJ, 1992, NEURON, V8, P107, DOI 10.1016/0896-6273(92)90112-Q; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RYDEL RE, 1987, J NEUROSCI, V7, P3639; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sambrook J, 1989, MOL CLONING LABORATO; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TOGARI A, 1985, J NEUROSCI, V5, P307; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; TURNER DC, 1989, J NEUROSCI, V9, P3287; TURNER DC, 1989, DEV NEUROSCI-BASEL, V11, P300, DOI 10.1159/000111908; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372	56	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5557	5565						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449918				2022-12-25	WOS:A1993KR82200034
J	PRINTZ, RL; KOCH, S; POTTER, LR; ODOHERTY, RM; TIESINGA, JJ; MORITZ, S; GRANNER, DK				PRINTZ, RL; KOCH, S; POTTER, LR; ODOHERTY, RM; TIESINGA, JJ; MORITZ, S; GRANNER, DK			HEXOKINASE-II MESSENGER-RNA AND GENE STRUCTURE, REGULATION BY INSULIN, AND EVOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; CLONED CDNA; GLUCOKINASE GENE; SKELETAL-MUSCLE; LIVER GLUCOKINASE; EXPRESSION; GLUCOSE; TRANSCRIPTION; PURIFICATION	A DNA segment that is highly conserved in glucokinase (hexokinase IV) and hexokinase I cDNA was used to identify specific cDNAs in a library prepared from rat adipose tissue mRNA. Some of these cDNAs were identified as being hexokinase I cDNA. Others, although similar to both the glucokinase and hexokinase I cDNAs, were unique. Two of these unique cDNAs overlapped and contained an open reading frame that encoded a protein of 103 kDa which, when expressed in Escherichia coli, had kinetic properties characteristic of hexokinase II. The entire hexokinase II mRNA sequence and the exon-intron structure of the hexokinase II gene were determined. A single transcription initiation site and two distinct termination sites account for the two observed hexokinase II RNA species of 5500 and 4400 nucleotides that were detected when either of the cDNAs was used as a hybridization probe against poly(A)+ RNA isolated from rat adipose tissue. Hexokinase II mRNA was decreased in adipose tissue from diabetic rats, but was restored by insulin treatment to levels found in nondiabetic control rats. Insulin also induced hexokinase II mRNA in two adipose cell lines (3T3-F442A and BFC-1B) and two skeletal muscle cell lines (C2C12 and L6). In L6 cells, this increase was accounted for by a corresponding increase of hexokinase II gene transcription. Comparison of the structures of the hexokinase II and glucokinase genes support the hypothesis that the 100-kDa hexokinase arose by gene duplication and tandem ligation of a 50-kDa glucokinase-like ancestral gene.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS, 707 LIGHT HALL, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK35107, DK07061] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007061, R01DK035107, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN MB, 1980, BIOCHEM J, V185, P565, DOI 10.1042/bj1850565; ANDREASSON K, 1991, ACTA PHYSIOL SCAND, V142, P255, DOI 10.1111/j.1748-1716.1991.tb09154.x; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; BEALE E, 1984, DIABETES, V33, P328, DOI 10.2337/diabetes.33.4.328; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Bessman S P, 1980, Curr Top Cell Regul, V16, P55; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIEN CT, 1989, BIOCHEM BIOPH RES CO, V165, P817, DOI 10.1016/S0006-291X(89)80039-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRAPKIEWICZ NB, 1989, NUCLEIC ACIDS RES, V17, P6651, DOI 10.1093/nar/17.16.6651; CHRIST B, 1986, BIOCHEM J, V238, P185, DOI 10.1042/bj2380185; DENDUNNEN JT, 1987, NUCLEIC ACIDS RES, V15, P2772; EASTERBY JS, 1971, FEBS LETT, V18, P23, DOI 10.1016/0014-5793(71)80397-6; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FRANK SK, 1986, ARCH BIOCHEM BIOPHYS, V249, P61, DOI 10.1016/0003-9861(86)90560-6; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HANSEN R, 1967, ENDOCRINOLOGY, V81, P1397, DOI 10.1210/endo-81-6-1397; HANSEN RJ, 1970, ENDOCRINOLOGY, V86, P57, DOI 10.1210/endo-86-1-57; HOLROYDE MJ, 1976, FEBS LETT, V62, P215, DOI 10.1016/0014-5793(76)80056-7; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1968, ANN NY ACAD SCI, V151, P351, DOI 10.1111/j.1749-6632.1968.tb11900.x; KATZEN HM, 1966, BIOCHEM BIOPH RES CO, V24, P531, DOI 10.1016/0006-291X(66)90352-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITAN IB, 1981, TRENDS NEUROSCI, V4, P38, DOI 10.1016/0166-2236(81)90014-X; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MORGAN HE, 1961, J BIOL CHEM, V236, P262; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PILKIS SJ, 1970, BIOCHIM BIOPHYS ACTA, V215, P461, DOI 10.1016/0304-4165(70)90097-8; PRINTZ RL, 1991, DIABETES S1, V40, pA8; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SCHOR M, 1990, BIOCH INT, V22, P467; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WALKER D. G., 1966, ESSAYS BIOCHEM, V2, P33; WALTERS E, 1967, BIOCHEM J, V104, P778, DOI 10.1042/bj1040778; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	62	174	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5209	5219						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444897				2022-12-25	WOS:A1993KP88400093
J	ALARCON, C; LINCOLN, B; RHODES, CJ				ALARCON, C; LINCOLN, B; RHODES, CJ			THE BIOSYNTHESIS OF THE SUBTILISIN-RELATED PROPROTEIN CONVERTASE PC3, BUT NOT THAT OF THE PC2 CONVERTASE, IS REGULATED BY GLUCOSE IN PARALLEL TO PROINSULIN BIOSYNTHESIS IN RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY-GRANULE; MESSENGER-RNA; TRANSLATIONAL CONTROL; COORDINATE REGULATION; BETA-CELL; PROTEINS; KEX2; CDNA; FURIN; IDENTIFICATION	The biosynthesis of proinsulin is specifically stimulated by glucose in the pancreatic beta-cell, and this, in turn, places an increased demand on the mechanism for proinsulin to insulin conversion. Proteolytic proinsulin processing is catalyzed by two endopeptidases putatively identified as the subtilisin-related PC2 and PC3 convertases (Bennett, D. L., Bailyes, E. M., Nielson, E., Guest, P. C., Rutherford, N. G., Arden, S. D., and Hutton, J. C. (1992) J. Biol. Chem. 267, 15229-15236; Bailyes, E. M., Shennan, K. I. J., Seal, A. J., Smeekens, S. P., Steiner, D. F., Hutton, J. C., and Docherty, K. (1992) Biochem. J. 285, 391-394). In this study, we demonstrate in isolated rat pancreatic islets that the biosynthesis of PC3 was specifically stimulated by glucose relatively parallel to that of proinsulin. In contrast, however, PC2 biosynthesis was not glucose-regulated. The stimulation of PC3 and proinsulin biosynthesis was observed above a threshold of 4 mM glucose and reached a maximum (about 7-10-fold) above 10 mM glucose concentrations. Glucose stimulation for PC3 and proinsulin biosynthesis was rapid (occurring within 20 min and reaching a maximum by 60 min) and was not affected by the additional presence of actinomycin D, suggesting regulation predominately at the translational level. Moreover, the intracellular signals for glucose-stimulated PC3 and proinsulin biosynthesis appeared to be similar, requiring the metabolism of glucose. PC3 has been implicated as the key endopeptidase in proinsulin to insulin conversion, in that it is the enzyme which preferentially initiates the process (Rhodes, C. J., Lincoln, B., and Shoelson, S. E. (1992) J. Biol. Chem. 267, 22719-22727). We suggest that co-ordinate stimulation of PC3 biosynthesis, along with that of its proinsulin substrate, elucidates an additional control point by which the mechanism of proprotein processing might be regulated.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,EP JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NCRR NIH HHS [BRGS07RR05673] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BAILYES EM, 1991, ENZYME, V45, P301, DOI 10.1159/000468903; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V179, P1311, DOI 10.1016/0006-291X(91)91716-P; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; EIDEN LE, 1987, CELL MOL NEUROBIOL, V7, P339, DOI 10.1007/BF00733787; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1992, J BIOL CHEM, V267, P22401; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGAMATSU S, 1987, ENDOCRINOLOGY, V120, P1225, DOI 10.1210/endo-120-4-1225; NIELSEN DA, 1985, J BIOL CHEM, V260, P13586; PAOLILLO L, 1992, EMBO J, V11, P2399, DOI 10.1002/j.1460-2075.1992.tb05304.x; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; RHODES CJ, 1987, FEBS LETT, V215, P179, DOI 10.1016/0014-5793(87)80137-0; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590	42	144	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4276	4280						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440711				2022-12-25	WOS:A1993KN53300068
J	AWAD, JA; MORROW, JD; TAKAHASHI, K; ROBERTS, LJ				AWAD, JA; MORROW, JD; TAKAHASHI, K; ROBERTS, LJ			IDENTIFICATION OF NON-CYCLOOXYGENASE-DERIVED PROSTANOID (F2-ISOPROSTANE) METABOLITES IN HUMAN URINE AND PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; LIVER NECROSIS; PROSTAGLANDINS; SERIES; NONCYCLOOXYGENASE; ENDOPEROXIDES; EICOSANOIDS; DERIVATIVES; MECHANISM; INVIVO	Free radicals are thought to play an important role in many types of tissue injury. Recently, we reported that a series of prostaglandin F2-like compounds (F2-isoprostanes) capable of exerting potent biological activity are produced in vivo by free radical-induced lipid peroxidation. Their formation is independent of the cyclooxygenase enzyme and has been shown to increase profoundly in animal models of free radical injury and lipid peroxidation. We now report the identification of F-ring isoprostane metabolites in human urine and plasma utilizing a gas chromatographic/mass spectrometric assay for the major urinary metabolite of prostaglandin D2(9alpha,11beta-dihydroxy-15-oxo-2,3, 18,19-tetranorprost-5-ene-1,20-dioic acid). Evidence confirming these metabolites as tetranor, dicarboxylic acid compounds containing one double bond, cis-cyclopentane ring hydroxyls, and one keto group similar in structure to the major urinary metabolite of prostaglandin D2 was obtained by analysis of human urine by electron ionization mass spectrometry. Levels of these metabolites in normal human urine were determined and found to be unaffected by cyclooxygenase inhibitors. Evidence that these metabolites arise from F2-isoprostanes was obtained by demonstrating that (a) marked increases in plasma levels and urinary excretion of these metabolites, which were unaffected by coadministration of indomethacin, occurred in rats administered CCl4 to induce F2-isoprostane formation and (b) marked increases in levels of these metabolites in plasma and urine resulted from the intravenous infusion of F2-isoprostanes into a rat. Quantification of these isoprostane metabolites in urine and plasma may provide a reliable index of endogenous isoprostane production which could prove to be an important advance in our ability to assess oxidant stress in vivo in humans.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056, P50GM015431] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07028] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1979, TOXICOL APPL PHARM, V50, P467, DOI 10.1016/0041-008X(79)90400-9; CATELLA F, 1986, AM J MED, V81, P23, DOI 10.1016/0002-9343(86)90905-8; DWORSKI R, 1989, AM REV RESPIR DIS, V139, P46, DOI 10.1164/ajrccm/139.1.46; FROLICH JC, 1975, J CLIN INVEST, V55, P763, DOI 10.1172/JCI107987; GRANSTRO.E, 1971, J BIOL CHEM, V246, P7470; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; JACKSON EK, 1989, ADV PROSTAGLANDIN TH, V18, P322; LISTON TE, 1985, J BIOL CHEM, V260, P3172; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MURPHY RC, 1982, METHOD ENZYMOL, V86, P547; NUGTEREN DH, 1975, J BIOL CHEM, V250, P2808; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; PACEASCIAK C, 1971, J CHROMATOGR, V56, P129, DOI 10.1016/S0021-9673(00)97786-0; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PRAKASH C, 1988, J CHEM SOC PERK T 1, P2821, DOI 10.1039/p19880002821; PRYOR WA, 1976, LIPIDS, V11, P370, DOI 10.1007/BF02532843; PRYOR WA, 1975, J ORG CHEM, V40, P3615, DOI 10.1021/jo00912a038; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; SLATER TF, 1984, METHOD ENZYMOL, V105, P283	24	155	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4161	4169						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440704				2022-12-25	WOS:A1993KN53300055
J	LAVOIE, JN; GINGRASBRETON, G; TANGUAY, RM; LANDRY, J				LAVOIE, JN; GINGRASBRETON, G; TANGUAY, RM; LANDRY, J			INDUCTION OF CHINESE-HAMSTER HSP27 GENE-EXPRESSION IN MOUSE CELLS CONFERS RESISTANCE TO HEAT-SHOCK - HSP27 STABILIZATION OF THE MICROFILAMENT ORGANIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STRESS PROTEINS; SACCHAROMYCES-CEREVISIAE; INDUCED THERMOTOLERANCE; ACTIN POLYMERIZATION; MAMMALIAN-CELLS; RAT FIBROBLASTS; HEPATOMA-CELLS; RODENT CELLS; PHOSPHORYLATION	Heat shock induces in cells the development of a transient state of thermotolerance thought to result from the induction of heat shock proteins. To assess directly whether a transient overexpression of one of these proteins, HSP27, can contribute to increased cellular resistance, mouse NIH/3T3 cells were cotransfected with a plasmid containing the Chinese hamster HSP27 gene under the control of the metallothionein promoter and a plasmid containing the neo gene. Stable transfectant cell lines were selected for resistance to the antibiotic G418. Analyses of several stable transfectant cell lines indicated that expression of Chinese hamster HSP27 could be selectively induced by exposure to 3 muM CdCl2, a concentration that had no effect on the induction of the endogenous heat shock proteins (HSP). In clone 15, the level of HSP27 increased steadily during the first day of exposure to CdCl2, from a concentration of 1 mug/mg of total protein to 7 mug/mg. After withdrawal of CdCl2, the level of HSP27 returned to normal within the next 5 days. Accumulation of the Chinese hamster HSP27 was accompanied by a progressive development of thermoresistance that attained a level approaching heat shock-induced thermotolerance. After CdCl2 removal, thermal resistance and HSP27 decayed in a coordinated manner. In control cells transfected with the neo gene only, increased thermoresistance was not induced by 3 muM CdCl2; in these cells, an exposure to 20 muM CdCl2 was required to induce a level of thermoresistance comparable to that induced by 3 muM CdCl2 in clone 15. Elevated expression of HSP27 was accompanied by an increased stability of stress fibers during hyperthermia. The protein also partially prevented actin depolymerization during acute exposure to cytochalasin D and reduced cytotoxicity and growth inhibition of chronic exposures to the drug. The results indicated that accumulation of HSP27, as it occurs after a mild heat shock or other inducing treatments, is sufficient for acquisition of thermotolerance that may result in part from a stabilization of actin filaments.	UNIV LAVAL,HOTEL DIEU QUEBEC,CTR RECH CANCEROL,11 COTE PALAIS,QUEBEC CITY G1R 2J6,PQ,CANADA; CHU LAVAL,CTR RECH,GENET CELLULAIRE & MOLEC LAB,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University; Laval University				Lavoie, Josee N/0000-0001-6912-1132				ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; CALTABIANO MM, 1986, J BIOL CHEM, V261, P3381; COURGEON AM, 1984, EXP CELL RES, V153, P515, DOI 10.1016/0014-4827(84)90618-9; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GROSE JH, 1991, ADV PROSTAG THROMB L, V21, P145; GUESDON F, 1991, J IMMUNOL, V147, P3402; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HUOT J, 1991, CANCER RES, V51, P5245; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KOLEGA J, 1991, J CELL BIOL, V114, P993, DOI 10.1083/jcb.114.5.993; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANDRY J, 1983, CAN J BIOCHEM CELL B, V61, P428, DOI 10.1139/o83-058; LANDRY J, 1987, THERMOTOLERANCE, V1, P145; LASZLO A, 1988, INT J HYPERTHER, V4, P513, DOI 10.3109/02656738809027695; LAVOIE J, 1990, NUCLEIC ACIDS RES, V18, P1637, DOI 10.1093/nar/18.6.1637; LEE YJ, 1987, CANCER RES, V47, P5960; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LI GC, 1982, HEAT SHOCK BACTERIA, P395; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; OHTSUKA K, 1986, RADIAT RES, V108, P34, DOI 10.2307/3576967; OHTSUKA K, 1987, Journal of Cell Biology, V105, p73A; Price-Haughey J, 1987, Experientia Suppl, V52, P465; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SHELTON KR, 1986, J BIOL CHEM, V261, P1935; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WATSON K, 1984, FEBS LETT, V172, P299, DOI 10.1016/0014-5793(84)81145-X; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WELCH WJ, 1988, J CELL BIOL, V106, P1117, DOI 10.1083/jcb.106.4.1117; WIDELITZ RB, 1986, MOL CELL BIOL, V6, P1088, DOI 10.1128/MCB.6.4.1088; WIEGANT FAC, 1987, CANCER RES, V47, P1674; ZHOU M, 1993, IN PRESS J BIOL CHEM	56	450	457	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3420	3429						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429018				2022-12-25	WOS:A1993KM16100063
J	LOUNSBURY, KM; SCHLEGEL, B; PONCZ, M; BRASS, LF; MANNING, DR				LOUNSBURY, KM; SCHLEGEL, B; PONCZ, M; BRASS, LF; MANNING, DR			ANALYSIS OF GZ-ALPHA BY SITE-DIRECTED MUTAGENESIS - SITES AND SPECIFICITY OF PROTEIN KINASE-C-DEPENDENT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; HUMAN-PLATELETS; PERTUSSIS TOXIN; INOSITOL PHOSPHATES; PHOSPHOLIPASE-C; CYCLIC-GMP; SUBUNIT; THROMBIN; CELLS; GQ	The G protein alpha subunit G(zalpha) is a substrate for phosphorylation by protein kinase C. The phosphorylation has been documented both in human platelets and in vitro and is characterized by a high degree of selectivity in relation to other G protein alpha subunits. We have demonstrated previously by phosphoamino acid analysis and CNBr peptide mapping that phosphorylation occurs at a serine residue(s) within the NH2-terminal 53 residues of G(zalpha). In this study, we have examined the site of phosphorylation using site-directed mutagenesis. G(zalpha) variants containing selected substitutions of alanine for serine residues were expressed in human kidney 293 cells, and the ability of each to be phosphorylated in response to phorbol 12-myristate 13-acetate was examined. A focus was placed on Ser25 and Ser27, the 2 serine residues within a sequence of G(zalpha) used to obtain a phosphorylation-sensitive antibody. The results demonstrate that Ser27 is the primary site of phosphorylation. Conversion of Ser27 to an alanine resulted in a 65% decrease in incorporation of [P-32] phosphate; conversion of Ser25 had no effect. Conversion of Ser16, which like Ser25 and Ser27 conforms to a consensus site for protein kinase C, resulted in a modest (15%) decrease. The conversion of both Ser16 and Ser27 resulted in an 80% suppression of incorporation. In addition to these results, we have extended studies of the subunit and kinase selectivity of phosphorylation in platelets. We show here that under conditions promoting phorbol 12-myristate 13-acetate-stimulated phosphorylation of G(zalpha) in permeabilized platelets, G(qalpha) is not phosphorylated. Moreover, G(ialpha), G(zalpha), and G(qalpha) were not phosphorylated in response to analogues of cAMP or cGMP. Thus, only G(zalpha) is phosphorylated in platelets and only in response to activation of protein kinase C.	UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DEPT HEMATOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	LOUNSBURY, KM (corresponding author), UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA.				NCI NIH HHS [CA39712] Funding Source: Medline; NHLBI NIH HHS [HL45181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Brass L F, 1991, Prog Hemost Thromb, V10, P127; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; NAKASHIMA S, 1986, BIOCHEM BIOPH RES CO, V135, P1099, DOI 10.1016/0006-291X(86)91041-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SANE DC, 1989, BIOCHEM BIOPH RES CO, V165, P708, DOI 10.1016/S0006-291X(89)80024-5; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILLIAMS AG, 1990, BLOOD, V76, P721	26	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3494	3498						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429024				2022-12-25	WOS:A1993KM16100073
J	NGUYEN, TT; MUENCH, KA; BRYANT, FR				NGUYEN, TT; MUENCH, KA; BRYANT, FR			INACTIVATION OF THE RECA-PROTEIN BY MUTATION OF HISTIDINE-97 OR LYSINE-248 AT THE SUBUNIT INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; EXCHANGE; RENATURATION; PURIFICATION; COMPLEXES; SEQUENCES; VECTORS; CLONING	We have used site-directed mutagenesis to prepare two new mutant recA proteins, one in which histidine 97 has been replaced by alanine, and another in which lysine 248 has been replaced by alanine. Although these mutant proteins were originally designed from different considerations, they turned out to have remarkably similar properties. Both the [H97A]recA protein and the [K248A]recA protein bind poorly to single-stranded DNA, have no single-stranded DNA-dependent ATP hydrolysis activity, and do not promote renaturation of complementary single-stranded DNA molecules or the ATP-dependent three-strand exchange reaction. Furthermore, both mutant proteins are defective in Mg2+-induced helical filament formation. To account for these results, we propose that the mutation of either histidine 97 or lysine 248 alters subunit interactions between recA monomers and that this leads to the loss of cooperative single-stranded DNA binding and DNA pairing activities. This proposal is consistent with the recently determined x-ray structure of the recA protein, which shows that although histidine 97 and lysine 248 are distant from one another in the monomer structure, these two residues are on the opposing complementary faces of the recA subunit and pack against each other at the interface between adjacent recA monomers in the helical filament (Story, R. M., Weber, 1. T., and Steitz, T. A. (1992) Nature 355, 318-325).	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,615 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; BRYANT FR, 1986, J BIOL CHEM, V261, P2988; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; BRYANT FR, 1989, BIOCHEMISTRY-US, V28, P1062, DOI 10.1021/bi00429a021; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; GRIFFITH JD, 1988, CRC CRIT REV BIOC S1, V23, P43; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEGENDRE N, 1990, Biotechniques, V9, P788; MENGE KL, 1988, BIOCHEMISTRY-US, V27, P2635, DOI 10.1021/bi00407a055; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUENCH KA, 1991, J BIOL CHEM, V266, P844; PRASAD BVV, 1987, J MOL BIOL, V193, P579; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; SCOTT JF, 1978, J BIOL CHEM, V253, P3292; STASIAK A, 1986, BIOPHYS J, V49, P5, DOI 10.1016/S0006-3495(86)83569-X; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3107	3113						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428989				2022-12-25	WOS:A1993KM16100017
J	UCHIDA, K; SUZUKI, H; MARUTA, H; ABE, H; AOKI, K; MIWA, M; TANUMA, S				UCHIDA, K; SUZUKI, H; MARUTA, H; ABE, H; AOKI, K; MIWA, M; TANUMA, S			PREFERENTIAL DEGRADATION OF PROTEIN-BOUND (ADP-RIBOSE)N BY NUCLEAR POLY(ADP-RIBOSE) GLYCOHYDROLASE FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); GUINEA-PIG LIVER; ADP-RIBOSYLATION; HUMAN-ERYTHROCYTES; PURIFICATION; IDENTIFICATION; EXPRESSION; THYMUS; GENE; DNA	Poly(ADP-ribose) glycohydrolase, extensively purified to homogeneity from nuclei of human placenta, is composed of a single polypeptide with a molecular mass of 71,000 daltons on sodium dodecyl sulfate-polyacrylamide gel. Judging from its physico-chemical and catalytic properties, the enzyme is similar to the nuclear glycohydrolase (glycohydrolase I), but not to the cytoplasmic glycohydrolase (glycohydrolase II) that has been purified from guinea pig liver (Tanuma, S., Kawashima, K., and Endo, H. (1986) J. Biol. Chem. 261, 965-969; Maruta, H., Inageda, K., Aoki, T., Nishina, H., and Tanuma, S. (1991) Biochemistry 30, 5907-5912). The rates of hydrolysis of (ADP-ribose)n bound to various proteins by the purified nuclear glycohydrolase were higher than those of the corresponding free polymers. Kinetic analyses revealed that the enzyme had more activity toward poly(ADP-ribose) bound to histone H1 or to poly(ADP-ribose) polymerase than toward oligo(ADP-ribose) bound to cytoplasmic proteins from mitochondria or mRNA ribonucleoprotein although the K(m) and V(max) values were dependent on the chain length (n). In contrast, cytoplasmic glycohydrolase purified from human erythrocytes was more active toward oligo(ADP-ribose) (n = 2.6 or 4.2) bound to the cytoplasmic proteins than to poly(ADP-ribose) (n = 14.6) bound to histone H1, and their kinetic parameters of glycohydrolase II were rather dependent on the acceptor molecules for (ADP-ribose)n. These results suggest that poly(ADP-ribose) glycohydrolase I may play an important role in regulation of poly(ADP-ribosyl)ation levels on chromosomal proteins in nuclei.	UNIV TSUKUBA,INST BASIC MED SCI,DEPT BIOCHEM,1-1-1 TENNOUDAI,TSUKUBA,IBARAKI 305,JAPAN; NATL CANC CTR,RES INST,DIV BIOCHEM,TOKYO 104,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; SCI UNIV TOKYO,FAC PHARMACEUT SCI,DEPT BIOCHEM,TOKYO 162,JAPAN	University of Tsukuba; National Cancer Center - Japan; Tokyo Institute of Technology; Tokyo University of Science								Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; FUTAI M, 1967, J BIOL CHEM, V242, P5301; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL P, 1982, PROG NUCLEIC ACID RE, V27, P1, DOI 10.1016/S0079-6603(08)60596-6; MARUTA H, 1991, BIOCHEMISTRY-US, V30, P5907, DOI 10.1021/bi00238a014; MIWA M, 1974, J BIOL CHEM, V249, P3475; MIWA M, 1971, J BIOL CHEM, V246, P6362; MIWA M, 1990, ADP RIBOSYLATING TOX, P543; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKA J, 1984, J BIOL CHEM, V259, P986; RECHSTEINER M, 1976, NATURE, V259, P695, DOI 10.1038/259695a0; SHIMA T, 1969, J BIOL CHEM, V244, P6632; Sugimura T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P127, DOI 10.1016/S0079-6603(08)60102-6; SUZUKI H, 1987, BIOCHEM BIOPH RES CO, V146, P403, DOI 10.1016/0006-291X(87)90543-2; TANUMA S, 1982, BIOCHEM BIOPH RES CO, V104, P483, DOI 10.1016/0006-291X(82)90662-3; TANUMA S, 1986, BIOCHEM BIOPH RES CO, V136, P1110, DOI 10.1016/0006-291X(86)90448-1; TANUMA S, 1989, BIOCHEM BIOPH RES CO, V163, P1047, DOI 10.1016/0006-291X(89)92327-9; TANUMA S, 1990, EUR J BIOCHEM, V191, P57, DOI 10.1111/j.1432-1033.1990.tb19093.x; TANUMA S, 1983, J BIOL CHEM, V258, P5371; TANUMA SI, 1986, BIOCHEM BIOPH RES CO, V135, P979, DOI 10.1016/0006-291X(86)91024-7; TANUMA SI, 1986, J BIOL CHEM, V261, P965; TAVASSOLI M, 1983, EUR J BIOCHEM, V135, P449, DOI 10.1111/j.1432-1033.1983.tb07672.x; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WIELCKENS K, 1983, J BIOL CHEM, V258, P4098	28	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3194	3200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428996				2022-12-25	WOS:A1993KM16100029
J	CASTLE, VP; OU, XL; OROURKE, K; DIXIT, VM				CASTLE, VP; OU, XL; OROURKE, K; DIXIT, VM			HIGH-LEVEL THROMBOSPONDIN-1 EXPRESSION IN 2 NIH 3T3 CLONED LINES CONFERS SERUM-INDEPENDENT AND ANCHORAGE-INDEPENDENT GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISTEP CARCINOGENESIS; PLATELET THROMBOSPONDIN; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CELLS; ONCOGENES; CDNA; TRANSFORMATION; TUMORIGENESIS; PROLIFERATION	Thrombospondin (TSP) is a trimeric molecule synthesized by a variety of normal and transformed cells and secreted into the extracellular matrix. A number of studies have shown TSP to be intimately involved in the regulation of cellular proliferation. These include the findings that TSP is a mitogen-inducible immediate-early response gene; it localizes to areas of cellular proliferation in the developing mouse embryo; it augments the proliferative response to epidermal growth factor; anti-TSP monoclonal antibodies block cell proliferation; and TSP levels correlate directly with the growth and invasive phenotype and inversely with the degree of differentiation of squamous carcinoma cells. To determine whether TSP could behave as an oncogene, conferring serum and anchorage independence, NIH 3T3 cells were stably transfected with a TSP expression vector. Clones producing high levels of TSP displayed enhanced viability and a proliferative advantage in serum-reduced media. Moreover, this growth advantage could be specifically negated by treatment of the transfected cells with anti-TSP monoclonal antibodies. While the TSP overexpressing clones were capable of anchorage-independent growth in soft agar, surprisingly, they were incapable of forming tumors in nude mice, possibly due to the in vivo antiangiogenic activity of TSP. Regardless, these studies demonstrate that overexpression of thrombospondin, a constituent of the extracellular matrix, results in serum and anchorage independent growth, attributes normally associated with the transformed phenotype.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE ST,BOX 0602,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,COMM CELL & MOLEC BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL CANCER INSTITUTE [R01CA058182] Funding Source: NIH RePORTER; NCI NIH HHS [CAO 1599-01, CA 58182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1986, P NATL ACAD SCI USA, V83, P5449, DOI 10.1073/pnas.83.15.5449; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HARPEL PC, 1990, J BIOL CHEM, V265, P11289; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIOTTA LA, 1984, AM J PATHOL, V117, P339; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MILLER AD, 1984, CELL, V36, P51; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	32	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2899	2903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428963				2022-12-25	WOS:A1993KK81500094
J	KHAN, SH; CRAWLEY, SC; KANIE, O; HINDSGAUL, O				KHAN, SH; CRAWLEY, SC; KANIE, O; HINDSGAUL, O			A TRISACCHARIDE ACCEPTOR ANALOG FOR N-ACETYLGLUCOSAMINYLTRANSFERASE-V WHICH BINDS TO THE ENZYME BUT STERICALLY PRECLUDES THE TRANSFER-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE; GLYCOSYLTRANSFERASES; GLYCOSYLATION; RECOGNITION; INHIBITORS	Development of inhibitors specific for the glycosyltransferases involved in the biosynthesis of asparagine-linked sugar chains has been undertaken in the hopes that these compounds may serve as tools to elucidate the roles of complex carbohydrates in biological recognition events. We report here the first example of a glycosyltransferase acceptor analog in which strategic replacement of a nonreacting hydroxyl group with a larger substituent produces a molecule which is recognized by the enzyme but does not react because of a steric block to the glycosyl transfer reaction. N-Acetylglucosaminyltransferase V catalyzes the transfer of GlcNAc from the sugar nucleotide donor UDP-GlcNAc to the 6-OH group of mannose in the synthetic trisaccharide acceptor betaGlcNAc(1 --> 2)alphaMan(1 --> 6)betaGlc-O(CH2)7CH3 (K(m) = 23 +/- 2 muM; V(max) = 116 +/- 3 pmol/h) to form the tetrasaccharide betaGlcNAc(1 --> 2)(betaGlcNAc(1 --> 6))alphaMan(1 --> 6)betaGlc-O(CH2)7CH3. The acceptor analog produced by replacement of the adjacent nonreacting 4-OH group of the mannose residue with an O-methyl group was not a substrate for the enzyme but was found to be a good competitive inhibitor of GlcNAc transferase V with K(i) = 14 +/- 2 muM. To test the theory that it was the presence of the large methyl group which prevented the glycosyl transfer reaction the 4'-deoxygenated analog was synthesized. It was found to be a good substrate with K(m) = 74 +/- 6 muM and an almost 5-fold higher k(cat) (V(max) = 535 +/- 13 pmol/h). NMR data show no evidence of important conformational differences between the trisaccharide analogs, and kinetic experiments detected no differences for the binding of UDP-GIcNAc in their presence. The conclusion was therefore reached that the large methyl group introduced on O-4' sterically prevented the formation of product even though both potential substrates were bound by the enzyme. This ''steric exclusion'' strategy offers potential for the design of inhibitors for that class of glycosyltransferases in which the reactive hydroxyl group is also an essential recognition element.	UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA; UNIV ALBERTA, DEPT FOOD SCI, EDMONTON T6G 2G2, ALBERTA, CANADA	University of Alberta; University of Alberta			Kanie, Osamu/D-1741-2010	Kanie, Osamu/0000-0003-4147-6868				BEYER TA, 1981, ADV ENZYMOL, V52, P24; BOCK K, 1992, CARBOHYD RES, V228, P1, DOI 10.1016/S0008-6215(00)90544-5; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DENNIS JW, 1989, CANCER RES, V49, P945; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Feizi T, 1991, CURR OPIN STRUC BIOL, V1, P766, DOI 10.1016/0959-440X(91)90176-T; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; KAUR KJ, 1992, CARBOHYD RES, V226, P219, DOI 10.1016/0008-6215(92)84069-5; Khan S.H., 1992, GLYCOCONJUGATES COMP, P361; KHAN SH, 1990, CARBOHYD RES, V205, P385, DOI 10.1016/0008-6215(90)80156-W; PALCIC MM, 1989, J BIOL CHEM, V264, P17174; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRITCHETT TJ, 1987, VIROLOGY, V160, P502, DOI 10.1016/0042-6822(87)90026-2; ROSEVEAR PR, 1982, BIOCHEMISTRY-US, V21, P1421, DOI 10.1021/bi00535a049; SEGEL IH, 1975, ENZYME KINETICS, P46; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6	20	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2468	2473						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428922				2022-12-25	WOS:A1993KK81500035
J	ROY, P; CHATELLARD, C; LEMAY, G; CRINE, P; BOILEAU, G				ROY, P; CHATELLARD, C; LEMAY, G; CRINE, P; BOILEAU, G			TRANSFORMATION OF THE SIGNAL PEPTIDE MEMBRANE ANCHOR DOMAIN OF A TYPE-II TRANSMEMBRANE PROTEIN INTO A CLEAVABLE SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; SACCHAROMYCES-CEREVISIAE; HUMAN LYSOZYME; COS-1 CELLS; SEQUENCE; SECRETION; SITE; DNA; RESIDUES; ENKEPHALINASE	Rabbit neutral endopeptidase-24.11 is a type II transmembrane protein with a 27-amino acid residue positively charged NH2-terminal cytoplasmic domain, a 23-amino acid residue hydrophobic signal peptide/membrane anchor domain, and a large catalytic COOH-terminal domain exposed on the exoplasmic side of the membrane. In order to study the mechanism of membrane anchoring of neutral endopeptidase-24.11, we created mutants in which the cytoplasmic tail was deleted. Expression of these mutants in COS-1 cells resulted in the secretion of approximately 10-20% of the protein into the culture medium, due possibly to the cleavage of part or all of the signal peptide/membrane anchor domain by the rough endoplasmic reticulum signal peptidase. In a second set of mutants, a hydrophilic sequence (GSQNS) was inserted midway in the signal peptide/membrane anchor domain of neutral endopeptidase-24.11. When this hydrophilic sequence was introduced into the full-length neutral endopeptidase-24.11, approximately 20% of the enzyme activity was recovered in the culture medium. This proportion increased to 93% when the cytosolic tail was deleted. Sequencing of the [H-3]tyrosine- or [H-3]isoleucine-labeled secreted protein indicated that proteolysis, possibly by signal peptidase, occurred on the COOH-terminal side of the signal peptide/membrane anchor domain. We conclude that the efficient cleavage of the signal peptide/membrane anchor domain and secretion of the protein require both the deletion of the cytosolic domain and the presence of a hydrophilic sequence.	UNIV MONTREAL,FAC MED,DEPT BIOCHIM,CP 6128,SUCC A,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRD P, 1990, J BIOL CHEM, V265, P8420; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRINE P, 1985, BIOCHEM BIOPH RES CO, V131, P255, DOI 10.1016/0006-291X(85)91796-6; DEJONG WW, 1978, BIOCHEM BIOPH RES CO, V82, P532, DOI 10.1016/0006-291X(78)90907-5; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOMEZ S, 1989, EMBO J, V8, P2911, DOI 10.1002/j.1460-2075.1989.tb08440.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JABBAR MA, 1987, MOL CELL BIOL, V7, P1476, DOI 10.1128/MCB.7.4.1476; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAY G, 1989, J BIOL CHEM, V264, P15620; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MUELLER M, 1982, Journal of Biological Chemistry, V257, P11860; MURAKAMI H, 1982, P NATL ACAD SCI-BIOL, V79, P1158, DOI 10.1073/pnas.79.4.1158; NAGAHORA H, 1988, FEBS LETT, V238, P329, DOI 10.1016/0014-5793(88)80506-4; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P21797; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SINGER SJ, 1990, ANN REV CELL BIOL, V6, P287; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; STRAUSS AW, 1979, P NATL ACAD SCI USA, V76, P4225, DOI 10.1073/pnas.76.9.4225; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRELLA G, 1974, IMMUNOCHEMISTRY, V11, P157, DOI 10.1016/0019-2791(74)90213-4; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; YOST CS, 1983, CELL, V34, P759	47	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2699	2704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428944				2022-12-25	WOS:A1993KK81500066
J	TANIGUCHI, T; KITAGAWA, H; YASUE, S; YANAGI, S; SAKAI, K; ASAHI, M; OHTA, S; TAKEUCHI, F; NAKAMURA, S; YAMAMURA, H				TANIGUCHI, T; KITAGAWA, H; YASUE, S; YANAGI, S; SAKAI, K; ASAHI, M; OHTA, S; TAKEUCHI, F; NAKAMURA, S; YAMAMURA, H			PROTEIN-TYROSINE KINASE P72(SYK) IS ACTIVATED BY THROMBIN AND IS NEGATIVELY REGULATED THROUGH CA2+ MOBILIZATION IN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT PLATELETS; YES PROTEIN; PHOSPHORYLATION; SECRETION; PURIFICATION; AGGREGATION; MECHANISMS; EXPRESSION; MEMBRANE; VANADATE	Activation of platelets by thrombin results in a dramatic increase in tyrosine phosphorylation on multiple cellular proteins (Ferrell, J. E., and Martin, G. S. (1988) Mol. Cell. Biol. 8, 3603-3610; Golden, A., and Brugge, J. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 901-905; Nakamura, S., and Yamamura, H. (1989) J. Biol. Chem. 264, 7089-7091). However, none of the responsible protein-tyrosine kinase has been reported so far. We report here that p72syk, one of the non-receptor-type protein-tyrosine kinases, is activated following thrombin stimulation in blood platelets. Washed porcine platelets were stimulated by thrombin, and the activation of p72syk was assessed in an immunoprecipitation kinase assay. The activity of p72syk increased within 5 s, reached a maximum at 10 s, and decreased to a basal level within 60 s after 0.5 unit/ml thrombin stimulation. The amount of immunoprecipitated p72syk was not altered throughout the time course. This activation was greatly enhanced in a dose-dependent manner and was completely canceled by the pretreatment of platelet suspension with hirudin, a specific antagonist of thrombin. In the Ca2+-depleted condition both extra- and intracellularly, the activation of p72syk was still persistent; in contrast, the deactivation process was completely abrogated even at 120 s after thrombin stimulation. In addition, the replenishment of Ca2+ resulted in a similar deactivation pattern as seen in the Ca2+-rich condition. Furthermore, this deactivation was also canceled by the pretreatment of platelets with W7, a calmodulin antagonist, as well as ML9, a myosin-light-chain kinase inhibitor. These results indicate that p72syk can be a responsible enzyme to the protein-tyrosine phosphorylation events following the platelet activation by thrombin and may be negatively regulated by Ca2+ in a calmodulin-dependent manner, inter alia myosin light-chain kinase, in thrombin-stimulated platelets.	FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN	University of Fukui								APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; DHAR A, 1990, MOL PHARMACOL, V37, P519; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUADETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238; HORAK ID, 1990, ONCOGENE, V5, P597; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INAZU T, 1990, BIOCHEM BIOPH RES CO, V170, P259, DOI 10.1016/0006-291X(90)91268-W; KOBAYASHI T, 1990, EUR J BIOCHEM, V188, P535, DOI 10.1111/j.1432-1033.1990.tb15433.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KROLL MH, 1989, BLOOD, V74, P1181; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YAMADA T, 1991, BIOCHEM BIOPH RES CO, V180, P1325, DOI 10.1016/S0006-291X(05)81340-3; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	28	141	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2277	2279						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428900				2022-12-25	WOS:A1993KK81500003
J	VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W				VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W			EFFECT OF BCL-2 PROTOONCOGENE EXPRESSION ON CELLULAR-SENSITIVITY TO TUMOR NECROSIS FACTOR-MEDIATED CYTOTOXICITY	ONCOGENE			English	Article							DNA FRAGMENTATION; FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; THYMOCYTE APOPTOSIS; TRANSGENIC MICE; GENE-EXPRESSION; RESISTANT CELLS; CYTO-TOXICITY; B-CELLS; DEATH	Introduction and expression of the proto-oncogene bcl-2 (B-cell lymphoma/leukemia 2) has been shown to extend the survival of certain hematopoietic cell lines after growth factor deprivation, by blocking apoptosis or programmed cell death. We investigated the effect of bcl-2 expression on cellular sensitivity to lysis by tumor necrosis factor (TNF), a cytokine capable of inducing apoptosis in several tumor cell lines. Introduction of the human bcl-2 gene in the highly TNF-sensitive L929 mouse fibrosarcoma cell fine did not result in altered TNF sensitivity. Likewise, NIH3T3 and REF cells, which are resistant to TNF cytotoxicity but become TNF sensitive upon cotreatment with actinomycin D or upon expression of the adenovirus EIA gene, did not show altered TNF sensitivity upon bcl-2 transfection. Despite constitutive expression of the endogenous bcl-2 gene, human MCF7 breast carcinoma cells, as well as HL60 promyelocytic leukemia and U937 histiocytic lymphoma cell lines were found to be TNF sensitive. bcl-2-overexpressing derivatives of these cell lines did not acquire reduced TNF sensitivity and still exhibited the characteristic pattern of internucleosomal DNA fragmentation of TNF-induced apoptosis. Moreover, bcl-2 expression in the interleukin 3 (IL-3)-dependent myeloid cell line 32D protected these cells from apoptosis resulting from growth factor deprivation, but not from apoptosis induced by TNF. These data clearly establish the absence of a correlation between bcl-2 gene expression and cellular sensitivity to TNF-induced cell lysis. These findings are discussed in the context of the hypothesis of different pathways for induction of apoptosis, only some of which are affected by bcl-2 expression.	STATE UNIV GHENT,MOLEC BIOL LAB,K L LEDEGANCKSTR 35,B-9000 GHENT,BELGIUM; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	Ghent University; University of Pennsylvania			van Roy, Frans M/C-6123-2009; Beyaert, Rudi/B-2589-2009	van Roy, Frans M/0000-0003-4358-1039; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LASTER SM, 1988, J IMMUNOL, V141, P2629; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, IN PRESS CANCER RES, V52; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEALE ML, 1988, IMMUNOLOGY, V64, P81; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RUBIN BY, 1988, CANCER RES, V48, P6006; RUFF MR, 1981, LYMPHOKINES, V2, P235; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1990, VIROLOGY, V176, P362, DOI 10.1016/0042-6822(90)90006-D; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WARING P, 1990, J BIOL CHEM, V265, P14476; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	55	121	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1075	1081						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455935				2022-12-25	WOS:A1993KT22000033
J	PUKAZHENTHI, BS; MUNIAPPA, N; VIJAY, IK				PUKAZHENTHI, BS; MUNIAPPA, N; VIJAY, IK			ROLE OF SULFHYDRYL-GROUPS IN THE FUNCTION OF GLUCOSIDASE-I FROM MAMMARY-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOSIDASE; ASPARAGINE-LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM MEMBRANE; LIVER GOLGI MEMBRANES; MUNG BEAN SEEDLINGS; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; TRANSCRIPTIONAL REGULATION	Glucosidase I initiates the processing of asparagine-linked glycoproteins by excising the distal alpha1,2-linked glucosyl residue from the Glc3Man9GlcNAc2 oligosaccharide, soon after its en bloc transfer from the lipid-linked donor to the nascent polypeptide. 1-Deoxynojirimycin, an analog of D-glucose, is a potent competitive inhibitor of the enzyme. Sulfhydryl-seeking reagents also strongly inhibit the enzyme, implying the involvement of an -SH group in its activity. To test this hypothesis, glucosidase I was purified from the rat mammary gland and its active site was loaded with 1-deoxynojirimycin, to protect such a group(s), while -SH groups on the remaining surface of the enzyme were blocked with N-ethylmaleimide or para-chloromercuriphenylsulfonic acid. Deoxynojirimycin was removed by dialysis to expose the active site -SH group(s). This group(s) was then tagged with 3-(N-maleimidopropionyl)biocytin (MPB) and detected with I-125-streptavidin on Western blots. A series of experiments is presented to show that indeed a critical -SH group(s) is located within the catalytic site of the enzyme. Additionally, the enzyme also possesses one or more sulfhydryls and disulfide bonds in its primary structure. The experimental approach outlined here should apply to identify reactive sulfhydryl groups in other catalytically active proteins.	UNIV MARYLAND, DEPT ANIM SCI, COLL PK, MD 20742 USA; UNIV MARYLAND, CTR AGR BIOTECHNOL, COLL PK, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BAUSE E, 1989, EUR J BIOCHEM, V183, P661, DOI 10.1111/j.1432-1033.1989.tb21096.x; BAUSE E, 1986, FEBS LETT, V206, P208, DOI 10.1016/0014-5793(86)80982-6; BAYER EA, 1987, ANAL BIOCHEM, V161, P262, DOI 10.1016/0003-2697(87)90450-7; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; FENG Y, 1992, J BIOL CHEM, V267, P5817; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GHEBREHIWET B, 1988, J IMMUNOL METHODS, V110, P251, DOI 10.1016/0022-1759(88)90111-1; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KAUSHAL GP, 1991, INT C BIOCH TORONTO; KILKER RD, 1981, J BIOL CHEM, V256, P5299; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, J BIOL CHEM, V267, P7570; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MARTINIUK F, 1985, J BIOL CHEM, V260, P1238; MONIS E, 1987, EUR J BIOCHEM, V168, P287, DOI 10.1111/j.1432-1033.1987.tb13419.x; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOSCKOVITZ R, 1988, J BIOL CHEM, V263, P1017; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROFFMAN E, 1986, BIOCHEM BIOPH RES CO, V136, P80, DOI 10.1016/0006-291X(86)90879-X; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SCHWEDEN J, 1989, BIOCHEM J, V264, P347, DOI 10.1042/bj2640347; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SHAILUBHAI K, 1987, BIOCHEM J, V247, P555, DOI 10.1042/bj2470555; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; SZUMILO T, 1986, ARCH BIOCHEM BIOPHYS, V247, P261, DOI 10.1016/0003-9861(86)90583-7; TABAS I, 1978, J BIOL CHEM, V253, P7779; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VIJAY IK, 1980, J BIOL CHEM, V255, P1210; VIJAY IK, 1982, EUR J BIOCHEM, V126, P167, DOI 10.1111/j.1432-1033.1982.tb06762.x; WANG XC, 1990, J BIOL CHEM, V265, P17849; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; YADAV SP, 1991, J BIOL CHEM, V266, P698	74	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6445	6452						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454617				2022-12-25	WOS:A1993KT36800055
J	SLONINA, AE; SCOTT, TC; LEHRMAN, MA				SLONINA, AE; SCOTT, TC; LEHRMAN, MA			GENE INACTIVATION IN LEC35.1 (MANNOSYLATION-DEFECTIVE) CHINESE-HAMSTER OVARY CELLS - A CAUTIONARY NOTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; DNA; MUTATION; MEMBRANE; MUTANT	In Lec35.1 CHO mutants, mannose-P-dolichol is synthesized but does not participate in the production of glycosylphosphatidylinositol (GPI) anchor precursors or dolichol-linked oligosaccharides. We tested Lec35.1 cells for stable expression of a cDNA encoding GPI-anchored human folate-binding protein (FBP) with the eukaryotic expression vector pJB20. All normal transfectants, but no Lec35.1 transfectants, expressed FBP activity. However, rather than an inability to produce GPI anchors, lack of FBP expression in Lec35.1 was caused by gradual inactivation of the FBP cDNA. FBP cDNA became fully inactive after 2-3 months of culture, and FBP activity was not restored upon correction of the Lec35 mutation. Southern blot analysis revealed that inactivation was associated with gross rearrangement of FBP cDNA. The cellular FBP gene remained intact. Because the Lec35.1 cell line has the ability to inactivate transfected human FBP cDNA, caution should be exercised when expressing transfected cDNAs in Lec35.1 and similar GPI anchor/glycosylation mutants. Interestingly, these results suggest similarities between the Lec35.1 defect and the human disease paroxysmal nocturnal hemoglobinuria, which may involve gradual inactivation of a gene necessary for mannosylation of GPI anchor precursors.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; CAMP LA, 1993, J BIOL CHEM, V268, P6721; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MAHONEY JF, 1992, BLOOD, V79, P1400; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; ROSSE WF, 1990, CLIN IMMUNOHEMATOLOG, P593; ZENG YC, 1990, J BIOL CHEM, V265, P2296; ZHU XY, 1992, J BIOL CHEM, V267, P8895	18	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6729	6733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454645				2022-12-25	WOS:A1993KT36800093
J	YANG, Q; CO, D; SOMMERCORN, J; TONKS, NK				YANG, Q; CO, D; SOMMERCORN, J; TONKS, NK			CLONING AND EXPRESSION OF PTP-PEST - A NOVEL, HUMAN, NONTRANSMEMBRANE PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; XENOPUS OOCYTES; SKELETAL-MUSCLE; PURIFICATION; INSULIN; CELLS; SEQUENCE; KINASES; FAMILY; MICROINJECTION	The polymerase chain reaction was used to amplify protein tyrosine phosphatase (PTPase)-related cDNA from a template of total RNA isolated from human skeletal muscle. A novel PTPase, which we term PTP-PEST, was detected by this method. The polymerase chain reaction fragment was used to screen two different HeLa cell libraries to obtain full length cDNA clones. The cDNA predicts a protein of 510 amino acids, approximately 60 kDa, that does not contain an obvious signal sequence or transmembrane segment suggesting it is a nonreceptor type enzyme. The PTPase domain is located in the N-terminal portion of the molecule and displays approximately 35% identity to other members of this family of enzymes. The C-terminal segment is rich in Pro, Glu, Asp, Ser, and Thr residues, possessing features of PEST motifs which have previously been identified in proteins with very short intracellular half-lives. The protein was expressed in Escherichia coli as a fusion product with glutathione S-transferase. Intrinsic activity was demonstrated in vitro against a variety of phosphotyrosine-containing substrates including BIRK, the autophosphorylated cytoplasmic kinase domain of the insulin receptor beta subunit. It did not dephosphorylate phosphoseryl-phosphorylase a. PTP-PEST mRNA is broadly distributed in a variety of cell lines. Stimulation of human rhabdomyosarcoma A204 cells, a transformed muscle line, with insulin led to an approximately 4-fold induction of PTP-PEST mRNA within 36 h.	NIDDKD,CLIN DIABET & NUTR SECT,PHOENIX,AZ 85016	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	YANG, Q (corresponding author), COLD SPRING HARBOR LAB,DEMEREC BLDG,POB 100,COLD SPRING HARBOR,NY 11724, USA.				NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840, P30CA045508] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840, CA45508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAEDA R, 1991, J CLIN INVEST, V87, P1017, DOI 10.1172/JCI115060; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, J BIOL CHEM, V267, P140; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1991, BLOOD, V78, P2222; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	36	86	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6622	6628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454633				2022-12-25	WOS:A1993KT36800079
J	DAHMS, NM; ROSE, PA; MOLKENTIN, JD; ZHANG, Y; BRZYCKI, MA				DAHMS, NM; ROSE, PA; MOLKENTIN, JD; ZHANG, Y; BRZYCKI, MA			THE BOVINE MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR - THE ROLE OF ARGININE RESIDUES IN MANNOSE 6-PHOSPHATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND INTERACTIONS; BETA-GALACTOSIDASE; MALFOLDED PROTEINS; CRYSTAL-STRUCTURE; CLONING; PURIFICATION; EXPRESSION; CELLS; DNA; BIOSYNTHESIS	The extracytoplasmic region of the bovine cation-independent mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) consists of 15 homologous repeating domains, each of which is approximately 147 residues in length. The receptor contains two high affinity mannose 6-phosphate (Man-6-P) binding sites and our recent studies (Westlund, B., Dahms, N. M., and Kornfeld, S. (1991) J. Biol. Chem. 266, 23233-23239) have localized these two binding sites to domains 1-3 and 7-11. To further define the location of the Man-6-P binding sites and to determine the role of specific arginine residues in Man-6-P binding, site-directed mutagenesis was utilized to create truncated soluble forms of the M6P/IGF-II receptor in conjunction with either conservative (Lys) or nonconservative (Ala) replacement of arginine residues. These mutants were expressed transiently in COS-1 cells and assayed for their ability to bind phosphomannosyl residues by affinity chromatography. Analysis of the ligand binding activity of carboxyl-terminal truncated forms of the receptor's extracytoplasmic region demonstrated that the second Man-6-P binding site is contained within domains 7-9. Substitution of Arg435 in domain 3 of the amino-terminal binding site and Arg1334 in domain 9 of the second binding site results in a dramatic loss of ligand binding activity. However, substitutions at positions 435 and/or 1334 did not affect the secretion, glycosylation, or immunoreactivity of these truncated proteins. Taken together, these results indicate that Arg435 and Arg1334 are essential components of the M6P/IGF-II receptor's high affinity Man-6-P binding sites.			DAHMS, NM (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.			Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R56DK042667, R01DK042667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRETTHAU.RK, 1973, BIOCHEMISTRY-US, V12, P1251, DOI 10.1021/bi00731a002; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FEIGE JJ, 1988, J CELL PHYSIOL, V136, P33, DOI 10.1002/jcp.1041360105; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MA ZM, 1992, J BIOL CHEM, V267, P19017; MA ZM, 1991, J BIOL CHEM, V266, P10589; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; TOMODA H, 1991, CARBOHYD RES, V213, P37, DOI 10.1016/S0008-6215(00)90596-2; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	46	89	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5457	5463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449908				2022-12-25	WOS:A1993KR82200020
J	KVALNESKRICK, KL; TRAUT, TW				KVALNESKRICK, KL; TRAUT, TW			CLONING, SEQUENCING, AND EXPRESSION OF A CDNA-ENCODING BETA-ALANINE SYNTHASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; PYRIMIDINE CATABOLISM; PROTEINS; ENZYMES; DNA; PURIFICATION; BINDING; THYMINE; URACIL; ASSAY	A cDNA for beta-alanine synthase from rat liver has been isolated, sequenced, and characterized. Beta-alanine synthase clones were isolated from rat liver cDNA libraries in lambdagt11, using affinity-purified polyclonal antibodies against beta-alanine synthase protein. Beta-alanine synthase protein was not expressed with equal efficiency by all clones. One of the expressed fusion proteins has normal specific enzyme activity, and a second has reduced specific activity. Both clones were completely sequenced and yielded identical DNA sequence, except that one clone contained an additional 36 bases of 5' sequence. The various clones of this cDNA code for an EcoRI insert of 1.5 +/- 0.1 kb, and the open reading frame corresponds to a protein of 393 amino acids (M(r) = 44,042), in good agreement with the M(r) of approximately 42,000 for the native enzyme on SDS-gel electrophoresis. An 11-amino acid sequence was obtained from a tryptic peptide of native beta-alanine synthase; 11 codons for these same amino acids were found at the expected site in the sequenced cDNA, and confirm the open reading frame of the beta-alanine synthase cDNA. Chemical analysis of the native enzyme shows 2 zinc atoms per subunit, and the sequence of beta-alanine synthase contains 2 putative zinc-binding site motifs. Comparison of amino acid sequence, deduced from the cDNA sequence, to sequences in the protein data base showed that it is a unique sequence and that it has about 20% identity to aspartate carbamoyltransferase, ornithine carbamoyltransferase, urease, and leucine aminopeptidase; enzymes that bind comparable ligands or have a similar mechanism.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			kvalnes, kalla/F-9380-2013; mo, qin/O-7877-2014					AULD DS, 1988, METHOD ENZYMOL, V158, P13, DOI 10.1016/0076-6879(88)58043-6; BAKKEREN JAJM, 1984, CLIN CHIM ACTA, V140, P247, DOI 10.1016/0009-8981(84)90206-7; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BRAAKHEKKE JP, 1987, J NEUROL SCI, V78, P71, DOI 10.1016/0022-510X(87)90079-7; CHOQUET D, 1988, NEUROSCI LETT, V84, P329, DOI 10.1016/0304-3940(88)90530-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P7; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE SH, 1987, YEAST, V3, P63, DOI 10.1002/yea.320030202; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MATTHEWS MM, 1987, J BIOL CHEM, V262, P7232; MATTHEWS MM, 1992, ARCH BIOCHEM BIOPHYS, V293, P254, DOI 10.1016/0003-9861(92)90393-B; Miller J.H., 1972, EXPT MOL GENETICS; NAGUIB FNM, 1985, CANCER RES, V45, P5405; ORENSANZ LM, 1988, NEUROCHEM RES, V13, P1133, DOI 10.1007/BF00971630; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZHERRANZ A, 1985, HORM METAB RES, V17, P588, DOI 10.1055/s-2007-1013613; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCRIVER CS, 1983, METABOLIC BASIS INHE, P570; SMITH DP, 1990, BIOTECHNIQUES, V9, P50; TAMAKI N, 1987, EUR J BIOCHEM, V169, P21, DOI 10.1111/j.1432-1033.1987.tb13575.x; TOGGENBURGER G, 1982, J NEUROCHEM, V39, P176, DOI 10.1111/j.1471-4159.1982.tb04716.x; TRAUT TW, 1984, BIOCHEMISTRY-US, V23, P2533, DOI 10.1021/bi00306a033; TREMBLAY N, 1988, NEUROSCIENCE, V26, P745, DOI 10.1016/0306-4522(88)90096-6; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; UENO S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P233; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VEILLON C, 1987, METHOD ENZYMOL, V54, P446; Wadman S K, 1984, Adv Exp Med Biol, V165 Pt A, P109; WADMAN SK, 1985, J INHERIT METAB DIS, V8, P113, DOI 10.1007/BF01811484; WILCKEN B, 1985, J INHERIT METAB DIS, V8, P115, DOI 10.1007/BF01811485; YUEN SW, 1989, PROTEIN SEQUENCES US, V38; 1991, PROMEGA PROTOCOLS AP, P227	40	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5686	5693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449931				2022-12-25	WOS:A1993KR82200050
J	RACCHI, M; WATZKE, HH; HIGH, KA; LIVELY, MO				RACCHI, M; WATZKE, HH; HIGH, KA; LIVELY, MO			HUMAN COAGULATION FACTOR-X DEFICIENCY CAUSED BY A MUTANT SIGNAL PEPTIDE THAT BLOCKS CLEAVAGE BY SIGNAL PEPTIDASE BUT NOT TARGETING AND TRANSLOCATION TO THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION; NASCENT PREPROLACTIN; RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; FACTOR-IX; SEQUENCE; SITE; GENE; PURIFICATION; POLYPEPTIDE	Human factor X(Santo Domingo) is a form of coagulation factor X in which a mutation within the signal peptide region of the precursor protein has been correlated genetically with a severe deficiency of factor X in the affected individual. A point mutation results in substitution of Arg for Gly at the critical -3 position of the factor X signal peptide. To determine the biochemical effect of this mutation on the biosynthesis of factor X, the wild-type and mutant factor X cDNAs were subcloned into a vector for transcription and translation in vitro. Translation products of mRNAs encoding portions of both mutant and wild-type proteins were used in a systematic biochemical approach to evaluate directly the effect of the mutation on targeting, transport, and proteolytic processing in vitro. The results show that targeting and transport of factor X(Santo Domingo) to the endoplasmic reticulum are functionally dissociated from the removal of the signal peptide by signal peptidase. Factor X(Santo Domingo) is translocated into the endoplasmic reticulum but not processed by signal peptidase. Transient expression of the wild-type and mutant factor X in human embryonic kidney 293 cells revealed apparently normal secretion of the glycosylated two-chain form of factor X but no secretion of factor X(Santo Domingo). Thus, the inability of signal peptidase to cleave factor X(Santo Domingo) is directly responsible for the absence of circulating factor X and leads to the bleeding diathesis in the affected individual.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	Wake Forest University; Wake Forest Baptist Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			High, Katherine A./AAB-9322-2020; Racchi, Marco/G-6104-2018	Racchi, Marco/0000-0002-7185-7808	NHLBI NIH HHS [HL06350, HL48322] Funding Source: Medline; NIGMS NIH HHS [GM32861] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032861] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLF GR, 1990, J BIOL CHEM, V265, P9290; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLANCHARD RA, 1985, BLOOD S, V66, pA331; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRENNAN SO, 1990, P NATL ACAD SCI USA, V87, P26, DOI 10.1073/pnas.87.1.26; DALY M, 1990, FEBS LETT, V273, P87, DOI 10.1016/0014-5793(90)81057-U; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; JACKSON RC, 1983, METHOD ENZYMOL, V96, P784; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P21797; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; STANTON C, 1992, BIOCHEM J, V284, P25, DOI 10.1042/bj2840025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISVIKIS S, 1990, HUM GENET, V84, P373; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATZKE HH, 1991, J CLIN INVEST, V88, P1685, DOI 10.1172/JCI115484; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	33	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5735	5740						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449937				2022-12-25	WOS:A1993KR82200057
J	PICHER, M; COTE, YP; BELIVEAU, R; POTIER, M; BEAUDOIN, AR				PICHER, M; COTE, YP; BELIVEAU, R; POTIER, M; BEAUDOIN, AR			DEMONSTRATION OF A NOVEL TYPE OF ATP-DIPHOSPHOHYDROLASE (EC-3.6.1.5) IN THE BOVINE LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ADENOSINE DIPHOSPHATASE; ADENINE-NUCLEOTIDES; PULMONARY CIRCULATION; PLATELET-AGGREGATION; RHODNIUS-PROLIXUS; ENDOTHELIAL-CELLS; DIABETES-MELLITUS; PURIFICATION; APYRASE	A novel type of ATP-diphosphohydrolase (ATPDase) is demonstrated in bovine lung. The enzyme has an optimum pH of 7.5 and catalyzes the hydrolysis of the beta- and gamma-phosphate residues from diphospho- and triphosphonucleosides. It requires Ca2+ or Mg2+ and is insensitive to ouabain, an inhibitor of Na+/K+-ATPase, P1,P5-di(adenosine 5')-pentaphosphate, an inhibitor of adenylate kinase, and tetramisole, an inhibitor of alkaline phosphatase. In contrast, sodium azide (10 mM), a known inhibitor of ATPDases and mitochondrial ATPases, as well as mercuric chloride (10 muM) and gossypol (2,2'-bis[8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]) (35 muM) are powerful inhibitors of this enzyme. The same inhibition profile is obtained with ATP or ADP as substrate, thereby supporting the concept of a common catalytic site for these substrates. This is further confirmed by enzyme localization after polyacrylamide gel electrophoresis under nondenaturing conditions and by kinetic properties, namely pH dependence profiles, heat inactivation, and Co-60 irradiation-inactivation curves. The native molecular mass of the enzyme calculated from Co-60 gamma-irradiation-inactivation curves is estimated at 70 +/- 3 kDa, whereas K(m,app) and V(max,app) of the ATPDase are evaluated at 7 +/- 2 muM and 1.1 +/- 0.3 mumol of P(i)/min/mg protein, respectively. A comparison of the kinetic properties of this ATPDase with those of pig pancreas (Type I) and bovine aorta (Type II) lead us to believe that this enzyme is an hitherto undescribed type of ATPDase. By reference to the previously described ATPDase, we propose to identify this enzyme as ATPDase Type III (EC 3.6.1.5).	UNIV SHERBROOKE,FAC SCI,DEPT BIOL,SHERBROOKE J1K 2R1,QUEBEC,CANADA; UNIV QUEBEC,DEPT CHIM,MONTREAL H3C 3P8,QUEBEC,CANADA; HOP ST JUSTINE,GENET MED SECT,MONTREAL H3T 1C5,QUEBEC,CANADA	University of Sherbrooke; University of Quebec; University of Quebec Montreal; Universite de Montreal								ASTER RH, 1964, J CLIN INVEST, V43, P843, DOI 10.1172/JCI104970; BAKHLE YS, 1983, DIABETOLOGIA, V24, P455; BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P349, DOI 10.1016/0033-0620(88)90003-5; BERN MM, 1978, DIABETES, V27, P342, DOI 10.2337/diab.27.3.342; BINET L, 1950, PRESSE MED, V53, P1201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P443; CHELLIAH R, 1983, Q J EXP PHYSIOL CMS, V68, P289, DOI 10.1113/expphysiol.1983.sp002724; COLEMAN RW, 1990, FASEB J, V4, P1425; COTE YP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P187, DOI 10.1016/0167-4838(91)99008-G; COTE YP, 1992, BIOCHIM BIOPHYS ACTA, V1139, P133, DOI 10.1016/0925-4439(92)90092-2; COTE YP, 1992, IN PRESS BIOCH BIOPH; CURDOVA E, 1982, FOLIA MICROBIOL, V27, P159, DOI 10.1007/BF02877394; CUSACK NJ, 1983, BIOCHEM J, V214, P975, DOI 10.1042/bj2140975; DAWSON JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P566, DOI 10.1016/0005-2736(86)90148-3; Dixon M., 1979, ENZYMES, Vthird; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; GORDON EL, 1989, J BIOL CHEM, V264, P18986; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAMLYN JM, 1983, BIOCHEM J, V214, P59, DOI 10.1042/bj2140059; HASLAM RJ, 1981, RECEPTORS RECOGNIT B, V12, P223; JOHNSON M, 1979, THROMB HAEMOSTASIS, V45, P333; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; Kalckar HM, 1944, J BIOL CHEM, V153, P355; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; KEPNER GR, 1968, BIOCHIM BIOPHYS ACTA, V163, P188, DOI 10.1016/0005-2736(68)90097-7; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; KNOWLES AF, 1983, BIOCHIM BIOPHYS ACTA, V731, P88, DOI 10.1016/0005-2736(83)90401-7; KRISHNAN PS, 1951, ARCH BIOCHEM BIOPHYS, V32, P230, DOI 10.1016/0003-9861(51)90265-2; KRISHNAN PS, 1949, ARCH BIOCHEM, V20, P272; KRISHNAN PS, 1949, ARCH BIOCHEM, V20, P261; LAGARDE M, 1980, THROMB RES, V19, P823, DOI 10.1016/0049-3848(80)90010-9; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; LEAKE DS, 1983, BIOCHIM BIOPHYS ACTA, V762, P52, DOI 10.1016/0167-4889(83)90116-7; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LEBEL D, 1980, J BIOL CHEM, V255, P1227; LIEBERMAN GE, 1982, THROMB HAEMOSTASIS, V47, P249; MAGOCSI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P163, DOI 10.1016/0005-2736(91)90159-6; MANT MJ, 1981, BRIT J HAEMATOL, V48, P601, DOI 10.1111/j.1365-2141.1981.00601.x; MAZELIS M, 1959, PLANT PHYSIOL, V34, P153, DOI 10.1104/pp.34.2.153; MEYERHOF O, 1945, J BIOL CHEM, V157, P105; MIURA Y, 1987, THROMB RES, V45, P201; NISHIKAWA AH, 1966, THESIS OREGON STATE; PAPAMARCAKI T, 1990, MOL CELL BIOCHEM, V97, P1; PEARSON JD, 1985, ANNU REV PHYSIOL, V47, P617, DOI 10.1146/annurev.ph.47.030185.003153; PEARSON JD, 1980, BIOCHEM J, V190, P421, DOI 10.1042/bj1900421; PEARSON JD, 1985, BIOCHEM J, V230, P503, DOI 10.1042/bj2300503; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; RIBEIRO JMC, 1980, J INSECT PHYSIOL, V26, P303, DOI 10.1016/0022-1910(80)90138-9; RIBEIRO JMC, 1984, J EXP BIOL, V108, P1; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; RIBEIRO JMC, 1979, AN ACAD BRAS CIENC, V51, P182; Ryan J W, 1971, Trans Assoc Am Physicians, V84, P297; SMITH JJB, 1980, EXPERIENTIA, V36, P898, DOI 10.1007/BF01953780; TOGNOLI L, 1981, BIOCHIM BIOPHYS ACTA, V642, P1, DOI 10.1016/0005-2736(81)90132-2; TRAVERSO.A, 1965, ARCH BIOCHEM BIOPHYS, V109, P173, DOI 10.1016/0003-9861(65)90303-6; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; VARA F, 1981, BIOCHEM J, V197, P637, DOI 10.1042/bj1970637; WHICHMANN K, 1983, J REPROD FERTIL, V69, P259; YAGI K, 1989, EUR J BIOCHEM, V180, P509, DOI 10.1111/j.1432-1033.1989.tb14675.x; YAGI K, 1991, BIOCHEM BIOPH RES CO, V180, P1200, DOI 10.1016/S0006-291X(05)81323-3; [No title captured]	62	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4699	4703						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444844				2022-12-25	WOS:A1993KP88400024
J	POON, D; KNITTLE, RA; SABELKO, KA; YAMAMOTO, T; HORIKOSHI, M; ROEDER, RG; WEIL, PA				POON, D; KNITTLE, RA; SABELKO, KA; YAMAMOTO, T; HORIKOSHI, M; ROEDER, RG; WEIL, PA			GENETIC AND BIOCHEMICAL ANALYSES OF YEAST TATA-BINDING PROTEIN MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION-FACTOR; MAJOR LATE PROMOTER; WHOLE-CELL EXTRACT; HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; CONSERVED DOMAIN	We have taken a combined genetic and biochemical approach to study TATA-binding protein (TBP) structure-function relationships. Using site-directed mutagenesis coupled with a screen for conditional lethal growth, we have isolated a number of temperature-sensitive TBP alleles in the region of amino acid positions 188, 189, and 190. Conditional growth is not a result of increased TBP turnover as most of the mutant proteins are stable in vivo as evidenced by immunoblot detection of TBP steady-state levels. DNA binding assays reveal that mutations at position 188 do not affect DNA binding activity of these mutants, even at high temperatures. Utilizing whole cell extracts which contain mutant TBPs in in vitro transcription experiments, we confirm that TBP is required for transcription by all three nuclear polymerases. However, certain of our TBP mutants are only compromised for RNA polymerase II transcription.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	Vanderbilt University; Rockefeller University; University of Tokyo			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				[Anonymous], 1991, Methods Enzymol, V194, P1; ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KLOESKE AJ, 1992, CELL, V69, P883; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3331; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG CK, 1989, J BIOL CHEM, V264, P1092; Weinmann Roberto, 1992, Gene Expression, V2, P81; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	77	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5005	5013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444878				2022-12-25	WOS:A1993KP88400067
J	WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG				WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG			SEVERELY DECREASED MARCK EXPRESSION CORRELATES WITH RAS-REVERSION BUT NOT WITH MITOGENIC RESPONSIVENESS	ONCOGENE			English	Article							PROTEIN-KINASE-C; MAJOR SPECIFIC SUBSTRATE; TRANSFORMED-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PHOSPHOINOSITIDE HYDROLYSIS; CELLULAR SUBSTRATE; FLAT REVERTANTS; GROWTH-FACTOR; BOVINE BRAIN; GENE-PRODUCT	Phorbol ester-inducible phosphorylation of MARCKS, the '80-kDa' substrate of protein kinase C, was undetectable in several phenotypically dominant, non-transformed revertants independently derived from the ras-transformed cell line NIH3T3 DT-ras. Extremely low expression of MARCKS protein accounted for this apparent lack of phosphorylation. MARCKS-encoding mRNA levels were correspondingly decreased relative to normal and ras-transformed cells in all four ras revertant cell lines studied: C-11 and F-2, derived by 5-azacytidine treatment and selection with ouabain; CHP 9CJ, derived by ethytmethane sulfonate mutagenesis and selection with cis-hydroxy-L-proline; and 12-V3, derived by transfection with the human Krev-1 gene. However, re-expression of MARCKS after transfection of a cloned MARCKS cDNA into the C-11 ras revertant cells was not sufficient to induce retransformation. In fact, no significant difference in sensitivity to mitogenic stimulation by phorbol esters was observed among several cell lines expressing widely varying levels of MARCKS. This evidence argues against a direct role for MARCKS in mitogenic signaling. However, the strong correlation between attentuation of MARCKS expression and phenotypically dominant ras reversion suggests that a common negative regulatory mechanism might be responsible for both effects, presenting a potentially useful strategy for identifying factors involved in transducing the ras signal.	UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710	University of Vermont; Duke University; Howard Hughes Medical Institute			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NCI NIH HHS [CA-43551] Funding Source: Medline; NIEHS NIH HHS [ES 01247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P61; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAMATA T, 1987, ONCOGENE, V1, P37; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MORRIS JDH, 1989, ONCOGENE, V4, P27; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PIZON V, 1988, ONCOGENE, V3, P201; ROSEN A, 1989, J BIOL CHEM, V264, P9118; Sambrook J, 1989, MOL CLONING LABORATO; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	38	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					755	760						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437859				2022-12-25	WOS:A1993KN00800028
J	LEUNG, T; HOW, BE; MANSER, E; LIM, L				LEUNG, T; HOW, BE; MANSER, E; LIM, L			GERM-CELL BETA-CHIMAERIN, A NEW GTPASE-ACTIVATING PROTEIN FOR P21RAC, IS SPECIFICALLY EXPRESSED DURING THE ACROSOMAL ASSEMBLY STAGE IN RAT TESTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHORBOL ESTER BINDING; KINASE-C; N-CHIMAERIN; GENE; SEQUENCE; MEMBRANE; PRODUCT; ENCODES; DOMAIN; YEAST	Diverse GTPase-activating proteins (GAPs) for the p21rho subfamily were detected by a novel overlay assay (Manser, E., Leung, T., Monfries, C., Teo, M., Hall, C., and Lim, L. (1992) J. Biol. Chem. 267, 16025-16028), with some GAPs being tissue-specific. Using a PCR strategy exploiting conserved regions common to rho/rac-GAPs, we have isolated a rat testis cDNA encoding a 34-kDa rac-GAP termed beta-chimaerin, as it was highly related to n-chimaerin, containing both a GAP domain (77% identity) and the phorbol ester-binding region (93% identity). Beta-chimaerin mRNA is expressed exclusively in the testis at the onset of sexual maturation. In situ hybridization and cell fractionation analyses show beta-chimaerin mRNA expression to be stage-specific, paralleling acrosomal assembly at the late stage of spermatogenesis. A corresponding testis-specific 30-kDa rac-GAP was detected. The testis-specific and stage-dependent expression of this new member of the chimaerin family offer an alternative model system for investigating the functional role of this class of p21 GAPs, particularly in relation to cytoskeletal reorganization.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	LEUNG, T (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERNSTEIN G, 1992, CELL, V70, P411; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARRETT MD, 1989, J BIOL CHEM, V260, P10; GEORGE JM, 1992, MOL BRAIN RES, V12, P323, DOI 10.1016/0169-328X(92)90134-W; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; LEUNG TKC, 1987, J NEUROCHEM, V49, P232, DOI 10.1111/j.1471-4159.1987.tb03420.x; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; MANSER E, 1992, J BIOL CHEM, V267, P16025; MORALES CR, 1989, MOL ENDOCRINOL, V3, P725, DOI 10.1210/mend-3-4-725; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Perry B, 1961, AM J ANAT, V108, P47; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V670, P387; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHERRIF A, 1992, SCIENCE, V256, P248; TILNEY LG, 1978, J CELL BIOL, V77, P536, DOI 10.1083/jcb.77.2.536	30	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3813	3816						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440677				2022-12-25	WOS:A1993KN53300005
J	YU, J; MCLAUGHLIN, S; FREEDMAN, RB; HIRST, TR				YU, J; MCLAUGHLIN, S; FREEDMAN, RB; HIRST, TR			CLONING AND ACTIVE-SITE MUTAGENESIS OF VIBRIO-CHOLERAE DSBA, A PERIPLASMIC ENZYME THAT CATALYZES DISULFIDE BOND FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI THIOREDOXIN; RIBONUCLEASE-A; REDOX BUFFER; B-SUBUNIT; ISOMERASE; PROTEINS; IDENTIFICATION; ISOMERIZATION; SUBSTITUTION	Recently, a gene (dsbA) involved in the biogenesis of secreted oligomeric enterotoxins in Vibrio cholerae was described, which encodes an exported protein possessing a -Cys-Pro-His-Cys- motif similar to that found in the active sites of eukaryotic and prokaryotic thioldisulfide oxidoreductases (Yu, J., Webb, H., and Hirst, T. R (1992) Mol. Microbiol. 6, 1949-1958). Here, we report the cloning of the dsbA gene of V. cholerae and the demonstration that the encoded periplasmic enzyme has disulfide isomerase-like activity. Oligonucleotide-directed mutagenesis of either of the 2 Cys residues to Ala in the putative active site of DsbA abolished both its isomerase activity and its capacity to promote enterotoxin biogenesis. We conclude that the Cys residues constitute the active site domain of DsbA and are essential for its activity in vivo and in vitro.	UNIV KENT, BIOL LAB, CANTERBURY CT2 7NJ, KENT, ENGLAND	University of Kent				McLaughlin, Stephen/0000-0001-9135-6253	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARTH PT, 1988, BIOCHEM SOC T, V16, P57, DOI 10.1042/bst0160057; BLACKBURN EC, 1991, THESIS U KENT CANTER; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Sambrook J, 1989, MOL CLONING LABORATO; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SVENNERHOLM AM, 1978, CURR MICROBIOL, V1, P19, DOI 10.1007/BF02601701; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; VUORI K, 1992, J BIOL CHEM, V267, P7211; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x	38	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4326	4330						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440717				2022-12-25	WOS:A1993KN53300075
J	BERRYMAN, DE; BENSADOUN, A				BERRYMAN, DE; BENSADOUN, A			SITE-DIRECTED MUTAGENESIS OF A PUTATIVE HEPARIN BINDING DOMAIN OF AVIAN LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCANS; CULTURED ADIPOCYTES; CDNA SEQUENCE; BOVINE MILK; DEGRADATION; INACTIVATION; SECRETION; DECREASES	Lipoprotein lipase (LPL) binds to heparin and heparan sulfate proteoglycans. We have employed site-directed mutagenesis to dissect one of the proposed heparin binding domains of avian LPL, which contains the sequence Arg-Lys-Asn-Arg (amino acids 281-284). Various single, double, and triple mutants of chicken LPL were constructed in order to alter the positive charge of this region. The mutant and wild-type cDNAs were subcloned into an expression vector, pRc/CMV, and expressed in Chinese hamster ovary cells. In general, the LPL mutants with a decrease in regional positive charge showed a decrease in affinity for heparin and heparan sulfate proteoglycans. The greatest effect was seen with the triple mutant, LPL 5G, in which all of the positively charged amino acids were altered to neutral residues. On a heparin-Sepharose column, LPL 5G eluted at 0.96 M NaCl compared with 1.35 M for wild-type LPL. This mutant also had the lowest specific activity with 1.5 mueq fatty acid/mug/h for the cell-associated pool and with no detectable activity in the media. Wild-type cells, however, produced a lipase with a specific activity of 12.4 and 13.1 mueq fatty acid/mug/h for cell-associated and media lipase pools, respectively. LPL 5G also showed a decrease in affinity for the heparan sulfate proteoglycans on the cell surface of Chinese hamster ovary cells. In conclusion, the region of avian LPL between Arg281 and Arg284 does appear to be involved in heparin-binding; however, additional regions must be involved since binding was not completely abolished. In addition, specific activity of the cell-associated and secreted LPL is correlated to affinity of the enzyme for heparan sulfate chains.	CORNELL UNIV,DIV NUTR SCI,321 SAVAGE HALL,ITHACA,NY 14853; CORNELL UNIV,DIV BIOL SCI,ITHACA,NY 14853	Cornell University; Cornell University				Berryman, Darlene/0000-0003-4240-9229	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSON G, 1977, BIOCHEM J, V167, P109, DOI 10.1042/bj1670109; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CISAR LA, 1989, J BIOL CHEM, V264, P1767; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; CUPP M, 1987, J BIOL CHEM, V262, P6383; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EGELRUD T, 1973, BIOCHIM BIOPHYS ACTA, V296, P124, DOI 10.1016/0005-2760(73)90051-9; EMI M, 1990, J BIOL CHEM, V265, P5910; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; KOMPIANG IP, 1976, J LIPID RES, V17, P498; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLIVECRONA T, 1977, FED PROC, V36, P60; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1992, J LIPID RES, V33, P1165; ROBINSON DS, 1987, LIPOPROTEIN LIPASE, P1; ROJAS C, 1990, BIOCHEM J, V271, P11, DOI 10.1042/bj2710011; Sambrook J, 1989, MOL CLONING LABORATO; WANG CS, 1992, BIOCHIM BIOPHYS ACTA, V1123, P1, DOI 10.1016/0005-2760(92)90165-R	31	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3272	3276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429005				2022-12-25	WOS:A1993KM16100041
J	DEB, S; HAMLIN, GP; ROBY, KF; KWOK, SCM; SOARES, MJ				DEB, S; HAMLIN, GP; ROBY, KF; KWOK, SCM; SOARES, MJ			HETEROLOGOUS EXPRESSION AND CHARACTERIZATION OF PROLACTIN-LIKE PROTEIN-A - IDENTIFICATION OF SERUM BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; PLACENTAL LACTOGEN-I; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; RAT TROPHOBLAST CELLS; ADIPOSE CONVERSION; ANTIPEPTIDE ANTIBODIES; 3T3 CELLS; MOLECULAR-CLONING; RECEPTOR; FAMILY	In this report, we describe the heterologous expression of prolactin-like protein-A (PLP-A) in Chinese hamster ovary (CHO) cells, the characterization of recombinant PLP-A, and the identification of serum PLP-A-binding proteins. CHO cell and native placental PLP-A showed similar immunoreactive characteristics and electrophoretic mobilities. N-terminal sequencing verified the identity and purity of the recombinant PLP-A species and the site of cleavage of the signal peptide from the mature secreted PLP-A species. Recombinant PLP-A lacked activity in standardized prolactin and growth hormone in vitro bioassays. Antibodies generated to recombinant PLP-A facilitated the cellular localization of PLP-A and the identification of high molecular weight PLP-A complexes. Cross-linking analyses of radioiodinated PLP-A with serum harvested from late gestation rats indicated the presence of two major cross-linked complexes migrating under reducing conditions at 130 and 250 kDa and two minor cross-linked complexes migrating at 70 and 110 kDa. Binding of PLP-A to serum proteins was specific for PLP-A and not effectively competed by other members of the prolactin/growth hormone family. The PLP-A binding species were also found in serum from non-pregnant female and male rats.	UNIV KANSAS,MED CTR,DEPT PHYSIOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT BIOCHEM,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center				Kwok, Simon/0000-0001-6003-5350	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029036] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20676, HD-07502, HD-29036] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BAUMBACH WR, 1989, GENE DEV, V3, P199; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOTHWELL A, 1990, METHODS CLONING GENE, P145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WJ, 1989, ENDOCRINOLOGY, V125, P1565, DOI 10.1210/endo-125-3-1565; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; COLOSI P, 1988, ENDOCRINOLOGY, V123, P2662, DOI 10.1210/endo-123-6-2662; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEB S, 1991, ENDOCRINOLOGY, V128, P3066, DOI 10.1210/endo-128-6-3066; DEB S, 1989, J BIOL CHEM, V264, P14348; DEB S, 1990, MOL CELL ENDOCRINOL, V74, P163, DOI 10.1016/0303-7207(90)90118-R; DEB S, 1991, J BIOL CHEM, V266, P23027; DEB S, 1991, J BIOL CHEM, V266, P1605; DEB S, 1989, MOL CELL ENDOCRINOL, V63, P45, DOI 10.1016/0303-7207(89)90080-4; DJIAN P, 1985, J CELL PHYSIOL, V124, P554, DOI 10.1002/jcp.1041240327; DUCKWORTH ML, 1986, J BIOL CHEM, V261, P879; GOUT PW, 1980, CANCER RES, V40, P2433; HUNT JS, 1988, PLACENTA, V9, P159, DOI 10.1016/0143-4004(88)90014-8; LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORIKAWA M, 1984, MOL CELL BIOL, V4, P228, DOI 10.1128/MCB.4.2.228; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; ROBERTSON MC, 1990, ENDOCRINOLOGY, V127, P702, DOI 10.1210/endo-127-2-702; ROBY KF, 1991, MOL CELL ENDOCRINOL, V79, P13, DOI 10.1016/0303-7207(91)90090-F; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; Sambrook J, 1989, MOL CLONING LABORATO; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOARES MJ, 1988, J ENDOCRINOL, V116, P101, DOI 10.1677/joe.0.1160101; SOARES MJ, 1987, J REPROD FERTIL, V79, P335, DOI 10.1530/jrf.0.0790335; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SOUTHARD JN, 1991, MOL CELL ENDOCRINOL, V79, pC133, DOI 10.1016/0303-7207(91)90084-6; SOUTHARD JN, 1989, ENDOCRINOLOGY, V125, P791, DOI 10.1210/endo-125-2-791; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; WISE LS, 1979, J BIOL CHEM, V254, P273	43	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3298	3305						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429006				2022-12-25	WOS:A1993KM16100045
J	KROLL, MH; HELLUMS, JD; GUO, ZZ; DURANTE, W; RAZDAN, K; HRBOLICH, JK; SCHAFER, AI				KROLL, MH; HELLUMS, JD; GUO, ZZ; DURANTE, W; RAZDAN, K; HRBOLICH, JK; SCHAFER, AI			PROTEIN-KINASE-C IS ACTIVATED IN PLATELETS SUBJECTED TO PATHOLOGICAL SHEAR-STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; VONWILLEBRAND-FACTOR INTERACTION; MURINE MONOCLONAL-ANTIBODY; INOSITOL TRISPHOSPHATE; GLYCOPROTEIN-IIIA; REGULATORY ROLE; VWF MULTIMERS; PHORBOL ESTER; AGGREGATION; FIBRINOGEN	High levels of fluid shear stress at the blood vessel wall directly stimulate von Willebrand factor (vWF)-mediated platelet adhesion and aggregation and thereby contribute to the pathogenesis of arterial thrombosis. We have found that a pathological level of arterial wall shear stress (90 dynes/cm2) induces platelet aggregation that is associated with the phosphorylation of pleckstrin, a M(r) 47,000 protein kinase C substrate (p47). Shear-induced p47 phosphorylation depends entirely on vWF binding to platelet glycoprotein (Gp) Ib and GpIIb-IIIa, and the specific inhibition of protein kinase C with the staurosporine analogue Ro 31-7549 inhibits the full aggregation response to shear. Shear stress-induced platelet p47 phosphorylation occurs independent of any measurable change in diacylglycerol mass or hydrolysis of phosphatidylinositol 4,5-bisphosphate. These results indicate that mechanical shear stress induces vWF to bind to platelet GpIb and GpIIb-IIIa, stimulating a diacylglycerol-independent pathway of protein kinase C activation that contributes to platelet aggregation in response to shear.	VET AFFAIRS MED CTR,HOUSTON,TX 77001; RICE UNIV,BIOMED ENGN LAB,HOUSTON,TX 77251	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rice University	KROLL, MH (corresponding author), BAYLOR COLL MED,HEMATOL SECT,MS 902,6565 FANNIN,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002311, K08HL002154, R01HL036045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36045, HL02154, HL02311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAXTER G, 1992, J BIOL CHEM, V267, P1910; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P191; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOW TW, 1992, BLOOD, V80, P113; COLLER BS, 1983, BLOOD, V61, P99; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIMOTO E, 1991, INT J BIOCHEM, V23, P507; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; KROLL MH, 1989, BLOOD, V74, P1181; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MOAKE JL, 1988, BLOOD, V71, P1366; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIEN JR, 1990, LANCET, V335, P711, DOI 10.1016/0140-6736(90)90815-M; PHILLIPS MD, 1988, BLOOD, V72, P1898; PRIESS J, 1986, J BIOL CHEM, V261, P8597; ROTH GJ, 1991, BLOOD, V77, P5; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; VANWILLIGEN G, 1991, BIOCHEM J, V273, P115, DOI 10.1042/bj2730115; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WEINSTEIN M, 1991, BLOOD, V78, P2291; WEISS HJ, 1986, J CLIN INVEST, V78, P1072, DOI 10.1172/JCI112663; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WERNER MH, 1991, BLOOD, V78, P435; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; YAMANISHI J, 1983, BIOCHEM BIOPH RES CO, V112, P778, DOI 10.1016/0006-291X(83)91529-2	43	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3520	3524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429027				2022-12-25	WOS:A1993KM16100077
J	COOK, RK; ROOT, D; MILLER, C; REISLER, E; RUBENSTEIN, PA				COOK, RK; ROOT, D; MILLER, C; REISLER, E; RUBENSTEIN, PA			ENHANCED STIMULATION OF MYOSIN SUBFRAGMENT-1 ATPASE ACTIVITY BY ADDITION OF NEGATIVELY CHARGED RESIDUES TO THE YEAST ACTIN NH2 TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALI LIGHT-CHAINS; NON-MUSCLE CELLS; SACCHAROMYCES-CEREVISIAE; SLIDING MOVEMENT; DICTYOSTELIUM-DISCOIDEUM; CYTOPLASMIC MYOSINS; IONIC-STRENGTH; AMINO TERMINUS; BINDING SITES; CROSS-LINKING	We examined the effects of yeast actin NH2-terminal mutations on actomyosin interactions and the function of actin in vivo through measurements of actin-activated ATPase activity, cosedimentation with rabbit muscle myosin subfragment 1 (S-1), in vitro motility, and invertase secretion assays. As reported earlier (Cook, R. K., Blake, W., and Rubenstein, P. A. (1992) J. Biol. Chem. 267, 9430-9436), elimination of NH2-terminal acidic residues from yeast actin results in an increased actin bundling, decreased actin-activated S1 ATPase, and complete inhibition of actin filament sliding over myosin. Here we show that the addition of 2 new acidic residues to the NH2 terminus of yeast actin increased the V(max) value and the catalytic efficiency of the actin-activated ATPase activity of S-1. However, the binding of actin to S-1 in the presence of ATP and the velocities of actin sliding over myosin in the in vitro motility assays were not affected by this mutation. Thus, the number of actin NH2-terminal negative charges is important for actin activation of myosin S-1 ATPase activity, while only a minimum number of acidic residues is required for actin sliding over myosin in vitro. The number of actin NH2-terminal negative charges therefore appears to determine the efficiency with which the energy from ATP hydrolysis is converted to filament sliding.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	COOK, RK (corresponding author), UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA.			Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR022031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 22031, R01 AR022031] Funding Source: Medline; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASPENSTROM P, 1992, FEBS LETT, V303, P59, DOI 10.1016/0014-5793(92)80477-X; ASPENSTROM P, 1991, EUR J BIOCHEM, V200, P35, DOI 10.1111/j.1432-1033.1991.tb21045.x; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; Cantor C., 1980, BIOPHYSICAL CHEM 3, P892; CHALOVICH JM, 1984, BIOCHEMISTRY-US, V23, P4885, DOI 10.1021/bi00316a011; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1991, J BIOL CHEM, V266, P16825; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; DASGUPTA G, 1991, BIOCHEMISTRY-US, V30, P9961, DOI 10.1021/bi00105a021; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; DOI Y, 1987, EUR J BIOCHEM, V164, P89, DOI 10.1111/j.1432-1033.1987.tb10997.x; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; Goldstein A, 1975, Methods Enzymol, V42, P504; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MILLER L, 1987, BIOCHEMISTRY-US, V26, P6064, DOI 10.1021/bi00393a018; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POPE B, 1981, EUR J BIOCHEM, V117, P201; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; RADIKA K, 1984, ANAL BIOCHEM, V141, P413, DOI 10.1016/0003-2697(84)90063-0; REDMAN K, 1981, J BIOL CHEM, V256, P3226; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P711; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	47	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2410	2415						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428914				2022-12-25	WOS:A1993KK81500027
J	KEETON, TP; BURK, SE; SHULL, GE				KEETON, TP; BURK, SE; SHULL, GE			ALTERNATIVE SPLICING OF EXONS ENCODING THE CALMODULIN-BINDING DOMAINS AND C-TERMINI OF PLASMA-MEMBRANE CA2+-ATPASE ISOFORM-1, ISOFORM-2, ISOFORM-3, AND ISOFORM-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP ISOFORMS; CA-2+ PUMP; MOLECULAR-CLONING; CA-2+-ATPASE GENE; SKELETAL-MUSCLE; SMOOTH-MUSCLE; EXPRESSION; SEQUENCE; ATPASE; KIDNEY	Rat plasma membrane Ca2+-ATPase (PMCA) mRNAs were examined by S1 nuclease protection (isoform 1) and polymerase chain reaction (isoforms 1, 2, 3, and 4) and the corresponding genes were analyzed to determine the tissue-specific splicing patterns involving exons encoding the calmodulin-binding domains and C termini. Splicing of PMCA1 involves a single 154-nucleotide exon that can be either included or excluded; when the exon is included four different splice donor sites, at positions 87, 114, 152, and 154, can be utilized. PMCA2 mRNAs are generated either by the inclusion of a 172-nucleotide exon, by the inclusion of both the 172-nucleotide exon and a 55-nucleotide exon, or by the exclusion of both exons. Four PMCA3 mRNAs arise by alternative splicing of a 154-nucleotide exon, in patterns that are analogous to those of PMCA1, and additional mRNAs are generated by the inclusion of a 68-nucleotide exon immediately before the 154-nucleotide exon. The simplest splicing pattern occurs in PMCA4, where a single 175-nucleotide exon is either included or excluded. The alternative mRNAs for each of the four genes are expressed in a tissue-specific manner and encode enzyme variants with different combinations of calmodulin-binding domains and C termini.			KEETON, TP (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.				NHLBI NIH HHS [HL41558] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041558] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; DEJAEGERE S, 1990, BIOCHEM J, V271, P655, DOI 10.1042/bj2710655; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; GREEB J, 1989, J BIOL CHEM, V264, P18569; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; KHAN I, 1991, BIOCHEM J, V277, P345, DOI 10.1042/bj2770345; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	24	149	156	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2740	2748						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428948				2022-12-25	WOS:A1993KK81500072
J	NARUO, K; SEKO, C; KUROSHIMA, K; MATSUTANI, E; SASADA, R; KONDO, T; KUROKAWA, T				NARUO, K; SEKO, C; KUROSHIMA, K; MATSUTANI, E; SASADA, R; KONDO, T; KUROKAWA, T			NOVEL SECRETORY HEPARIN-BINDING FACTORS FROM HUMAN GLIOMA-CELLS (GLIA-ACTIVATING FACTORS) INVOLVED IN GLIAL-CELL GROWTH - PURIFICATION AND BIOLOGICAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; OLIGODENDROCYTE DEVELOPMENT; COMMON PROGENITOR; MATURATION FACTOR; BRAIN; TRANSFORMATION; INVITRO; INTERLEUKIN-1; PROLIFERATION; STIMULATION	Growth factors for rat primary glial cells were identified in conditioned medium of a human glioma-derived cell line. The factors, designated glia-activating factors (GAFs), were purified to homogeneity by a combination of heparin affinity chromatography, gel filtration, and high performance liquid chromatography on a heparin affinity column and a C4 reversed-phase column. GAFs could be resolved into three peaks by C4 column chromatography. The M(r) values of these three proteins were estimated to be 30,000, 29,000, and 25,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. These M(r) values were in good agreement with the value of 26,000 +/- 3,000 estimated from the elution volume upon gel filtration chromatography under nondenaturing conditions. These data suggested that each of the GAFs consists of a single polypeptide chain and has no subunit structures. These three purified GAFs had almost the same growth-stimulating effect on glial cells in vitro, and the half-maximal dose was around 10(-11) M. Concanavalin A staining and glycopeptide N-glycosidase treatment of GAFs indicated that an asparagine-linked oligosaccharide chain(s) was attached to these three kinds of GAFs. Microsequencing of each GAF revealed a single amino-terminal sequence with no significant homology to any known protein, and the amino-terminal sequence of the 30-kDa GAF included that of the 29-kDa GAF. GAFs also stimulated the cell growth of oligodendrocyte type 2 astrocyte progenitor cells, BALB/c3T3 fibroblasts, and PC-12 cells but not that of human umbilical vein endothelial cells.	NATL MED CTR,DEPT NEUROSURG,SHINJUKU KU,TOKYO 162,JAPAN		NARUO, K (corresponding author), TAKEDA CHEM IND LTD,DIV RES & DEV,BIOL RES LABS,YODOGAWA KU,OSAKA 532,JAPAN.							BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BESNARD F, 1987, NEUROSCI LETT, V73, P287, DOI 10.1016/0304-3940(87)90260-6; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; ECCLESTON PA, 1985, DEV BRAIN RES, V21, P315, DOI 10.1016/0165-3806(85)90221-4; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HELDIN CH, 1977, EXP CELL RES, V109, P429, DOI 10.1016/0014-4827(77)90023-4; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KAN M, 1985, IN VITRO CELL DEV B, V21, P181; KATO T, 1981, BRAIN RES, V212, P393, DOI 10.1016/0006-8993(81)90471-6; KATO T, 1984, BRAIN RES, V301, P83, DOI 10.1016/0006-8993(84)90405-0; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDER J, 1986, ASTROCYTES BIOCH PHY, V2, P295; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MANTHORPE M, 1986, ASTROCYTES CELL BIOL, V2, P315; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PRUSS RM, 1982, DEV BRAIN RES, V2, P19; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; SIMPSON DL, 1982, J NEUROSCI RES, V8, P453, DOI 10.1002/jnr.490080233; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0	40	85	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2857	2864						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428960				2022-12-25	WOS:A1993KK81500088
J	JAKUBOWSKI, H				JAKUBOWSKI, H			PROOFREADING AND THE EVOLUTION OF A METHYL DONOR FUNCTION - CYCLIZATION OF METHIONINE TO S-METHYL HOMOCYSTEINE THIOLACTONE BY ESCHERICHIA-COLI METHIONYL-TRANSFER RNA-SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID SYNTHETASE; SACCHAROMYCES-CEREVISIAE; EDITING MECHANISM; PROTEIN-SYNTHESIS; HYDROXY ANALOGS; AMINO-ACIDS; SEQUENCE; DEACYLATION; ISOLEUCINE; VALINE	A cyclic sulfonium compound, S-methyl homocysteine thiolactone (SMHT), is formed from methionine during in vitro tRNA aminoacylation catalyzed by Escherichia coli methionyl-tRNA synthetase. The mechanism of SMHT formation involves enzymatic deacylation of Met-tRNA (k = 0.06 s-1) and, to a lesser extent, Met-AMP (k = 0.02 s-1). Cyclization of methionine, reminiscent of cyclization of homocysteine during editing, illustrates the limited ability of methionyl-tRNA synthetase to discriminate against the cognate methionine at the editing site designed for the noncognate homocysteine. In early stages of biotic evolution, SMHT, a sulfonium compound, may have fulfilled the present day methyl donor function of S-adenosylmethionine. Existing homologies between methionyl-tRNA synthetase and S-adenosylmethionine synthetase indicate evolutionary relatedness of the two proteins.			JAKUBOWSKI, H (corresponding author), UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 	NCRR NIH HHS [2S07RR05393] Funding Source: Medline; NIGMS NIH HHS [GM27711] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027711] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; CANTONI GL, 1953, J BIOL CHEM, V204, P403; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; DEV IK, 1984, J BIOL CHEM, V259, P8402; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ENGLISCHPETERS S, 1990, BIOCHEMISTRY-US, V29, P7953, DOI 10.1021/bi00486a025; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; GHOSH G, 1991, J BIOL CHEM, V266, P17136; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JAKUBOWSKI H, 1993, FASEB J, V7, P168, DOI 10.1096/fasebj.7.1.8422964; JAKUBOWSKI H, 1978, BIOCHIM BIOPHYS ACTA, V518, P345, DOI 10.1016/0005-2787(78)90191-0; JAKUBOWSKI HZ, 1977, ANAL BIOCHEM, V82, P29, DOI 10.1016/0003-2697(77)90130-0; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; von der Haar F, 1976, Biochemistry, V15, P4131, DOI 10.1021/bi00663a034; YARUS M, 1972, P NATL ACAD SCI USA, V69, P1915, DOI 10.1073/pnas.69.7.1915	30	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6549	6553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454625				2022-12-25	WOS:A1993KT36800068
J	LIN, LW; LIU, TY				LIN, LW; LIU, TY			ISOLATION AND CHARACTERIZATION OF C-REACTIVE PROTEIN (CRP) CDNA AND GENOMIC DNA FROM XENOPUS-LAEVIS - A SPECIES REPRESENTING AN INTERMEDIATE STAGE IN CRP EVOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; BINDING-SITE; ACID; PURIFICATION; DETERMINANTS; SEQUENCE; SYSTEM	C-reactive protein (CRP) is a prototypic acute phase protein in human and rabbit. Although it is structurally and functionally conserved from invertebrate to human, there are species-specific differences in patterns of expression and putative function. To further investigate the biological significance, regulation, and evolution of CRP, we isolated Xenopus CRP and subsequently derived and sequenced corresponding cDNA and the genomic clones. The structure and expression of Xenopus CRP were also compared to those of the other CRPs. Analyses of the amino acid sequence and the nucleotide sequence reveal that the mature Xenopus CRP is a 222-amino acid protein preceded by a 16-residue signal peptide. During development, Xenopus CRP is expressed, only when the liver appears, and therefore is not likely to play a role in early embryonic development. Compared to other species, Xenopus CRP is present at an intermediate low level of <1 mug/ml in the normal serum. Unlike human and rabbit CRP, Xenopus CRP is not induced by turpentine or heatshock treatment. The heatshock consensus sequence (Woo, P., Korenberg, J. R., and Whitehead, A. S. (1985) J. Biol. Chem. 265, 4136-4142) are not present in the Xenopus CRP gene. It is suggested that Xenopus CRP represents a transitional period in CRP evolution when host defenses switched from primitive innate immunity to a much more complex immune system. The constitutive functions of CRP gradually became less essential as the result of the development of a complex immune system.			LIN, LW (corresponding author), US FDA, CTR BIOL EVALUAT & RES, DIV BIOCHEM & BIOPHYS, BETHESDA, MD 20892 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSBEL FM, 1987, CURRENT PROTOCOLS MO, V1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOUT D, 1986, SCIENCE, V231, P153, DOI 10.1126/science.3079916; CARUTHERS MH, 1982, GENETIC ENG, V4, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANG CV, 1985, J BIOL CHEM, V260, P9713; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUPASQUIER L, 1989, ANNU REV IMMUNOL, V7, P251, DOI 10.1146/annurev.immunol.7.1.251; EZEKOWITZ RAB, 1988, J CELL SCI, P121; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZMORAN H, 1968, J MOL BIOL, V32, P467, DOI 10.1016/0022-2836(68)90023-5; FROHMAN MA, 1990, PCR PROTOCOLS GUIDE, P21; GAL K, 1955, Acta Microbiol Acad Sci Hung, V3, P41; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUO LH, 1983, NUCLEIC ACIDS RES, V11, P5521, DOI 10.1093/nar/11.16.5521; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOKAMA Y, 1962, J BACTERIOL, V83, P1017, DOI 10.1128/JB.83.5.1017-1024.1962; JAMES K, 1983, J IMMUNOL, V131, P2930; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SP, 1990, J BIOL CHEM, V265, P4136; LIU T, 1991, J BIOL CHEM, V266, P14813; LIU TY, 1982, ANN NY ACAD SCI, V389, P151, DOI 10.1111/j.1749-6632.1982.tb22133.x; Maniatis T., 1982, MOL CLONING; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OLIVEIRA EB, 1980, J IMMUNOL, V124, P1396; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PIED S, 1989, INFECT IMMUN, V57, P278, DOI 10.1128/IAI.57.1.278-282.1989; ROBEY FA, 1985, J EXP MED, V161, P1344, DOI 10.1084/jem.161.6.1344; ROBEY FA, 1983, J BIOL CHEM, V258, P3889; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROBEY FA, 1981, J BIOL CHEM, V256, P969; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SYIN C, 1986, J BIOL CHEM, V261, P5473; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; WEISS J, 1978, J BIOL CHEM, V253, P2664; WOO P, 1985, J BIOL CHEM, V260, P3384	51	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6809	6815						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454653				2022-12-25	WOS:A1993KT36800104
J	PAUDEL, HK; ZWIERS, H; WANG, JH				PAUDEL, HK; ZWIERS, H; WANG, JH			PHOSPHORYLASE-KINASE PHOSPHORYLATES THE CALMODULIN-BINDING REGULATORY REGIONS OF NEURONAL TISSUE-SPECIFIC PROTEINS B-50 (GAP-43) AND NEUROGRANIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SYNAPTIC PLASMA-MEMBRANES; LONG-TERM POTENTIATION; GROWTH-RELATED PROTEIN; C SUBSTRATE; RAT-BRAIN; POLYPHOSPHOINOSITIDE METABOLISM; PHORBOL DIESTERS; BOVINE BRAIN; CONE PROTEIN	Neuronal tissue-specific proteins B-50 (GAP-43, neuromodulin) and neurogranin are phosphorylated by phosphorylase kinase with stoichiometries of 0.4 and 0.5 mol of phosphate/mol of protein, respectively. The apparent K(m) and k(cat) values determined at pH 8.2 for neurogranin phosphorylation are 28.4 muM and 139.3 min-1, respectively, and for B-50 phosphorylation are 22.8 muM and 33.2 min-1, respectively. As a substrate of phosphorylase kinase, phosphorylase is approximately 44 and approximately 13 times better than B-50 and neurogranin, respectively. Both proteins are better substrates of protein kinase C than of phosphorylase kinase and are phosphorylated on a single site by phosphorylase kinase. The sequence analyses of tryptic phosphopeptides isolated from neurogranin and B-50 phosphorylated by phosphorylase kinase revealed the same amino acid sequence, IQASF, indicating that phosphorylase kinase phosphorylates the calmodulin-binding regulatory regions of B-50 and neurogranin previously known to be phosphorylated by protein kinase C (Coggins, P. J., and Zwiers, H. (1989) J. Neurochem. 53, 1895-1901; Baudier, J., Deloulme, J. C., Dorsselaer, A. V., Black, D., and Matthes, W. D. (1991) J. Biol. Chem. 266, 229-237). In rat brain synaptosomes, a relatively high phosphorylase kinase specific activity is detected, and approximately 32% activity is associated with synaptic membranes where B-50 is localized. In rat brain homogenate and synaptosomal membranes, phosphorylation of a protein that co-migrates with B-50 on SDS-polyacrylamide gel electrophoresis is enhanced in the presence of exogenous phosphorylase kinase.	UNIV CALGARY, FAC MED, DEPT MED PHYSIOL & MED BIOCHEM, CALGARY T2N 4N1, AB, CANADA	University of Calgary	PAUDEL, HK (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, MRC, CELL REGULAT GRP, 3330 HOSP DR NW, CALGARY T2N 4N1, AB, CANADA.							ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALOYO VJ, 1988, NEUROCHEM RES, V13, P343, DOI 10.1007/BF00972484; ALOYO VJ, 1983, J NEUROCHEM, V41, P649, DOI 10.1111/j.1471-4159.1983.tb04790.x; APEL ED, 1991, J BIOL CHEM, V266, P10544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECKENRIDGE BM, 1965, J NEUROCHEM, V12, P51, DOI 10.1111/j.1471-4159.1965.tb10251.x; BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; BROWNING M, 1979, SCIENCE, V203, P60, DOI 10.1126/science.214855; BROWNING M, 1979, NATURE, V278, P273, DOI 10.1038/278273a0; CHAN SY, 1986, J NEUROSCI, V6, P3618; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN P, 1975, EUR J BIOCHEM, V51, P79, DOI 10.1111/j.1432-1033.1975.tb03909.x; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; DEGRAAN PNE, 1988, J RECEPTOR RES, V8, P345, DOI 10.3109/10799898809048997; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEPAOLIROACH AA, 1979, J BIOL CHEM, V254, P4212; DOMBRADI VK, 1984, ARCH BIOCHEM BIOPHYS, V230, P615, DOI 10.1016/0003-9861(84)90443-0; DRUMMOND GI, 1970, J NEUROCHEM, V17, P475, DOI 10.1111/j.1471-4159.1970.tb00524.x; EDWARDS C, 1974, J NEUROCHEM, V22, P565, DOI 10.1111/j.1471-4159.1974.tb06896.x; EICHBERG J, 1986, BIOCHEM BIOPH RES CO, V136, P1007, DOI 10.1016/0006-291X(86)90433-X; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FOLBERGROVA J, 1977, BRAIN RES, V135, P337, DOI 10.1016/0006-8993(77)91036-8; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; HAJOS F, 1975, BRAIN RES, V93, P485, DOI 10.1016/0006-8993(75)90186-9; HORL WH, 1978, BIOCHEMISTRY-US, V17, P759; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUSTON RB, 1968, BIOCHEMISTRY-US, V7, P2116, DOI 10.1021/bi00846a014; JOLLES J, 1980, NATURE, V286, P623, DOI 10.1038/286623a0; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KOSIK KS, 1988, NEURON, V1, P127, DOI 10.1016/0896-6273(88)90196-1; Krebs E G, 1968, Adv Enzyme Regul, V6, P245, DOI 10.1016/0065-2571(68)90016-2; KREBS EG, 1966, PHARMACOL REV, V18, P163; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOWNE D, 1971, J PHYSIOL-LONDON, V212, P503, DOI 10.1113/jphysiol.1971.sp009338; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MCGUIRE CB, 1988, DEV BRAIN RES, V41, P277, DOI 10.1016/0165-3806(88)90189-7; MCMASTER D, 1988, BRAIN RES BULL, V21, P265, DOI 10.1016/0361-9230(88)90241-9; NELSON RB, 1989, J NEUROSCI, V9, P381; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; NIELANDER HB, 1987, NEUROSCI RES COMMUN, V1, P163; NOLAN C, 1964, BIOCHEMISTRY-US, V3, P542, DOI 10.1021/bi00892a013; PAUDEL HK, 1991, J BIOL CHEM, V266, P16524; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROSENTHAL A, 1987, EMBO J, V6, P3641, DOI 10.1002/j.1460-2075.1987.tb02696.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SODERLING TR, 1979, P NATL ACAD SCI USA, V76, P2536, DOI 10.1073/pnas.76.6.2536; SPENCER SA, 1992, J BIOL CHEM, V267, P9059; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TABATABAI LB, 1978, J BIOL CHEM, V253, P2196; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; VIRIYA J, 1979, BIOCHEM BIOPH RES CO, V87, P17, DOI 10.1016/0006-291X(79)91641-3; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0; ZWIERS H, 1980, J NEUROCHEM, V34, P1689, DOI 10.1111/j.1471-4159.1980.tb11262.x	78	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6207	6213						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454596				2022-12-25	WOS:A1993KT36800023
J	WEITZEL, F; WENDEL, A				WEITZEL, F; WENDEL, A			SELENOENZYMES REGULATE THE ACTIVITY OF LEUKOCYTE 5-LIPOXYGENASE VIA THE PEROXIDE TONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SELENIUM DEFICIENCY; RAT; MEMBRANE; PROTEIN; ACID	The variation of the selenium status of leukocytes was used as a tool to investigate the influence of selenium-containing glutathione peroxidases on the formation of 5-lipoxygenase metabolites in vitro and ex vivo. Selenium-deficient rat basophilic leukemia cells had <1% of control glutathione peroxidase activity and 35% of control phospholipid hydroperoxide-glutathione peroxidase activity. Upon stimulation, these cells released an 8-fold amount of lipoxygenase metabolites compared to controls. No (5S)-hydroperoxyeicosatetraenoic acid was detectable in whole cells; however, it was found in homogenates of selenium-deficient cells. Addition of 0.25 mug/ml selenium to selenium-deficient cells restored control phospholipid hydroperoxide-glutathione peroxidase activity within 8 h, whereas glutathione peroxidase activity needed 7 days. 12 h after resupplementation, selenium-deficient cells had 3% glutathione peroxidase and 100% phospholipid hydroperoxide-glutathione peroxidase activity compared to controls. Resupplemented cells released control amounts of 5-lipoxygenase metabolites, indicating that restoration of phospholipid hydroperoxide-glutathione peroxidase activity is associated with a selenium-adequate leukotriene metabolism. Leukocytes that were isolated from selenium-deficient rats released a 7-fold amount of total lipoxygenase metabolites compared to cells from control animals. By injecting normally fed rats with 500 mug/kg selenium as Na2SeO3, leukocyte phospholipid hydroperoxide-glutathione peroxidase activity was raised 8-fold within 114 h compared to controls. Leukocytes from these animals produced significantly less lipoxygenase metabolites than controls. These findings indicate that phospholipid hydroperoxide-glutathione peroxidase activity is primarily responsible for the reduction of 5-hydroperoxyeicosatetraenoic acid and therefore governs the actual activity of leukocyte 5-lipoxygenase via regulating the tone of endogenous hydroperoxides.	UNIV CONSTANCE,FAC BIOL,POB 5560,W-7750 CONSTANCE,GERMANY	University of Konstanz								AHARONY D, 1987, PROSTAGLANDINS, V33, P85, DOI 10.1016/0090-6980(87)90307-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT RW, 1983, BIOCHEM BIOPH RES CO, V117, P183, DOI 10.1016/0006-291X(83)91558-9; BURK RF, 1983, ANNU REV NUTR, V3, P53, DOI 10.1146/annurev.nu.03.070183.000413; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; GROSSMANN A, 1983, EUR J BIOCHEM, V135, P549, DOI 10.1111/j.1432-1033.1983.tb07687.x; HATZELMANN A, 1989, EUR J BIOCHEM, V180, P527, DOI 10.1111/j.1432-1033.1989.tb14678.x; HATZELMANN A, 1987, EUR J BIOCHEM, V169, P175, DOI 10.1111/j.1432-1033.1987.tb13595.x; HAURAND M, 1988, BIOL CHEM H-S, V369, P133, DOI 10.1515/bchm3.1988.369.1.133; HJARTH R, 1981, J IMMUNOL METHODS, V43, P95; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; Lian S.-T., 1984, SE BIOL MED, P938; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SKOOG MT, 1986, PROSTAGLANDINS, V31, P577, DOI 10.1016/0090-6980(86)90118-8; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; Wendel A, 1981, Methods Enzymol, V77, P325	21	166	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6288	6292						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454601				2022-12-25	WOS:A1993KT36800034
J	CLARENC, JP; LEBLEU, B; LEONETTI, JP				CLARENC, JP; LEBLEU, B; LEONETTI, JP			CHARACTERIZATION OF THE NUCLEAR-BINDING SITES OF OLIGODEOXYRIBONUCLEOTIDES AND THEIR ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; TRANSPORT; PROTEINS	The intracellular fate of antisense oligodeoxyribonucleotide (oligomers) is poorly understood. Recent observations strongly suggest that after endocytosis and escape from the endocytic compartments, oligomers accumulate in the nuclei of eukaryotic cells by simple diffusion. Isolated nuclei were used to determine the number of these nuclear binding sites and their affinity for phosphodiester, phosphorothioate, and methylphosphonate oligomers. These cell-free assays were correlated with intact cell microinjection experiments. Great differences have been observed between these analogs. These data are helpful in understanding the fate of oligomers and the mechanism of their action and could be helpful for a more rational design of antisense molecules.	UNIV MONTPELLIER 2,INST GENET MOLEC,CNRS,UA 1191,F-34095 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier								BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHIN D J, 1990, New Biologist, V2, P1091; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1986, ANN REV CELL BIOL, V2, P67; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Geselowitz D A, 1992, Antisense Res Dev, V2, P17; GUDAS JM, 1986, J CELL PHYSIOL, V128, P441, DOI 10.1002/jcp.1041280313; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Maniatis T., 1982, MOL CLONING; MILLER PS, 1991, OLIGONUCLEOTIDES ANA, P136; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAY JW, 1975, EXP CELL RES, V94, P47, DOI 10.1016/0014-4827(75)90529-7; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454	17	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5600	5604						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449923				2022-12-25	WOS:A1993KR82200040
J	DECAROLIS, E; DELUCA, V				DECAROLIS, E; DELUCA, V			PURIFICATION, CHARACTERIZATION, AND KINETIC-ANALYSIS OF A 2-OXOGLUTARATE-DEPENDENT DIOXYGENASE INVOLVED IN VINDOLINE BIOSYNTHESIS FROM CATHARANTHUS-ROSEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL HYDROXYLASE REACTION; HYOSCYAMINE 6-BETA-HYDROXYLASE; MOLECULAR-CLONING; CULTURED ROOTS; MECHANISM; ENZYME; NIGER; PROTEINS; SEEDS	A 2-oxoglutarate-dependent dioxygenase (EC 1.14.11.11) which catalyzes the hydroxylation at position 4 of the indole alkaloid, desacetoxyvindoline has been purified to near homogeneity from Catharanthus roseus. The purification procedure combined conventional chromatographic methods and cosubstrate affinity chromatography on alpha-ketoglutarate-Sepharose. The specific activity of the 4-hydroxylase was enriched over 2000-fold compared to the crude homogenate with a recovery of 1.6%. The molecular mass of the native and denatured 4-hydroxylase was found to be 45 and 44.7 kDa, respectively, suggesting that the native enzyme is a monomer. Two-dimensional isoelectric focusing under denaturing conditions resolved the purified 4-hydroxylase into three charge isoforms of pl values 4.6, 4.7, and 4.8. The enzyme did not require most divalent cations, but inactive enzyme was reactivated in a time-dependent manner by incubation with ferrous ions. The mechanism of action of desacetoxyvindoline 4-hydroxylase was investigated. The results of substrate interaction kinetics and product inhibition studies suggest an Ordered Ter Ter mechanism where 2-oxoglutarate is the first substrate to bind followed by the binding of O2 and desacetoxyvindoline. The first product to be released was deacetylvindoline followed by CO2 and succinate, respectively.	UNIV MONTREAL, INST RECH BIOL VEGETALE, DEPT SCI BIOL, 4101 RUE SHERBROOKE E, MONTREAL H1X 2B2, PQ, CANADA	Universite de Montreal								BALSEVICH J, 1986, HETEROCYCLES, V24, P2415, DOI 10.3987/R-1986-09-2415; BERG RA, 1973, J BIOL CHEM, V248, P1175; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITSCH L, 1986, EUR J BIOCHEM, V156, P569, DOI 10.1111/j.1432-1033.1986.tb09616.x; CLELAND WW, 1967, ENZYMES, V2, P1; DECAROLIS E, 1990, PLANT PHYSIOL, V94, P1323, DOI 10.1104/pp.94.3.1323; DELUCA V, 1987, PLANT PHYSIOL, V85, P1099, DOI 10.1104/pp.85.4.1099; DELUCA V, 1985, J PLANT PHYSIOL, V121, P417, DOI 10.1016/S0176-1617(85)80078-X; DELUCA V, 1989, P NATL ACAD SCI USA, V86, P2582; DELUCA V, 1988, CELL CULT SOMATIC CE, V4, P385; DETHIER M, 1992, IN PRESS PHYTOCHEMIS; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P83; DOTZLAF JE, 1987, J BACTERIOL, V169, P1611, DOI 10.1128/jb.169.4.1611-1618.1987; ENDO T, 1988, PHYTOCHEMISTRY, V27, P2147, DOI 10.1016/0031-9422(88)80114-6; FAHN W, 1990, PLANT CELL REP, V8, P613, DOI 10.1007/BF00270066; HASHIMOTO T, 1987, EUR J BIOCHEM, V164, P277, DOI 10.1111/j.1432-1033.1987.tb11055.x; HASHIMOTO T, 1986, PLANT PHYSIOL, V81, P619, DOI 10.1104/pp.81.2.619; HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033; JOHNSON IS, 1960, CANCER RES, V20, P1016; KWAK SS, 1988, PLANT CELL PHYSIOL, V29, P935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE T, 1989, PLANTA, V179, P211, DOI 10.1007/BF00393691; MATSUDA J, 1991, J BIOL CHEM, V266, P9460; MORRISON JF, 1971, J BIOL CHEM, V246, P3977; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P51, DOI 10.1016/0005-2744(80)90041-8; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TUDERMAN L, 1977, EUR J BIOCHEM, V80, P341, DOI 10.1111/j.1432-1033.1977.tb11888.x; YAMADA Y, 1990, P JPN ACAD B-PHYS, V66, P73, DOI 10.2183/pjab.66.73; 1988, AFFINITY CHROMATOGR, P3	33	65	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5504	5511						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449913				2022-12-25	WOS:A1993KR82200026
J	NICHOLAS, RA; LAMSON, DR; SCHULTZ, DE				NICHOLAS, RA; LAMSON, DR; SCHULTZ, DE			PENICILLIN-BINDING PROTEIN-1B FROM ESCHERICHIA-COLI CONTAINS A MEMBRANE ASSOCIATION SITE IN ADDITION TO ITS TRANSMEMBRANE ANCHOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; ACTIVE-SITE; PEPTIDOGLYCAN SYNTHETASE; CELLULAR DIVISION; TRYPTIC PEPTIDE; ALPHA-COMPONENT; SOLUBLE FORM; PURIFICATION; LOCALIZATION; 1B	A working structural model of penicillin-binding protein 1B (PBP 1B) from Escherichia coli derived from previous data consists of a highly charged amino-terminal cytoplasmic tail, a 23-amino-acid hydrophobic transmembrane anchor, and a 758-amino-acid periplasmic domain. Using an engineered thrombin cleavage site, we have investigated the solubility properties of the periplasmic domain of PBP 1B. Twelve amino acids, comprised of the consensus thrombin cleavage site (LVPR down GS) and flanking glycine residues, were inserted into PBP 1B just past its putative transmembrane segment. To aid in purification, a hexahistidine tag was also inserted at its amino terminus, and the engineered protein (PBP 1B-GT/H6) was purified and characterized. Inclusion of the thrombin cleavage site had no effect on the protein's intrinsic tryptophan fluorescence and affinity for [C-14]penicillin G, indicating that the protein structure was not significantly perturbed. PBP 1B-GT/H6 was readily cleaved by thrombin at low thrombin/protein ratios to a protein with properties consistent with the removal of its cytoplasmic tail and transmembrane regions. Cleavage of the protein was dependent upon the presence of the thrombin cleavage site, and the thrombin-cleaved protein (PBP 1B(per)) displayed an identical affinity for [C-14] penicillin G binding as wild-type PBP 1B and uncleaved PBP 1B-GT/H6. [C-14]Penicillin G-labeled PBP 1B(per) eluted from a gel filtration column in the presence but not in the absence of 0.7% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid, and PBP 1B(per) was found entirely in the membrane fraction of a thrombin digest of membranes containing overproduced PBP 1B-GT/H6. To further characterize this unusual solubility behavior, purified PBP 1B(per) was reconstituted into lipid vesicles, which were then floated on a sucrose gradient. Floated vesicles contained > 95% of total I-125-penicillin V binding, indicating that PBP 1B(per) directly associates with lipid membranes. These results strongly suggest that the periplasmic domain of PBP 1B associates with membranes independent of its amino terminal transmembrane region.			NICHOLAS, RA (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CB 7365 FLOB,CHAPEL HILL,NC 27599, USA.				NIAID NIH HHS [AI-27039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI H, 1987, FEBS LETT, V226, P150, DOI 10.1016/0014-5793(87)80569-0; ADACHI H, 1992, BIOCHEMISTRY-US, V31, P430, DOI 10.1021/bi00117a018; BAYER MH, 1990, J BACTERIOL, V172, P125, DOI 10.1128/JB.172.1.125-135.1990; BEGG KJ, 1990, J BACTERIOL, V172, P6697, DOI 10.1128/jb.172.12.6697-6703.1990; BLASZCZAK LC, 1989, J LABELLED COMPD RAD, V27, P401, DOI 10.1002/jlcr.2580270406; BOWLER LD, 1989, MOL MICROBIOL, V3, P1277, DOI 10.1111/j.1365-2958.1989.tb00278.x; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BROOMESMITH JK, 1985, EUR J BIOCHEM, V147, P437, DOI 10.1111/j.1432-1033.1985.tb08768.x; CHOI DS, 1986, J BIOL CHEM, V261, P8953; CURTIS NAC, 1979, ANTIMICROB AGENTS CH, V16, P533, DOI 10.1128/AAC.16.5.533; DELPORTILLO FG, 1991, J BACTERIOL, V173, P4530, DOI 10.1128/JB.173.14.4530-4532.1991; DENBLAAUWEN T, 1990, J BACTERIOL, V172, P7284, DOI 10.1128/jb.172.12.7284-7288.1990; EDELMAN A, 1987, MOL MICROBIOL, V1, P101, DOI 10.1111/j.1365-2958.1987.tb00533.x; GHUYSEN JM, 1986, BIOCHEM J, V235, P159, DOI 10.1042/bj2350159; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KATO J, 1985, MOL GEN GENET, V200, P272, DOI 10.1007/BF00425435; KATO J, 1984, MOL GEN GENET, V196, P449, DOI 10.1007/BF00436192; KECK W, 1985, P NATL ACAD SCI USA, V82, P1999, DOI 10.1073/pnas.82.7.1999; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALHOTRA KT, 1992, J BIOL CHEM, V267, P11386; MOTTL H, 1991, EUR J BIOCHEM, V200, P767, DOI 10.1111/j.1432-1033.1991.tb16243.x; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1982, BIOCHEM BIOPH RES CO, V105, P1546, DOI 10.1016/0006-291X(82)90964-0; NAKAGAWA J, 1980, AGR BIOL CHEM TOKYO, V44, P3041, DOI 10.1080/00021369.1980.10864458; NICHOLAS RA, 1985, J BACTERIOL, V164, P456, DOI 10.1128/JB.164.1.456-460.1985; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; NICHOLAS RA, 1985, J BIOL CHEM, V260, P6394; NICHOLAS RA, 1985, BIOCHEMISTRY-US, V24, P3448, DOI 10.1021/bi00335a009; PRATT JM, 1986, EMBO J, V5, P2399, DOI 10.1002/j.1460-2075.1986.tb04510.x; Schultz D E, 1991, Protein Expr Purif, V2, P339, DOI 10.1016/1046-5928(91)90092-W; SPRATT B G, 1988, P292; SPRATT BG, 1983, J GEN MICROBIOL, V129, P1247; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; SUZUKI H, 1987, J BACTERIOL, V169, P891, DOI 10.1128/jb.169.2.891-893.1987; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; TAMAKI S, 1977, P NATL ACAD SCI USA, V74, P5472, DOI 10.1073/pnas.74.12.5472; TAMURA T, 1980, P NATL ACAD SCI-BIOL, V77, P4499, DOI 10.1073/pnas.77.8.4499; WAXMAN DJ, 1979, J BIOL CHEM, V254, P4863; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; YOUSIF SY, 1985, J GEN MICROBIOL, V131, P2839	44	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5632	5641						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449926				2022-12-25	WOS:A1993KR82200044
J	EXPOSITO, JY; DALESSIO, M; DILIBERTO, M; RAMIREZ, F				EXPOSITO, JY; DALESSIO, M; DILIBERTO, M; RAMIREZ, F			COMPLETE PRIMARY STRUCTURE OF A SEA-URCHIN TYPE-IV COLLAGEN-ALPHA CHAIN AND ANALYSIS OF THE 5' END OF ITS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRONGYLOCENTROTUS-PURPURATUS; DEVELOPMENTAL REGULATION; ALPHA-2(IV) COLLAGEN; EMBRYO; EXPRESSION; SEQUENCE; ALPHA-1(IV); PROMOTER; ORGANIZATION; MOLECULES	We isolated several overlapping cDNAs from Strongylocentrotus purpuratus coding for a nonfibrillar collagen chain structurally homologous to the vertebrate type IV collagen chains and arbitrarily termed 3alpha chain. The deduced amino acid sequence of the sea urchin polypeptide includes a 28-residue signal peptide, a 14-residue amino-terminal non-collagenous segment, a triple-helical domain of 1390 residues containing 23 imperfections, and a 226-residue carboxyl-terminal non-collagenous region. Comparison of the sea urchin amino- and carboxyl-terminal non-collagenous domains with those of the vertebrate type IV collagen chains indicated a high level of sequence identity to the alpha1(IV) and alpha5(IV) chains. This evolutionary relationship was further strengthened by the analysis of the genomic organization of the 5' portion of the sea urchin gene, which also provided the composition of some of the upstream sequences. In addition, this work demonstrated that our gene product is identical to that encoded by the partial cDNA clone recently isolated by others (Wessel, G. M., Etkin, M., and Benson, S. (1991) Dev. Biol. 148, 261-272) who demonstrated its involvement in the biomineralization process of cultured mesenchyme cells.			EXPOSITO, JY (corresponding author), CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029, USA.		D'Alessio, Marina/AAA-1306-2019	Exposito, Jean-Yves/0000-0002-4926-4942	NIGMS NIH HHS [GM-41849] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041849] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON S, 1990, EXP CELL RES, V188, P141, DOI 10.1016/0014-4827(90)90289-M; BLANKENSHIP J, 1984, EXP CELL RES, V152, P98, DOI 10.1016/0014-4827(84)90233-7; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BURBELO P, 1988, P NATL ACAD SCI USA, V85, P9674; BURKE RD, 1989, COMP BIOCHEM PHYS B, V94, P41, DOI 10.1016/0305-0491(89)90007-2; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; GUO XD, 1989, J BIOL CHEM, V264, P17574; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MINAFRA S, 1975, Bollettino di Zoologia, V42, P205; MORRISON KE, 1991, J BIOL CHEM, V266, P34; NEMER M, 1988, BIOCHIM BIOPHYS ACTA, V950, P445, DOI 10.1016/0167-4781(88)90143-1; PARR BA, 1990, J BIOL CHEM, V265, P1408; PETTITT J, 1991, J BIOL CHEM, V266, P16149; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAITTA B, 1989, BIOCHEM BIOPH RES CO, V158, P633, DOI 10.1016/0006-291X(89)92768-X; SHIMIZU K, 1990, BIOCHIM BIOPHYS ACTA, V1038, P39, DOI 10.1016/0167-4838(90)90007-3; SOININEN R, 1988, J BIOL CHEM, V263, P17217; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VENKATESAN M, 1986, P NATL ACAD SCI USA, V83, P3351, DOI 10.1073/pnas.83.10.3351; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5; WESSEL GM, 1991, DEV BIOL, V148, P261, DOI 10.1016/0012-1606(91)90335-Z; WESSEL GM, 1984, DEV BIOL, V103, P235, DOI 10.1016/0012-1606(84)90025-3; ZHOU J, 1992, J BIOL CHEM, V267, P12475	38	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5249	5254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444899				2022-12-25	WOS:A1993KP88400098
J	FRAMSON, P; BORNSTEIN, P				FRAMSON, P; BORNSTEIN, P			A SERUM RESPONSE ELEMENT AND A BINDING-SITE FOR NF-Y MEDIATE THE SERUM RESPONSE OF THE HUMAN THROMBOSPONDIN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; HETEROLOGOUS SUBUNITS; DNA-REPLICATION; MESSENGER-RNA; GLIAL-CELLS; 1ST INTRON; 3T3 CELLS; PROTEINS; PROMOTER	The expression of thrombospondin 1 (TSP 1), a member of the TSP gene family, is rapidly induced by growth factors. We tested the ability of human TSP 1-chloramphenicol acetyltransferase constructs to respond to serum in stably transfected NIH-3T3 cells. Two transcriptional elements in the TSP 1 promoter, a distal element at -1280 and a proximal element at -65, were required for the response of the human TSP 1 gene to serum. The distal element contains the 5'-CC(A + T)6GG-3' consensus sequence characteristic of a serum-response element (SRE). Deletions or mutations in this element reduced the serum response of the TSP 1 gene by 80-90%. In gel-shift assays, the -1280 element and the c-fos SRE cross-competed, whereas their functional and binding mutants did not. The proximal element contains the sequence 5'-GGCCAATGG G-3', which closely resembles the consensus binding motif for the CCAAT-binding factor NF-Y (CBF, CP1, alphaCP1). Deletions or mutations in this element also reduced the serum response by 80-90%. Methylation interference analysis of the -65 region identified a pattern of contacts with nuclear factors resembling that for NF-Y, and an NF-Y-binding site and the proximal TSP 1 element cross-competed in gel-shift assays, whereas their binding mutants did not. Finally, an abbreviated TSP 1 promoter/5'-flank, containing the SRE- and NF-Y-binding sites, mediated a serum response that was close in magnitude to that of the parent promoter. We conclude that the serum response of the human TSP 1 gene requires the coordinated function of an SRE- and NF-Y-binding site.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 18645, HL 07312] Funding Source: Medline; NIDCR NIH HHS [DE 08229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312, P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ASCH AS, 1986, P NATL ACAD SCI USA, V83, P2904, DOI 10.1073/pnas.83.9.2904; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KIM CG, 1990, J BIOL CHEM, V265, P13362; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAU LF, 1991, HORMONAL CONTROL GEN, V6, P257; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LI XY, 1992, J BIOL CHEM, V267, P8984; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Liska Deann J., 1992, Gene Expression, V2, P379; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METZ F, 1991, ONCOGENE, V6, P2165; PUGH BF, 1992, J BIOL CHEM, V267, P679; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Sambrook J., 1989, MOL CLONING; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRONCHE F, 1991, J MOL BIOL, V221, P31; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VOS HL, 1992, J BIOL CHEM, V267, P12192; VUORIO T, 1990, J BIOL CHEM, V265, P22480; ZHU H, 1991, NEW BIOL, V3, P455; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	69	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4989	4996						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444876				2022-12-25	WOS:A1993KP88400065
J	GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R				GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R			ANALYSIS OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GAP-RELATED DOMAIN BY SITE-DIRECTED MUTAGENESIS	ONCOGENE			English	Article							AFFINITY CAMP PHOSPHODIESTERASE; GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; RAS GTPASE; MAMMALIAN GAP; YEAST; IDENTIFICATION; SEQUENCE; ENCODES	The gene for von Recklinghausen neurofibromatosis type 1 (NF1) was recently identified by positional cloning and found to encode a protein with sequence similarity to a family of eucaryotic GTPase-activating proteins (GAPs). Expression of the NF1-GAP-related domain (NF1GRD) has been shown to complement yeast strains deficient in the yeast GAP homologs, IRA1 and IRA2, to interact with human RAS proteins and to accelerate the conversion of ras-GTP to ras-GDP. Further analysis of this region has revealed a number of residues that are highly conserved between members of the GAP family. Mutational analysis of a representative number of these residues produced one of three effects: (1) no change in NF1GRD function. (2) complete disruption of NF1GRD function and (3) intermediate retention of NF1GRD function. One of these mutations at residue 1423 was shown to have reduced ability to negatively regulate ras in yeast, which is interesting in tight of a recent report demonstrating a similar naturally occurring mutation in human malignancies.	UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; Cold Spring Harbor Laboratory				Gutmann, David/0000-0002-3127-5045; Marchuk, Douglas/0000-0002-3110-6671; Wigler, Michael/0000-0003-4396-1971	NINDS NIH HHS [NS23410] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023410] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, IN PRESS MOL CELL BI; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1992, NEW BIOL, V4, P247; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1987, P NATL ACAD SCI USA, V262, P10426; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LI Y, 1992, CELL, V69, P1; Maniatis T., 1982, MOL CLONING; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SHERMAN F, 1986, LABORATORY COURSE MA; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	39	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					761	769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437860				2022-12-25	WOS:A1993KN00800029
J	SUN, Y; HEGAMYER, G; COLBURN, NH				SUN, Y; HEGAMYER, G; COLBURN, NH			NASOPHARYNGEAL CARCINOMA SHOWS NO DETECTABLE RETINOBLASTOMA SUSCEPTIBILITY GENE ALTERATIONS	ONCOGENE			English	Note							EPSTEIN-BARR VIRUS; HUMAN PROSTATE CARCINOMA; CELL LINES HNE-1; LARGE T-ANTIGEN; HUMAN BLADDER; RB GENE; INACTIVATION; EXPRESSION; PROTEIN; MUTATIONS	Since multistage carcinogenesis is frequently associated with the loss of suppressor gene activity, and since in over 90% of cases of nasopharyngeal carcinoma (NPC) p53 alterations are not involved [Sun, Y., Hegamyer, G.H., Cheng, Y.-J., Hildesheim, A., Chen, J.-Y., Chen, I.-H., Cao, Y., Yao, K.-T. & Colburn, N.H. (1992). Proc. Natl. Acad. Sci. USA, 89, 6516-6520] we investigated the possible involvement of the inactivation of the retinoblastoma susceptibility gene (RB) in nasopharyngeal carcinogenesis. We analysed the expression, gross structure and possible point mutation of the RB gene in an NPC cell line as well as seven NPC biopsies obtained from seven patients. The NPC cell line expresses the RB gene with a normal size and abundance, as assayed by reverse transcriptase polymerase chain reaction (RT-PCR) and Northern hybridization. No point mutation was detected in two independent E1A/large T-binding regions, which are the common sites for mutations in the RB gene. NPC biopsies also showed no point mutations at four exon-intron boundaries at which point mutations have been reported in other human carcinomas. The biopsies and cell tine had no deletions in the promoter region of the gene and showed no gross deletions or rearrangements. Taken together, we conclude that, in contrast to multistage carcinogenesis leading to human retinoblastoma, osteogenic sarcomas and carcinomas of lung, breast, bladder and prostate, nasopharyngeal carcinogenesis appears unlikely to involve RB gene alterations.	NCI, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; NCI, FCRDC, DYNCORP, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYNTON RF, 1991, CANCER RES, V51, P5766; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG J, 1990, BLOOD, V75, P730; DETHE G, 1982, VIRAL INFECTIONS HUM, P126; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LERMAN MI, 1991, HUM GENET, V86, P567; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509; 1978, SCI SINICA, V21, P127	42	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					791	795						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437863				2022-12-25	WOS:A1993KN00800033
J	ARVIDSON, DN; PFAU, J; HATT, JK; SHAPIRO, M; PECORARO, FS; YOUDERIAN, P				ARVIDSON, DN; PFAU, J; HATT, JK; SHAPIRO, M; PECORARO, FS; YOUDERIAN, P			TRYPTOPHAN SUPER-REPRESSORS WITH ALANINE-77 CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI-TRP REPRESSOR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; OPERATOR COMPLEX; BINDING; DNA; APOREPRESSOR; SPECIFICITIES; EXPRESSION; RESOLUTION	The binding of L-tryptophan to Escherichia coli tryptophan aporepressor enables the holorepressor complex to bind operator DNA tightly. The side chain of residue alanine 77 is located in one of the most flexible regions of Trp repressor, between residues critical for binding DNA. Codon-directed mutagenesis was used to make genes encoding mutant Trp repressors with each of the 19 naturally occurring amino acid changes of Ala77. The 19 mutant proteins are made at the same steady-state levels as wild type. Sensitive challenge phage assays show that 7 of the 19 mutant proteins (Cys, Ser, Val, Leu, Thr, Ile, and Lys) are more active than wild-type protein when tryptophan is limiting in vivo. Among these 7 mutant super-aporepressors, proteins with Cys and Ser changes also are super-holorepressors, because they repress better than wild-type holorepressor when tryptophan is in excess. These results and others suggest that super-aporepressors associate more poorly than wild-type aporepressor with nonspecific DNA. Consistent with this idea, these 7 changes are predicted to disrupt the tertiary structure of aporepressor, but have more limited effects on the structure of holorepressor.	CALIF INST BIOL RES,LA JOLLA,CA 92037					Hatt, Janet/0000-0002-5666-0994	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012629, R01GM034150] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34150, GM 12629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARVIDSON DN, 1991, GENETICS, V128, P29; ARVIDSON DN, 1991, BIOTECHNIQUES, V11, P733; ARVIDSON DN, 1989, THESIS U CALIFORNIA; BASS S, 1988, SCIENCE, V242, P240, DOI 10.1126/science.3140377; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENSON N, 1986, GENETICS, V114, P1; BROWN KD, 1971, J BACTERIOL, V108, P386, DOI 10.1128/JB.108.1.386-399.1971; DELSAL G, 1987, NUCLEIC ACIDS RES, V15, P10047; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GUNSALUS RP, 1986, J BACTERIOL, V167, P272, DOI 10.1128/jb.167.1.272-278.1986; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HEFFRON F, 1977, P NATL ACAD SCI USA, V74, P702, DOI 10.1073/pnas.74.2.702; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOBE A, 1974, J MOL BIOL, V85, P231, DOI 10.1016/0022-2836(74)90362-3; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, GENETICS, V120, P651; KLIG LS, 1988, J BIOL CHEM, V263, P243; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MARMORSTEIN RQ, 1991, BIOCHEMISTRY-US, V30, P1141, DOI 10.1021/bi00218a036; MARMORSTEIN RQ, 1989, NUCLEIC ACIDS MOL BI, P56; MARMORSTEIN RQ, 1989, THESIS U CHICAGO CHI; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SEGEL IH, BIOCH CALCULATIONS; SMITH HO, 1964, P NATL ACAD SCI USA, V52, P356, DOI 10.1073/pnas.52.2.356; von Hippel P. H, 1979, BIOL REGULATION DEV, V1, P279; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	33	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4362	4369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440721				2022-12-25	WOS:A1993KN53300080
J	GARCIA, C; MONTERO, M; ALVAREZ, J; CRESPO, MS				GARCIA, C; MONTERO, M; ALVAREZ, J; CRESPO, MS			BIOSYNTHESIS OF PLATELET-ACTIVATING-FACTOR (PAF) INDUCED BY CHEMOTACTIC PEPTIDE IS MODULATED AT THE LYSO-PAF - ACETYL-COA ACETYLTRANSFERASE LEVEL BY CALCIUM TRANSIENT AND PHOSPHATIDIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HEMATOPOIETIC-CELL LINES; DEPENDENT PROTEIN-KINASE; FREE ARACHIDONIC-ACID; HUMAN-NEUTROPHILS; PHOSPHOLIPID-METABOLISM; INDEPENDENT TRANSACYLASE; RABBIT NEUTROPHILS; LYMPHOID-CELLS; HYDROLYSIS	The chemotactic peptide fMLP (N-formyl-methionyl-leucyl-phenylalanine) induced the production of platelet-activating factor (PAF) by human polymorphonuclear leukocytes (PMN) incubated with cytochalasin B (CB). CoA-independent transacylase showed similar activity in both resting and stimulated PMN, and PAF production only occurred when lyso-PAF:acetyl-CoA acetyltransferase had been converted into the high activity form. PAF formation was coincidental with an increase of the concentration of cytosolic Ca2+ ([Ca2+]i), and with an enhanced formation of 1-O-[H-3]alkyl-2-acyl-sn-glycerol. Both fMLP-induced PAF production and the activation of lyso-PAF:acetyl-CoA acetyltransferase were diminished by propranolol. Since several molecular species of phosphatidic acid (PA) produced an inhibition of both PAF production and acetyltransferase activation on intact cells, a portion of the inhibitory effect of propranolol was related to the accumulation of PA. Furthermore, whereas CB increased both the extent and the duration of the fMLP-induced [Ca2+]i transient, propranolol was found to inhibit the CB-induced increase of the [Ca2+]i transient. These data indicate that both the attenuation of [Ca2+]i transient and the accumulation of PA may operate as termination signals for PAF production by acting on lyso-PAF:acetyl-CoA acetyltransferase.	FAC MED VALLADOLID,CONSEJO SUPER INVEST,DEPT BIQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN		GARCIA, C (corresponding author), FDN JIMENEZ DIAZ,MADRID,SPAIN.		Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014; Garcia, Carolina/E-9104-2015	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653; Garcia, Carolina/0000-0001-5138-6191				ALBERT DH, 1983, J BIOL CHEM, V258, P97; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLANK ML, 1983, J CHROMATOGR, V273, P415, DOI 10.1016/S0378-4347(00)80963-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURGOYNE RD, 1990, TRENDS BIOCHEM SCI, V15, P365, DOI 10.1016/0968-0004(90)90227-3; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; FERNANDEZGALLARDO S, 1992, BRIT J PHARMACOL, V105, P119, DOI 10.1111/j.1476-5381.1992.tb14221.x; FRANSON R, 1974, J LIPID RES, V15, P380; GARCIA MD, 1991, BIOCHEM J, V273, P573, DOI 10.1042/bj2730573; GARCIA MD, 1990, BIOCHEM J, V268, P91, DOI 10.1042/bj2680091; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, P515; JALINK K, 1990, J BIOL CHEM, V265, P12232; KANAHO Y, 1991, J IMMUNOL, V146, P3536; LIN PY, 1991, J IMMUNOL, V146, P1609; LUDWIG JC, 1984, ARCH BIOCHEM BIOPHYS, V232, P102, DOI 10.1016/0003-9861(84)90525-3; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1987, J IMMUNOL, V139, P154; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELOSIN JM, 1991, BIOCHEM J, V278, P29, DOI 10.1042/bj2780029; SMITH CD, 1985, J BIOL CHEM, V260, P5875; TAKENAWA T, 1985, BIOCHEM PHARMACOL, V34, P1931; TREVES S, 1987, EXP CELL RES, V168, P285, DOI 10.1016/0014-4827(87)90001-2; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VADAS P, 1984, J LAB CLIN MED, V104, P873; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; VOLPI M, 1983, BIOCHEM BIOPH RES CO, V112, P957, DOI 10.1016/0006-291X(83)91711-4; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; WYKLE RL, 1980, J BIOL CHEM, V255, P256	42	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4001	4008						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440692				2022-12-25	WOS:A1993KN53300032
J	HOUSLEY, TJ; BAUMANN, AP; BRAUN, ID; DAVIS, G; SEPERACK, PK; WILHELM, SM				HOUSLEY, TJ; BAUMANN, AP; BRAUN, ID; DAVIS, G; SEPERACK, PK; WILHELM, SM			RECOMBINANT CHINESE-HAMSTER OVARY CELL MATRIX METALLOPROTEASE-3 (MMP-3, STROMELYSIN-1) - ROLE OF CALCIUM IN PROMATRIX METALLOPROTEASE-3 (PRO-MMP-3, PROSTROMELYSIN-1) ACTIVATION AND THERMOSTABILITY OF THE LOW MASS CATALYTIC DOMAIN OF MMP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; CYSTEINE SWITCH; SYNOVIAL FIBROBLASTS; PURIFICATION; TISSUE; PROCOLLAGENASE; EXPRESSION; THERMOLYSIN; PROTEINS; TRANSIN	Recombinant human fibroblast pro-MMP-3 (prostromelysin-1) expressed in Chinese hamster ovary cells and the zymogen from cultured human dermal fibroblasts have been purified by monoclonal antibody immunoaffinity chromatography, and the role of Ca2+ in proenzyme activation and thermostability of the low mass catalytic domain of MMP-3 has been investigated. In the presence of high Ca2+ (5.0 mM), the organomercurial aminophenylmercuric acetate (APMA) initiated the stepwise removal of both NH2- and COOH-terminal domains from both recombinant and dermal fibroblast proenzymes, resulting in the generation of a heterogeneous family of nonglycosylated low mass truncated active enzyme species beginning at Phe83. However, in the presence of low Ca2+ (0.1 mM), incubation of recombinant pro-MMP-3 with or without APMA did not result in formation of either the high or low mass forms of active MMP-3 but resulted in complete autolysis of both enzyme species. The concentration of Ca2+ required for optimal pro-MMP-3 activation and stability of the low mass catalytic domain was 2.0 mM. The low mass truncated enzyme species containing the catalytic domain were remarkably heat-stable (90 min at 60-degrees-C) in high Ca2+ (5.0 mM) but rapidly autolyzed when heated at 60-degrees-C in low Ca2+ (0.1 mM). The thermostability properties of MMP-3 appeared to be specific for Ca2+, since no other divalent metal ions tested were able to confer thermostability to the low mass catalytic domain of MMP-3. From homology to the thermostable bacterial metalloprotease, thermolysin, two putative Ca2+ binding sites were found in the catalytic domain of MMP-3 and several other members of the MMP gene family. These putative Ca2+ binding sites are postulated to play an important role in stabilizing active MMP-3 and other members of the matrix metalloprotease gene family by protecting them against autolysis.	MILES RES CTR,INST BONE & CARTILAGE METAB,W HAVEN,CT 06516; MILES RES CTR,INST MOLEC BIOL,W HAVEN,CT 06516									BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; CASE JP, 1989, AM J PATHOL, V135, P1055; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; HARRISON R, 1989, ANAL BIOCHEM, V180, P110, DOI 10.1016/0003-2697(89)90096-1; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; HOWELL D, 1991, ARTHRITIS ALLIED CON, P1723; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1990, CONNECT TISSUE RES, V25, P49, DOI 10.3109/03008209009009812; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PARK AJ, 1991, J BIOL CHEM, V266, P1584; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; Sambrook J, 1989, MOL CLONING LABORATO; SELTZER JL, 1976, ARCH BIOCHEM BIOPHYS, V173, P355, DOI 10.1016/0003-9861(76)90270-8; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; Wilhelm S M, 1992, Matrix Suppl, V1, P37; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU JJ, 1991, J BIOL CHEM, V266, P5625	43	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4481	4487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440730				2022-12-25	WOS:A1993KN53300096
J	IWAMOTO, A; PARK, MY; MAEDA, M; FUTAI, M				IWAMOTO, A; PARK, MY; MAEDA, M; FUTAI, M			DOMAINS NEAR ATP GAMMA PHOSPHATE IN THE CATALYTIC SITE OF H+-ATPASE - MODEL PROPOSED FROM MUTAGENESIS AND INHIBITOR STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; PROTON-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING DOMAIN; GLYCINE-RICH SEQUENCE; ONCOGENE PRODUCT P21; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; SECONDARY-STRUCTURE; PROTEINS; ACID	The betaGly-149 residue is in a glycine-rich sequence (Gly-Gly-Ala-Gly-Val-Gly-Lys-Thr; residues 149-156) of the Escherichia coli H+-ATPase (ATP synthase) beta subunit. Substitution of betaGly-149 by Ser suppressed the effect of the betaSer-174 --> Phe mutation (Iwamoto, A., Omote, H., Hanada, H., Tomioka, N., Itai, A., Maeda, M., and Futai, M. (1991) J. Biol. Chem. 266, 16350-16355), suggesting that betaGly-149 is located near betaSer-174. In this study, we introduced different residues at position 149 and found that a single mutant betaCys-149 was defective. The effect of betaCys-149 mutation was suppressed by betaGly-172 --> Glu, betaSer-174 --> Phe, betaGlu-192 --> Val, or betaVal-198 --> Ala replacement. These results suggest that betaGly-149, betaGly-172, betaSer-174, betaGlu-192, and betaVal-198 residues are located close together in the catalytic site. From these findings we propose a model of the catalytic site of the enzyme near the gamma phosphate moiety of ATP. F1 enzymes with the double mutations betaCys-149/betaGlu-172, betaCys-149/betaPhe-174, betaCys-149/betaVal-192, and betaCys-149/betaAla-198 were less sensitive than wild-type F1 to dicyclohexylcarbodiimide and adenosine triphosphopyridoxal (an affinity analogue of ATP forming a Schiff base with the epsilon-amino group of betaLys-155 or betaLys-201), and became sensitive to N-ethylmaleimide in an ATP-protected manner. These results of inhibitor studies are consistent with the proposed model.			IWAMOTO, A (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.							ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; IDA K, 1991, J BIOL CHEM, V266, P5424; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHMI N, 1988, J BIOL CHEM, V263, P14261; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	31	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3156	3160						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428992				2022-12-25	WOS:A1993KM16100024
J	KATO, M; MIZUSHIMA, S				KATO, M; MIZUSHIMA, S			TRANSLOCATION OF CONJUGATED PRESECRETORY PROTEINS POSSESSING AN INTERNAL NONPEPTIDE DOMAIN INTO EVERTED MEMBRANE-VESICLES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; SECRETORY PROTEINS; SIGNAL PEPTIDE; SECA PROTEIN; CYTOPLASMIC MEMBRANE; AMINO TERMINUS; ATP; RECONSTITUTION; PROOMPA; COMPONENTS	Polypeptides comprising 20 amino acid residues (Y2) were covalently bound to the carboxyl terminus of a truncated proOmpA (proOmpA-D72C) through N,N'-bis(3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine (X). The length of the inverted linker domain was 2.8 nm. proOmpA-D72C-X-Y2 thus synthesized was subjected to in vitro translocation into everted membrane vesicles of Escherichia coli. The conjugated protein was translocation-competent in terms of both proteinase K resistance and signal peptide cleavage, when a proton motive force (DELTAmu(H+)) was imposed. The translocation was ATP-dependent. The proteinase K-treatment resulted in the digestion of SecA, SecE, and SecY in the membrane, suggesting that the proteinase K resistance of the Y2 domain was not due to its interaction with these Sec proteins in the secretory machinery. In the absence of DELTAmu(H+), the translocation ceased at the linker domain. Upon the imposition of DELTAmu(H+), the linker-Y2 domain underwent translocation, which did not require ATP hydrolysis as in the case of the translocation of the latter portion of usual secretory proteins. The translocation was prevented by anti-Y2 IgG even when DELTAmu(H+) was imposed. Another conjugated protein, which possesses a polypeptide comprising 61 amino acid residues after the linker (proOmpA-D72C-X-Lpp'), was synthesized. This compound was also translocated into everted membrane vesicles with cleavage of the signal peptide. These results suggest that substances to be translocated through the secretory machinery need not necessarily be solely held together by polypeptide bonds.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Kato, Masashi/AAG-3755-2021	Kato, Masashi/0000-0002-8951-3640				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; HIKITA C, 1992, J BIOL CHEM, V267, P12375; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU HM, 1991, J BIOL CHEM, V266, P9977; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, IN PRESS EMBO J, V12; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TANI K, 1991, FEBS LETT, V285, P127, DOI 10.1016/0014-5793(91)80741-K; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358	33	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3586	3593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429035				2022-12-25	WOS:A1993KM16100086
J	RIEDEL, H; PARISSENTI, AM; HANSEN, H; SU, LH; SHIEH, HL				RIEDEL, H; PARISSENTI, AM; HANSEN, H; SU, LH; SHIEH, HL			STIMULATION OF CALCIUM-UPTAKE IN SACCHAROMYCES-CEREVISIAE BY BOVINE PROTEIN KINASE-C-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; CA-2+ INFLUX; YEAST-CELLS; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; MATING PHEROMONE; GENE-EXPRESSION; DOWN-REGULATION; MEMBRANE; ACTIVATION	Ca2+ plays essential roles as a second messenger often in synergism with the calcium- and phospholipid-dependent phorbol ester, receptor, protein kinase C (PKC), which stimulates Ca2+ influx in various cell types in a potential positive feedback mechanism. To address the compatibility of these mechanisms between lower eukaryotes and mammals, we have stably expressed bovine PKCalpha in the yeast Saccharomyces cerevisiae. We find that phorbol ester binding sites are created which stimulate a specific calcium- and phospholipid-dependent catalytic activity in vitro. Phorbol ester activation in vivo stimulates PKC down-regulation, uptake of extracellular Ca2+, Ca2+ dependence of cell viability, and changes in cell morphology. This may represent activation of a putative PKC-mediated signaling pathway utilized by functional yeast homologs of mammalian PKC isoforms. These are suggested by some protein data; however, their genes have not yet been characterized (Simon, A. J., Milner, Y., Saville, S. P., Dvir, A., Mochly-Rosen, D., and Orr, E. (1991) Proc. R. Soc. Lond. B 243, 165-171). Our findings indicate that bovine PKCalpha is functional in yeast and stimulates calcium uptake in a manner similar to some of its responses in mammalian cells, which suggests compatible aspects of higher and lower eukaryotic signaling pathways and the feasibility of dissecting parts of the action of common signaling mediators in a simple genetic model.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	RIEDEL, H (corresponding author), JOSLIN DIABET CTR, MOLEC BIOL SECT, BOSTON, MA 02215 USA.							ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BORBOLLA M, 1980, J MEMBRANE BIOL, V54, P149, DOI 10.1007/BF01940568; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BROACH JR, 1983, EXPT MANIPULATION GE, P84; Campbell A.K, 1983, INTRACELLULAR CALCIU; CIGAN AM, 1987, GENE, V59, P1; DROMS KA, 1991, MOL CARCINOGEN, V4, P1, DOI 10.1002/mc.2940040102; EILAM Y, 1982, BIOCHIM BIOPHYS ACTA, V692, P238, DOI 10.1016/0005-2736(82)90527-2; EILAM Y, 1990, J GEN MICROBIOL, V136, P861, DOI 10.1099/00221287-136-5-861; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; FIELDS FO, 1991, COLD SPRING HARB SYM, V53, P557; FUJIKI H, 1985, P JPN ACAD B-PHYS, V61, P45, DOI 10.2183/pjab.61.45; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HU KQ, 1990, J BIOL CHEM, V265, P13864; IIDA H, 1990, J BIOL CHEM, V265, P21216; IIDA H, 1990, J BIOL CHEM, V265, P13391; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWAI T, 1992, J BIOCHEM, V112, P7, DOI 10.1093/oxfordjournals.jbchem.a123868; KESSELS BGF, 1987, J GEN MICROBIOL, V133, P843; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MARSH L, 1988, COLD SPRING HARB SYM, V53, P557, DOI 10.1101/SQB.1988.053.01.064; MAZUREK N, 1987, P NATL ACAD SCI USA, V84, P1277, DOI 10.1073/pnas.84.5.1277; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; Rose A H, 1975, Methods Cell Biol, V12, P1; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; SIMON AJ, 1992, YEAST, V8, pS387; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P17301; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; THEUVENET APR, 1986, BIOCHIM BIOPHYS ACTA, V855, P383, DOI 10.1016/0005-2736(86)90084-2; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; ZHERELOVA OM, 1989, FEBS LETT, V242, P330, DOI 10.1016/0014-5793(89)80495-8	52	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3456	3462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429022				2022-12-25	WOS:A1993KM16100068
J	COYNE, KE; CRISCI, A; LUBLIN, DM				COYNE, KE; CRISCI, A; LUBLIN, DM			CONSTRUCTION OF SYNTHETIC SIGNALS FOR GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR ATTACHMENT - ANALYSIS OF AMINO-ACID-SEQUENCE REQUIREMENTS FOR ANCHORING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEINS; ALKALINE-PHOSPHATASE; HYDROPHOBIC SEGMENT; TRYPANOSOMA-BRUCEI; PROTEIN; COMPLEMENT; ANTIGEN; PEPTIDE	Many membrane proteins are anchored to the cell surface through covalent attachment to a glycosyl-phosphatidylinositol (GPI) structure. The GPI anchor is added to proteins in the endoplasmic reticulum following recognition of a signal in the COOH terminus of the protein. We show that the GPI anchoring signal can be completely recreated by the synthetic polymer Ser3-Thr8-Leu14, but not Thr11-Leu14, inserted at the COOH terminus of a protein. This is consistent with previous reports that a small amino acid such as Ser, Gly, or Ala, but not Thr, is required at the GPI attachment site. Analysis of synthetic amino acid sequences established a basic three-part signal for GPI anchoring: a cleavage/attachment domain that requires small amino acids at the first (GPI anchor attachment) and third positions but with little specificity at the middle position, a spacer domain of approximately 8-12 amino acids, and a hydrophobic domain of at least 11 amino acids. The ability to design a totally synthetic GPI anchoring signal will allow precise probing of the fine structure of this signal.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041297, R21GM041297] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41297] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BERGER J, 1988, J BIOL CHEM, V263, P10016; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; GERBER LD, 1992, J BIOL CHEM, V267, P12168; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; SMITH JD, 1990, FASEB J, V4, P2188; SPARROW RL, 1983, HUM IMMUNOL, V7, P1, DOI 10.1016/0198-8859(83)90002-2; SU B, 1989, MOL CELL BIOL, V9, P3369, DOI 10.1128/MCB.9.8.3369; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; WANECK GL, 1988, P NATL ACAD SCI USA, V85, P577, DOI 10.1073/pnas.85.2.577; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8	32	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6689	6693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454641				2022-12-25	WOS:A1993KT36800087
J	CHIANCONE, E; ELBER, R; ROYER, WE; REGAN, R; GIBSON, QH				CHIANCONE, E; ELBER, R; ROYER, WE; REGAN, R; GIBSON, QH			LIGAND-BINDING AND CONFORMATION CHANGE IN THE DIMERIC HEMOGLOBIN OF THE CLAM SCAPHARCA-INAEQUIVALVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMERIC HEMOGLOBINS; HEME-PROTEINS; MYOGLOBIN; DYNAMICS; COOPERATIVITY; KINETICS	The reaction with carbon monoxide of the cooperative dimeric hemoglobin from Scapharca inaequivalvis has been examined by flash photolysis. In the nanosecond time range, geminate rebinding of 5% of dissociated CO occurs with a rate constant of 1.4 x 10(7) s-1. There is a change in absorbance of deoxyhemoglobin following photolysis at a rate of 1.2 x 10(6) s-1, consistent with a shift in the position of the Soret band to longer wavelengths. The amplitude of the change is proportional to the population of deoxydimer. In much of the Soret region this change is greater than the absorbance excursion associated with geminate recombination. There is at least one other slower change associated with the singly liganded species. Geminate rebinding of NO has components of 50, 8, and 0.035 ns-1, accounting for 75%, 25%, and less than 1% of the total reaction observed after a 35-ps photolysis flash. Simulation of diffusion of NO by molecular dynamics shows the ligands moving from the heme pocket to a subsidiary space between the edge of the heme and the surface of the protein.	UNIV ILLINOIS,DEPT CHEM,CHICAGO,IL 60680; HEBREW UNIV JERUSALEM,FRITZ HABER RES CTR,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHYS CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV MASSACHUSETTS,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Cornell University	CHIANCONE, E (corresponding author), UNIV ROMA LA SAPIENZA,CTR STUDIO BIOL MOLEC,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,I-00185 ROME,ITALY.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276, R01GM041905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43323] Funding Source: Medline; NIGMS NIH HHS [GM-41905, GM-14276] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; ANTONINI E, 1984, J BIOL CHEM, V259, P6730; ANTONINI E, 1982, STRUCTURE FUNCTION R, P67; BELLELLI A, 1990, J BIOL CHEM, V265, P13595; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CHIANCONE E, 1989, J BIOL CHEM, V264, P21062; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1989, J BIOL CHEM, V264, P100; IKEDASAITO M, 1983, J MOL BIOL, V170, P1009, DOI 10.1016/S0022-2836(83)80200-9; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	19	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5711	5718						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449933				2022-12-25	WOS:A1993KR82200053
J	HANSEN, JC; LOHR, D				HANSEN, JC; LOHR, D			ASSEMBLY AND STRUCTURAL-PROPERTIES OF SUBSATURATED CHROMATIN ARRAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; NUCLEOSOME; HISTONES; MECHANISM	Nucleosomes have been reconstituted onto dodecameric repeats of a 208-base pair nucleosome positioning sequence at various subsaturating molar ratios of histone octamer to DNA repeat (r). These reconstitutes have been characterized with respect to lattice site occupancy distributions, nucleosome positioning, chromatin folding, and histone octamer dissociation. Reconstitution at 0.3 less-than-or-equal-to r less-than-or-equal-to 0.9 produces subsaturated chromatin templates with distinct compositional limits, n +/- 2 nucleosomes, where n is the average number of nucleosomes present on the template at that r value. Nucleosomes on subsaturated arrays occupy the same set of specific positions within the repeat unit as they do on saturated templates, with only very slight differences in the relative frequency of occupation of the various positions. The nucleosomes on very subsaturated templates, i.e. r less-than-or-equal-to 0.5, are generally spread out. However, some nucleosome clustering is observed on these very subsaturated templates. These results indicate that assembly of nucleosomes onto this DNA lattice is not a strongly cooperative process. In 200 mM NaCl, subsaturated reconstitutes exhibit reduced levels of folding and histone octamer dissociation compared with saturated arrays. These results provide a framework for understanding the structural features of regions of chromatin partially depleted of nucleosomes.	ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe	HANSEN, JC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037788, R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07187] Funding Source: Medline; NIGMS NIH HHS [GM37788, GM45916] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1981, DOI 10.1021/bi00356a022; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CUSICK ME, 1983, BIOCHEMISTRY-US, V22, P3873, DOI 10.1021/bi00285a024; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1991, J MOL BIOL, V219, P391, DOI 10.1016/0022-2836(91)90179-A; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; LOHR D, 1987, J BIOL CHEM, V262, P15589; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1988, CHROMATIN, P360; VANHOLDE KE, 1978, BIOPOLYMERS, V25, P1981; VANHOLDE KE, 1988, CHROMATIN, P293; VANHOLDE KE, 1985, PHYSICAL BIOCH, P120; WIDMER RM, 1984, EMBO J, V3, P1635, DOI 10.1002/j.1460-2075.1984.tb02022.x; Wolffe A P, 1991, Trends Cell Biol, V1, P61, DOI 10.1016/0962-8924(91)90091-M	25	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5840	5848						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449950				2022-12-25	WOS:A1993KR82200073
J	LAWTON, MP; PHILPOT, RM				LAWTON, MP; PHILPOT, RM			FUNCTIONAL-CHARACTERIZATION OF FLAVIN-CONTAINING MONOOXYGENASE-1B1 EXPRESSED IN SACCHAROMYCES-CEREVISIAE AND ESCHERICHIA-COLI AND ANALYSIS OF PROPOSED FAD-BINDING AND MEMBRANE-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; COVALENT STRUCTURE; MULTIPLE FORMS; RABBIT LIVER; RAT; LUNG; PULMONARY; PROTEINS; DISTINCT; MOUSE	A cDNA encoding the flavin-containing monooxygenase of rabbit lung (FMO 1B1) was expressed in yeast and Escherichia coli and the recombinant enzymes characterized. A high copy, isopropyl-1-thio-beta-D-galactopyranoside (IPTG)-inducible E. coli expression vector, pKKHC, was used for expression in E. coli strain JM109, and a galactose-inducible vector, YEp53, was used for expression in yeast strain 334. Following transcriptional induction with IPTG or galactose, subcellular fractions were prepared and analyzed immunochemically and catalytically. Antibodies to rabbit FMO 1B1 were used to detect the recombinant proteins in the 100,000 x g pellet prepared from the 10,000 x g supernatant fraction of yeast homogenates and the 2,000 x g supernatant fraction of E. coli homogenates. No FMO 1B1 was detected in cytosol. Mobilities of the recombinant proteins in SDS-polyacrylamide gel electrophoresis appeared identical to that of the native microsomal enzyme. Catalytic similarity to the native FMO 1B1 was demonstrated by the ability of the expressed enzymes to metabolize methimazole, thiourea, dimethylaniline, and cysteamine, but not chlorpromazine or imipramine. In addition, the recombinant enzymes exhibited a number of the unique physical properties associated with FMO 1B1, including stability to elevated temperature and activation by sodium cholate and magnesium chloride. Based on the specific content of FAD, the level of expression was estimated to be approximately 2% of the total protein in the E. coli 100,000 x g particulate fraction and 1% in the fraction from yeast. To demonstrate the utility of the E. coli expression system for studying structure/function relationships of the flavin-containing monooxygenase, two mutant FMOs were expressed and characterized. One mutant, formed by deletion of a putative membrane-anchoring peptide (the 26 carboxyl-terminal amino acids) was tested for membrane association. No difference in the subcellular distribution was found between the truncated and unmodified proteins, suggesting that the 26-residue COOH-terminal peptide is not important in membrane association. Catalytic analysis of the truncated FMO 1B1 established its functional similarity to the full-length protein, indicating that the COOH terminus does not contribute to any of the unique properties of the lung enzyme. A second mutant cDNA was generated by changing the third glycine of the consensus FAD-pyrophosphate-binding site (GxGxxG) to valine. The resulting protein was immunochemically similar to the unmodified form but was catalytically inactive. Total flavin content of the particulate fraction from cells transformed with the glycine-to-valine mutant was similar to that of cells transformed with the vector alone. These results indicate that expression of the flavin-containing monooxygenase in E. coli will be useful in structural analysis of this enzyme.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ARMSTRONG KA, 1989, YEAST GENETIC ENG, P165; ATTAASAFOADJEI E, 1993, IN PRESS J BIOL CHEM; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BLACK SD, 1982, J BIOL CHEM, V257, P5929; CASHMAN JR, 1981, BIOCHEM BIOPH RES CO, V98, P147, DOI 10.1016/0006-291X(81)91881-7; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DEVEREUX TR, 1977, CHEM-BIOL INTERACT, V18, P277, DOI 10.1016/0009-2797(77)90014-X; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; DOMIN BA, 1984, ANAL BIOCHEM, V136, P390, DOI 10.1016/0003-2697(84)90234-3; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSER R, 1990, BIOCHEMISTRY-US, V29, P119, DOI 10.1021/bi00453a014; GOLD L, 1990, P11; GOMI T, 1989, J BIOL CHEM, V264, P16138; GUAN SH, 1990, BIOCHEM BIOPH RES CO, V170, P937, DOI 10.1016/0006-291X(90)92181-X; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LI YC, 1991, J BIOL CHEM, V266, P19186; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OHMIYA Y, 1981, PHARMACOLOGY, V22, P172, DOI 10.1159/000137487; OZOLS J, 1990, J BIOL CHEM, V265, P10289; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; OZOLS J, 1989, BIOCHEM BIOPH RES CO, V163, P49, DOI 10.1016/0006-291X(89)92097-4; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYNES RE, 1985, ARCH BIOCHEM BIOPHYS, V240, P77, DOI 10.1016/0003-9861(85)90010-4; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; ZIEGLER D M, 1971, Xenobiotica, V1, P523; ZIEGLER DM, 1988, DRUG METAB REV, P1	43	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5728	5734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449936				2022-12-25	WOS:A1993KR82200056
J	WAXMAN, L; CONNOLLY, TM				WAXMAN, L; CONNOLLY, TM			ISOLATION OF AN INHIBITOR SELECTIVE FOR COLLAGEN-STIMULATED PLATELET-AGGREGATION FROM THE SOFT TICK ORNITHODOROS-MOUBATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; ANTICOAGULANT PEPTIDE TAP; LEECH HIRUDO-MEDICINALIS; ADHESION; SALIVA; PROTEINS; IDENTIFICATION; THROMBOSIS; COMPLEX; MODEL	Soluble extracts from the soft tick Ornithodoros moubata were found to inhibit collagen-, ADP-, and thrombin-stimulated platelet aggregation. One inhibitory component was purified to homogeneity by a combination of gel filtration, ion-exchange, and reverse phase high pressure liquid chromatography. The purified activity, named moubatin, is a protein of molecular weight 17,000 and it inhibits the aggregation of washed human platelets stimulated by collagen with an IC50 of approximately 50 nM in the standard assay. At a concentration of moubatin that maximally inhibited collagen-stimulated platelet aggregation, no inhibition of aggregation initiated by other effectors, including arachidonic acid, thrombin, ristocetin, and the calcium ionophore A23187, was observed. Moubatin also inhibits collagen-dependent aggregation in plasma. At a higher concentration of moubatin (>1 muM) it was also possible to demonstrate an inhibitory effect on the final extent of aggregation induced by a low concentration of ADP. Although moubatin selectively inhibits platelet activation by collagen, it has only a minimal effect on the adhesion of platelets to collagen. The amino acid sequences of peptides derived from proteolytic cleavage of moubatin suggest that moubatin is a unique protein, consistent with its novel functional activity.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486	Merck & Company								COLLER BS, 1989, BLOOD, V74, P182; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; JORDAN SP, 1990, BIOCHEMISTRY-US, V29, P11095, DOI 10.1021/bi00502a012; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KELLER PM, 1992, J BIOL CHEM, V267, P6899; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MARKWARDT F, 1970, METHOD ENZYMOL, V19, P925; MUNRO R, 1991, BLOOD COAGUL FIBRIN, V2, P179, DOI 10.1097/00001721-199102000-00027; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; RIGBI M, 1987, COMP BIOCHEM PHYS C, V88, P95, DOI 10.1016/0742-8413(87)90052-1; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SARDANA M, 1991, J BIOL CHEM, V266, P13560; SCHAFFER LW, 1991, CIRCULATION, V84, P1741, DOI 10.1161/01.CIR.84.4.1741; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SMITH JB, 1991, FEBS LETT, V283, P307, DOI 10.1016/0014-5793(91)80615-A; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; VLASUK GP, 1991, THROMB HAEMOSTASIS, V65, P257; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510	23	92	99	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5445	5449						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449906				2022-12-25	WOS:A1993KR82200018
J	EVANS, MK; ROBBINS, JH; GANGES, MB; TARONE, RE; NAIRN, RS; BOHR, VA				EVANS, MK; ROBBINS, JH; GANGES, MB; TARONE, RE; NAIRN, RS; BOHR, VA			GENE-SPECIFIC DNA-REPAIR IN XERODERMA-PIGMENTOSUM COMPLEMENTATION GROUP-A, GROUP-C, GROUP-D, AND GROUP-F - RELATION TO CELLULAR-SURVIVAL AND CLINICAL-FEATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE DNA; DIHYDROFOLATE-REDUCTASE GENE; IRRADIATED MAMMALIAN-CELLS; PYRIMIDINE DIMERS; TRANSCRIBED STRAND; COCKAYNE SYNDROME; DHFR GENE; FIBROBLASTS; SENSITIVITY; EFFICIENT	We have examined the gene- and strand-specific DNA repair of UV-induced cyclobutane pyrimidine dimers in fibroblasts from normal individuals and from patients with the DNA repair-deficient disorder xeroderma pigmentosum (XP). Cells were studied from XP complementation groups A, C, D, and F. DNA repair was assessed in the essential, active gene, dihydrofolate reductase (DHFR), in the active c-myc protooncogene, and in the transcriptionally inactive delta-globin gene. In addition, repair was studied in the individual strands of the DHFR gene in normal and group C cells. In the two strains of group C cells, we find preferential DNA repair of the DHFR gene and a strand bias of the repair with more repair in the transcribed strand. This is in general accordance with previously published reports (Venema, J., van Hoffen, A., Natarajan, A. T., van Zeeland, A. A., and Mullenders, L. H. F. (1990) Nucleic Acids Res. 18, 443-448; Venema, J., van Hoffen, A., Karcagi, V., Natarajan, A. T., van Zeeland, A. A., and Mullenders, L. H. F. (1991) Mol. Cell. Biol. 11, 4128-4134), but we now find that there is more repair in the nontranscribed strand and less in the transcribed strand than what has been observed previously. In XP group A and D strains, we find little or no gene-specific DNA repair. In cells from an individual in XP complementation group F, we find less repair of dimers in the active gene than what has been observed for the overall genome. We have also measured the colony-forming ability of the strains after treatment with UV and find that this measure of survival does not correlate with the level of gene-specific repair of dimers. Thus, XP group F represents a novel repair phenotype with little or no gene-specific repair of dimers, but with relatively high UV resistance. We also evaluate the XP patients' clinical features in relation to gene-specific repair of dimers.	NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; NCI,DIV CANC BIOL DIAG & CTR,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,DIV CANC ETIOL,BIOSTAT BRANCH,BETHESDA,MD 20892; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,SMITHVILLE,TX 78957	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center			Bohr, Vilhelm/AAP-5931-2020; Evans, Michele Kim/AAE-4776-2019	Evans, Michele/0000-0002-8546-2831				ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; BARRETT SF, 1981, J INVEST DERMATOL, V76, P59, DOI 10.1111/1523-1747.ep12524886; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; DERKALOUSTIAN VM, 1974, J INVEST DERMATOL, V63, P392; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA Y, 1981, GANN MONOGR CANCER R, V27, P33; GANESAN AK, 1980, DNA REPAIR LABORAT A, V1, P90; HAYAKAWA H, 1985, MUTAT RES, V80, P381; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; KONDO S, 1989, PHOTODERMATOLOGY, V6, P89; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LONGRIDGE NS, 1976, J LARYNGOL OTOL, V90, P539, DOI 10.1017/S0022215100082438; Mansbridge J. N., 1983, CELLULAR RESPONSES D, P195; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; NORRIS PG, 1988, J AM ACAD DERMATOL, V18, P1185, DOI 10.1016/S0190-9622(88)70121-8; PATERSON MC, 1982, PROGR MUTATION RES, V4, P183; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; SADHU C, 1988, BIOTECHNIQUES, V6, P20; TAKEBE H, 1980, GENETIC ENV FACTORS, P259; TARONE RE, 1983, MUTAT RES, V3, P79; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; THRUSH DC, 1974, J NEUROL SCI, V22, P91, DOI 10.1016/0022-510X(74)90057-4; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; YAMAMURA K, 1989, BRIT J DERMATOL, V121, P471, DOI 10.1111/j.1365-2133.1989.tb15514.x; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4; ZELLE B, 1979, MUTAT RES, V62, P363, DOI 10.1016/0027-5107(79)90091-5	33	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4839	4847						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444862				2022-12-25	WOS:A1993KP88400045
J	FARWELL, AP; DIBENEDETTO, DJ; LEONARD, JL				FARWELL, AP; DIBENEDETTO, DJ; LEONARD, JL			THYROXINE TARGETS DIFFERENT PATHWAYS OF INTERNALIZATION OF TYPE-II IODOTHYRONINE 5'-DEIODINASE IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; STIMULATED GLIAL-CELLS; THYROID-HORMONE; CYTOSKELETAL FRAMEWORK; ACTIN POLYMERIZATION; CULTURED ASTROCYTES; CEREBRAL-CORTEX; CYTOCHALASIN-B; MEMBRANE; PROTEINS	In the brain, thyroid hormone dynamically regulates levels of the short-lived plasma membrane protein, type II iodothyronine 5'-deiodinase. In cultured astrocytes, thyroxine modulates deiodinase levels by activating cytoskeletal-plasma membrane interactions that increase the rate of inactivation of the enzyme. Here we characterized the effects of these thyroxine-dependent cytoskeletal interactions upon the route of internalization of the deiodinase by following the intracellular transit of the affinity-labeled substrate-binding subunit of the deiodinase (p29). Thyroxine rapidly induced the inactivation of the deiodinase and initiated the binding of p29 to F-actin. By 40 min, >75% of the p29 had been transported to an endosomal pool, which was followed by dissociation of the F-actin-p29 complex. There was no significant accumulation of p29 in the dense lysosomes seen in the presence of thyroxine. In the absence of thyroxine, p29 was internalized and transported to the dense lysosomes at a rate parallel to the inactivation rate of the deiodinase (t1/2 0.75 and 0.64 h, respectively) without involvement with the microfilaments. These data demonstrate that thyroxine targets type II iodothyronine 5'-deiodinase to an endosomal pool by activating specific protein-F-actin interactions involved in microfilament-mediated intracellular protein trafficking.			FARWELL, AP (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT MED,DIV ENDOCRINOL & METAB,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Farwell, Alan/0000-0001-7716-2719	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038772, K08DK002005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07648] Funding Source: Medline; NIDDK NIH HHS [DK02005, DK38772] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXLINE SG, 1974, J CELL BIOL, V62, P647, DOI 10.1083/jcb.62.3.647; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIU FC, 1984, J NEUROCHEM, V42, P166, DOI 10.1111/j.1471-4159.1984.tb09713.x; CIECHANOVER A, 1983, J BIOL CHEM, V258, P681; CONNOLLY JA, 1984, J CELL BIOL, V99, P148, DOI 10.1083/jcb.99.1.148; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; EVANS WH, 1978, PREPARATION CHARACTE, P93; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; FARWELL AP, 1992, THYROID, V2, pS60; HAYDEN JH, 1988, CELL MOTIL CYTOSKEL, V10, P255, DOI 10.1002/cm.970100130; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; KARIN M, 1981, J BIOL CHEM, V256, P3245; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; KOONCE MP, 1986, J CELL BIOL, V103, P605, DOI 10.1083/jcb.103.2.605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Leonard JL, 1986, THYROID HORMONE META, P189; MANGEAT PH, 1988, BIOL CELL, V64, P261, DOI 10.1016/0248-4900(88)90001-9; MARUGG RA, 1990, J STRUCT BIOL, V105, P146, DOI 10.1016/1047-8477(90)90108-O; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; PERTOFT H, 1979, SEPARATION CELLS SUB, P67; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMITH TJ, 1989, J BIOL CHEM, V264, P687; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; VEDELER A, 1990, CELL BIOL INT REP, V14, P211, DOI 10.1016/S0309-1651(05)80003-7; VEDELER A, 1991, MOL CELL BIOCHEM, V100, P183; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WAHL GM, 1981, METHODS TRANSFER DNA; WEEKE J, 1973, SCAND J CLIN LAB INV, V321, P357	44	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5055	5062						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444882				2022-12-25	WOS:A1993KP88400073
J	ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA				ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA			HA-RAS FUNCTIONS DOWNSTREAM FROM PROTEIN-KINASE-C IN V-FPS-INDUCED GENE-EXPRESSION MEDIATED BY TPA RESPONSE ELEMENTS	ONCOGENE			English	Note							PHOSPHOLIPASE-D; TYROSINE KINASES; BINDING-PROTEIN; ONCOGENIC RAS; 3T3 CELLS; ACTIVATION; SRC; HYDROLYSIS; PHOSPHATIDYLCHOLINE; TRANSFORMATION	v-Fps activates promoters under the control of the 12-O-tetradecanoyl phorbol 13-acetate (TPA) response element (TRE). The induction of TRE-mediated transcription by v-Fps was sensitive to a dominant-negative mutant of Ha-Ras. An activated derivative of Ha-Ras, v-Ha-Ras, also activated TRE-mediated transcription. v-Fps-induced TRE-mediated gene expression was sensitive to depleting cells of protein kinase C (PKC), whereas v-Ha-Ras-induced TRE-mediated transcription was insensitive to PKC depletion, suggesting that Ha-Ras functions downstream from PKC in v-Fps-induced TRE-mediated gene expression. Consistent with this hypothesis, the induction of TRE-mediated gene expression by phorbol esters that activate PKC directly was blocked by the dominant-negative Ha-Ras mutant. Thus, v-Fps-induced activation of TRE-mediated gene expression is via an intracellular signaling mechanism that is dependent upon both PKC and Ha-Ras and Ha-Ras functions downstream from PKC.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)					NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ALEXANDROPOULOS K, 1991, J BIOL CHEM, V266, P15583; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	46	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					803	807						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437865				2022-12-25	WOS:A1993KN00800035
J	CHENG, JT; HSU, HL; HWANG, LY; BAER, R				CHENG, JT; HSU, HL; HWANG, LY; BAER, R			PRODUCTS OF THE TAL1-ONCOGENE - BASIC HELIX LOOP HELIX PROTEINS PHOSPHORYLATED AT SERINE RESIDUES	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ENHANCER-BINDING; TAL-1 GENE; SCL GENE; C-MYC; EXPRESSION; LOCUS	TAL1 gene rearrangement is observed in nearly 30% of patients with T-cell acute lymphoblastic leukemia (T-ALL), and thus it represents the most common genetic lesion associated with this disease. Nevertheless, the presence of TAL1 gene products in normal or leukemic cells has not been reported. Therefore, immunoprecipitation with anti-TAL1 antisera was used to demonstrate the presence of TAL1 phosphoproteins, pp42TAL1 and pp22TAL1, in both T-ALL and erythroleukemia cell lines. The pp42TAL1 and pp22TAL1 proteins appear to be phosphorylated forms of full-length and truncated TAL1 gene products respectively. Phosphoamino acid analysis revealed that pp42TAL1 contains phosphoserine residues. The TAL1 phosphoproteins were detected in all of the T-ALL cell lines that harbor obvious TAL1 gene rearrangements. Interestingly, pp42TAL1 and pp22TAL1 were also present in some, but not all, of the T-ALL lines without detectable TAL1 gene alterations. Therefore, TAL1 activation may promote leukemogenesis in a far greater proportion of T-ALL patients than the 30% that bear gross TAL1 gene rearrangements.	UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER; NCI NIH HHS [CA46593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FITZGERALD TJ, 1991, BLOOD, V78, P2686; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GREEN AR, 1991, ONCOGENE, V6, P475; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MINOWADA J, 1988, Cancer Reviews, V10, P1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RG, 1981, J IMMUNOL, V126, P596; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	35	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437851				2022-12-25	WOS:A1993KN00800019
J	STELLRECHT, CMM; FRAIZER, G; SELVANAYAGAM, C; CHAO, LY; LEE, A; SAUNDERS, GF				STELLRECHT, CMM; FRAIZER, G; SELVANAYAGAM, C; CHAO, LY; LEE, A; SAUNDERS, GF			TRANSCRIPTIONAL REGULATION OF A HEMATOPOIETIC PROTEOGLYCAN CORE PROTEIN GENE DURING HEMATOPOIESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LEUKEMIA-CELL-LINE; SECRETORY GRANULE PROTEOGLYCAN; PEPTIDE CORE; MEGAKARYOBLASTIC DIFFERENTIATION; MOLECULAR-CLONING; HUMAN-MONOCYTES; HL-60 CELLS; C-MYC; EXPRESSION	The expression of a hematopoietic proteoglycan core protein (HpPG) gene is up-regulated during the early stages of myeloblast differentiation at a time point coinciding with the beginning of granule genesis (Stellrecht, C. M., Mars, W. M., Miwa, H., Beran, M., and Saunders, G. F. (1991) Differentiation 48, 127-135). The mechanism of this up-regulatory event was investigated by analyzing the expression and regulation of the HpPG gene during the differentiation of the pluripotent hematopoietic cell line, K562. The level of HpPG gene expression in these cells was up-regulated approximately 10-fold upon 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced megakaryocytic differentiation, as measured by Northern blot analysis. The HpPG gene's expression remained relatively unchanged during hemin-induced erythroid differentiation, further demonstrating the specificity of this regulatory event for granule-producing cell lineages. The effect of TPA induction on HpPG gene expression was also assessed during the differentiation of the myeloid leukemia cell line, HL-60. The expression of the gene was down-regulated approximately 20-fold upon TPA-induced differentiation into macrophage-like cells. In contrast, only a minimal decrease in HpPG gene expression was detected in gamma-interferon-induced monocyte differentiation. No detectable changes in expression levels were seen in HL-60 cells differentiated into granulocytes with retinoic acid or dimethyl sulfoxide. Nuclear runoff analysis demonstrated that the regulation of the HpPG gene is under transcriptional control in both TPA-induced differentiation systems.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,BOX 117,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								ALITALO R, 1990, BLOOD, V75, P1974; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1987, MOL CELL BIOL, V7, P33, DOI 10.1128/MCB.7.1.33; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRETONGORIUS J, 1978, BLOOD, V51, P45; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIORDA R, 1990, NAT IMMUN CELL GROW, V9, P91; GREENBERG ME, 1990, CURRENT PROTOCOLS MO; HUANG SS, 1982, J BIOL CHEM, V257, P1546; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUIKART SD, 1984, CANCER RES, V44, P2907; MACGREGOR PF, 1990, ONCOGENE, V5, P451; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROUDFOOT NJ, 1982, CELL, V31, P553, DOI 10.1016/0092-8674(82)90311-7; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SEGAL AW, 1974, LANCET, V2, P1248; STELLRECHT CM, 1991, DIFFERENTIATION, V48, P127, DOI 10.1111/j.1432-0436.1991.tb00251.x; STELLRECHT CM, 1989, NUCLEIC ACIDS RES, V17, P7623; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; STEVENS RL, 1987, J IMMUNOL, V139, P863; STEVENS RL, 1987, BIOL PROTEOGLYCANS; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TABILIO A, 1983, CANCER RES, V43, P4569; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4078	4084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440699				2022-12-25	WOS:A1993KN53300044
J	HAWKINS, PT; STEPHENS, LR; PIGGOTT, JR				HAWKINS, PT; STEPHENS, LR; PIGGOTT, JR			ANALYSIS OF INOSITOL METABOLITES PRODUCED BY SACCHAROMYCES-CEREVISIAE IN RESPONSE TO GLUCOSE STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIVATED NEUTROPHILS; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; CDC25 GENE; YEAST; KINASE; PATHWAY; MUTANTS; CAMP	When cultures of Saccharomyces cerevisiae are grown to stationary phase in medium containing [H-3] inositol, significant amounts of radioactivity can be detected in phosphatidylinositol, phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-bisphosphate. Addition of glucose to such cultures results in the generation of [H-3]glycerophosphoinositol, [H-3]glycerophosphoinositol 4-phosphate, and [H-3]glycerophosphoinositol 4,5-bisphosphate in the extracellular medium. We found no evidence, however, for the stimulated formation of other inositol polyphosphates. This result suggests that glucose does not stimulate the ''phospholipase C'' signalling pathway established in higher eukaryotic cells but, in contrast, stimulates specific phospholipases A or B. A variety of cell division cycle (cdc) mutants have been studied to investigate the relationship between cell cycle progression and inositol metabolism in S. cerevisiae. Mutants which are defective for completion of cell cycle ''START'' (i.e. commitment to mitosis) show reduced formation of glycerophosphoinositol 4-phosphate and glycerophosphoinositol 4,5-bisphosphate in response to glucose. In contrast, cdc mutants which are defective in post-''START'' processes show a larger glucose response than wild type cells. These results suggest that deacylation of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate may be coordinated with cell cycle control in S. cerevisiae.	SMITH KLINE BEECHAM,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND	GlaxoSmithKline				stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464				ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ANGUS WW, 1975, J BIOL CHEM, V250, P22; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIE CP, 1989, MOL PHARMACOL, V35, P526; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUTELET F, 1985, EMBO J, V4, P2635, DOI 10.1002/j.1460-2075.1985.tb03981.x; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CERBON J, 1970, J BACTERIOL, V102, P97; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; CONNOLLY BM, 1983, CURR GENET, V7, P309, DOI 10.1007/BF00376076; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; EILAM Y, 1990, J GEN MICROBIOL, V136, P861, DOI 10.1099/00221287-136-5-861; GRADO C, 1961, J BIOL CHEM, V236, P54; GRANOT D, 1991, P NATL ACAD SCI USA, V88, P5724, DOI 10.1073/pnas.88.13.5724; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; KAILBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172; KATO H, 1989, J BIOL CHEM, V264, P3116; LOPES MD, 1990, MOL CELL BIOL, V10, P2966, DOI 10.1128/MCB.10.6.2966; MCKENZIE MA, 1983, J BACTERIOL, V156, P421, DOI 10.1128/JB.156.1.421-423.1983; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; NEIMAN AM, 1990, CELL REGUL, V1, P391, DOI 10.1091/mbc.1.5.391; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1980, GENETICS, V95, P561; SCHOMERUS C, 1992, FEBS LETT, V307, P249, DOI 10.1016/0014-5793(92)80688-D; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VANAELST L, 1991, J GEN MICROBIOL, V137, P341, DOI 10.1099/00221287-137-2-341; VANDEMORTEL JBJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P421, DOI 10.1016/0005-2728(88)90019-9; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	43	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3374	3383						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429013				2022-12-25	WOS:A1993KM16100056
J	VAUGHAN, PJ; CUNNINGHAM, DD				VAUGHAN, PJ; CUNNINGHAM, DD			REGULATION OF PROTEASE NEXIN-1 SYNTHESIS AND SECRETION IN CULTURED BRAIN-CELLS BY INJURY-RELATED FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; GLIA-DERIVED NEXIN; SERINE PROTEASES; INHIBITORY ACTIVITY; OUTGROWTH ACTIVITY; HUMAN-FIBROBLASTS; PROMOTING FACTOR; RAT ASTROBLASTS; NERVOUS-SYSTEM; GROWTH-FACTOR	The clotting protease thrombin might contribute to cell damage following brain injury by its ability to retract processes on neurons and astrocytes. Protease nexin-1 (PN-1), a potent inhibitor of thrombin, is localized around cerebral blood vessels where it may protect these cells from extravasated thrombin during injury or alteration of the blood-brain barrier. Here we examined the effects of several injury-related factors on the regulation of PN-1 in cultured brain cells. Interleukin-1, tumor necrosis factor-alpha, and transforming growth factor-beta stimulated the secretion of PN-1 by the neuroblastoma cell line SK-N-SH. This cell line comprises both neuronal and glial cells. Analyses using cloned derivatives of these two cell types showed that PN-1 was secreted by the glial cells; PN-1 secretion was stimulated 90-fold by interleukin-1, 15-fold by tumor necrosis factor-alpha, 10-fold by tumor growth factor-beta, and 4-fold by platelet-derived growth factor. Measurements of newly synthesised PN-1 demonstrated that these factors produced an equivalent stimulation of PN-1 synthesis. The neuronal cells secreted two thrombin-binding proteins distinct from PN-1. Interactions between these two cell types regulated the secretion of PN-1 and the two thrombin-binding proteins.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [R01AG010598] Funding Source: NIH RePORTER; NIA NIH HHS [AG10598] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHOI BH, 1990, AM J PATHOL, V137, P741; CICCARONE V, 1989, CANCER RES, V49, P219; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FARMER L, 1990, DEV NEUROSCI-BASEL, V12, P73, DOI 10.1159/000111836; FARRELL DH, 1986, P NATL ACAD SCI USA, V83, P6858, DOI 10.1073/pnas.83.18.6858; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GLOOR S, 1986, CELL, V47, P687; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HAWKINS RL, 1986, BRAIN RES, V398, P63, DOI 10.1016/0006-8993(86)91250-3; HERLYN M, 1991, LAB INVEST, V65, P262; JONES A, 1990, IMMUNOLOGY, V71, P236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORET C, 1989, J BIOL CHEM, V264, P8319; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; REINHARD E, 1988, NEURON, V1, P387, DOI 10.1016/0896-6273(88)90188-2; ROSENBLATT DE, 1987, BRAIN RES, V415, P40, DOI 10.1016/0006-8993(87)90267-8; ROSS RA, 1983, J NATL CANCER I, V71, P741; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; WAGNER SL, 1988, BIOCHEMISTRY-US, V27, P2173, DOI 10.1021/bi00406a053; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WAGNER SL, 1991, J NEUROCHEM, V56, P234, DOI 10.1111/j.1471-4159.1991.tb02586.x; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284; WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	41	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3720	3727						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429047				2022-12-25	WOS:A1993KM16100105
J	JUNG, S; LOWE, SE; HOLLINGSWORTH, RI; ZEIKUS, JG				JUNG, S; LOWE, SE; HOLLINGSWORTH, RI; ZEIKUS, JG			SARCINA-VENTRICULI SYNTHESIZES VERY LONG-CHAIN DICARBOXYLIC-ACIDS IN RESPONSE TO DIFFERENT FORMS OF ENVIRONMENTAL-STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; LIPID-COMPOSITION; 27-HYDROXYOCTACOSANOIC ACID; CLOSTRIDIUM-ACETOBUTYLICUM; THERMAL REGULATION; MEMBRANE FLUIDITY; ZYMOMONAS-MOBILIS; ETHANOL; ALCOHOLS	Changes in the composition of membrane lipids in a strictly anaerobic, facultative acidophilic eubacterium, Sarcina ventriculi, were studied in response to various forms of environmental stress. Changes in lipid composition and structure occurred in response to changes in environmental pH. At neutral pH, the predominant membrane fatty acids ranged in chain length from C-14 to C18. However, when cells were grown at pH 3.0, a family of unique very long chain fatty acids containing 32-36 carbon atoms was synthesized and accounted for 50% of the total membrane fatty acids. These acids were identified as very long chain alpha,omega-dicarboxylic acids ranging in length from 28 to 36 carbons by electron impact mass spectrometry of methyl and (perdeuterio) methyl ester derivatives. These methyl esters all bore a vicinal dimethyl group toward the center of the chain. The assignment of the structures was confirmed by isolating one of the very long chain unusual fatty acids as the ester form after methanolysis and performing further analyses including H-1 and C-13 NMR spectroscopy and Fourier transform infrared spectroscopy. Coupling this information with the data from gas chromatography/mass spectrometry analysis, the exact structure was confirmed as alpha,omega-15,16-dimethyltricotanedioate dimethyl ester. Addition of alcohols, either metabolic (0.25 M ethanol) or nonmetabolic (0.05 M butanol) to cells grown at pH 7.0, or thermal stress (growth temperature at pH 7.0 was raised from 37 to 45 or 55-degrees-C) also resulted in the synthesis of these very long chain fatty acids. Synthesis of these very long chain alpha,omega-dicarboxylic acids was reversed by reducing the temperature back to 37-degrees-C. S. ventriculi is also unusual in that the membrane components are not the usual phospholipid components but appear to be predominantly glycolipids.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT MICROBIOL & PUBL HLTH, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, NATL SCI FDN CTR MICROBIOL ECOL, E LANSING, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; National Science Foundation (NSF)								BAER SH, 1987, APPL ENVIRON MICROB, V53, P2854, DOI 10.1128/AEM.53.12.2854-2861.1987; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; Canale-Parola E, 1986, BERGEYS MANUAL SYSTE, V2, P1100; CANALEPAROLA E, 1970, BACTERIOL REV, V34, P82, DOI 10.1128/MMBR.34.1.82-97.1970; CAREY VC, 1983, J BACTERIOL, V154, P1291, DOI 10.1128/JB.154.3.1291-1300.1983; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DOMBEK KM, 1984, J BACTERIOL, V157, P233, DOI 10.1128/JB.157.1.233-239.1984; FOSTER JW, 1990, J BACTERIOL, V172, P771, DOI 10.1128/jb.172.2.771-778.1990; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOODWIN S, 1987, J BACTERIOL, V169, P2150, DOI 10.1128/jb.169.5.2150-2157.1987; HAZLEWOOD G, 1979, J GEN MICROBIOL, V112, P15, DOI 10.1099/00221287-112-1-15; HAZLEWOOD GP, 1980, BIOCHEM J, V191, P555, DOI 10.1042/bj1910555; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P14039; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; HOLME JD, 1983, ANAL CHEM, P436; INGRAM LO, 1982, J BACTERIOL, V149, P166, DOI 10.1128/JB.149.1.166-172.1982; INGRAM LO, 1976, J BACTERIOL, V125, P670, DOI 10.1128/JB.125.2.670-678.1976; INGRAM LO, 1990, CRIT REV BIOTECHNOL, V9, P305; INGRAM LO, 1980, J BACTERIOL, V144, P481, DOI 10.1128/JB.144.2.481-488.1980; INGRAM LO, 1977, CAN J MICROBIOL, V23, P779, DOI 10.1139/m77-115; KELL DB, 1981, BIOCHEM BIOPH RES CO, V99, P81, DOI 10.1016/0006-291X(81)91715-0; KLEIN RA, 1979, BIOCHEM J, V183, P691, DOI 10.1042/bj1830691; LEPAGE C, 1987, J GEN MICROBIOL, V133, P103; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOWE SE, 1989, J BACTERIOL, V171, P3775, DOI 10.1128/jb.171.7.3775-3781.1989; LOWE SE, 1991, ARCH MICROBIOL, V155, P325; MARR AG, 1962, J BACTERIOL, V84, P1260, DOI 10.1128/JB.84.6.1260-1267.1962; MORRIS LJ, 1962, CHEM IND-LONDON, P1238; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; PLESSET J, 1982, BIOCHEM BIOPH RES CO, V108, P1340, DOI 10.1016/0006-291X(82)92147-7; Pond JL, 1986, THERMOPHILES GEN MOL, P107; REZANKA T, 1990, FEMS MICROBIOL ECOL, V73, P231, DOI 10.1016/0378-1097(90)90735-9; SCHMIDT A, 1986, APPL MICROBIOL BIOT, V25, P32; SPECTOR MP, 1986, J BACTERIOL, V173, P3907; SPROTT GD, 1991, J BACTERIOL, V173, P3907, DOI 10.1128/JB.173.12.3907-3910.1991; SULLIVAN KH, 1979, J BACTERIOL, V138, P133, DOI 10.1128/JB.138.1.133-138.1979; TERRACCIANO JS, 1988, APPL ENVIRON MICROB, V54, P1989, DOI 10.1128/AEM.54.8.1989-1995.1988; TILAK KVB, 1970, SCI CULT, V36, P399; UCHIDA K, 1974, BIOCHIM BIOPHYS ACTA, V348, P86; UCHIDA K, 1974, BIOCHIM BIOPHYS ACTA, V369, P146, DOI 10.1016/0005-2760(74)90248-3; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987	42	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2828	2835						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428957				2022-12-25	WOS:A1993KK81500084
J	SZE, JY; KOHLHAW, GB				SZE, JY; KOHLHAW, GB			PURIFICATION AND STRUCTURAL CHARACTERIZATION OF TRANSCRIPTIONAL REGULATOR LEU3 OF YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; POLYACRYLAMIDE GELS; SYNTHETIC PEPTIDES; GENE-EXPRESSION; ACTIVATOR LEU3; GAL4; PROTEINS; BINDING; REGION	The transcriptional regulatorv protein, Leu3 of Saccharomyces cerevisiae was enriched approximately 70-fold above wild type level in yeast cells carrying a pGAL1-LEU3 expression vector. Sustained overproduction of Leu3 following induction by galactose required elevated intracellular levels of alpha-isopropylmalate, a leucine pathway intermediate known to act as transcriptional co-activator. Starting with galactose-induced cells, the Leu3 protein was purified about 3,500-fold (i.e. 245,000-fold over wild type level) by a procedure that included treatment of the cell-free extract with polyethylenimine, fractionation with ammonium sulfate, heat treatment, and DNA affinity chromatography. Highly purified preparations still showed two protein bands when subjected to polyacrylamide electrophoresis under denaturing conditions. Their apparent molecular masses were about 104,000 and 110,000 kDa. The smaller of these values was very close to the maximum molecular weight obtained previously for Leu3 protein translated in vitro in a rabbit reticulocyte lysate. (The molecular weight deduced from the open reading frame of the LEU3 gene is 100,162.) Both protein bands reacted with antibodies raised against different portions of the Leu3 molecule and were, therefore, likely to represent two forms of Leu3. Treatment with calf intestinal phosphatase quantitatively converted the slower moving band into the faster moving one. Conversion was prevented by inorganic phosphate, a phosphatase inhibitor. These experiments showed that the two bands very likely correspond to phosphorylated and nonphosphorylated forms of Leu3. Phosphorylation did not appear to affect the DNA binding function of Leu3, but (indirect) effects on the activation function or effects on the modulation by alpha-isopropylmalate have not been ruled out. Electrophoretic mobility shift assays were used to estimate the apparent dissociation constants of the two specific Leu3-DNA complexes routinely seen in these assays. The values obtained were 1.1 and 2.6 nM. Finally, using size exclusion chromatography, native Leu3 protein was shown to have dimeric structure, irrespective of the state of phosphorylation.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; DANKERT JR, 1985, BIOCHEMISTRY-US, V24, P2754, DOI 10.1021/bi00332a024; DAVIS RW, 1980, ADV BACTERIAL GENET, P201; FALCO SC, 1985, NUCLEIC ACIDS RES, V13, P4011, DOI 10.1093/nar/13.11.4011; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; JONES EW, 1977, GENETICS, V85, P23; JUE R, 1978, BIOCHEMISTRY-US, V17, P5399, DOI 10.1021/bi00618a013; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; MANIATIS T, 1982, MOL CLONING LABORATO, P247; MARTINEZARIAS A, 1984, NATURE, V307, P740, DOI 10.1038/307740b0; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; PETERS MH, 1990, ARCH BIOCHEM BIOPHYS, V276, P294, DOI 10.1016/0003-9861(90)90041-V; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; SHERMAN F, 1979, METHODS YEAST GENETI, P61; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU K, 1991, MOL SWITCH STRUCTURE, V3, P28; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	41	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2505	2512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428928				2022-12-25	WOS:A1993KK81500041
J	BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI				BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS ARE ALTERED IN PLATELET HYPERAGGREGATION IN IDDM	ONCOGENE			English	Note							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; KINASE-C; PHOSPHOLIPASE-C; GENE-PRODUCT; ACTIVATION; PHOSPHORYLATION; PURIFICATION; THROMBIN; MEMBRANES; CYTOSOL	We examined the hypothesis that hyperaggregating platelets from patients with insulin dependent diabetes mellitus (IDDM) have an alteration in location and function of the guanine nucleotide (GTP)-binding proteins. Platelets from 10 IDDM and 12 age-matched healthy control subjects were collected and washed. Thrombin-induced platelet aggregation (0.025 and 0.05 units for 60 seconds) was increased in IDDM (8.3 +/- 1.8% vs 22.3 +/- 4.4%, P < .05 and 49.9 +/- 7.3% vs 70.9 +/- 7.0%, P < .05). Four small molecular weight GTP-binding proteins were identified by binding of [P-32]-GTP on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the cytosol and membranes of these platelets. Each showed specificity for binding [P-32]-GTP by competitive inhibition with unlabeled GTP. The total of the 27/28 kDa proteins was decreased in the membrane fraction (414 +/- 30 vs 252 +/- 40 dpm mug-1 protein x min, P < .05) and increased in the cytosolic fraction (62 +/- 8 vs 129 +/- 21 dpm unit-1 LDH x min, P < .05) in IDDM. The 21 kDa protein (60.3 +/- 3.5 vs 45.4 +/- 2.9 dpm mug-1 protein x min, P < .05) was decreased in platelet membrane in persons with IDDM. In conclusion, increased platelet aggregation in IDDM is accompanied by an altered cellular distribution of a 27/28 kDa GTP-binding protein. These data suggest that the low molecular weight GTP-binding proteins of the 27/28 kDa range may play an important regulatory role in the hyperaggregatory platelets in diabetes.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550; EASTERN VIRGINIA MED SCH,DIABET RES INST,DEPT INTERNAL MED,NORFOLK,VA 23501	University of Texas System; University of Texas Medical Branch Galveston; Eastern Virginia Medical School	BASTYR, EJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ENDOCRINOL,3152 MED RES BLDG,GALVESTON,TX 77555, USA.		Bastyr, Edward/AFP-2625-2022					BALDASSARE JJ, 1986, BIOCHEM BIOPH RES CO, V137, P801, DOI 10.1016/0006-291X(86)91150-2; BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P56, DOI 10.1021/bi00427a009; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BASTYR EJ, 1989, DIABETES, V38, P1097, DOI 10.2337/diabetes.38.9.1097; BASTYR EJ, 1992, THROMB RES, V65, P241, DOI 10.1016/0049-3848(92)90244-5; BASTYR EJ, 1987, DIABETES S1, V236, pA208; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; COLWELL JA, 1976, DIABETES, V25, P826; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P840; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KLAFF LJ, 1981, AM J MED, V70, P627, DOI 10.1016/0002-9343(81)90585-4; Kobbah M, 1985, Acta Paediatr Scand Suppl, V320, P50; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; NAGATA K, 1989, J BIOL CHEM, V264, P17000; OHMORI T, 1989, J BIOL CHEM, V264, P1877; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; STASIA MJ, 1989, BIOCHEMISTRY-US, V28, P9659, DOI 10.1021/bi00451a018; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P759; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; 1979, DIABETES, V28, P1039	31	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					515	518						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426753				2022-12-25	WOS:A1993KN00600033
J	COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP				COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP			TRANSCRIPTIONAL REGULATION IN THE TESTIS - A ROLE FOR TRANSCRIPTION FACTOR AP-1 COMPLEXES AT VARIOUS STAGES OF SPERMATOGENESIS	ONCOGENE			English	Article							MALE GERM LINE; C-FOS PROTEIN; IMMEDIATE-EARLY GENE; LEUCINE ZIPPER; JUN-B; DIFFERENTIAL EXPRESSION; BINDING AFFINITIES; MESSENGER-RNA; ONC GENES; CELLS	The products of two proto-oncogenes, c-fos and c-jun, have been implicated in signal transduction pathways as regulators of gene expression. Both proto-oncogenes are members of gene families encoding closely related proteins that together make up transcription factor AP-1. The expression of members of this transcription factor has been associated with cellular pathways that result in both mitosis and differentiation. We have been studying the process of spermatogenesis, which is a complex, continual cycle of cell renewal, proliferation and differentiation. Using a seasonal breeder, the European red fox (Vulpes vulpes), as our model, we have examined the expression of five AP-1 family members (c-fos, fra-1, fra-2, c-jun and junB) with a view to elucidating their role in the regulation of spermatogenesis. Unique patterns of expression, falling into three broad categories, were observed for the five genes: (i) continuous expression throughout the spermatogenic cycle (c-fos); (ii) expression only at times corresponding to the onset and shutdown of spermatogenesis (fra-1, fra-2 and c-jun); and (iii) expression only at the onset of the cycle (junB). Furthermore, the proteins were expressed in both premeiotic and post-meiotic cell types, suggesting a role in haploid, as well as diploid, gene expression in this tissue. The data suggest distinct, although not necessarily unrelated, roles for the different components of transcription factor AP-1 in the regulation of spermatogenesis.	CSIRO,DIV WILDLIFE & ECOL,COOPERAT RES CTR BIO CONTROL VERTEBRATE PESTS,LYNEHAM,ACT 2602,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	COHEN, DR (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.			Cohen, Donna/0000-0002-0419-9542				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; Englund J., 1970, Viltrevy, V8, P1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MATSUI M, 1990, ONCOGENE, V5, P249; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHIN C, 1990, J NEUROCHEM, V55, P1050, DOI 10.1111/j.1471-4159.1990.tb04595.x; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	42	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					443	455						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426749				2022-12-25	WOS:A1993KN00600024
J	PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM				PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM			A CELL-CULTURE MODEL SYSTEM FOR GENETIC ANALYSES OF THE CELL-CYCLE BY TARGETED HOMOLOGOUS RECOMBINATION	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; MAMMALIAN-CELLS; POLYOMA-VIRUS; 3T3 CELLS; C-MYC; GROWTH; PROTEIN; TRANSFORMATION; ONCOGENE; EXPRESSION	Analysis of how external proliferation signals impinge on the regulation of the cell cycle is ideally performed in cells that are capable of normal physiological withdrawal into the quiescent (G0) phase of the cell cycle as well as resumption of growth following appropriate stimuli. Targeted homologous recombination (gene targeting) provides an important new approach to determine the function of specific genes in these cellular processes. Current gene targeting methodology necessitates the use of immortal and stably diploid cell lines. This report investigates several rodent cell lines, by both genetic and physiological criteria, for use in gene targeting studies of the G0 to G1 transition. All murine cell lines examined were aneuploid. Some rat cell lines were euploid by chromosome number, but three specific genes, c-myc, c-raf-1 and Rb, were not always diploid. Only one cell line, an early-passage subclone of the Rat-I cell line, was diploid for c-myc, c-raf-I and Rb. An hprt- derivative of this cell line was isolated (designated TGR-1) and its karyotype was established by G-banding. TGR-1 cells were shown to withdraw into G0 upon serum starvation and to uniformly enter S phase after refeeding. Expression patterns of the c-myc, c-raf-1 and Rb genes and several properties of the gene products were found to be normal. The frequency of targeted homologous recombination of the c-myc and c-raf-1 loci was found to be within values observed with other cell lines. Thus, by both genetic and physiological criteria the TGR-1 cell line is a good model system for the analysis of the roles of c-myc, c-raf-1 and Rb in signal transduction, and will probably prove useful in studies involving other genes.	YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University				Shichiri, Masayoshi/0000-0002-5704-1378	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM41690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERINSTEIN N, 1992, MOL CELL BIOL, V12, P360, DOI 10.1128/MCB.12.1.360; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAMERINI-OTERO R D, 1990, New Biologist, V2, P337; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DAVIS AC, 1992, MOL CELL BIOL, V12, P2769, DOI 10.1128/MCB.12.6.2769; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; HARLOW E, 1988, ANTOBODIES; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOLCH W, 1990, ONCOGENE, V5, P713; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PARKER BA, 1979, J VIROL, V52, P456; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING; SEDIVY JM, 1989, P NATL ACAD SCI USA, V86, P227, DOI 10.1073/pnas.86.1.227; SEDIVY JM, 1987, CELL, V50, P379, DOI 10.1016/0092-8674(87)90492-2; SEDIVY JM, 1992, GENE TARGETING; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1989, BLOOD, V74, P529	50	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455944				2022-12-25	WOS:A1993KT22000011
J	BRODBECK, RM; SAMANDARI, T; BROWN, JL				BRODBECK, RM; SAMANDARI, T; BROWN, JL			EFFECTS OF MUTATIONS THAT ALTER THE GLU(264)-LYS(387) SALT BRIDGE ON THE SECRETION OF ALPHA-1-PROTEINASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN; S-VARIANT; PIZ-ALPHA-1-ANTITRYPSIN VARIANT; INTRACELLULAR DEGRADATION; MOLECULAR-BASIS; DEFICIENCY; PROTEINS; EXPRESSION; RECEPTOR; MUTANTS	The possibility that low circulating levels of alpha-1-proteinase inhibitor (A1Pi) in individuals homozygous for the S variant result from disruption of a salt bridge between Glu264 and Lys387 was examined. Mutations effecting this salt bridge were constructed by either altering the common M variant cDNA so that Glu264 was replaced by Val to produce the S variant (A1PiV264) or Lys387 was replaced by Arg (A1PiR387), Asn (A1PiN387), Glu (A1PiE387), Gly (A1PiG387), Ile (A1piI387), or Leu (A1PiL387). Measurements of secretion from transiently transfected COS cells showed that A1PiG387 and A1Pil387 are secreted as well as and at least as rapidly as A1PiM; the S variant and A1PiL387 are secreted to about the same extent as, but somewhat more slowly, than A1PiM; and the variants containing polar or charged residues at position 387 are poorly secreted, and unlike the other variants in this series undergo significant degradation by 2 h of chase. We conclude that the low circulating level of A1PiS is not due to inefficient secretion nor to excessive intracellular degradation of this variant. In addition we suspect that the lack of secretion of variants with Lys387 replaced by other charged or polar residues is due to alteration of a highly conserved sequence near the carboxyl terminus of A1Pi.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,B-121,4200 E 9TH AVE,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37128] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRANTLY M, 1988, AM J MED, V84, P13; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL DT, 1989, J BIOL CHEM, V264, P10477; ENGH R, 1989, PROTEIN ENG, V2, P407, DOI 10.1093/protein/2.6.407; ERICKSSON S, 1964, ACTA MED SCAND, V175, P197; Fagerhol M K, 1981, Adv Hum Genet, V11, P1; FAGERHOL MK, 1969, SCAND J CLIN LAB INV, V23, P97, DOI 10.3109/00365516909078092; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HELIG JS, 1989, CURRENT PROTOCOLS MO; HIRAKI DD, 1986, J IMMUNOL, V136, P4291; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JEPPSSON JO, 1978, CLIN SCI MOL MED, V55, P103, DOI 10.1042/cs0550103; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MCCRACKEN AA, 1991, J BIOL CHEM, V266, P7578; MCCRACKEN AA, 1989, MOL CELL BIOL, V9, P1406, DOI 10.1128/MCB.9.4.1406; OGUSHI F, 1988, AM REV RESPIR DIS, V137, P364, DOI 10.1164/ajrccm/137.2.364; OWEN MC, 1976, BRIT MED J, V1, P130; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROBALOCORDEIRO AJA, 1987, EUR J RESPIR DIS, V70, P261; SIFERS RN, 1989, J BIOL CHEM, V264, P2997; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; YOSHIDA A, 1979, ARCH BIOCHEM BIOPHYS, V195, P591, DOI 10.1016/0003-9861(79)90385-0	36	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6771	6776						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454649				2022-12-25	WOS:A1993KT36800099
J	CHEUNG, PH; THOMPSON, NL; EARLEY, K; CULIC, O; HIXSON, D; LIN, SH				CHEUNG, PH; THOMPSON, NL; EARLEY, K; CULIC, O; HIXSON, D; LIN, SH			CELL-CAM105 ISOFORMS WITH DIFFERENT ADHESION FUNCTIONS ARE COEXPRESSED IN ADULT-RAT TISSUES AND DURING LIVER DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEA GENE FAMILY; CELL-CAM 105; CROSSREACTING ANTIGEN NCA; BILIARY GLYCOPROTEIN-I; CARCINOEMBRYONIC ANTIGEN; HEPATOCELLULAR CARCINOMAS; MOLECULAR-CLONING; ECTO-ATPASE; COLON MUCOSA; ALTERED FORM	The rat hepatocyte cell adhesion molecule cell-CAM105 has recently been shown to be composed of at least two isoforms. Expression of the two isoforms in different tissues and during fetal liver development in rats was studied by RNase protection using a probe which could specifically and simultaneously detect both isoforms. This probe revealed protected fragments of expected lengths for the L-form and the S-form in RNA samples isolated from various adult rat tissues. High levels of the L-form and S-form messages were detected in liver and intestine, moderate levels were detected in lung, and weak signals were detected in muscle, kidney, and spleen. In liver development studies, the messages for cell-CAM105 showed a major increase on the first day after birth compared to the fetal stage, and both isoform messages were proportionally increased. These results indicate that both cell-CAM105 isoforms may have function(s) related to hepatocyte differentiation. To study the adhesion function of cell-CAM105 isoforms, full-length cDNAs for these isoforms were expressed in insect cells. The insect cells expressing the L-form cell-CAM105 were found to aggregate. However, expression of S-form cell-CAM105 did not support cell aggregation. These results indicate that L-form, but not S-form, cell-CAM105 directly mediates the cell adhesion function.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,BOX 89,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; BROWN UNIV,RHODE ISL HOSP,DEPT MED ONCOL,PROVIDENCE,RI 02903	University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043189] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA42715] Funding Source: Medline; NIGMS NIH HHS [GM43189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU TM, 1972, NATURE, V238, P152, DOI 10.1038/238152a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FRITSCHE R, 1977, IMMUNOCHEMISTRY, V14, P119, DOI 10.1016/0019-2791(77)90290-7; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HIXSON DC, 1985, MOL DETERMINANTS ANI, P253; KUPCHIK HZ, 1972, GASTROENTEROLOGY, V63, P95; KUROKI M, 1988, CANCER LETT, V43, P151, DOI 10.1016/0304-3835(88)90228-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; MCENTIRE KD, 1989, CANCER RES, V49, P6795; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; NIIKURA M, 1992, J VIROL, V66, P2631, DOI 10.1128/JVI.66.5.2631-2638.1992; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1987, EXP CELL RES, V171, P1, DOI 10.1016/0014-4827(87)90246-1; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V146, P464, DOI 10.1016/0006-291X(87)90552-3; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; SABOLIC I, 1992, AM J PHYSIOL, V262, pF217, DOI 10.1152/ajprenal.1992.262.2.F217; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; THOMPSON JA, 1987, P NATL ACAD SCI USA, V84, P2965, DOI 10.1073/pnas.84.9.2965; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; THOMPSON NL, 1991, BIOCHEM J, V273, P497, DOI 10.1042/bj2730497; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; VONKLEIST S, 1969, INT J CANCER, V4, P874; WALSH FS, 1988, NEUROCHEM INT, V12, P263, DOI 10.1016/0197-0186(88)90163-5; WATANABE S, 1988, J BIOL CHEM, V263, P2049; ZIMMERMANN W, 1989, BIOCHEM BIOPH RES CO, V163, P1197, DOI 10.1016/0006-291X(89)91105-4; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	51	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6139	6146						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454589				2022-12-25	WOS:A1993KT36800013
J	CHOGLAY, AA; PURDOM, IF; HULMES, DJS				CHOGLAY, AA; PURDOM, IF; HULMES, DJS			PROCOLLAGEN BINDING TO SPHINGOMYELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX VESICLE PROTEINS; I PROCOLLAGEN; PULMONARY SURFACTANT; EXTRACELLULAR-MATRIX; MINERAL FORMATION; LIPID-COMPOSITION; COLLAGEN; CARTILAGE; MEMBRANES; ASSOCIATION	The interactions of [H-3]procollagen I with various phospholipids were studied by density gradient centrifugation. At physiological conditions of pH, ionic strength, and temperature, there was no evidence for procollagen binding to phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine liposomes. In contrast, procollagen I bound strongly to sphingomyelin liposomes in a reversible and saturable manner, with an apparent dissociation constant (K(d)) of 2.6 nm. Binding occurred over a range of temperatures (4-37-degrees-C) and was relatively unaffected by salt concentrations up to 1.2 M NaCl. Binding was observed in phosphate buffers, but not in the presence of high concentrations of Tris or Hepes. Bovine serum albumin had no effect on procollagen binding to sphingomyelin, and neither did unlabeled type I collagen, with or without the nonhelical telopeptides. Procollagen II and denatured procollagen I also bound to sphingomyelin. Procollagen binding to sphingomyelin at 35-degrees-C was considerably reduced when small amounts of phosphatidylcholine were present, although binding was partially restored when the temperature was reduced below the corresponding phase transition temperature. Purified unlabeled procollagen COOH-terminal propeptides successfully competed for binding, and I-125-labeled COOH-terminal propeptides bound to sphingomyelin in the absence of procollagen. Weaker binding to sphingomyelin, mediated by the collagen triple helical region, was also observed; but this was dominated by the sphingomyelin-COOH-terminal propeptide interaction. The data suggest a novel mechanism for matrix vesicle-mediated biomineralization.	UNIV EDINBURGH, DEPT BIOCHEM, HUGH ROBSON BLDG, GEORGE SQ, EDINBURGH EH8 9XD, SCOTLAND	University of Edinburgh				Hulmes, David/0000-0002-0651-1317	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALI SY, 1976, FED PROC, V35, P135; ANDERSON HC, 1989, LAB INVEST, V60, P320; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; Birk DE., 1991, MATRIX ASSEMBLY, P221; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; COHEN R, 1984, BIOCHIM BIOPHYS ACTA, V778, P94, DOI 10.1016/0005-2736(84)90452-8; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DEHM P, 1973, EUR J BIOCHEM, V35, P159, DOI 10.1111/j.1432-1033.1973.tb02821.x; DELPOZO AM, 1988, COLLAGEN REL RES, V8, P133; DELPOZO AM, 1989, MATRIX, V9, P405, DOI 10.1016/S0934-8832(89)80046-0; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Gennis R. B., 1989, BIOMEMBRANE, P1; GOLDBERG BD, 1982, J CELL BIOL, V95, P752, DOI 10.1083/jcb.95.3.752; HALE JE, 1987, J BIOL CHEM, V262, P1916; HAVERSTICK DM, 1987, P NATL ACAD SCI USA, V84, P4475, DOI 10.1073/pnas.84.13.4475; HAY ED, 1991, CELL BIOL EXTRACELLU, P1; HAYASHI T, 1979, BIOCHEMISTRY-US, V18, P4182, DOI 10.1021/bi00586a022; HINEK A, 1987, J CELL BIOL, V104, P1435, DOI 10.1083/jcb.104.5.1435; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1990, FIBRONECTINS, P1; KING RJ, 1983, J BIOL CHEM, V258, P672; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KUMAR A, 1985, BIOCHEMISTRY-US, V24, P5157, DOI 10.1021/bi00340a030; KUROKI Y, 1991, BIOCHEM INT, V24, P225; LELOUS M, 1982, BIOCHIM BIOPHYS ACTA, V708, P26, DOI 10.1016/0167-4838(82)90199-6; LENTZ BR, 1981, BIOCHEMISTRY-US, V20, P6803, DOI 10.1021/bi00527a010; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; MAUCH C, 1988, J CELL BIOL, V106, P205, DOI 10.1083/jcb.106.1.205; MELLOR SJ, 1991, BIOCHEM J, V276, P777, DOI 10.1042/bj2760777; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; MOULD AP, 1987, J MOL BIOL, V195, P543, DOI 10.1016/0022-2836(87)90182-3; NEW RRC, 1990, LIPOSOMES PRACTICAL, P1; OLSEN BR, 1977, BIOCHEMISTRY-US, V16, P3030, DOI 10.1021/bi00632a034; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; OZGUNES N, 1988, BIOCHEM MED METAB B, V40, P269, DOI 10.1016/0885-4505(88)90128-4; PAJEAN M, 1991, INT J PHARM, V77, P31, DOI 10.1016/0378-5173(91)90298-3; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; PHELPS RG, 1985, COLLAGEN REL RES, V5, P405; POOLE AR, 1984, J CELL BIOL, V98, P54, DOI 10.1083/jcb.98.1.54; PRIGENTDACHARY J, 1986, EUR J BIOCHEM, V155, P133, DOI 10.1111/j.1432-1033.1986.tb09468.x; PUSEY PN, 1989, ROY SOC CH, V74, P90; RINTOUL DA, 1979, J BIOL CHEM, V254, P70; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS GF, 1986, J BIOL CHEM, V261, P14283; Ruoslahti E., 1991, CELL BIOL EXTRACELLU, P343; SMITH GN, 1989, MATRIX, V9, P186; TALL AR, 1978, J CLIN INVEST, V62, P836, DOI 10.1172/JCI109196; UNTRACHT SH, 1977, J BIOL CHEM, V252, P4449; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WATKINS MS, 1977, BIOCHEM BIOPH RES CO, V79, P640, DOI 10.1016/0006-291X(77)91160-3; WIESSNER JH, 1982, BIOCHIM BIOPHYS ACTA, V689, P490, DOI 10.1016/0005-2736(82)90307-8; WU CH, 1991, J BIOL CHEM, V266, P2983; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117	74	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6107	6114						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454585				2022-12-25	WOS:A1993KT36800008
J	JIANG, Y; SMALE, ST; GRALLA, JD				JIANG, Y; SMALE, ST; GRALLA, JD			A COMMON ATP REQUIREMENT FOR OPEN COMPLEX-FORMATION AND TRANSCRIPTION AT PROMOTERS CONTAINING INITIATOR OR TATA ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVATES TRANSCRIPTION; PREINITIATION COMPLEX; MECHANISM; INVITRO; FORM; DIRECTS; BINDING; PROTEIN; INVIVO	The involvement of ATP during transcription initiation from three basic types of RNA polymerase II promoters was investigated. Hydrolysis of the beta-gamma bond of ATP was found to be required for transcription at TATA, initiator, and initiator + TATA promoters. For all three promoters, ATP is required to melt the transcription start site region during formation of a functional open transcription complex. The use of ATP to open the DNA strands occurs rapidly. The resulting open complex is transient, since the start site re-closes rapidly upon initiation. The requirements for efficient open complex formation were similar to those for transcription in that both upstream elements and a basal element, either TATA or initiator, were necessary. The results further suggest that TATA-dependent and initiator-dependent preinitiation complex assembly pathways converge, prior to a step in which the strands are rapidly opened in the presence of ATP, to form analogous open complexes.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANDLER DW, 1980, BIOCHEMISTRY-US, V19, P1604, DOI 10.1021/bi00549a012; CHANDLER DW, 1981, NUCLEIC ACIDS RES, V9, P6031, DOI 10.1093/nar/9.22.6031; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KIM WY, 1986, J BIOL CHEM, V261, P14219; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	35	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6535	6540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454623				2022-12-25	WOS:A1993KT36800066
J	WEBER, J; LEE, RSF; WILKEMOUNTS, S; GRELL, E; SENIOR, AE				WEBER, J; LEE, RSF; WILKEMOUNTS, S; GRELL, E; SENIOR, AE			COMBINED APPLICATION OF SITE-DIRECTED MUTAGENESIS, 2-AZIDO-ATP LABELING, AND LIN-BENZO-ATP BINDING TO STUDY THE NONCATALYTIC SITES OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTON-ATPASE; HEART MITOCHONDRIAL F1-ATPASE; ISOLATED-ALPHA-SUBUNIT; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; CATALYTIC PROPERTIES; MUTANT STRAINS; UNCA MUTANTS; ADENINE-NUCLEOTIDES	Noncatalytic nucleotide sites of Escherichia coli F1-ATPase were studied by site-directed mutagenesis, covalent photolabeling with 2-azido-ATP, and lin-benzo-ATP binding. In wild-type, 89% of 2-azido-ATP label was bound to beta-subunit, whereas in the betaY354F mutant, 95% of the label was bound to alpha-subunit. In the alphaR365Y mutant, label was seen on both alpha (38%) and beta (62%); whereas in the alphaR365F mutant, 93% was on beta. The fluorescence of noncatalytic site-bound lin-benzo-ATP was quenched markedly in F1 from wild-type (76% quench), alphaR365F (85%), alphaR365Y (90%), and alphaR365Y, betaY354F (83%), but only by 28% in betaY354F. These results together demonstrate that residues alphaR365 and betaY354 lie close to the base moiety of adenine nucleotide bound in F1 noncatalytic sites. From comparison of sequences of alpha- and beta-subunits, it appears that residue alphaR365 in noncatalytic sites is equivalent to residue betaY331 of the catalytic sites. Two unintended mutants were obtained in which alpha-subunit was increased in length by 17 amino acids due to repeat of residues alpha361 to alpha377, with either F or Y in the repeated alpha365 position. Soluble F1 was obtained from both mutants, with novel properties.	MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY	Max Planck Society	WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; DUNN SD, 1980, J BIOL CHEM, V255, P1857; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; IDA K, 1991, J BIOL CHEM, V266, P5424; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LEONARD NJ, 1978, BIOCHEMISTRY-US, V17, P3677, DOI 10.1021/bi00611a001; LEONARD NJ, 1976, J AM CHEM SOC, V98, P3987, DOI 10.1021/ja00429a040; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MELESE T, 1988, J BIOL CHEM, V263, P5833; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P5569; RAO R, 1988, J BIOL CHEM, V263, P15957; RAO R, 1988, J BIOL CHEM, V263, P5640; SENDA M, 1983, ARCH BIOCHEM BIOPHYS, V220, P398, DOI 10.1016/0003-9861(83)90429-0; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; STAROS JV, 1980, TRENDS BIOCHEM SCI, V5, P320, DOI 10.1016/0968-0004(80)90140-1; VANDEYAR M, 1977, GENE, V65, P129; VERBURG JG, 1990, J BIOL CHEM, V265, P8065; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1990, J BIOL CHEM, V265, P10884; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; WISE JG, 1981, J BIOL CHEM, V256, P383; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916; [No title captured]	56	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6241	6247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454597				2022-12-25	WOS:A1993KT36800028
J	FUH, G; COLOSI, P; WOOD, WI; WELLS, JA				FUH, G; COLOSI, P; WOOD, WI; WELLS, JA			MECHANISM-BASED DESIGN OF PROLACTIN RECEPTOR ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; SERUM BINDING-PROTEIN; MUTATIONAL ANALYSIS; EXPRESSION; CLONING; LIVER; FORM; IDENTIFICATION; DETERMINANTS; PURIFICATION	The mechanism of action of two forms of the prolactin (PRL) receptor was studied using analogs of human growth hormone (hGH). At low concentrations (approximately 1 pM), hGH binds and stimulates proliferation of Nb2 cells containing the 391-residue PRL receptor as well as murine lyphoid FDC-P1 cells transfected with the 591-residue hPRL receptor. However, at high concentrations (approximately 70 muM) hGH inhibits proliferation of both these cell lines. Such a ''bell-shaped'' hormone response curve was observed for hGH stimulation of the hGH receptor (Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V., and Wells, J. A. (1992) Science 256, 1677-1680) and is consistent with the sequential formation of an active hormone-(receptor)2 complex in which hGH binds through a first site (Site 1) to a first receptor and then through a second site (Site 2) to a second receptor. By analogy to hGH activation of the hGH receptor, we find that hGH variants that are mutated in Site 1 or Site 2 are greatly reduced as agonists. Similarly, only Site 2 mutants are potent antagonists of either hGH or hPRL stimulated cell proliferation. These and other data support the notion that hGH and hPRL activate the PRL receptor by sequential dimerization and provide a rational basis for the design of potent antagonists to the prolactin receptor.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ALI S, 1991, J BIOL CHEM, V266, P20110; ASHKENAZI A, 1987, FEBS LETT, V210, P51, DOI 10.1016/0014-5793(87)81296-6; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P949, DOI 10.1210/mend-3-6-949; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUT PW, 1980, CANCER RES, V40, P2433; Kelly P A, 1991, Oxf Surv Eukaryot Genes, V7, P29; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; Schlechte J, 1980, Endocr Rev, V1, P295; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253	27	131	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5376	5381						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449901				2022-12-25	WOS:A1993KR82200009
J	MEJEAN, V; CLAVERYS, JP				MEJEAN, V; CLAVERYS, JP			DNA PROCESSING DURING ENTRY IN TRANSFORMATION OF STREPTOCOCCUS-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC TRANSFORMATION; DIPLOCOCCUS-PNEUMONIAE; DEOXYRIBONUCLEIC ACID; DONOR DNA; PNEUMOCOCCUS; MUTAGENESIS; GLYCOSYLASE; COMPETENCE; EFFICIENCY; BREAKAGE	The current model for processing DNA during entry in the transformation of Streptococcus pneumoniae is that following double-strand cleavage of DNA bound at the cell surface, uptake of one strand proceeds linearly from a newly formed 3'-end with simultaneous degradation of the opposite strand. Two important predictions of this model have been tested in the work reported here: first that the polarity of DNA degradation is the opposite of that for entry, and second that the rate of DNA degradation is (at least) equal to the rate of entry. The processing of DNA during entry was investigated using donor molecules constructed in vitro and labeled in one strand only. With uniformly labeled donor molecules, an amount of label equivalent to that taken up by the cells was recovered in acid-soluble form in the transformation medium. Experiments with 3'- or 5'-end-labeled molecules revealed that whereas essentially all of the 3'-end label was susceptible to degradation, most 5'-end label was resistant. Kinetic analysis of both entry and degradation revealed very similar rates for these processes, about 100 nucleotides s-1 at 31-degrees-C, suggesting that they occur concomitantly. Entry and degradation appear to proceed with opposite polarity, 3' --> 5' for entry and 5' --> 3' for degradation. A prediction of the entry model, that a single-strand interruption would inhibit the uptake of DNA sequences located 5' to the nick, was confirmed experimentally. Therefore, we suggest that an intact sugar phosphate backbone is required by the entry machinery for continuous uptake.	UNIV TOULOUSE 3,CNRS,UNITE MICROBIOL & GENET MOLECUL,UPR9007,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Mejean, Vincent/0000-0001-6533-5846				BALGANESH TS, 1984, GENE, V29, P221, DOI 10.1016/0378-1119(84)90182-3; CHEN JD, 1991, J BACTERIOL, V173, P283, DOI 10.1128/jb.173.1.283-290.1991; CLAVERYS JP, 1980, MOL GEN GENET, V178, P191, DOI 10.1007/BF00267229; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; GABOR M, 1966, P NATL ACAD SCI USA, V56, P1441, DOI 10.1073/pnas.56.5.1441; GOODGAL SH, 1990, J BACTERIOL, V172, P5924, DOI 10.1128/jb.172.10.5924-5928.1990; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; GUILD WR, 1963, P NATL ACAD SCI USA, V50, P106, DOI 10.1073/pnas.50.1.106; LACKS S, 1962, J MOL BIOL, V5, P119, DOI 10.1016/S0022-2836(62)80067-9; LACKS S, 1976, J MOL BIOL, V101, P255, DOI 10.1016/0022-2836(76)90376-4; LACKS S, 1974, P NATL ACAD SCI USA, V71, P2305, DOI 10.1073/pnas.71.6.2305; LACKS S, 1979, J BACTERIOL, V138, P404, DOI 10.1128/JB.138.2.404-409.1979; LACKS S, 1975, J BACTERIOL, V124, P1321, DOI 10.1128/JB.124.3.1321-1329.1975; LACKS S, 1973, J BACTERIOL, V114, P152; LACKS S, 1977, MODERN TRENDS BACTER, P35; LACKS SA, 1977, MICROBIAL INTERACTIO, P179; MEJEAN V, 1988, MOL GEN GENET, V213, P444, DOI 10.1007/BF00339614; MEJEAN V, 1984, J BACTERIOL, V158, P1175; MEJEAN V, 1991, NUCLEIC ACIDS RES, V19, P5525, DOI 10.1093/nar/19.20.5525; MEJEAN V, 1989, GENETIC TRANSFORMATI, P41; MORRISON DA, 1973, J BACTERIOL, V115, P1055, DOI 10.1128/JB.115.3.1055-1062.1973; MORRISON DA, 1973, BIOCHIM BIOPHYS ACTA, V299, P545, DOI 10.1016/0005-2787(73)90226-8; MORRISON DA, 1972, J BACTERIOL, V112, P1157, DOI 10.1128/JB.112.3.1157-1168.1972; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; POZZI G, 1987, FEMS MICROBIOL LETT, V41, P309; PUYET A, 1990, J MOL BIOL, V213, P727, DOI 10.1016/S0022-2836(05)80259-1; SETO H, 1975, J BACTERIOL, V122, P676, DOI 10.1128/JB.122.2.676-685.1975; SHOEMAKER NB, 1974, MOL GEN GENET, V128, P283, DOI 10.1007/BF00268516; TOMASZ A, 1973, BACTERIAL TRANSFORMA, P81	29	54	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5594	5599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449922				2022-12-25	WOS:A1993KR82200039
J	NILSSON, I; VONHEIJNE, G				NILSSON, I; VONHEIJNE, G			DETERMINATION OF THE DISTANCE BETWEEN THE OLIGOSACCHARYLTRANSFERASE ACTIVE-SITE AND THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; ESCHERICHIA-COLI; GLYCOSYLATION; SEQUENCE; RECEPTOR; MUTAGENESIS; TRANSLATION; TOPOLOGY	By in vitro transcription/translation of model proteins in the presence of dog pancreas microsomes, we have measured the minimum distance of an acceptor site from the lumenal end of a transmembrane segment required for N-linked glycosylation, both when the acceptor site is placed N- and C-terminally to the membrane anchor. We observe a sharp threshold at a distance of 12-14 residues, suggesting that the oligosaccharyltransferase active site is 30-40 angstrom above the membrane and is oriented roughly parallel to the membrane surface.	KAROLINSKA INST,CTR STRUCT BIOCHEM,DEPT MOLEC BIOL,NOVUM,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet			Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				AVANOV AY, 1991, MOL BIOL+, V25, P237; BERGMANN CC, 1989, EMBO J, V8, P1695, DOI 10.1002/j.1460-2075.1989.tb03561.x; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; ERICKSON BW, 1976, PROTEINS; FRANGIONE B, 1980, BIOCHEMISTRY-US, V19, P4304, DOI 10.1021/bi00559a024; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JI, 1992, J BIOL CHEM, V267, P938; LILJESTROM P, 1991, J VIROL, V65, P147; MOORE KE, 1987, J BIOL CHEM, V262, P8806; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	22	377	383	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5798	5801						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449946				2022-12-25	WOS:A1993KR82200066
J	ROBITZKI, A; BODENBACH, L; VOSS, H; PYERIN, W				ROBITZKI, A; BODENBACH, L; VOSS, H; PYERIN, W			HUMAN CASEIN KINASE-II - THE SUBUNIT-ALPHA PROTEIN ACTIVATES TRANSCRIPTION OF THE SUBUNIT-BETA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; ESCHERICHIA-COLI; CELLS; PHOSPHORYLATION; EXPRESSION; CLONING; STIMULATION; FIBROBLASTS; PROMOTER	Casein kinase II (CKII), an ubiquitous serine/threonine protein kinase in control of a variety of crucial cellular functions, is composed of catalytic subunits (alpha and alpha') and regulatory subunits (beta). The adjusted activity of CKII is determined by the actual conformational state of CKIIbeta and the stoichiometry of the CKII subunits. Thus, the expression control of CKIIbeta is of particular concern. Carrying out gel shifts and footprints with affinity-purified proteins and cellular extracts in combination with mutational analysis we find that aside NF1 and Sp1, two out of the many factors predicted to bind to the upstream promoter region of the human CKIIbeta gene (Voss, H., Wirkner, U., Jakobi, R., Hewitt, N. A., Schwager, C., Zimmermann, J., Ansorge, W., and Pyerin, W. (1991) J. Biol. Chem. 266, 13706-13711), CKIIalpha protein is able to complex with the CKIIbeta gene promoter. The complex of CKIIbeta-DNA/CKIIalpha-protein is shown to occur within the 170-239-base pair (bp) segment upstream of the first transcription start site of the gene. The DNA motif contains, in a distance of 44 bp, two GC-rich boxes, 5'-GGGGCCC and 5'-CCCCTGGGC, and represents a novel cis-acting element; the binding of the CKIIalpha protein activates the CKIIbeta gene promoter. This is manifested by driving the expression of the indicator gene luciferase or of CKIIalpha-cDNA in HeLa cells. The binding of the CKIIalpha protein is inhibited due to CKIIbeta protein addition or by mimicking the corresponding situation in vivo by overexpression of the CKII subunits. The data suggest that cells may maintain a certain CKII subunit stoichiometry via transcriptional control; excess of nuclear CKIIalpha protein could activate the CKIIbeta gene transcription causing CKIIbeta protein to increase which, in turn, could feed back to abolish the action of CKIIalpha at the CKIIbeta gene promoter.	GERMAN CANC RES CTR, W-6900 HEIDELBERG 1, GERMANY; EUROPEAN MOLEC BIOL LAB, BIOCHEM INSTRUMENTAT, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)								ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, J BIOL CHEM, V258, P1403; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEM BIOPH RES CO, V173, P862, DOI 10.1016/S0006-291X(05)80866-6; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HU E, 1991, J BIOL CHEM, V266, P19796; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1987, ENZYMES, V17; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYERIN W, 1988, BIOL CHEM H-S, V369, P896; PYERIN W, 1992, RECENT ADV CELL MOL, V4, P87; PYERIN W, 1992, ANN NY ACAD SCI, V650, P295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; VOSS H, 1991, J BIOL CHEM, V266, P13706; WIRKNER U, 1992, BIOCHIM BIOPHYS ACTA, V1131, P220, DOI 10.1016/0167-4781(92)90083-C; YANGFENG TL, 1990, GENOMICS, V8, P741, DOI 10.1016/0888-7543(90)90266-W; YANGFENG TL, 1991, NUCLEIC ACIDS RES, V19, P7125, DOI 10.1093/nar/19.25.7125; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	49	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5694	5702						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449932				2022-12-25	WOS:A1993KR82200051
J	ARAKAWA, H; IWASATO, T; HAYASHIDA, H; SHIMIZU, A; HONJO, T; YAMAGISHI, H				ARAKAWA, H; IWASATO, T; HAYASHIDA, H; SHIMIZU, A; HONJO, T; YAMAGISHI, H			THE COMPLETE MURINE IMMUNOGLOBULIN CLASS SWITCH REGION OF THE ALPHA-HEAVY CHAIN GENE-HIERARCHICAL REPETITIVE STRUCTURE AND RECOMBINATION BREAKPOINTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC ONCOGENE; CIRCULAR DNA; NUCLEOTIDE-SEQUENCES; GAMMA-GENES; PLASMACYTOMAS; MECHANISM; EPSILON; REARRANGEMENT; TRANSLOCATION; DUPLICATION	A 7255-base pair (bp) sequence, including the previously sequenced murine segments of Ialpha, Salpha, and Calpha, has been completed. Homology matrix comparison revealed a switch repetitive region of 4.2 kilobases (kb) composed of 20-80-bp homology runs, including the previously assigned Salpha region. We distinguished several stretches of duplication, i.e. the central 0.8-kb repetitive region, with some 80-bp staggered consensus repeats containing 20-30-bp subsets, made up of the primordial pentamers CTG(A/G)G. All the breakpoints of the Salpha switch recombination, including those generated by the translocation of the c-myc protooncogene and those catalyzed by bacterial extracts, are located within the consensus sequence subsets of the 4.2-kb repetitive region.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN; KYOTO UNIV,CTR MOLEC BIOL & GENET,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University			Honjo, Tasuku/N-4470-2016					AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; AKIRA S, 1983, CELL, V34, P545, DOI 10.1016/0092-8674(83)90387-2; CALAME K, 1982, P NATL ACAD SCI-BIOL, V79, P6994, DOI 10.1073/pnas.79.22.6994; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HAYASHIDA H, 1984, EMBO J, V3, P2047, DOI 10.1002/j.1460-2075.1984.tb02090.x; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; IWASATO T, 1992, J EXP MED, V175, P1539, DOI 10.1084/jem.175.6.1539; KATAOKA T, 1980, P NATL ACAD SCI-BIOL, V77, P919, DOI 10.1073/pnas.77.2.919; KATAOKA T, 1983, P NATL ACAD SCI-BIOL, V80, P2666, DOI 10.1073/pnas.80.9.2666; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; MARCU KB, 1982, NATURE, V298, P87, DOI 10.1038/298087a0; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; Miyata T, 1985, Interferon, V6, P1; MOWATT MR, 1986, J IMMUNOL, V136, P2674; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; OBATA M, 1981, P NATL ACAD SCI-BIOL, V78, P2437, DOI 10.1073/pnas.78.4.2437; Ott D E, 1989, Int Immunol, V1, P582, DOI 10.1093/intimm/1.6.582; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SZUREK P, 1985, J IMMUNOL, V135, P620; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; WU TT, 1984, EMBO J, V3, P2033, DOI 10.1002/j.1460-2075.1984.tb02088.x; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4651	4655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444838				2022-12-25	WOS:A1993KP88400017
J	DIDONATO, A; CIARDIELLO, MA; DENIGRIS, M; PICCOLI, R; MAZZARELLA, L; DALESSIO, G				DIDONATO, A; CIARDIELLO, MA; DENIGRIS, M; PICCOLI, R; MAZZARELLA, L; DALESSIO, G			SELECTIVE DEAMIDATION OF RIBONUCLEASE-A - ISOLATION AND CHARACTERIZATION OF THE RESULTING ISOASPARTYL AND ASPARTYL DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; PANCREATIC RIBONUCLEASE; NONENZYMATIC DEAMIDATION; CRYSTAL-STRUCTURE; DISULFIDE LOOP; RESIDUES; ASPARAGINYL; RESOLUTION; SEQUENCE; PROTEINS	Selective deamidation of proteins and peptides is a reaction of great interest, whether it has physiological significance as in protein aging, or occurs as a disturbing event in the preparation of natural or recombinant proteins. Deamidation of bovine pancreatic ribonuclease A, RNase A, a classical model protein, has been reported to occur only after denaturation of the protein, or under harsh conditions. In this paper convenient procedures are described for selective deamidation of Asn67 in native RNase A under mild conditions. Furthermore, for the first time, both products of deamidation were isolated: the aspartyl and the isoaspartyl containing protein derivatives. Replacement of Asn67 with either residue lowers the catalytic activity of the enzyme, on RNA and on model substrates, except when a dinucleotide with a purine on the 5' side is the substrate. In the latter case an intriguing increase in the specificity constant is observed. The Asp67 derivative was found to refold, after full denaturation and reduction, at the same rate as the fully amidated protein, whereas the iso-Asp67 derivative refolded at half that rate. It is hypothesized that this effect is due to a delayed formation of disulfide 65-72 for the presence of the abnormal isopeptide bond between residues 67 and 68.	UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,VIA MEZZOCANNONE 16,I-80134 NAPLES,ITALY; UNIV NAPLES,DIPARTIMENTO CHIM,I-80134 NAPLES,ITALY	University of Naples Federico II; University of Naples Federico II				CIARDIELLO, MARIA ANTONIETTA/0000-0002-7203-0554; DI DONATO, Alberto/0000-0001-9129-9850				ALTMANN KH, 1990, J AM CHEM SOC, V112, P4926, DOI 10.1021/ja00168a044; ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1984, J BIOL CHEM, V259, P714; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; BORNSTEIN P, 1970, J BIOL CHEM, V245, P4854; Bornstein P, 1977, Methods Enzymol, V47, P132; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DIDONATO A, 1981, BIOCHEMISTRY-US, V20, P7232, DOI 10.1021/bi00528a028; DIDONATO A, 1986, BIOCHEMISTRY-US, V25, P8361, DOI 10.1021/bi00374a005; GEIGER T, 1987, J BIOL CHEM, V262, P785; GOREN HJ, 1970, BIOCHEMISTRY-US, V9, P974, DOI 10.1021/bi00806a037; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; KUNITZ M, 1946, J BIOL CHEM, V164, P563; MANJULA BN, 1976, INT J PEPT PROT RES, V8, P275; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTIN PD, 1987, J BIOL CHEM, V262, P15930; MATSUO H, 1975, PROTEIN SEQUENCE DET, P105; MAZZARELLA L, 1987, GAZZ CHIM ITAL, V117, P91; MILBURN PJ, 1988, J PROTEIN CHEM, V7, P377, DOI 10.1007/BF01024887; MONTELIONE GT, 1984, J AM CHEM SOC, V106, P7946; MONTELIONE GT, 1989, ACCOUNTS CHEM RES, V22, P70, DOI 10.1021/ar00158a004; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; NEMETHY G, 1979, P NATL ACAD SCI USA, V76, P6050, DOI 10.1073/pnas.76.12.6050; PALMIERI M, 1985, EUR J BIOCHEM, V152, P275, DOI 10.1111/j.1432-1033.1985.tb09194.x; PICCOLI R, 1984, J BIOL CHEM, V259, P693; PICCOLI R, 1982, FEBS LETT, V140, P307, DOI 10.1016/0014-5793(82)80920-4; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; QUARTO N, 1987, J REPROD FERTIL, V80, P81, DOI 10.1530/jrf.0.0800081; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; TAKAHASHI S, 1976, B I CHEM RES KYOTO U, V54, P141; THANNHAUSER TW, 1985, BIOCHEMISTRY-US, V24, P7681, DOI 10.1021/bi00347a027; VENKATESH YP, 1985, INT J PEPT PROT RES, V25, P27; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WALKER EJ, 1978, BIOCHEM J, V173, P1; WALKER EJ, 1975, BIOCHEM J, V147, P425, DOI 10.1042/bj1470425; WEARNE SJ, 1989, PROTEINS, V5, P8, DOI 10.1002/prot.340050103; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WLODAWER A, 1985, BIOL MACROMOL, V2, P395; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	43	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4745	4751						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444851				2022-12-25	WOS:A1993KP88400032
J	PRIVALLE, CT; FRIDOVICH, I				PRIVALLE, CT; FRIDOVICH, I			IRON SPECIFICITY OF THE FUR-DEPENDENT REGULATION OF THE BIOSYNTHESIS OF THE MANGANESE-CONTAINING SUPEROXIDE-DISMUTASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATION; ANAEROBIC BIOSYNTHESIS; INDUCTION; GENE; MECHANISM; PROTEIN; OPERON; EXPRESSION; CHELATORS; REPRESSOR	The Fur protein, which regulates iron uptake in Escherichia coli, also represses the biosynthesis of the manganese-containing superoxide dismutase (MnSOD). A strain of E. coli bearing a lacZ fusion to the aerobactin operon was used to compare the metal specificities of the regulation of MnSOD and of aerobactin by Fur. Iron, but not manganese, acted as a corepressor of the Fur-dependent inhibition of MnSOD biosynthesis. The iron-mediated inhibition of MnSOD biosynthesis was dependent upon an intact fur locus, indicating that the effect of iron is mediated by the fur gene product. The suppression of the accumulation of MnSOD by iron, but not by manganese, was not due to destabilization of the MnSOD polypeptide by iron. Thus this effect of iron was also seen in a sodA::lacZ operon fusion in which the production of beta-galactosidase was regulated by the sodA promoter. In contrast, both iron and manganese served as corepressors of aerobactin biosynthesis. It thus appears that the effectiveness of specific metal cations to act as corepressors with Fur varies with the gene being regulated by the Fur-metal complex.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1985, J BACTERIOL, V161, P450, DOI 10.1128/JB.161.1.450-453.1985; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; GREGORY EM, 1973, J BACTERIOL, V114, P543, DOI 10.1128/JB.114.2.543-548.1973; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; HANTKE K, 1981, MOL GEN GENET, V182, P288, DOI 10.1007/BF00269672; HASSAN HM, 1987, J BIOL CHEM, V262, P17173; HASSAN HM, 1984, FEMS MICROBIOL LETT, V25, P233; HASSAN HM, 1992, P NATL ACAD SCI USA, V89, P3217, DOI 10.1073/pnas.89.8.3217; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HASSAN HM, 1980, J BACTERIOL, V141, P156, DOI 10.1128/JB.141.1.156-163.1980; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LWORY OH, 1951, J BIOL CHEM, V193, P265; Miller J.H., 1972, EXPT MOL GENETICS; MOODY CS, 1984, J BIOL CHEM, V259, P2821; NAIK SM, 1990, P NATL ACAD SCI USA, V87, P2618, DOI 10.1073/pnas.87.7.2618; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; POSTLE K, 1990, J BACTERIOL, V172, P2287, DOI 10.1128/jb.172.5.2287-2293.1990; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; PRIVALLE CT, 1992, J BIOL CHEM, V267, P9140; PUGH SYR, 1985, J BACTERIOL, V162, P196, DOI 10.1128/JB.162.1.196-202.1985; PUGH SYR, 1984, J BACTERIOL, V160, P137, DOI 10.1128/JB.160.1.137-142.1984; SCHIAVONE JR, 1988, J BIOL CHEM, V263, P4269; TAKEDA Y, 1986, NUCLEIC ACIDS RES, V14, P4577, DOI 10.1093/nar/14.11.4577; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	31	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5178	5181						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444893				2022-12-25	WOS:A1993KP88400089
J	CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF				CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF			GENOMIC STRUCTURE, CDNA-SEQUENCE, AND EXPRESSION OF GLY96, A GROWTH FACTOR-INDUCIBLE IMMEDIATE-EARLY GENE ENCODING A SHORT-LIVED GLYCOSYLATED PROTEIN	ONCOGENE			English	Note							NF-KAPPA-B; C-FOS; CELLS; FIBROBLASTS; TRANSITION; MYC; SET	We report the cDNA sequence and genomic structure of gly96, an immediate early gene inducible by serum growth factors in mouse fibroblasts. It encodes a 153-amino acid protein that does not share significant sequence similarity with any known protein. In the adult mouse, gly96 is expressed predominantly in the lung, testes and the uterus. We have identified the Gly96 protein in Balb/c 3T3 cells using affinity-purified antibodies recognizing the Gly96 polypeptide. We show that Gly96 is glycosylated and has a short half-life in serum stimulated fibroblasts.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565, R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [CA52220, CA46565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P1151	22	55	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					797	801						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437864				2022-12-25	WOS:A1993KN00800034
J	OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H				OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H			ESCAPE FROM REDOX REGULATION ENHANCES THE TRANSFORMING ACTIVITY OF FOS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; CHICKEN-EMBRYO FIBROBLASTS; JUN PROTO-ONCOGENE; C-JUN; LEUCINE ZIPPER; V-FOS; GENE FAMILY; PROTEINS; PHOSPHORYLATION	Fos and Jun form dimeric complexes that bind to DNA sequences containing activator protein 1 (AP-1) sites and regulate gene expression. The in vitro DNA-binding activity of these proteins is sensitive to reduction-oxidation (redox). Reduction of a single conserved cysteine residue, located in the DNA-binding domain, either by reducing agents or by a nuclear redox factor (Ref-1), is required for AP-1 DNA-binding activity. Replacing the critical cysteine with serine results in a protein that can bind to DNA in vitro even under oxidizing conditions. To determine whether redox control affects the function of Fos in vivo, we have constructed, and compared the properties of, retroviral vectors expressing either a truncated Fos protein (F118-211) or a truncated Fos protein in which the critical cysteine was replaced by serine (FC154S). In infected chicken embryo fibroblasts (CEFs), both vectors expressed similar levels of Fos protein, which formed heterodimers with Jun at equivalent efficiencies. However, extracts from cells expressing FC154S exhibited a threefold increase in AP-1 DNA-binding activity compared with cells expressing F118-211. Furthermore, this enhanced binding activity was resistant to treatment with the oxidizing agent diamide. Infection of CEFs by virus expressing FC154S resulted in increased numbers of transformed colonies and an increase in colony size compared with those obtained following infection by virus expressing Fos 118-211. These results suggest that redox regulation may limit the total level of functional Fos-Jun complexes in vivo and that escape from this control enhances transforming activity.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo			Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1988, SCIENCE, V239, P1150; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KENUWEIN T, 1987, CELL, V48, P647; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	106	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					695	701						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437852				2022-12-25	WOS:A1993KN00800021
J	BAGLIA, FA; JAMESON, BA; WALSH, PN				BAGLIA, FA; JAMESON, BA; WALSH, PN			IDENTIFICATION AND CHARACTERIZATION OF A BINDING-SITE FOR FACTOR-XIIA IN THE APPLE-4 DOMAIN OF COAGULATION FACTOR-XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HEAVY-CHAIN; FACTOR-IX; FUNCTIONAL-CHARACTERIZATION; ACTIVATION; MECHANISM; PLASMA; ANTIBODIES; IONS	Previously we have characterized a binding site for high M(r) kininogen in the first of four tandem-repeat (Apple) domains within the heavy chain region of factor XI (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1990) J. Biol. Chem. 265, 4149-4154; Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1991) J. Biol. Chem. 267, 4247-4252), whereas a substrate binding site for factor IX was localized to the second Apple (A2) domain (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1991) J. Biol. Chem. 266, 24190-24197). To define the factor XI domain that binds factor XIIa, we have screened a panel of synthetic peptides for their capacity to inhibit factor XI activation by factor XIIa. Peptide Gly326-Lys357 (located in the A4 domain) is a noncompetitive inhibitor of factor XI activation by factor XIIa (K(i) = 3.75 muM), whereas structurally similar peptides from the A1, A2, and A3 domains were required at >1000-fold higher concentrations for similar effects. The same peptide (Gly326-Lys357) is a competitive inhibitor of factor XIIa amidolytic activity (K(i) = 3.8 muM) suggesting that it binds near the active site of factor XIIa. Computer modeling was used to predict the secondary and tertiary structure of the A4 domain of factor XI that interacts with factor XIIa. Rationally designed, conformationally constrained peptides were synthesized comprising residues Ala317-Gly326, Lys331-Lys340, and Gly344-Gly350, which act in concert to inhibit factor XI-activation by factor XIIa. Finally, a conformationally constrained peptide spanning residues Ala317-Gly350 inhibits factor XIIa-catalyzed factor XI activation 50% at a concentration of 5 x 10(-7) M. These results, interpreted in the context of the model, suggest that the sequence of amino acids from Ala317 through Gly350 of the heavy chain of the A4 domain of factor XI contains three peptide structures, possibly consisting of three antiparallel beta-strands that together comprise a contact surface for interacting with factor XIIa.	TEMPLE UNIV, HLTH SCI CTR,SCH MED,SOL SHERRY THROMBOSIS RES CTR, 3400 N BROAD ST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University					NHLBI NIH HHS [HL45486, HL46213, HL25661] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, R01HL025661, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA H, 1986, J CLIN INVEST, V78, P1631, DOI 10.1172/JCI112756; ASAKAI R, 1987, BIOCHEMISTRY-US, V25, P2417; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1989, BLOOD, V74, P244; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FAIR BD, 1977, P SOC EXP BIOL MED, V155, P199; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KIRBY EP, 1983, BLOOD, V61, P652; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAGNI MV, 1985, BLOOD, V65, P719; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; SCOTT CF, 1984, BLOOD, V63, P42; SEGAL IH, 1974, ENZYME KINETICS, P100; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1992, IN PRESS METHODS ENZ	30	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3838	3844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440679				2022-12-25	WOS:A1993KN53300011
J	ELSHOURBAGY, NA; KORMAN, DR; WU, HL; SYLVESTER, DR; LEE, JA; NUTHALAGANTI, P; BERGSMA, DJ; KUMAR, CS; NAMBI, P				ELSHOURBAGY, NA; KORMAN, DR; WU, HL; SYLVESTER, DR; LEE, JA; NUTHALAGANTI, P; BERGSMA, DJ; KUMAR, CS; NAMBI, P			MOLECULAR CHARACTERIZATION AND REGULATION OF THE HUMAN ENDOTHELIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SEQUENCE-ANALYSIS; BINDING-SITES; MESSENGER-RNA; FUNCTIONAL EXPRESSION; I-125 ENDOTHELIN-1; CLONING; CDNA; CELLS; RAT	Endothelin receptors (ETRs) are distributed throughout a variety of tissues. Two human cDNAs were identified which encode distinct ETR proteins. One cDNA encoded a 427-amino acid protein that shared 91% identity to rat ET(A)R. The second cDNA encoded a 442-amino acid protein that was 88% identical to rat ET(B)R. Ligand binding studies of the cloned receptors expressed in COS cells confirmed that they were pharmacologically ET(A)R and ET(B)R subtypes; although the selective antagonist BQ123 showed a potency similar to ET-3 in displacing I-125-ET-1 binding to ET(A)R. This observation contrasts with rat ET(A)R pharmacology where BQ123 has a 100-fold higher affinity than ET3. Chinese hamster ovary cells expressing the human ET(A)R displayed equal potencies in displacing I-125-ET-1 binding, which indicates that rat and human ET(A)R are pharmacologically distinct. Electrophysiological studies of both ETRs expressed in Xenopus oocytes revealed that they are functional. Northern analysis indicated that the two ETRs are differentially expressed in many tissues. Marmosets maintained on a high fat/high cholesterol diet exhibited 3-fold increase in ET(B)R mRNA levels with little change in ET(A)R mRNA levels. Availability of cDNA clones for ETR subtypes can open avenues for future analysis of their role in pathophysiology of various diseases.	SMITHKLINE BEECHAM PHARMACEUT, DEPT RENAL PHARMACOL, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline	ELSHOURBAGY, NA (corresponding author), SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC GENET, KING OF PRUSSIA, PA 19406 USA.		chitta, suresh kumar/N-1569-2016; Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CALVO JJ, 1990, ENDOCRINOLOGY, V126, P2288, DOI 10.1210/endo-126-5-2288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHVIGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294; CYR C, 1991, BIOCHEM BIOPH RES CO, V181, P184, DOI 10.1016/S0006-291X(05)81399-3; DAVENPORT AP, 1989, J CARDIOVASC PHARM, V13, pS166, DOI 10.1097/00005344-198900135-00045; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON RAF, 1988, ANNU REP MED CHEM, V23, P221; ELSHOURBAGY NA, 1992, EUR J BIOCHEM, V204, P491, DOI 10.1111/j.1432-1033.1992.tb16659.x; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HOFFMAN A, 1990, AM J HYPERTENS, V3, P789, DOI 10.1093/ajh/3.10.789; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; JONES CR, 1989, NEUROSCI LETT, V97, P276, DOI 10.1016/0304-3940(89)90610-1; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KLOOG Y, 1989, FEBS LETT, V253, P199, DOI 10.1016/0014-5793(89)80958-5; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSEKI C, 1989, NEUROSCI RES, V6, P581, DOI 10.1016/0168-0102(89)90047-3; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LYSKO PG, 1991, NEUROPEPTIDES, V18, P83, DOI 10.1016/0143-4179(91)90005-4; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAMUTA M, 1991, BIOCHEM BIOPH RES CO, V177, P34, DOI 10.1016/0006-291X(91)91944-8; NAMBI P, 1992, J BIOL CHEM, V267, P19555; NAMBI P, 1990, EUR J PHARMACOL, V187, P113, DOI 10.1016/0014-2999(90)90346-8; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8; ROSOLOWSKY LJ, 1990, ENDOCRINOLOGY, V126, P1860, DOI 10.1210/endo-126-4-1860; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V161, P320, DOI 10.1016/0006-291X(89)91599-4; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMPSON WK, 1991, ENDOCRINOLOGY, V128, P1465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHICHIRI M, 1989, BIOCHEM BIOPH RES CO, V163, P1332, DOI 10.1016/0006-291X(89)91124-8; SHICHIRI M, 1990, HYPERTENSION, V15, P493, DOI 10.1161/01.HYP.15.5.493; SHIGENO T, 1990, CEREBROVAS BRAIN MET, V2, P227; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; STOJIKOVIC SS, 1990, MOL PHARMACOL, V39, P762; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X	67	183	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3873	3879						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440682				2022-12-25	WOS:A1993KN53300016
J	MAEDAYORITA, K; MASSEY, V				MAEDAYORITA, K; MASSEY, V			ON THE REACTION-MECHANISM OF PHENOL HYDROXYLASE - NEW INFORMATION OBTAINED BY CORRELATION OF FLUORESCENCE AND ABSORBENCY STOPPED FLOW STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE HALF-REACTION; PARA-HYDROXYBENZOATE HYDROXYLASE; CONTAINING MONO-OXYGENASE; ABSORPTION-SPECTRA; ANTHRANILATE HYDROXYLASE; FLAVIN INTERMEDIATE; DERIVATIVES; SUBSTRATE; RADICALS; YEAST	Steps in the hydroxylation pathway of the flavoprotein phenol hydroxylase with resorcinol as substrate have been studied by a combination of fluorescence and absorbance stopped flow techniques. In the presence of azide, a series of highly fluorescent oxygenated flavin intermediates has been observed, corresponding to those previously detected by absorbance measurements (Detmer, K., and Massey, V. (1985) J. Biol. Chem. 260, 5998-6005). In addition, yet another intermediate has been found as the immediate product of the reaction of the reduced enzyme with O2. This new species is non-fluorescent in the presence of azide, but fluorescent in the absence of monovalent anions and had escaped detection in previous absorbance studies because of the similarity in its rates of formation and conversion to the next intermediate and similarity in their spectra. These two early intermediates are tentatively identified as the anionic and protonated species of the flavin C4a-hydroperoxide or, alternatively, as two conformationally different forms of the enzyme hydroperoxide. The next intermediate, previously referred to as intermediate II, is also highly fluorescent and so is considered unlikely to be due to a complex of a flavin alkoxyl radical and a substituted cyclohexadienyl radical, as proposed by Anderson et al. (Anderson, R. F., Patel, K. B., and Stratford, M. R. L. (1990) J. Biol. Chem. 265, 1952-1957). The conversion of intermediate II to the next intermediate, intermediate III (the C4a-hydroxyflavin), is characterized by a large substrate deuterium isotope effect in the 320-390 nm range, but not by fluorescence or by absorbance at wavelengths >400 nm. This is ascribed to dissociation from the enzyme of a cyclohexadienone product, leaving the enzyme in its C4a-hydroxyflavin form. The latter eliminates H2O to re-form oxidized flavin, but in a competing reaction, in the presence of excess substrate, forms a very stable complex, which decays orders of magnitude more slowly than the uncomplexed enzyme.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV TOKUSHIMA,INST ENZYME RES,DIV ENZYME REGULAT,TOKUSHIMA 770,JAPAN	University of Michigan System; University of Michigan; Tokushima University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1987, J BIOL CHEM, V262, P17475; ANDERSON RF, 1991, J BIOL CHEM, V266, P13086; ANDERSON RF, 1990, J BIOL CHEM, V265, P1952; Ballou D. P., 1982, FLAVINS FLAVOPROTEIN, P301; BEATY NB, 1981, J BIOL CHEM, V256, P4619; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; BRISSETTE P, 1987, FLAVINS FLAVOPROTEIN, P573; BRUICE TC, 1983, J CHEM SOC CHEM COMM, P14, DOI 10.1039/c39830000014; BRUICE TC, 1980, ACCOUNTS CHEM RES, V13, P256, DOI 10.1021/ar50152a002; DETMER K, 1984, J BIOL CHEM, V259, P1265; DETMER K, 1984, Journal of Biological Chemistry, V259, P1532; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1974, BIOCHEM BIOPH RES CO, V57, P1018, DOI 10.1016/0006-291X(74)90798-0; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; KEMAL C, 1977, J AM CHEM SOC, V99, P7272, DOI 10.1021/ja00464a030; KEMAL C, 1976, P NATL ACAD SCI USA, V734, P995; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MERENYI G, 1991, J AM CHEM SOC, V113, P9371, DOI 10.1021/ja00024a054; NEUJAHR HY, 1973, EUR J BIOCHEM, V35, P386, DOI 10.1111/j.1432-1033.1973.tb02851.x; NEUJAHR HY, 1978, J BIOL CHEM, V253, P8835; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; POWLOWSKI J, 1989, J BIOL CHEM, V264, P16008; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; SPECTOR T, 1972, J BIOL CHEM, V247, P5632; STRICKLAND S, 1973, J BIOL CHEM, V248, P2953; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TAYLOR MG, 1991, J BIOL CHEM, V266, P8291; THORNELEY RN, 1974, BIOCHIM BIOPHYS ACTA, V333, P487, DOI 10.1016/0005-2728(74)90133-9; VERVOORT J, 1992, EUR J BIOCHEM, V206, P479, DOI 10.1111/j.1432-1033.1992.tb16950.x; WESSIAK A, 1983, J AM CHEM SOC, V105, P4809, DOI 10.1021/ja00352a045; [No title captured]	36	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4134	4144						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440702				2022-12-25	WOS:A1993KN53300052
J	MOORE, SEH; SPIRO, RG				MOORE, SEH; SPIRO, RG			INHIBITION OF GLUCOSE TRIMMING BY CASTANOSPERMINE RESULTS IN RAPID DEGRADATION OF UNASSEMBLED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							N-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; PRE-GOLGI DEGRADATION; ENDOPLASMIC-RETICULUM; RAT-LIVER; 1-DEOXYNOJIRIMYCIN; GLYCOPROTEINS; CLEAVAGE; ANTIGEN	The CMT-cK(d)1 cell line provides a system for studying the initial processing steps of N-linked oligosaccharides as these cells have been shown to produce major histocompatibility complex (MHC) class I molecules which, due to a defect in assembly, recycle between the endoplasmic reticulum and a pre-Golgi compartment, failing to reach the cell surface (Hsu, V. W., Yuan, L. C., Nuchtern, J. G., Lippincott-Schwartz, J., Hammerling, G. J., and Klausner, R. D. (1991) Nature 352, 441-444). In the present study we observed that when the MHC class I heavy chain of these CMT cells was pulse-radiolabeled with [S-35]methionine in the presence of the glucosidase inhibitor, castanospermine (CST), it underwent a rapid degradation during a 60-min chase, in contrast to control cells in which it remained stable during that period. The CST-promoted instability of the MHC molecule appeared to be specific, as it did not occur when 1-deoxymannojirimycin, an inhibitor of mannosidase, was added to the cells. Although endomannosidase was found to be present in the CMT cells, the electrophoretic mobility of the MHC heavy chain produced in the presence of CST indicated that deglucosylation through the alternate route provided by this enzyme did not occur. Furthermore, gamma-interferon did not prevent the rapid disappearance of the MHC molecule, although it brought about entry of this glycoprotein into the secretory pathway in cells incubated without CST. The results of our studies suggest that retention of glucose on N-linked oligosaccharides may under certain circumstances provide a signal for pre-Golgi protein degradation.	JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, 1 JOSLIN PL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Moore, Stuart/AAF-3920-2021	Moore, Stuart/0000-0002-1020-2242	NIDDK NIH HHS [DK17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; DURONIO V, 1988, J BIOL CHEM, V263, P5436; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KIMBALL ES, 1983, CONTEMP TOP MOLEC IM, V9, P1; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLAUSNER R D, 1989, New Biologist, V1, P3; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SAMUELSON LE, 1985, CELL, V43, P223; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SPIRO RG, 1982, PHILOS T ROY SOC B, V300, P117, DOI 10.1098/rstb.1982.0160; STANNARD BS, 1988, J BIOL CHEM, V263, P8309; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997	27	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3809	3812						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440676				2022-12-25	WOS:A1993KN53300004
J	PROCTOR, RH; HOHN, TM				PROCTOR, RH; HOHN, TM			ARISTOLOCHENE SYNTHASE - ISOLATION, CHARACTERIZATION, AND BACTERIAL EXPRESSION OF A SESQUITERPENOID BIOSYNTHETIC GENE (ARI1) FROM PENICILLIUM-ROQUEFORTI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-SPOROTRICHIOIDES; FARNESYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; TRICHODIENE SYNTHASE; PARTIAL-PURIFICATION; MOLECULAR-CLONING; PR TOXIN; CYCLASE; SEQUENCE; SYNTHETASE	Aristolochene is the likely precursor of the sesquiterpenoid toxins produced by a number of filamentous fungi. One of these, PR-toxin, is produced by Penicillium roqueforti. We report here the isolation of a gene (Ari1) coding for the sesquiterpene cyclase, aristolochene synthase (AS), from P. roqueforti. Nucleotide sequence analysis of genomic and cDNA clones revealed that the Ari1 gene contains two introns. A Protein A/AS fusion enzyme was expressed in Escherichia coli and shown to have sesquiterpene cyclase activity. Analysis of the Protein A/AS fusion enzyme reaction mixtures by TLC and gas chromatography/mass spectrometry identified aristolochene as a major product. The Ari1 gene encodes a polypeptide of molecular weight 39,200. Expression of Ari1 occurs in stationary phase cultures of P. roqueforti and appears to be transcriptionally regulated.	USDA ARS, NATL CTR AGR UTILIZAT RES, MYCOTOXIN RES UNIT, 1815 N UNIV ST, PEORIA, IL 61604 USA	United States Department of Agriculture (USDA)								ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BAKER R, 1981, J CHEM ECOL, V7, P135, DOI 10.1007/BF00988641; BOWERS WS, 1977, SCIENCE, V196, P680, DOI 10.1126/science.558651; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1990, J AM CHEM SOC, V112, P3209, DOI 10.1021/ja00164a051; CANE DE, 1987, J ANTIBIOT, V40, P1331, DOI 10.7164/antibiotics.40.1331; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; CANE DE, 1989, J AM CHEM SOC, V111, P8914, DOI 10.1021/ja00206a022; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; DESJARDINS AE, 1992, MOL PLANT MICROBE IN, V5, P214, DOI 10.1094/MPMI-5-214; DHAR TK, 1982, TETRAHEDRON LETT, V23, P5459; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; Fourney R.M., 1988, FOCUS, V10, P5; GOVINDACHARI TR, 1970, TETRAHEDRON, V26, P615, DOI 10.1016/S0040-4020(01)97854-8; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOHN TM, 1992, MOL PLANT MICROBE IN, V5, P249, DOI 10.1094/MPMI-5-249; HOHN TM, 1989, APPL ENVIRON MICROB, V55, P1500, DOI 10.1128/AEM.55.6.1500-1503.1989; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V275, P92, DOI 10.1016/0003-9861(89)90353-6; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; KENFIELD D, 1989, EXPERIENTIA, V45, P900, DOI 10.1007/BF01954070; MACKO V, 1983, TOXINS PLANT PATHOGE, P41; MUNCK SL, 1990, ARCH BIOCHEM BIOPHYS, V282, P58, DOI 10.1016/0003-9861(90)90086-E; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; POLONELLI L, 1978, MYCOPATHOLOGIA, V66, P99, DOI 10.1007/BF00429600; RICHE C, 1974, TETRAHEDRON LETT, P2765, DOI 10.1016/S0040-4039(01)91735-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STILL PE, 1972, FED PROC, V31, pA733; STOESSL A, 1976, PHYTOCHEMISTRY, V15, P855, DOI 10.1016/S0031-9422(00)84361-7; SUGAWARA F, 1985, P NATL ACAD SCI USA, V82, P8291, DOI 10.1073/pnas.82.24.8291; TIRILLY Y, 1983, PHYTOCHEMISTRY, V22, P2082, DOI 10.1016/0031-9422(83)80051-X; VOGELI U, 1990, PLANT PHYSIOL, V93, P182, DOI 10.1104/pp.93.1.182; Wei R. D., 1976, ANIMAL PLANT MICROBI, P137; WEI RD, 1978, APPL ENVIRON MICROB, V35, P797, DOI 10.1128/AEM.35.4.797-799.1978; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0	45	96	119	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4543	4548						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440737				2022-12-25	WOS:A1993KN53300106
J	ACTON, S; RESNICK, D; FREEMAN, M; EKKEL, Y; ASHKENAS, J; KRIEGER, M				ACTON, S; RESNICK, D; FREEMAN, M; EKKEL, Y; ASHKENAS, J; KRIEGER, M			THE COLLAGENOUS DOMAINS OF MACROPHAGE SCAVENGER RECEPTORS AND COMPLEMENT COMPONENT-C1Q MEDIATE THEIR SIMILAR, BUT NOT IDENTICAL, BINDING SPECIFICITIES FOR POLYANIONIC LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HAMSTER-CELL MUTANTS; CHOLESTEROL DEPOSITION; OVARY CELLS; PROTEIN; C1Q; MOLECULES; HOMOLOGY; ATHEROSCLEROSIS; ENDOCYTOSIS	Macrophage scavenger receptors have been implicated in the development of atheroselerosis and other macrophage-associated functions, including host defense. The mechanism by which these receptors bind a wide array of polyanions, such as acetylated low density lipoprotein (Ac-LDL), with high affinity has not yet been elucidated; however, it has been proposed that the positively charged extracellular collagenous domain of scavenger receptors plays a key role in ligand binding. To test this proposal, we generated truncation mutants of the bovine and murine scavenger receptors and studied their expression in transiently transfected COS cells. These mutants contain only 8 (bovine) or 5 (murine) of the 24 Gly-X-Y tripeptide repeats found in the collagenous domains of the full-length receptors. Immunochemical analyses established that the truncation of the bovine scavenger receptor did not interfere significantly with its synthesis, trimerization, post-translational processing, intracellular transport, surface expression, or stability. However, unlike their full-length counterparts, the truncated bovine and murine receptors were unable to bind Ac-LDL. Thus, the collagenous domain was necessary for normal ligand binding. In addition, cotransfection of the expression vector for the truncated bovine scavenger receptor with that for the full-length receptor resulted in dramatically reduced activity of the full-length construct (dominant negative effect). A ligand bead-binding assay was used to show that the isolated collagenous domain from a different protein, complement component C1q, could bind a wide variety of polyanions with a specificity which was similar, but not identical, to that of scavenger receptors. These results suggest that the collagenous domain of the scavenger receptor is both necessary and sufficient to determine the broad binding specificity that characterizes this unusual receptor. Scavenger receptors and C1q, along with the mannose-binding protein, conglutinin, and lung surfactant apoprotein A, help define a set of proteins which all contain short collagenous domains and which all appear to participate in host defense. Their short collagenous domains may contribute significantly to their host-defense functions.	MIT,DEPT BIOL,RM E25-236,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027168] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484, HL45098] Funding Source: Medline; NIAID NIH HHS [AI-27168] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BOHNSACK JF, 1985, P NATL ACAD SCI USA, V82, P3824, DOI 10.1073/pnas.82.11.3824; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ENTWISTLE RA, 1988, BIOCHEMISTRY-US, V27, P507, DOI 10.1021/bi00401a073; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUAN E, 1991, J BIOL CHEM, V266, P20345; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HUGHESJONES NC, 1978, IMMUNOLOGY, V34, P459; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG HX, 1991, J IMMUNOL, V146, P2324; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1991, CIRCULATION, V84, P11229; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, IN PRESS J BIOL CHEM, V268; LOOS M, 1983, CURR TOP MICROBIOL, V102, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P1221; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; RAEPPLE E, 1976, IMMUNOCHEMISTRY, V13, P251, DOI 10.1016/0019-2791(76)90223-8; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; REID KBM, 1982, BIOCHEM SOC T, V11, P1; RESNICK D, 1993, J BIOL CHEM, V268, P3538; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENBERG AM, 1988, J RHEUMATOL, V15, P1091; ROSS GF, 1986, J BIOL CHEM, V261, P14283; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; TALL AR, 1978, J CLIN INVEST, V62, P836, DOI 10.1172/JCI109196; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; VIA DP, 1992, P NATL ACAD SCI USA, V89, P6780, DOI 10.1073/pnas.89.15.6780; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2	45	133	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3530	3537						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429029				2022-12-25	WOS:A1993KM16100079
J	BROWN, DG; SUN, XM; COHEN, GM				BROWN, DG; SUN, XM; COHEN, GM			DEXAMETHASONE-INDUCED APOPTOSIS INVOLVES CLEAVAGE OF DNA TO LARGE FRAGMENTS PRIOR TO INTERNUCLEOSOMAL FRAGMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-DEATH; ENDONUCLEASE; ACTIVATION; THYMOCYTES; INHIBITION	Apoptosis is a major form of cell death, characterized morphologically by chromatin condensation and biochemically by endonuclease cleavage of DNA into oligonucleosomal fragments. Recently, we reported that zinc arrested dexamethasone-induced apoptosis in thymocytes at an early stage, as characterized morphologically by condensation of heterochromatin into clumps abutting the nuclear membrane. In this study, we show that zinc completely inhibits endonuclease cleavage of DNA into oligonucleosomal fragments but does not prevent the cleavage of DNA into high molecular weight fragments. These results indicate that the formation of these high molecular weight fragments, which correlates with the very early morphological features of apoptosis, is a critical event in glucocorticoid-induced apoptosis. The formation of these high molecular weight fragments, despite the inhibition by zinc of the endonuclease cleavage of DNA, suggests that key enzyme(s), other than the Ca2+/Mg2+-dependent endonuclease, are involved at the earliest stages of induction of apoptosis.	MRC, TOXICOL UNIT, WOODMANSTERNE RD, CARSHALTON SM5 4EF, SURREY, ENGLAND				Cohen, Gerald M/A-1687-2008					ANAND R, 1990, GEL ELECTROPHORESIS, P101; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARBIERI D, 1992, BIOCHEM BIOPH RES CO, V187, P1256, DOI 10.1016/0006-291X(92)90438-Q; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; Kerr J.F.R., 1987, P93; RAFFRAY M, 1991, ARCH TOXICOL, V65, P135, DOI 10.1007/BF02034940; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHIMIZU T, 1990, BIOCHEM BIOPH RES CO, V169, P1172, DOI 10.1016/0006-291X(90)92019-V; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOLOVYAN VT, 1991, MOL BIOL+, V25, P1159; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WALKER PR, 1991, CANCER RES, V51, P1078; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	23	445	457	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3037	3039						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428979				2022-12-25	WOS:A1993KM16100006
J	GROLLMAN, EF; SAJI, M; SHIMURA, Y; LAU, JTY; ASHWELL, G				GROLLMAN, EF; SAJI, M; SHIMURA, Y; LAU, JTY; ASHWELL, G			THYROTROPIN REGULATION OF SIALIC-ACID EXPRESSION IN RAT-THYROID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; COMPLEX CARBOHYDRATE UNITS; TISSUE-SPECIFIC EXPRESSION; GROWTH FACTOR-I; PORCINE THYROGLOBULIN; GENE-EXPRESSION; POTENTIAL ROLE; LOCALIZATION; RESIDUES; RECEPTOR	The present study, utilizing the hormone-responsive rat thyroid cell line FRTL-5, presents evidence establishing the regulatory role of thyrotropin in modulating mRNA for beta-galactoside alpha2,6-sialyltransferase, the enzyme responsible for the expression of alpha2,6-linked sialic acid. Both the cell surface membrane and the thyroglobulin secreted by cells grown in the presence of this hormone exhibit a marked decrease in the level of alpha2,6-bound sialic acid with little or no change in the number of alpha2,3-sialic acid residues. An additional, and unexpected, sequel is the finding of a coordinated decrease in all of the core monosaccharide constituents of the secreted thyroglobulin. Both of the above phenomenological changes appear to be at some variance with previously described systems wherein thyrotropin was deemed to increase glycosylation. It is anticipated that further resolution of this apparent difference may provide a clearer definition for the role of the carbohydrate moiety in affecting the biological function of thyroglobulin.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute	GROLLMAN, EF (corresponding author), NIDDKD,BIOCHEM & METAB LAB,BLDG 10,RM 9B12,BETHESDA,MD 20892, USA.		Saji, Motoyasu/E-4007-2011		NIGMS NIH HHS [GM38193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ALQUIER C, 1988, HISTOCHEMISTRY, V89, P171, DOI 10.1007/BF00489920; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; ARIMA T, 1972, J BIOL CHEM, V247, P1825; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BELLUR S, 1990, ENDOCRINOLOGY, V127, P1526, DOI 10.1210/endo-127-3-1526; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DIJESO B, 1992, J BIOL CHEM, V267, P1938; DUNN JT, 1991, WERNER INGBARS THYRO, P98; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUKUDA M, 1971, BIOCHEM J, V123, P407, DOI 10.1042/bj1230407; FUKUDA M, 1971, BIOCHEM J, V123, P415, DOI 10.1042/bj1230415; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MONACO F, 1975, ENDOCRINOLOGY, V97, P347, DOI 10.1210/endo-97-2-347; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RONIN C, 1986, J BIOL CHEM, V261, P7287; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SPIRO MJ, 1968, J BIOL CHEM, V243, P6520; SPIRO MJ, 1988, ENDOCRINOLOGY, V123, P56; SPIRO MJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P35, DOI 10.1016/0003-9861(80)90403-8; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; SPIRO RG, 1965, J BIOL CHEM, V240, P1603; Taurog A., 1991, WERNER INGBARS THYRO, P51; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; THALL A, 1991, ACTA ENDOCRINOL-COP, V124, P692, DOI 10.1530/acta.0.1240692; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WEN DX, 1992, J BIOL CHEM, V267, P2512; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701	45	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3604	3609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429037				2022-12-25	WOS:A1993KM16100088
J	MIRET, JJ; MILLA, MG; LAHUE, RS				MIRET, JJ; MILLA, MG; LAHUE, RS			CHARACTERIZATION OF A DNA MISMATCH-BINDING ACTIVITY IN YEAST EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX PLASMID DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; HUMAN-CELLS; MUTY GENE; NUCLEAR EXTRACTS; PROTEIN BINDS	An activity present in nuclear extracts of the yeast Saccharomyces cerevisiae binds specifically to oligonucleotides containing DNA mismatches, as judged by a band shift assay. The specificity of this activity for mismatched DNA was confirmed by competition experiments; binding to radiolabeled heteroduplexes was abolished in the presence of excess unlabeled heteroduplex but not when excess unlabeled homoduplex was added. Both T/G and T/- (single base deletion) mispairs were recognized in each of two sequence contexts. Binding was also observed with G/G, G/A, A/C, and T/C mismatches, but recognition of a C/C mispair was very weak. Competition studies with the various mismatches were consistent with the idea that a single activity recognizes all mispairs tested. Extracts from strains mutant in either or both of two putative mismatch recognition functions, MSH2 and MSH3, were also tested. Mismatch-binding activity was present in extracts of msh3- strains but completely absent in msh2- strains. The molecular weight of the major binding protein was estimated by UV cross-linking experiments to be approximately 110 kDa, in good agreement with the size predicted for Msh2 protein (Reenan, R. A. and Kolodner, R. D. (1992) Genetics 132, 963-973).	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,55 LAKE AVE N,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester				Lahue, Robert/0000-0002-8870-5616	NIGMS NIH HHS [GM 44824] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044824] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; AU KG, 1992, J BIOL CHEM, V267, P12142; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; CHANG DY, 1991, NUCLEIC ACIDS RES, V19, P4761, DOI 10.1093/nar/19.17.4761; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; FUJII H, 1989, J BIOL CHEM, V264, P10057; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1988, J BACTERIOL, V170, P197, DOI 10.1128/jb.170.1.197-202.1988; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LIEB M, 1985, MOL GEN GENET, V199, P465; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LU AL, 1988, GENETICS, V118, P593; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PRIEBE SD, 1988, J BACTERIOL, V170, P190, DOI 10.1128/jb.170.1.190-196.1988; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RADMAN M, 1988, MISMATCH REPAIR GENE; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; REWINSKI C, 1987, NUCLEIC ACIDS RES, V15, P8205, DOI 10.1093/nar/15.20.8205; ROSE MD, 1988, METHODS YEAST GENETI, pCH6; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WILLIAMSON MS, 1985, GENETICS, V110, P609	43	31	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3507	3513						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429025				2022-12-25	WOS:A1993KM16100075
J	SAMANTA, AK; DUTTA, S; ALI, E				SAMANTA, AK; DUTTA, S; ALI, E			MODIFICATION OF SULFHYDRYL-GROUPS OF INTERLEUKIN-8 (IL-8) RECEPTOR IMPAIRS BINDING OF IL-8 AND IL-8-MEDIATED CHEMOTACTIC RESPONSE OF HUMAN POLYMORPHONUCLEAR NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; HUMAN DERMAL FIBROBLASTS; ACTIVATING PEPTIDE; FACTOR-ALPHA; PROTEINS; EXPRESSION; FAMILY; PURIFICATION; RELEASE	Interleukin-8 (IL-8), a monocyte-derived neutrophil chemotactic agent, has a potential role in the regulation of inflammatory responses. The specific receptor for IL-8 has been identified and characterized on the surface of human neutrophils (Samanta, A. K., Oppenheim, J. J., and Matsushima, K. (1989) J. Exp. Med. 169, 1185-1189). The present study demonstrates that at least two sulfhydryl groups of this receptor from human neutrophils participate in the binding of IL-8. Incubation of neutrophils with sulfhydryl group-modifying reagents, N-ethylmaleimide and diazene dicarboxylic acid bis-N,N-dimethylamide (diamide), severely impaired the binding of I-125-IL-8 to neutrophils. Treatment with 0.8 mM N-ethylmaleimide and 0.4 mM diamide inhibit binding of I-125-IL-8 to the neutrophils by 62 and 60%, respectively. These inhibitory effects could be reversed by 84-87% by treatment with 2-4 mM dithiothreitol. The saturable amount of the ligand, IL-8, provided partial protection against the modifying reagents. N-Ethylmaleimide and diamide at a concentration of 0.4 mM reduced chemotactic migration of neutrophils in a Boyden chamber by 95 and 60%, respectively. At a concentration of 0.4 mM, N-ethylmaleimide reduced the IL-8-induced (10 mug/ml) release of myeloperoxidase by 50%. Under identical conditions, 0.4 mM diamide could reduce release of myeloperoxidase by 63%. Finally, N-ethylmaleimide severely affected the overall binding and total uptake of I-125-IL-8 to the neutrophils at 37-degrees-C, a condition required for receptor-mediated internalization of the ligand and recycling of the receptor to the surface of neutrophils. Nitro blue tetrazolium reduction test of the lipopolysaccharide-stimulated neutrophils indicates that compared to control general metabolic functions of thiolmodified cells were markedly retained. These data suggest that at least two conformationally vicinal free reactive sulfhydryl groups are located in the binding domain of the receptor in neutrophils which are essential for IL-8-mediated biological responses.			SAMANTA, AK (corresponding author), INDIAN INST CHEM BIOL,DIV IMMUNOBIOL,CALCUTTA 700032,W BENGAL,INDIA.							BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DJEU JY, 1990, J IMMUNOL, V144, P2205; FURUTA R, 1989, J BIOCHEM-TOKYO, V106, P436, DOI 10.1093/oxfordjournals.jbchem.a122870; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOSOWER EM, 1974, BIOCHEM BIOPH RES CO, V59, P347, DOI 10.1016/S0006-291X(74)80213-5; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; LACE JK, 1975, AM J MED, V58, P685, DOI 10.1016/0002-9343(75)90505-7; LANE TA, 1981, BLOOD, V58, P228; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; Means G.E., 1971, CHEM MODIFICATION PR; MELON MG, 1976, J CELL BIOL, V70, P226; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHNITZEL W, 1991, BIOCHEM BIOPH RES CO, V180, P301, DOI 10.1016/S0006-291X(05)81292-6; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THORNTON AJ, 1990, J IMMUNOL, V144, P2609; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	38	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6147	6153						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454590				2022-12-25	WOS:A1993KT36800014
J	KURABAYASHI, M; JEYASEELAN, R; KEDES, L				KURABAYASHI, M; JEYASEELAN, R; KEDES, L			ANTINEOPLASTIC AGENT DOXORUBICIN INHIBITS MYOGENIC DIFFERENTIATION OF C2 MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-FACTOR; CARDIAC ACTIN GENE; SKELETAL-MUSCLE; MYOCARDIAL-CELLS; DNA-BINDING; MYOD FAMILY; EXPRESSION; PROTEINS; TRANSCRIPTION; PROMOTER	Doxorubicin (Dox, adriamycin), an antineoplastic agent that can cause dilated cardiomyopathy, selectively inhibits muscle-specific gene expression in rodent cardiac muscle cells. This study shows that Dox treatment of proliferating C2 myoblasts, an established cell line from mouse skeletal muscle, completely prevents both fusion and accumulation of muscle-specific gene transcripts without significantly altering non-muscle gene transcripts. When added to high density cultures, Dox only blocked myotube formation but did not inhibit induction of muscle-specific genes. Transient transfection into C2 myoblasts showed that the transcriptional expression of chloramphenicol acetyltransferase reporter plasmids regulated by either the cardiac alpha-actin promoter or the muscle creatine kinase enhancer, but not with a viral or beta-actin promoter, was significantly diminished by Dox in a dose-dependent manner. Moreover, exposure of C2 myoblasts to Dox had a profound effect on the expression of regulatory genes critical to the myogenic differentiation program; mRNAs for MyoD and myogenin were dramatically reduced and Id mRNA was concomitantly increased. In addition, there was diminished DNA binding activity of the muscle-specific transcription factor, MEF-2. These results suggest that Dox inhibits myogenesis by preventing muscle-specific gene expression, possibly through affecting the myogenic programs controlled by muscle-specific transcription factors.	UNIV SO CALIF,SCH MED,INST GENET MED,2011 ZONAL AVE,HMR413,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California								AUFFRAY C, 1980, NUCLEIC ACIDS RES, V8, P1231, DOI 10.1093/nar/8.6.1231; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUNWALD E, 1984, TXB CARDIOVASCULAR M, P409; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOVIEL DB, 1991, J CELL BIOCHEM     S, V15, P69; DOROSHOW JH, 1985, AM J PATHOL, V118, P288; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; GAHLMANN R, 1990, J BIOL CHEM, V265, P12520; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; GUSTAFSON TA, 1988, MOL CELL BIOL, V7, P4100; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEWIS W, 1986, LAB INVEST, V54, P416; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Muscat George E. O., 1992, Gene Expression, V2, P111; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2025; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	42	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5524	5529						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449915				2022-12-25	WOS:A1993KR82200029
J	YODERHILL, J; PAUSE, A; SONENBERG, N; MERRICK, WC				YODERHILL, J; PAUSE, A; SONENBERG, N; MERRICK, WC			THE P46 SUBUNIT OF EUKARYOTIC INITIATION-FACTOR (EIF)-4F EXCHANGES WITH EIF-4A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; CAP-BINDING-PROTEIN; SIGMA-70 SUBUNIT; TRANSLATION; RECOGNITION; POLYMERASE; COMPLEX	The p46 subunit of eukaryotic initiation factor (eIF)-4F purified from rabbit reticulocyte lysate has previously been found to be composed of eIF-4AI and eIF-4AII in a 4:1 ratio, respectively, whereas the free form of rabbit eIF-4A is composed solely of eIF-4AI. Using sucrose gradient centrifugation and an m7GTP-Sepharose 4B assay, it was shown that eIF-4A exchanges with the p46 subunit of eIF-4F. Incubation of [C-14]eIF-4A and eIF-4F resulted in the incorporation of [C-14] eIF-4A into the eIF-4F complex. Conversely, the [C-14] p46 subunit of [C-14]eIF-4F was shown to dissociate from the [C-14]eIF-4F complex in the presence of eIF-4A, presumably due to the incorporation of unlabeled eIF-4A. Similar experiments were conducted in which C-14-labeled initiation factors were incubated with rabbit reticulocyte lysate. When [C-14]eIF-4A was incubated with lysate, [C-14]eIF-4A became incorporated into the eIF-4F complex present in the lysate. Additionally, when [C-14]eIF-4F was incubated with lysate, the [C-14]p46 subunit of [C-14]eIF-4F dissociated from the [C-14]eIF-4F complex, most likely due to the exchange of unlabeled eIF-4A (present in the lysate) with the [C-14]p46 subunit. The exchange of mouse eIF-4AI and eIF-4AII expressed in Escherichia coli was also investigated in the presence of eIF-4F and rabbit reticulocyte lysate. Both the sucrose gradient experiments and m7GTP-Sepharose 4B assays demonstrated that the [C-14]p46 subunit of [C-14]eIF-4F was displaced in the presence of eIF-4AI or eIF-4AII and that mouse [C-14]eIF-4AI or [C-14]eIF-4AII became incorporated into the eIF-4F complex in the same manner as rabbit reticulocyte eIF-4A.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 146,PQ,CANADA	Case Western Reserve University; McGill University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; EDERY I, 1983, J BIOL CHEM, V258, P1398; EHRENFELD E, 1982, CELL, V28, P435, DOI 10.1016/0092-8674(82)90195-7; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; JENTOFT JE, 1979, J BIOL CHEM, V254, P4366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK WC, 1987, TRANSLATIONAL REGULA, P265; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RAY BK, 1986, J BIOL CHEM, V261, P1466; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SARKAR G, 1985, J BIOL CHEM, V260, P3831; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9539	26	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5566	5573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449919				2022-12-25	WOS:A1993KR82200035
J	HAMAWY, MM; MERGENHAGEN, SE; SIRAGANIAN, RP				HAMAWY, MM; MERGENHAGEN, SE; SIRAGANIAN, RP			CELL ADHERENCE TO FIBRONECTIN AND THE AGGREGATION OF THE HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTOR SYNERGISTICALLY REGULATE TYROSINE PHOSPHORYLATION OF 105-115-KDA PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; VIRUS-TRANSFORMED CELLS; TUMOR-NECROSIS-FACTOR; SIGNAL TRANSDUCTION; 2H3 CELLS; HISTAMINE-RELEASE; HUMAN NEUTROPHILS; PHORBOL ESTER; T-CELLS; EXTRACELLULAR-MATRIX	Adherence of cells to extracellular matrix components modulates cellular responses. Here we compared the array of tyrosine phosphorylated proteins induced by the aggregation of the high affinity receptor for IgE (FcepsilonRI) in fibronectin-adherent and in nonadherent rat basophilic leukemia (RBL-2H3) cells. Adherence to fibronectin in the absence of FcepsilonRI aggregation induced tyrosine phosphorylation of 105-115-kDa proteins. This phosphorylation was reversed by EDTA and by a synthetic peptide containing the sequence Arg-Gly-Asp, demonstrating a requirement for fibronectin-integrin interaction. Aggregation of FcepsilonRI in fibronectin-adherent cells markedly enhanced the tyrosine phosphorylation of the same 105-115-kDa proteins. There were minimal differences in tyrosine phosphorylation of other proteins induced by the aggregation of FcepsilonRI in nonadherent and in fibronectin-adherent cells. Direct activation of protein kinase C and/or increase in calcium influx induced the phosphorylation of the 105-115-kDa proteins only in fibronectin-adherent cells. The magnitude of the phosphorylation of the 105-115-kDa proteins induced by the aggregation of FcepsilonRI in fibronectin-adherent cells was substantially greater than the sum of that due to adherence to fibronectin and the aggregation of FcepsilonRI in nonadherent cells. Therefore, cell adherence and the aggregation of FcepsilonRI synergistically regulate tyrosine phosphorylation of the 105-115 kDa proteins.			HAMAWY, MM (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DAVIS LS, 1990, J IMMUNOL, V145, P785; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EISEMAN E, 1992, NATURE, V355, P78; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1992, J IMMUNOL, V148, P524; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORVATH AR, 1990, ONCOGENE, V5, P1349; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIN PY, 1991, J IMMUNOL, V146, P1609; LO TN, 1987, J BIOL CHEM, V262, P4141; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1990, J EXP MED, V172, P185; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAHARA N, 1990, J HISTOCHEM CYTOCHEM, V38, P975, DOI 10.1177/38.7.1693935; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TAPLEY P, 1989, ONCOGENE, V4, P325; THOMPSON HL, 1990, J IMMUNOL, V145, P3425; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERTH DK, 1984, J BIOL CHEM, V259, P5264; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMADA A, 1991, J IMMUNOL, V146, P53; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU KT, 1991, J BIOL CHEM, V266, P22564	62	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5227	5233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444898				2022-12-25	WOS:A1993KP88400095
J	MALAVIYA, R; MALAVIYA, R; JAKSCHIK, BA				MALAVIYA, R; MALAVIYA, R; JAKSCHIK, BA			REVERSIBLE TRANSLOCATION OF 5-LIPOXYGENASE IN MAST-CELLS UPON IGE/ANTIGEN STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-INDUCED PERITONITIS; ARACHIDONATE 5-LIPOXYGENASE; MEMBRANE ASSOCIATION; HISTAMINE-RELEASE; HUMAN-LEUKOCYTES; PURIFICATION; PROTEIN; MICE; CALCIUM; LEUKOTRIENES	The 5-lipoxygenase catalyzes the first two steps in the metabolism of arachidonic acid to leukotrienes. It has been shown that the calcium influx into leukocytes following stimulation by A23187 activates the enzyme and causes its translocation to the membrane. Leukotrienes are formed, and then the enzyme seems to be irreversibly inactivated. In the present investigation we have compared the effect of receptor-mediated mast cell activation (IgE/antigen) and A23187 on 5-lipoxygenase activity and translocation to the membrane. In contrast to the ionophore, IgE/antigen, which initiated the formation of similar amounts of leukotrienes as A23187, caused minor inactivation of the enzyme. Immunoblot analysis demonstrated that after antigen the membrane association of the 5-lipoxygenase was reversible, while with A23187 the translocation continued during the time of observation (60 min). Addition of a calcium chelator after ionophore challenge, prevented further inactivation of the enzyme and reversed its membrane binding. The data suggest that the continuous influx of calcium with A23187 is responsible for the extensive inactivation of the 5-lipoxygenase. In contrast, during receptor-mediated stimulation the transient increase in intracellular calcium seems to conserve the enzyme activity.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)								BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; ISHIZAKA T, 1981, J ALLERGY CLIN IMMUN, V67, P90, DOI 10.1016/0091-6749(81)90002-6; JAKSCHIK BA, 1983, ADV PROSTAG THROMB L, V11, P141; JAKSCHIK BA, 1992, EICOSANOIDS, V5, P39; JAKSCHIK BA, 1980, NATURE, V287, P51, DOI 10.1038/287051a0; JAKSCHIK BA, 1980, BIOCHEM BIOPH RES CO, V95, P103, DOI 10.1016/0006-291X(80)90710-X; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIU FT, 1980, J IMMUNOL, V124, P2728; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; OCHI K, 1983, J BIOL CHEM, V258, P5754; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; RAMOS BF, 1991, J IMMUNOL, V147, P1636; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; UEDA N, 1986, J BIOL CHEM, V261, P7982; WEI L, 1988, J IMMUNOL, V140, P2361; WEI YF, 1986, J IMMUNOL, V137, P1993; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; XU L, 1993, IN PRESS PROSTAGLAND; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, J IMMUNOL, V149, P2482; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	37	90	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4939	4944						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444871				2022-12-25	WOS:A1993KP88400058
J	MIZUNO, T; IWASHINA, M; ITAKURA, M; HAGIWARA, H; HIROSE, S				MIZUNO, T; IWASHINA, M; ITAKURA, M; HAGIWARA, H; HIROSE, S			A VARIANT FORM OF THE TYPE-C ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR GENERATED BY ALTERNATIVE RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEARANCE RECEPTOR; FUNCTIONAL EXPRESSION; BOVINE KIDNEY; CDNA; LUNG; SITE; PURIFICATION; EFFICIENT; SEQUENCE; CELLS	A novel form of type C atrial natriuretic peptide receptor (ANP-C) was identified, characterized, and shown to be a product of alternative RNA splicing. Sequencing of several clones of ANP-C cDNA isolated from a bovine lung cDNA library revealed the presence of a new clone encoding a 536-amino acid ANP-C. The nucleotide sequence of this novel clone is very similar to that of the previously cloned ANP-C which consists of 537 amino acids. The sole difference between the two clones is the presence or absence of a very short segment of only 3 base pairs (bp), by which the sequence Ser472-Gly473 of the longer form is changed to Cys472 in the variant form; the other regions are identical. Alignment of the cDNA sequences with that of the ANP-C gene indicated that the two forms of ANP-C receptor arise from a single gene by alternative splicing using one donor and two closely located acceptor sites. Biochemical and pharmacological characterization using a mammalian cDNA expression system indicated that the two variants are similar in their subunit structures, in ligand-binding properties, and even in internalization kinetics. Polymerase chain reaction amplification of the transcripts demonstrated that 1) although the novel form is a minor species, it is present in various tissues such as the lung, kidney, adrenal, and vascular smooth muscle and endothelial cells and 2) the ratio of the novel variant form to the original longer form remains almost constant in these tissues. The alternative splicing reported here contributes to the diversity of ANP receptors; however, its physiological significance remains to be clarified.			MIZUNO, T (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARBERS DL, 1991, PHARMACOL THERAPEUT, V50, P337, DOI 10.1016/0163-7258(91)90049-R; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HIROSE S, 1985, BIOCHEM BIOPH RES CO, V130, P574, DOI 10.1016/0006-291X(85)90455-3; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KAWAGUCHI S, 1989, J HISTOCHEM CYTOCHEM, V37, P1739, DOI 10.1177/37.11.2553804; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAHEKI T, 1989, J BIOCHEM-TOKYO, V106, P627, DOI 10.1093/oxfordjournals.jbchem.a122907; SAHEKI T, 1991, J BIOL CHEM, V266, P11122; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SHIMONAKA M, 1987, AM J PHYSIOL, V253, pF1058, DOI 10.1152/ajprenal.1987.253.5.F1058; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UCHIDA K, 1989, BIOCHEM J, V263, P671, DOI 10.1042/bj2630671; UCHIDA K, 1989, AM J PHYSIOL, V256, pH311, DOI 10.1152/ajpheart.1989.256.1.H311	30	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5162	5167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444892				2022-12-25	WOS:A1993KP88400087
J	GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M				GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M			SERUM FACTORS AND V-SRC CONTROL 2 COMPLEMENTARY MITOGENIC PATHWAYS IN QUAIL NEURORETINAL CELLS IN CULTURE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; EPIDERMAL GROWTH-FACTOR; AMINO-ACID-SEQUENCES; PROTEIN GENES RPS12; TYROSINE KINASES; C-JUN; PLATELET PROTEIN; RAT FIBROBLASTS; INDUCIBLE GENE; TRANSFORMATION	Quail neuroretinal cells (QNR cells) from 7-day-old embryos do not proliferate even in the presence of 8% fetal calf serum. After infection by the Rous sarcoma virus (RSV) they proliferate actively and exhibit a transformed phenotype; this effect is mediated by the oncoprotein pp60v-src. Secondary cultures infected by the thermosensitive strain tsNY68 of RSV are blocked in G0 either by thermal inactivation of pp60v-src at 41.5-degrees-C or by serum deprivation at the permissive temperature (36.5-degrees-C). Cell division is reinduced either by pp60v-src thermal renaturation or by subsequent serum addition. Our results indicate that v-src and serum control two synergic pathways leading to G0/G1 transition in QNR cells. In order to characterize genes related to the mitogenic and transforming effects of v-src in nerve cells, we have constructed a cDNA library from QNR cells transformed by tsNY68. We report the properties of five molecular clones isolated by differential screening of this library. Unlike immediate-early genes like c-fos, they are induced in mid and late G1. Four of them correspond to unknown mRNAs and the last one codes for nucleolin. This set of v-src-regulated genes is likely to code for functions deficient in terminally differentiated QNR cells and necessary for the progression in G1.	CNRS,CTR BIOL CELLULAIRE,F-94205 IVRY,FRANCE; INST CURIE,F-91405 ORSAY,FRANCE; INST CURIE,BIOCHIM LAB,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GILLET, G (corresponding author), ENS LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON,FRANCE.		gillet, germain/A-9095-2013; Herault, Yann/B-5500-2012	Herault, Yann/0000-0001-7049-6900; Volovitch, Michel/0000-0002-7488-764X; GILLET, Germain/0000-0002-1514-327X				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GOLDEN A, 1988, ONCOGENE HDB, P149; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1991, NUCLEIC ACIDS RES, V19, P4001, DOI 10.1093/nar/19.14.4001; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAHNER D, 1991, ONCOGENE, V6, P1259; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1983, BRAIN RES, V275, P53, DOI 10.1016/0006-8993(83)90416-X; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PINES J, 1990, New Biologist, V2, P389; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; REED JC, 1991, CELL GROWTH DIFFER, V2, P231; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RYAZANOV A G, 1990, New Biologist, V2, P843; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WEHLAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1990, MOL CELL BIOL, V10, P1301, DOI 10.1128/MCB.10.4.1301; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	48	34	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					565	574						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437841				2022-12-25	WOS:A1993KN00800006
J	MOISEYEVA, EP; WELLER, PA; ZHIDKOVA, NI; CORBEN, EB; PATEL, B; JASINSKA, I; KOTELIANSKY, VE; CRITCHLEY, DR				MOISEYEVA, EP; WELLER, PA; ZHIDKOVA, NI; CORBEN, EB; PATEL, B; JASINSKA, I; KOTELIANSKY, VE; CRITCHLEY, DR			ORGANIZATION OF THE HUMAN GENE ENCODING THE CYTOSKELETAL PROTEIN VINCULIN AND THE SEQUENCE OF THE VINCULIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC VARIANTS; GROWTH-FACTOR ACTIVATION; C-FOS; SMOOTH-MUSCLE; META-VINCULIN; EXTRACELLULAR-MATRIX; MOUSE FIBROBLASTS; FOCAL ADHESIONS; BINDING-SITE; ACTIN GENES	The human vinculin gene contains 22 exons ranging in size from 71 base pairs (bp) to 303 bp (average 155 bp) with the exception of exon 22 which contains 144 bp of coding sequence and 1848 bp of 3'-untranslated sequence including two polyadenylation signals. There is a limited correlation between exon boundaries and functional domains within the vinculin molecule. The talin-binding domain in vinculin spans residues 1-258, and the first 6 exons encode residues 1-261. Similarly, the predicted boundaries of the central repeat domain (residues 259-589) are close to the boundaries of exons 7 and 12. Analysis of vinculin mRNAs in human uterus showed that alternative splicing of the gene is limited to exon 19, which encodes the 68 amino acids included in the muscle-specific isoform called metavinculin. We have determined 1.1 kilobases of sequence 5' of the transcription start site. The vinculin promoter lacks a TATA box, but does contain six Sp1 sites, and a CArG box at position -262 which forms the core of the serum response element found in immediate-early response genes. Expression of a vinculin promoter/CAT construct is serum-inducible in NIH3T3 cells demonstrating that the promoter does contain a functional serum response element.	UNIV LEICESTER, DEPT BIOCHEM, UNIV RD, LEICESTER LE1 7RH, ENGLAND; ACAD MED SCI, CARDIOL RES CTR USSR, MOSCOW 121552, RUSSIA; ECOLE NORM SUPER, PHYSIOPATHOL LAB, CNRS, URA 1337, F-75231 PARIS 05, FRANCE	University of Leicester; National Medical Research Center of Cardiology; Russian Academy of Medical Sciences; Centre National de la Recherche Scientifique (CNRS)			Clarke, Liz/K-7353-2012	Clarke, Liz/0000-0001-9866-0493				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BELLAS RE, 1991, J BIOL CHEM, V266, P12008; BENDORI R, 1987, EMBO J, V6, P2897, DOI 10.1002/j.1460-2075.1987.tb02593.x; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURN P, 1987, SCIENCE, V235, P476, DOI 10.1126/science.3099391; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BYRNE BJ, 1992, J BIOL CHEM, V267, P12845; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRITCHLEY DR, 1991, BIOCHEM SOC T, V19, P1028, DOI 10.1042/bst0191028; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DUBAND JL, 1990, DEVELOPMENT, V108, P421; DUBAND JL, 1990, CELL DIFFER DEV, V30, P55, DOI 10.1016/0922-3371(90)90074-7; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; GEIGER B, 1982, J MOL BIOL, V159, P685, DOI 10.1016/0022-2836(82)90108-5; GILMORE AP, 1992, J CELL SCI, V103, P719; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GLUKHOVA MA, 1990, J BIOL CHEM, V265, P13042; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KANEDA S, 1990, J BIOL CHEM, V265, P20277; KELLIE S, 1987, FEBS LETT, V213, P428, DOI 10.1016/0014-5793(87)81536-3; KOTELIANSKY VE, 1992, EUR J BIOCHEM, V204, P767, DOI 10.1111/j.1432-1033.1992.tb16692.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEHTONEN E, 1983, EXP CELL RES, V144, P191, DOI 10.1016/0014-4827(83)90453-6; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; ORITA S, 1989, GENE, V75, P13; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RIVERA V M, 1990, New Biologist, V2, P751; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SILICIANO JD, 1987, J CELL BIOL, V104, P473, DOI 10.1083/jcb.104.3.473; SMITH GM, 1988, EMBO J, V7, P3975, DOI 10.1002/j.1460-2075.1988.tb03285.x; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; Treisman R, 1990, Semin Cancer Biol, V1, P47; TURNER CE, 1989, J BIOL CHEM, V264, P11938; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WAITES GT, 1992, J BIOL CHEM, V267, P6263; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WELLER PA, 1990, P NATL ACAD SCI USA, V87, P5667, DOI 10.1073/pnas.87.15.5667; WERTH DK, 1984, J BIOL CHEM, V259, P5264; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; ZIESKE JD, 1989, J CELL BIOL, V109, P571, DOI 10.1083/jcb.109.2.571	63	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4318	4325						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440716				2022-12-25	WOS:A1993KN53300074
J	TRYBUS, KM; CHATMAN, TA				TRYBUS, KM; CHATMAN, TA			CHIMERIC REGULATORY LIGHT-CHAINS AS PROBES OF SMOOTH-MUSCLE MYOSIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; RABBIT SKELETAL-MUSCLE; GIZZARD MYOSIN; HEAVY-CHAIN; PHOSPHORYLATION; CONFORMATION; ACTIN; BINDING; IDENTIFICATION; PURIFICATION	Functional domains of the smooth muscle regulatory light chain (LC) were identified from the assembly and motor properties of smooth muscle myosin containing chimeric LCs, in which the N- and C-terminal halves of the smooth and skeletal LCs were interchanged. A C-terminal domain was also expressed. The affinity of these LCs for the smooth muscle myosin heavy chain (HC) is: wild-type LC > N-skeletal/C-smooth > N-smooth/C-skeletal almost-equal-to skeletal LC >> C-terminal domain. The C-terminal half of the LC thus contains an isoform-specific HC binding site, but the two halves of the LC must interact for tight binding. Smooth muscle myosin containing chimeric or skeletal LCs can no longer assume the folded monomeric conformation, suggesting that control of assembly involves both halves of the LC. Dephosphorylation/phosphorylation of the N-skeletal/C-smooth chimera nonetheless regulates the ability of smooth muscle myosin to move actin. Myosin containing phosphorylated N-smooth/C-skeletal or skeletal LCs, in contrast, is locked in the ''off'' state. Interactions between the stronger binding C-terminal domain of the LC and the HC are therefore primarily responsible for the regulatory capabilities of this subunit. Localization of the regulatory LC at the head/rod junction by electron microscopy establishes that phosphorylation-induced changes must be transmitted over 10 nm within the head for product release to be enhanced.			TRYBUS, KM (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.				NHLBI NIH HHS [HL38113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA TS, 1985, J BIOL CHEM, V260, P202; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; CROSS RA, 1985, FEBS LETT, V188, P367, DOI 10.1016/0014-5793(85)80404-X; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HAMBLY B, 1991, BIOPHYS J, V59, P127, DOI 10.1016/S0006-3495(91)82205-6; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MESSER N, 1991, J MOL BIOL, V218, P825, DOI 10.1016/0022-2836(91)90270-G; MESSER NG, 1988, FEBS LETT, V234, P49, DOI 10.1016/0014-5793(88)81300-0; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; NATH N, 1986, BIOCHEMISTRY-US, V25, P6169, DOI 10.1021/bi00368a051; ONISHI H, 1986, J BIOCHEM, V100, P1433, DOI 10.1093/oxfordjournals.jbchem.a121849; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAJASEKHARAN KN, 1991, ARCH BIOCHEM BIOPHYS, V288, P584, DOI 10.1016/0003-9861(91)90240-J; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SARASWAT LD, 1992, J BIOL CHEM, V267, P21112; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SZENTGYORGYI AG, 1986, MYOLOGY, P589; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WAGNER PD, 1982, METHOD ENZYMOL, V85, P72; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	43	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4412	4419						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440724				2022-12-25	WOS:A1993KN53300087
J	ABE, Y; SHIRANE, K; YOKOSAWA, H; MATSUSHITA, H; MITTA, M; KATO, I; ISHII, S				ABE, Y; SHIRANE, K; YOKOSAWA, H; MATSUSHITA, H; MITTA, M; KATO, I; ISHII, S			ASPARAGINYL ENDOPEPTIDASE OF JACK BEAN-SEEDS - PURIFICATION, CHARACTERIZATION, AND HIGH UTILITY IN PROTEIN-SEQUENCE ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCANAVALIN-A; COTYLEDONS	Asparaginyl endopeptidase was highly purified from mature seeds of the jack bean (Canavalia ensiformis). The final enzyme preparation showed a single peak in high-performance liquid chromatography on a reversed-phase column, and the material in the peak gave the following NH2-terminal amino acid sequence on Edman degradation for 25 cycles: H-Glu-Val-Gly-Thr-Arg-Trp-Ala-Val-Leu-Val-Ala-Gly-Ser-Asn-Gly-Tyr-Gly-Asn-Tyr-Arg-His-Gln-Ala-Asp-Val-. Behavior of the enzyme toward various protease inhibitors suggested that it belongs to a family of cysteine proteases. Strict substrate specificity of this enzyme was verified by the use of 14 polypeptide substrates including those derived from proteins. Almost all the peptide bonds on the carboxyl side of Asn residues were susceptible to the enzyme. The exceptions were cases where the residue was at the NH2 terminus or the second position from the NH2 terminus of substrates and where it was N-glycosylated Asn. Peptide bonds on the carboxyl side of any other amino acid residues were not cleaved. These properties promise the high utility of this novel endopeptidase in protein sequence analysis. Identity of jack bean asparaginyl endopeptidase with a processing enzyme responsible for maturation of concanavalin A from its precursor is also discussed.	HOKKAIDO UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN	Hokkaido University; Takara Holdings Inc.				Shirane, Katsunori/0000-0002-8838-1535				BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BAUMGARTNER B, 1977, EUR J BIOCHEM, V77, P223, DOI 10.1111/j.1432-1033.1977.tb11661.x; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHRISTENSEN U, 1985, J BIOCHEM-TOKYO, V98, P1263, DOI 10.1093/oxfordjournals.jbchem.a135393; CSOMA C, 1984, BIOCHEM J, V222, P769, DOI 10.1042/bj2220769; FRUTON JS, 1950, J BIOL CHEM, V190, P39; KAJIMA S, 1990, BIOTECHNOLOGY, V8, P449; KAJIWARA K, 1991, J BIOCHEM-TOKYO, V110, P350, DOI 10.1093/oxfordjournals.jbchem.a123584; KUMAZAKI T, 1992, J BIOCHEM-TOKYO, V112, P11, DOI 10.1093/oxfordjournals.jbchem.a123847; MEANAWY MA, 1990, AM J TROP MED HYG, V43, P67; NISHIDA S, 1985, BIOCHEM J, V226, P879, DOI 10.1042/bj2260879; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; YOKOSAWA H, 1977, J BIOCHEM-TOKYO, V82, P869, DOI 10.1093/oxfordjournals.jbchem.a131763	15	125	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3525	3529						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429028				2022-12-25	WOS:A1993KM16100078
J	BIANCHINI, L; TODDERUD, G; GRINSTEIN, S				BIANCHINI, L; TODDERUD, G; GRINSTEIN, S			CYTOSOLIC [CA2+] HOMEOSTASIS AND TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-GAMMA-2 IN HL-60 GRANULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; G-PROTEINS; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; NEUTROPHIL ACTIVATION; RESPIRATORY BURST; HUMAN-LYMPHOCYTES; TUMOR PROMOTER; CALCIUM ENTRY; COMPLETE CDNA	Activated phagocytes produce large amounts of reactive oxygen intermediates, including peroxides. In addition to their microbicidal effect, it has recently been suggested that reactive oxygen species play a role as intracellular messengers. The mechanism of action remains unknown, but peroxides have been reported to increase tyrosine phosphorylation, an effect potentiated by vanadate. In this report we studied the effects of a combination of H2O2 and vanadate on Ca2+ homeostasis in granulocytic HL60 cells. The peroxides induced a transient elevation of cytosolic [Ca2+] associated with release from internal stores. Ca2+ mobilization was accompanied by increased generation of inositol 1,4,5-trisphosphate, implicating phospholipase C (PLC). A sizable increase in phosphotyrosine accumulation by several polypeptides in the M(r) 20,000 to 250,000 range preceded the [Ca2+] changes. We therefore considered the possibility that tyrosine phosphorylation of a phospholipase mediates the observed effects. Differentiated (granulocytic) HL60 cells did not have detectable levels of PLC-gamma1 but had substantial PLC-gamma2. Immunoprecipitation and immunoblotting experiments demonstrated that PLC-gamma2 becomes tyrosine-phosphorylated upon treatment of the cells with peroxides of vanadate. If associated with activation, such phosphorylation of PLC-gamma2 can account for the rise in [Ca2+]. Although capable of mobilizing internal Ca2+ stores, the peroxides failed to produce the sustained [Ca2+] increase predicted by the ''capacitative'' model. Mn2+ influx determinations indicated that this is due to impairment of divalent cation entry by the peroxides, uncoupling the plasma membrane from the internal stores. Changes in [Ca2+] homeostasis could mediate some of the messenger actions of reactive oxygen species.	HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA; VANDERBILT UNIV, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Vanderbilt University								ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BRADFORD PG, 1985, MOL PHARMACOL, V27, P74; CHAUDHRI G, 1989, J IMMUNOL, V143, P1290; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KAMPS MP, 1988, ONCOGENE, V2, P305; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KRAUSE KH, 1990, CLIN BIOCHEM, V23, P159, DOI 10.1016/0009-9120(90)80030-M; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MACDOUGALL SL, 1988, CELL, V54, P229, DOI 10.1016/0092-8674(88)90555-7; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMORI H, 1979, BIOCHEM PHARMACOL, V28, P333, DOI 10.1016/0006-2952(79)90524-0; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARIS S, 1987, J BIOL CHEM, V262, P1977; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	55	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3357	3363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429012				2022-12-25	WOS:A1993KM16100054
J	CHATTERJEE, S				CHATTERJEE, S			NEUTRAL SPHINGOMYELINASE INCREASES THE BINDING, INTERNALIZATION, AND DEGRADATION OF LOW-DENSITY LIPOPROTEINS AND SYNTHESIS OF CHOLESTERYL ESTER IN CULTURED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE SPHINGOMYELIN	I have investigated the effects of human urinary neutral sphingomyelinase (N-SMase) (Chatterjee, S., and Ghosh, N. (1989) J. Biol. Chem. 264, 12554-12561) on the cell-surface binding, internalization, and degradation of I-125-low density lipoprotein (LDL) and on cholesteryl ester synthesis in cultured human fibroblasts. N-SMase exerted a concentration-dependent continuous stimulation of I-125-LDL cell-surface binding, internalization, and degradation in normal human fibroblasts. A 3-fold increase in binding, internalization, and degradation was observed at the maximum amount (600 units of N-SMase/ml) examined. This phenomenon was accompanied by a continuous stimulation of cholesteryl ester synthesis. A 5-fold increase in cholesteryl ester synthesis was observed after incubation for 4 h with N-SMase. Antibody against N-SMase and heat inactivation of N-SMase compromised the stimulatory effects of N-SMase on I-125-LDL metabolism and cholesteryl ester synthesis in these cells. Incubation of cells with phospholipase D and phospholipase C did not alter I-125-LDL binding, internalization, or degradation. This finding suggests that the stimulatory effects of N-SMase on LDL metabolism and on cholesteryl ester synthesis in fibroblasts is specific. Moreover, unlabeled LDL competitively displaced I-125-LDL from binding to N-SMase-treated cells. None of the precursors of sphingomyelin could mimic the stimulatory effects of N-SMase on I-125-LDL metabolism in these cells. Taken together, these studies suggest that one of the biological roles of N-SMase involves modulating LDL metabolism and cholesterol metabolism in fibroblasts.			CHATTERJEE, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,LIPID RES ATHEROSCLEROSIS UNIT,BALTIMORE,MD 21287, USA.				NIDDK NIH HHS [R0-1-DK-31722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHATTERJEE S, 1987, Journal of Biochemical Toxicology, V2, P181, DOI 10.1002/jbt.2570020304; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHATTERJEE S, 1979, J BIOL CHEM, V254, P3704; CHATTERJEE S, 1976, P NATL ACAD SCI USA, V73, P4339, DOI 10.1073/pnas.73.12.4339; CHATTERJEE S, 1981, EUR J BIOCHEM, V120, P435, DOI 10.1111/j.1432-1033.1981.tb05721.x; CHATTERJEE S, 1991, FASEB J, V5, P6353; ESSELMAN WJ, 1973, METHOD ENZYMOL, V27, P140; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, V1, P1215; GUPTA AK, 1991, J LIPID RES, V32, P125; HAKOMORI S, 1981, ANN REV BIOCH, V50, P753; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAVEL RJ, 1955, J CLIN INVEST, V34, P345; KIM MY, 1991, J BIOL CHEM, V2664, P84; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P1131; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; STECK TL, 1988, J BIOL CHEM, V263, P13023; XU XX, 1991, J BIOL CHEM, V266, P24849	22	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3401	3406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429015				2022-12-25	WOS:A1993KM16100060
J	PARSONAGE, D; MILLER, H; ROSS, RP; CLAIBORNE, A				PARSONAGE, D; MILLER, H; ROSS, RP; CLAIBORNE, A			PURIFICATION AND ANALYSIS OF STREPTOCOCCAL NADH PEROXIDASE EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN REDOX CENTER; FAECALIS 10C1; MECHANISM; CLONING	Using the T7 RNA polymerase expression system, a modified plasmid vector has been developed which gives reliable, high level expression in Escherichia coli of the gene encoding streptococcal NADH peroxidase. The recombinant enzyme has been purified to homogeneity using a revised protocol which yields over 35 mg of pure protein per liter of culture. Recombinant NADH peroxidase is fully active and exhibits spectroscopic and redox properties identical to those for the enzyme purified from Streptococcus faecalis 10C1. Reductive titrations and thiol analyses confirm the presence of the unusual cysteine-sulfenic acid (Cys-SOH) redox center identified previously. N-terminal sequence analysis, analytical gel filtration, and preliminary x-ray diffraction data all confirm the structural identity of the recombinant and S. faecalis enzymes. Steady-state kinetic analysis of the peroxidase, coupled with results from static titration experiments is consistent with a limiting type of ternary complex mechanism and allows the determination of many of the corresponding kinetic constants. In addition, preliminary H-1 NMR spectra of the enzyme at millimolar concentrations show good dispersion in the amide region and indicate that the recombinant peroxidase is suitable for one-dimensional NMR work with labeled amino acids.			PARSONAGE, D (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.		Ross, Paul/A-7584-2015; Miller, Holly/I-6942-2015	Ross, Paul/0000-0003-4876-8839; Miller, Holly/0000-0002-9076-5335	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035394] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35394] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLAIBORNE A, 1992, TRENDS BIOCHEM SCI, V17, P183, DOI 10.1016/0968-0004(92)90263-9; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, DOI 10.1016/C2013-0-04130-8; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; DOLIN MI, 1982, EXPERIENCES BIOCH PE, P293; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MILLER H, 1990, J BIOL CHEM, V265, P9857; Palmer G, 1968, BIOL OXIDATIONS, P263; POOLE LB, 1989, J BIOL CHEM, V264, P12322; POOLE LB, 1989, J BIOL CHEM, V264, P12330; POOLE LB, 1986, J BIOL CHEM, V261, P4525; POOLE LB, 1988, BIOCHEM BIOPH RES CO, V153, P261; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; ROSS RP, 1991, J MOL BIOL, V221, P857, DOI 10.1016/0022-2836(91)80180-3; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STOLL VS, 1988, ARCH BIOCHEM BIOPHYS, V260, P752, DOI 10.1016/0003-9861(88)90505-X; STOLL VS, 1991, BIOCHEMISTRY-US, V30, P942, DOI 10.1021/bi00218a009; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	18	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3161	3167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428993				2022-12-25	WOS:A1993KM16100025
J	NARANDA, T; REMACHA, M; BALLESTA, JPG				NARANDA, T; REMACHA, M; BALLESTA, JPG			THE ACTIVITY-CONTROLLING PHOSPHORYLATION SITE IS NOT THE SAME IN THE 4 ACIDIC RIBOSOMAL-PROTEINS FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI; ARTEMIA-SALINA; RAT-LIVER; MONOCLONAL-ANTIBODIES; EUKARYOTIC CELLS; 60S RIBOSOMES; YEAST; SUBUNIT; SEQUENCE	By using site-directed mutagenesis and chemical analysis of phosphopeptides, a unique phosphorylation site has been shown at serine 73 in the amino acid sequence of the Saccharomyces cerevisiae acidic ribosomal protein YP1beta(L44'). The mutation in this position prevents in vitro phosphorylation by protein kinases that modify the wild-type polypeptide. The unphosphorylatable mutated protein is unable to bind to the ribosomes and to rescue the growth deficiency of yeast strains in which the corresponding original gene is inactivated by gene disruption. Sequencing of tryptic phosphopeptides has shown that acidic proteins YP1alpha and YP2alpha(L44) are also phosphorylated at positions near the carboxyl end. These results contrast with the data indicating that in the highly homologous protein YP2beta, phosphorylation takes place at serine 19, close to the amino terminus. The results show that phosphorylation is definitely required for the biological activity of these ribosomal proteins. However, the differences in the phosphorylation sites suggest that the effect of this modification is not the same in all of them, confirming the heterologous role of these peculiar ribosomal components. In fact, the different context of the modification sites in the four polypeptides suggests the existence of more than one protein kinase specific for this set of proteins.			NARANDA, T (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, CANTO BLANCO, E-28049 MADRID, SPAIN.		Remacha, Miguel/G-1250-2016					AMONS R, 1979, FEBS LETT, V104, P85, DOI 10.1016/0014-5793(79)81089-3; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIELKA H, 1982, EUKARYOTIC RIBOSOME; CORREAS I, 1992, J BIOL CHEM, V267, P15721; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; HASLER P, 1991, J BIOL CHEM, V266, P13815; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; Juan Vidales F, 1981, Biochem Biophys Res Commun, V98, P717, DOI 10.1016/0006-291X(81)91172-4; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; JUANVIDALES F, 1981, BIOCHIM BIOPHYS ACTA, V656, P28; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUDLICKI W, 1980, BIOCHIM BIOPHYS ACTA, V633, P376, DOI 10.1016/0304-4165(80)90196-8; LILJAS A, 1991, INT REV CYTOL, V124, P103; LIN A, 1982, J BIOL CHEM, V257, P9189; MAASSEN JA, 1985, EUR J BIOCHEM, V149, P609, DOI 10.1111/j.1432-1033.1985.tb08968.x; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MITSUI K, 1989, BIOCHEM BIOPH RES CO, V161, P1001, DOI 10.1016/0006-291X(89)91342-9; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3575, DOI 10.1093/nar/16.8.3575; MOLLER W, 1975, P NATL ACAD SCI USA, V72, P4744, DOI 10.1073/pnas.72.12.4744; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; OLSON HM, 1986, J BIOL CHEM, V261, P6924; PILECKI M, 1992, EUR J BIOCHEM, V206, P259, DOI 10.1111/j.1432-1033.1992.tb16924.x; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1988, J BIOL CHEM, V263, P9094; REYES R, 1977, EUR J BIOCHEM, V73, P25, DOI 10.1111/j.1432-1033.1977.tb11288.x; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, BIOCHEMISTRY-US, V20, P3263, DOI 10.1021/bi00514a043; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SCHIJMAN AG, 1990, NUCLEIC ACIDS RES, V18, P3399, DOI 10.1093/nar/18.11.3399; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; TSURUGI K, 1978, J BIOL CHEM, V253, P946; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VANAGTHOVEN AJ, 1977, BIOCHEM BIOPH RES CO, V77, P989, DOI 10.1016/S0006-291X(77)80075-2; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2599, DOI 10.1093/nar/20.10.2599; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; ZINKER S, 1976, J BIOL CHEM, V251, P1799	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2451	2457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428920				2022-12-25	WOS:A1993KK81500033
J	PORTER, DJT; SPECTOR, T				PORTER, DJT; SPECTOR, T			ALTERNATIVE SUBSTRATES FOR CALF INTESTINAL ADENOSINE-DEAMINASE - A PRE-STEADY-STATE KINETIC-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; FLUORESCENCE; MECHANISM; ANALOG; STABILIZATION; DERIVATIVES; INHIBITORS; ADENINE	The protein fluorescence of adenosine deaminase (ADA) was perturbed during the deamination of adenosine and four analogues of adenosine. The kineties for the approach to the steady-state during turnover were monitored by fluorescence changes associated with formation of enzymatic intermediates. These kinetic data and the steady-state kinetic data were analyzed in terms of the kinetic scheme as follows. [GRAPHICS] The steady-state turnover number was assigned to k2, which was 244 s-1 for adenosine and 1.1 x 10(-3) s-1 for 6-methylamino-2-aminopurine arabinoside (aMDAP). Values for the association rate constants, k1, and the dissociation rate constants, k-1, were calculated from the kinetics for the approach to the steady state. k1 varied from 31 x 10(6) M-1 s-1 for adenosine to 2.8 x 10(6) M-1 s-1 for N-6-methyladenine arabinoside. k-1 varied from 500 s-1 for adenosine to 31 s-1 for aMDAP. The latter value was confirmed (22 s-1) by spectrofluorometrically monitoring the trapping of ADA by excess erythro-9-(2-hydroxy-3-nonyl) adenine as aMDAP-ADA dissociated. The ratio of k2 to k-1, which determines the commitment to catalysis, decreased from 0.49 for adenosine to 3.5 x 10(-5) for aMDAP. The K(m) values calculated from k1, k-1, and k2 were similar to the values determined from steady-state kinetic data. The spectrum of enzyme-bound aMDAP resembled protonated aMDAP.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							CAIOLFA VR, 1990, FEBS LETT, V260, P19, DOI 10.1016/0014-5793(90)80055-N; CERCIGNANI G, 1991, ANAL BIOCHEM, V192, P312, DOI 10.1016/0003-2697(91)90541-Z; Chance B, 1943, J BIOL CHEM, V151, P553; Cleland W. W., 1986, INVESTIGATIONS RATES, V6, P791; FRICK L, 1986, BIOCHEMISTRY-US, V25, P1616, DOI 10.1021/bi00355a025; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; IKEHARA M, 1974, BIOCHIM BIOPHYS ACTA, V338, P512, DOI 10.1016/0304-4165(74)90313-4; JONES W, 1989, BIOCHEMISTRY-US, V28, P1242, DOI 10.1021/bi00429a043; KOSZALKA GW, 1991, ANTIMICROB AGENTS CH, V35, P1437, DOI 10.1128/AAC.35.7.1437; KRENITSKY TA, 1981, CARBOHYD RES, V97, P139, DOI 10.1016/S0008-6215(00)80531-5; KREYSZIG E, 1963, ADV ENG MATH, P95; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P39, DOI 10.1021/bi00116a008; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P8450, DOI 10.1021/bi00399a063; KURZ LC, 1985, BIOCHEMISTRY-US, V24, P1342, DOI 10.1021/bi00327a011; OROZCO M, 1989, MOL PHARMACOL, V35, P257; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P3386, DOI 10.1021/bi00768a011; PHILIPS AV, 1989, BIOCHEMISTRY-US, V28, P2040, DOI 10.1021/bi00431a012; PHILIPS AV, 1987, BIOCHEMISTRY-US, V26, P2893, DOI 10.1021/bi00384a034; SCHAEFFER HJ, 1958, J AM CHEM SOC, V80, P3738, DOI 10.1021/ja01547a068; SPECTOR T, 1984, ANAL BIOCHEM, V138, P242, DOI 10.1016/0003-2697(84)90796-6; SPECTOR T, 1983, BIOCHEM PHARMACOL, V32, P2505, DOI 10.1016/0006-2952(83)90010-2; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P7378, DOI 10.1021/bi00397a027; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2480	2485						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428924				2022-12-25	WOS:A1993KK81500037
J	KOHLHUBER, F; STROBL, LJ; EICK, D				KOHLHUBER, F; STROBL, LJ; EICK, D			EARLY DOWN-REGULATION OF C-MYC IN DIMETHYLSULFOXIDE-INDUCED MOUSE ERYTHROLEUKEMIA (MEL) CELLS IN MEDIATED AT THE P1/P2 PROMOTERS	ONCOGENE			English	Note							RNA POLYMERASE-II; PREMATURE TERMINATION; 5' END; GENE; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; REQUIREMENTS; ARREST; BLOCK	A block of RNA elongation in exon 1 of the murine c-myc gene has been described for normal mouse fibroblasts, lymphoid and myeloid cell lines and mouse erythroleukemia (MEL) cells. MEL cells differentiate after induction with the chemical agent dimethylsulfoxide (DMSO). The rapid initial down-regulation of c-myc that occurs after treatment with DMSO has been explained by an increase in the block of RNA elongation within the 3' part of c-myc exon 1. In contrast to these reports, we find that down-regulation of c-myc in DMSO-induced MEL cells occurs at the c-myc P1 and P2 promoters. The P1 promoter is repressed by inhibition of initiation, whereas transcription of P2 RNA is blocked by retention of RNA polymerase II at or close to the P2 promoter. The earlier described block of RNA elongation at a run of five thymidines in the 3' part of c-myc exon 1 was not observed.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH 70,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PLET A, 1992, ONCOGENE, V7, P1847; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1991, ADV CANCER RES, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; WRIGHT S, 1991, P NATL ACAD SCI USA, V88, P11383, DOI 10.1073/pnas.88.24.11383	21	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455938				2022-12-25	WOS:A1993KT22000037
J	MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH				MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH			HUMAN PAPILLOMAVIRUS TYPE-16 E7 REGULATES E2F AND CONTRIBUTES TO MITOGENIC SIGNALING	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; KINASE-II PHOSPHORYLATION; TRANSCRIPTION FACTOR; DNA-SYNTHESIS; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; ADENOVIRUS E1A; RB PROTEIN; 3T3 CELLS; TRANSFORMATION	We have produced human papillomavirus type 16 E7 protein in a bacterial expression system and examined the mitogenic activity of this protein in Swiss 3T3 cells after scrape loading. The ability of E7 to induce cellular DNA synthesis in quiescent mouse fibroblasts is strongly enhanced by the presence of a single growth factor such as insulin. Although only weakly mitogenic, introduction of E7 alone resulted in the rapid induction of the transcriptionally active form of E2F, which was not enhanced further by the addition of insulin. Mutant E7 proteins defective for RB binding failed to induce the active form of E2F or act synergistically with insulin to stimulate DNA synthesis. The ability of E7 to regulate E2F may therefore be necessary, but is not sufficient, for full induction of DNA synthesis.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; MRC National Institute for Medical Research				Davies, Rachel/0000-0002-2162-6219				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; METCALFE JC, 1985, J CELL SCI, P199; MORRIS JDH, 1989, ONCOGENE, V4, P27; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1992, ONCOGENE, V7, P1681; PATRIDGE JF, 1991, EMBO J, V10, P3819; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROZENGURT E, 1985, J CELL SCI, P229; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	45	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455943				2022-12-25	WOS:A1993KT22000010
J	SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T				SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T			A NOVEL YES-RELATED KINASE, YRK, IS EXPRESSED AT ELEVATED LEVELS IN NEURAL AND HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; AVIAN-SARCOMA VIRUS; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; FIBRONECTIN GENE; SRC FAMILY; TRANSFORMATION; FYN; ASSOCIATION	While screening a chicken kidney cDNA library for the normal homolog of the yes oncogene, we isolated a clone that encodes a novel non-receptor type protein tyrosine kinase of the Src family. We named this gene product Yrk (York), as an acronym for Yes-related kinase. As predicted from the cDNA sequence, the Yrk protein consists of 536 amino acids and has all the canonical features of a Src kinase. At the amino terminus it contains a myristylation signal, followed by a unique domain, SH3 and SH2 motifs, an ATP binding site, a kinase region and a carboxy-terminal sequence with a potential regulatory tyrosine at position 530. The sequence of the Yrk protein showed 79% identity with human Fyn and 72% identity with chicken Yes. To eliminate the possibility that the Yrk protein is an avian homolog of mammalian Fyn, we isolated and sequenced the chicken fyn cDNA. The sequence data together with Southern and Northern blot analyses showed that the chicken yrk gene is distinct from the chicken fyn gene. Antibodies generated against the unique domain of the yrk protein expressed in bacteria precipitated a 60-kDa protein that was active in an immune complex kinase assay and was phosphorylated on tyrosine. Expression of the Yrk protein in adult chicken tissues was elevated in cerebellum and spleen. Relatively high levels of Yrk were also found in lung and skin.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Rockefeller University; University of Tokyo	SUDOL, M (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BRADFORD M, 1988, ANAL BIOCHEM, V58, P705; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FAGAN JB, 1981, J BIOL CHEM, V256, P520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, IN PRESS MOL BASIS H; SUDOL M, 1992, IN PRESS NEUROCHEM I; TOYOSHIMA K, 1990, ADV SEC MESS PHOSPH, V24, P284; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; Veillette A, 1991, Semin Immunol, V3, P143; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOSHIDA M, 1980, NATURE, V287, P653, DOI 10.1038/287653a0; ZHAO YH, 1990, ONCOGENE, V5, P1629	39	62	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455940				2022-12-25	WOS:A1993KT22000002
J	REMALEY, AT; WONG, AW; SCHUMACHER, UK; MENG, MS; BREWER, HB; HOEG, JM				REMALEY, AT; WONG, AW; SCHUMACHER, UK; MENG, MS; BREWER, HB; HOEG, JM			O-LINKED GLYCOSYLATION MODIFIES THE ASSOCIATION OF APOLIPOPROTEIN A-II TO HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; ACID SEQUENCE; C-III; EXPRESSION; PARTICLES; SECRETION; APOCIII; GENE	O-Linked glycosylation is a common post-translational modification of apolipoproteins, but no structural or functional role for it has been identified. We examined the biosynthesis of apolipoprotein (apo) A-II in Hep G2 cells and in glycosylation-defective Chinese hamster ovary (CHO) cell mutants transfected with apoA-II cDNA. Three monomeric isoforms of apoA-II with an apparent molecular mass of 8.5, 9.8, and 11.4 kDa were synthesized by Hep G2 cells and transfected wild-type CHO cells. The 9.8- and 11.4-kDa isoforms were sialylated but not the 8.5-kDa isoform. Transfected ldlD cells, which are defective in the biosynthesis of galactose and N-acetylgalactosamine, only produced the 8.5-kDa isoform; however, when grown in media supplemented with these sugars, ldlD cells produced all three isoforms of apoA-II. Pulse-chase analysis of ldlD cells showed that glycosylation was not necessary for secretion of apoA-II. Glycosylation did modify the association of apoA-II with nascent high density lipoprotein (HDL) recreted by Hep G2 cells. The sialylated isoforms were lipid-poor and were present in the lipoprotein-deficient density range, whereas the nonsialylated 8.5-kDa isoform was associated with LpA-I, A-II lipoprotein particles in the HDL density range. ApoA-II from transfected IdlD cells, regardless of glycosylation, were lipid-poor. When preincubated with HDL from serum, however, sialylated apoA-II from both IdlD cells and Hep G2 cells associated with lipoprotein particles within the HDL3 density, whereas nonsialylated apoA-II was found throughout the HDL density range. In summary, O-linked glycosylation is not necessary for the secretion of apoA-II but does modify the association of apoA-II to HDL and may, therefore, play an important role in the metabolism of HDL.			REMALEY, AT (corresponding author), NHLBI,BLDG 10 7N114,BETHESDA,MD 20892, USA.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BEG ZH, 1989, J BIOL CHEM, V264, P6913; BISGAIER CL, 1987, J LIPID RES, V28, P693; BLACK SC, 1990, DIABETIC MED, V7, P532, DOI 10.1111/j.1464-5491.1990.tb01437.x; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; BREWER HB, 1990, CURR OPIN LIPIDOL, V1, P200; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; EGGERMAN TL, 1991, J LIPID RES, V32, P821; GLASS C, 1985, J BIOL CHEM, V260, P744; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GOTTO AM, 1971, NEW ENGL J MED, V284, P813, DOI 10.1056/NEJM197104152841503; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HOLDSWORTH G, 1982, J CLIN INVEST, V69, P932, DOI 10.1172/JCI110532; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; HUSSAIN MM, 1990, BIOCHEMISTRY-US, V29, P209, DOI 10.1021/bi00453a029; ITO Y, 1989, J LIPID RES, V30, P1781; JAHN CE, 1983, FEBS LETT, V131, P366; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JONAS A, 1980, J BIOL CHEM, V255, P2183; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; KRIEGER M, 1989, METHODS CELL BIOL B, V32, P58; LACKNER KJ, 1984, FEBS LETT, V175, P159, DOI 10.1016/0014-5793(84)80590-6; LACKNER KJ, 1985, J BIOL CHEM, V260, P703; LAMONFAVA S, 1987, J BIOL CHEM, V262, P8944; MAEDA H, 1987, J LIPID RES, V28, P1405; MALLORY JB, 1987, J BIOL CHEM, V262, P4241; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCCALL MR, 1989, J LIPID RES, V30, P1579; MCCONATHY WJ, 1987, J LIPID RES, V28, P1193; RADER DJ, 1991, J LIPID RES, V32, P1849; RASMUSSEN JR, 1991, BIOL CARBOHYDRATES, V3, P179; REMALEY AT, 1991, J BIOL CHEM, V266, P24176; ROGHANI A, 1988, J BIOL CHEM, V263, P17925; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; URGE L, 1992, BIOCHEM BIOPH RES CO, V184, P1125, DOI 10.1016/0006-291X(92)90709-T; VAITH P, 1978, BIOCHIM BIOPHYS ACTA, V541, P234, DOI 10.1016/0304-4165(78)90396-3; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; ZANNI EE, 1989, J BIOL CHEM, V264, P9137; ZANNIS VI, 1982, J BIOL CHEM, V257, P536; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006; ZANNIS VI, 1991, CURR OPIN LIPIDOL, V2, P149	50	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6785	6790						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8454651				2022-12-25	WOS:A1993KT36800101
J	ODA, Y; HERRMANN, J; GITT, MA; TURCK, CW; BURLINGAME, AL; BARONDES, SH; LEFFLER, H				ODA, Y; HERRMANN, J; GITT, MA; TURCK, CW; BURLINGAME, AL; BARONDES, SH; LEFFLER, H			SOLUBLE LACTOSE-BINDING LECTIN FROM RAT INTESTINE WITH 2 DIFFERENT CARBOHYDRATE-BINDING DOMAINS IN THE SAME PEPTIDE-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN SPLENIC GALAPTIN; BOVINE HEART-MUSCLE; FULL-LENGTH CDNA; MASS-SPECTROMETRY; MESSENGER-RNA; RECOGNITION DOMAINS; ADHESION RECEPTORS; VERTEBRATE LECTINS; MOLECULAR-CLONING	Of the multiple soluble lactose-binding (S-Lac) lectins in rat intestine, the major one, tentatively designated RI-H, was previously isolated as a polypetide of molecular weight approximately 17,000. We here report the sequence of RI-H, as determined both at the peptide level and at the nucleotide level. Surprisingly the cDNA encodes a protein of molecular weight approximately 36,000, and this protein contains two homologous but distinct domains each with sequence elements that are conserved among all S-Lac lectins. The C-terminal domain, designated domain II, corresponds to the lectin with M(r) of 17,000 previously isolated from intestinal extracts and shown to have lactose binding activity. By preparing recombinant protein containing only the N-terminal domain, designated domain I, we here directly demonstrate that it too binds lactose and a related range of sugars that are roughly similar to domain II, but clearly distinct. The new lectin, which we designate L-36, is highly expressed in full-length form in rat small and large intestine and stomach but was not detected in eight other tissues including lung, liver, kidney, and spleen. Each domain has approximately 35% sequence identity with the other domain and with the carbohydrate-binding domain of L-29, another S-Lac lectin, but only about 15% identity with other known S-Lac lectins.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,DEPT PSYCHIAT,BOX F-0984,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO1614] Funding Source: Medline; NHLBI NIH HHS [HL38627] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALLEN HJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P523, DOI 10.1016/0003-9861(87)90610-2; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEYER EC, 1982, J CELL BIOL, V92, P28, DOI 10.1083/jcb.92.1.28; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FALICK AM, 1989, ANAL BIOCHEM, V182, P165, DOI 10.1016/0003-2697(89)90736-7; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FRIGERI LG, 1992, J IMMUNOL, V148, P861; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; HARRISON FL, 1991, J CELL SCI, V100, P9; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HO MK, 1982, J IMMUNOL, V128, P1221; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MERKLE RK, 1989, ARCH BIOCHEM BIOPHYS, V274, P404, DOI 10.1016/0003-9861(89)90453-0; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; ODA Y, 1991, GENE, V99, P279; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSE K, 1988, BIOCHEM J, V252, P191; ROSEN SD, 1990, AM J RESP CELL MOL, V3, P397, DOI 10.1165/ajrcmb/3.5.397; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA A, 1990, BIOCHEMISTRY-US, V29, P5309, DOI 10.1021/bi00474a014; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; VATH JE, 1990, INT J MASS SPECTROM, V100, P287, DOI 10.1016/0168-1176(90)85079-H; WALES R, 1992, ARCH BIOCHEM BIOPHYS, V294, P291, DOI 10.1016/0003-9861(92)90171-R; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; Wetzel R, 1990, BIOCONJUGATE CHEM, V1, P114, DOI 10.1021/bc00002a005; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847; WOO HJ, 1990, J BIOL CHEM, V265, P7097	65	173	181	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5929	5939						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449956				2022-12-25	WOS:A1993KR82200086
J	SHOHET, JM; PEMBERTON, P; CARROLL, MC				SHOHET, JM; PEMBERTON, P; CARROLL, MC			IDENTIFICATION OF A MAJOR BINDING-SITE FOR COMPLEMENT C3 ON THE IGG1 HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE PATHWAY; IMMUNE-COMPLEXES; 3RD COMPONENT; ACTIVATION; C-3; LOCALIZATION; CONVERTASE; PROTEINS; RECEPTOR; C4B	Activation of the alternative pathway of complement by immune complexes involves the covalent attachment of the third component (C3) to the IgG heavy chain. In order to localize the site/sites of attachment, adducts of human C3.IgG were digested in situ with endoproteinase Lys-C and Staphylococcus aureus V8 protease, and the fragments were analyzed. The dimeric peptide containing the covalent bond, identified by alkylation of the free thiol group (Cys1010) with iodo[C-14]acetamide, was isolated by high-performance liquid chromatography fractionation. A double sequence with NH2 termini corresponding to position 134 of IgG heavy chain and position 1002 of the C3alpha' chain was found by analysis with automated Edman degradation. The intact dimeric peptide had a mass of 3453 Da and was composed of IgG and C3 fragments with predicted sizes of 23 and 12 residues, respectively. The IgG peptide includes a cluster of six potential acceptor sites for ester bond formation. Thus, it appears that C3 binding is limited to a single region within the CH1 domain of the IgG1 heavy chain.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; CHILDRENS HOSP MED CTR,DIV IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Boston University; Harvard University; Boston Children's Hospital					NCRR NIH HHS [RR00317] Funding Source: Medline; NICHD NIH HHS [HD 17461-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; ARVIEUX J, 1988, IMMUNOLOGY, V65, P229; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P436, DOI 10.1002/rcm.1290031208; BITTERSUERMANN D, 1989, CURR TOP MICROBIOL I, V153, P223; CAMPBELL RD, 1980, BIOCHEM J, V189, P67, DOI 10.1042/bj1890067; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DODDS AW, 1988, COMPLEMENT INFLAMMAT, V5, P89, DOI 10.1159/000463039; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1980, J EXP MED, V152, P20, DOI 10.1084/jem.152.1.20; FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22; FEARON DT, 1989, CURR TOP MICROBIOL I, V153, P83; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; ISENMAN DE, 1988, BAILLIERE CLIN IMMUN, V2, P975; JUHASZ P, 1992, 12TH P AM PEPT S; KABAT EA, 1987, SEQUENCES IMMUNOGLOB; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KIM YU, 1992, J BIOL CHEM, V267, P4171; KLAUS GG, 1977, J IMMUNOL, V135, P4100; LAW SKA, 1984, BIOCHEMISTRY-US, V23, P3267, DOI 10.1021/bi00309a022; LEVINE RP, 1983, ANN NY ACAD SCI, V421, P235, DOI 10.1111/j.1749-6632.1983.tb18112.x; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MASTUMOTO AK, 1991, J EXP MED, V173, P55; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MULLEREBERHARD HJ, 1972, J EXP MED, V135, P1003, DOI 10.1084/jem.135.4.1003; OCHS HD, 1983, CLIN EXP IMMUNOL, V53, P208; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; ROSS GD, 1979, FED PROC, V38, P1467; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; SHOHET JM, 1991, J BIOL CHEM, V266, P18520; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TACK BF, 1985, COMPLEMENT, P49; TAKATA Y, 1984, J IMMUNOL, V132, P2531; THOMAS ML, 1982, P NATL ACAD SCI-BIOL, V79, P1054, DOI 10.1073/pnas.79.4.1054; TSUNASAWA S, 1985, J BIOCHEM-TOKYO, V97, P701, DOI 10.1093/oxfordjournals.jbchem.a135108; VALIM YML, 1991, CLIN EXP IMMUNOL, V84, P1, DOI 10.1111/j.1365-2249.1991.tb08115.x; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	42	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5866	5871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8449952				2022-12-25	WOS:A1993KR82200077
J	MESRI, EA; KREITMAN, RJ; FU, YM; EPSTEIN, SE; PASTAN, I				MESRI, EA; KREITMAN, RJ; FU, YM; EPSTEIN, SE; PASTAN, I			HEPARIN-BINDING TRANSFORMING GROWTH-FACTOR ALPHA-PSEUDOMONAS EXOTOXIN-A - A HEPARAN SULFATE-MODULATED RECOMBINANT TOXIN CYTOTOXIC TO CANCER-CELLS AND PROLIFERATING SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PROTEIN; FIBROBLAST GROWTH; ANIMAL TOXICITY; CHIMERIC TOXINS; ATHEROSCLEROSIS; IMMUNOTOXIN; AERUGINOSA; DOMAINS; MICE	TGFalpha-PE40, a recombinant toxin in which transforming growth factor alpha (TGFalpha) is fused to a mutant form of Pseudomonas exotoxin, is selectively cytotoxic to cells bearing epidermal growth factor (EGF) receptors. Heparin binding EGF-like growth factor is a potent mitogen for smooth muscle cells capable of binding to both the EGF receptor and to immobilized heparin (Higashiyama, S., Abraham, J., Miller, J., Fiddes, J., and Klagsbrun, M. (1991) Science 251, 936-938). To study the effect of the heparin-binding domain in a chimeric toxin targeted to the EGF receptor, we fused the DNA sequence corresponding to the putative NH2-terminal heparin-binding (HB) domain of HB-EGF to chimeric toxins composed of TGFalpha and two different recombinant forms of Pseudomonas exotoxin (PE). One of these is a truncated form of PE devoid of the binding domain (TGFalpha-PE38); another is a mutant form of full-length toxin containing inactivating mutations in the binding domain and an altered carboxyl terminus (TGFalpha-PE(4E)KDEL). The resulting chimeric toxins HB-TGFalpha-PE38 and HB-TGFalpha-PE(4E)KDEL were expressed in Escherichia coli as inclusion bodies, refolded, and purified by heparin affinity chromatography. Both of the toxins were eluted from heparin at 0.8 M NaCl, in contrast to their respective TGFalpha toxins which were eluted at 0.15 M. Binding studies on A431 cells showed that the HB-TGFalpha toxins bound to the EGF receptor with an affinity similar to that of the TGFalpha toxins. However, cell killing studies on a panel of malignant cell lines showed that cytotoxicity was strongly affected by the presence of the HB domain. Cell lines expressing high numbers of EGF receptors such as A431 and KB were less sensitive to toxins containing the HB domain. Cells with low number of EGF receptors had similar responses to both types of toxins (MCF-7 and LNCaP) or were more sensitive to the toxin with the added HB domain (HEP-G2). HB-TGFalpha-PE(4E)KDEL was over 10-fold more cytotoxic against proliferating vascular smooth muscle cells (VSMC) than to quiescent VSMC. Moreover, HB-TGFalpha-PE(4E)KDEL was 6-fold more potent than TGFalpha-PE(4E)KDEL to proliferating VSMC. Competition studies with EGF and/or heparin showed that heparin blocks the cytotoxicity of HB-TGF toxins and the inhibitory action of heparin is stronger in cells expressing lower number of EGF receptors. In addition, experiments with heparitinase-treated cells showed that in cells with low numbers of EGF receptors the binding of the HB domain to cell surface heparan sulfate proteoglycans appears to facilitate the internalization of the toxin. We conclude that addition of a HB domain to TGFalpha-PE38 or TGFalpha-PE(4E)KDEL confers the ability to bind to and to be modulated by heparin-like molecules and increases their cytotoxicity to cells expressing low numbers of EGF receptor and proliferating smooth muscle cells.	NCI, DIV CANC DIAG BIOL & CTR, MOLEC BIOL LAB, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; BATRA JK, 1992, IN PRESS MOL IMMUNOL; BIRO S, 1992, CIRC RES, V71, P640, DOI 10.1161/01.RES.71.3.640; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EPSTEIN SE, 1991, CIRCULATION, V84, P778, DOI 10.1161/01.CIR.84.2.778; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; GREGORY H, 1975, NATURE, V257, P235; HEIMBROOK DC, 1990, P NATL ACAD SCI USA, V87, P4697, DOI 10.1073/pnas.87.12.4697; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGSHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KARNOVSKY MJ, 1989, ANN NY ACAD SCI, V556, P268; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLAGSBRUN M, 1992, J CELL BIOCHEM, V16, P6; KREITMAN RJ, 1991, BIOCONJUGATE CHEM, V3, P1992; KREITMAN RJ, 1991, BIOCONJUGATE CHEM, V3, P63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; OGATA M, 1990, J BIOL CHEM, V265, P20678; PAI LH, 1991, CANCER RES, V51, P2808; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PRIOR TI, 1991, CANCER RES, V51, P174; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; WOOLF N, 1990, BRIT MED BULL, V46, P960, DOI 10.1093/oxfordjournals.bmb.a072448; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	52	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4853	4862						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444864				2022-12-25	WOS:A1993KP88400047
J	SHELNESS, GS; LIN, LJ; NICCHITTA, CV				SHELNESS, GS; LIN, LJ; NICCHITTA, CV			MEMBRANE TOPOLOGY AND BIOGENESIS OF EUKARYOTIC SIGNAL PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; YEAST SEC11 PROTEIN; ESCHERICHIA-COLI; MICROSOMAL-MEMBRANES; ROUGH MICROSOMES; LEADER PEPTIDASE; RECOGNITION PARTICLE; SECRETORY PROTEINS; HYDROPHOBIC DOMAIN; CHARGED RESIDUES	The signal peptidase complex (SPC) is a hetero-oligomeric membrane protein containing subunits of 12, 18, 21, 22/23, and 25 kDa. The 18- and 21-kDa subunits are mammalian homologs of SEC11 protein, which is necessary for signal peptide processing and cell viability in the yeast Saccharomyces cerevisiae. The functional and/or structural contributions of the 12-, 22/23-, and 25-kDa subunits to SPC activity have not yet been elucidated. To explore the structure of SPC subunits and their relationships to signal peptide processing and protein translocation, we have examined their endoplasmic reticulum (ER) membrane topology and biogenesis. Signal peptidase activity and SPC subunits are resistant to protease treatment in intact and detergent-solubilized membranes. Heat-denatured SPC subunits and SPC subunits translated in vitro are, however, protease sensitive, suggesting that the assembly of the oligomeric complex confers protease resistance. To define the membrane topology of SPC subunits, both wild-type subunits and subunit fusion proteins containing additional sites for N-linked glycosylation were assembled into microsomal membranes in vitro. Despite the presence of multiple hydrophobic domains, each subunit is anchored to the ER membrane by a single amino-terminal transmembrane domain in an N(cytoplasmic) C(exoplasmic) (type II) orientation. This topology places the bulk of the protein mass in the ER lumen and positions a putative serine-containing active site domain in SPC 18 and 21 at the same relative distance from the membrane as the analogous region in Escherichia coli leader peptidase. These studies have also revealed that, in spite of the temporal and perhaps physical association of the SPC with the process of protein translocation, SPC subunits integrate into the ER membrane by a signal recognition particle-dependent pathway and, hence, rely on the existence of a preformed translocation apparatus for their own membrane assembly.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	SHELNESS, GS (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA.				NCRR NIH HHS [S07 RR-05404] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005404] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1991, Current Opinion in Cell Biology, V3, P580, DOI 10.1016/0955-0674(91)90026-U; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; HORTSCH M, 1988, BIOCHEM BIOPH RES CO, V150, P111, DOI 10.1016/0006-291X(88)90493-7; HORTSCH M, 1987, INTEGRATION CONTROL, P3; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P181; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SUNG M, 1992, J BIOL CHEM, V267, P13154; TALMADGE K, 1980, P NATL ACAD SCI-BIOL, V77, P3369, DOI 10.1073/pnas.77.6.3369; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	60	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5201	5208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8444896				2022-12-25	WOS:A1993KP88400092
J	BANIK, U; MANDAL, NC; BHATTACHARYYA, B; ROY, S				BANIK, U; MANDAL, NC; BHATTACHARYYA, B; ROY, S			A FLUORESCENCE ANISOTROPY STUDY OF TETRAMER-DIMER EQUILIBRIUM OF LAMBDA-REPRESSOR AND ITS IMPLICATION FOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; OPERATOR; DNA; DISSOCIATION; SUBUNIT	Tetramer-dimer equilibrium of lambda repressor has been studied by fluorescence anisotropy techniques. We have chosen 1-dimethylamino napthalene-5-sulfonyl chloride (dansyl chloride)-labeled repressor to study the dissociation-association equilibrium, because of relatively long life-time of the probe (> 10 ns). Polarization of the dansyl-labeled repressor decreases with decreasing protein concentrations in the range of 20 to 0.2 muM. The decrease of anisotropy was shown to be due to reversible dissociation of the protein. Size exclusion high-performance liquid chromatography studies and polyacrylamide gel electrophoresis under native conditions (Ferguson plot) confirmed that at around 20 muM concentrations the repressor exists in predominantly tetrameric form, whereas in lower concentrations it exists in predominantly dimer form. A dissociation constant of 2.3 +/- 0.9 muM was estimated in 0.1 M potassium phosphate, pH 8.0, at 25-degrees-C. A stoichiometric amount of isolated single operator shifted the tetramer-dimer equilibrium toward the dimer. Increased ionic strength had only a modest effect on the dissociation constant. The thermodynamic constants for the dissociation reaction calculated from the Van't Hoff plot was +26.6 kcal/mol for DELTAH and +64.7 e.u. for DELTAS. The rotational correlation times derived from isothermal Perrin plot indicated elongated dimers and tetramers.	BOSE INST,DEPT BIOPHYS,P-1-12,CALCUTTA IMPROVEMENT TRUST SCHEME 7-M,CALCUTTA 700054,INDIA; BOSE INST,DEPT BIOCHEM,CALCUTTA 700054,INDIA	Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute								AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BANIK U, 1992, EUR J BIOCHEM, V206, P15, DOI 10.1111/j.1432-1033.1992.tb16896.x; BENECKY MJ, 1990, BIOCHEMISTRY-US, V29, P3082, DOI 10.1021/bi00464a027; BHATTACHARYYA T, 1991, EUR J BIOCHEM, V200, P739, DOI 10.1111/j.1432-1033.1991.tb16239.x; BRACK C, 1975, J MOL BIOL, V96, P139, DOI 10.1016/0022-2836(75)90187-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantor C.R., 1980, BIOPHYS CHEM; CHADWICK P, 1970, COLD SPRING HARB SYM, V35, P283, DOI 10.1101/SQB.1970.035.01.038; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; HSIEH WT, 1985, BIOCHEMISTRY-US, V24, P3043, DOI 10.1021/bi00333a036; Johnson A D, 1980, Methods Enzymol, V65, P839; KLOTZ IM, 1975, PROTEINS, V1; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P6518, DOI 10.1021/bi00441a053; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; Ptashne M., 1986, A GENETIC SWITCH; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SAHA R, 1992, J BIOL CHEM, V267, P5862; SAUER RT, 1978, BIOCHEMISTRY-US, V17, P1092, DOI 10.1021/bi00599a024; SENEAR DF, 1986, BIOCHEMISTRY-US, V25, P7344, DOI 10.1021/bi00371a016; SHORE JD, 1976, BIOCHEMISTRY-US, V15, P875, DOI 10.1021/bi00649a023; STEC WJ, 1985, J CHROMATOGR, V326, P263, DOI 10.1016/S0021-9673(01)87452-5; WEAST RC, 1977, CRC HDB CHEM PHYSICS; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; WEISS MA, 1987, J BIOMOL STRUCT DYN, V5, P539, DOI 10.1080/07391102.1987.10506412; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; Yguerabide J, 1972, Methods Enzymol, V26, P498	33	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3938	3943						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440687				2022-12-25	WOS:A1993KN53300024
J	FIFE, RS; KLUVEBECKERMAN, B; HOUSER, DS; PROCTOR, C; LIEPNIEKS, J; MASUDA, I; MCCARTY, DJ; RYAN, LM				FIFE, RS; KLUVEBECKERMAN, B; HOUSER, DS; PROCTOR, C; LIEPNIEKS, J; MASUDA, I; MCCARTY, DJ; RYAN, LM			EVIDENCE THAT A 550,000-DALTON CARTILAGE MATRIX GLYCOPROTEIN IS A CHONDROCYTE MEMBRANE-ASSOCIATED PROTEIN CLOSELY RELATED TO CERULOPLASMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-CHELATE CHROMATOGRAPHY; CANINE ARTICULAR-CARTILAGE; ENZYME-LINKED IMMUNOASSAY; OSTEO-ARTHRITIS; PROTEOGLYCAN AGGREGATE; BINDING-ACTIVITY; ANCHORIN-CII; FACTOR-VIII; IDENTIFICATION; RECEPTORS	Cartilage matrix glycoprotein (CMGP) is a disulfide-bonded 550,000-dalton protein that is synthesized by chondrocytes and ciliary epithelial cells. We have purified the protein from bovine and porcine articular cartilage and have sequenced two peptides, which both have significant homology with human ceruloplasmin, a copper-binding oxidase. Immunolocation analysis indicates that a commercial polyclonal antiserum to human ceruloplasmin reacts with bovine cartilage CMGP. Chelating columns made with copper bind CMGP from bovine cartilage extracts. CMGP is present in bovine chondrocyte membrane preparations purified from sucrose density gradients. Oligonucleotide probes have been synthesized based on the published sequence of the 3'-untranslated region and a portion of the C terminus of human ceruloplasmin and have been used to amplify a cDNA fragment from bovine cartilage and human liver libraries. CMGP demonstrates oxidase activity towards p-phenylenediamine similar to that of ceruloplasmin. These studies suggest that CMGP is closely related to, if not identical with, ceruloplasmin. It is possible that CMGP may be involved in metal transport into and/or within the chondrocyte.	MED COLL WISCONSIN, DEPT MED, DIV RHEUMATOL, MILWAUKEE, WI 53226 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Medical College of Wisconsin; Indiana University System; Indiana University-Purdue University Indianapolis	FIFE, RS (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV RHEUMATOL, INDIANAPOLIS, IN 46202 USA.		Houser, Dorian/AAG-6359-2020		NIAMS NIH HHS [AR 39250, AR 38656, AR 20582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038656, P60AR020582, P50AR039250] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNAUD P, 1988, METHOD ENZYMOL, V163, P441; BARNES G, 1984, BIOCHEM BIOPH RES CO, V125, P157, DOI 10.1016/S0006-291X(84)80348-4; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BROADLEY C, 1989, AM J PATHOL, V135, P647; CATES GA, 1978, BIOCHEM J, V174, P873, DOI 10.1042/bj1740873; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CYBORON GW, 1982, J BIOL CHEM, V257, P4141; DESHMUKH K, 1976, EUR J BIOCHEM, V69, P117, DOI 10.1111/j.1432-1033.1976.tb10864.x; ENGELKE DR, 1988, P NATL ACAD SCI USA, V85, P544, DOI 10.1073/pnas.85.2.544; ENOMOTO M, 1989, BIOCHEM BIOPH RES CO, V162, P1222, DOI 10.1016/0006-291X(89)90804-8; FERNANDEZ MP, 1988, J BIOL CHEM, V263, P5921; FIFE R, 1991, CLIN RES, V39, pA180; FIFE RS, 1989, J CLIN INVEST, V84, P1432, DOI 10.1172/JCI114317; FIFE RS, 1985, J HISTOCHEM CYTOCHEM, V33, P127, DOI 10.1177/33.2.3881518; FIFE RS, 1984, BIOCHIM BIOPHYS ACTA, V802, P506, DOI 10.1016/0304-4165(84)90370-2; FIFE RS, 1986, ARTHRITIS RHEUM, V29, P1256, DOI 10.1002/art.1780291011; FIFE RS, 1988, ARTHRITIS RHEUM, V31, P553, DOI 10.1002/art.1780310414; FIFE RS, 1986, ARTHRITIS RHEUM, V29, P1493, DOI 10.1002/art.1780291211; HADDAD A, 1991, EXP EYE RES, V53, P615, DOI 10.1016/0014-4835(91)90221-Y; HARRIS ED, 1991, P SOC EXP BIOL MED, V196, P130, DOI 10.3181/00379727-196-43171B; HILDEBRAND RL, 1979, RAPID DIAGNOSIS INFE, P71; KIKUCHI H, 1981, ANAL BIOCHEM, V115, P109, DOI 10.1016/0003-2697(81)90532-7; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MCCARTHY MT, 1989, J CELL PHYSIOL, V141, P191, DOI 10.1002/jcp.1041410127; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; OMOTO E, 1990, ARCH BIOCHEM BIOPHYS, V282, P34, DOI 10.1016/0003-9861(90)90083-B; ONO T, 1991, JPN J CANCER RES, V82, P486, DOI 10.1111/j.1349-7006.1991.tb01875.x; PALMOSKI MJ, 1983, ARTHRITIS RHEUM, V26, P528, DOI 10.1002/art.1780260412; PLAAS AHK, 1983, BIOCHEM J, V214, P855, DOI 10.1042/bj2140855; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; RENNARD SI, 1981, ARCH BIOCHEM BIOPHYS, V207, P399, DOI 10.1016/0003-9861(81)90047-3; RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0; RYAN TP, 1992, ARCH BIOCHEM BIOPHYS, V293, P1, DOI 10.1016/0003-9861(92)90357-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO M, 1990, J BIOL CHEM, V265, P2533; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SESSIONS CM, 1987, ENDOCRINOLOGY, V120, P2108, DOI 10.1210/endo-120-5-2108; STEVENS RL, 1986, ENDOCRINOLOGY, V118, P573, DOI 10.1210/endo-118-2-573; TAKAHASHI N, 1983, P NATL ACAD SCI-BIOL, V80, P115, DOI 10.1073/pnas.80.1.115; TAYLOR AM, 1988, FEBS LETT, V236, P33, DOI 10.1016/0014-5793(88)80280-1; THONAR EJM, 1982, J BIOL CHEM, V257, P4173; TORRES AR, 1979, BIOCHIM BIOPHYS ACTA, V576, P385, DOI 10.1016/0005-2795(79)90413-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNDERHILL CB, 1987, J BIOL CHEM, V262, P13142; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS KC, 1985, AM J PHYSIOL, V249, pE76; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X; YANG F, 1986, P NATL ACAD SCI USA, V83, P3257, DOI 10.1073/pnas.83.10.3257; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752; YANG FM, 1990, J BIOL CHEM, V265, P10780	55	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4407	4411						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440723				2022-12-25	WOS:A1993KN53300086
J	KNOLL, LJ; GORDON, JI				KNOLL, LJ; GORDON, JI			USE OF ESCHERICHIA-COLI STRAINS CONTAINING FAD MUTATIONS PLUS A TRIPLE PLASMID EXPRESSION SYSTEM TO STUDY THE IMPORT OF MYRISTATE, ITS ACTIVATION BY SACCHAROMYCES-CEREVISIAE ACYL-COA SYNTHETASE, AND ITS UTILIZATION BY SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA - PROTEIN N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; ADP-RIBOSYLATION FACTOR; COENZYME-A CARBOXYLASE; BINDING-PROTEIN; SUBSTRATE-SPECIFICITY; NUCLEOTIDE-SEQUENCE; CANDIDA-LIPOLYTICA; OPERON FUSION; RAT-LIVER; GENE	A system is described for studying protein N-myristoylation, a eukaryotic protein modification, in Escherichia coli strains containing components of eukaryotic metabolic pathways that regulate metabolism of myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) substrates. Three recombinant plasmids were used to simultaneously direct synthesis of Saccharomyces cerevisiae Nmt1p, a substrate protein (S. cerevisiae ADP-ribosylation factor 1, Arf1p), and one of the acyl-CoA synthetases produced by S. cerevisiae (Faa1p) in isogenic strains of bacteria with wild type or mutant alleles of genes comprising the regulon for fatty acid degradation (FadR, FadE, FadL and FadD). Incorporation of exogenous tritiated myristate into Arf1p and bacterial phospholipid biosynthetic pathways was analyzed. Removal of FadL, a 448-residue protein necessary for efficient transport of fatty acids across the outer membrane, had no detectable effect on Nmt1p-dependent N-myristoylation of Arf1p. This finding is consistent with the notion that permeation of C14:0 across the bacterial inner membrane can occur by simple diffusion. Studies of strains that contain a mutation in FadE which inhibits beta-oxidation of exogenous fatty acids, confirm that Nmt1p retains its specificity for-myristoyl-CoA over palmitoyl-CoA in E. coli. A mutation that inactivates FadD, a 580-residue protein which is the only acyl-CoA synthetase produced by this bacterium, completely blocks incorporation of exogenous myristate into Arf1p. This failure to be incorporated indicates that myristoyl-acyl carrier protein, generated by inner membrane acyl-acyl carrier protein synthetase, is not a substrate for Nmt1p. S. cerevisiae Faa1p can partially complement this mutant fadD allele. It can fully ''restore'' N-myristoylation of Arf1p. Faa1p can also rescue growth at 37-degrees-C of fadD- strains on minimal media supplemented with C12:0, although this rescue becomes less efficient as the chain length of the supplemental fatty acid increases. In addition, S. cerevisiae Faa1p is better able to direct myristoyl-CoA to the bacteria's phospholipid biosynthetic pathways than FadD, while FadD is more efficient at directing myristoyl-CoA to the genetically engineered protein N-myristoylation pathway. Since cellular acyl-CoA synthetase activity in S. cerevisiae has been distributed to at least two functionally differentiated proteins, this system should be useful for comparing their structure-activity relationships as well as their interactions with Nmt1p in an organelle-free environment.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; COOPER RB, 1989, J LIPID RES, V30, P1719; DEBOER HA, 1983, DNA-J MOLEC CELL BIO, V2, P231, DOI 10.1089/dna.1983.2.231; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HSU L, 1991, J BIOL CHEM, V266, P13783; HUGHES KT, 1988, J BACTERIOL, V170, P1666, DOI 10.1128/jb.170.4.1666-1671.1988; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMEDA K, 1985, BIOCHIM BIOPHYS ACTA, V840, P29, DOI 10.1016/0304-4165(85)90158-8; KAMIRYO T, 1979, P NATL ACAD SCI USA, V76, P4390, DOI 10.1073/pnas.76.9.4390; KAMIRYO T, 1977, P NATL ACAD SCI USA, V74, P4947, DOI 10.1073/pnas.74.11.4947; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KOHLWEIN SD, 1984, BIOCHIM BIOPHYS ACTA, V792, P310, DOI 10.1016/0005-2760(84)90198-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1989, J BIOL CHEM, V264, P12339; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1992, J BIOL CHEM, V267, P17095; MANGROO D, 1991, FASEB J, V5, pA1509; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; NOY N, 1985, BIOCHEMISTRY-US, V24, P3521, DOI 10.1021/bi00335a020; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; NUNN WD, 1979, J BIOL CHEM, V254, P9130; NUNN WD, 1986, J BIOL CHEM, V261, P167; NUNN WD, 1987, ESCHERICHIA COLI SAL, V1, P3155; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; OLINS PO, 1989, J BIOL CHEM, V264, P16973; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; RANGWALA SH, 1991, BIO-TECHNOL, V9, P477, DOI 10.1038/nbt0591-477; ROCK CO, 1985, J BIOL CHEM, V260, P2720; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SALLUS L, 1983, J BACTERIOL, V155, P1450, DOI 10.1128/JB.155.3.1450-1454.1983; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708	76	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4281	4290						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	8440712				2022-12-25	WOS:A1993KN53300069
J	FUNNELL, BE; GAGNIER, L				FUNNELL, BE; GAGNIER, L			THE P1 PLASMID PARTITION COMPLEX AT PARS .2. ANALYSIS OF PARB PROTEIN-BINDING ACTIVITY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; UNIT-COPY MINIPLASMIDS; ESCHERICHIA-COLI; DAUGHTER CELLS; DNA; IHF; PURIFICATION; PRODUCT; GENE	The P1 plasmid prophage is partitioned by a very high affinity protein complex at its partition site, parS, that contains the P1 ParB protein and Escherichia coli integration host factor (IHF). ParB binds to regions of parS that flank the IHF binding site. In this report, we have examined the sequences to which ParB binds, the spatial relationship between them, and the effect of IHF on ParB binding patterns. Methylation protection and interference experiments were performed on supercoiled plasmids. Mutations that interfered with the action of both proteins in vivo were identified following random mutagenesis of parS. These studies revealed that ParB binds to a complicated, nonsymmetrical region in the right side of parS. ParB recognizes a partial copy of this sequence, TCGCCA, in the left side of parS with much lower affinity. The presence of IHF greatly facilitates the interaction of ParB with parS such that both sides bind with an equal affinity that is much greater than to either side alone. The stimulation by IHF is strongly influenced by helical phasing. These observations support the proposal that ParB is directed, by the bend created by IHF, to bind simultaneously to properly placed sequences flanking the IHF site.			FUNNELL, BE (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA.			Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; AUSTIN S, 1983, J MOL BIOL, V169, P353, DOI 10.1016/S0022-2836(83)80055-2; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEVARGAS LM, 1989, SCIENCE, V244, P1457; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; GILBERT W, 1976, A BENZON S, V9, P139; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOTTESMAN ME, 1968, J MOL BIOL, V31, P487, DOI 10.1016/0022-2836(68)90423-3; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LEDERBERG J, 1953, GENETICS, V53, P51; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; NASH HA, 1981, J BIOL CHEM, V256, P9246; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; Sambrook J, 1989, MOL CLONING LABORATO; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; Silhavy T.J., 1984, EXPT GENE FUSIONS; STERNBERG N, 1983, J BACTERIOL, V153, P800, DOI 10.1128/JB.153.2.800-812.1983; STERNBERG N, 1979, VIROLOGY, V96, P129, DOI 10.1016/0042-6822(79)90179-X; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON JF, 1986, J BACTERIOL, V168, P1343, DOI 10.1128/jb.168.3.1343-1351.1986; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	32	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3616	3624						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8429038				2022-12-25	WOS:A1993KM16100090
J	GILLERON, M; VERCAUTEREN, J; PUZO, G				GILLERON, M; VERCAUTEREN, J; PUZO, G			LIPOOLIGOSACCHARIDIC ANTIGEN CONTAINING A NOVEL C4-BRANCHED 3,6-DIDEOXY-ALPHA-HEXOPYRANOSE TYPIFIES MYCOBACTERIUM-GASTRI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREHALOSE-CONTAINING LIPOOLIGOSACCHARIDES; MAGNETIC-RESONANCE SPECTROSCOPY; MULTIPLE QUANTUM NMR; STRUCTURAL ELUCIDATION; KANSASII; GLYCOLIPIDS; SENSITIVITY; OLIGOSACCHARIDES; MONOSACCHARIDES; ASSIGNMENTS	Lipooligosaccharides (LOSs) have recently been proposed as markers of mycobacterial avirulence. They have been characterized in Mycobacterium kansasii cell wall and were investigated in Mycobacterium gastri since the distinction between the two mycobacterial species remains in some question. A set of unknown LOSs was isolated from M. gastri W471. The highly antigenic lipooligosaccharide, LOS-III, was purified and appeared in all the M. gastri strains investigated regardless of their morphology. Moreover, by enzyme-linked immunosorbent assay and chromatogaphic approaches, it was found that LOS-III unambiguously distinguished M. gastri from the opportunistic pathogen M. kansasii. The LOS-III structure was established from its native form using NMR spectroscopy. This strategy revealed the presence of a supplementary monosaccharide (X) which was not characterized by routine carbohydrate analysis. Its core structure, 3,6-dideoxy-alpha-hexopyranose, was established from the complete assignment of the H-1 and C-13 spectra by two-dimensional homonuclear (COSY, HOHAHA) and heteronuclear H-1-C-13 heteronuclear multiple quantum correlation spectroscopy (HMQC) and HMQC-HOHAHA spectroscopy. Due to the absence of a proton at C4, the key data of the C4 side chain structure came from the heteronuclear multiple bond correlation spectroscopy (HMBC) spectrum. It was revealed to be a C-alkyl chain of partial structure 1,3-dimethoxypropyl. From the HMBC spectrum, this novel C-branched monosaccharide was located at the nonreducing end of the LOS, while the putative reducing end was found to consist of a 2',4,6-triacylated alpha-alpha-trehalose. The following structure, based on the evidence presented in this paper, is proposed for LOS-III: Xpalpha(1-->3)[L-Xylpbeta(1-->4)](6)3-O-Me-Rhapalpha(1-->3)D-Galpbeta(1-->3) D-Glcpbeta(1-->4)2-O-acyl-D-Glcp-alpha(1<-->1)alpha4,6-di-O-acyl-D-Glcp.	CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, F-31062 TOULOUSE, FRANCE; FAC PHARM BORDEAUX, PHARMACOGNOSIE LAB, F-33076 BORDEAUX, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux			Vercauteren, Joseph/AAF-7151-2019	Vercauteren, Joseph/0000-0002-0201-1235; GILLERON, Martine/0000-0002-2581-3302				ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V29, P234, DOI 10.1021/bi00453a032; ANGYAL SJ, 1972, AUST J CHEM, V25, P1965; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1984, J CARBOHYD CHEM, V3, P593, DOI 10.1080/07328308408057920; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BRADBURY JH, 1984, CARBOHYD RES, V126, P125, DOI 10.1016/0008-6215(84)85131-9; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; COLLINS FM, 1981, INFECT IMMUN, V32, P614, DOI 10.1128/IAI.32.2.614-624.1981; DABROWSKI J, 1989, METHOD ENZYMOL, V179, P122; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; FOURNIE JJ, 1987, J BIOL CHEM, V262, P3180; FOURNIE JJ, 1987, J BIOL CHEM, V262, P3174; GAGNAIRE D, 1978, ORG MAGN RESONANCE, V11, P344, DOI 10.1002/mrc.1270110706; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GILLERON M, 1990, EUR J BIOCHEM, V189, P167, DOI 10.1111/j.1432-1033.1990.tb15473.x; GORSHKOVA RP, 1984, CARBOHYD RES, V126, P308, DOI 10.1016/0008-6215(84)85389-6; Hanessian S, 1966, Adv Carbohydr Chem Biochem, V21, P143; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P1; HUNTER SW, 1984, J BIOL CHEM, V259, P9729; HUNTER SW, 1985, BIOCHEMISTRY-US, V24, P2798, DOI 10.1021/bi00332a030; HUNTER SW, 1988, BIOCHEMISTRY-US, V27, P1549, DOI 10.1021/bi00405a023; HUNTER SW, 1983, J BIOL CHEM, V258, P481; IMAEDA T, 1988, INT J SYST BACTERIOL, V38, P151, DOI 10.1099/00207713-38-2-151; JARDINE I, 1989, ANAL CHEM, V61, P416, DOI 10.1021/ac00180a008; KAPLAN G, 1987, J IMMUNOL, V138, P3028; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LIND A, 1984, MYCOBACTERIA SOURCE, P67; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCNEIL M, 1987, J BACTERIOL, V169, P3312, DOI 10.1128/jb.169.7.3312-3320.1987; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; NUNN PP, 1988, BRIT MED BULL, V44, P801, DOI 10.1093/oxfordjournals.bmb.a072284; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RASTOGI N, 1988, BIOCHIMIE, V70, P1101, DOI 10.1016/0300-9084(88)90272-6; RIVIERE M, 1988, J CHROMATOGR, V445, P87, DOI 10.1016/S0021-9673(01)84510-6; RIVIERE M, 1987, J BIOL CHEM, V262, P14879; ROGALL T, 1990, J GEN MICROBIOL, V136, P1915, DOI 10.1099/00221287-136-9-1915; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VERCELLONE A, 1988, CHEM PHYS LIPIDS, V48, P129, DOI 10.1016/0009-3084(88)90140-5; WAYNE LG, 1978, J GEN MICROBIOL, V109, P319, DOI 10.1099/00221287-109-2-319; ZUBKOV VA, 1989, BIOORG KHIM+, V15, P192	49	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3168	3179						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428994				2022-12-25	WOS:A1993KM16100026
J	HARDIG, Y; REZAIE, A; DAHLBACK, B				HARDIG, Y; REZAIE, A; DAHLBACK, B			HIGH-AFFINITY BINDING OF HUMAN VITAMIN-K-DEPENDENT PROTEIN S TO A TRUNCATED RECOMBINANT BETA-CHAIN OF C4B-BINDING PROTEIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN C4-BINDING PROTEIN; HUMAN-COMPLEMENT; MOLECULAR-CLONING; C3B INACTIVATOR; HUMAN-PLASMA; FACTOR-VIII; C4B; PROTEOLYSIS; RECEPTOR; FAMILY	C4b-binding protein (C4BP) is a plasma glycoprotein that contains independent binding sites for complement component C4b and anticoagulant vitamin K-dependent protein S. C4BP is composed of seven alpha-chains (70 kDa) and one beta-chain (45 kDa) joined by disulfide bonds. In addition to non-repeat regions, the alpha- and beta-chains contain eight and three tandemly arranged modules, respectively, designated short consensus repeats (SCRs). C4b binds to the alpha-chains while it has been suggested, though not conclusively shown, that the beta-chain binds protein S. A truncated recombinant beta-chain composed of the three SCRs was expressed as a fusion protein with an epitope for a calcium-dependent monoclonal antibody (HPC4) in a procaryotic expression system. A signal peptide from the pelB gene of Erwinia carotovora directed expression to the medium from which the recombinant protein was purified using a HPC4 affinity column. On unreduced polyacrylamide gel electrophoresis in the presence of SDS, the recombinant protein demonstrated two closely spaced bands (M(r) = 19,000 and 20,000), whereas after reduction a broad band with an apparent molecular weight of 25,000 was obtained. On I-125-protein S ligand blotting, only one of the unreduced bands was found to bind protein S. The protein corresponding to this band bound protein S with almost as high affinity as intact C4BP, and it completely inhibited binding of protein S to intact C4BP. After reduction, the protein S binding ability was lost.The multiple carbohydrate side chains present in the native beta-chain of C4BP were apparently not required for protein S binding, as the recombinant beta-chain was not glycosylated. These results demonstrate that the protein S binding site of C4BP is contained within the three SCR modules of its beta-chain.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation	HARDIG, Y (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN.			Dahlback, Bjorn/0000-0003-1546-0328				BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BLOBEL GG, 1975, J CELL BIOL, V17, P835; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KRISTENSEN T, 1987, FASEB J, V46, P2463; LAW SKA, 1988, COMPLEMENT; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; Maizel JV, 1971, METHOD VIROL, V5, P179; MOORE MD, 1987, P NATL ACAD SCI USA, V84, P9194, DOI 10.1073/pnas.84.24.9194; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGASAWA S, 1983, FEBS LETT, V164, P135, DOI 10.1016/0014-5793(83)80036-2; NAGASAWA S, 1980, J IMMUNOL, V125, P578; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; SUZUKI K, 1988, J BIOL CHEM, V263, P17034; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047	42	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3033	3036						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428978				2022-12-25	WOS:A1993KM16100005
J	POURCHER, T; ZANI, ML; LEBLANC, G				POURCHER, T; ZANI, ML; LEBLANC, G			MUTAGENESIS OF ACIDIC RESIDUES IN PUTATIVE MEMBRANE-SPANNING SEGMENTS OF THE MELIBIOSE PERMEASE OF ESCHERICHIA-COLI .1. EFFECT ON NA+-DEPENDENT TRANSPORT AND BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION SPECIFICITY; SUGAR BINDING; CARRIER; VESICLES; SYSTEM; IDENTIFICATION; GENE; LI+	Four aspartic acids, distributed in different putative membrane-spanning segments of the NH2-terminal domain of melibiose (mel) permease (D31 in helix I, D51 and D55 in helix II, and D120 in helix IV) were individually replaced by either Asn or Cys using site-directed mutagenesis. mel permease with either neutral residues at position 51, 55, or 120 or permease with a Cys in place of D31 does not catalyze significant Na+-linked methyl-1-thio-beta-D-galactopyranoside (TMG) accumulation. Binding studies of a high affinity ligand (p-nitrophenyl-alpha-D-galactopyranoside (NPG)) on de-energized membrane vesicles indicate that these modified transporters (i) retain the ability to bind the alpha-galactosides NPG or melibiose and the beta-galactoside TMG and (ii) exhibit a Na+-independent sugar-binding phenotype. In contrast, mel permease with an Asn residue at position 31 mediates Na+-coupled TMG transport and displays a Na+-dependent sugar binding phenotype, but requires a higher concentration of sodium than wild-type permease to produce maximal stimulation of sugar binding. The observation that individual mutation of the Asp residue at position 31, 51, 55, or 120 systematically and selectively modifies the contribution of the coupling ion to the early step of the transport reaction, i.e. cosubstrate binding, raises the possibility that (i) these 4 aspartic residues are at or near the cationic binding site of mel permease, (ii) the NH2-terminal domain of mel permease in which they are distributed accommodates or is part of the cationic binding site, and (iii) the oxygen atoms of these Asp side chains contribute to coordination of the coupling ion.	CEA,DEPT BIOL CELLULAIRE & MOLEC,LAB J MAETZ,F-06230 VILLEFRANCHE MER,FRANCE	CEA				Pourcher, Thierry/0000-0003-2839-4622				BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1989, THESIS HARVARD MED U; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; COHN DE, 1980, BIOCHEMISTRY-US, V19, P4237, DOI 10.1021/bi00559a015; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; HANATANI M, 1984, J BIOL CHEM, V259, P1807; KABACK HR, 1971, METHOD ENZYMOL, V31, P698; KAWAKAMI T, 1989, J BIOL CHEM, V263, P14276; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBLANC G, 1993, IN PRESS ION COUPLED; LEBLANC G, 1988, MOL BASIS BIOMEMBRAN, P53; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIIYA S, 1982, J BIOL CHEM, V257, P8902; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1992, BIOCHEMISTRY-US, V31, P5225, DOI 10.1021/bi00137a018; POURCHER T, 1990, BIOCHEMISTRY-US, V29, P690, DOI 10.1021/bi00455a014; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON TH, 1982, MEMBRANES TRANSPORT, P33; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985; ZANI ML, 1993, J BIOL CHEM, V268, P3216	32	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3209	3215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428997				2022-12-25	WOS:A1993KM16100031
J	TOMKA, MA; CATALANO, CE				TOMKA, MA; CATALANO, CE			PHYSICAL AND KINETIC CHARACTERIZATION OF THE DNA PACKAGING ENZYME FROM BACTERIOPHAGE-LAMBDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; COHESIVE END SITE; ESCHERICHIA-COLI; SECONDARY STRUCTURE; COS DNA; RESTRICTION ENDONUCLEASE; NUCLEOTIDE-SEQUENCE; TERMINASE; INVITRO; PROTEINS	Terminases are enzymes common to complex double-stranded DNA viruses and are required for packaging of the viral genome into a preformed capsid. The over-expression of bacteriophage lambda-terminase in Escherichia coli has been previously reported (Chow, S., Daub, E., and Murialdo, H. (1987) Gene (Amst.) 60, 277-289), and we present here a purification scheme for the isolation of milligram quantities of protein which is homogenous (>97%) as determined by SDS-polyacrylamide gel electrophoresis. Lambda-terminase is composed of the gene products of Nu1 and A. Using N-terminal amino acid sequence analysis of the purified protein, we have determined a subunit stoichiometry of 2 gpNu1 polypeptides/gpA molecule in terminase holoenzyme. The circular dichroism spectrum for the purified holoenzyme has been obtained and is consistent with a protein complex composed primarily of alpha-helical structure. The endonucleolytic activity of the enzyme (the TER reaction) has been optimized with respect to pH, salt, and polyamine concentrations. Divalent metal ion is strictly required for the reaction and may be satisfied by either magnesium or manganese, but not by any of the other metals examined. E. coli integration host factor in amounts stoichiometric with the DNA substrate stimulates the TER reaction, but only when the enzyme is present in limiting amounts. Increasing the enzyme/DNA ratio attenuates the observed stimulation by integration host factor. A kinetic analysis of the TER reaction suggests that the assembly of multiple terminase protomers is required for efficient cleavage of viral DNA and that this reaction appears to be stoichiometric, rather than catalytic under the reaction conditions utilized. The implications of these results with respect to the packaging of viral DNA by terminase enzymes are discussed.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,DENVER,CO 80262	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Catalano, Carlos E./0000-0003-2349-5758				BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BECKER A, 1977, VIROLOGY, V78, P277, DOI 10.1016/0042-6822(77)90099-X; BECKER A, 1978, P NATL ACAD SCI USA, V75, P4199, DOI 10.1073/pnas.75.9.4199; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; CID H, 1982, FEBS LETT, V150, P247, DOI 10.1016/0014-5793(82)81344-6; DAWSON RMC, 1986, DATA BIOCH RES, P542; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1988, MOL GEN GENET, V212, P142, DOI 10.1007/BF00322457; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; Furth M., 1983, LAMBDA 2, P145; GAINIER J, 1978, J MOL BIOL, V120, P97; GAMAS P, 1986, MOL GEN GENET, V202, P855; GILADI H, 1990, J MOL BIOL, V213, P181; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILL SC, 1990, ANAL BIOCHEM, V189, P283; GOLD M, 1983, J BIOL CHEM, V258, P4619; GOLD M, 1986, NUCLEIC ACIDS RES, V14, P9797, DOI 10.1093/nar/14.24.9797; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIFFO G, 1989, J MOL BIOL, V209, P55, DOI 10.1016/0022-2836(89)90169-1; HAN H, 1991, BIOCHEMISTRY-US, V30, P11104, DOI 10.1021/bi00110a012; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KORNBERG A, 1992, DNA REPLICATION, P111; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MELGAR E, 1968, J BIOL CHEM, V243, P4409; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; PARRIS W, 1988, J BIOL CHEM, V263, P8413; Record M T Jr, 1985, Adv Biophys, V20, P109; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROIZMAN B, 1991, FUNDAMENTAL VIROLOGY, V2, P863; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SHINDER G, 1989, NUCLEIC ACIDS RES, V17, P2005, DOI 10.1093/nar/17.5.2005; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; WOOD WB, 1979, COMPREHENSIVE VIROLO, V13, P581; WOODHEAD JL, 1981, EUR J BIOCHEM, V115, P293, DOI 10.1111/j.1432-1033.1981.tb05237.x; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; XIN W, 1988, NUCLEIC ACIDS RES, V16, P2015, DOI 10.1093/nar/16.5.2015; ZWELLING LA, 1988, BIOCHEM BIOPH RES CO, V152, P808, DOI 10.1016/S0006-291X(88)80110-4; [No title captured]	55	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3056	3065						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	8428984				2022-12-25	WOS:A1993KM16100011
J	JOUNEAUX, C; AUDIGIER, Y; GOLDSMITH, P; PECKER, F; LOTERSZTAJN, S				JOUNEAUX, C; AUDIGIER, Y; GOLDSMITH, P; PECKER, F; LOTERSZTAJN, S			G(S) MEDIATES HORMONAL INHIBITION OF THE CALCIUM-PUMP IN LIVER PLASMA-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CARBOXYL-TERMINAL DECAPEPTIDE; BETA-GAMMA-SUBUNITS; CA-2+ PUMP; ADENYLATE-CYCLASE; ALPHA-SUBUNIT; IDENTIFICATION; RECEPTOR; GS; CALCITONIN	We have reported that the calcium pump in liver plasma membranes is coupled to G(s) or a G(s)-like protein. However, we show here that isoproterenol, which activated adenylyl cyclase via G(s), had no effect on the calcium pump, while human calcitonin, human parathyroid hormone, and mini-glucagon, which inhibited this system, did not affect adenylyl cyclase activity. In order to determine the nature of the G protein coupled to the calcium pump, we used the RM antibody, raised against the carboxyl-terminal decapeptide of G(s)alpha, which antagonized adenylyl cyclase activation by isoproterenol or glucagon. The RM antibody specifically blocked calcium pump inhibition by mini-glucagon, calcitonin, or parathyroid hormone, while it did not affect guanosine 5'-O-(thiotriphosphate) inhibition. Its effect was mimicked the corresponding decapeptide RMHLRQYELL. The AS/7 antibody, reactive with G(t)alpha, G(i)1alpha, and G(i)2alpha, was ineffective. Complementation of liver plasma membranes with in vitro translated G(s)alpha-2, the large form of G(s)alpha, led to a 40% decrease in calcium pump activity, with a parallel 2-fold increase in adenylyl cyclase activity. In vitro translated G(i)1alpha did not affect the calcium pump activity, while it evoked a 40% inhibition of adenylyl cyclase activity. We conclude that a same G(s)alpha may be coupled either to the calcium pump or to adenylyl cyclase. However, G(s) is functionally specialized, since it does not ensure cross-talk between the two receptor-effector systems. These results point out the possible compartmentalization of G(s).	NIDDKD, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA; CNRS, INSERM ENDOCRINOL, F-34094 MONTPELLIER, FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	JOUNEAUX, C (corresponding author), HOP HENRI MONDOR, INSERM, U99, F-94010 CRETEIL, FRANCE.		Lotersztajn, Sophie/K-9160-2017	lotersztajn, Sophie/0000-0002-0053-7807				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLACHE P, 1990, J BIOL CHEM, V265, P21514; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHASE LR, 1969, ENDOCRINOLOGY, V84, P761, DOI 10.1210/endo-84-4-761; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOTERSZTAJN S, 1990, BIOL COUN S, P141; LOTERSZTAJN S, 1987, J BIOL CHEM, V262, P3114; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; LOTERSZTAJN S, 1981, J BIOL CHEM, V256, P1209; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MCKENZIE RC, 1990, BIOCHEM J, V266, P817; MURPHY PM, 1992, J BIOL CHEM, V267, P883; NAIR BG, 1990, J BIOL CHEM, V265, P21317; PAVOINE C, 1987, J BIOL CHEM, V262, P5113; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMAGUCHI M, 1984, ENDOCRINOL JAPON, V31, P327	34	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2368	2372						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428911				2022-12-25	WOS:A1993KK81500021
J	KACZMAREK, E; LEE, MH; MCDONAGH, J				KACZMAREK, E; LEE, MH; MCDONAGH, J			INITIAL INTERACTION BETWEEN FIBRIN AND TISSUE PLASMINOGEN-ACTIVATOR (T-PA) - THE GLY-PRO-ARG-PRO BINDING-SITE ON FIBRIN(OGEN) IS IMPORTANT FOR T-PA ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CHROMATOGRAPHY; MONOCLONAL-ANTIBODY; STRUCTURAL DOMAINS; KRINGLE-2 DOMAIN; LYS-PLASMINOGEN; HUMAN-PLASMA; ONE-CHAIN; POLYMERIZATION; FRAGMENTS; ACID	Gly-Pro-Arg-Pro (GPRP) is a potent inhibitor of fibrin polymerization. It also causes a concentration-dependent inhibition of the activation of plasminogen by t-PA when soluble desAABB-fibrinogen (fibrin II) or fibrinogen are used as promoters of t-PA. Fibrinogen has a much weaker promoter activity than does fibrin II. Experiments were undertaken to explain the mechanism of action of GPRP on plasminogen activation. Kinetic data indicated that when GPRP was present in the assay system, the fibrinogen)-GPRP complex was ineffective as a t-PA promoter. Only the free forms of fibrin II or fibrinogen were promoters of t-PA. GPRP specifically eluted t-PA, which was previously bound to a fibrin-Sepharose column, and also inhibited t-PA binding to fibrin-Sepharose in a concentration-dependent manner. These experiments were compared to those with other tetrapeptides: GHRP, GPGG, and GRGD. Only GHRP, which is known to hind more weakly to fibrinogen) than GPRP, had any effect. These results suggest that the GPRP binding site on the fibrinogen) molecule is important for t-PA activation and is a binding site for t-PA in the initial interaction between t-PA and fibrin. We propose that at or near the GPRP binding site on fibrin there is an initial binding site for t-PA. We hypothesize that kringle 1, which contains the sequence G128RRP, may be involved in the initial binding of t-PA to fibrin.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KACZMAREK, E (corresponding author), BETH ISRAEL HOSP,DEPT PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL-33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1986, BIOCHIM BIOPHYS ACTA, V872, P261, DOI 10.1016/0167-4838(86)90279-7; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; Blomback B., 1956, ARK KEMI, V10, P415; BOSMA PJ, 1988, EUR J BIOCHEM, V172, P399, DOI 10.1111/j.1432-1033.1988.tb13900.x; COLLEN D, 1987, J CELL BIOCHEM, V33, P77, DOI 10.1002/jcb.240330202; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EASTMAN D, 1992, BIOCHEMISTRY-US, V31, P419, DOI 10.1021/bi00117a016; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GAFFNEY PJ, 1988, P NATL ACAD SCI USA, V85, P3595, DOI 10.1073/pnas.85.10.3595; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUI KY, 1986, HYBRIDOMA, V5, P215, DOI 10.1089/hyb.1986.5.215; HUSAIN SS, 1989, BLOOD, V74, P999; IKENAKA Y, 1992, BLOOD COAGUL FIBRIN, V3, P381; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEE MH, 1991, BLOOD, V78, P1744; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MATSUDA M, 1991, BIOMED PROGR, V4, P51; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1985, BIOCHEM J, V225, P149, DOI 10.1042/bj2250149; POZDNJAKOVA TM, 1979, THROMB RES, V16, P283, DOI 10.1016/0049-3848(79)90292-5; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROOTBERNSTEIN RS, 1984, P NATL ACAD SCI-BIOL, V81, P4339, DOI 10.1073/pnas.81.14.4339; SHIMIZU A, 1989, THROMB HAEMOSTASIS, V62, P70; SHIMIZU A, 1992, P NATL ACAD SCI USA, V89, P2888, DOI 10.1073/pnas.89.7.2888; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P20, DOI 10.1016/0005-2795(70)90194-7; WASSER MNJM, 1990, THROMB HAEMOSTASIS, V63, P39; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; YONEKAWA O, 1992, BIOCHEM J, V283, P187, DOI 10.1042/bj2830187	42	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2474	2479						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428923				2022-12-25	WOS:A1993KK81500036
J	MOORE, JT; SILVERSMITH, RE; MALEY, GF; MALEY, F				MOORE, JT; SILVERSMITH, RE; MALEY, GF; MALEY, F			T4-PHAGE DEOXYCYTIDYLATE DEAMINASE IS A METALLOPROTEIN CONTAINING 2 ZINC ATOMS PER SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSITION-STATE ANALOG; METAL-BINDING DOMAINS; SINGLE HYDROXYL GROUP; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; ADENOSINE-DEAMINASE; QUATERNARY STRUCTURE; CYTIDINE DEAMINASE; AFFINITY	Deoxycytidylate (dCMP) deaminase, a hexameric allosteric enzyme induced on infection of Escherichia coli by bacteriophage T4, was shown to contain two atoms of zinc per subunit by atomic absorption spectroscopy. One zinc appears to be involved in catalysis, as described for adenosine deaminase (Sharaff, A. J., Wilson, D. K., Chang, Z., and Quiocho, F. A. (1992) J. Mol. Biol. 226, 917-921) and cytidine deaminase (Yang, C., Carlow, D., Wolfenden, R., and Short, S. A. (1992) Biochemistry 31, 4168-4174). This thesis is supported by the finding that the enzyme loses about 80% of its activity in the presence of o-phenanthroline. It has also been found that zinc is released when the enzyme is denatured in the presence of the metallochromic indicator, 4-(2-pyridylazo)resorcinol. Renaturation of the deaminase to an active form occurred in the presence but not in the absence of zinc. The second atom of zinc is proposed to be located in a region of T4-dCMP deaminase that resembles a zinc finger. This region, which has the sequence His-X3-Cys-X14-His-X3-His, would represent a zinc-binding motif that has not been described previously.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201; UNION COLL,DEPT CHEM,SCHENECTADY,NY 12308	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Union College					NCI NIH HHS [CA44355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JR, 1980, J BIOL CHEM, V225, P7583; ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; ASHLEY GW, 1984, J BIOL CHEM, V259, P3621; BERG JM, 1990, J BIOL CHEM, V265, P6513; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHIU CS, 1977, J BIOL CHEM, V252, P8603; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DRAKE JC, 1980, BIOCHEM PHARMACOL, V29, P807, DOI 10.1016/0006-2952(80)90561-4; FRICK L, 1989, BIOCHEMISTRY-US, V28, P9423, DOI 10.1021/bi00450a027; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GERHART JC, 1967, J BIOL CHEM, V242, P2886; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; JONES W, 1989, BIOCHEMISTRY-US, V28, P1242, DOI 10.1021/bi00429a043; KATI WM, 1989, BIOCHEMISTRY-US, V28, P7919, DOI 10.1021/bi00445a055; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; KURTZ LC, 1985, BIOCHEMISTRY-US, V24, P1342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; MALEY F, 1967, METHOD ENZYMOL, V12, P170; MALEY GF, 1983, J BIOL CHEM, V258, P8290; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1972, J BIOL CHEM, V247, P940; MALEY GF, 1972, J BIOL CHEM, V247, P931; MALEY GF, 1963, SCIENCE, V141, P1278, DOI 10.1126/science.141.3587.1278; MALEY GF, 1964, J BIOL CHEM, V239, P1168; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MATHEWS CK, 1983, BACTERIOPHAGE T4, P59; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ROSENBUSCH JP, 1971, J BIOL CHEM, V246, P1644; SCARANO E, 1963, J BIOL CHEM, V238, P1556; SHARFF AJ, 1992, J MOL BIOL, V226, P917, DOI 10.1016/0022-2836(92)91040-V; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; WHEELER L, 1992, J BIOL CHEM, V267, P7664; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003	38	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2288	2291						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428902				2022-12-25	WOS:A1993KK81500006
J	QUINTANA, DG; GARRIGA, P; MANYOSA, J				QUINTANA, DG; GARRIGA, P; MANYOSA, J			QUANTITATIVE CHARACTERIZATION OF THE STRUCTURE OF RHODOPSIN IN DISC MEMBRANE BY MEANS OF FOURIER TRANSFORM INFRARED SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURES; CIRCULAR-DICHROISM; PURPLE MEMBRANE; GLOBULAR-PROTEINS; IR SPECTROSCOPY; ALPHA-HELICES; SPECTRA; BACTERIORHODOPSIN; WATER; POLYPEPTIDES	Fourier transform infrared (FTIR) spectroscopy has been used for the detailed characterization and quantification of the secondary structure of bovine rhodopsin in native disc membranes. FTIR spectra were obtained in aqueous media, both in (H2O)-H-1 and in (H2O)-H-2. Analysis of spectra by means of Fourier self-deconvolution, complemented with maximum likelihood restoration and Fourier derivative, has allowed the characterization of major amide I secondary structure-sensitive component bands of structural relevance which had not been detected before. In consequence, we show a richer secondary structure for rhodopsin than previously described. Our results indicate a total regular helix content around 51% which would include not only the main alpha1-type helix but also 3(10)-like helix. The presence of distorted helicoid sequences might furthermore increase to a certain extent the total helix amount. It is also indicated that a significant proportion of the amino acid residues are involved in extended/beta-structures and in reverse turns, as well as in ''random'' segments, which had not been directly demonstrated before. 61 +/- 4% of rhodopsin is determined to be solvent-accessible, which is a substantially higher value than previously reported. Helices account for most of the inaccessible moiety.			QUINTANA, DG (corresponding author), UNIV AUTONOMA BARCELONA, FAC MED, DEPT BIOQUIM & BIOL MOLEC, UNITAT BIOFIS, E-08193 BARCELONA, SPAIN.		Quintana, David G/M-5628-2018; Garriga, Pere/C-1949-2017	Garriga, Pere/0000-0003-4234-8382; Quintana, David G./0000-0002-4909-6686				ABBOTT TP, 1990, APPL SPECTROSC, V44, P899, DOI 10.1366/0003702904086966; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; BUSTAMANTE C, 1983, P NATL ACAD SCI-BIOL, V80, P3568, DOI 10.1073/pnas.80.12.3568; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAMERON DG, 1987, APPL SPECTROSC, V41, P539, DOI 10.1366/0003702874448445; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CASTRESANA J, 1988, BIOCHEM BIOPH RES CO, V152, P69, DOI 10.1016/S0006-291X(88)80681-8; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; DENOYER LK, 1990, AM LAB, V22, P21; DENOYER LK, 1991, AM LAB, V23; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DRATZ EA, 1979, PHOTOCHEM PHOTOBIOL, V29, P661, DOI 10.1111/j.1751-1097.1979.tb07746.x; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P2025, DOI 10.1002/bip.360231016; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; EARNEST TN, 1987, THESIS BOSTON U; HARIS PI, 1989, BIOCHIM BIOPHYS ACTA, V995, P160, DOI 10.1016/0167-4838(89)90075-7; HARIS PI, 1988, BIOCHIM BIOPHYS ACTA, V943, P375, DOI 10.1016/0005-2736(88)90571-8; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; KAMPS KMP, 1982, BIOCHIM BIOPHYS ACTA, V687, P296, DOI 10.1016/0005-2736(82)90558-2; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; MANTSCH HH, 1988, J MOL STRUCT, V173, P285, DOI 10.1016/0022-2860(88)80061-9; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; MOFFATT DJ, 1986, NRCC B, V18; NABEDRYK E, 1985, BIOPHYS J, V48, P873, DOI 10.1016/S0006-3495(85)83848-0; OSBORNE HB, 1977, FEBS LETT, V84, P217, DOI 10.1016/0014-5793(77)80691-1; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PAK WL, 1988, PHOTOCHEM PHOTOBIOL, V47, P877, DOI 10.1111/j.1751-1097.1988.tb01670.x; PAPPIN DJC, 1984, INT J BIOL MACROMOL, V6, P73, DOI 10.1016/0141-8130(84)90066-7; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; PRESTRELSKI SJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P111, DOI 10.1016/0003-9861(91)90335-G; PRESTRELSKI SJ, 1991, PROTEIN ENG, V4, P739, DOI 10.1093/protein/4.7.739; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROTHSCHILD KJ, 1980, BIOCHIM BIOPHYS ACTA, V596, P338, DOI 10.1016/0005-2736(80)90121-2; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P69; SHICHI H, 1974, Journal of Supramolecular Structure, V2, P7, DOI 10.1002/jss.400020103; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; THANKI N, 1991, J MOL BIOL, V221, P669, DOI 10.1016/0022-2836(91)80080-E; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YASUI SC, 1986, BIOPOLYMERS, V25, P79, DOI 10.1002/bip.360250107	49	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2403	2409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8428913				2022-12-25	WOS:A1993KK81500026
